aspirin has been researched along with Cardiovascular Diseases in 2346 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Inflammation contributes to this risk but the role of lipid mediators, with central roles in inflammation, in HIV infection remain to be established; further aspirin reduces CVD risk in the general population through production of some of these anti-inflammatory lipid mediators, but they have not been studied in PWH." | 9.69 | Pro-inflammatory and pro-resolving lipid mediators of inflammation in HIV: effect of aspirin intervention. ( Aberg, JA; Brown, TT; Dalli, J; Funderburg, N; Gupta, A; Hunt, PW; Kitch, D; Moisi, D; O'Brien, MP; Shivakoti, R; Tien, PC, 2023) |
| "Background We aimed to evaluate the age-dependent effect of ticagrelor monotherapy after 3-month dual-antiplatelet therapy (DAPT) versus ticagrelor-based 12-month DAPT on major bleeding and cardiovascular events in patients with acute coronary syndrome." | 9.41 | Age-Dependent Effect of Ticagrelor Monotherapy Versus Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events: A Post Hoc Analysis of the TICO Randomized Trial. ( Ahn, CM; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BG; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Shin, DH, 2021) |
| "Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy." | 9.34 | Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. ( Ahn, CM; Cho, DK; Cho, JY; Cho, S; Cho, YH; Choi, D; Her, AY; Hong, BK; Hong, MK; Hong, SJ; Jang, Y; Jeon, DW; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Kwon, H; Nam, CM; Shin, DH; Suh, Y; Yoo, SY; Yun, KH, 2020) |
| "Adding rivaroxaban to aspirin in patients with stable atherosclerotic disease reduces the recurrence of cardiovascular disease (CVD) but increases the risk of major bleeding." | 9.30 | Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. ( Alings, M; Berkowitz, SD; Bosch, J; de Vries, TI; Dorresteijn, JAN; Dyal, L; Eikelboom, JW; Fox, KAA; van der Graaf, Y; Visseren, FLJ; Westerink, J, 2019) |
| "In patients with stable coronary artery disease, addition of rivaroxaban to aspirin lowered major vascular events, but increased major bleeding." | 9.27 | Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. ( Anand, SS; Avezum, AA; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Connolly, SJ; Cook Bruns, N; Dagenais, G; Dans, AL; Dyal, L; Eikelboom, JW; Felix, C; Fox, KAA; Guzik, TJ; Ha, JW; Hori, M; Keltai, K; Lanas, F; Lisheng, L; Lonn, E; Maggioni, AP; Metsarinne, K; O'Donnell, M; Parkhomenko, AN; Torp-Pedersen, C; Varigos, JD; Widimsky, P; Yusoff, K; Yusuf, S, 2018) |
| " Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear." | 9.27 | Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. ( Adler, A; Armitage, J; Aung, T; Baigent, C; Barton, J; Bodansky, J; Bowman, L; Buck, G; Chen, F; Collins, R; Cox, J; Farmer, A; Haynes, R; Lay, M; Mafham, M; McPherson, R; Murawska, A; Murphy, K; Neil, A; Parish, S; Peto, R; Sammons, E; Simpson, D; Stevens, W; Wallendszus, K; Waters, E; Young, A, 2018) |
| "The use of low-dose aspirin as a primary prevention strategy in older adults resulted in a significantly higher risk of major hemorrhage and did not result in a significantly lower risk of cardiovascular disease than placebo." | 9.27 | Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. ( Abhayaratna, WP; Beilin, LJ; Brauer, D; Cloud, G; Donnan, GA; Eaton, CB; Ernst, ME; Fitzgerald, SM; Grimm, R; Jelinek, M; Johnston, CI; Kirpach, B; Lockery, JE; Mahady, SE; Malik, M; Margolis, KL; McNeil, JJ; Murray, AM; Nelson, MR; Orchard, SG; Radziszewska, B; Reid, CM; Ryan, J; Satterfield, S; Shah, RC; Stocks, N; Storey, E; Tonkin, AM; Trevaks, RE; Williamson, JD; Wolfe, R; Wood, EM; Woods, RL, 2018) |
| "For this industry-independent, double-blind, double-dummy, randomised trial done in one academic hospital in Hong Kong, we screened patients with arthritis and cardiothrombotic diseases who were presenting with upper gastrointestinal bleeding, were on NSAIDs, and require concomitant aspirin." | 9.24 | Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. ( Au, KWL; Chan, FKL; Chan, H; Cheong, PK; Ching, JYL; Kee, KM; Kyaw, MH; Lam, K; Lee, V; Lo, A; Ng, SC; Suen, BY; Tse, YK; Wong, GLH; Wong, VWS; Wu, JCY, 2017) |
| "Low-dose aspirin was associated with small absolute risk reductions in major cardiovascular disease events and small absolute increases in major bleeding." | 9.22 | Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. ( Bean, SI; Evans, CV; Guirguis-Blake, JM; Perdue, LA; Senger, CA, 2022) |
| "The role of aspirin in primary prevention of cardiovascular diseases (CVD) has been extensively evaluated; however, the results provided over the years have been controversial." | 9.22 | Aspirin for Primary Prevention of Cardiovascular Diseases: "WALTZ" with the Evidence. ( Dimitriadis, K; Lazarou, E; Soulaidopoulos, S; Tsioufis, K; Tsioufis, P, 2022) |
| "Aspirin (acetylsalicylic acid, ASA) is inexpensive and is established in preventing cardiovascular disease (CVD) and colorectal adenomas." | 9.22 | Aspirin and omega-3 polyunsaturated fatty acid use and their interaction in cardiovascular diseases and colorectal adenomas. ( Block, RC; Mousa, SA; Wang, IE; Yi, S, 2022) |
| " Whether aspirin may reduce the risk for CVD, death, and kidney failure outcomes is uncertain." | 9.22 | Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. ( Bostom, A; Carpenter, M; Dad, T; Hunsicker, L; Joseph, A; Kusek, JW; Levey, AS; Pfeffer, M; Tighiouart, H; Weiner, DE, 2016) |
| "Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding." | 9.22 | Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016) |
| "In patients with a myocardial infarction more than 1 year previously, treatment with ticagrelor significantly reduced the risk of cardiovascular death, myocardial infarction, or stroke and increased the risk of major bleeding." | 9.20 | Long-term use of ticagrelor in patients with prior myocardial infarction. ( Bansilal, S; Bengtsson, O; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Fish, MP; Goto, S; Hamm, C; Held, P; Im, K; Jensen, EC; Kiss, RG; Magnani, G; Murphy, SA; Nicolau, JC; Oude Ophuis, T; Ruda, M; Sabatine, MS; Spinar, J; Steg, PG; Storey, RF; Theroux, P; Wiviott, SD, 2015) |
| "Prospective data to examine the association of homocysteine with age-related macular degeneration (AMD) are limited." | 9.20 | Prospective study of plasma homocysteine level and risk of age-related macular degeneration in women. ( Buring, JE; Christen, WG; Cook, NR; Ridker, PM, 2015) |
| " EC-ASA 325 mg in a secondary cardiovascular disease prevention population taking aspirin 325 mg daily for ≥3 months and at risk for ASA-associated gastric ulcers (GUs)." | 9.19 | PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: results of two 6-month, phase 3 studies. ( Cryer, BL; Eisen, GM; Fort, JG; Goldstein, JL; Lanas, A; Miller, AB; O'Connor, C; Scheiman, JM; Whellan, DJ; Zhang, Y, 2014) |
| "Rectal indomethacin has been proven to be effective for prevention of post-ERCP pancreatitis (PEP) but its impact on bleeding after biliary sphincterotomy (BABES) and cardiovascular mortality has not been extensively studied." | 9.19 | Does rectal indomethacin given for prevention of post-ERCP pancreatitis increase bleeding after biliary endoscopic sphincterotomy or cardiovascular mortality?: Post hoc analysis using prospective clinical trial data. ( Patai, Á; Patai, ÁV; Solymosi, N, 2014) |
| "To investigate the prevalent of aspirin resistance (AR) in Chinese stroke patients and its association with recurrent stroke and other vascular events, including cardiovascular disease and death." | 9.17 | Aspirin resistance in Chinese stroke patients increased the rate of recurrent stroke and other vascular events. ( Chi, L; Lin, J; Yi, X; Zhou, Q, 2013) |
| "Aspirin-related peptic ulcers are a common disorder." | 9.16 | Esomeprazole alone compared with esomeprazole plus aspirin for the treatment of aspirin-related peptic ulcers. ( Chen, WC; Ger, LP; Hsu, PI; Lai, KH; Lin, SY; Liu, CP; Mar, GY, 2012) |
| " We aimed to clarify the efficacy of rabeprazole for preventing peptic ulcer, esophagitis, and gastrointestinal symptoms associated with LDA." | 9.16 | Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial. ( Azuma, T; Fujisawa, T; Fujita, T; Hayakumo, T; Inokuchi, H; Kawai, T; Kutsumi, H; Kuwayama, H; Matsubara, Y; Miyaji, H; Murakami, M; Sanuki, T; Terao, S; Yamazaki, Y; Yoshida, S, 2012) |
| "Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed." | 9.16 | Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ, 2012) |
| " In this randomized, open-label, multicenter trial, we compared aspirin (ASA) or fixed low-dose warfarin (WAR) versus low molecular weight heparin (LMWH) for preventing thromboembolism in patients with myeloma treated with thalidomide-based regimens." | 9.15 | Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Caravita, T; Carella, AM; Cavo, M; Cellini, C; Crippa, C; Elice, F; Evangelista, A; Galli, M; Gentilini, F; Magarotto, V; Marasca, R; Montefusco, V; Morabito, F; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Polloni, C; Pulini, S; Ria, R; Romano, A; Rossi, D; Tacchetti, P; Tosi, P; Zamagni, E; Zambello, R, 2011) |
| "Famotidine is effective in the prevention of gastric and duodenal ulcers, and erosive oesophagitis in patients taking low-dose aspirin." | 9.14 | Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. ( Bezlyak, V; McCloskey, C; Prasad, R; Taha, AS, 2009) |
| "To test whether alternate-day low-dose aspirin affects incidence of age-related macular degeneration (AMD) in a large-scale randomized trial of women." | 9.14 | Low-dose aspirin and medical record-confirmed age-related macular degeneration in a randomized trial of women. ( Buring, JE; Chew, EY; Christen, WG; Glynn, RJ, 2009) |
| "One hundred and twenty-one consecutive patients with metabolic syndrome were randomized into three groups, receiving 100 mg/day of aspirin, 300 mg/day of aspirin or a placebo, respectively, for 2 weeks." | 9.14 | Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome. ( Adhikari, CM; Gao, XR; Guo, XG; He, XY; Lin, J; Peng, LY; Zhai, YS; Zhang, LY; Zuo, ZY, 2009) |
| "It is uncertain whether aspirin therapy should be continued after endoscopic hemostatic therapy in patients who develop peptic ulcer bleeding while receiving low-dose aspirin." | 9.14 | Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. ( Chan, FK; Ching, JY; Chiu, PW; Lau, JY; Lee, YT; Leung, VK; Sung, JJ; Wong, VW; Wu, JC, 2010) |
| "It is unknown whether there is an interaction between aspirin and angiotensin receptor blockers on outcomes in patients with heart failure (HF)." | 9.14 | Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. ( Chang, SM; Dunlap, ME; Granger, CB; Johansson, PA; Kosolcharoen, P; McMurray, JJ; Michelson, EL; Murray, DR; Olofsson, B; Pfeffer, MA; Solomon, SD; Swedberg, K; Yusuf, S, 2010) |
| " 25,086 individuals with acute coronary syndromes and intended early PCI were randomly assigned to double-dose (600 mg on day 1, 150 mg on days 2-7, then 75 mg daily) versus standard-dose (300 mg on day 1 then 75 mg daily) clopidogrel, and high-dose (300-325 mg daily) versus low-dose (75-100 mg daily) aspirin." | 9.14 | Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. ( Ajani, AE; Avezum, A; Bassand, JP; Budaj, A; Chrolavicius, S; Di Pasquale, G; Eikelboom, JW; Faxon, DP; Fox, KA; Gao, P; Granger, CB; Jolly, SS; Joyner, CD; Macaya, C; Mehta, SR; Montalescot, G; Niemela, K; Rupprecht, HJ; Steg, PG; Tanguay, JF; White, HD; Widimsky, P; Yusuf, S, 2010) |
| "In patients with an acute coronary syndrome who were referred for an invasive strategy, there was no significant difference between a 7-day, double-dose clopidogrel regimen and the standard-dose regimen, or between higher-dose aspirin and lower-dose aspirin, with respect to the primary outcome of cardiovascular death, myocardial infarction, or stroke." | 9.14 | Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KA; Granger, CB; Jolly, S; Joyner, CD; Mehta, SR; Pogue, J; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2010) |
| "We randomly assigned patients who had adenomas removed before study entry to receive placebo (679 patients) or 200 mg (685 patients) or 400 mg (671 patients) of celecoxib twice daily." | 9.12 | Celecoxib for the prevention of sporadic colorectal adenomas. ( Anderson, WF; Bagheri, D; Bertagnolli, MM; Boisserie, F; Burn, J; Chung, DC; Corle, D; Dewar, T; Eagle, CJ; Foley, TR; Gordon, GB; Hawk, ET; Hess, TM; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Solomon, SD; Sylwestrowicz, T; Tang, J; Viner, JL; Wittes, J; Woloj, GM; Zauber, AG, 2006) |
| "The Prevention of Colorectal Sporadic Adenomatous Polyps trial was a randomized, placebo-controlled, double-blind study of the COX-2 inhibitor celecoxib given daily in a single 400-mg dose." | 9.12 | Celecoxib for the prevention of colorectal adenomatous polyps. ( Arber, N; Bhadra, P; Dite, P; Eagle, CJ; Fowler, R; Gerletti, P; Hajer, J; Lechuga, MJ; Levin, B; Macdonald, K; Rácz, I; Rosenstein, RB; Solomon, SD; Spicak, J; Tang, J; Wittes, J; Zauber, AG; Zavoral, M, 2006) |
| "Low-dose aspirin taken every other day helps prevent stroke in women aged 45 years and older, but does not prevent a first myocardial infarction (MI) or cardiovascular death among healthy women." | 9.12 | Aspirin prevents stroke but not MI in women; vitamin E has no effect on CV disease or cancer. ( Buring, JE, 2006) |
| "To determine the cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib." | 9.12 | Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. ( Abramson, SB; Chesebro, JH; Farkouh, ME; Fuster, V; Greenberg, JD; Hochman, JS; Jeger, RV; Kirshner, H; Lay, CL; Matchaba, PT; Mellein, B; Ramanathan, K; Ruland, S; Verheugt, FW, 2007) |
| "The use of aspirin for the prevention of thrombotic complications in polycythemia vera is controversial." | 9.11 | Efficacy and safety of low-dose aspirin in polycythemia vera. ( Barbui, T; Gisslinger, H; Kutti, J; Landolfi, R; Marchioli, R; Patrono, C; Tognoni, G, 2004) |
| "We performed a randomized, double-blind, multicenter study to test the efficacy of triflusal (600 mg/d) versus aspirin (325 mg/d) for prevention of vascular events in patients with stroke or transient ischemic attack (Triflusal versus Aspirin in Cerebral Infarction Prevention [TACIP])." | 9.10 | Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. ( Alvarez-Sabín, J; Ferro, JM; Jiménez, MD; Lago, A; Matías-Guiu, J; Melo, T; Torres, F, 2003) |
| "To assess the tolerability of rofecoxib compared with naproxen for treatment of osteoarthritis." | 9.10 | Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. ( Dixon, ME; Geba, GP; Johansson, G; Lisse, JR; Mollen, AJ; Perlman, M; Polis, AB; Schechtman, J; Shoemaker, JR; Skalky, CS, 2003) |
| "Antiplatelet therapy with aspirin and systematic anticoagulation with warfarin reduce cardiovascular morbidity and mortality after myocardial infarction when given alone." | 9.08 | Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. ( , 1997) |
| "To review the clinical evidence of the effect of aspirin as primary prevention for patients with diabetes mellitus and in healthy elderly." | 9.05 | Role of Aspirin for Primary Prevention in Persons with Diabetes Mellitus and in the Elderly. ( Baliga, RR; Patel, NJ, 2020) |
| "The safety and efficacy of aspirin for the primary prevention of cardiovascular disease in patients with diabetes mellitus remains controversial." | 9.05 | Aspirin for primary prevention of cardiovascular outcomes in diabetes mellitus: An updated systematic review and meta-analysis. ( Ali, F; Kaluski, E; Khan, MU; Khan, SU; Krasuski, RA; Lone, AN; Mookadam, F; Shahzeb Khan, M; Talluri, S; Ul Abideen Asad, Z, 2020) |
| "The benefits of aspirin for primary prevention of stroke are uncertain." | 9.05 | Aspirin for primary prevention of stroke in individuals without cardiovascular disease-A meta-analysis. ( Costello, M; Ferguson, J; Gorey, S; Halloran, MO; Judge, C; Loughlin, E; Murphy, R; Nolan, A; O'Canavan, M; O'Donnell, MJ; Ruttledge, S, 2020) |
| "The Aspirin Myocardial Infarction Study (AMIS) was a multicenter, randomized, double-blind, placebo-controlled trial of 1." | 9.05 | The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group. ( , 1980) |
| "The role for aspirin in cardiovascular primary prevention remains controversial, with potential benefits limited by an increased bleeding risk." | 9.01 | Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis. ( Roddick, AJ; Zheng, SL, 2019) |
| "In the context of contemporary primary prevention guidelines, the effect of aspirin on myocardial infarction risk was significantly attenuated, whereas its major bleeding and hemorrhagic stroke complications were retained." | 9.01 | A Meta-Analysis of Aspirin for the Primary Prevention of Cardiovascular Diseases in the Context of Contemporary Preventive Strategies. ( Khan, B; Khan, SA; Latham, SB; Rao, SV; Shah, R, 2019) |
| "While the use of aspirin in the secondary prevention of cardiovascular (CVD) is well established, aspirin in primary prevention is not systematically recommended because the absolute CV event reduction is similar to the absolute excess in major bleedings." | 8.95 | Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk. ( Battistoni, A; Coluccia, R; De Caterina, R; Gallo, G; Volpe, M, 2017) |
| "Aspirin is indicated for primary and secondary prevention of cardiovascular diseases (CVD) by major guidelines." | 8.95 | Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. ( Bliden, K; Chaudhary, R; Gurbel, PA; Sharma, T; Tantry, U, 2017) |
| "To evaluate the risk for serious bleeding with regular aspirin use in cardiovascular disease (CVD) primary prevention." | 8.93 | Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force. ( Burda, BU; Evans, CV; Guirguis-Blake, JM; Whitlock, EP; Williams, SB, 2016) |
| "This review highlights practical aspects related to aspirin therapy in cardiovascular diseases, specifically, the benefits and hazards in different clinical settings." | 8.91 | A Balanced View of Efficacy and Safety of Aspirin in Cardiovascular Diseases. ( Brugada, P; Casado-Arroyo, R; Lanas, A, 2015) |
| "Prescribed in patients with a history of myocardial infarction, stroke, transient ischemic attack, coronary intervention or bypass surgery, aspirin is one of the medications most commonly used in the secondary prevention of cardiovascular diseases." | 8.90 | PA32540 for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers. ( Adams, S; Duffy, D; Rooney, B; Whellan, DJ, 2014) |
| "Aspirin is used to prevent ischemic stroke and other types of cardiovascular disease." | 8.87 | Gender differences in the primary prevention of stroke with aspirin. ( Adelman, EE; Brown, DL; Lisabeth, L, 2011) |
| " Recent randomized controlled trials in patients who are at moderately increased risk of ulcers have shown that the proton pump inhibitor esomeprazole (the S-isomer of racemic omeprazole) reduces the gastroduodenal ulcer incidence by approximately 70-85% and the gastrointestinal bleeding risk by as much as 90%." | 8.87 | Reducing the risk of gastroduodenal ulcers with a fixed combination of esomeprazole and low-dose acetyl salicylic acid. ( Yeomans, ND, 2011) |
| "The benefits of aspirin therapy in reducing the subsequent risk of myocardial infarction, stroke and death is well documented in individuals with cardiovascular disease including those with diabetes mellitus (DM)." | 8.85 | Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitus. ( Soran, H; Williams, S; Younis, N, 2009) |
| "To determine the effectiveness and safety of thienopyridine derivatives (ticlopidine and clopidogrel) versus aspirin for preventing serious vascular events (stroke, myocardial infarction (MI) or vascular death) in patients at high risk, and specifically in patients with a previous TIA or ischaemic stroke." | 8.85 | Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. ( Hankey, GJ; Mason, G; Maurice, JB; Sudlow, CL; Wedderburn, CJ, 2009) |
| "Aspirin for prevention of colorectal cancer is controversial." | 8.84 | The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. ( Barrowman, N; Code, C; Dubé, C; Lewin, G; Moher, D; Rostom, A; Sampson, M; Tsertsvadze, A, 2007) |
| "Acetylsalicylic acid (aspirin) is widely used as antiplatelet therapy for the primary and secondary prevention of cardiovascular diseases." | 8.83 | [Aspirin for primary prevention of cardiovascular diseases in diabetic patients: focus on gender difference and insulin resistance]. ( Legrand, DA; Scheen, AJ, 2006) |
| "The following four studies were evaluated: the Coumadin Aspirin Reinfarction Study (CARS); the Combination Hemotherapy and Mortality Prevention (CHAMP) Study; the Warfarin, Aspirin Reinfarction Study (WARIS)-II; the Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT)-2 Study." | 8.82 | [Secondary prevention after acute myocardial infarction: aspirin, warfarin or both?]. ( Landmark, K; Madsen, S; Reikvam, A, 2003) |
| "The increasing burden of cardiovascular diseases in developed, as well as developing countries, underscores the need for the more widespread and appropriate use of aspirin in secondary prevention of occlusive vascular events during acute evolving myocardial infarction (MI) and in primary prevention." | 8.82 | The role of aspirin in cardiovascular diseases--forgotten benefits? ( Hennekens, CH; Williams, A, 2004) |
| "Aspirin, nonsteroidal antiinflammatory drugs (NSAIDs), and cyclooxygenase-2 (COX-2) inhibitors are widely used in patients with rheumatoid arthritis." | 8.82 | Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: possible interactions and implications for treatment of rheumatoid arthritis. ( Buring, JE; Gaziano, JM; Hennekens, CH; Kurth, T, 2004) |
| "In the secondary prevention of cardiovascular, cerebrovascular, and ischemic events, the evidence supports that the benefits of aspirin treatment significantly outweigh the risk of a major hemorrhage." | 8.82 | Risk of hemorrhagic stroke with aspirin use: an update. ( Gorelick, PB; Weisman, SM, 2005) |
| "To determine the cardiovascular and coronary risk thresholds at which aspirin for primary prevention of coronary heart disease is safe and worthwhile." | 8.81 | Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. ( Ghahramani, P; Jackson, PR; Ramsay, LE; Sanmuganathan, PS; Wallis, EJ, 2001) |
| "The most widely studied and prescribed antiplatelet agent for the prevention of stroke and other serious vascular events among high vascular risk patients is aspirin." | 8.80 | Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. ( Dunbabin, DW; Hankey, GJ; Sudlow, CL, 2000) |
| "Nonsteroidal antiinf lammatory drugs (NSAIDs) remain the mainstay of the pharmacologic management for relieving osteoarthritis pain, and low-dose aspirin is often prescribed to osteoarthritis patients who are at high risk of cardiovascular disease (CVD)." | 8.31 | Interactions of Nonsteroidal Antiinflammatory Drugs and Aspirin and Risk of Cardiovascular Disease in Patients With Osteoarthritis. ( Lane, NE; Lei, G; Li, X; Wei, J; Zeng, C; Zhang, Y, 2023) |
| "To evaluate the association between CDS tools and racial and sex disparities in the aspirin use, blood pressure control, cholesterol management, and smoking cessation (ABCS) care quality metrics among smaller primary care practices." | 8.31 | Differences in Use of Clinical Decision Support Tools and Implementation of Aspirin, Blood Pressure Control, Cholesterol Management, and Smoking Cessation Quality Metrics in Small Practices by Race and Sex. ( Atem, FD; Balasubramanian, BA; Marino, M; Roberts, MM; Wells, R, 2023) |
| "To evaluate the association between aspirin use during first pregnancy and later maternal cardiovascular risk." | 8.12 | Association between aspirin use during pregnancy and cardiovascular risk factors 2-7 years after delivery: The nuMoM2b Heart Health Study. ( Bairey Merz, N; Barnes, S; Catov, J; Chung, JH; Greenland, P; Grobman, W; Haas, D; Hoffman, M; Levine, LD; McNeil, R; Mercer, B; Parker, CB; Saade, G; Shanks, A; Silver, RM; Simhan, H; Theilen, LH; Thorsten, V; Varagic, J; Wapner, R, 2022) |
| "The US Preventive Services Task Force (USPSTF) is updating its 2016 recommendation on the use of aspirin for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC)." | 8.12 | Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Modeling Study for the US Preventive Services Task Force. ( Dehmer, SP; Evans, CV; Guirguis-Blake, JM; Maciosek, MV; O'Keefe, LR; Perdue, LA, 2022) |
| "Patients with diabetes and no obstructive coronary artery disease (CAD) as assessed by coronary angiography (CAG) are frequently treated with aspirin and statins." | 8.12 | Statin but not aspirin treatment is associated with reduced cardiovascular risk in patients with diabetes without obstructive coronary artery disease: a cohort study from the Western Denmark Heart Registry. ( Bøtker, HE; Heide-Jørgensen, U; Maeng, M; Olesen, KKW; Sørensen, HT; Thim, T; Thomsen, RW, 2022) |
| "This study aimed to investigate the cost-effectiveness of low-dose rivaroxaban plus aspirin versus aspirin alone for patients with stable cardiovascular diseases in the Taiwan setting." | 8.02 | Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases. ( Chang, WT; Chen, ZC; Chou, CC; Lee, MC; Liao, CT; Strong, C; Toh, HS; Wu, WS; Yu, T, 2021) |
| "Patients taking low-dose aspirin to prevent cardiovascular disease (CVD) may also benefit from a reduced risk of colorectal cancer (CRC)." | 8.02 | Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis. ( De Caterina, R; Krucien, N; Marsh, K; Seo, J; Soriano Gabarró, M; Tervonen, T; Vora, P; Wissinger, U, 2021) |
| "Aspirin reduced the risks of MACCE and cancer without increasing the bleeding risk in elderly Koreans with hypertension, T2DM, or dyslipidemia." | 7.96 | Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea. ( Jung, M; Lee, S, 2020) |
| " Among current therapies, low-dose aspirin has been shown to reduce cardiovascular thrombosis." | 7.96 | A Pathophysiologic Primary Prevention Review of Aspirin Administration to Prevent Cardiovascular Thrombosis. ( Burchiel, S; Eaton, RP; Schade, DS, 2020) |
| "Several clinical trials reported that clopidogrel was superior to aspirin in secondary stroke prevention by reducing the risk of major adverse cardiovascular events (MACE)." | 7.91 | Aspirin better than clopidogrel on major adverse cardiovascular events reduction after ischemic stroke: A retrospective nationwide cohort study. ( Chan, L; Chen, YC; Hsu, CY; Hu, CJ; Lin, CL; Muo, CH; Vidyanti, AN; Wu, D, 2019) |
| "Whether the benefits of aspirin for the primary prevention of cardiovascular disease (CVD) outweigh its bleeding harms in some patients is unclear." | 7.91 | Personalized Prediction of Cardiovascular Benefits and Bleeding Harms From Aspirin for Primary Prevention: A Benefit-Harm Analysis. ( Choi, YH; Grey, C; Harwood, M; Jackson, R; Kerr, A; Mehta, S; Poppe, K; Pylypchuk, R; Selak, V; Wells, S; Wu, B, 2019) |
| "A significant proportion of patients discontinue their aspirin in the time approaching a breast or colorectal cancer-specific death." | 7.91 | End-of-life prescribing of aspirin in patients with breast or colorectal cancer. ( Barron, TI; Bennett, K; Brown, C; Cranfield, F; Murphy, L; Sharp, L; Smith, A; Visvanathan, K, 2019) |
| "Many prognostic models for cardiovascular risk can be used to estimate aspirin's absolute benefits, but few bleeding risk models are available to estimate its likely harms." | 7.91 | Predicting Bleeding Risk to Guide Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Cohort Study. ( Grey, C; Harwood, M; Jackson, R; Kerr, A; Mehta, S; Poppe, K; Pylypchuk, R; Selak, V; Wells, S; Wu, B, 2019) |
| "Despite the known protective cardiovascular effect of aspirin, former studies identified its prior exposure to an acute coronary syndrome (ACS) as an independent risk factor for adverse events." | 7.88 | Prior exposure to aspirin in acute coronary syndrome patients: a cardiovascular risk marker or a predictor of adverse outcome? A contemporary data of a national registry. ( Belo, A; Correia, J; Morais, J; Ruivo, C; Sá, FM; Santos, LG, 2018) |
| "Our findings suggest that a cumulative aspirin dosage of more than 88,900 mg daily was associated with a reduced risk of breast cancer in women with diabetes." | 7.85 | Low-Dose Aspirin Reduces Breast Cancer Risk in Women with Diabetes: A Nationwide Retrospective Cohort Study in Taiwan. ( Chiou, JY; Huang, CN; Kornelius, E; Lai, YR; Lo, SC; Peng, CH; Yang, YS, 2017) |
| "Elderly, hospitalized coronary artery disease patients on regular aspirin treatment were enrolled from January 2014 to September 2016." | 7.85 | Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease. ( Chen, XH; Feng, XR; Fu, SW; He, XQ; Liang, WY; Liu, ML; Liu, WW; McCaffrey, TA; Zhang, JW, 2017) |
| "Adjusted survival curves showed that the usage of aspirin was not associated with ischemic stroke, hospitalization for bleeding events, cardiovascular mortality or all-cause mortality, however, it was significantly associated with renal failure." | 7.85 | Different impact of aspirin on renal progression in patients with predialysis advanced chronic kidney disease with or without previous stroke. ( Chang, HR; Hsiao, KC; Huang, JY; Hung, TW; Lee, CT; Liaw, YP, 2017) |
| "In the SMILE-4 study, zofenopril + acetyl salicylic acid (ASA) was more effective than ramipril + ASA on 1-year prevention of major cardiovascular events (MACE) in patients with acute myocardial infarction complicated by left ventricular dysfunction." | 7.83 | Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients. ( Ambrosio, G; Ambrosioni, E; Borghi, C; Novo, S; Omboni, S; Vinereanu, D, 2016) |
| "Evidence indicates that aspirin is effective for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC) but also increases the risk for gastrointestinal (GI) and cerebral hemorrhages." | 7.83 | Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force. ( Dehmer, SP; Flottemesch, TJ; LaFrance, AB; Maciosek, MV; Whitlock, EP, 2016) |
| "The USPSTF recommends initiating low-dose aspirin use for the primary prevention of CVD and CRC in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years." | 7.83 | Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. ( Bibbins-Domingo, K, 2016) |
| "This model demonstrates that increased use of rivaroxaban in inadequately-managed NVAF patients could avoid 456 081 non-fatal ischemic strokes (IS) and 76 975 cardiovascular deaths over 10 years in Japan." | 7.83 | Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan. ( Briere, JB; Evers, T; Hori, M; Ikeda, S; Koretsune, Y; Matsuda, S; Montouchet, C; Okumura, K; Rossi, B; Ruff, L; Watanabe-Fujinuma, E, 2016) |
| "To investigate the impact of blood type, functional polymorphism (T-1676C) of the COX-1 gene promoter, and clinical factors on the development of peptic ulcer during cardiovascular prophylaxis with low-dose aspirin." | 7.80 | Impact of blood type, functional polymorphism (T-1676C) of the COX-1 gene promoter and clinical factors on the development of peptic ulcer during cardiovascular prophylaxis with low-dose aspirin. ( Chen, A; Chen, HP; Chen, WC; Hsu, PI; Kao, SS; Kuo, CH; Lai, KH; Peng, NJ; Tsay, FW; Tseng, HH; Wang, PY, 2014) |
| "To examine the association between cardioprotective use of low-dose aspirin and the risk of recurrent gout attacks among gout patients." | 7.80 | Low-dose aspirin use and recurrent gout attacks. ( Chaisson, C; Chen, C; Choi, H; Hunter, DJ; Neogi, T; Zhang, Y, 2014) |
| "To examine the relationship between aspirin intake and early age-related macular degeneration (AMD) among an Asian population." | 7.79 | Is aspirin intake associated with early age-related macular degeneration? The Singapore Indian Eye Study. ( Cheung, GC; Cheung, N; Mitchell, P; Tay, WT; Wang, JJ; Wong, TY, 2013) |
| "Considerable evidence suggests that aspirin has a chemopreventive effect on colorectal cancer (CRC)." | 7.79 | The association between low-dose aspirin use and the incidence of colorectal cancer: a nationwide cohort study. ( Chen, JS; Chiou, MJ; Huang, WK; Kuo, CF; Lin, YC; See, LC; Yang, TS; Yu, KH, 2013) |
| "Patients with established coronary artery disease (CAD) are likely to receive a combination of aspirin, a statin, and blood pressure (BP)-lowering agents." | 7.79 | The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease. ( Bots, ML; Grobbee, DE; Lafeber, M; Nathoe, H; Spiering, W; van der Graaf, Y; Visseren, FL, 2013) |
| "Little is known about how discontinuation of low-dose aspirin therapy after peptic ulcer bleeding affects patient mortality or acute cardiovascular events." | 7.79 | Discontinuation of low-dose aspirin therapy after peptic ulcer bleeding increases risk of death and acute cardiovascular events. ( Bottai, M; Derogar, M; Lu, Y; Lundell, L; Orsini, N; Sadr-Azodi, O; Sandblom, G, 2013) |
| "To determine whether regular aspirin use is associated with a higher risk for developing age-related macular degeneration (AMD) by using analyzed data from a 15-year prospective cohort." | 7.79 | The association of aspirin use with age-related macular degeneration. ( Liew, G; Mitchell, P; Rochtchina, E; Wang, JJ; Wong, TY, 2013) |
| "To characterize the clinical presentation of a cohort of patients with coronary artery disease (CAD) and aspirin reactions." | 7.79 | Characterization of aspirin allergies in patients with coronary artery disease. ( Feng, CH; Stevenson, DD; White, AA, 2013) |
| "Aspirin is an antiplatelet drug widely used for the prevention of cardiovascular disease; however, it is known to increase bleeding events." | 7.78 | Impact of platelet reactivity on long-term clinical outcomes and bleeding events in Japanese patients receiving antiplatelet therapy with aspirin. ( Higashi, T; Horiuchi, H; Ikeda, T; Kawato, M; Kimura, T; Kita, T; Kondo, H; Shirakawa, R; Tabuchi, A; Takahashi, K; Tamura, T; Taniguchi, R; Toma, M; Watanabe, H; Watanabe, S; Yamane, K; Yoshikawa, Y, 2012) |
| "A previously healthy 60-year-old man receiving aspirin for primary prevention of cardiovascular disease presented with hemoptysis after 1 week of treatment for his back pain with diclofenac." | 7.77 | Hemoptysis under diclofenac and antiplatelet doses of aspirin. ( Yiannakopoulou, EC, 2011) |
| "To examine the effect of proton pump inhibitors on adverse cardiovascular events in aspirin treated patients with first time myocardial infarction." | 7.77 | Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Grove, EL; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Olesen, JB; Selmer, C; Torp-Pedersen, C, 2011) |
| "The authors investigated the use of warfarin at hospital discharge in 557 consecutive patients, mean age 76 years, with nonvalvular atrial fibrillation (AF) at a university hospital." | 7.76 | Association of warfarin use with CHADS(2) score in 441 patients with nonvalvular atrial fibrillation and no contraindications to warfarin. ( Aronow, WS; Bakerywala, S; Desai, HV; Gandhi, K; Laimuanpuii, J; Peterson, SJ; Sharma, M, 2010) |
| "High-dose aspirin (≥500 mg daily) reduces long-term incidence of colorectal cancer, but adverse effects might limit its potential for long-term prevention." | 7.76 | Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. ( Algra, A; Elwin, CE; Meade, TW; Norrving, B; Rothwell, PM; Warlow, CP; Wilson, M, 2010) |
| "To assess the prognosis of patients presenting with an acute coronary syndrome (ACS) despite chronic clopidogrel therapy (CCT)." | 7.75 | Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy. ( Bonello, L; De Labriolle, A; Kent, KM; Lemesle, G; Pichard, AD; Roy, P; Satler, LF; Steinberg, DH; Suddath, WO; Torguson, R; Waksman, R, 2009) |
| "Although different populations were examined for the incidence of aspirin resistance, the frequency and related risk factors for aspirin resistance in patients with metabolic syndrome have not been reported yet." | 7.74 | The frequency of aspirin resistance and its risk factors in patients with metabolic syndrome. ( Agacdiken, A; Baytugan, NZ; Kahraman, G; Kilic, T; Komsuoglu, B; Sahin, T; Ural, D; Ural, E, 2007) |
| "Blood levels of long-chain n-3 fatty acids were associated with decreased risk of colorectal cancer among men not using aspirin." | 7.74 | Blood levels of long-chain polyunsaturated fatty acids, aspirin, and the risk of colorectal cancer. ( Campos, H; Hall, MN; Li, H; Ma, J; Sesso, HD; Stampfer, MJ; Willett, WC, 2007) |
| "A goal of the Women's Health Study was to evaluate the balance of benefits and risks of low-dose aspirin in the primary prevention of stroke in healthy women." | 7.74 | CON: Should aspirin be used in all women older than 65 years to prevent stroke? ( Buring, JE, 2007) |
| " The aims of the present study were: to verify the incidence of Normal Weight Obese (NWO) syndrome; to evaluate by PINI the effect of 8 weeks acetyl salicylic (100 mg/die) and atorvastatin (10 mg/die) combined treatment on chronic inflammation in 52 selected HD patients." | 7.74 | Anti-inflammatory effects of combined treatment with acetyl salicylic acid and atorvastatin in haemodialysis patients affected by Normal Weight Obese syndrome. ( De Angelis, S; De Lorenzo, A; Di Daniele, N; Di Renzo, L; Miani, N; Noce, A; Tozzo, C, 2008) |
| "The aim of this study was to evaluate the relationship of obesity, leptin, insulin resistance and C-reactive protein (CRP) with coronary heart disease (CHD) risk factors in patients with Type 2 diabetes mellitus (DM) with CHD compared with those with Type 2 DM without CHD." | 7.73 | Plasma leptin concentration in patients with Type 2 diabetes: relationship to cardiovascular disease risk factors and insulin resistance. ( Abdella, NA; Al Jebely, S; Al Mohammedi, H; Al Ozairi, ES; Mojiminiyi, OA; Moussa, MA; Zaki, M, 2005) |
| "There have been no randomized trials of cardioprotective therapy after acute myocardial infarction in patients with chronic kidney disease who should be largely eligible for aspirin (acetylsalicylic acid; ASA) and beta-blockers (BB) as a base of therapy." | 7.71 | Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. ( Borzak, S; Garg, M; Hudson, MP; Manley, HJ; McCullough, PA; Sandberg, KR, 2002) |
| "To analyse the incidence and factors influencing the occurrence of UGIB in patients taking low-dose aspirin for the prevention of cardiovascular diseases outside clinical trials." | 7.71 | Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. ( Arroyo, MT; Ferreira, IJ; Lanas, A; Serrano, P, 2002) |
| " Using a nested case-control design, we measured urinary 11-dehydro thromboxane B2 levels, a marker of in vivo thromboxane generation, in 488 cases treated with aspirin who had myocardial infarction, stroke, or cardiovascular death during 5 years of follow-up and in 488 sex- and age-matched control subjects also receiving aspirin who did not have an event." | 7.71 | Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. ( Eikelboom, JW; Hirsh, J; Johnston, M; Weitz, JI; Yi, Q; Yusuf, S, 2002) |
| " It is generally accepted that in aspirin-induced asthma (AIA) the bronchospasm is provoked by inhibition of prostaglandin synthesis with overproduction of cysteinyl leukotrienes." | 7.71 | [Tolerability of Asacard--controlled-release aspirin and aspirin-induced asthma]. ( Bochenek, G; Gicquel, M; Nizankowska-Mogilnicka, E; Swierczyńska, M; Szczeklik, A; Vivet, P, 2002) |
| "To identify the clinical and radiologic features of intracerebral hemorrhage (ICH) in aspirin users." | 7.70 | Aspirin-associated intracerebral hemorrhage: clinical and radiologic features. ( Chan, YL; Kay, R; Lam, WW; Mok, V; Tang, A; Wong, KS; Woo, J, 2000) |
| "This self-matched control study aimed to compare the efficiency of two different regimens of active treatment: aspirin in low (100 mg daily) versus intermediate (500 mg daily) doses in abolishing angiotensin-converting enzyme inhibitor (ACEI)-induced cough." | 7.70 | Intermediate but not low doses of aspirin can suppress angiotensin-converting enzyme inhibitor-induced cough. ( Fisman, EZ; Grossman, E; Motro, M; Nosrati, I; Shemesh, J; Tenenbaum, A, 2000) |
| "Terutroban is a specific TP receptor antagonist with antithrombotic, antivasoconstrictive, and antiatherosclerotic properties, which may be of interest for the secondary prevention of ischemic stroke." | 6.74 | Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with ( Amarenco, P; Bousser, MG; Chamorro, A; Fisher, M; Ford, I; Fox, K; Hennerici, MG; Mattle, HP; Rothwell, PM, 2009) |
| "Current acetylsalicylic acid (ASA) dosing algorithms for the prevention of secondary thrombotic events in acute coronary syndrome (ACS) patients are inconsistent and lack sufficient data support." | 6.48 | Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature. ( Berger, JS; Katona, B; Maya, J; Mwamburi, M; Ranganathan, G; Sallum, RH; Xu, Y, 2012) |
| "Paralleling the rise in obesity, the cardiometabolic syndrome is a rapidly growing health problem in the United States." | 6.45 | Utility of aspirin therapy in patients with the cardiometabolic syndrome and diabetes. ( Gardner, DW; Gardner, M; Lastra, G; Manrique, C; Palmer, J; Sowers, JR, 2009) |
| "Aspirin is an effective antithrombocyte agent, the efficiency and safety of which has been demonstrated by numerous studies." | 6.43 | [The modern view on the use of aspirin for the primary prophylaxis of cardiovascular diseases in women]. ( Arablinskiĭ, AV; Zakharov, OV, 2006) |
| " The data reported in the literature do not however enable any evidenced-based decision on dosing for the diabetic population with numerous cardiovascular risks." | 6.41 | [Prevention of cardiovascular diseases in type 2 diabetes with aspirin]. ( Duly-Bouhanick, B; Guilloteau, G; Hadjadj, S; Menard, S; Plun-Favreau, J; Soares-Barbosa, S, 2001) |
| "Aspirin was also associated with significantly fewer reinfarctions and strokes." | 6.38 | Aspirin in chronic cardiovascular disease and acute myocardial infarction. ( Hennekens, CH, 1990) |
| "Aspirin has been convincingly shown to reduce stroke and death in men with transient ischemic attacks (it may possibly be beneficial to women also), myocardial infarction and death in patients with unstable angina, thromboembolic complications associated with artificial heart valves in patients receiving oral anticoagulants (although gastrointestinal bleeding is prohibitive with this combination), and thrombotic occlusion of silicone rubber arteriovenous cannulae in uremic patients undergoing hemodialysis." | 6.15 | Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis. ( Harker, LA, 1986) |
| "Aspirin is an essential drug in the prevention of atherosclerotic cardiovascular disease (ASCVD)." | 5.91 | Appropriateness of aspirin use among diabetic patients in primary prevention of atherosclerotic cardiovascular diseases: an analysis of the ASSOS study. ( Basaran, O; Celik, O; Cil, C; Demirci, E; Dogan, V; Kaya, C; Kırıs, T; Memic Sancar, K; Orscelik, O; Resulzade, MM; Tanık, VO, 2023) |
| " Inflammation contributes to this risk but the role of lipid mediators, with central roles in inflammation, in HIV infection remain to be established; further aspirin reduces CVD risk in the general population through production of some of these anti-inflammatory lipid mediators, but they have not been studied in PWH." | 5.69 | Pro-inflammatory and pro-resolving lipid mediators of inflammation in HIV: effect of aspirin intervention. ( Aberg, JA; Brown, TT; Dalli, J; Funderburg, N; Gupta, A; Hunt, PW; Kitch, D; Moisi, D; O'Brien, MP; Shivakoti, R; Tien, PC, 2023) |
| "Aspirin and atorvastatin could play a role in targeting HIV-associated inflammation." | 5.69 | An open label randomized controlled trial of atorvastatin versus aspirin in elite controllers and antiretroviral-treated people with HIV. ( Baker, JV; Gorelick, RJ; Krishnan, S; Laidlaw, E; Lisco, A; Manion, M; Migueles, SA; Mystakelis, HA; Poole, A; Rupert, A; Sereti, I; Welker, JL; Wilson, E, 2023) |
| "In this post hoc secondary analysis of the ADAPTABLE randomized clinical trial, enteric-coated aspirin was not associated with significantly higher risk of myocardial infarction, stroke, or death or with lower bleeding risk compared with uncoated aspirin, regardless of dose, although a reduction in bleeding with enteric-coated aspirin cannot be excluded." | 5.69 | Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial. ( Benziger, CP; Effron, MB; Farrehi, PM; Girotra, S; Gupta, K; Harrington, RA; Hernandez, AF; Jain, SK; Jones, WS; Knowlton, KU; Marquis-Gravel, G; Muñoz, D; Pepine, CJ; Polonsky, TS; Re, RN; Roe, MT; Rothman, RL; Sleem, A; Stebbins, A; Whittle, J; Wruck, LM, 2023) |
| "Class 1 obesity is associated with enhanced platelet activation in response to AA in patients on dual antiplatelet therapy." | 5.62 | Residual platelet reactivity in low-dose aspirin-treated patients with class 1 obesity. ( Eichelberger, B; Gremmel, T; Kopp, CW; Lee, S; Panzer, S, 2021) |
| " The Management of Aspirin-induced Gastrointestinal Complications (MAGIC) study clarified the rates of major CV and bleeding events with long-term use of aspirin in patients with prior CV diseases in real-world clinical practice." | 5.56 | Major cardiovascular and bleeding events with long-term use of aspirin in patients with prior cardiovascular diseases: 1-year follow-up results from the Management of Aspirin-induced Gastrointestinal Complications (MAGIC) study. ( Goto, S; Hiraishi, H; Ikeda, Y; Okada, Y; Origasa, H; Shimada, K; Sugano, K; Uchiyama, S; Uemura, N, 2020) |
| " Low-dose aspirin is of proven benefit in the secondary prevention of myocardial infarction (MI) and stroke in people with pre-existing CVD." | 5.51 | Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiov ( Dumbleton, J; Fitzmaurice, D; Fraser, SD; Fuat, A; Gallagher, H; Griffith, KE; Hawkey, CJ; Henderson, RA; Lord, J; Lown, M; Maishman, T; Moore, MV; Roderick, PJ; Stevens, P; Stevenson, D; Taal, MW; Whitehead, A, 2022) |
| "A polypill that includes key medications associated with improved outcomes (aspirin, angiotensin-converting-enzyme [ACE] inhibitor, and statin) has been proposed as a simple approach to the secondary prevention of cardiovascular death and complications after myocardial infarction." | 5.51 | Polypill Strategy in Secondary Cardiovascular Prevention. ( Alonso Garcia, A; Andres, V; Barczi, G; Baviera, M; Beghi, E; Bejot, Y; Bhatt, DL; Bueno, H; Castellano, JM; Colivicchi, F; Collier, T; Cordero, A; Di Fusco, SA; Doehner, W; Domingo-Fernández, A; Ecarnot, F; Fernandez Alvira, JM; Fernandez Ferro, J; Fernandez-Ortiz, A; Foresta, A; Fuster, V; Ibañez, B; Kasprzak, M; Linhart, A; Lopez, N; Lozano, I; Lubanda, JC; Marin Ortuño, F; Merkely, B; Meyer, A; Ojeda-Fernandez, L; Owen, R; Perel, P; Pocock, SJ; Ponikowski, P; Proietti, M; Quesada, AJ; Rodriguez-Manero, M; Roncaglioni, MC; Sanchez, PL; Schiele, F; Schoos, MM; Simon, T; Van de Werf, F; Vazquez Rodriguez, JM; Vivas, D, 2022) |
| "Aspirin has been associated with reduced incidence and mortality of colorectal and a few other cancers." | 5.48 | Does low-dose aspirin use for cardiovascular disease prevention reduce colorectal cancer deaths? A comparison of two cohorts in the Florence district, Italy. ( Barchielli, A; Manneschi, G; Mantellini, P; Miccinesi, G; Orso, F; Puliti, D; Ventura, L; Zappa, M, 2018) |
| "HPR-aspirin was persistent 75days later in 36% patients." | 5.43 | High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction. ( Dillinger, JG; Drouet, L; Henry, P; Saeed, A; Sideris, G; Silberman, SM; Sollier, CB; Spagnoli, V; Voicu, S, 2016) |
| "In warfarin-treated patients, each 5% LVEF decrement significantly increased the stroke risk (adjusted hazard ratio, 1." | 5.43 | Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial. ( Anker, SD; Buchsbaum, R; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Teerlink, JR; Thompson, JL, 2016) |
| "Diabetes mellitus has been associated with a substantially increased risk of both first and recurrent atherothrombotic events, which makes aspirin therapy of potential value in these subjects." | 5.43 | Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus. ( Angiolillo, DJ; Capodanno, D, 2016) |
| "Background We aimed to evaluate the age-dependent effect of ticagrelor monotherapy after 3-month dual-antiplatelet therapy (DAPT) versus ticagrelor-based 12-month DAPT on major bleeding and cardiovascular events in patients with acute coronary syndrome." | 5.41 | Age-Dependent Effect of Ticagrelor Monotherapy Versus Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events: A Post Hoc Analysis of the TICO Randomized Trial. ( Ahn, CM; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BG; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Shin, DH, 2021) |
| "Evidence regarding using acetylsalicylic acid (aspirin) for the prevention of cardiovascular (CV) events in patients with diabetes mellitus (DM) is inconsistent." | 5.41 | Acetylsalicylic Acid (Aspirin) for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ( Cheema, AN; Eckstein, J; Lam, A; Liu, S, 2023) |
| "Considering MACEs, myocardial infarction, all kinds of stroke, ischemic stroke, and major bleeding, low-dose aspirin plus rivaroxaban 2." | 5.41 | Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis. ( Chen, X; Jiang, L; Liu, C; Su, J; Zheng, N; Zhong, J, 2023) |
| "The appropriate dose of aspirin to lower the risk of death, myocardial infarction, and stroke and to minimize major bleeding in patients with established atherosclerotic cardiovascular disease is a subject of controversy." | 5.41 | Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. ( Ahmad, FS; Alikhaani, JD; Anderson, RD; Antman, EM; Bell, DS; Benziger, CP; Berdan, LG; Bradley, SM; Brown, LS; Campbell, JR; Carton, TW; Crenshaw, DL; Curtis, LH; Davidson, DR; DeWalt, DA; Edgley, K; Effron, MB; Farrehi, P; Fintel, DJ; Fonarow, GC; Ford, DE; Girotra, S; Goldberg, YH; Gregoire, KC; Gupta, K; Hammill, BG; Handberg, EM; Harrington, RA; Harris, DF; Haynes, K; Hernandez, AF; Hess, R; Jain, SK; Jones, WS; Kaushal, R; Kho, AN; Knowlton, KU; Kraschnewski, JL; Kripalani, S; Manning, BR; Marcus, GM; Marquis-Gravel, G; Masoudi, FA; McClay, JC; McCormick, TE; McTigue, KM; Merritt, JG; Modrow, MF; Mulder, H; Muñoz, D; Nauman, E; Paranjape, A; Pencina, MJ; Pepine, CJ; Polonsky, TS; Qualls, LG; Re, RN; Riley, D; Robertson, HR; Roe, MT; Roger, VL; Rothman, RL; Sharlow, AG; Shenkman, EA; VanWormer, JJ; Waitman, LR; Whittle, J; Wruck, LM; Zemon, DN; Zhou, L, 2021) |
| "Aspirin treatment decreased 8-OHdG levels (P < 0." | 5.35 | Low-dose aspirin prevents age-related endothelial dysfunction in a mouse model of physiological aging. ( Boulanger, E; Bulckaen, H; Corman, B; Creusy, C; Garçon, G; Gaxatte, C; Gosset, P; Prévost, G; Puisieux, F; Robitaille, G; Roquet, V; Shirali, P, 2008) |
| "In patients without an established indication for oral anticoagulation after successful TAVR, a treatment strategy including rivaroxaban at a dose of 10 mg daily was associated with a higher risk of death or thromboembolic complications and a higher risk of bleeding than an antiplatelet-based strategy." | 5.34 | A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. ( Baldus, S; Dangas, GD; De Backer, O; Gilard, M; Giustino, G; Guimarães, AHC; Gullestad, L; Herrmann, HC; Kini, A; Mack, M; Makkar, RR; Mehran, R; Möllmann, H; Moreno, R; Schäfer, U; Seeger, J; Søndergaard, L; Tchétché, D; Thomitzek, K; Tijssen, JGP; Valgimigli, M; van Amsterdam, RGM; Volkl, AA; von Lewinski, D; Vranckx, P; Welsh, RC; Wildgoose, P; Windecker, S; Wöhrle, J; Zazula, A, 2020) |
| " In a randomized, double-blind, placebo-controlled trial of 85 recently bereaved participants, we determined whether β-blocker (metoprolol 25 mg) and aspirin (100 mg) reduce cardiovascular risk markers and anxiety, without adversely affecting bereavement intensity." | 5.34 | The effect of metoprolol and aspirin on cardiovascular risk in bereavement: A randomized controlled trial. ( Bartrop, R; Buckley, T; Dent, J; Fethney, J; Havyatt, J; McKinley, S; Mihailidou, AS; Morel-Kopp, MC; Prigerson, HG; Spinaze, M; Tofler, GH; Ward, C; Whitfield, V, 2020) |
| "5 mg twice daily plus aspirin was associated with a significantly lower incidence of the composite outcome of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or death from cardiovascular causes than aspirin alone." | 5.34 | Rivaroxaban in Peripheral Artery Disease after Revascularization. ( Anand, SS; Bauersachs, RM; Berkowitz, SD; Bonaca, MP; Brodmann, M; Capell, WH; Debus, ES; Diao, L; Diaz, R; Fanelli, F; Gudz, I; Haskell, LP; Hess, CN; Hiatt, WR; Jaeger, N; Kittelson, JM; Krievins, DK; Mátyás, L; Muehlhofer, E; Nehler, MR; Pap, AF; Patel, MR, 2020) |
| "5 mg twice daily) plus aspirin (100 mg daily) versus placebo plus aspirin in patients with diabetes mellitus versus without diabetes mellitus in preventing major vascular events." | 5.34 | Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial. ( Anand, SS; Avezum, A; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Connolly, SJ; Diaz, R; Eikelboom, JW; Fox, KAA; Lewis, BS; Maggioni, AP; Probstfield, J; Ryden, L; Shestakovska, O; Steg, PG; Szarek, M; Verma, S; Widimský, P; Yusuf, S, 2020) |
| "Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy." | 5.34 | Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. ( Ahn, CM; Cho, DK; Cho, JY; Cho, S; Cho, YH; Choi, D; Her, AY; Hong, BK; Hong, MK; Hong, SJ; Jang, Y; Jeon, DW; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Kwon, H; Nam, CM; Shin, DH; Suh, Y; Yoo, SY; Yun, KH, 2020) |
| "Among patients undergoing TAVI who did not have an indication for oral anticoagulation, the incidence of bleeding and the composite of bleeding or thromboembolic events at 1 year were significantly less frequent with aspirin than with aspirin plus clopidogrel administered for 3 months." | 5.34 | Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. ( Baan, J; Brouwer, J; Buysschaert, I; Chan Pin Yin, DRPP; De Bruyne, B; Delewi, R; Dubois, CLF; Ferdinande, B; Frambach, P; Hermanides, RS; Holvoet, W; Kelder, JC; Nijenhuis, VJ; Peper, J; Rensing, BJWM; Roosen, J; Schotborgh, CE; Stella, PR; Swaans, MJ; Ten Berg, JM; Thielen, FWF; Timmers, L; Toušek, P; van 't Hof, AWJ; van der Harst, P; Van Der Heyden, JAS; van der Kley, F; van Houwelingen, GK; Veenstra, L, 2020) |
| "Adding rivaroxaban to aspirin in patients with stable atherosclerotic disease reduces the recurrence of cardiovascular disease (CVD) but increases the risk of major bleeding." | 5.30 | Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. ( Alings, M; Berkowitz, SD; Bosch, J; de Vries, TI; Dorresteijn, JAN; Dyal, L; Eikelboom, JW; Fox, KAA; van der Graaf, Y; Visseren, FLJ; Westerink, J, 2019) |
| " In patients with prior coronary artery disease or peripheral arterial disease the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial revealed that compared with acetylsalicylic acid alone, dual pathway inhibition with low-dose rivaroxaban (2." | 5.30 | Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. ( Coppens, M; Eikelboom, JWA; Weitz, JI, 2019) |
| "Ticlopidine is an antiplatelet agent that has been proven efficacious in preventing vascular events in patients with a history of vasculopathy." | 5.30 | Ticlopidine-associated pancytopenia: implications of an acetylsalicylic acid alternative. ( Armstrong, PW; Brown, NE; Gill, S; Majumdar, S, 1997) |
| "In patients with stable coronary artery disease, addition of rivaroxaban to aspirin lowered major vascular events, but increased major bleeding." | 5.27 | Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. ( Anand, SS; Avezum, AA; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Connolly, SJ; Cook Bruns, N; Dagenais, G; Dans, AL; Dyal, L; Eikelboom, JW; Felix, C; Fox, KAA; Guzik, TJ; Ha, JW; Hori, M; Keltai, K; Lanas, F; Lisheng, L; Lonn, E; Maggioni, AP; Metsarinne, K; O'Donnell, M; Parkhomenko, AN; Torp-Pedersen, C; Varigos, JD; Widimsky, P; Yusoff, K; Yusuf, S, 2018) |
| " The combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke (126 [5%] of 2492 vs 174 [7%] of 2504; hazard ratio [HR] 0·72, 95% CI 0·57-0·90, p=0·0047), and major adverse limb events including major amputation (32 [1%] vs 60 [2%]; HR 0·54 95% CI 0·35-0·82, p=0·0037)." | 5.27 | Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. ( Aboyans, V; Alings, M; Anand, SS; Avezum, AA; Bangdiwala, SI; Bhatt, DL; Bosch, J; Branch, K; Chen, E; Commerford, PJ; Connolly, SJ; Diaz, R; Eikelboom, JW; Fox, KAA; Hart, RG; Kakkar, AK; Keltai, K; Leong, DP; Lewis, BS; Lopez-Jaramillo, P; Maggioni, AP; Misselwitz, F; O'Donnell, M; Pogosova, N; Ryden, L; Störk, S; Vanassche, T; Varigos, JD; Vinereanu, D; Widimsky, P; Yusuf, S; Zhu, J, 2018) |
| "In patients with ischaemic stroke at high risk of cerebral haemorrhage, cilostazol was non-inferior to aspirin for the prevention of cardiovascular events, but did not reduce the risk of haemorrhagic stroke." | 5.27 | Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial. ( Ahn, SH; Heo, SH; Hong, KS; Hwang, YH; Jung, JM; Kang, DW; Kim, BJ; Kim, YJ; Kwon, JH; Kwon, SU; Lee, EJ; Lee, J; Lee, JH; Lee, JS; Navarro, JC; Park, JH; Park, JM; Rha, JH; Seo, WK; Sohn, SI; Wong, LKS; Yu, S, 2018) |
| "The Healthy Hearts in the Heartland (H3) study is part of a nationwide effort, EvidenceNOW, seeking to better understand the ability of small primary care practices to improve "ABCS" clinical quality measures: appropriate Aspirin therapy, Blood pressure control, Cholesterol management, and Smoking cessation." | 5.27 | Design of healthy hearts in the heartland (H3): A practice-randomized, comparative effectiveness study. ( Brown, T; Chung, I; Ciolino, JD; Jackson, KL; Kho, AN; Liss, DT; Murakami, L; Persell, SD; Walunas, TL, 2018) |
| " Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear." | 5.27 | Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. ( Adler, A; Armitage, J; Aung, T; Baigent, C; Barton, J; Bodansky, J; Bowman, L; Buck, G; Chen, F; Collins, R; Cox, J; Farmer, A; Haynes, R; Lay, M; Mafham, M; McPherson, R; Murawska, A; Murphy, K; Neil, A; Parish, S; Peto, R; Sammons, E; Simpson, D; Stevens, W; Wallendszus, K; Waters, E; Young, A, 2018) |
| "The use of low-dose aspirin as a primary prevention strategy in older adults resulted in a significantly higher risk of major hemorrhage and did not result in a significantly lower risk of cardiovascular disease than placebo." | 5.27 | Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. ( Abhayaratna, WP; Beilin, LJ; Brauer, D; Cloud, G; Donnan, GA; Eaton, CB; Ernst, ME; Fitzgerald, SM; Grimm, R; Jelinek, M; Johnston, CI; Kirpach, B; Lockery, JE; Mahady, SE; Malik, M; Margolis, KL; McNeil, JJ; Murray, AM; Nelson, MR; Orchard, SG; Radziszewska, B; Reid, CM; Ryan, J; Satterfield, S; Shah, RC; Stocks, N; Storey, E; Tonkin, AM; Trevaks, RE; Williamson, JD; Wolfe, R; Wood, EM; Woods, RL, 2018) |
| "For this industry-independent, double-blind, double-dummy, randomised trial done in one academic hospital in Hong Kong, we screened patients with arthritis and cardiothrombotic diseases who were presenting with upper gastrointestinal bleeding, were on NSAIDs, and require concomitant aspirin." | 5.24 | Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. ( Au, KWL; Chan, FKL; Chan, H; Cheong, PK; Ching, JYL; Kee, KM; Kyaw, MH; Lam, K; Lee, V; Lo, A; Ng, SC; Suen, BY; Tse, YK; Wong, GLH; Wong, VWS; Wu, JCY, 2017) |
| "5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone." | 5.24 | Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. ( Alings, M; Anand, SS; Avezum, A; Bhatt, DL; Bosch, J; Branch, KRH; Chen, E; Commerford, PJ; Connolly, SJ; Cook Bruns, N; Dagenais, GR; Dans, AL; Diaz, R; Eikelboom, JW; Ertl, G; Felix, C; Fox, KAA; Guzik, TJ; Hart, RG; Hori, M; Kakkar, AK; Keltai, M; Kim, JH; Lanas, F; Leong, D; Lewis, BS; Liang, Y; Lonn, EM; Lopez-Jaramillo, P; Maggioni, AP; Metsarinne, KP; Misselwitz, F; O'Donnell, M; Parkhomenko, AN; Piegas, LS; Pogosova, N; Probstfield, J; Ryden, L; Shestakovska, O; Steg, PG; Störk, S; Tonkin, AM; Torp-Pedersen, C; Verhamme, PB; Vinereanu, D; Widimsky, P; Yusoff, K; Yusuf, S; Zhu, J, 2017) |
| "The use of aspirin in subjects with no overt CVD was associated with a neutral effect on all-cause death and a modest lower risk of major cardiovascular events at the price of an increased risk in major bleeding." | 5.22 | Efficacy and Safety of Aspirin for Primary Cardiovascular Risk Prevention in Younger and Older Age: An Updated Systematic Review and Meta-analysis of 173,810 Subjects from 21 Randomized Studies. ( Agnello, F; Buccheri, S; Calderone, D; Capodanno, D; Franchina, G; Greco, A; Ingala, S; Scalia, L, 2022) |
| "To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review on the effectiveness of aspirin to reduce the risk of CVD events (myocardial infarction and stroke), cardiovascular mortality, and all-cause mortality in persons without a history of CVD." | 5.22 | Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. ( Barry, MJ; Cabana, M; Chelmow, D; Coker, TR; Davidson, KW; Davis, EM; Donahue, KE; Jaén, CR; Krist, AH; Kubik, M; Li, L; Mangione, CM; Ogedegbe, G; Pbert, L; Ruiz, JM; Stevermer, J; Tseng, CW; Wong, JB, 2022) |
| "Low-dose aspirin was associated with small absolute risk reductions in major cardiovascular disease events and small absolute increases in major bleeding." | 5.22 | Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. ( Bean, SI; Evans, CV; Guirguis-Blake, JM; Perdue, LA; Senger, CA, 2022) |
| " In patients with established cardiovascular disease, clopidogrel was associated with a 17% relative-risk reduction for nonfatal MI, borderline decreased risk for MACE, and similar risk for all-cause mortality, stroke, and major bleeding compared with aspirin." | 5.22 | Clopidogrel Monotherapy versus Aspirin Monotherapy in Patients with Established Cardiovascular Disease: Systematic Review and Meta-Analysis. ( Diener, HC; Kyriakoulis, IG; Ntaios, G; Sagris, D; Tasoudis, PT, 2022) |
| "The role of aspirin in primary prevention of cardiovascular diseases (CVD) has been extensively evaluated; however, the results provided over the years have been controversial." | 5.22 | Aspirin for Primary Prevention of Cardiovascular Diseases: "WALTZ" with the Evidence. ( Dimitriadis, K; Lazarou, E; Soulaidopoulos, S; Tsioufis, K; Tsioufis, P, 2022) |
| "Aspirin (acetylsalicylic acid, ASA) is inexpensive and is established in preventing cardiovascular disease (CVD) and colorectal adenomas." | 5.22 | Aspirin and omega-3 polyunsaturated fatty acid use and their interaction in cardiovascular diseases and colorectal adenomas. ( Block, RC; Mousa, SA; Wang, IE; Yi, S, 2022) |
| "Aspirin cannot be routinely recommended for the primary prevention of CVD in individuals with CKD as there is no evidence for its benefit but there is an increased risk of bleeding." | 5.22 | Aspirin for the primary prevention of cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. ( Ashton, L; Brunskill, NJ; Burton, JO; Gray, LJ; Major, RW; Pallikadavath, S, 2022) |
| " Whether aspirin may reduce the risk for CVD, death, and kidney failure outcomes is uncertain." | 5.22 | Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. ( Bostom, A; Carpenter, M; Dad, T; Hunsicker, L; Joseph, A; Kusek, JW; Levey, AS; Pfeffer, M; Tighiouart, H; Weiner, DE, 2016) |
| "Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding." | 5.22 | Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016) |
| "In patients with a myocardial infarction more than 1 year previously, treatment with ticagrelor significantly reduced the risk of cardiovascular death, myocardial infarction, or stroke and increased the risk of major bleeding." | 5.20 | Long-term use of ticagrelor in patients with prior myocardial infarction. ( Bansilal, S; Bengtsson, O; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Fish, MP; Goto, S; Hamm, C; Held, P; Im, K; Jensen, EC; Kiss, RG; Magnani, G; Murphy, SA; Nicolau, JC; Oude Ophuis, T; Ruda, M; Sabatine, MS; Spinar, J; Steg, PG; Storey, RF; Theroux, P; Wiviott, SD, 2015) |
| "Prospective data to examine the association of homocysteine with age-related macular degeneration (AMD) are limited." | 5.20 | Prospective study of plasma homocysteine level and risk of age-related macular degeneration in women. ( Buring, JE; Christen, WG; Cook, NR; Ridker, PM, 2015) |
| "International, multicenter, randomized, double-blinded, placebo-controlled trial comparing extended (30-months) thienopyridine vs placebo in patients taking aspirin who completed 12 months of DAPT without bleeding or ischemic events after receiving stents." | 5.20 | Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. ( Cutlip, DE; Darius, H; Driscoll-Shempp, P; Garratt, KN; Gershlick, AH; Iancu, AC; Kandzari, DE; Kereiakes, DJ; Lee, DP; Massaro, JM; Mauri, L; Meredith, IT; Ormiston, J; Simon, DI; Steg, PG; Tanguay, JF; Trebacz, J; Windecker, S; Yeh, RW, 2015) |
| "213 patients with type 2 diabetes mellitus and hypertension were randomized to amlodipine 5 mg, or amlodipine 5 mg + ASA 100 mg for 3 months (Phase A); then, if adequate blood pressure control was reached patients terminated the study; otherwise, amlodipine was up-titrated to 10 mg/day for further 3 months and compared to amlodipine 10 mg + ASA 100 mg (Phase B)." | 5.20 | A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk. ( D'Angelo, A; Derosa, G; Maffioli, P; Mugellini, A; Pesce, RM, 2015) |
| "The current results suggest that continued use of anti-aggregant monotherapy does not increase the risk of overall bleeding or reintervention for patients undergoing transurethral resection of bladder neoplasms and that suspending aspirin before such a procedure is therefore unnecessary." | 5.19 | Risks and complications of transurethral resection of bladder tumor among patients taking antiplatelet agents for cardiovascular disease. ( Bozzini, G; Carmignani, L; Casellato, S; Marenghi, C; Picozzi, S; Ricci, C, 2014) |
| " EC-ASA 325 mg in a secondary cardiovascular disease prevention population taking aspirin 325 mg daily for ≥3 months and at risk for ASA-associated gastric ulcers (GUs)." | 5.19 | PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: results of two 6-month, phase 3 studies. ( Cryer, BL; Eisen, GM; Fort, JG; Goldstein, JL; Lanas, A; Miller, AB; O'Connor, C; Scheiman, JM; Whellan, DJ; Zhang, Y, 2014) |
| "Once-daily, low-dose aspirin did not significantly reduce the risk of the composite outcome of cardiovascular death, nonfatal stroke, and nonfatal myocardial infarction among Japanese patients 60 years or older with atherosclerotic risk factors." | 5.19 | Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. ( Ando, K; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Yamazaki, T; Yokoyama, K, 2014) |
| "Rectal indomethacin has been proven to be effective for prevention of post-ERCP pancreatitis (PEP) but its impact on bleeding after biliary sphincterotomy (BABES) and cardiovascular mortality has not been extensively studied." | 5.19 | Does rectal indomethacin given for prevention of post-ERCP pancreatitis increase bleeding after biliary endoscopic sphincterotomy or cardiovascular mortality?: Post hoc analysis using prospective clinical trial data. ( Patai, Á; Patai, ÁV; Solymosi, N, 2014) |
| "To investigate the prevalent of aspirin resistance (AR) in Chinese stroke patients and its association with recurrent stroke and other vascular events, including cardiovascular disease and death." | 5.17 | Aspirin resistance in Chinese stroke patients increased the rate of recurrent stroke and other vascular events. ( Chi, L; Lin, J; Yi, X; Zhou, Q, 2013) |
| "Aspirin-related peptic ulcers are a common disorder." | 5.16 | Esomeprazole alone compared with esomeprazole plus aspirin for the treatment of aspirin-related peptic ulcers. ( Chen, WC; Ger, LP; Hsu, PI; Lai, KH; Lin, SY; Liu, CP; Mar, GY, 2012) |
| " We aimed to clarify the efficacy of rabeprazole for preventing peptic ulcer, esophagitis, and gastrointestinal symptoms associated with LDA." | 5.16 | Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial. ( Azuma, T; Fujisawa, T; Fujita, T; Hayakumo, T; Inokuchi, H; Kawai, T; Kutsumi, H; Kuwayama, H; Matsubara, Y; Miyaji, H; Murakami, M; Sanuki, T; Terao, S; Yamazaki, Y; Yoshida, S, 2012) |
| "Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed." | 5.16 | Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ, 2012) |
| " In this randomized, open-label, multicenter trial, we compared aspirin (ASA) or fixed low-dose warfarin (WAR) versus low molecular weight heparin (LMWH) for preventing thromboembolism in patients with myeloma treated with thalidomide-based regimens." | 5.15 | Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Caravita, T; Carella, AM; Cavo, M; Cellini, C; Crippa, C; Elice, F; Evangelista, A; Galli, M; Gentilini, F; Magarotto, V; Marasca, R; Montefusco, V; Morabito, F; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Polloni, C; Pulini, S; Ria, R; Romano, A; Rossi, D; Tacchetti, P; Tosi, P; Zamagni, E; Zambello, R, 2011) |
| " For over a decade, aspirin has been prescribed for primary prevention of cardiovascular disease and for patients with the coronary artery disease risk equivalents; yet, there is no substantial evidence of an appropriate risk-benefit ratio to support this practice." | 5.15 | Reconsidering low-dose aspirin therapy for cardiovascular disease: a study protocol for physician and patient behavioral change. ( Folks, B; Leblanc, WG; Pace, WD; Staton, EW, 2011) |
| " Thus, we investigated whether sP-selectin dosage might reflect platelet function in patients with risk factors for or with established cardiovascular diseases and whether its levels can be modulated by aspirin therapy." | 5.14 | Soluble P-selectin as a marker of in vivo platelet activation. ( Ciatti, F; Ferroni, P; Guadagni, F; La Farina, F; Magnapera, A; Martini, F; Riondino, S, 2009) |
| "Famotidine is effective in the prevention of gastric and duodenal ulcers, and erosive oesophagitis in patients taking low-dose aspirin." | 5.14 | Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. ( Bezlyak, V; McCloskey, C; Prasad, R; Taha, AS, 2009) |
| "To test whether alternate-day low-dose aspirin affects incidence of age-related macular degeneration (AMD) in a large-scale randomized trial of women." | 5.14 | Low-dose aspirin and medical record-confirmed age-related macular degeneration in a randomized trial of women. ( Buring, JE; Chew, EY; Christen, WG; Glynn, RJ, 2009) |
| "One hundred and twenty-one consecutive patients with metabolic syndrome were randomized into three groups, receiving 100 mg/day of aspirin, 300 mg/day of aspirin or a placebo, respectively, for 2 weeks." | 5.14 | Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome. ( Adhikari, CM; Gao, XR; Guo, XG; He, XY; Lin, J; Peng, LY; Zhai, YS; Zhang, LY; Zuo, ZY, 2009) |
| "It is uncertain whether aspirin therapy should be continued after endoscopic hemostatic therapy in patients who develop peptic ulcer bleeding while receiving low-dose aspirin." | 5.14 | Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. ( Chan, FK; Ching, JY; Chiu, PW; Lau, JY; Lee, YT; Leung, VK; Sung, JJ; Wong, VW; Wu, JC, 2010) |
| "The Aspirin for Asymptomatic Atherosclerosis trial was an intention-to-treat double-blind randomized controlled trial conducted from April 1998 to October 2008, involving 28,980 men and women aged 50 to 75 years living in central Scotland, free of clinical cardiovascular disease, recruited from a community health registry, and had an ABI screening test." | 5.14 | Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. ( Butcher, I; Fowkes, FG; Fox, KA; Leng, GC; Lowe, GD; Murray, GD; Pell, AC; Price, JF; Sandercock, PA; Stewart, MC, 2010) |
| "It is unknown whether there is an interaction between aspirin and angiotensin receptor blockers on outcomes in patients with heart failure (HF)." | 5.14 | Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. ( Chang, SM; Dunlap, ME; Granger, CB; Johansson, PA; Kosolcharoen, P; McMurray, JJ; Michelson, EL; Murray, DR; Olofsson, B; Pfeffer, MA; Solomon, SD; Swedberg, K; Yusuf, S, 2010) |
| " 25,086 individuals with acute coronary syndromes and intended early PCI were randomly assigned to double-dose (600 mg on day 1, 150 mg on days 2-7, then 75 mg daily) versus standard-dose (300 mg on day 1 then 75 mg daily) clopidogrel, and high-dose (300-325 mg daily) versus low-dose (75-100 mg daily) aspirin." | 5.14 | Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. ( Ajani, AE; Avezum, A; Bassand, JP; Budaj, A; Chrolavicius, S; Di Pasquale, G; Eikelboom, JW; Faxon, DP; Fox, KA; Gao, P; Granger, CB; Jolly, SS; Joyner, CD; Macaya, C; Mehta, SR; Montalescot, G; Niemela, K; Rupprecht, HJ; Steg, PG; Tanguay, JF; White, HD; Widimsky, P; Yusuf, S, 2010) |
| "In patients with an acute coronary syndrome who were referred for an invasive strategy, there was no significant difference between a 7-day, double-dose clopidogrel regimen and the standard-dose regimen, or between higher-dose aspirin and lower-dose aspirin, with respect to the primary outcome of cardiovascular death, myocardial infarction, or stroke." | 5.14 | Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KA; Granger, CB; Jolly, S; Joyner, CD; Mehta, SR; Pogue, J; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2010) |
| "The HOT (Hypertension Optimal Treatment) study randomly assigned participants with diastolic hypertension to aspirin (75 mg) or placebo." | 5.14 | Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. ( Cass, A; Chalmers, J; Gallagher, MP; Jardine, MJ; Lambers Heerspink, HJ; Ninomiya, T; Perkovic, V; Turnbull, F; Zanchetti, A; Zoungas, S, 2010) |
| "To investigate the effect of low-dose aspirin administered in the morning or evening on the rate of discontinuation of prolonged-release nicotinic acid (Niaspan) due to flushing in patients at elevated cardiovascular risk." | 5.13 | Influence of the timing of low-dose aspirin on tolerability of prolonged-release nicotinic acid in patients at elevated cardiovascular risk. ( Alves, JD; Darioli, R; Hostalek, U; Steinhagen-Thiessen, E; Vogt, A, 2008) |
| "The present study suggested benefit of tailored antiplatelet therapy during elective PCI with GP IIb/IIIa antagonist for clopidogrel nonresponders without increased bleeding risk." | 5.13 | Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. ( Alessi, MC; Bali, L; Bonnet, JL; Cuisset, T; Frere, C; Lambert, M; Morange, PE; Moro, PJ; Mouret, JP; Quilici, J, 2008) |
| "Although aspirin has no significant risk on primary endpoints of cardiovascular events and bleeding outcomes in patients with diabetes compared to control, major adverse cardiovascular events (MACE) were significantly lower in the aspirin group." | 5.12 | Benefits and Risks Associated With Aspirin Use in Patients With Diabetes for the Primary Prevention of Cardiovascular Events and Mortality: A Meta-Analysis. ( Gu, Q; Li, X; Ma, H; Niu, H; Wang, R, 2021) |
| " Overall, clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from cardiovascular causes." | 5.12 | Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. ( Berger, PB; Bhatt, DL; Black, HR; Boden, WE; Booth, J; Brennan, DM; Cacoub, P; Cohen, EA; Creager, MA; Easton, JD; Fabry-Ribaudo, L; Flather, MD; Fox, KA; Hacke, W; Haffner, SM; Hamm, CW; Hankey, GJ; Johnston, SC; Mak, KH; Mas, JL; Montalescot, G; Pearson, TA; Steg, PG; Steinhubl, SR; Topol, EJ; Weber, MA, 2006) |
| "We randomly assigned patients who had adenomas removed before study entry to receive placebo (679 patients) or 200 mg (685 patients) or 400 mg (671 patients) of celecoxib twice daily." | 5.12 | Celecoxib for the prevention of sporadic colorectal adenomas. ( Anderson, WF; Bagheri, D; Bertagnolli, MM; Boisserie, F; Burn, J; Chung, DC; Corle, D; Dewar, T; Eagle, CJ; Foley, TR; Gordon, GB; Hawk, ET; Hess, TM; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Solomon, SD; Sylwestrowicz, T; Tang, J; Viner, JL; Wittes, J; Woloj, GM; Zauber, AG, 2006) |
| "The Prevention of Colorectal Sporadic Adenomatous Polyps trial was a randomized, placebo-controlled, double-blind study of the COX-2 inhibitor celecoxib given daily in a single 400-mg dose." | 5.12 | Celecoxib for the prevention of colorectal adenomatous polyps. ( Arber, N; Bhadra, P; Dite, P; Eagle, CJ; Fowler, R; Gerletti, P; Hajer, J; Lechuga, MJ; Levin, B; Macdonald, K; Rácz, I; Rosenstein, RB; Solomon, SD; Spicak, J; Tang, J; Wittes, J; Zauber, AG; Zavoral, M, 2006) |
| "Low-dose aspirin taken every other day helps prevent stroke in women aged 45 years and older, but does not prevent a first myocardial infarction (MI) or cardiovascular death among healthy women." | 5.12 | Aspirin prevents stroke but not MI in women; vitamin E has no effect on CV disease or cancer. ( Buring, JE, 2006) |
| "To determine the cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib." | 5.12 | Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. ( Abramson, SB; Chesebro, JH; Farkouh, ME; Fuster, V; Greenberg, JD; Hochman, JS; Jeger, RV; Kirshner, H; Lay, CL; Matchaba, PT; Mellein, B; Ramanathan, K; Ruland, S; Verheugt, FW, 2007) |
| "Subjects 18 years or older with osteoarthritis, without gastroduodenal ulcer or erosive esophagitis at baseline endoscopy, and a cardiovascular indication for prophylaxis low-dose (81 or 325 mg) aspirin were prescribed open-label aspirin and blindly randomized to celecoxib 200 mg/day or naproxen 500 mg twice daily plus lansoprazole 30 mg once daily." | 5.12 | Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. ( Amer, F; Cryer, B; Goldstein, JL; Hunt, B, 2007) |
| "Low-dose aspirin and diuretics are commonly co-utilized in patients with cardiovascular diseases." | 5.12 | Potential adverse effects of a low-dose aspirin-diuretic combination on kidney function. ( Sweileh, WM, 2007) |
| "The use of aspirin for the prevention of thrombotic complications in polycythemia vera is controversial." | 5.11 | Efficacy and safety of low-dose aspirin in polycythemia vera. ( Barbui, T; Gisslinger, H; Kutti, J; Landolfi, R; Marchioli, R; Patrono, C; Tognoni, G, 2004) |
| "The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study was designed to evaluate the efficacy and safety of clopidogrel plus aspirin versus placebo plus aspirin in patients with established coronary, cerebral, or peripheral arterial disease or in patients with multiple risk factors for atherothrombosis who have not yet sustained an ischemic event." | 5.11 | Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. ( Bhatt, DL; Topol, EJ, 2004) |
| "Randomized trials have shown that low-dose aspirin decreases the risk of a first myocardial infarction in men, with little effect on the risk of ischemic stroke." | 5.11 | A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. ( Buring, JE; Cook, NR; Gaziano, JM; Gordon, D; Hennekens, CH; Lee, IM; Manson, JE; Ridker, PM, 2005) |
| "During a 1-year treatment period, simvastatin, 20 mg/d, produced a sustained reduction of approximately one quarter in low-density lipoprotein cholesterol levels, with no evidence of toxicity, and aspirin, 100 mg/d, did not substantially increase the risk for a major bleeding episode." | 5.11 | First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. ( Altmann, P; Armitage, J; Baigent, C; Baxter, A; Cairns, HS; Collins, R; Foley, RN; Frighi, V; Kourellias, K; Landray, M; Leaper, C; Ratcliffe, PJ; Rogerson, M; Scoble, JE; Tomson, CR; Warwick, G; Wheeler, DC, 2005) |
| "We randomly assigned patients with transient ischemic attack or stroke caused by angiographically verified 50 to 99 percent stenosis of a major intracranial artery to receive warfarin (target international normalized ratio, 2." | 5.11 | Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. ( Benesch, CG; Chaturvedi, S; Chimowitz, MI; Frankel, MR; Hertzberg, VS; Howlett-Smith, H; Jovin, TG; Kasner, SE; Levine, SR; Lynn, MJ; Romano, JG; Sila, CA; Stern, BJ, 2005) |
| "We performed a randomized, double-blind, multicenter study to test the efficacy of triflusal (600 mg/d) versus aspirin (325 mg/d) for prevention of vascular events in patients with stroke or transient ischemic attack (Triflusal versus Aspirin in Cerebral Infarction Prevention [TACIP])." | 5.10 | Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. ( Alvarez-Sabín, J; Ferro, JM; Jiménez, MD; Lago, A; Matías-Guiu, J; Melo, T; Torres, F, 2003) |
| "To assess the tolerability of rofecoxib compared with naproxen for treatment of osteoarthritis." | 5.10 | Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. ( Dixon, ME; Geba, GP; Johansson, G; Lisse, JR; Mollen, AJ; Perlman, M; Polis, AB; Schechtman, J; Shoemaker, JR; Skalky, CS, 2003) |
| "These associations between self-selected aspirin use and CVD risk factors increase the likelihood of residual confounding and emphasize the need for large-scale randomized trials, such as the ongoing Women's Health Study, to detect reliably the most plausible small to moderate effects of aspirin in the primary prevention of stroke and CVD-related death." | 5.09 | Self-selected posttrial aspirin use and subsequent cardiovascular disease and mortality in the physicians' health study. ( Buring, JE; Cook, NR; Hebert, PR; Hennekens, CH; Manson, JE, 2000) |
| "0001) after adjustment for age, aspirin use, smoking, physical activity, body mass index, and history of angina, hypertension, and high cholesterol." | 5.09 | Alcohol consumption and risk of coronary heart disease by diabetes status. ( Ajani, UA; Buring, JE; Gaziano, JM; Hennekens, CH; Liu, S; Lotufo, PA; Manson, JE, 2000) |
| "Antiplatelet therapy with aspirin and systematic anticoagulation with warfarin reduce cardiovascular morbidity and mortality after myocardial infarction when given alone." | 5.08 | Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. ( , 1997) |
| "To evaluate the efficacy of low-dose aspirin in the primary prevention of myocardial infarction among patients with chronic stable angina." | 5.07 | Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. ( Buring, JE; Gaziano, JM; Hennekens, CH; Manson, JE; Ridker, PM, 1991) |
| "Per 1200 persons taking aspirin for primary prevention for 5 years, there will be 4 fewer MACEs, 3 fewer ischaemic strokes, 3 more intracranial haemorrhages and 8 more major bleeding events." | 5.05 | A comparison of contemporary versus older studies of aspirin for primary prevention. ( Ebell, MH; Moriarty, F, 2020) |
| "Our review indicated that aspirin use in CKD patients had no prevention effect on cardiovascular events and no statistically significant reduction in risk of cardiovascular or all-cause mortality, with a significant increased risk of minor bleeding and renal events." | 5.05 | Is there a cardiovascular protective effect of aspirin in chronic kidney disease patients? A systematic review and meta-analysis. ( He, Y; Li, M; Lu, H; Qu, B; Wu, H; Wu, L, 2020) |
| " Older studies on aspirin for primary prevention were positive or neutral as to the primary ischemic endpoint (often represented by MACE), but the reduction in nonfatal ischemic events seemed largely counterbalanced by an increase in bleeding events." | 5.05 | Aspirin for primary cardiovascular prevention: why the wonder drug should not be precipitously dismissed. ( Aimo, A; De Caterina, R, 2020) |
| " In this review, we discuss the possible repurposing of drugs approved for cardiovascular diseases, such as β-blockers, angiotensin converting enzyme inhibitors (ACE-Is), angiotensin II receptor blockers (ARBs), statins, aspirin, cardiac glycosides and low-molecular-weight heparins (LMWHs)." | 5.05 | Repurposing of drugs approved for cardiovascular diseases: Opportunity or mirage? ( Camera, M; Castiglioni, L; Gelosa, P; Sironi, L, 2020) |
| "To review the clinical evidence of the effect of aspirin as primary prevention for patients with diabetes mellitus and in healthy elderly." | 5.05 | Role of Aspirin for Primary Prevention in Persons with Diabetes Mellitus and in the Elderly. ( Baliga, RR; Patel, NJ, 2020) |
| "Aspirin was associated with a slight decrease in AMI and ischemic stroke in absolute terms, with no differences in cardiovascular mortality." | 5.05 | Aspirin in primary prevention. Meta-analysis stratified by baseline cardiovascular risk. ( Lobo, M; Masson, G; Masson, W; Molinero, G, 2020) |
| "The safety and efficacy of aspirin for the primary prevention of cardiovascular disease in patients with diabetes mellitus remains controversial." | 5.05 | Aspirin for primary prevention of cardiovascular outcomes in diabetes mellitus: An updated systematic review and meta-analysis. ( Ali, F; Kaluski, E; Khan, MU; Khan, SU; Krasuski, RA; Lone, AN; Mookadam, F; Shahzeb Khan, M; Talluri, S; Ul Abideen Asad, Z, 2020) |
| "The benefits of aspirin for primary prevention of stroke are uncertain." | 5.05 | Aspirin for primary prevention of stroke in individuals without cardiovascular disease-A meta-analysis. ( Costello, M; Ferguson, J; Gorey, S; Halloran, MO; Judge, C; Loughlin, E; Murphy, R; Nolan, A; O'Canavan, M; O'Donnell, MJ; Ruttledge, S, 2020) |
| "The Aspirin Myocardial Infarction Study (AMIS) was a multicenter, randomized, double-blind, placebo-controlled trial of 1." | 5.05 | The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group. ( , 1980) |
| "The role for aspirin in cardiovascular primary prevention remains controversial, with potential benefits limited by an increased bleeding risk." | 5.01 | Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis. ( Roddick, AJ; Zheng, SL, 2019) |
| " The 2017 European Society of Cardiology (ESC)/European Society for Vascular Surgery (ESVS) guidelines recommend for patients with asymptomatic CAAD ≥60% the use of aspirin 75 to 100 mg once daily or clopidogrel 75 mg once daily at the exception of patient at very high bleeding risk." | 5.01 | Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. ( Aboyans, V; Anand, SS; Bauersachs, R; Bosch, J; Debus, ES; Eikelboom, JW; Mazzolai, L; Nehler, M; Nikol, S; Pastori, D; Patel, MR; Ricco, JB; Tanguay, JF; Verhamme, P; Violi, F, 2019) |
| " Similarly, in patients with stable coronary artery disease, two-thirds of whom had a history of myocardial infarction, dual antithrombotic therapy with very-low-dose rivaroxaban and aspirin also resulted in improved ischaemic outcomes." | 5.01 | Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease? ( Geisler, T; Kristensen, SD; Storey, RF; Sumaya, W, 2019) |
| "In the context of contemporary primary prevention guidelines, the effect of aspirin on myocardial infarction risk was significantly attenuated, whereas its major bleeding and hemorrhagic stroke complications were retained." | 5.01 | A Meta-Analysis of Aspirin for the Primary Prevention of Cardiovascular Diseases in the Context of Contemporary Preventive Strategies. ( Khan, B; Khan, SA; Latham, SB; Rao, SV; Shah, R, 2019) |
| "The recent trials confirm that, in modern primary prevention populations, the cardiovascular benefit of aspirin is small and comes with a clear increase in risk for bleeding." | 5.01 | Aspirin for primary prevention of cardiovascular disease: is it time to move on? ( Knickelbine, T; Miedema, MD, 2019) |
| "While the use of aspirin in the secondary prevention of cardiovascular (CVD) is well established, aspirin in primary prevention is not systematically recommended because the absolute CV event reduction is similar to the absolute excess in major bleedings." | 4.95 | Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk. ( Battistoni, A; Coluccia, R; De Caterina, R; Gallo, G; Volpe, M, 2017) |
| "Aspirin reduces the risk of nonfatal myocardial infarction and stroke, and the risk of colorectal cancer." | 4.95 | Aspirin for Primary Prevention. ( Owens, DK; Richman, IB, 2017) |
| " With respect to intracranial hemorrhage, aspirin + clopidogrel yielded worse outcomes than 7 treatments, including placebo, apixaban, aspirin, aspirin + dipyridamole, cilostazol, clopidogrel, and dabigatran (OR, 2." | 4.95 | The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis. ( Chang, S; Chang, Y; Lu, S; Sun, Q; Zhang, Y, 2017) |
| "The Dual Antiplatelet Therapy (DAPT) study demonstrated that DAPT beyond 1-year after drug-eluting stent (DES) implantation, as compared with aspirin therapy alone, significantly reduced the risk of major cardiovascular and cerebrovascular events, which was mainly driven by the large risk reduction for myocardial infarction (MI)." | 4.95 | Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: A comparison between the DAPT study and 9 other trials evaluating DAPT duration. ( Kimura, T; Morimoto, T; Natsuaki, M; Shiomi, H; Toyota, T, 2017) |
| "The available evidence demonstrates that the use of clopidogrel plus aspirin in people at high risk of cardiovascular disease and people with established cardiovascular disease without a coronary stent is associated with a reduction in the risk of myocardial infarction and ischaemic stroke, and an increased risk of major and minor bleeding compared with aspirin alone." | 4.95 | Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. ( Bellesini, M; Donadini, MP; Middeldorp, S; Squizzato, A; Takeda, A, 2017) |
| "Aspirin is indicated for primary and secondary prevention of cardiovascular diseases (CVD) by major guidelines." | 4.95 | Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. ( Bliden, K; Chaudhary, R; Gurbel, PA; Sharma, T; Tantry, U, 2017) |
| "To evaluate the risk for serious bleeding with regular aspirin use in cardiovascular disease (CVD) primary prevention." | 4.93 | Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force. ( Burda, BU; Evans, CV; Guirguis-Blake, JM; Whitlock, EP; Williams, SB, 2016) |
| "To conduct systematic reviews of aspirin and 1) total cancer mortality and incidence in persons eligible for primary prevention of cardiovascular disease (CVD) and 2) colorectal cancer (CRC) mortality and incidence in persons at average CRC risk." | 4.93 | Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the U.S. Preventive Services Task Force. ( Anderson, ML; Buist, DS; Burda, BU; Chubak, J; Kamineni, A; Whitlock, EP; Williams, SB, 2016) |
| "We searched articles describing the use aspirin for secondary prevention of stroke and cardiovascular events in PubMed published until May 2016." | 4.93 | Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events. ( Bliden, KP; Byun, S; Chaudhary, R; Gurbel, PA; Tantry, US, 2016) |
| "To review advances in the individualized assessment for ASCVD and bleeding risk, and to provide an update of the randomized clinical trial evidence that examined the use of aspirin for primary prevention (primarily for ASCVD, and secondarily for colorectal cancer)." | 4.93 | Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease: Advances in Diagnosis and Treatment. ( Manson, JE; Mora, S, 2016) |
| "The net clinical benefit of aspirin in primary prevention is uncertain as the reduction in occlusive events needs to be balanced against the increase in gastro-intestinal and cerebral bleedings." | 4.93 | Aspirin use for primary prevention in elderly patients. ( Terrosu, P, 2016) |
| "A literature search was conducted using the terms cardiovascular disease, aspirin, diabetes mellitus to identify trials of patients with diabetes who received aspirin for primary prevention of CVD." | 4.93 | Aspirin for primary prevention of cardiovascular disease in patients with diabetes: A meta-analysis. ( Berlie, HD; Garwood, CL; Kokoska, LA; Wilhelm, SM, 2016) |
| " We focus on 4 commonly used cardiovascular drug classes: aspirin, statins, beta-blockers, and angiotensin-converting enzyme inhibitors given to patients after myocardial infarction." | 4.91 | Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care. ( Julian, DG; Pocock, SJ; Rossello, X, 2015) |
| "This review highlights practical aspects related to aspirin therapy in cardiovascular diseases, specifically, the benefits and hazards in different clinical settings." | 4.91 | A Balanced View of Efficacy and Safety of Aspirin in Cardiovascular Diseases. ( Brugada, P; Casado-Arroyo, R; Lanas, A, 2015) |
| " Moreover, the results of clinical studies have shown that the antiplatelet drug aspirin reduces the incidence of vascular events and colorectal cancer." | 4.90 | Role of platelets in inflammation and cancer: novel therapeutic strategies. ( Alberti, S; Dovizio, M; Guillem-Llobat, P; Patrignani, P, 2014) |
| " pylori) infection, nonsteroidal anti-inflammatory drugs (NSAID) or low dose aspirin (ASA) use significantly and independently increased the risk for the development of peptic ulcer disease." | 4.90 | Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: old question new insights. ( Gargallo, CJ; Lanas, A; Sostres, C, 2014) |
| "The efficacy of aspirin in primary and secondary prevention of cardiovascular diseases has been convincingly demonstrated." | 4.90 | Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin. ( Bliden, KP; Contino, CJ; Franzese, CJ; Gesheff, MG; Gurbel, PA; Rafeedheen, R; Tantry, US, 2014) |
| "Prescribed in patients with a history of myocardial infarction, stroke, transient ischemic attack, coronary intervention or bypass surgery, aspirin is one of the medications most commonly used in the secondary prevention of cardiovascular diseases." | 4.90 | PA32540 for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers. ( Adams, S; Duffy, D; Rooney, B; Whellan, DJ, 2014) |
| "Once-daily, low-dose aspirin is a cornerstone in the prophylaxis and treatment of cardiovascular diseases." | 4.89 | Identifying determinants of variability to tailor aspirin therapy. ( Dragani, A; Pagliaccia, F; Rocca, B, 2013) |
| " Of 2 treatment trials meeting inclusion criteria, 1 large trial (n = 3350) showed that low-dose aspirin did not prevent CVD events in persons with a screen-detected low ABI but may have increased the risk for major bleeding events." | 4.89 | The ankle-brachial index for peripheral artery disease screening and cardiovascular disease prediction among asymptomatic adults: a systematic evidence review for the U.S. Preventive Services Task Force. ( Johnson, ES; Lin, JS; Olson, CM; Whitlock, EP, 2013) |
| " The existence of a common pathophysiologic background is also suggested by the evidence that aspirin, low-molecular weight heparin (LMWH) and warfarin are recommended for the prevention and treatment of both venous and arterial thrombosis." | 4.88 | Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update. ( Ageno, W; Di Minno, G; Di Minno, MN; Prandoni, P; Tufano, A, 2012) |
| "Although the addition of aspirin to clopidogrel resulted in small relative reductions in major cardiovascular events, myocardial infarction, and stroke, it also resulted in a relative increase in major bleeding events." | 4.88 | Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis. ( He, J; Lu, J; Qin, YY; Wei, X; Wu, MJ; Xu, JF; Ye, XF; Zhou, YH, 2012) |
| "To evaluate the efficacy and safety of the polypill for prevention of cardiovascular disease (CVD) and stroke and to present literature related to the polypill components (statin, aspirin, antihypertensive) for primary prevention of CVD and stroke." | 4.88 | A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke. ( Carey, KM; Comee, MR; Donovan, JL; Kanaan, AO, 2012) |
| "The meta-analysis results consistently indicate that, in individuals at low risk for cardiovascular disease, aspirin reduces the risk of MI at the cost of an increase in major bleeding and produces a modest nominally significant reduction in total mortality." | 4.88 | The aspirin controversy in primary prevention. ( Eikelboom, JW; Raju, NC, 2012) |
| "In those who have already survived myocardial infarction (MI) or stroke, or have had a transient ischaemic episode (TIA), daily low dose aspirin (ASA) reduces the risk of recurrences by an amount that greatly exceeds the risk of serious bleeding (secondary prevention)." | 4.88 | Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents. ( Meade, T, 2012) |
| " In absolute terms, these relative risks indicate that for every 10,000 diabetic patients treated with aspirin, 109 MACE may be prevented at the expense of 19 major bleeding events (with the caveat that the relative risk for the latter is not statistically significant)." | 4.87 | Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. ( Butalia, S; Ghali, WA; Leung, AA; Rabi, DM, 2011) |
| "Aspirin is used to prevent ischemic stroke and other types of cardiovascular disease." | 4.87 | Gender differences in the primary prevention of stroke with aspirin. ( Adelman, EE; Brown, DL; Lisabeth, L, 2011) |
| "The benefit of aspirin to prevent cardiovascular events in subjects without clinical cardiovascular disease relative to the increased risk of bleeding is uncertain." | 4.87 | Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. ( Baker, GS; Berger, JS; Hiatt, WR; Krantz, MJ; Lala, A, 2011) |
| " Recent randomized controlled trials in patients who are at moderately increased risk of ulcers have shown that the proton pump inhibitor esomeprazole (the S-isomer of racemic omeprazole) reduces the gastroduodenal ulcer incidence by approximately 70-85% and the gastrointestinal bleeding risk by as much as 90%." | 4.87 | Reducing the risk of gastroduodenal ulcers with a fixed combination of esomeprazole and low-dose acetyl salicylic acid. ( Yeomans, ND, 2011) |
| "The aim of this systematic review and meta-analysis was to understand whether continued aspirin therapy is a risk factor for bleeding complications after ultrasound-guided biopsy of the prostate." | 4.87 | Transrectal ultrasound-guided prostate biopsies in patients taking aspirin for cardiovascular disease: A meta-analysis. ( Bozzini, G; Carmignani, L; Gaeta, M; Negri, E; Pavesi, M; Picozzi, S; Ricci, C, 2011) |
| " Aspirin and, more recently, clopidogrel are among the most important treatments of cardiovascular diseases." | 4.86 | [Long-term use of oral antiplatelet therapy: from studies to practice]. ( Helft, G, 2010) |
| "To review the guideline recommendations on aspirin use in primary prevention of cardiovascular diseases." | 4.86 | [Primary prevention of cardiovascular disease with aspirin: what do the guidelines say?]. ( Brotons Cuixart, C; Moral Peláez, I, 2010) |
| "Aspirin (ASA) use for secondary prevention in patients with cardiovascular (CV) disease is well established through its beneficial effects on the reduction of myocardial infarction, ischemic stroke and CV mortality." | 4.86 | Aspirin for the prevention of cardiovascular morbidity. ( Haider, B; Kaluski, E; Klapholz, M; Maher, J; Sanchez-Ross, M; Waller, AH, 2010) |
| " Monotherapy with either aspirin or clopidogrel, reduces the rate of stroke, myocardial infarction, and cardiovascular death in patients suffering from peripheral arterial disease." | 4.85 | Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy? ( Milani, RV, 2009) |
| "To determine the benefits and harms of taking aspirin for the primary prevention of myocardial infarctions, strokes, and death." | 4.85 | Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. ( Ko, S; Miller, T; Wolff, T, 2009) |
| " If alternative interventions, such as smoking cessation or low-dose aspirin treatment were included in the analysis, statin therapy became less cost-effective." | 4.85 | Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium. ( De Laet, C; Franco, O; Neyt, M; Ramaekers, D; Van Brabandt, H, 2009) |
| "The benefits of aspirin therapy in reducing the subsequent risk of myocardial infarction, stroke and death is well documented in individuals with cardiovascular disease including those with diabetes mellitus (DM)." | 4.85 | Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitus. ( Soran, H; Williams, S; Younis, N, 2009) |
| "The present review focuses on the roles of thromboxane A2 (TxA2) in arterial thrombosis, atherogenesis, vascular stent-related ischemic events and renal proteinuria." | 4.85 | Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. ( Alberts, P; Bounameaux, H; Fontana, P; Mann, J; Sakariassen, KS; Sorensen, AS, 2009) |
| " The ratios of RRs comparing the benefit of aspirin among patients with diabetes compared with patients without diabetes for mortality, myocardial infarction, and ischemic stroke were 1." | 4.85 | Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. ( Aggarwal, NR; Albuquerque, FN; Calvin, AD; Elamin, MB; Erwin, PJ; Fernandez-Balsells, MM; Geske, JB; Lampropulos, JF; Montori, VM; Murad, MH; Shi, Q; Smith, SA, 2009) |
| "To determine the effectiveness and safety of thienopyridine derivatives (ticlopidine and clopidogrel) versus aspirin for preventing serious vascular events (stroke, myocardial infarction (MI) or vascular death) in patients at high risk, and specifically in patients with a previous TIA or ischaemic stroke." | 4.85 | Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. ( Hankey, GJ; Mason, G; Maurice, JB; Sudlow, CL; Wedderburn, CJ, 2009) |
| "Theoretical models suggest that a polypill containing low-dose aspirin, three blood pressure-lowering drugs at half dose and a potent statin, administered to a large proportion of the population at risk for cardiovascular events, could reduce ischemic heart disease and strokes by over 80%." | 4.85 | Polypill: the evidence and the promise. ( Lonn, E; Yusuf, S, 2009) |
| " We used the search terms metabolic syndrome, abdominal obesity, waist circumference, insulin resistance, cardiovascular disease, prediabetes, diabetes, treatment, prevention, aspirin, hypertension, cholesterol, atherogenic dyslipidemia, lifestyle therapy, diet, and exercise." | 4.84 | A practical "ABCDE" approach to the metabolic syndrome. ( Bansal, S; Blaha, MJ; Blumenthal, RS; Defilippis, AP; Golden, SH; Rouf, R, 2008) |
| "Aspirin is the best chemoprevention agent for colorectal cancer risk reduction despite the fact that the evidence for a decrease in mortality is weak." | 4.84 | Cyclooxygenase-2 inhibitors in colorectal cancer prevention: counterpoint. ( Hunt, R; Jankowski, J, 2008) |
| " I have selected 4 translations in the field of vascular neurology in which I have been involved in different respects: (1) the translation of results from men to women, taking the example of aspirin which, in primary prevention, decreases the risk of myocardial infarction in men and the risk of cerebral infarction in women, the reason for this sex difference being so far unknown; (2) the 'inverse translational research', from bedside to bench, taking the example of the disease we have identified--CADASIL--and showing how the study of one patient and his family led to the identification of a gene, Notch3, so far unknown in humans and to the discovery of its key role in the physiology of vascular smooth muscle cells; (3) the translation from individual case reports to multidisciplinary trials taking the example of hemicraniectomy in malignant cerebral infarction and emphasizing the interest in such rare and severe conditions of pooling and reporting the results of randomized clinical trials before the results of individual trials, and (4) the translation from research to practice, emphasizing not the well-known 'evidence to practice gap' but the slippery slope of 'lack of evidence to overpractice', taking the example of patent foramen ovale closure in migraine." | 4.84 | Some translations in vascular neurology. The Johann Jacob Wepfer Award 2008. ( Bousser, MG, 2008) |
| "Aspirin for prevention of colorectal cancer is controversial." | 4.84 | The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. ( Barrowman, N; Code, C; Dubé, C; Lewin, G; Moher, D; Rostom, A; Sampson, M; Tsertsvadze, A, 2007) |
| "Aspirin should be used to treat patients with acute myocardial infarction (MI) and continued indefinitely to reduce vascular death, nonfatal MI, and nonfatal stroke." | 4.84 | Antiplatelet therapy in the treatment of atherothrombotic disease: considering the evidence. ( Aronow, WS, 2007) |
| "Aspirin is recommended as cardiovascular disease prevention in patients with diabetes mellitus." | 4.84 | [Low-dose aspirin in patients with diabete melitus: risks and benefits regarding macro and microvascular complications]. ( Camargo, EG; Gross, JL; Lavinsky, J; Silveiro, SP; Weinert, LS, 2007) |
| "To quantify the impact of clopidogrel plus aspirin on the individual outcomes of death, myocardial infarction, or stroke in patients with established cardiovascular disease, or in patients with multiple risk factors for vascular disease." | 4.84 | Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials. ( Bavry, AA; Bhatt, DL; Duggal, S; Helton, TJ; Kumbhani, DJ; Roukoz, H, 2007) |
| "Clopidogrel has demonstrated improved outcomes for patients with acute coronary syndromes in several large randomized controlled trials." | 4.84 | Clopidogrel: who, when, and how? ( Cannon, CP, 2007) |
| "In secondary prevention among male and female survivors of prior myocardial infarction (MI), occlusive stroke, transient ischemic attack, and other high-risk conditions, long-term use of aspirin confers very similar statistically significant and clinically important reductions in MI, stroke, and cardiovascular death." | 4.84 | Aspirin in the treatment and prevention of cardiovascular disease: current perspectives and future directions. ( Hennekens, CH, 2007) |
| "Aspirin is the main actor in primary and secondary preventive treatments in cardiovascular diseases." | 4.84 | Aspirin and gastrointestinal toxicity. ( Törüner, M, 2007) |
| " Eligible studies were prospective, randomized controlled trials of aspirin therapy in participants without cardiovascular disease that reported data on myocardial infarction (MI), stroke, and cardiovascular mortality." | 4.83 | Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. ( Avanzini, F; Berger, JS; Brown, DL; Pangrazzi, I; Roncaglioni, MC; Tognoni, G, 2006) |
| "Nonopioid analgesics, which include acetaminophen, aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and cyclooxygenase-2 (COX-2)-specific inhibitors (coxibs), are frequently used for the relief of mild-to-moderate pain." | 4.83 | Clinical implications of nonopioid analgesia for relief of mild-to-moderate pain in patients with or at risk for cardiovascular disease. ( Whelton, A, 2006) |
| "This review examines ulcers and gastrointestinal bleeding with low-dose aspirin, focusing on randomized placebo-controlled trials." | 4.83 | Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk? ( Laine, L, 2006) |
| "Ulcer complications associated with the use of NSAIDs, in high-risk patients, are often caused by a failure to identify patients' risk factors, concomitant use of aspirin or multiple NSAIDs, and underutilization of gastroprotective agents." | 4.83 | Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks. ( Chan, FK, 2006) |
| "Acetylsalicylic acid (aspirin) is widely used as antiplatelet therapy for the primary and secondary prevention of cardiovascular diseases." | 4.83 | [Aspirin for primary prevention of cardiovascular diseases in diabetic patients: focus on gender difference and insulin resistance]. ( Legrand, DA; Scheen, AJ, 2006) |
| " Over the 10 to 15 years after clinical diagnosis, tight glycemic control probably reduces the risk for blindness and end-stage renal disease, and aggressive control of hypertension, lipid therapy, and aspirin use reduce cardiovascular events." | 4.82 | Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. ( Donahue, K; Frame, P; Harris, R; Lohr, KN; Rathore, SS; Woolf, SH, 2003) |
| "The following four studies were evaluated: the Coumadin Aspirin Reinfarction Study (CARS); the Combination Hemotherapy and Mortality Prevention (CHAMP) Study; the Warfarin, Aspirin Reinfarction Study (WARIS)-II; the Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT)-2 Study." | 4.82 | [Secondary prevention after acute myocardial infarction: aspirin, warfarin or both?]. ( Landmark, K; Madsen, S; Reikvam, A, 2003) |
| "Among the 55 580 randomized participants (11 466 women), aspirin was associated with a statistically significant 32% reduction in the risk of a first MI and a significant 15% reduction in the risk of all important vascular events, but had no significant effects on nonfatal stroke or vascular death." | 4.82 | An update on aspirin in the primary prevention of cardiovascular disease. ( Eidelman, RS; Hebert, PR; Hennekens, CH; Weisman, SM, 2003) |
| "The increasing burden of cardiovascular diseases in developed, as well as developing countries, underscores the need for the more widespread and appropriate use of aspirin in secondary prevention of occlusive vascular events during acute evolving myocardial infarction (MI) and in primary prevention." | 4.82 | The role of aspirin in cardiovascular diseases--forgotten benefits? ( Hennekens, CH; Williams, A, 2004) |
| "Aspirin, nonsteroidal antiinflammatory drugs (NSAIDs), and cyclooxygenase-2 (COX-2) inhibitors are widely used in patients with rheumatoid arthritis." | 4.82 | Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: possible interactions and implications for treatment of rheumatoid arthritis. ( Buring, JE; Gaziano, JM; Hennekens, CH; Kurth, T, 2004) |
| "The uncertainty of cardioprotection by naproxen has encouraged its combination with aspirin in patients with arthritis and cardiovascular disease." | 4.82 | Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. ( Capone, ML; Di Gregorio, P; Grana, M; Merciaro, G; Patrignani, P; Renda, G; Ricciotti, E; Sciulli, MG; Tacconelli, S, 2005) |
| "In the secondary prevention of cardiovascular, cerebrovascular, and ischemic events, the evidence supports that the benefits of aspirin treatment significantly outweigh the risk of a major hemorrhage." | 4.82 | Risk of hemorrhagic stroke with aspirin use: an update. ( Gorelick, PB; Weisman, SM, 2005) |
| " Aspirin is one of the most prescribed treatments in the prevention of cardiovascular diseases." | 4.82 | [Should we treat all diabetic patients with aspirin in primary prevention?]. ( De Moerloose, P; Philippe, J; Righetti, A, 2005) |
| "Antiplatelet therapy, most notably aspirin, has been well documented to reduce risks of subsequent cardiovascular disease (CVD) in secondary prevention, acute myocardial infarction (MI), acute occlusive stroke, as well as in primary prevention." | 4.81 | Update on aspirin in the treatment and prevention of cardiovascular disease. ( Hennekens, CH, 2002) |
| "To determine the cardiovascular and coronary risk thresholds at which aspirin for primary prevention of coronary heart disease is safe and worthwhile." | 4.81 | Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. ( Ghahramani, P; Jackson, PR; Ramsay, LE; Sanmuganathan, PS; Wallis, EJ, 2001) |
| "Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardial infarction, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation." | 4.81 | Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. ( , 2002) |
| "Aspirin, a potent platelet inhibitor, is widely used in patients with cardiovascular diseases." | 4.80 | [Aspirin and prevention of cardiovascular risk]. ( Gabriel Steg, P; Karila-Cohen, D, 2000) |
| "The most widely studied and prescribed antiplatelet agent for the prevention of stroke and other serious vascular events among high vascular risk patients is aspirin." | 4.80 | Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. ( Dunbabin, DW; Hankey, GJ; Sudlow, CL, 2000) |
| "Randomized trials of aspirin have been conducted in three main populations: patients with evolving acute myocardial infarction (MI), patients with a history of cardiovascular disease and apparently healthy subjects." | 4.80 | Aspirin in the treatment and prevention of cardiovascular disease. ( Buring, JE; Gaziano, JM; Skerrett, PJ, 2000) |
| " In selected patients at high risk of event and low risk of bleeding, especially those undergoing recent and complex coronary revascularization using drug-eluting stents (DES) ("revascularization-driven effect"), DAPT is superior to single antiplatelet therapy with aspirin." | 4.31 | Dual pathway inhibition in atherothrombosis prevention: yes, now we can! ( Bhatt, DL; Biondi-Zoccai, G; Franchi, F; Gaspardone, A; Lavalle, C; Mamas, MA; Romagnoli, E; Severino, P; Summaria, F; Versaci, F, 2023) |
| "Nonsteroidal antiinf lammatory drugs (NSAIDs) remain the mainstay of the pharmacologic management for relieving osteoarthritis pain, and low-dose aspirin is often prescribed to osteoarthritis patients who are at high risk of cardiovascular disease (CVD)." | 4.31 | Interactions of Nonsteroidal Antiinflammatory Drugs and Aspirin and Risk of Cardiovascular Disease in Patients With Osteoarthritis. ( Lane, NE; Lei, G; Li, X; Wei, J; Zeng, C; Zhang, Y, 2023) |
| "Among patients with established cardiovascular disease, the ADAPTABLE trial found no significant differences in cardiovascular events and bleeding rates between 81 mg and 325 mg of aspirin (ASA) daily." | 4.31 | Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE. ( Anderson, RD; Benziger, CP; Bradley, SM; DeWalt, DA; Effron, MB; Farrehi, P; Girotra, S; Gupta, K; Harrington, RA; Hernandez, AF; Jain, SK; Jones, WS; Kim, H; Knowlton, KU; Mehta, H; Muñoz, D; Pepine, CJ; Polonsky, TS; Rothman, RL; Stebbins, A; Whittle, J; Wruck, LM; Zhou, L, 2023) |
| "To evaluate the effects of aspirin in the primary prevention, we evaluated disability grades and mortality after ischemic/hemorrhagic stroke and myocardial infarction (MI)." | 4.31 | Pre-aspirin use has no benefit on the neurological disability and mortality after cardiovascular events: A nation-wide population-based cohort study. ( Kang, MJ; Kim, HS; Kim, JH; Lee, JH; Lim, HS; Park, D; Yoon, SY, 2023) |
| "Aspirin-exacerbated respiratory disease (AERD) consists of chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, and hypersensitivity to aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)." | 4.31 | Association Between Aspirin-Exacerbated Respiratory Disease and Atherosclerotic Cardiovascular Disease: A Retrospective Review of US Claims Data. ( Adame, MJ; Kuo, YF; Raji, M; Shan, Y; Tripple, JW; Zhang, Y, 2023) |
| "To evaluate the association between CDS tools and racial and sex disparities in the aspirin use, blood pressure control, cholesterol management, and smoking cessation (ABCS) care quality metrics among smaller primary care practices." | 4.31 | Differences in Use of Clinical Decision Support Tools and Implementation of Aspirin, Blood Pressure Control, Cholesterol Management, and Smoking Cessation Quality Metrics in Small Practices by Race and Sex. ( Atem, FD; Balasubramanian, BA; Marino, M; Roberts, MM; Wells, R, 2023) |
| "Low-dose acetylsalicylic acid (aspirin) prevents stroke and myocardial infarction in patients with cardiovascular disease (CVD), but whether it should be used for primary CVD prevention in older Chinese adults remains unclear." | 4.12 | The Effect of Aspirin on the Primary Prevention of Major Adverse Cardiac and Cerebrovascular Events in Chinese Older Adults: A Registration Study. ( Sun, R; Sun, X; Zhang, L, 2022) |
| "Cardiovascular disease preventive services (aspirin use, blood pressure control, and smoking-cessation support) are crucial to controlling cardiovascular diseases." | 4.12 | Cardiovascular Disease Preventive Services Among Smaller Primary Care Practices. ( Balasubramanian, BA; Cohen, DJ; Edwards, ST; Lindner, S; Marino, M; McConnell, KJ; Solberg, L; Springer, R; Stange, KC; Ward, R, 2022) |
| "To evaluate the association between aspirin use during first pregnancy and later maternal cardiovascular risk." | 4.12 | Association between aspirin use during pregnancy and cardiovascular risk factors 2-7 years after delivery: The nuMoM2b Heart Health Study. ( Bairey Merz, N; Barnes, S; Catov, J; Chung, JH; Greenland, P; Grobman, W; Haas, D; Hoffman, M; Levine, LD; McNeil, R; Mercer, B; Parker, CB; Saade, G; Shanks, A; Silver, RM; Simhan, H; Theilen, LH; Thorsten, V; Varagic, J; Wapner, R, 2022) |
| "The US Preventive Services Task Force (USPSTF) is updating its 2016 recommendation on the use of aspirin for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC)." | 4.12 | Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Modeling Study for the US Preventive Services Task Force. ( Dehmer, SP; Evans, CV; Guirguis-Blake, JM; Maciosek, MV; O'Keefe, LR; Perdue, LA, 2022) |
| "Patients with diabetes and no obstructive coronary artery disease (CAD) as assessed by coronary angiography (CAG) are frequently treated with aspirin and statins." | 4.12 | Statin but not aspirin treatment is associated with reduced cardiovascular risk in patients with diabetes without obstructive coronary artery disease: a cohort study from the Western Denmark Heart Registry. ( Bøtker, HE; Heide-Jørgensen, U; Maeng, M; Olesen, KKW; Sørensen, HT; Thim, T; Thomsen, RW, 2022) |
| "This study aimed to investigate the cost-effectiveness of low-dose rivaroxaban plus aspirin versus aspirin alone for patients with stable cardiovascular diseases in the Taiwan setting." | 4.02 | Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases. ( Chang, WT; Chen, ZC; Chou, CC; Lee, MC; Liao, CT; Strong, C; Toh, HS; Wu, WS; Yu, T, 2021) |
| "We selected newly diagnosed ischemic stroke patients aged ≥20years who were newly treated with aspirin or clopidogrel from 2003-2010 Korean National Health Insurance Service-National Sample Cohort, a random sample of 2." | 4.02 | Non-persistence with anti-platelet therapy and long-term mortality after ischemic stroke: A nationwide study. ( Cho, B; Choi, HC; Kim, SJ; Kwon, OD; Lee, EJ, 2021) |
| "Acetylsalicylic acid (aspirin) is commonly used for primary and secondary prevention of cardiovascular diseases." | 4.02 | The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection. ( Avramovich, E; Frenkel-Morgenstern, M; Golan-Cohen, A; Gorohovski, A; Green, I; Magen, E; Merzon, E; Vinker, S, 2021) |
| "Patients taking low-dose aspirin to prevent cardiovascular disease (CVD) may also benefit from a reduced risk of colorectal cancer (CRC)." | 4.02 | Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis. ( De Caterina, R; Krucien, N; Marsh, K; Seo, J; Soriano Gabarró, M; Tervonen, T; Vora, P; Wissinger, U, 2021) |
| "Aspirin reduced the risks of MACCE and cancer without increasing the bleeding risk in elderly Koreans with hypertension, T2DM, or dyslipidemia." | 3.96 | Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea. ( Jung, M; Lee, S, 2020) |
| "5 mg rivaroxaban twice daily plus 100 mg aspirin once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for the prevention of cardiovascular events in patients with coronary artery disease and/or peripheral arterial disease." | 3.96 | Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study. ( Joore, M; Petersohn, S; Pouwels, X; Ramaekers, B; Ten Cate-Hoek, A, 2020) |
| "To investigate the long-term clinical benefit of dual antiplatelet therapy with potent P2Y12 inhibitors compared to clopidogrel in patients with acute coronary syndrome (ACS)." | 3.96 | Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients. ( Gager, GM; Hengstenberg, C; Jilma, B; Kolesnik, E; Lang, IM; Prüller, F; Siller-Matula, JM; Toma, A; von Lewinski, D; Wallner, M; Winter, MP, 2020) |
| "Antiplatelet therapy is the mainstay preventive strategy for cardiovascular diseases, and dual antiplatelet therapy comprising aspirin and a P2Y12 inhibitor is the standard treatment for patients who underwent percutaneous coronary intervention." | 3.96 | New methodological approaches for assessing thrombus formation in cardiovascular disease. ( Dahlen, J; Hosokawa, K; Nagasato, T; Ohnishi-Wada, T; Oyamada, C; Sameshima-Kaneko, H, 2020) |
| " Among current therapies, low-dose aspirin has been shown to reduce cardiovascular thrombosis." | 3.96 | A Pathophysiologic Primary Prevention Review of Aspirin Administration to Prevent Cardiovascular Thrombosis. ( Burchiel, S; Eaton, RP; Schade, DS, 2020) |
| " For patients with MINS who are not at high risk of bleeding, physicians should consider initiating dabigatran 110 mg twice daily and low-dose aspirin." | 3.96 | Myocardial injury after non-cardiac surgery: diagnosis and management. ( Devereaux, PJ; Szczeklik, W, 2020) |
| "Several clinical trials reported that clopidogrel was superior to aspirin in secondary stroke prevention by reducing the risk of major adverse cardiovascular events (MACE)." | 3.91 | Aspirin better than clopidogrel on major adverse cardiovascular events reduction after ischemic stroke: A retrospective nationwide cohort study. ( Chan, L; Chen, YC; Hsu, CY; Hu, CJ; Lin, CL; Muo, CH; Vidyanti, AN; Wu, D, 2019) |
| "Whether the benefits of aspirin for the primary prevention of cardiovascular disease (CVD) outweigh its bleeding harms in some patients is unclear." | 3.91 | Personalized Prediction of Cardiovascular Benefits and Bleeding Harms From Aspirin for Primary Prevention: A Benefit-Harm Analysis. ( Choi, YH; Grey, C; Harwood, M; Jackson, R; Kerr, A; Mehta, S; Poppe, K; Pylypchuk, R; Selak, V; Wells, S; Wu, B, 2019) |
| "A significant proportion of patients discontinue their aspirin in the time approaching a breast or colorectal cancer-specific death." | 3.91 | End-of-life prescribing of aspirin in patients with breast or colorectal cancer. ( Barron, TI; Bennett, K; Brown, C; Cranfield, F; Murphy, L; Sharp, L; Smith, A; Visvanathan, K, 2019) |
| "The aim of this study was to investigate the relation between bladder cancer risk and the use of selected drugs for cardiovascular disease (CVD) prevention, such as aspirin, statins, and calcium channel blockers (CCBs)." | 3.91 | Bladder cancer risk in users of selected drugs for cardiovascular disease prevention. ( Bosetti, C; Galfano, A; Guercio, V; La Vecchia, C; Libra, M; Montella, M; Polesel, J; Serraino, D; Tavani, A; Turati, F, 2019) |
| "Acetylsalicylic acid (ASA, aspirin) is a medication widely used for primary and secondary prevention of cardiovascular diseases, which are the leading cause of morbidity and mortality worldwide." | 3.91 | Aspirin for patients undergoing major lung resections: hazardous or harmless?†. ( Messerschmidt, A; Schneider, T; Stamenovic, D, 2019) |
| "Circulating MPA are a robust marker of platelet activity and monocyte inflammation, unaffected by low-dose aspirin, and are significantly elevated in subjects with CVD, particularly those with PAD." | 3.91 | Circulating monocyte-platelet aggregates are a robust marker of platelet activity in cardiovascular disease. ( Allen, N; Barrett, TJ; Berger, JS; Guo, Y; Hochman, JS; Nardi, M; Ramkhelawon, B; Rockman, CB, 2019) |
| "Many prognostic models for cardiovascular risk can be used to estimate aspirin's absolute benefits, but few bleeding risk models are available to estimate its likely harms." | 3.91 | Predicting Bleeding Risk to Guide Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Cohort Study. ( Grey, C; Harwood, M; Jackson, R; Kerr, A; Mehta, S; Poppe, K; Pylypchuk, R; Selak, V; Wells, S; Wu, B, 2019) |
| "Aspirin has been widely used for the prevention of cardiovascular diseases, but its antiplatelet efficiency varies between individuals." | 3.91 | miR-34b-3p May Promote Antiplatelet Efficiency of Aspirin by Inhibiting Thromboxane Synthase Expression. ( Chen, XH; Fu, SW; Liu, ML; Liu, WW; Wang, H, 2019) |
| "Despite the known protective cardiovascular effect of aspirin, former studies identified its prior exposure to an acute coronary syndrome (ACS) as an independent risk factor for adverse events." | 3.88 | Prior exposure to aspirin in acute coronary syndrome patients: a cardiovascular risk marker or a predictor of adverse outcome? A contemporary data of a national registry. ( Belo, A; Correia, J; Morais, J; Ruivo, C; Sá, FM; Santos, LG, 2018) |
| "Aspirin is a commonly used medicine for primary and secondary prevention of cardiovascular diseases." | 3.88 | Aspirin is associated with low oral pH levels and antacid helps to increase oral pH. ( Dilina, N; Ediriweera, DS; Fernando, D; Fernando, I; Kurera, J; Kurukulasuriya, B; Saparamadu, V, 2018) |
| "Clopidogrel plus aspirin is associated with a reduced risk for myocardial infarction and ischemic stroke and an increased risk for major bleeding compared with aspirin alone among patients at high risk for or with an established cardiovascular disease but without a coronary stent." | 3.88 | Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events. ( Bellesini, M; Donadini, MP; Squizzato, A, 2018) |
| "Major bleeding rates were obtained from the PREDICT primary care study, a large New Zealand cohort of people eligible for CVD risk assessment, after excluding those with no other indications for (eg, established CVD) or contraindications/cautions (eg, prior major bleed) to aspirin use." | 3.88 | Are the benefits of aspirin likely to exceed the risk of major bleeds among people in whom aspirin is recommended for the primary prevention of cardiovascular disease? ( Jackson, R; Kerr, A; Poppe, K; Selak, V; Wells, S, 2018) |
| "Our findings suggest that a cumulative aspirin dosage of more than 88,900 mg daily was associated with a reduced risk of breast cancer in women with diabetes." | 3.85 | Low-Dose Aspirin Reduces Breast Cancer Risk in Women with Diabetes: A Nationwide Retrospective Cohort Study in Taiwan. ( Chiou, JY; Huang, CN; Kornelius, E; Lai, YR; Lo, SC; Peng, CH; Yang, YS, 2017) |
| "Elderly, hospitalized coronary artery disease patients on regular aspirin treatment were enrolled from January 2014 to September 2016." | 3.85 | Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease. ( Chen, XH; Feng, XR; Fu, SW; He, XQ; Liang, WY; Liu, ML; Liu, WW; McCaffrey, TA; Zhang, JW, 2017) |
| " Dual antiplatelet therapy or at least aspirin is recommended to be continued considering the relative risk of stent thrombosis especially during the 4 weeks after DES implantation." | 3.85 | Risk of non-cardiac surgery after percutaneous coronary intervention with drug-eluting stents. ( Bahk, JH; Jung, DE; Jung, SA; Kim, WH; Park, SK, 2017) |
| "Adjusted survival curves showed that the usage of aspirin was not associated with ischemic stroke, hospitalization for bleeding events, cardiovascular mortality or all-cause mortality, however, it was significantly associated with renal failure." | 3.85 | Different impact of aspirin on renal progression in patients with predialysis advanced chronic kidney disease with or without previous stroke. ( Chang, HR; Hsiao, KC; Huang, JY; Hung, TW; Lee, CT; Liaw, YP, 2017) |
| "In the SMILE-4 study, zofenopril + acetyl salicylic acid (ASA) was more effective than ramipril + ASA on 1-year prevention of major cardiovascular events (MACE) in patients with acute myocardial infarction complicated by left ventricular dysfunction." | 3.83 | Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients. ( Ambrosio, G; Ambrosioni, E; Borghi, C; Novo, S; Omboni, S; Vinereanu, D, 2016) |
| "A growing body of evidence indicates that use of low-dose aspirin (LDA) reduces the risk of certain adenocarcinomas." | 3.83 | Risk of prostate cancer in low-dose aspirin users: A retrospective cohort study. ( Cancian, M; Cricelli, C; Cricelli, I; Lapi, F; Levi, M; Parretti, D; Simonetti, M; Sobrero, A, 2016) |
| "Evidence indicates that aspirin is effective for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC) but also increases the risk for gastrointestinal (GI) and cerebral hemorrhages." | 3.83 | Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force. ( Dehmer, SP; Flottemesch, TJ; LaFrance, AB; Maciosek, MV; Whitlock, EP, 2016) |
| "The USPSTF recommends initiating low-dose aspirin use for the primary prevention of CVD and CRC in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years." | 3.83 | Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. ( Bibbins-Domingo, K, 2016) |
| "This model demonstrates that increased use of rivaroxaban in inadequately-managed NVAF patients could avoid 456 081 non-fatal ischemic strokes (IS) and 76 975 cardiovascular deaths over 10 years in Japan." | 3.83 | Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan. ( Briere, JB; Evers, T; Hori, M; Ikeda, S; Koretsune, Y; Matsuda, S; Montouchet, C; Okumura, K; Rossi, B; Ruff, L; Watanabe-Fujinuma, E, 2016) |
| "This population-based time series study used administrative health data linked to 45 and Up Study participants with a high risk of cardiovascular disease (CVD) to assess the possible impact of the NPS MedicineWise program on first-time aspirin prescriptions and primary stroke-related hospitalizations." | 3.83 | Using Large-Scale Linkage Data to Evaluate the Effectiveness of a National Educational Program on Antithrombotic Prescribing and Associated Stroke Prevention in Primary Care. ( Bartlett, M; Khan, R; Liu, Z; Moorin, R; Tofler, G; Worthington, J; Zuo, Y, 2016) |
| "This study was conducted to determine whether there is additive benefit of dual-antiplatelet therapy (DAPT) with aspirin (acetylsalicylic acid [ASA]) and clopidogrel compared with ASA monotherapy among patients with symptomatic peripheral arterial disease." | 3.81 | Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease. ( Amsterdam, EA; Anderson, DR; Armstrong, EJ; Bang, H; Freischlag, JA; Laird, JR; Singh, GD; Yeo, KK, 2015) |
| "CYP2C19 genotype and the residual platelet reactivity (RPR) were measured in 361 coronary heart disease patients (male, mean age 69yrs), and the risk of cardiovascular events over a 3-month follow-up was assessed to evaluate the impact of co-administration of esomeprazole during dual antiplatelet therapy with aspirin and clopidogrel." | 3.81 | Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy. ( Akasaka, T; Arima, Y; Hokimoto, S; Kaikita, K; Kumagae, N; Morita, K; Nakagawa, K; Ogawa, H; Oniki, K; Sakamoto, K; Tabata, N; Tsujita, K; Yamamoto, E, 2015) |
| "Patients with cardiovascular disease are frequently on aspirin, which may place them at risk for bleeding during surgical procedures." | 3.81 | Utility of VerifyNow for Point-of-Care Identification of an Aspirin Effect Prior to Emergency Cardiac Surgery. ( Dasgupta, A; Nguyen, AN; Wahed, A; Welsh, KJ, 2015) |
| "Screening of patients with defective genetic variants of UGT1A6 and CYP2C9*3 helps in identifying patients at risk of aspirin induced gastritis." | 3.81 | The Implication of the Polymorphisms of COX-1, UGT1A6, and CYP2C9 among Cardiovascular Disease (CVD) Patients Treated with Aspirin. ( Azreen, NI; Bannur, Z; Darinah, N; Derahman, A; Gunasekaran, OA; Hamidi, H; Jalil, NJ; Kek, TL; Maskon, O; Rafizi, M; Salleh, MZ, 2015) |
| "To investigate the impact of blood type, functional polymorphism (T-1676C) of the COX-1 gene promoter, and clinical factors on the development of peptic ulcer during cardiovascular prophylaxis with low-dose aspirin." | 3.80 | Impact of blood type, functional polymorphism (T-1676C) of the COX-1 gene promoter and clinical factors on the development of peptic ulcer during cardiovascular prophylaxis with low-dose aspirin. ( Chen, A; Chen, HP; Chen, WC; Hsu, PI; Kao, SS; Kuo, CH; Lai, KH; Peng, NJ; Tsay, FW; Tseng, HH; Wang, PY, 2014) |
| "To examine the association between cardioprotective use of low-dose aspirin and the risk of recurrent gout attacks among gout patients." | 3.80 | Low-dose aspirin use and recurrent gout attacks. ( Chaisson, C; Chen, C; Choi, H; Hunter, DJ; Neogi, T; Zhang, Y, 2014) |
| "To examine the relationship between aspirin intake and early age-related macular degeneration (AMD) among an Asian population." | 3.79 | Is aspirin intake associated with early age-related macular degeneration? The Singapore Indian Eye Study. ( Cheung, GC; Cheung, N; Mitchell, P; Tay, WT; Wang, JJ; Wong, TY, 2013) |
| " In addition, patients in the 6 am to 2 pm subgroup were more likely older, white race, and male, with higher rates of home aspirin use and lower rates of obesity." | 3.79 | Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry. ( Antman, EM; Cannon, CP; Foody, JM; Giugliano, RP; Li, S; Mogabgab, O; Sabatine, MS; Wang, TY; Wiviott, SD, 2013) |
| " This adherence was concerned particularly with co-medication in patients diagnosed with hypertension, aspirin prescription in elderly patients and the achievement of target lipid levels following the prescription of statins." | 3.79 | Sex-specific-differences in cardiometabolic risk in type 1 diabetes: a cross-sectional study. ( Hintersteiner, J; Johnson, J; Kamyar, MR; Kautzky, A; Kautzky-Willer, A; Lemmens-Gruber, R; Saukel, J; Stich, K, 2013) |
| "Considerable evidence suggests that aspirin has a chemopreventive effect on colorectal cancer (CRC)." | 3.79 | The association between low-dose aspirin use and the incidence of colorectal cancer: a nationwide cohort study. ( Chen, JS; Chiou, MJ; Huang, WK; Kuo, CF; Lin, YC; See, LC; Yang, TS; Yu, KH, 2013) |
| "Patients with established coronary artery disease (CAD) are likely to receive a combination of aspirin, a statin, and blood pressure (BP)-lowering agents." | 3.79 | The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease. ( Bots, ML; Grobbee, DE; Lafeber, M; Nathoe, H; Spiering, W; van der Graaf, Y; Visseren, FL, 2013) |
| "64%) relative increase in the use of aspirin or warfarin in the population with atrial fibrillation 6 and 12 months after the program, respectively, and in a 1." | 3.79 | Improving cardiovascular disease management in Australia: NPS MedicineWise. ( Bartlett, MJ; Gadzhanova, SV; Roughead, EE, 2013) |
| "Little is known about how discontinuation of low-dose aspirin therapy after peptic ulcer bleeding affects patient mortality or acute cardiovascular events." | 3.79 | Discontinuation of low-dose aspirin therapy after peptic ulcer bleeding increases risk of death and acute cardiovascular events. ( Bottai, M; Derogar, M; Lu, Y; Lundell, L; Orsini, N; Sadr-Azodi, O; Sandblom, G, 2013) |
| "To determine whether regular aspirin use is associated with a higher risk for developing age-related macular degeneration (AMD) by using analyzed data from a 15-year prospective cohort." | 3.79 | The association of aspirin use with age-related macular degeneration. ( Liew, G; Mitchell, P; Rochtchina, E; Wang, JJ; Wong, TY, 2013) |
| "To characterize the clinical presentation of a cohort of patients with coronary artery disease (CAD) and aspirin reactions." | 3.79 | Characterization of aspirin allergies in patients with coronary artery disease. ( Feng, CH; Stevenson, DD; White, AA, 2013) |
| " In the management of aspirin-related uncomplicated peptic ulcers in patients requiring antiplatelet therapies, continuing aspirin plus a powerful proton pump inhibitor is the choice of treatment." | 3.78 | New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment. ( Hsu, PI, 2012) |
| "Thromboxane B2 (TxB2) and particularly 11-dehydrothromboxane B2 (11-dTxB2) are widely used as prognostic risk markers of platelet activation in cardiovascular diseases." | 3.78 | The purification step is not crucial in EIA measurements of thromboxane B2 and 11-dehydrothromboxane B2 in human plasma. ( Alusik, S; Bednar, F; Mottlova, J; Paluch, Z; Sadilkova, L, 2012) |
| "The incidence of postoperative definitive gastric ulcers in Japanese patients receiving ≤100 mg enteric-coated aspirin was 0." | 3.78 | Gastric injury caused by low-dose aspirin therapy in consecutive Japanese patients: a prospective study. ( Akita, S; Akiyama, J; Fukuda, S; Hosaka, S; Kashima, T; Kimura, S; Mizoue, T; Ozawa, N, 2012) |
| "Aspirin is an antiplatelet drug widely used for the prevention of cardiovascular disease; however, it is known to increase bleeding events." | 3.78 | Impact of platelet reactivity on long-term clinical outcomes and bleeding events in Japanese patients receiving antiplatelet therapy with aspirin. ( Higashi, T; Horiuchi, H; Ikeda, T; Kawato, M; Kimura, T; Kita, T; Kondo, H; Shirakawa, R; Tabuchi, A; Takahashi, K; Tamura, T; Taniguchi, R; Toma, M; Watanabe, H; Watanabe, S; Yamane, K; Yoshikawa, Y, 2012) |
| "A previously healthy 60-year-old man receiving aspirin for primary prevention of cardiovascular disease presented with hemoptysis after 1 week of treatment for his back pain with diclofenac." | 3.77 | Hemoptysis under diclofenac and antiplatelet doses of aspirin. ( Yiannakopoulou, EC, 2011) |
| "Aspirin is recommended as preventive therapy in patients with cardiovascular diseases (CVD), diabetes mellitus, and high cardiovascular risk due to multiple risk factors." | 3.77 | A national survey on aspirin patterns of use and persistence in community outpatients in Italy. ( Bianchi, C; Cricelli, C; Filippi, A; Mazzaglia, G; Parazzini, F; Sessa, E, 2011) |
| "To examine the effect of proton pump inhibitors on adverse cardiovascular events in aspirin treated patients with first time myocardial infarction." | 3.77 | Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Grove, EL; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Olesen, JB; Selmer, C; Torp-Pedersen, C, 2011) |
| "We conducted a retrospective cohort study to assess CV outcomes of 9753 patients taking dual antiplatelet therapy of aspirin plus clopidogrel with or without a PPI after hospitalization for acute coronary syndrome (ACS)." | 3.77 | Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome. ( Chen, PF; Hsiao, FY; Huang, WF; Mullins, CD; Tsai, YW; Wen, YW, 2011) |
| "The authors investigated the use of warfarin at hospital discharge in 557 consecutive patients, mean age 76 years, with nonvalvular atrial fibrillation (AF) at a university hospital." | 3.76 | Association of warfarin use with CHADS(2) score in 441 patients with nonvalvular atrial fibrillation and no contraindications to warfarin. ( Aronow, WS; Bakerywala, S; Desai, HV; Gandhi, K; Laimuanpuii, J; Peterson, SJ; Sharma, M, 2010) |
| "The aim of the study was to evaluate the effect of the concomitant treatment with proton-pump inhibitors (PPIs) and clopidogrel on the incidence of stent thrombosis, acute coronary syndrome (ACS) and death in patients who underwent percutaneous coronary intervention (PCI) and stent implantation." | 3.76 | Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. ( Brozovic, I; Farhan, S; Geppert, A; Huber, K; Jarai, R; Siller-Matula, J; Smetana, P; Tentzeris, I; Wojta, J, 2010) |
| "High-dose aspirin (≥500 mg daily) reduces long-term incidence of colorectal cancer, but adverse effects might limit its potential for long-term prevention." | 3.76 | Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. ( Algra, A; Elwin, CE; Meade, TW; Norrving, B; Rothwell, PM; Warlow, CP; Wilson, M, 2010) |
| " The quality of control of diabetes, hypertension or hyperlipidemia and the use of aspirin were assessed in 2914 patients at baseline and after 3,7 years." | 3.75 | ["Diabetes in Germany"(DIG) study. A prospective 4-year-follow-up study on the quality of treatment for type 2 diabetes in daily practice]. ( Benke, I; Hanefeld, M; Köhler, C; Ott, P; Stelzer, J, 2009) |
| "To assess the prognosis of patients presenting with an acute coronary syndrome (ACS) despite chronic clopidogrel therapy (CCT)." | 3.75 | Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy. ( Bonello, L; De Labriolle, A; Kent, KM; Lemesle, G; Pichard, AD; Roy, P; Satler, LF; Steinberg, DH; Suddath, WO; Torguson, R; Waksman, R, 2009) |
| "Encourage men age 45 to 79 years to use aspirin when the potential benefit of a reduction in myocardial infarctions outweighs the potential harm of an increase in gastrointestinal hemorrhage." | 3.75 | Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. ( , 2009) |
| "This study was conducted to compare the risk of recurrent hospitalization for major gastrointestinal (GI) complications (peptic ulcer, bleeding, and perforation) in patients at high GI risk who require ongoing antiplatelet therapy (aspirin [acetylsalicylic acid] or clopidogrel) with or without proton pump inhibitors (PPIs)." | 3.75 | A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding. ( Chang, PY; Chen, PF; Hsiao, FY; Huang, WF; Kuo, KN; Tsai, YW; Wen, YW, 2009) |
| "(1) For patients with acute coronary syndromes who have undergone percutaneous angioplasty and stenting, the best-assessed treatment for preventing relapses is a combination of aspirin and clopidogrel; (2) Prasugrel, an antiplatelet drug belonging the same chemical class as clopidogrel, is authorized in the EU for use in this indication; (3) Clinical evaluation is based on a randomized double-blind trial comparing prasugrel + aspirin versus clopidogrel + aspirin in 13 608 patients with acute coronary syndromes, half of whom were treated for at least 15 months." | 3.75 | Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. ( , 2009) |
| "Sulfinpyrazone1 has long been recognised as a potent uricosuric agent, but has more recently been studied extensively as a platelet inhibitor and antithrombotic agent." | 3.75 | Sulfinpyrazone: a review of its pharmacological properties and therapeutic use. ( Margulies, EH; Sherry, S; White, AM, 1980) |
| "Aspirin has been shown to reduce the number of transient ischemic attacks (TIA), stroke and death in patients with multiple TIA." | 3.75 | Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells. ( Turpie, AG, 1982) |
| "Patients with coronary heart disease (CHD) require long-term therapy with low-dose aspirin (ASA)." | 3.74 | Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention. ( Fendrick, AM; Saini, SD; Scheiman, J; Schoenfeld, P, 2008) |
| "Although evidence suggests that aspirin and celecoxib may reduce the risk of esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus (BE), these drugs can also cause harmful side effects." | 3.74 | Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus. ( Broughton, DE; Gazelle, GS; Hur, C; Nishioka, NS; Ozanne, E; Yachimski, P, 2008) |
| "Previously we studied 298 patients admitted to hospital with symptoms suggestive of an acute myocardial infarction (MI) despite treatment with aspirin, and 70 patients (23." | 3.74 | Variation and importance of aspirin resistance in patients with known cardiovascular disease. ( Haghfelt, T; Jørgensen, B; Korsholm, L; Kristensen, SR; Licht, PB; Mickley, H; Poulsen, TS, 2007) |
| "Although different populations were examined for the incidence of aspirin resistance, the frequency and related risk factors for aspirin resistance in patients with metabolic syndrome have not been reported yet." | 3.74 | The frequency of aspirin resistance and its risk factors in patients with metabolic syndrome. ( Agacdiken, A; Baytugan, NZ; Kahraman, G; Kilic, T; Komsuoglu, B; Sahin, T; Ural, D; Ural, E, 2007) |
| "Blood levels of long-chain n-3 fatty acids were associated with decreased risk of colorectal cancer among men not using aspirin." | 3.74 | Blood levels of long-chain polyunsaturated fatty acids, aspirin, and the risk of colorectal cancer. ( Campos, H; Hall, MN; Li, H; Ma, J; Sesso, HD; Stampfer, MJ; Willett, WC, 2007) |
| "A goal of the Women's Health Study was to evaluate the balance of benefits and risks of low-dose aspirin in the primary prevention of stroke in healthy women." | 3.74 | CON: Should aspirin be used in all women older than 65 years to prevent stroke? ( Buring, JE, 2007) |
| "Aspirin is a common preventative therapy in patients at risk for cardiovascular diseases, yet little is known about how aspirin protects the vasculature in hypercholesterolemia." | 3.74 | Roles of platelet and endothelial cell COX-1 in hypercholesterolemia-induced microvascular dysfunction. ( Granger, DN; Specian, RD; Tailor, A; Wallace, JL; Wood, KC, 2007) |
| "Treatment with aspirin is underused for PP in patients with diabetes mellitus in Primary Care." | 3.74 | Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain. ( Fernández-de-Bobadilla, J; Frías-Garrido, X; Navarro-Artieda, R; Rejas-Gutiérrez, J; Ruiz-Riera, R; Sicras-Mainar, A, 2007) |
| " Aspirin use has been shown to be effective in reducing the number of nonfatal myocardial infarction (MI) and fatal CHD, though studies of aspirin effects in women have found a significant reduction in ischemic stroke but no significant effect on fatal or nonfatal MI or CVD death." | 3.74 | Aspirin use in the prevention of cardiovascular events. ( Crutcher, JM; Daniels, C; Mallonee, S, 2007) |
| "In some patients with stable and unstable angina pectoris and in some donors without clinical manifestations of cardiovascular diseases and other pathologies, spontaneous platelet aggregation was completely suppressed by glycoprotein IIb-IIIa antagonists blocking the interaction of this glycoprotein with fibrinogen." | 3.74 | Participation of IIb-IIIa glycoprotein in spontaneous platelet aggregation. ( Buryachkovskaya, LI; Kadinskaya, MI; Khaspekova, SG; Mazurov, AV; Shvartsman, AL; Sirotkina, OV; Sivachenko, EB; Taraskina, AE; Uchitel', IA; Vavilova, TV; Zabotina, AM; Zueva, EE, 2007) |
| " The aims of the present study were: to verify the incidence of Normal Weight Obese (NWO) syndrome; to evaluate by PINI the effect of 8 weeks acetyl salicylic (100 mg/die) and atorvastatin (10 mg/die) combined treatment on chronic inflammation in 52 selected HD patients." | 3.74 | Anti-inflammatory effects of combined treatment with acetyl salicylic acid and atorvastatin in haemodialysis patients affected by Normal Weight Obese syndrome. ( De Angelis, S; De Lorenzo, A; Di Daniele, N; Di Renzo, L; Miani, N; Noce, A; Tozzo, C, 2008) |
| "The current standard of care for anti-thrombotic therapy with primary PCI for acute ST elevation myocardial infarction (STEMI) is aspirin, clopidogrel, unfractionated heparin and platelet glycoprotein IIb/IIIa inhibitors." | 3.74 | What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice? ( Brodie, BR, 2008) |
| "A literature search was conducted using EMBASE (1980-January 2008), PubMed (1966-January 2008), Google, and a manual search of the reference lists using the search terms gastrointestinal bleed, gastrointestinal hemorrhage, peptic ulcer hemorrhage, ASA, aspirin, Plavix, clopidogrel, and PPI." | 3.74 | Single antiplatelet therapy for patients with previous gastrointestinal bleeds. ( Ackman, ML; Gellatly, RM, 2008) |
| " The cost-effectiveness of longer combination therapy depends critically on the balance of thrombotic event rates, durable efficacy, and the increased bleeding rate in patients taking clopidogrel." | 3.73 | A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. ( Heidenreich, PA; Schleinitz, MD, 2005) |
| "The aim of this study was to evaluate the relationship of obesity, leptin, insulin resistance and C-reactive protein (CRP) with coronary heart disease (CHD) risk factors in patients with Type 2 diabetes mellitus (DM) with CHD compared with those with Type 2 DM without CHD." | 3.73 | Plasma leptin concentration in patients with Type 2 diabetes: relationship to cardiovascular disease risk factors and insulin resistance. ( Abdella, NA; Al Jebely, S; Al Mohammedi, H; Al Ozairi, ES; Mojiminiyi, OA; Moussa, MA; Zaki, M, 2005) |
| "Ninety nine patients (30 women, 63+/-10 years) treated for stable cardiovascular diseases with aspirin 100-325 mg/day were studied." | 3.73 | [Frequency and characteristics of aspirin resistance in Chilean cardiovascular patients]. ( Conte L, G; Cuneo V, M; Dussaillant N, G; Fardella B, P; Zapata M, M, 2005) |
| "To present our own experience with the maintenance of anticoagulant therapy with oral coumarin-type drugs and/or acetylsalicylic acid in patients with cardiovascular diseases who undergo oral surgical procedures." | 3.73 | Oral surgery procedures in patients on anticoagulants. Preliminary report. ( Cieślik, T; Cieślik-Bielewska, A; Pelc, R, 2005) |
| "Warfarin and aspirin are commonly used to prevent cardiovascular diseases." | 3.73 | [Characteristics of colon cancer diagnosed in patients taking aspirin or warfarin]. ( Kim, BC; Kim, S; Kim, TI; Kim, WH; Park, S; Shin, SJ, 2005) |
| " Statin users were stratified in different cohorts according to drug use, aspirin use and hospital admission for cardiovascular diseases." | 3.72 | Statin compliance in the Umbrian population. ( Abraha, I; Montedori, A; Romagnoli, C; Rossi, M; Stracci, F, 2003) |
| "There have been no randomized trials of cardioprotective therapy after acute myocardial infarction in patients with chronic kidney disease who should be largely eligible for aspirin (acetylsalicylic acid; ASA) and beta-blockers (BB) as a base of therapy." | 3.71 | Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. ( Borzak, S; Garg, M; Hudson, MP; Manley, HJ; McCullough, PA; Sandberg, KR, 2002) |
| "To analyse the incidence and factors influencing the occurrence of UGIB in patients taking low-dose aspirin for the prevention of cardiovascular diseases outside clinical trials." | 3.71 | Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. ( Arroyo, MT; Ferreira, IJ; Lanas, A; Serrano, P, 2002) |
| " Using a nested case-control design, we measured urinary 11-dehydro thromboxane B2 levels, a marker of in vivo thromboxane generation, in 488 cases treated with aspirin who had myocardial infarction, stroke, or cardiovascular death during 5 years of follow-up and in 488 sex- and age-matched control subjects also receiving aspirin who did not have an event." | 3.71 | Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. ( Eikelboom, JW; Hirsh, J; Johnston, M; Weitz, JI; Yi, Q; Yusuf, S, 2002) |
| " It is generally accepted that in aspirin-induced asthma (AIA) the bronchospasm is provoked by inhibition of prostaglandin synthesis with overproduction of cysteinyl leukotrienes." | 3.71 | [Tolerability of Asacard--controlled-release aspirin and aspirin-induced asthma]. ( Bochenek, G; Gicquel, M; Nizankowska-Mogilnicka, E; Swierczyńska, M; Szczeklik, A; Vivet, P, 2002) |
| " The medications were pravastatin, a cholesterol-lowering drug for the prevention of cardiovascular disease; alendronate, a bisphosphonate for the treatment and prevention of osteoporosis; and aspirin, which is used for the prevention of cardiovascular disease." | 3.70 | Coverage by the news media of the benefits and risks of medications. ( Bero, L; Henry, D; Lee, K; Mah, C; Moynihan, R; Ross-Degnan, D; Soumerai, SB; Watkins, J, 2000) |
| "To identify the clinical and radiologic features of intracerebral hemorrhage (ICH) in aspirin users." | 3.70 | Aspirin-associated intracerebral hemorrhage: clinical and radiologic features. ( Chan, YL; Kay, R; Lam, WW; Mok, V; Tang, A; Wong, KS; Woo, J, 2000) |
| "This self-matched control study aimed to compare the efficiency of two different regimens of active treatment: aspirin in low (100 mg daily) versus intermediate (500 mg daily) doses in abolishing angiotensin-converting enzyme inhibitor (ACEI)-induced cough." | 3.70 | Intermediate but not low doses of aspirin can suppress angiotensin-converting enzyme inhibitor-induced cough. ( Fisman, EZ; Grossman, E; Motro, M; Nosrati, I; Shemesh, J; Tenenbaum, A, 2000) |
| "(1) Aspirin reduces acute-phase mortality after myocardial infarction, and also reduces the risk of myocardial infarction and death in patients with unstable angina." | 3.70 | Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention. ( , 2000) |
| " To assess the accuracy of self-reports of cataract, we compared the self-reports with medical record data obtained from diagnosing ophthalmologists and optometrists for participants in the Physicians' Health Study, a randomized trial of aspirin and beta-carotene among 22,071 male U." | 3.69 | Confirmation of self-reported cataract in the Physicians' Health Study. ( Buring, JE; Christen, WG; Glynn, RJ; Hennekens, CH; Manson, JE; Seddon, JM, 1994) |
| "Regular use of analgesic drugs containing phenacetin is associated with an increased risk of hypertension and mortality and morbidity due to cardiovascular disease, as well as an increased risk of mortality due to cancer and urologic or renal disease." | 3.68 | An epidemiologic study of abuse of analgesic drugs. Effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968 to 1987) ( Dubach, UC; Rosner, B; Stürmer, T, 1991) |
| "Results of recent clinical trials on secondary prevention of ischemic heart disease indicate that judicious, long-term administration of adrenergic beta blockers and platelet-active drugs such as aspirin and Persantine (dipyridamole) would seem to yield protection against mortality associated with acute myocardial infarction, including sudden death." | 3.67 | Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases. ( Borhani, NO, 1985) |
| " Seven recently completed clinical trials, the Coronary Drug Project, the Aspirin Myocardial Infarction Study, the Anturane Reinfarction Trial, the Hypertension Detection and Follow-Up Program and three drug trials of betablockers, are reviewed from the perspective of both their clinical and methodological significance." | 3.66 | Overview of recent clinical and methodological advances from clinical trials of cardiovascular disease. ( Friedewald, WT; Schoenberger, JA, 1982) |
| " Guidelines are also inconsistent in the recommendation of routine ASA use for primary prevention of CVD, but advocate dosing as a "one-size-fits-all" approach." | 3.30 | Prospective, randomized, controlled, trial to assess ASA DOSing by body mass index in HEalthy volunteers (DOSE study). ( Hutchinson, D; Kim, K; Kirkham, A; Kroencke, R; Munger, M; Nay, I; Rondina, M; Tolley, ND; Trujillo, T, 2023) |
| "We randomly assigned 116 patients with type 2 diabetes and cardiovascular risk factors but no evident cardiovascular disease to receive aspirin at a dose of 100 mg or cilostazol at a dose of 200 mg daily for 14 days." | 3.11 | Comparative Study of Ex Vivo Antiplatelet Activity of Aspirin and Cilostazol in Patients with Diabetes and High Risk of Cardiovascular Disease. ( Hong, S; Lee, WJ; Park, CY, 2022) |
| "Rivaroxaban treatment for 20 weeks (n = 89) resulted in a significant improvement of post-ischaemic forearm blood flow (3." | 3.01 | Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers. ( Birkenfeld, AL; Bornstein, SR; Hanefeld, M; Henkel, E; Matschke, JB; Pistrosch, F; Schipp, B; Schipp, D; Sradnick, J; Weigmann, I, 2021) |
| "Aspirin was not associated with significant bleeding excess." | 3.01 | Fixed dose combination therapies in primary cardiovascular disease prevention in different groups: an individual participant meta-analysis. ( Dagenais, GR; Gao, P; Joseph, P; Malekzadeh, R; Pais, P; Roshandel, G; Yusuf, S, 2023) |
| "Aspirin has been demonstrated to have a clear benefit in secondary prevention of cardiovascular disease, but recent primary prevention trials have at best demonstrated a small benefit." | 3.01 | Aspirin and lipoprotein(a) in primary prevention. ( Bhatia, HS, 2023) |
| "Aspirin users were at significantly lower risk of all-cause mortality compared to nonusers (HR = 0." | 3.01 | Association between aspirin use and cardiovascular outcomes in ALLHAT participants with and without chronic kidney disease: A post hoc analysis. ( Bond, M; Conant, A; Desai, N; Rahman, M; Wilson, B, 2021) |
| "Proteinuria was independently associated with the incidence of primary cardiovascular events in diabetic patients." | 2.94 | Proteinuria is independently associated with the incidence of primary cardiovascular events in diabetic patients. ( Jinnouchi, H; Masuda, I; Matsumoto, C; Morimoto, T; Nakayama, M; Ogawa, H; Okada, S; Saito, Y; Soejima, H; Waki, M, 2020) |
| "We analysed hospitalized patients who ingested ASA at least 30 min prior to metamizole (recommended dosing group, n = 15), metamizole prior or simultaneously with ASA (not recommended dosing group, n = 16) and patients with unknown or mixed intake (mixed dosing group, n = 5)." | 2.94 | Intake of aspirin prior to metamizole does not completely prevent high on treatment platelet reactivity. ( Bertsche, T; Dietze, C; Gockel, I; Josten, C; Kaiser, T; Petros, S; Pfrepper, C; Remane, Y; Schiek, S, 2020) |
| "Aspirin treatment for two weeks showed no hyperuricaemic effect in people over 60." | 2.94 | Effect of low-dose aspirin on serum uric acid levels in Chinese individuals over 60: subanalysis of a multicentre randomized clinical trial. ( Chen, XH; Liang, WY; Liu, ML; Liu, WW; Wang, H; Zhang, P, 2020) |
| "For patients with inguinal hernias, laparoscopic TAPP repair is completely safe to be performed on those taking low-dose acetylsalicylic acid when it was only ceased on the operation day, with intravenous salvianolate given after the operation instead." | 2.90 | Continuation of low-dose acetylsalicylic acid during perioperative period of laparoscopic inguinal hernia repair is safe: results of a prospective clinical trial. ( Han, H; Liu, Y; Ruze, R; Wang, M; Xiong, Y; Yan, Z; Zhan, H; Zhang, G, 2019) |
| "Aspirin treatment may have reduced CVEs within a high CVE risk elderly population subgroup." | 2.90 | Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70). ( Ando, K; Goto, Y; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Uemura, Y; Yamazaki, T; Yokoyama, K, 2019) |
| " These drugs are well tolerated in the short term, but long-term treatment was associated with adverse events in observational studies." | 2.90 | Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. ( Alings, M; Anand, SS; Avezum, A; Bhatt, DL; Bosch, J; Branch, KRH; Bruns, NC; Commerford, PJ; Connolly, SJ; Dagenais, GR; Dans, AL; Diaz, R; Dyal, L; Eikelboom, JW; Ertl, G; Felix, C; Fox, KAA; Guzik, TJ; Hart, RG; Hori, M; Kakkar, AK; Keltai, M; Kim, JH; Lanas, F; Leong, D; Lewis, BS; Liang, Y; Lonn, EM; Lopez-Jaramillo, P; Maggioni, AP; Metsarinne, KP; Moayyedi, P; Muehlhofer, E; O'Donnell, M; Parkhomenko, AN; Piegas, LS; Pogosova, N; Probstfield, J; Ryden, L; Shestakovska, O; Steg, PG; Störk, S; Tonkin, AM; Torp-Pedersen, C; Verhamme, PB; Vinereanu, D; Widimsky, P; Yusoff, K; Yusuf, S; Zhu, J, 2019) |
| "Acute minor ischemic stroke (AMIS) or transient ischemic attack (TIA) is a common cerebrovascular event with a considerable high recurrence." | 2.87 | Rationale and Study Design for a Single-Arm Phase IIa Study Investigating Feasibility of Preventing Ischemic Cerebrovascular Events in High-Risk Patients with Acute Non-disabling Ischemic Cerebrovascular Events Using Remote Ischemic Conditioning. ( Feng, WW; Ji, XM; Li, SJ; Liu, SM; Meng, R; Ovbiagele, B; Ren, CH; Song, HQ; Zhao, WL, 2018) |
| " Decreased trend of negative outcomes could be observed in patients with double dosage of clopidogrel, but the difference was not significant." | 2.87 | Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients With High Posttreatment Platelet Reactivity: Results of the CREATIVE Trial. ( Chen, J; Gao, R; Huang, X; Qiao, S; Tang, YD; Wang, W; Wu, Y; Xu, B; Yan, H; Yang, M; Yang, Y; Zhang, K, 2018) |
| "The primary end point was total cancer incidence." | 2.87 | Effect of Aspirin on Cancer Chemoprevention in Japanese Patients With Type 2 Diabetes: 10-Year Observational Follow-up of a Randomized Controlled Trial. ( Doi, N; Jinnouchi, H; Masuda, I; Matsumoto, C; Morimoto, T; Nakayama, M; Ogawa, H; Okada, S; Saito, Y; Sakuma, M; Soejima, H; Waki, M, 2018) |
| "Aspirin treatment (100 mg/day) (n = 50) or usual therapy (n = 61)." | 2.87 | Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study). ( Abad, S; Arroyo, D; Bernis, C; de Sequera, P; de Vinuesa, SG; Delgado, R; Fernández-Juárez, G; Goicoechea, M; Luño, J; Morales, E; Ortiz, A; Quiroga, B; Torres, A; Verdalles, U; Verde, E, 2018) |
| " Previous pharmacokinetic and pharmacodynamic studies have suggested that the aspirin formulation (enteric-coated) and dosing schedule (once daily) studied in randomized trials for primary prevention of CV events defining contemporary clinical practice may not leverage the full potential of the drug, particularly in patients with diabetes." | 2.82 | Aspirin for Primary Cardiovascular Prevention in Patients with Diabetes: Uncertainties and Opportunities. ( Bloom, S; Del Bianco-Rondeau, M; Lordkipanidzé, M; Marquis-Gravel, G; Rabasa-Lhoret, R; Robert-Halabi, M; Tardif, JC, 2022) |
| "Evidence on aspirin and cancer comes from two main sources: (1) the effect of aspirin upon biological mechanisms in cancer, and (2) clinical studies of patients with cancer, some of whom take aspirin." | 2.82 | Aspirin and cancer: biological mechanisms and clinical outcomes. ( Delon, C; Elwood, P; Morgan, G; Pickering, J; Protty, M; Watkins, J, 2022) |
| " Because increased platelet reactivity and/or turnover are postulated mechanisms, we examined whether higher and/or more frequent aspirin dosing might reduce platelet reactivity more effectively." | 2.82 | Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes. ( Bethel, MA; Coleman, RL; Harrison, P; Hill, L; Holman, RR; Kennedy, I; Oulhaj, A; Sourij, H; Sun, Y; Tucker, L; White, S, 2016) |
| "Most retinal or subretinal hemorrhages in eyes enrolled in CATT were less than 1 DA." | 2.82 | Association between Antiplatelet or Anticoagulant Drugs and Retinal or Subretinal Hemorrhage in the Comparison of Age-Related Macular Degeneration Treatments Trials. ( Ahmed, O; Daniel, E; Grunwald, JE; Maguire, MG; Martin, DF; Ying, GS, 2016) |
| " Adverse events (AEs) caused study withdrawal in 13." | 2.82 | Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk. ( Cryer, BL; Eisen, GM; Fort, JG; Goldstein, JL; Lanas, A; Scheiman, JM; Whellan, DJ, 2016) |
| "Triflusal was more effective and demonstrated a more consistent impact on the improvement of symptoms and blood flow in patients with PVD than aspirin." | 2.80 | Effect of Triflusal on Primary Vascular Dysregulation Compared with Aspirin: A Double-Blind, Randomized, Crossover Trial. ( Chang, HJ; Cho, IJ; Chung, N; Hong, GR; Jang, Y; Kim, KJ; Rah, YM; Shin, S, 2015) |
| "Nonalcoholic steatohepatitis is a common finding in patients with CVD." | 2.80 | PolyPill for Prevention of Cardiovascular Disease in an Urban Iranian Population with Special Focus on Nonalcoholic Steatohepatitis: A Pragmatic Randomized Controlled Trial within a Cohort (PolyIran - Liver) - Study Protocol. ( Hemming, K; Jafari, E; Khoshnia, M; Malekzadeh, R; Marshall, T; Merat, S; Nateghi, A; Poustchi, H; Radmard, AR; Shiravi Khuzani, A, 2015) |
| " An additional aim is to assess the effect of the polypill on LDL-c and BP compared to the administration of separate pills of identically dosed components of the polypill." | 2.79 | The evening versus morning polypill utilization study: the TEMPUS rationale and design. ( Bots, ML; Grobbee, DE; Lafeber, M; Rodgers, A; Spiering, W; Thom, S; Visseren, FL; Webster, R, 2014) |
| "Secondary end points were the restenosis rate on duplex ultrasound, the rate of major adverse cardiac events, and target lesion event-free survival." | 2.78 | Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. ( Hamasaki, T; Hirano, K; Iida, O; Inoue, N; Isshiki, T; Kawasaki, D; Miyamoto, A; Miyashita, Y; Nakamura, M; Nanto, S; Shinozaki, N; Shintani, Y; Soga, Y; Suzuki, K; Tsuchiya, T; Urasawa, K; Yokoi, H; Yokoi, Y; Zen, K, 2013) |
| "Although low-dose acetylsalicylic acid (ASA) is recommended for prevention of cardiovascular events in at-risk patients, its long-term use can be associated with the risk of peptic ulcer and upper gastrointestinal (GI) symptoms that may impact treatment compliance." | 2.78 | Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial. ( Agewall, S; Herlitz, J; Lanas, A; Nagy, P; Nauclér, EC; Scheiman, JM; Svedberg, LE; Veldhuyzen van Zanten, SJ, 2013) |
| " The anti-platelet effect may be diminished by poor glycemic control or inadequate dosing of aspirin." | 2.77 | The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus. ( Bähler, L; Gerdes, VE; Hoekstra, JB; Holleman, F; Kamphuisen, PW; Lemkes, BA; Nieuwland, R; Stroobants, AK; Van Den Dool, EJ, 2012) |
| "Treatment with aspirin resulted in a 7." | 2.75 | To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. ( Darvish, B; Eintrei, C; Fredrikson, M; Gupta, A; Järhult, J; Krook, H; Nyström, M; Oscarsson, A; Pettersson, E; Swahn, E, 2010) |
| "We evaluated the bioavailability of each ingredient of the Polycap and determined any drug-drug interactions relative to single component reference preparations." | 2.75 | Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers. ( Chakraborty, BS; Desai, J; Ghosh, C; Jha, V; Khamar, B; Patel, A; Shah, G; Shah, T, 2010) |
| "Women who had ever reported asthma or COPD were associated with an increased diabetes risk; the multivariate RRs were 1." | 2.75 | Asthma, chronic obstructive pulmonary disease, and type 2 diabetes in the Women's Health Study. ( Buring, JE; Klevak, A; Liu, S; Manson, JE; Song, Y, 2010) |
| "To achieve this goal, we have studied the effects of these two dosing regimens on platelet function in healthy women meeting the WHS inclusion criteria using a randomized design." | 2.74 | Aspirin administered to women at 100 mg every other day produces less platelet inhibition than aspirin administered at 81 mg per day: implications for interpreting the women's health study. ( Hillman, RS; Swaim, L, 2009) |
| "Documented clinical type 2 diabetes was prospectively evaluated throughout the trial." | 2.74 | A randomized trial of low-dose aspirin in the prevention of clinical type 2 diabetes in women. ( Buring, JE; Cook, NR; Manson, JE; Pradhan, AD; Ridker, PM, 2009) |
| "Terutroban is a specific TP receptor antagonist with antithrombotic, antivasoconstrictive, and antiatherosclerotic properties, which may be of interest for the secondary prevention of ischemic stroke." | 2.74 | Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with ( Amarenco, P; Bousser, MG; Chamorro, A; Fisher, M; Ford, I; Fox, K; Hennerici, MG; Mattle, HP; Rothwell, PM, 2009) |
| "Aspirin/dipyridamole was more effective than aspirin therapy in reducing BV at shear rates of 1 s(-1) (-3." | 2.73 | Treatment with aspirin and dipyridamole is more effective than aspirin in reducing low shear blood viscosity. ( Rosenson, RS, 2008) |
| "In aspirin-treated patients, urinary concentrations of 11-dehydro thromboxane B(2) are an externally valid and potentially modifiable determinant of stroke, myocardial infarction, or cardiovascular death in patients at risk for atherothrombotic events." | 2.73 | Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. ( Bhatt, DL; Easton, JD; Eikelboom, JW; Fox, KA; Hamm, C; Hankey, GJ; Hu, T; Johnston, SC; Mak, KH; Montalescot, G; Steg, PG; Steinhubl, SR; Thom, J; Topol, EJ, 2008) |
| "In this study of patients with type 2 diabetes, low-dose aspirin as primary prevention did not reduce the risk of cardiovascular events." | 2.73 | Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. ( Doi, N; Jinnouchi, H; Kanauchi, M; Morimoto, T; Nakayama, M; Ogawa, H; Saito, Y; Sugiyama, S; Uemura, S, 2008) |
| "Aspirin was associated with decreased risk of stroke in all patients (relative risk [RR], 0." | 2.73 | Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). ( Akizawa, T; Asano, Y; Bragg-Gresham, JL; Ethier, J; Gillespie, BW; Mason, N; Piera, L; Young, EW, 2007) |
| "In at-risk patients with type 2 diabetes, intensive intervention with multiple drug combinations and behavior modification had sustained beneficial effects with respect to vascular complications and on rates of death from any cause and from cardiovascular causes." | 2.73 | Effect of a multifactorial intervention on mortality in type 2 diabetes. ( Gaede, P; Lund-Andersen, H; Parving, HH; Pedersen, O, 2008) |
| "Cardiovascular diseases are currently among the leading causes of morbidity and mortality in many developed countries." | 2.72 | The Role of Thromboxane in the Course and Treatment of Ischemic Stroke: Review. ( Brodowski, J; Drozd, A; Kotlęga, D; Kozioł, I; Szczuko, M, 2021) |
| "Aspirin has been the mainstay of both secondary and primary prevention of cardiovascular disease for half a century." | 2.72 | Aspirin in Primary Prevention: What Changed? A Critical Appraisal of Current Evidence. ( Dasa, O; Pearson, TA; Pepine, CJ, 2021) |
| "Development of preeclampsia can be decreased by prescribing low-dose aspirin to high-risk women." | 2.72 | Family History of Hypertension, Cardiovascular Disease, or Diabetes and Risk of Developing Preeclampsia: A Systematic Review. ( Kay, VR; Smith, GN; Wedel, N, 2021) |
| "Colonic diverticulitis is a painful gastrointestinal disease that recurs unpredictably and can lead to chronic gastrointestinal symptoms." | 2.72 | AGA Clinical Practice Update on Medical Management of Colonic Diverticulitis: Expert Review. ( Peery, AF; Shaukat, A; Strate, LL, 2021) |
| "G6PD deficiency is typically asymptomatic and many CVD patients with this enzyme defect start to take long-term aspirin therapy without G6PD activity examination; however, no consensus on the safety of aspirin in this population has been reached." | 2.72 | Aspirin Therapy in Cardiovascular Disease with Glucose-6-Phosphate Dehydrogenase Deficiency, Safe or Not? ( Chen, C; Chen, J; Chen, Y; Jiang, Z; Li, J; Li, P; Liang, J; Ou, Z; Ouyang, F; Wei, J; Zeng, J, 2021) |
| " However, questions remain regarding the benefit-risk relationship in certain settings since long-term use of ASA is not devoid of risk." | 2.72 | Primary Prevention of CVD with Aspirin: Benefits vs Risks. ( Brunton, S; Weisman, SM, 2021) |
| "Aspirin treatment resulted in the inhibition of collagen-induced platelet aggregation, particularly the transition from small to large platelet aggregates." | 2.72 | Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. ( Kobayashi, Y; Madoiwa, S; Mimuro, J; Nonaka, T; Ohmori, T; Ozaki, Y; Sakata, Y; Yatomi, Y, 2006) |
| " It is also possible that drug interactions with statins might reduce aspirin bioavailability and/or activity, thereby reducing platelet inhibition in aspirin-resistant patients." | 2.72 | Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables. ( Alkonyi, B; Czopf, L; Feher, G; Kenyeres, P; Kesmarky, G; Koltai, K; Papp, E; Solyom, A; Toth, K, 2006) |
| "Aspirin resistance was defined as a mean aggregation of > or =70% with 10 microM ADP and > or =20% with 0." | 2.71 | A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. ( Gum, PA; Kottke-Marchant, K; Topol, EJ; Welsh, PA; White, J, 2003) |
| "Aspirin use at entry was also associated with a 4-fold (95% CI, 1." | 2.69 | Aspirin use and incident stroke in the cardiovascular health study. CHS Collaborative Research Group. ( Beauchamp, NJ; Hart, RG; Kronmal, RA; Manolio, TA; Newman, A; Talbert, RL, 1998) |
| "Beta-carotene's effect on cancer over nearly 13 years was examined overall and within subgroups defined by baseline characteristics using proportional-hazards models." | 2.69 | Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians' Health Study (United States). ( Buring, JE; Cook, NR; Hennekens, CH; Le, IM; Manson, JE, 2000) |
| "Physicians reporting migraine (n = 1479) had significantly increased risks of subsequent total stroke and ischemic stroke compared with those not reporting migraine." | 2.68 | Migraine and subsequent risk of stroke in the Physicians' Health Study. ( Buring, JE; Cook, N; Hebert, P; Hennekens, C; Kittross, A; Manson, J; Peto, R; Romero, J, 1995) |
| "Hypertension is associated with an increased risk of myocardial infarction, and borderline isolated systolic hypertension predicts a possible but more modest increase in risk." | 2.68 | Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians. ( Ajani, U; Berger, K; Glynn, RJ; Hennekens, CH; Manson, JE; O'Donnell, CJ; Ridker, PM, 1997) |
| " Further dosage adjustments are made in accordance with a set protocol." | 2.67 | The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results. ( Hansson, L; Zanchetti, A, 1994) |
| "Aspirin-treated subjects had a significant decrease in mean hemoglobin levels of 0." | 2.67 | Adverse effects of low-dose aspirin in a healthy elderly population. ( Campion, K; Donnan, GA; McNeil, JJ; Silagy, CA; Tonkin, AM; Worsam, B, 1993) |
| "Aspirin treatment should be considered only when the CV risk is very high and the bleeding risk is low, after taking into account the patient's preferences." | 2.66 | Aspirin for primary prevention of cardiovascular disease: Advice for a decisional strategy based on risk stratification. ( Aimo, A; De Caterina, R, 2020) |
| "Cardiovascular diseases are the leading cause of deaths in the world." | 2.66 | [Current antiplatelet agents, new inhibitors and therapeutic targets]. ( Benomar, A; Cadi, R; Cherrah, Y; El Alaoui, MZ; Guy, A; Khalki, L; Limami, Y; Mekhfi, H; Zaid, N; Zaid, Y, 2020) |
| "Preventing prostate cancer via dietary supplements should encourage a "first do no harm" or less-is-more approach until future evidence can reverse the concerning trend that more supplementation has resulted in either no impact or an increased risk of prostate cancer." | 2.66 | Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part III. ( Moyad, MA, 2020) |
| "Aspirin has demonstrated a clear benefit in secondary prevention of coronary syndrome, while aspirin's effect in primary prevention is unclear." | 2.66 | Aspirin in Primary Prevention of Cardiovascular Events. ( Rezkalla, SH; Soodi, D; VanWormer, JJ, 2020) |
| "The aspirin component was terminated earlier than scheduled, and the preliminary findings were published." | 2.66 | Final report on the aspirin component of the ongoing Physicians' Health Study. ( , 1989) |
| "Inflammation is a biological function which triggered after the mechanical tissue disruption or from the responses by the incidence of physical, chemical or biological negotiator in body." | 2.61 | Human disorders associated with inflammation and the evolving role of natural products to overcome. ( Kishore, N; Kumar, P; Shanker, K; Verma, AK, 2019) |
| "Aspirin, in 2017, has celebrated its 120th birthday." | 2.61 | Aspirin in primary prevention: the triumph of clinical judgement over complex equations. ( Santilli, F; Simeone, P, 2019) |
| " Key unresolved questions regarding the role of aspirin in primary prevention include the optimal drug formulation, dosing schedule, weight-based dose selection, and interplay between sex and treatment response." | 2.61 | Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease. ( Harrington, RA; Hernandez, AF; Jones, WS; Marquis-Gravel, G; Muñoz, D; Roe, MT, 2019) |
| " While the clinical significance of this interference is still unclear, this review sought to assess the body of literature which has evaluated the potential attenuation of the anti-platelet effect of aspirin when dosed concomitantly with an NSAID." | 2.61 | A narrative review of the cardiovascular risks associated with concomitant aspirin and NSAID use. ( Gurbel, P; Tantry, U; Weisman, S, 2019) |
| "Aspirin was associated with a lower incidence of myocardial infarction (RR 0." | 2.61 | Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. ( Bavry, AA; Elgendy, AY; Elgendy, IY; Gad, MM; Mahmoud, AN, 2019) |
| "Pregnancy-induced hypertension is a major cause of maternal and fetal morbidity and mortality." | 2.61 | Hypertension and Pregnancy: Management and Future Risks. ( Jim, B; Reddy, S, 2019) |
| "Aspirin has a well-established history of safety and efficacy in management of secondary cardiovascular protection in ischemic heart disease patients." | 2.61 | Secondary Prevention with Antithrombotic Therapies in Stable Ischemic Heart Disease Patients: a Review. ( Bhupathi, V; Shanker, A, 2019) |
| "Aspirin has potential benefits in cardiovascular primary prevention in diabetes." | 2.61 | Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. ( Buring, JE; Gaziano, JM; Khunti, K; Kunutsor, SK; Roncaglioni, MC; Seidu, S; Sesso, HD, 2019) |
| "Aspirin was associated with a higher risk of major bleeding (RR: 1." | 2.61 | Aspirin for Primary Prevention of Cardiovascular Events. ( Abbott, JD; Abdelaziz, HK; Aronow, HD; Bhatt, DL; Kon, DLC; Megaly, M; Mehta, JL; Pothineni, NVK; Potluri, R; Roberts, DH; Saad, M; Saleh, M, 2019) |
| "It has been now widely accepted that preeclampsia is most a systemic inflammatory and systemic vascular disease during pregnancy and then a lifelong risk factor for subsequent cardiovascular event in women's life." | 2.58 | [Preeclampsia: A challenge also for cardiologists]. ( Cournot, M; Lairez, O; Medzech, B, 2018) |
| "Cardiovascular diseases and cancers are the 2 main causes of mortality in industrialized countries." | 2.58 | [Is cancer a factor or a marker of cardiovascular risk in women?] ( Ancedy, Y; Chauvet-Droit, M; Cohen, A; Ederhy, S; Soulat-Dufour, L, 2018) |
| "Preventing prostate cancer via dietary supplements should encourage a "first do no harm", or less is more approach until future evidence can reverse the concerning trend that more supplementation has resulted in either no impact or an increased risk of prostate cancer." | 2.58 | Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part I. ( Moyad, MA, 2018) |
| "Background Systemic lupus erythematosus is associated with an increased risk of cardiovascular disease." | 2.55 | Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review. ( Afeltra, A; Fasano, S; Margiotta, DP; Navarini, L; Pantano, I; Pierro, L; Riccardi, A; Valentini, G, 2017) |
| " There were differences in the effect of aspirin by dosage and treatment duration on overall stroke outcomes (P for interaction for all < 0." | 2.55 | Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. ( Khunti, K; Kunutsor, SK; Seidu, S, 2017) |
| "Substantial evidence suggests that genetic predisposition plays a vital role in the physiopathology of this complex disease." | 2.55 | Cardiovascular pharmacogenetics: a promise for genomically-guided therapy and personalized medicine. ( El Amri, H; Zaiou, M, 2017) |
| "Activated platelets initiate thrombus formation." | 2.55 | Is arachidonic acid stimulation really a test for the response to aspirin? Time to think again? ( Ashby, A; Curzen, N; Khanna, V; Mahmoudi, M; Mariathas, M; Olechowski, B, 2017) |
| "Aspirin is a widely used medication and has become a cornerstone for treating cardiovascular disease." | 2.53 | Aspirin resistance and other aspirin-related concerns. ( Cai, G; Chen, P; Fu, Y; Lu, Y; Lu, Z; Zhou, W, 2016) |
| "Aspirin has been a cornerstone of cardiovascular disease prevention since the late 1980s." | 2.53 | Aspirin dosing frequency in the primary and secondary prevention of cardiovascular events. ( Becker, RC; Kim, J, 2016) |
| "Aspirin has been the cornerstone of therapy for the secondary prevention treatment of patients with cardiovascular disease since landmark trials were completed in the late 1970s and early 1980s that demonstrated the efficacy of aspirin for reducing the risk of ischemic events." | 2.53 | Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease. ( Fanaroff, AC; Roe, MT, 2016) |
| "Aspirin is likely to increase the risk of major bleeding events." | 2.53 | Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis. ( Brunskill, NJ; Dawson, S; Gray, LJ; Major, RW; Oozeerally, I; Riddleston, H, 2016) |
| " We conducted a systematic review to evaluate the evidence on the effects of different aspirin regimens in terms of timing (chronotherapy) or frequency of dosing in the prevention of cardiovascular disease." | 2.53 | The Effects of Different Aspirin Dosing Frequencies and the Timing of Aspirin Intake in Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review. ( Bayliss, S; Bem, D; Dretzke, J; Fitzmaurice, D; Hodgkinson, J; Lordkipanidzé, M; Moore, D; Stevens, S, 2016) |
| "Aspirin was associated with increased bleeding risks when combined with non-steroidal anti-inflammatory drugs, clopidogrel and selective serotonin reuptake inhibitors compared with monotherapy." | 2.53 | Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies. ( García Rodríguez, LA; Hennekens, CH; Lanas, A; Martín-Pérez, M; Rothwell, PM, 2016) |
| "Aspirin has higher side effect risks and requires a longer time to achieve benefit." | 2.52 | Primary prevention: do the very elderly require a different approach? ( Schwartz, JB, 2015) |
| "Aspirin is a paradigmatic example, as it is used for the primary and secondary prevention of cardiovascular disease and appears to have a beneficial impact on cancer risk." | 2.52 | Aspirin underuse, non-compliance or cessation: definition, extent, impact and potential solutions in the primary and secondary prevention of cardiovascular disease. ( Abbate, A; Agostoni, P; Biondi-Zoccai, G; Frati, G; Serrano, CV; Wu, Y, 2015) |
| "Among their beneficial effects, non-steroidal anti-inflammatory drugs may also exert several side effects which depend on the dosage and the type of these medications." | 2.52 | [Cardiovascular side effects of non-steroidal anti-inflammatory drugs in the light of recent recommendations. Diclofenac is not more dangerous]. ( Horváth, VJ; Koós, CG; Lakatos, P; Putz, Z; Szabó, G; Tabák, GÁ, 2015) |
| " However, NSAIDs are associated with a number of adverse effects, especially in patients with cardiovascular disease (CVD)." | 2.52 | Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease. ( Cicci, JD; Danelich, IM; Lose, JM; Reed, BN; Tefft, BJ; Wright, SS, 2015) |
| "Type 2 diabetes mellitus is characterised by persistent thromboxane (TX)-dependent platelet activation, regardless of disease duration." | 2.52 | Aspirin for primary prevention in diabetes mellitus: from the calculation of cardiovascular risk and risk/benefit profile to personalised treatment. ( Davì, G; Pignatelli, P; Santilli, F; Violi, F, 2015) |
| " Importantly, these drug-drug interactions have prognostic implications, since patients with high on-treatment platelet reactivity associated with reduced clopidogrel metabolism have an increased risk of ischemia." | 2.52 | Drug-drug interactions between clopidogrel and novel cardiovascular drugs. ( Angiolillo, DJ; Gaudio, C; Greco, C; Marazzi, G; Pelliccia, F; Rollini, F, 2015) |
| "Aspirin has been one of the most widely used medications since its first synthesis more than 100 years ago." | 2.52 | Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence. ( Huang, WK; See, LC; Tu, HT, 2015) |
| " Furthermore, it has been demonstrated that chronic use of low dose ASA results in a variety of lesions in the lower GI tract, including multiple petechiae, erosions, ulcers, diverticular bleeding and even circumferential ulcers with stricture." | 2.52 | Epidemiology of Low Dose Aspirin Damage in the Lower Gastrointestinal Tract. ( Lanas, A; Sostres, C, 2015) |
| "Aspirin therapy has proven clinical effectiveness in the prevention and treatment of CVD and is one of the most widely used drugs nationwide." | 2.50 | Aspirin for cardioprotection and strategies to improve patient adherence. ( Duffy, D; Kelly, E; Mills, G; Trang, A; Whellan, D, 2014) |
| "Obesity is a substantial cardiovascular risk factor, and recently, large trials of lifestyle and surgical (e." | 2.50 | Type 2 diabetes and cardiovascular disease: what next? ( Golden, SH; Joseph, JJ, 2014) |
| "Uncorrected bleeding diathesis might increase the risk and is considered to be an absolute contraindication for SWL." | 2.50 | Antiplatelet and anticoagulative medication during shockwave lithotripsy. ( Bründl, J; Burger, M; Chaussy, CG; Fritsche, HM; Gierth, M; Schnabel, MJ, 2014) |
| " In recent years, a growing body of evidence regarding potential risks from chronic use of NSAIDs has emerged." | 2.50 | Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes. ( Capodanno, D; Capranzano, P; Gargiulo, G; Longo, G; Tamburino, C, 2014) |
| "Aspirin was associated with reductions in major cardiovascular events (risk ratio, 0." | 2.50 | Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status. ( Bao, W; Chen, S; Hu, FB; Liu, L; Rong, Y; Shan, Z; Xie, M; Yang, W; Yu, X; Zhang, Y, 2014) |
| "Aspirin probably has a preventive effect on metastasis." | 2.49 | [Aspirin and cancer: evidence of a prophylactic effect]. ( Algra, AM; Nortier, JW, 2013) |
| "Aspirin has a well-established role in preventing adverse events in patients with known cardiovascular disease." | 2.49 | Aspirin: its risks, benefits, and optimal use in preventing cardiovascular events. ( Bavry, AA; Park, K, 2013) |
| "Aspirin is an important antiplatelet agent in the treatment of cardiovascular disease." | 2.49 | Cardiovascular prophylaxis and aspirin "allergy". ( Simon, RA; Woessner, KM, 2013) |
| "Aspirin reduced reported colorectal cancer (CRC) incidence (OR 0." | 2.49 | Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews. ( Clarke, A; Connock, M; Freeman, K; Grove, A; Gurung, B; Gurung, T; Johnson, S; Kandala, NB; Morrow, S; Sutcliffe, P, 2013) |
| " The goals of the clinical development program were to demonstrate the following: improved gastrointestinal safety of PA relative to enteric-coated aspirin alone; bioequivalence and comparative bioavailability between the PA compounds and currently marketed enteric-coated aspirin; and long-term safety." | 2.49 | PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection. ( Bliden, KP; Brener, M; Franzese, CJ; Gesheff, MG; Gurbel, PA; Tabrizchi, A; Tantry, U, 2013) |
| "Avoiding hypoglycemia is most important for elderly patients with long history of diabetes and atherosclerosis." | 2.49 | [Cardiovascular event in elderly patients with diabetes mellitus]. ( Nomura, K, 2013) |
| "Stroke is the second cause of death worldwide and one of the leading cause of disability." | 2.49 | Antiplatelets in stroke prevention. ( Buttà, C; Di Raimondo, D; Licata, G; Pinto, A; Tuttolomondo, A, 2013) |
| "In this meta-analysis, TAT was associated with significantly effective outcomes for TLR and TVR without any increase in major adverse events but was associated with tolerance issues compared with DAT after DES implantation." | 2.49 | Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials. ( Bonneau, HN; Kaneda, H; Koo, BK; Nagai, R; Sakurai, R, 2013) |
| " This systematic review assesses the efficacy and safety of adjunctive cilostazol to DAT in combination with DAT on reducing clinical adverse events." | 2.49 | Efficacy and safety of adjunctive cilostazol to dual antiplatelet therapy after stent implantation: an updated meta-analysis of randomized controlled trials. ( Ding, XL; Gao, J; Jiang, B; Miao, LY; Xie, C; Zhang, H; Zhang, JJ; Zhang, LL, 2013) |
| "Aspirin was discontinued and pantoprazole was started, with resolution of the bleeding." | 2.49 | Reinitiating aspirin therapy for primary prevention of cardiovascular events in a patient post-aspirin-induced upper gastrointestinal bleed: a case report and review of literature. ( Adly, G; Plakogiannis, R, 2013) |
| "Second, new findings about postoperative pain management in patients with preoperative pain and chronic opioid consumption are reported." | 2.48 | Room for improvement: unmet needs in postoperative pain management. ( Pogatzki-Zahn, EM; Schnabel, A; Zahn, PK, 2012) |
| "Patients with type 2 diabetes mellitus are at 2 to 4 times increased risk of cardiovascular events compared with those without diabetes, both among patients with multiple risk factors only and those with established atherothrombosis." | 2.48 | Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus. ( Bhatt, DL; Braunwald, E; Davidson, J; Hirshberg, B; Raz, I; Scirica, BM; Steg, PG; Udell, JA, 2012) |
| "This review explores the results of clinical studies on the influence of the combination esomeprazole (ESA) and ASA on pharmacokinetic (PK) parameters, and the role for such combination in prevention of CV events in patients at risk of gastric ulcers." | 2.48 | Pharmacokinetic and clinical evaluation of esomeprazole and ASA for the prevention of gastroduodenal ulcers in cardiovascular patients. ( Bardou, M; Barkun, AN; Goirand, F; Hamza, S; Le Ray, I, 2012) |
| "Current acetylsalicylic acid (ASA) dosing algorithms for the prevention of secondary thrombotic events in acute coronary syndrome (ACS) patients are inconsistent and lack sufficient data support." | 2.48 | Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature. ( Berger, JS; Katona, B; Maya, J; Mwamburi, M; Ranganathan, G; Sallum, RH; Xu, Y, 2012) |
| "Aspirin has been used for the prevention and treatment of cardiovascular disease (CVD) for several decades." | 2.48 | Aspirin for primary prevention of cardiovascular disease events. ( Morbitzer, KA; Moser, LR; Nemerovski, CW; Salinitri, FD, 2012) |
| " Furthermore, there is growing evidence that long-term use of aspirin decreases the risk of colorectal cancer, even at low doses." | 2.47 | Gastrointestinal effects of aspirin. ( Lanas, A; Sostres, C, 2011) |
| "Aspirin use was associated with a significantly lower risk of mortality (RR: 0." | 2.47 | Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis. ( Chambers, T; Gamble, JM; Mereu, L; Simpson, SH, 2011) |
| "Aspirin therapy was not associated with a statistically significant reduction in major cardiovascular events (relative risk [RR] 0." | 2.46 | Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. ( Fu, M; Ge, J; Sun, A; Wang, K; Wu, C; Zhang, C; Zhang, P; Zhang, S; Zou, Y, 2010) |
| "Age and history of thrombosis are the criteria used to stratify patients to the most appropriate therapeutic options." | 2.46 | JAK2 mutation and thrombosis in the myeloproliferative neoplasms. ( Vannucchi, AM, 2010) |
| "Aspirin was included in cost-effectiveness models that determined direct cost savings." | 2.46 | A review of international pharmacoeconomic models assessing the use of aspirin in primary prevention. ( Annemans, L; Bueno, H; Wittrup-Jensen, K, 2010) |
| " Until further reliable controlled data are available, this potential, but currently unproven, clinical interaction can be minimized by widely separating the dosing of clopidogrel and PPI." | 2.46 | NSAID-induced gastrointestinal and cardiovascular injury. ( Chan, FK; Ng, SC, 2010) |
| "Psoriasis is highly prevalent and is associated with skin-associated complaints as well as arthritis, depression and a lower quality of life." | 2.45 | Psoriasis: an opportunity to identify cardiovascular risk. ( Federman, DG; Gunderson, CG; Kirsner, RS; Prodanovich, S; Shelling, M, 2009) |
| " We conclude that the benefits of prasugrel are overestimated, and the risks, especially during chronic use are underestimated." | 2.45 | Prasugrel development - claims and achievements. ( Kopyleva, O; Serebruany, V; Shalito, I, 2009) |
| "Aspirin has been a commercial drug for over a century, although for most of this history, an understanding of its mechanism of action, as an inhibitor of cyclooxygenase (COX) activity and thus of prostanoid synthesis, was lacking." | 2.45 | Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges. ( Baigent, C; Patrono, C, 2009) |
| "The prevalence of Type 2 diabetes mellitus (DM) continues to increase globally and brings with it a parallel increase in the associated cardiovascular disease complications." | 2.45 | Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment. ( Mathewkutty, S; McGuire, DK, 2009) |
| "Aspirin therapy was associated with a reduction in the secondary outcome of nonfatal stroke (52 of 2823 vs 76 of 2446; RR, 0." | 2.45 | Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. ( Berger, JS; Hiatt, WR; Kittelson, JM; Krantz, MJ, 2009) |
| " For antiplatelet agents, the most important risk is excess bleeding, especially as emerging evidence suggests that excess bleeding is associated with adverse long-term outcomes; thus prevention and management of excess bleeding is critically important." | 2.45 | Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease. ( Spinler, SA, 2009) |
| "Paralleling the rise in obesity, the cardiometabolic syndrome is a rapidly growing health problem in the United States." | 2.45 | Utility of aspirin therapy in patients with the cardiometabolic syndrome and diabetes. ( Gardner, DW; Gardner, M; Lastra, G; Manrique, C; Palmer, J; Sowers, JR, 2009) |
| " The improved efficacy of multiple-drug therapy is associated with an increased risk of bleeding, which raises the issue of the dosing of these drugs." | 2.45 | Antiplatelet agents. ( Spectre, G; Varon, D, 2009) |
| " Off-label long-term use of COX2 inhibitors in patients with a history of colorectal adenomas in well-designed, placebo-controlled trials showed that treatment with these agents is associated with an increased rate of cardiovascular adverse effects." | 2.44 | Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal. ( Brune, K; Hinz, B; Renner, B, 2007) |
| " In secondary prevention, in a wide range of patients who have survived a prior myocardial infarction (MI), occlusive stroke, transient ischemic attack, as well as other high-risk conditions, long-term use of aspirin confers statistically significant and clinically important reductions in MI, stroke and CVD death." | 2.44 | The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease. ( Hennekens, CH; Schneider, WR, 2008) |
| "Aspirin therapy was associated with a significant 21% reduction in the risk of cardiovascular events (nonfatal MI, nonfatal stroke, and cardiovascular death) (95% confidence interval [CI], 0." | 2.44 | Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. ( Becker, RC; Berger, JS; Brown, DL, 2008) |
| "Aspirin resistance was assessed, using a variety of platelet function assays." | 2.44 | Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. ( Beattie, WS; Brister, SJ; Buchanan, MR; Krasopoulos, G, 2008) |
| "Aspirin resistance was required to have been measured by a standardized laboratory technique to be included in the analysis." | 2.44 | Pharmacogenetics of aspirin resistance: a comprehensive systematic review. ( Ferro, A; Goodman, T; Sharma, P, 2008) |
| " This article reviews the current state of selective COX-2 inhibitors, discusses the mechanistic evidence underlying the cardiovascular risk associated with selective COX-2 inhibition, outlines the pharmacodynamics of aspirin effects on platelets and the interference of propionic acid derivatives (ibuprofen and naproxen) with these effects, and poses that aspirin confounding may have led to the erroneous conclusion of naproxen-associated adverse cardiovascular outcomes in the ADAPT trial." | 2.43 | The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding. ( Konstantinopoulos, PA; Lehmann, DF, 2005) |
| "The Metabolic syndrome is a widely prevalent and multi-factorial disorder." | 2.43 | Metabolic syndrome. ( Agarwal, PK; Gogia, A, 2006) |
| "The metabolic syndrome is a clustering of risk factors including central obesity, insulin resistance, dyslipidaemia and hypertension." | 2.43 | Dyslipidaemia, hypercoagulability and the metabolic syndrome. ( Athyros, VG; Kakafika, AI; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP, 2006) |
| "Cardiovascular diseases are the major cause of death and a significant cause of disability in the Western world and more recently threaten to pose an increasing health burden on developing nations." | 2.43 | Drug therapies in the secondary prevention of cardiovascular diseases: Successes, shortcomings and future directions. ( Grewal, J; Lonn, E, 2006) |
| " Since the optimal dose of ASA for primary and secondary prevention of events in the broad population is uncertain, dosing considerations should include an evaluation of a patient's individual clinical status as well as an overall cardiovascular and cerebrovascular benefit vs." | 2.43 | The dose of aspirin for the prevention of cardiovascular and cerebrovascular events. ( Fisher, M; Knappertz, V, 2006) |
| "The principal presentations of Kawasaki disease include fever, bilateral nonexudative conjunctivitis, erythema of the lips and oral mucosa, changes in the extremities, rash, and cervical lymphadenopathy." | 2.43 | Kawasaki disease. ( Kim, DS, 2006) |
| "Pharmacologic and clinical studies focusing on the dose-response relationship of aspirin therapy were reviewed." | 2.42 | Aspirin dose for prevention of cardiovascular disease in diabetics. ( Jaber, LA; Nowak, SN, 2003) |
| "Pravastatin has a predominantly delayed antiatherogenic effect, and aspirin has an immediate antiplatelet effect, raising the possibility of additive clinical benefits." | 2.42 | Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. ( Belder, R; Berry, DA; Berry, SM; Byington, RP; Fiedorek, FT; Ford, NF; Hennekens, CH; Jukema, JW; Natarajan, K; Pitt, B; Sacks, FM; Sheng-Lin, C; Tonkin, A; Walker, AJ, 2004) |
| "Type 2 diabetes has now reached epidemic proportions across the world and is the cause of substantial morbidity and mortality." | 2.42 | Intense management of diabetes mellitus: role of glucose control and antiplatelet agents. ( Mudaliar, S, 2004) |
| "With aspirin there is a 1." | 2.42 | [Prevention of cardiovascular and degenerative diseases: I. Aspirin, statins, or vitamins?]. ( Martin-Du Pan, RC, 2003) |
| " Antioxidant and anti-inflammatory mechanisms with different dose-response relationships may contribute to the clinical effect of aspirin in cardiovascular disease." | 2.42 | Aspirin in cardiovascular disorders. What is the optimum dose? ( Kong, DF, 2004) |
| "Aspirin is an effective antiplatelet agent with proven benefit in the prevention of atherothrombotic complications of cardiovascular disease." | 2.42 | Aspirin resistance: current concepts. ( Freedman, JE; Jacobs, AK; Mason, PJ, 2004) |
| "Aspirin is a very useful medication for the prevention of cardiovascular thrombotic events in patients with or those at risk for cardiovascular disease (CVD)." | 2.42 | Cardioprotective effects and gastrointestinal risks of aspirin: maintaining the delicate balance. ( Kimmey, MB, 2004) |
| "Aspirin reduced all-cause mortality by 18%." | 2.41 | Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. ( Graham, DY; Weisman, SM, 2002) |
| "Patients with type 2 diabetes have a high risk of morbidity and premature mortality from cardiovascular disease." | 2.41 | [Prevention of cardiovascular disease in type 2 diabetes]. ( Birkeland, KI; Claudi, T; Hanssen, KF; Hansteen, V; Hjermann, I; Jenssen, T; Jervell, J; Os, I, 2000) |
| " In contrast, GI toxicity of the drug does appear to be dose related, consistent with dose- and dosing interval-dependent inhibition of COX-1 activity in the nucleated lining cells of the GI mucosa." | 2.41 | Aspirin: new cardiovascular uses for an old drug. ( Patrono, C, 2001) |
| " The data reported in the literature do not however enable any evidenced-based decision on dosing for the diabetic population with numerous cardiovascular risks." | 2.41 | [Prevention of cardiovascular diseases in type 2 diabetes with aspirin]. ( Duly-Bouhanick, B; Guilloteau, G; Hadjadj, S; Menard, S; Plun-Favreau, J; Soares-Barbosa, S, 2001) |
| "Aspirin has also demonstrated a potential ability to reduce the risk of deep venous thrombosis and pulmonary embolism." | 2.41 | An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I. ( Moyad, MA, 2001) |
| " These findings are likely to result, at least in part, from the antiplatelet action of naproxen, which has been shown to be potent and sustained during a typical dosing regimen (500 mg twice daily in VIGOR)." | 2.41 | Current perspective on the cardiovascular effects of coxibs. ( Konstam, MA; Weir, MR, 2002) |
| "Chronic hyperglycemia is then added to these risk markers." | 2.40 | Multifactorial aspects of the treatment of the type II diabetic patient. ( Colwell, JA, 1997) |
| "Aspirin was first synthesised 100 years ago and its preparation and marketing is generally reckoned to have been the foundation of the pharmaceutical industry." | 2.40 | Platelets, aspirin, and cardiovascular disease. ( Elwood, PC; Hughes, C; O'Brien, JR, 1998) |
| " The present article reviews the literature on oral anticoagulants combined with aspirin in the prevention and treatment of arterial thromboembolism and draws a comparison to oral anticoagulation alone and aspirin alone, respectively." | 2.39 | Oral anticoagulation alone or in combination with aspirin: risks and benefits. ( Bounameaux, H; de Moerloose, P; Hafner, J, 1996) |
| "Aspirin is a widely used and effective antithrombotic agent." | 2.39 | Aspirin therapy for cardiovascular disease. ( Goodnight, SH, 1996) |
| "Aspirin has many uses in cardiovascular disease." | 2.38 | The use of aspirin in cardiovascular disease. ( Byers, JF, 1993) |
| "The role of Kawasaki disease (KD) as a contributor to early childhood cardiac morbidity in Adelaide was investigated by a review of hospital admission and case-note data from January 1979 to June 1990." | 2.38 | Kawasaki disease in Adelaide: a review. ( Goldwater, PN; Smith, PK, 1993) |
| " Women presenting with unstable angina or myocardial infarction should receive aspirin 325 mg as soon as the diagnosis is confirmed, and this dosage should be continued on a chronic basis." | 2.38 | Aspirin for the prevention of vascular death in women. ( Corn, CR; Hamilton, SF; McAnally, LE, 1992) |
| "Aspirin was also associated with significantly fewer reinfarctions and strokes." | 2.38 | Aspirin in chronic cardiovascular disease and acute myocardial infarction. ( Hennekens, CH, 1990) |
| "Although Kawasaki disease has been reported throughout the world, it is more prevalent in Japan." | 2.37 | [Kawasaki syndrome. Apropos of a case]. ( Borde, M; Kubryk, N, 1984) |
| " Long term administration of doses of aspirin as low as 20mg daily depresses platelet thromboxane formation by more than 90%; however, higher doses appear to be necessary to prevent thromboxane-dependent platelet activation in vivo." | 2.37 | Aspirin in cardiovascular disease. ( FitzGerald, GA; Reilly, IA, 1988) |
| "lansoprazole was 0." | 1.91 | Cost-Effectiveness of Vonoprazan Compared With Proton Pump Inhibitors in Patients Taking Low-Dose Aspirin for Secondary Prevention of Cardiovascular Events in Japan. ( Deguchi, H; Fernandez, J; Igarashi, A; Ishii, M; Kawai, T; Suzuki, M; Tsujita, K, 2023) |
| "Epistaxis is the most common otolaryngological emergency and one-third of epistaxis patients regularly take low-dose acetylsalicylic acid (ASA) for the prevention of cardiovascular disease (CVD)." | 1.91 | The pattern of epistaxis recurrence in patients taking prophylactic acetylsalicylic acid (ASA) from a 10 year cohort. ( Hoch, S; Rudhart, S; Stanković, P; Stojković, S; Wilhelm, T, 2023) |
| " The 100 mg dosage was predominant in patients with ischemic heart disease with (64%) and without (64%) angina, as well as those with myocardial infarction (61." | 1.91 | Adherence to European guidelines for the use of aspirin in primary health care. ( Corte-Real, S; Dantas, A; Ferreira Moita, C; Marau, G, 2023) |
| "Aspirin is an essential drug in the prevention of atherosclerotic cardiovascular disease (ASCVD)." | 1.91 | Appropriateness of aspirin use among diabetic patients in primary prevention of atherosclerotic cardiovascular diseases: an analysis of the ASSOS study. ( Basaran, O; Celik, O; Cil, C; Demirci, E; Dogan, V; Kaya, C; Kırıs, T; Memic Sancar, K; Orscelik, O; Resulzade, MM; Tanık, VO, 2023) |
| "This study aimed to estimate how prevalent potential drug-drug interactions (pDDIs) were in patients with cardiovascular diseases who were hospitalized for more than 24 hours, and to determine the risk factors associated with these pDDIs." | 1.91 | Detection and analysis of potential drug-drug interactions among patients admitted to the cardiac care unit in a tertiary care hospital. ( Almaghaslah, D; Khaled, A; Makki, S; Nagib, R; Siddiqua, A, 2023) |
| " After adjusting for sociodemographic and common cardiovascular risk factors, we used multivariable logistic regression analysis to determine aspirin should be combined with which type of statin for better CVD preventive effects." | 1.91 | Cardiovascular disease preventive effects of aspirin combined with different statins in the United States general population. ( Huangtao, Z; Li, B; Liu, T; Pan, Y; Sun, L; Wang, B; Wang, J; Wang, S; Zhu, Z; Zuo, R, 2023) |
| " Large trials assessing use in the primary prevention setting and optimal dosing regimens were studied in the late 1990s and early 2000s." | 1.91 | Redefining the Roles of Aspirin across the Spectrum of Cardiovascular Disease Prevention. ( Bortfeld, KS; Brown, MT; Sperling, LS; Wenger, NK, 2023) |
| "The association between cancer and the use of pharmacological therapies varied between those with vs." | 1.91 | The underutilization of preventive cardiovascular measures in patients with cancer: an analysis of the Behavioural Risk Factor Surveillance System, 2011-22. ( Abushouk, AI; Addison, D; Blaes, A; Dent, SF; Fradley, MG; Moustafa, K; Munir, M; Neilan, TG; Nohria, A; Sayed, A; Virani, SS, 2023) |
| "Aspirin is an effective and low-cost option for reducing atherosclerotic cardiovascular disease (CVD) events and improving mortality rates among individuals with established CVD." | 1.91 | Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, and High-Income Countries. ( Aryal, KK; Atun, R; Azangou-Khyavy, M; Bahendeka, SK; Bärnighausen, T; Brant, LCC; Chung, GS; Cífková, R; Damasceno, A; Davies, JI; Farzadfar, F; Flood, D; Geldsetzer, P; Gurung, MS; Guwatudde, D; Haghshenas, R; Houehanou, C; Huffman, MD; Karki, KB; Lunet, N; Manne-Goehler, J; Marcus, ME; Martins, J; Mwangi, JK; Norov, B; Rohloff, P; Saeedi Moghaddam, S; Sibai, AM; Singh, K; Sturua, L; Sussman, JB; Theilmann, M; Vollmer, S; Yoo, SGK, 2023) |
| "Aspirin was used significantly more in people attending shared care (p < 0." | 1.72 | Appropriateness of aspirin prescribing for primary and secondary prevention of cardiovascular disease in type 2 diabetes in different care settings. ( Byrne, S; Cronin, H; O'Donovan, A; Tan, SY; Tuthill, A, 2022) |
| "Class 1 obesity is associated with enhanced platelet activation in response to AA in patients on dual antiplatelet therapy." | 1.62 | Residual platelet reactivity in low-dose aspirin-treated patients with class 1 obesity. ( Eichelberger, B; Gremmel, T; Kopp, CW; Lee, S; Panzer, S, 2021) |
| "Aspirin is the key treatment in the secondary prevention of atherosclerotic cardiovascular disease." | 1.62 | Association between renal function and platelet reactivity during aspirin therapy in elderly patients with atherosclerotic cardiovascular disease. ( Liang, W; Liu, M; Zhang, P, 2021) |
| " Panel members agreed to recognize polypill as effective in reducing cardiovascular events, blood pressure and lipids, cardiovascular risk and the weight of therapy, in therapeutic adherence improvement, in the absence of differences in bioavailability between drugs administered in fixed or free combinations and the better cost-effectiveness profile compared with standard care." | 1.62 | The value of the polypill in cardiovascular disease: an Italian multidisciplinary Delphi panel consensus. ( Bianchi, S; Cafiero, D; Corona, T; Gambarelli, G; Izzi, C; Lopatriello, S; Menditto, E; Minghetti, P; Misciagna, V; Perrone-Filardi, P; Piccinocchi, G; Putignano, D; Scaglione, F; Trifirò, G, 2021) |
| "Aspirin has long been recommended to reduce cardiovascular events." | 1.62 | Low-dose aspirin for primary prevention of cardiovascular disease: Trends in use patterns among African American adults in Minnesota, 2015-2019. ( Duval, S; Eder, MM; Finnegan, JR; Jones, C; Luepker, RV; Misialek, JR; Oldenburg, NC; Van't Hof, JR, 2021) |
| "Oral squamous cell carcinoma (OSCC) remains one of the most challenging clinical problems in the field due to its high rate of locoregional and distant metastases." | 1.62 | Low-dose aspirin confers a survival benefit in patients with pathological advanced-stage oral squamous cell carcinoma. ( Chen, CH; Chen, WC; Chiu, TJ; Fang, FM; Hsiao, CC; Huang, TL; Li, SH; Luo, SD; Wu, CN; Wu, SC; Yang, YH, 2021) |
| " The Management of Aspirin-induced Gastrointestinal Complications (MAGIC) study clarified the rates of major CV and bleeding events with long-term use of aspirin in patients with prior CV diseases in real-world clinical practice." | 1.56 | Major cardiovascular and bleeding events with long-term use of aspirin in patients with prior cardiovascular diseases: 1-year follow-up results from the Management of Aspirin-induced Gastrointestinal Complications (MAGIC) study. ( Goto, S; Hiraishi, H; Ikeda, Y; Okada, Y; Origasa, H; Shimada, K; Sugano, K; Uchiyama, S; Uemura, N, 2020) |
| "Aspirin was associated with reduced all-cause mortality." | 1.56 | All-cause mortality following low-dose aspirin treatment for patients with high cardiovascular risk in remote Australian Aboriginal communities: an observational study. ( Burgess, P; Connors, C; Falhammar, H; Guthridge, S; Jeyaraman, K; Maple-Brown, L; Zhao, Y, 2020) |
| " We found that more than half of patients prescribed with triple free drug combination therapy with ACEi plus CCB plus statin or ACEi plus statin plus low-dose aspirin, were found to be nonadherent to these treatments." | 1.56 | Adherence to Triple-Free-Drug Combination Therapies Among Patients With Cardiovascular Disease. ( Bettiol, A; Crescioli, G; Cricelli, C; Lapi, F; Lombardi, N; Marconi, E; Parretti, D; Simonetti, M; Vannacci, A, 2020) |
| "Chronic noninfectious diseases (cardiovascular, bronchopulmonary, oncological diseases and diabetes mellitus) are presently the most common cause of death worldwide, with cardiovascular diseases (CVD) being predominant." | 1.56 | [Primary prevention of chronic non-communicable diseases and acetylsalicylic acid: ambiguity of opinions]. ( Gaydina, TA; Kuznetsova, VA; Larina, VN; Mkrtychev, DS; Snezhko, ZV, 2020) |
| "Such combination is very useful for treating various cardiovascular diseases (CVD) including high blood pressure, hypercholesterolemia in addition to its antiplatelet aggregating activity." | 1.56 | Analysis of quinary therapy targeting multiple cardiovascular diseases using UV spectrophotometry and chemometric tools. ( Abdulwahab, S; Eissa, MS; Elsonbaty, A; Hassan, WS; Serag, A, 2020) |
| "Aspirin users were divided into three groups: continuous users (2006-2010), previous users (2006-2009), and new users (2010)." | 1.56 | Long-Term Aspirin Use and 5-Year Survival in Healthy Adults: A Population-Based Cohort Study in South Korea. ( Oh, TK; Song, IA, 2020) |
| "Cardiovascular diseases are the main drivers of the morbidity and mortality in Russian Federation." | 1.56 | [Decreasing cardiovascular morbidity: how to improve adherence to the treatment in the translational era]. ( Zhirov, IV, 2020) |
| ": The prevalence of hypertension, type 2 diabetes mellitus (DM2) and the metabolic syndrome continues to increase in Latin America, while the rates of diagnosis, treatment and control of these disorders remain low." | 1.51 | Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome. ( Accini, JL; Alcocer, L; Barbosa, E; Camacho, PA; Cobos, L; Coca, A; Diaz, M; Lanas, F; López-Jaramillo, P; Molina, DI; Pasquel, M; Ponte-Negretti, CI; Sanchez, R; Sebba-Barroso, W; Wyss, F; Zanchetti, A, 2019) |
| "Aspirin is an effective, low cost option to reduce cardiovascular events." | 1.51 | Aspirin Use for Cardiovascular Disease Prevention in an African American Population: Prevalence and Associations with Health Behavior Beliefs. ( Duval, S; Eder, M; Jones, C; Luepker, RV; Misialek, JR; Oldenburg, NC; Van't Hof, JR, 2019) |
| "Aspirin resistance was evaluated in aspirin-treated patients from the outpatient department." | 1.48 | PFA-100-measured aspirin resistance is the predominant risk factor for hospitalized cardiovascular events in aspirin-treated patients: A 5-year cohort study. ( Chen, HY; Chou, P, 2018) |
| "Although depressive disorders have been associated with increased risk of worse outcomes with cardiovascular diseases (CVDs), its relation with access to and quality of cardiovascular care is not well studied." | 1.48 | Impact of Depressive Disorder on Access and Quality of Care in Veterans With Prevalent Cardiovascular Disease. ( Butler, J; Lacey, M; Parikh, PB; Shroyer, AL; Srivastava, P, 2018) |
| "The sVEGFR-1 level of ESRD group was significantly higher (0." | 1.48 | Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease. Associations with laboratory findings, comorbidities, and medications. ( Acar, R; Erturk, I; Ozgurtas, T; Saglam, K; Yesildal, F, 2018) |
| "A one-dose-fits-all approach to use of aspirin has yielded only modest benefits in long-term prevention of cardiovascular events, possibly due to underdosing in patients of large body size and excess dosing in patients of small body size, which might also affect other outcomes." | 1.48 | Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. ( Belch, JFF; Cook, NR; Gaziano, JM; Mehta, Z; Morimoto, T; Price, JF; Roncaglioni, MC; Rothwell, PM, 2018) |
| "Aspirin was reported by about 11% patients, as being twice as used in men (11." | 1.48 | Epidemiology of non-steroidal anti-inflammatory drugs consumption in Spain. The MCC-Spain study. ( Alonso-Molero, J; Altzibar, JM; Amiano, P; Aragonés, N; Barricarte, A; Benavente, Y; Capelo, R; Castaño-Vinyals, G; Dávila-Batista, V; de Pedro, M; Dierssen-Sotos, T; Etxeberria, J; Fernández-Tardón, G; Fernández-Villa, T; Gómez-Acebo, I; Huerta, JM; Kogevinas, M; Llorca, J; Marcos-Gragera, R; Palazuelos-Calderón, C; Peiró, R; Pérez-Gómez, B; Pollán, M; Salcedo-Bellido, I; Tardón, A, 2018) |
| "Rivaroxaban alone did not produce any additional benefit compared with aspirin." | 1.48 | Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS. ( Anand, SS; Bhagirath, VC; Eikelboom, JW, 2018) |
| "Aspirin has been associated with reduced incidence and mortality of colorectal and a few other cancers." | 1.48 | Does low-dose aspirin use for cardiovascular disease prevention reduce colorectal cancer deaths? A comparison of two cohorts in the Florence district, Italy. ( Barchielli, A; Manneschi, G; Mantellini, P; Miccinesi, G; Orso, F; Puliti, D; Ventura, L; Zappa, M, 2018) |
| "Aspirin users were significantly older (P < 0." | 1.46 | Safety and feasibility of liver resection with continued antiplatelet therapy using aspirin. ( Hioki, M; Monden, K; Ohno, S; Ono, K; Sadamori, H; Sakaguchi, K; Saneto, H; Takakura, N; Ueki, T; Yabushita, K, 2017) |
| "Aspirin users were found to be at increased risk for major gastrointestinal bleeding." | 1.46 | Should This Patient Receive Aspirin?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. ( Burns, RB; Graham, K; Reynolds, EE; Sawhney, MS, 2017) |
| " However, there is lack of evidence whether shifting the time of intake or splitting the daily dose of P2Y12-inhibitors with a regular QD dosing (clopidogrel or prasugrel) to the evening would be effective to overcome platelet hyper-reactivity or to suppress the excess of cardiovascular events observed during morning hours." | 1.43 | Prevention of cardiovascular events with antiplatelet treatment: does time of intake matter for aspirin and ADP receptor blockers? ( Aradi, D; Gross, L; Sibbing, D, 2016) |
| "Daily generation of novel platelets may compromise aspirin's platelet inhibitory action, especially near the end of the regular 24-h dosing interval." | 1.43 | Evening intake of aspirin is associated with a more stable 24-h platelet inhibition compared to morning intake: a study in chronic aspirin users. ( Fuijkschot, WW; Smulders, YM; Thijs, A; van Diemen, JJ; Veen, G; Wessels, TJ, 2016) |
| "In conclusion, recurrence of CVEs occurred independently of HTPR and residual COX-1 activity." | 1.43 | Cardiovascular events occur independently of high on-aspirin platelet reactivity and residual COX-1 activity in stable cardiovascular patients. ( Abumiya, T; Furui, E; Hattori, A; Hosomi, N; Isshiki, T; Kada, A; Kaikita, K; Kario, K; Katayama, Y; Kawamura, A; Kimura, K; Kitagawa, K; Minematsu, K; Miyata, S; Miyata, T; Nagao, T; Nagatsuka, K; Nakagawara, J; Nakane, H; Nishikawa, M; Ogawa, H; Okada, H; Saito, K; Takiuchi, S; Tanaka, K; Taomoto, K; Uchiyama, S; Wada, H; Yamawaki, T; Yonemoto, N, 2016) |
| "HPR-aspirin was persistent 75days later in 36% patients." | 1.43 | High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction. ( Dillinger, JG; Drouet, L; Henry, P; Saeed, A; Sideris, G; Silberman, SM; Sollier, CB; Spagnoli, V; Voicu, S, 2016) |
| "Aspirin previously has been found to be associated with reduced carcinogenesis of prostate cells." | 1.43 | The association between regular use of aspirin and the prevalence of prostate cancer: Results from the National Health Interview Survey. ( Erickson, SR; Hansen, RA; Huang, WT; Wu, CH, 2016) |
| "In warfarin-treated patients, each 5% LVEF decrement significantly increased the stroke risk (adjusted hazard ratio, 1." | 1.43 | Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial. ( Anker, SD; Buchsbaum, R; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Teerlink, JR; Thompson, JL, 2016) |
| "Antiplatelet therapy in patients with chronic subdural hematoma (cSDH) presents significant neurosurgical challenges." | 1.43 | Does Early Resumption of Low-Dose Aspirin After Evacuation of Chronic Subdural Hematoma With Burr-Hole Drainage Lead to Higher Recurrence Rates? ( Fandino, J; Kamenova, M; Lutz, K; Mariani, L; Schaedelin, S; Soleman, J, 2016) |
| "Diabetes mellitus has been associated with a substantially increased risk of both first and recurrent atherothrombotic events, which makes aspirin therapy of potential value in these subjects." | 1.43 | Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus. ( Angiolillo, DJ; Capodanno, D, 2016) |
| " These results suggest that even the acute use of an NSAID (regardless of COX-2 selectivity) can induce gastric damage when combined with the long-term use of low-dose aspirin in an animal model." | 1.43 | Gastric and renal effects of COX-2 selective and non-selective NSAIDs in rats receiving low-dose aspirin therapy. ( Baglie, S; Baller, EM; Franco, GC; Gevert, MV; Lupepsa, AC; Moro, MG; Sanchez, PK; Tostes, AF, 2016) |
| "Radiation-treated head and neck cancer (HNC) patients are at high risk for developing radiation vasculopathy, as evidenced by an increased stroke risk." | 1.42 | Carotid intima-media thickness measurement promises to improve cardiovascular risk evaluation in head and neck cancer patients. ( Ahn, P; deGoma, E; Hajj, J; Jacoby, D; Javaheri, A; Lin, A; Quon, H, 2015) |
| " In addition, the variability in benefit achievable from the prescription of aspirin has led to a growing interest in considering whether there are more effective aspirin regimens than once-daily dosing or whether effectiveness is influenced by the time of day aspirin is taken (chronotherapy)." | 1.42 | Investigating the effectiveness of different aspirin dosing regimens and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: protocol for a systematic review. ( Bayliss, S; Bem, D; Dretzke, J; Fitzmaurice, D; Hodgkinson, J; Lordkipanidzé, M; Moore, D; Stevens, S, 2015) |
| "We used the Gail/National Cancer Institute approach for assessing benefits and harms." | 1.42 | Aspirin for Primary Prevention of Cardiovascular Disease and Cancer. A Benefit and Harm Analysis. ( Bossuyt, PM; Boyd, C; Puhan, MA; Stegeman, I; Yu, T, 2015) |
| "A total of 92 patients with prostate cancer were divided into observation group (n=44) and control group (n=48)." | 1.42 | Preventive Effects of Aspirin on Cardiovascular Complications in Prostate Cancer Cases after Endocrinotherapy. ( Chen, YF; Li, XX; Shan, YH; Wang, D; Zhang, YG, 2015) |
| "Aspirin has been shown to have relative beneficial effects in preventing a first myocardial infarction, but not stroke." | 1.42 | Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries? ( Nansseu, JR; Noubiap, JJ, 2015) |
| "Aspirin use was highest in those aged 65 to 74 years." | 1.42 | Population Trends in Aspirin Use for Cardiovascular Disease Prevention 1980-2009: The Minnesota Heart Survey. ( Duval, S; Hirsch, AT; Luepker, RV; Steffen, LM; Zantek, ND; Zhou, X, 2015) |
| "Aspirin resistance was measured in aspirin reaction units using VerifyNow(®)." | 1.40 | Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes. ( Ahn, KJ; Cho, JH; Choi, KM; Kang, JG; Kim, JD; Kim, JH; Lee, BW; Lee, KY; Mok, JO; Moon, MK; Park, CY; Park, JY; Park, SW, 2014) |
| "Cardiovascular diseases are the leading causes of disability and death in the United States." | 1.40 | A 16-month community-based intervention to increase aspirin use for primary prevention of cardiovascular disease. ( Duval, S; Finnegan, JR; Hirsch, AT; Jacobs, G; LaMarre, H; Luepker, RV; Miller, KH; Oldenburg, NC; Peterson, KA; Straka, RJ; Zantek, ND, 2014) |
| "adults have a heart attack or stroke, resulting in approximately 30 deaths every hour and, for nonfatal events, often leading to long-term disability." | 1.40 | Million hearts: prevalence of leading cardiovascular disease risk factors--United States, 2005-2012. ( George, MG; Gillespie, C; Jamal, A; Ritchey, MD; Wall, HK, 2014) |
| "Aspirin use has been shown to be an effective tool in cardiovascular disease (CVD) prevention among high-risk patients." | 1.40 | Use of aspirin for primary and secondary cardiovascular disease prevention in the United States, 2011-2012. ( Limacher, MC; Mainous, AG; Shorr, RI; Tanner, RJ, 2014) |
| " The reference dose of Diclofenac used in all randomized controlled trials is 150 mg/die; this controlled release dosage allows to decrease the number of daily administrations, ensuring a better patient compliance, especially if elderly and/or in polytherapy." | 1.40 | [Diclofenac: update on tolerableness and spinal anti-inflammatory action]. ( Sandri, A, 2014) |
| "PCNL is safe in patients continuing aspirin perioperatively and does not result in more blood transfusions, angioembolization procedures, or complications." | 1.40 | Continuing aspirin therapy during percutaneous nephrolithotomy: unsafe or under-utilized? ( Elsamra, SE; Hoenig, DM; Leavitt, DA; Moreira, DM; Okeke, Z; Smith, AD; Theckumparampil, N; Waingankar, N, 2014) |
| "Aspirin is an important part of primary cardiovascular disease prevention, but little is known about aspirin use patterns in regional health care systems." | 1.40 | Identifying opportunities to improve aspirin utilization for the primary prevention of cardiovascular disease in a regional health care system. ( Miller, AW; Rezkalla, H; VanWormer, JJ, 2014) |
| "Aspirin was administered, followed by whole-blood RNA microarray profiling, in a discovery cohort of healthy volunteers (HV1) (n = 50) and 2 validation cohorts of healthy volunteers (HV2) (n = 53) and outpatient cardiology patients (OPC) (n = 25)." | 1.39 | Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events. ( Becker, RC; Chi, JT; Cyr, D; Dungan, J; Ginsburg, GS; Katz, R; Kraus, WE; Lucas, J; McCaffrey, TA; Newby, LK; Ortel, TL; Voora, D, 2013) |
| "High platelet reactivity (HPR) under treatment with clopidogrel or aspirin is associated with adverse outcome." | 1.39 | Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. ( Christ, G; Delle-Karth, G; Drucker, C; Huber, K; Jilma, B; Maurer, G; Neunteufl, T; Siller-Matula, JM; Tolios, A, 2013) |
| "Aspirin resistance has been well reported in CVD." | 1.39 | Frequency, risk factors, prognosis, and genetic polymorphism of the cyclooxygenase-1 gene for aspirin resistance in elderly Chinese patients with cardiovascular disease. ( Cao, J; Fan, L; Hu, G; Hu, Y; Li, X; Liu, L; Zhu, B, 2013) |
| "Inflammation is postulated to link obesity and benign prostatic hyperplasia (BPH)." | 1.39 | Body mass index predicts failure of surgical management in benign prostatic hyperplasia. ( Dick, CP; Edwards, J; Halbert, GL; Horgan, PG; Orange, C; Qayyum, T; Underwood, MA; Walker, VC; Willder, JM, 2013) |
| "Patients who underwent ESD for early gastric neoplasms at the National Cancer Center Hospital, Korea, between November 2008 and January 2011 were enrolled." | 1.38 | Aspirin use and bleeding risk after endoscopic submucosal dissection in patients with gastric neoplasms. ( Cho, SJ; Choi, IJ; Kim, CG; Kim, HJ; Kim, YW; Kwak, MH; Lee, JH; Lee, JY; Nam, BH; Ryu, KW, 2012) |
| "Aspirin was not associated with a significant hemoglobin level variation (median decrease, 2." | 1.38 | Radical prostatectomy with robot-assisted radical prostatectomy and laparoscopic radical prostatectomy under low-dose aspirin does not significantly increase blood loss. ( Armand, C; Binhas, M; Marty, J; Plaud, B; Roudot-Thoraval, F; Salomon, L, 2012) |
| "Kawasaki disease was initially described by a Japanese paediatrician, Dr Tomisaku Kawasaki, in 1967." | 1.38 | Kawasaki disease: a case report and overview of symptoms, signs, investigations and treatment. ( Almeida, B; Brogan, P; Chawla, K; Gleeson, P, 2012) |
| "Aspirin is a key drug used in treating patients with a high risk to develop stroke, myocardial infarction and other cardiovascular events." | 1.38 | The prevalence and factors associated with aspirin resistance in patients premedicated with aspirin. ( Al-Azzam, SI; Alowidi, A; Alzoubi, KH; Khabour, O; Tawalbeh, D, 2012) |
| " Management is currently limited to dosing alteration and introduction of other antiplatelet agents." | 1.37 | Resistance to aspirin and clopidogrel therapy. ( Alam, S; Assaad, S; Beresian, J; Bitar, A; Charafeddine, K; Khoury, M; Musallam, KM; Taher, AT, 2011) |
| "A retrospective study of 58 adult hemophilia patients (≥35 years) attending Mayo Comprehensive Hemophilia Center between 1 January 2006 and 15 October 2009 were reviewed." | 1.37 | Cardiovascular disease risk factors: prevalence and management in adult hemophilia patients. ( Lim, MY; Pruthi, RK, 2011) |
| "Overall, men who developed cancer were less likely to have had hypercholesterolemia (odds ratio (OR) = 0." | 1.36 | Chronic disease in men with newly diagnosed cancer: a nested case-control study. ( Driver, JA; Gaziano, JM; Kurth, T; Yung, R, 2010) |
| "Aspirin use was reported in 50% of patients: 68." | 1.36 | Aspirin use in elderly women receiving medication therapy management services. ( Cooke, CE; Lee, HY; Tong, YP; Xing, S, 2010) |
| "The text of EMRs for 499 patients with type 2 diabetes was searched using NLP for evidence of aspirin use and its contraindications." | 1.36 | Automated processing of electronic medical records is a reliable method of determining aspirin use in populations at risk for cardiovascular events. ( Balasubramaniam, SC; Hanson, P; Pakhomov, SV; Shah, ND; Smith, SA, 2010) |
| "Diabetes and more specially type 2 diabetes are a major cardiovascular risk factor." | 1.36 | [Antiplatelet agents and diabetes mellitus]. ( Bal dit Sollier, C; Drouet, L; Henry, P, 2010) |
| "Aspirin has proven beneficial in the primary prevention of CHD, but is clearly underutilized in this role." | 1.35 | Aspirin for primary prevention of coronary heart disease: using the Framingham Risk Score to improve utilization in a primary care clinic. ( Dela Rosa, KM; Linz, PE; Romero, SC, 2008) |
| "To evaluate the association between type 2 diabetes and newly reported Parkinson's disease." | 1.35 | Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. ( Buring, JE; Driver, JA; Gaziano, JM; Kurth, T; Logroscino, G; Smith, A, 2008) |
| "Migraine and migraine aura status were self-reported." | 1.35 | Interrelationships among the MTHFR 677C>T polymorphism, migraine, and cardiovascular disease. ( Buring, JE; Kurth, T; Schürks, M; Zee, RY, 2008) |
| "examined Barrett's esophagus patient preferences for cancer chemoprevention with either aspirin or celecoxib." | 1.35 | Chemoprevention and Barrett's esophagus: decisions, decisions. ( Falk, GW; Jankowski, J, 2008) |
| "Stroke is an important outcome in cerebrovascular disease trials in the elderly, but it may be trumped by coronary heart disease as a more common end point." | 1.35 | Challenges of designing trials for the primary prevention of stroke. ( Gorelick, PB, 2009) |
| "Treatment patterns in migraine patients with cardiovascular risk factors are largely unknown." | 1.35 | Treatment choices and patterns in migraine patients with and without a cardiovascular risk profile. ( Egberts, AC; Tijssen, CC; Wammes-van der Heijden, EA, 2009) |
| "Aspirin did not inhibit and did not interfere with the effects of clopidogrel or cangrelor using this test." | 1.35 | Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin. ( Fox, SC; Heptinstall, S; May, JA; Neubert, U; Shah, A, 2009) |
| "Aspirin use was uncommon (<40% of patients)." | 1.35 | Use of cardioprotective medications in kidney transplant recipients. ( Cosio, FC; Fieberg, AM; Gaston, RS; Gourishankar, S; Halloran, P; Hunsicker, L; Kasiske, BL; Leduc, R; Matas, AJ; Rush, D, 2009) |
| "Aspirin use was associated with a lower risk of cardiovascular events (adjusted hazard ratio, 0." | 1.35 | Aspirin use, dose, and clinical outcomes in postmenopausal women with stable cardiovascular disease: the Women's Health Initiative Observational Study. ( Berger, JS; Brown, DL; Burke, GL; Kostis, JB; Langer, RD; Oberman, A; Wassertheil-Smoller, S; Wong, ND, 2009) |
| " The improved efficacy of multiple drug therapy is associated with an increased risk of bleeding, which raises the issue of the dosing of these drugs." | 1.35 | Frontiers in platelet inhibition. ( Shai, E; Spectre, G; Varon, D, 2009) |
| " However, the extent to which enhanced platelet function signals subsequent adverse clinical outcomes in patients with cardiovascular disease is unknown." | 1.35 | Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy. ( Christie, DJ; Gorman, RT; Kottke-Marchant, K, 2008) |
| "Aspirin treatment decreased 8-OHdG levels (P < 0." | 1.35 | Low-dose aspirin prevents age-related endothelial dysfunction in a mouse model of physiological aging. ( Boulanger, E; Bulckaen, H; Corman, B; Creusy, C; Garçon, G; Gaxatte, C; Gosset, P; Prévost, G; Puisieux, F; Robitaille, G; Roquet, V; Shirali, P, 2008) |
| "Treatment with aspirin and statin for every patient with diabetes has been postulated." | 1.35 | Should we be more aggressive in the therapy against cardiovascular risk factors? Should we prescribe statin and aspirin for every diabetic patient, or is it time for a polypill? ( Stirban, AO; Tschoepe, D, 2008) |
| " One hundred sixty-one patients on 100 mg of aspirin co-medication underwent elective coronary stenting and were given an initial dosage of 600 mg clopidogrel, followed by 75 mg clopidogrel daily." | 1.35 | How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. ( Engelhardt, A; Lask, S; Mügge, A; Neubauer, H, 2008) |
| "Aspirin treatment for primary prevention is cost-effective for men with a 10-year cardiovascular disease risk of >10% and for women with a risk of >15%." | 1.35 | Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. ( Algra, A; Buskens, E; Greving, JP; Koffijberg, H, 2008) |
| "The influence of long-term use of aspirin on total mortality in women remains uncertain." | 1.34 | Long-term aspirin use and mortality in women. ( Chan, AT; Colditz, GA; Feskanich, D; Fuchs, CS; Manson, JE; Stampfer, MJ, 2007) |
| "Aspirin treatment is effective in diabetic patients with cardiovascular disease and it does not significantly increase the risk of retinal haemorrhage, gastrointestinal bleeding or hemorrhagic stroke." | 1.33 | Use of antiplatelet therapy in a diabetic outpatient service of a large urban public hospital. ( Bruno, A; Dani, F; Degiovanni, M; Grassi, G; Maghenzani, G; Pagano, G, 2005) |
| "Aspirin responders were defined when closure time was > or =300 s." | 1.33 | Prevalence of aspirin resistance in patients with type 2 diabetes. ( Bocksch, W; Cabeza, N; Dietz, R; Ersel, S; Fateh-Moghadam, S; Gawaz, M; Htun, P; Plöckinger, U; Reuter, T, 2005) |
| " The aim of the monitoring of ASA therapy should be the identification of nonresponders to prevent a long-term intake of the drug without adequate benefit, to justify a dose escalation, or to initiate an alternative antiplatelet drug therapy." | 1.33 | Monitoring acetylsalicylic acid effects with the platelet function analyzer PFA-100. ( Feuring, M; Losel, R; Schultz, A; Wehling, M, 2005) |
| "We investigated whether use of low-dose enteric-coated (EC) aspirin for secondary prevention of cardiovascular events has sufficient bioavailability to achieve complete platelet cyclooxygenase (COX) inhibition in all individuals." | 1.33 | Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. ( Conroy, RM; Cox, D; Crean, P; Curtin, RJ; Dooley, M; Fitzgerald, DJ; Maree, AO, 2005) |
| "We report 72 patients with Kawasaki disease seen at this Centre over 7 years." | 1.33 | Cardiovascular involvement in Kawasaki disease. ( Ahamed, MZ; Narayanan, SN; Safia, M, 2005) |
| "Overweight and obesity are well-established risk factors for cardiovascular disease and decline in kidney function in individuals with existing chronic kidney disease (CKD)." | 1.33 | Association between body mass index and CKD in apparently healthy men. ( Buring, JE; Gaziano, JM; Gelber, RP; Kausz, AT; Kurth, T; Levey, AS; Manson, JE, 2005) |
| "Aspirin is an established therapy for primary and secondary prevention of CVD that may be underutilized in hemodialysis patients." | 1.33 | Underutilization of aspirin in hemodialysis patients for primary and secondary prevention of cardiovascular disease. ( Dempster, DW; DeVita, MV; Michelis, MF; Panagopoulos, G; Rosenstock, JL; Schwimmer, JA, 2005) |
| "Rectus sheath hematoma is an uncommon cause of acute abdomen and is known to mimic various common surgical conditions." | 1.33 | Massive rectus sheath hematoma. ( Hamdan, K; Rajagopal, AS; Shinkfield, M; Voight, S, 2006) |
| "Aspirin resistance was not related to age, glycohemoglobin, total cholesterol, or a history of cardiovascular disease." | 1.33 | Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. ( Aaronson, A; Abrahamson, M; Goldfine, AB; Mehta, SS; Silver, RJ, 2006) |
| "Aspirin treatment at the time of PCI significantly reduced the risk of death from any cause and cardiac death." | 1.33 | Impact of aspirin treatment on long-term outcome (over 10 years) after percutaneous coronary intervention. ( Akimoto, Y; Daida, H; Kasai, T; Kojima, T; Kurata, T; Miyauchi, K; Njaman, W; Ohta, H; Okazaki, S; Satoh, H; Yokoyama, K, 2006) |
| "From 1994 to 2003, 120 patients with Kawasaki disease diagnosed at our institution were included." | 1.33 | Characteristics of Kawasaki disease in infants younger than six months of age. ( Chang, FY; Chen, SJ; Hwang, B; Lee, PC; Lu, JH; Meng, CC, 2006) |
| "Hypertension is also one of the major atherosclerotic risk factors." | 1.33 | Aspirin therapy as primary prevention in hypertensive patients at Srinagarind hospital. ( Bumrerraj, S; Choenrungroj, T; Kosakarn, J; Limpawattana, P; Naranunn, P; Pradit, P; Premgamone, A; Punyamee, S; Sawanyawisuth, K; Thongmee, A, 2005) |
| "Diabetes mellitus is a major public health problem in the United States." | 1.33 | Increased cardiovascular risk associated with diabetes in Dallas County. ( Das, SR; de Lemos, JA; Dobbins, RL; McGuire, DK; Stanek, HG; Vaeth, PA, 2006) |
| "People with diabetes mellitus have higher risk of cardiovascular morbidity and mortality from thrombo-vascular complications than non-diabetics and it is recommended that they should use acetylsalicylic acid (ASA) as anitiplatelet agent regularly." | 1.33 | Acetylsalicylic acid (ASA) use among Polish adults with diabetes mellitus. ( Drzewoski, J; Liniarski, M; Olszewski, A; Sawer-Szewczyk, J; Stepień, A, 2005) |
| "Aspirin use was significantly associated with hypertension, ischaemic heart disease and diabetes mellitus." | 1.33 | Aspirin prophylaxis and the prevalence of anaemia. ( Azoulay, D; Hammerman-Rozenberg, R; Jacobs, JM; Stessman, J, 2006) |
| "Treatment with ibuprofen might limit the cardioprotective effects of aspirin." | 1.32 | Effect of ibuprofen on cardioprotective effect of aspirin. ( MacDonald, TM; Wei, L, 2003) |
| "Aspirin treatment for primary prevention is safe and useful at an annual coronary event risk > or = 1." | 1.32 | [Anticoagulation and antiaggregation in cardiac patients]. ( Meyer, BJ, 2003) |
| " The main finding of this exercise is the possibility that the long-term use of low dose aspirin may double the chances of individuals living a healthy life into their 90's." | 1.32 | A quantitative illustration of the public health potential of aspirin. ( Morgan, G, 2003) |
| "Erosive gastritis was noted more frequently in the aspirin group than in the control group." | 1.32 | [Gastroduodenal injury in patients with low-dose enteric coated aspirin treatment]. ( Ahn, YH; Hahm, JS; Han, DS; Kim, JB; Lee, HL; Park, JY; Sohn, JH, 2003) |
| "During follow-up 56 recurrences occurred, making a total of 110 episodes of vitreous haemorrhage in 79 eyes of 54 patients." | 1.32 | Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease? ( Banerjee, S; Denniston, AK; Dodson, PM; Gibson, JM, 2004) |
| "Diabetes Mellitus is a chronic disease frequently associated to ischemic heart disease and both disease require continuing medical care, aggressive treatment of other risk factors, educational programs for self management of disease to prevent acute complication." | 1.32 | [Recommendations for cardiovascular rehabilitation in diabetes mellitus]. ( Biorci, ML; Camerini, A; Chieffo, C; Comaschi, M; Faglia, E; Fattirolli, F; Gattone, M; Giorda, C; Griffo, R; Mannucci, E, 2003) |
| "Aspirin is a safe, inexpensive, and readily available therapy that is effective for preventing cardiovascular disease, and patients with type 2 DM are particularly likely to benefit from such preventive therapy." | 1.32 | Underuse of aspirin in type 2 diabetes mellitus: prevalence and correlates of therapy in rural Canada. ( Guirguis, LM; Johnson, JA; Klinke, JA; Lee, TK; Lewanczuk, RZ; Majumdar, SR; Toth, EL, 2004) |
| "Aspirin was prescribed (18%) primarily by the cardiologist." | 1.32 | [Practical prevention and treatment of cardiovascular diseases in patients with diabetes mellitus type 2 in an endocrinological department]. ( Abirova, ES; Daurbekova, LV; Giliarevskiĭ, SR; Murzabekova, LI; Orlov, VA, 2004) |
| "(2) Aspirin has essentially gastrointestinal adverse effects, whose incidence can be limited by prescribing a daily dose below 350 mg." | 1.31 | Antiplatelet drugs in cardiovascular prevention: take adverse effects and costs into account. ( , 2000) |
| "The purpose of treating hypertension is prevention of cardiovascular diseases." | 1.31 | [Pharmacological prevention of cardiovascular diseases in general practice]. ( Ellekjaer, H; Gjelsvik, B; Hetlevik, I; Holmen, J; Kimsås, A; Meland, E, 2000) |
| "Aspirin was used regularly by 37% of those with CVD and by 13% of those with risk factors only Adjusted odds of regular aspirin use were significantly greater for individuals with CVD than for those with one CVD risk factor (odds ratio [OR] = 4." | 1.31 | Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. ( Fagot-Campagna, A; Narayan, KM; Rolka, DB, 2001) |
| " Kawasaki disease is treated with intravenous gamma--globulin therapy and high dosage acetylsalicylic acid at the beginning of the disease." | 1.31 | [Kawasaki disease--personal observations]. ( Balcar-Boroń, A; Dylewska, K; Kojro-Wojcieszonek, A; Maćkowska, K; Masłowska, E, 2001) |
| "Aspirin resistance was defined as a mean aggregation of > or =70% with 10 microM ADP and a mean aggregation of > or =20% with 0." | 1.31 | Profile and prevalence of aspirin resistance in patients with cardiovascular disease. ( Brooks, L; Gum, PA; Gurm, H; Kottke-Marchant, K; Poggio, ED; Sapp, SK; Topol, EJ; Welsh, PA, 2001) |
| "OTC aspirin use was more common in those aged under 65 years, men, and the more affluent." | 1.31 | Factors affecting over-the-counter use of aspirin in the secondary prophylaxis of cardiovascular disease. ( Bedson, J; Croft, P; Lewis, M; Whitehurst, T, 2001) |
| "'Aspirin resistance' is a poorly defined term to describe the inability of aspirin to protect individuals from thrombotic complications and there are conflicting reports on incidence rates and clinical relevance of this phenomenon." | 1.31 | Towards a definition of aspirin resistance: a typological approach. ( Hohlfeld, T; Przytulski, B; Schanz, A; Schrör, K; Weber, AA, 2002) |
| "Appropriate treatment of hypercholesterolemia occurred in 96% of patients referred to a clinical pharmacy specialist, compared with 68% of those followed by primary care providers alone (p<0." | 1.31 | Optimizing drug therapy in patients with cardiovascular disease: the impact of pharmacist-managed pharmacotherapy clinics in a primary care setting. ( Beckey, NP; Geber, J; Korman, L; Parra, D, 2002) |
| "Aspirin use was assessed by questionnaires to study participants in November 1992 (Q92); cardiovascular diagnoses are based on general practice notifications to October 1992." | 1.30 | Aspirin use in middle-aged men with cardiovascular disease: are opportunities being missed? ( Ebrahim, S; McCallum, AK; Morris, RW; Thomson, A; Walker, M; Whincup, PH, 1997) |
| "Ticlopidine is an antiplatelet agent that has been proven efficacious in preventing vascular events in patients with a history of vasculopathy." | 1.30 | Ticlopidine-associated pancytopenia: implications of an acetylsalicylic acid alternative. ( Armstrong, PW; Brown, NE; Gill, S; Majumdar, S, 1997) |
| " Urinary 8-epi-PGF2 alpha was unchanged after 2-week dosing with aspirin and indobufen despite complete suppression of TX metabolite excretion." | 1.30 | In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. ( Alessandrini, P; Bon, GB; Bucciarelli, T; Ciabattoni, G; Cipollone, F; Costantini, F; Davi, G; Mezzetti, A; Minotti, G; Patrono, C, 1997) |
| "Treatment of cardiac arrhythmia by repeated intravenous injections of propranolol (1 mg/kg) or verapamil (1 mg/kg) was effective and prolonged survival time to 91." | 1.30 | Experimental treatment of the acute cardiovascular toxicity of caffeine. ( Diederich, KW; Strubelt, O, 1999) |
| "We report seven cases of Kawasaki disease (KD) who were admitted to Hospital University Sains Malaysia over a period of 8 years." | 1.29 | Kawasaki disease in Malaysia. ( Malik, AS, 1996) |
| "The pharmacokinetic profile of this new preparation fits that proposed by others to produce a selective inhibition of thromboxane synthesis by platelets." | 1.28 | [Pharmacokinetics of acetylsalicylic acid for the prophylaxis of cardiovascular pathology]. ( Artaza, MA; Castel, JM; Laporte, JR, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 72 (3.07) | 18.7374 |
| 1990's | 138 (5.88) | 18.2507 |
| 2000's | 828 (35.29) | 29.6817 |
| 2010's | 974 (41.52) | 24.3611 |
| 2020's | 334 (14.24) | 2.80 |
| Authors | Studies |
|---|---|
| Kishore, N | 1 |
| Kumar, P | 1 |
| Shanker, K | 1 |
| Verma, AK | 1 |
| Steurer, J | 1 |
| Mant, J | 1 |
| McManus, R | 1 |
| Joseph, P | 6 |
| Roshandel, G | 4 |
| Gao, P | 8 |
| Pais, P | 9 |
| Lonn, E | 4 |
| Xavier, D | 7 |
| Avezum, A | 9 |
| Zhu, J | 8 |
| Liu, L | 6 |
| Sliwa, K | 1 |
| Gamra, H | 3 |
| Bangdiwala, SI | 3 |
| Teo, K | 4 |
| Diaz, R | 9 |
| Dans, A | 4 |
| Lopez-Jaramillo, P | 9 |
| Prabhakaran, D | 6 |
| Castellano, JM | 4 |
| Fuster, V | 13 |
| Rodgers, A | 15 |
| Huffman, MD | 6 |
| Bosch, J | 12 |
| Dagenais, GR | 5 |
| Malekzadeh, R | 9 |
| Yusuf, S | 29 |
| Pistrosch, F | 1 |
| Matschke, JB | 1 |
| Schipp, D | 1 |
| Schipp, B | 1 |
| Henkel, E | 1 |
| Weigmann, I | 1 |
| Sradnick, J | 1 |
| Bornstein, SR | 1 |
| Birkenfeld, AL | 1 |
| Hanefeld, M | 2 |
| Jacobsen, AP | 2 |
| Lim, ZL | 2 |
| Chang, B | 2 |
| Lambeth, KD | 2 |
| Das, TM | 2 |
| Gorry, C | 2 |
| McCague, M | 2 |
| Wijns, W | 3 |
| Serruys, PWJC | 2 |
| Blumenthal, RS | 5 |
| Martin, SS | 2 |
| McEvoy, JW | 8 |
| Liang, Y | 4 |
| Gong, ZB | 1 |
| Lou, KJ | 1 |
| Liu, LS | 1 |
| Lin, X | 1 |
| Banaszak-Holl, J | 1 |
| Xie, J | 1 |
| Ward, SA | 2 |
| Brodaty, H | 1 |
| Storey, E | 5 |
| Shah, RC | 8 |
| Murray, A | 2 |
| Ryan, J | 4 |
| Orchard, SG | 7 |
| Fitzgerald, SM | 4 |
| McNeil, JJ | 18 |
| Ma, H | 1 |
| Gu, Q | 1 |
| Niu, H | 1 |
| Li, X | 5 |
| Wang, R | 2 |
| Kow, CS | 1 |
| Ramachandram, DS | 1 |
| Hasan, SS | 1 |
| Yorkgitis, BK | 1 |
| Tatum, DM | 1 |
| Taghavi, S | 1 |
| Schroeppel, TJ | 1 |
| Noorbakhsh, MR | 1 |
| Philps, FH | 1 |
| Bugaev, N | 1 |
| Mukherjee, K | 1 |
| Bellora, M | 1 |
| Ong, AW | 1 |
| Ratnasekera, A | 1 |
| Nordham, KD | 1 |
| Carrick, MM | 1 |
| Haan, JM | 1 |
| Lightwine, KL | 1 |
| Lottenberg, L | 1 |
| Borrego, R | 1 |
| Cullinane, DC | 1 |
| Berne, JD | 1 |
| Rodriguez Mederos, D | 1 |
| Hayward, TZ | 1 |
| Kerwin, AJ | 1 |
| Crandall, M | 1 |
| Auer, J | 2 |
| Lamm, G | 1 |
| McCarthy, L | 1 |
| Anthoulakis, C | 1 |
| Mamopoulos, A | 1 |
| Rousso, D | 1 |
| Karagiannis, A | 2 |
| Athanasiadis, A | 1 |
| Grimbizis, G | 1 |
| Athyros, V | 1 |
| Burns, RB | 2 |
| Pignone, M | 12 |
| Michos, ED | 4 |
| Kanjee, Z | 1 |
| Lyu, SQ | 1 |
| Wang, J | 5 |
| Wu, S | 1 |
| Zhang, H | 2 |
| Shao, XH | 1 |
| Yang, YM | 1 |
| Calderone, D | 2 |
| Greco, A | 1 |
| Ingala, S | 2 |
| Agnello, F | 1 |
| Franchina, G | 1 |
| Scalia, L | 1 |
| Buccheri, S | 1 |
| Capodanno, D | 8 |
| Gassanov, N | 1 |
| Eicke, M | 1 |
| Er, F | 1 |
| Zimbroff, RM | 1 |
| Ayers, G | 1 |
| Koncilja, K | 1 |
| Summaria, F | 1 |
| Biondi-Zoccai, G | 4 |
| Romagnoli, E | 1 |
| Mamas, MA | 1 |
| Franchi, F | 2 |
| Severino, P | 1 |
| Lavalle, C | 1 |
| Versaci, F | 1 |
| Gaspardone, A | 1 |
| Bhatt, DL | 40 |
| Montgomery, S | 1 |
| Miedema, MD | 4 |
| Dodson, JA | 2 |
| Szczuko, M | 1 |
| Kozioł, I | 1 |
| Kotlęga, D | 1 |
| Brodowski, J | 1 |
| Drozd, A | 1 |
| García Rodríguez, LA | 15 |
| Cea Soriano, L | 7 |
| de Abajo, FJ | 2 |
| Valent, F | 1 |
| Hallas, J | 1 |
| Gil, M | 1 |
| Cattaruzzi, C | 1 |
| Rodriguez-Martin, S | 1 |
| Vora, P | 4 |
| Soriano-Gabarró, M | 5 |
| Gaist, D | 1 |
| Bouvenot, G | 1 |
| Mujaj, B | 1 |
| Zhang, ZY | 1 |
| Yang, WY | 1 |
| Thijs, L | 1 |
| Wei, FF | 1 |
| Verhamme, P | 3 |
| Delles, C | 1 |
| Butler, J | 2 |
| Sever, P | 2 |
| Latini, R | 1 |
| Gf Cleland, J | 1 |
| Zannad, F | 2 |
| Staessen, JA | 1 |
| Murphy, E | 2 |
| Curneen, JMG | 1 |
| Sun, X | 2 |
| Sun, R | 1 |
| Zhang, L | 3 |
| Kim, BG | 1 |
| Hong, SJ | 2 |
| Kim, BK | 2 |
| Lee, SJ | 1 |
| Ahn, CM | 2 |
| Shin, DH | 2 |
| Kim, JS | 2 |
| Ko, YG | 2 |
| Choi, D | 2 |
| Hong, MK | 2 |
| Jang, Y | 3 |
| Mishu, MD | 1 |
| Zolper, EG | 1 |
| Dekker, PK | 1 |
| Fleury, CM | 1 |
| Bekeny, JC | 1 |
| Fan, KL | 1 |
| Attinger, CE | 1 |
| Evans, KK | 1 |
| Marino, M | 3 |
| Solberg, L | 1 |
| Springer, R | 2 |
| McConnell, KJ | 2 |
| Lindner, S | 2 |
| Ward, R | 3 |
| Edwards, ST | 1 |
| Stange, KC | 1 |
| Cohen, DJ | 6 |
| Balasubramanian, BA | 3 |
| Kim, K | 3 |
| Hennekens, CH | 57 |
| Martinez, L | 1 |
| Gaziano, JM | 22 |
| Pfeffer, MA | 7 |
| Biglione, B | 1 |
| Gitin, A | 1 |
| McCabe, JB | 1 |
| Cook, TD | 1 |
| DeMets, DL | 3 |
| Wood, SK | 3 |
| Harper, C | 1 |
| Mafham, M | 5 |
| Herrington, W | 1 |
| Staplin, N | 1 |
| Stevens, W | 4 |
| Wallendszus, K | 3 |
| Haynes, R | 5 |
| Landray, MJ | 1 |
| Parish, S | 4 |
| Bowman, L | 6 |
| Armitage, J | 7 |
| Lamy, A | 1 |
| Tong, W | 1 |
| Walli-Attaei, M | 1 |
| Dans, AL | 4 |
| Talukder, S | 2 |
| Santoso, A | 2 |
| Liuzzo, G | 2 |
| Patrono, C | 23 |
| Brown, K | 1 |
| Donato, AA | 1 |
| Kirac, D | 1 |
| Yaman, AE | 1 |
| Doran, T | 1 |
| Mihmanli, M | 1 |
| Keles, EC | 1 |
| Passacquale, G | 1 |
| Sharma, P | 3 |
| Perera, D | 1 |
| Ferro, A | 3 |
| Sairam, S | 1 |
| Sureen, A | 1 |
| Gutierrez, J | 1 |
| Dang, TQ | 1 |
| Mishra, K | 1 |
| Masson, W | 2 |
| Barbagelata, L | 1 |
| Lavalle-Cobo, A | 1 |
| Lobo, M | 2 |
| Masson, G | 2 |
| Nogueira, JP | 1 |
| Vergès, B | 1 |
| Cleland, JGF | 2 |
| Baumann, R | 1 |
| Retnam, R | 1 |
| Hernandez, CM | 1 |
| Edwards, V | 1 |
| Ryan, M | 1 |
| Hira, RS | 3 |
| Gosch, KL | 1 |
| Kazi, DS | 2 |
| Yeh, RW | 2 |
| Kataruka, A | 2 |
| Maddox, TM | 2 |
| Shah, T | 2 |
| Jneid, H | 3 |
| Virani, SS | 7 |
| Shami, JJP | 1 |
| Zhao, J | 1 |
| Pathadka, S | 1 |
| Wan, EYF | 1 |
| Blais, JE | 1 |
| Cheung, KS | 1 |
| Leung, WK | 2 |
| Wong, ICK | 1 |
| Chan, EW | 1 |
| Theilen, LH | 1 |
| Greenland, P | 2 |
| Varagic, J | 1 |
| Catov, J | 1 |
| Shanks, A | 1 |
| Thorsten, V | 1 |
| Parker, CB | 1 |
| McNeil, R | 1 |
| Mercer, B | 1 |
| Hoffman, M | 1 |
| Wapner, R | 2 |
| Haas, D | 1 |
| Simhan, H | 1 |
| Grobman, W | 1 |
| Chung, JH | 1 |
| Levine, LD | 1 |
| Barnes, S | 1 |
| Bairey Merz, N | 1 |
| Saade, G | 1 |
| Silver, RM | 1 |
| Del Bianco-Rondeau, M | 1 |
| Robert-Halabi, M | 1 |
| Bloom, S | 1 |
| Rabasa-Lhoret, R | 1 |
| Tardif, JC | 1 |
| Lordkipanidzé, M | 7 |
| Marquis-Gravel, G | 6 |
| Nelson, MR | 14 |
| Polekhina, G | 3 |
| Woods, RL | 12 |
| Reid, CM | 16 |
| Tonkin, AM | 16 |
| Wolfe, R | 12 |
| Murray, AM | 10 |
| Kirpach, B | 4 |
| Ernst, ME | 9 |
| Lockery, JE | 6 |
| Stocks, N | 3 |
| Zhou, Z | 2 |
| Bongiovanni, D | 1 |
| Han, J | 1 |
| Klug, M | 1 |
| Kirmes, K | 1 |
| Viggiani, G | 1 |
| von Scheidt, M | 2 |
| Schreiner, N | 1 |
| Condorelli, G | 1 |
| Laugwitz, KL | 1 |
| Bernlochner, I | 2 |
| Mohammadifard, N | 3 |
| Taheri, M | 1 |
| Haghighatdoost, F | 1 |
| Grau, N | 1 |
| Najafian, J | 1 |
| Sadeghi, M | 3 |
| Talaei, M | 1 |
| Sarrafzadegan, N | 3 |
| Hong, S | 1 |
| Lee, WJ | 1 |
| Park, CY | 2 |
| Sharif, F | 1 |
| Mylotte, D | 1 |
| Polkinghorne, KR | 2 |
| Wetmore, JB | 2 |
| Thao, LTP | 1 |
| Gallagher, H | 3 |
| Dumbleton, J | 1 |
| Maishman, T | 1 |
| Whitehead, A | 1 |
| Moore, MV | 1 |
| Fuat, A | 2 |
| Fitzmaurice, D | 5 |
| Henderson, RA | 1 |
| Lord, J | 1 |
| Griffith, KE | 1 |
| Stevens, P | 1 |
| Taal, MW | 1 |
| Stevenson, D | 1 |
| Fraser, SD | 1 |
| Lown, M | 2 |
| Hawkey, CJ | 1 |
| Roderick, PJ | 2 |
| Kristensen, SD | 6 |
| Olesen, KKW | 2 |
| Maeng, M | 3 |
| Mora, S | 11 |
| Shufelt, CL | 3 |
| Manson, JE | 29 |
| Davidson, KW | 1 |
| Barry, MJ | 1 |
| Mangione, CM | 1 |
| Cabana, M | 1 |
| Chelmow, D | 1 |
| Coker, TR | 1 |
| Davis, EM | 1 |
| Donahue, KE | 1 |
| Jaén, CR | 1 |
| Krist, AH | 1 |
| Kubik, M | 1 |
| Li, L | 2 |
| Ogedegbe, G | 2 |
| Pbert, L | 1 |
| Ruiz, JM | 1 |
| Stevermer, J | 1 |
| Tseng, CW | 1 |
| Wong, JB | 1 |
| Dehmer, SP | 2 |
| O'Keefe, LR | 1 |
| Evans, CV | 4 |
| Guirguis-Blake, JM | 4 |
| Perdue, LA | 2 |
| Maciosek, MV | 3 |
| Bean, SI | 1 |
| Senger, CA | 2 |
| Jin, J | 1 |
| Brett, AS | 1 |
| Seng Bong Ing, N | 1 |
| Amoud, R | 1 |
| Gamble, JM | 2 |
| Alsabbagh, MW | 1 |
| Khan, AA | 1 |
| Siddiqui, SA | 1 |
| Yasmin, F | 1 |
| Abidi, SM | 1 |
| Tariq, R | 1 |
| Ahmed, H | 1 |
| Murtaza, N | 1 |
| Jawed, F | 1 |
| Lashkerwala, SS | 1 |
| Moin, A | 1 |
| Shah, SMI | 1 |
| Ullah, I | 1 |
| Yousaf, Z | 1 |
| Faizan, M | 1 |
| Shahid, MH | 1 |
| Lavie, I | 1 |
| Lavie, M | 1 |
| Gafter-Gvili, A | 1 |
| Halperin, E | 1 |
| Abramovich-Yoffe, H | 1 |
| Avni, T | 1 |
| Luepker, RV | 12 |
| Eder, M | 4 |
| Finnegan, JR | 4 |
| Van't Hof, JR | 6 |
| Oldenburg, N | 2 |
| Duval, S | 10 |
| Wang, M | 2 |
| Yu, H | 1 |
| Li, Z | 1 |
| Gong, D | 1 |
| Liu, X | 3 |
| Tasoudis, PT | 1 |
| Kyriakoulis, IG | 1 |
| Sagris, D | 1 |
| Diener, HC | 4 |
| Ntaios, G | 1 |
| Saito, MS | 1 |
| Zatta, KC | 1 |
| Sathler, PC | 1 |
| Furtado, PS | 1 |
| C O Miguel, N | 1 |
| Frattani, FS | 1 |
| Berger, M | 1 |
| Lavayen, V | 1 |
| Pohlmann, AR | 1 |
| Guterres, SS | 1 |
| Lopez-Candales, A | 1 |
| Norgard, N | 1 |
| Mohamed, MG | 1 |
| Osman, M | 1 |
| Kheiri, B | 2 |
| Saleem, M | 1 |
| Lacasse, A | 1 |
| Alkhouli, M | 1 |
| Li, XL | 2 |
| Wang, Q | 3 |
| Jia, GD | 1 |
| Yin, HJ | 1 |
| Wang, YH | 1 |
| Hu, C | 1 |
| Wang, XQ | 1 |
| Yang, Y | 3 |
| Nugteren, MJ | 1 |
| de Borst, GJ | 3 |
| van den Broek, WWA | 1 |
| Ten Berg, JM | 3 |
| Kappelle, LJ | 2 |
| Ünlü, Ç | 1 |
| Al-Abdouh, A | 2 |
| Abusnina, W | 1 |
| Mhanna, M | 1 |
| Radideh, Q | 1 |
| Alzu'bi, H | 1 |
| Rmilah, AA | 1 |
| Jabri, A | 1 |
| Barbarawi, M | 2 |
| Obeidat, K | 1 |
| Alabduh, T | 1 |
| Alnabelsi, T | 1 |
| Paul, TK | 1 |
| Zheng, F | 1 |
| Stavrinou, P | 1 |
| Hu, W | 1 |
| Dimitriadis, K | 1 |
| Lazarou, E | 1 |
| Tsioufis, P | 1 |
| Soulaidopoulos, S | 1 |
| Tsioufis, K | 1 |
| Hu, X | 1 |
| Liu, C | 3 |
| Zhang, M | 1 |
| Zhang, W | 4 |
| Cavallari, I | 1 |
| Nobile, E | 1 |
| De Filippis, A | 1 |
| Veneziano, F | 1 |
| Maddaloni, E | 1 |
| Ussia, GP | 1 |
| Grigioni, F | 1 |
| Campos-Outcalt, D | 2 |
| Ishii, M | 1 |
| Kawai, T | 2 |
| Tsujita, K | 3 |
| Igarashi, A | 2 |
| Suzuki, M | 1 |
| Deguchi, H | 1 |
| Fernandez, J | 1 |
| Pocock, SJ | 2 |
| Quesada, AJ | 1 |
| Owen, R | 1 |
| Fernandez-Ortiz, A | 1 |
| Sanchez, PL | 1 |
| Marin Ortuño, F | 1 |
| Vazquez Rodriguez, JM | 1 |
| Domingo-Fernández, A | 1 |
| Lozano, I | 1 |
| Roncaglioni, MC | 8 |
| Baviera, M | 1 |
| Foresta, A | 1 |
| Ojeda-Fernandez, L | 1 |
| Colivicchi, F | 1 |
| Di Fusco, SA | 1 |
| Doehner, W | 1 |
| Meyer, A | 1 |
| Schiele, F | 2 |
| Ecarnot, F | 1 |
| Linhart, A | 1 |
| Lubanda, JC | 1 |
| Barczi, G | 1 |
| Merkely, B | 2 |
| Ponikowski, P | 2 |
| Kasprzak, M | 1 |
| Fernandez Alvira, JM | 1 |
| Andres, V | 1 |
| Bueno, H | 5 |
| Collier, T | 1 |
| Van de Werf, F | 1 |
| Perel, P | 1 |
| Rodriguez-Manero, M | 1 |
| Alonso Garcia, A | 1 |
| Proietti, M | 1 |
| Schoos, MM | 1 |
| Simon, T | 1 |
| Fernandez Ferro, J | 1 |
| Lopez, N | 1 |
| Beghi, E | 1 |
| Bejot, Y | 1 |
| Vivas, D | 1 |
| Cordero, A | 1 |
| Ibañez, B | 1 |
| Cofer, LB | 1 |
| Barrett, TJ | 2 |
| Berger, JS | 12 |
| Nudy, M | 2 |
| Cooper, JL | 1 |
| Reamy, BV | 1 |
| Viera, AJ | 3 |
| Elwood, P | 7 |
| Protty, M | 1 |
| Morgan, G | 13 |
| Pickering, J | 1 |
| Delon, C | 1 |
| Watkins, J | 2 |
| Tracer, H | 1 |
| Newhouse, CN | 1 |
| Michelotti, E | 1 |
| Negro, F | 1 |
| Morganti, R | 1 |
| De Caterina, R | 12 |
| Lacaze, P | 3 |
| Bakshi, A | 1 |
| Riaz, M | 2 |
| Owen, A | 4 |
| Bhatia, HS | 2 |
| Natarajan, P | 1 |
| Beilin, L | 2 |
| Nicholls, SJ | 3 |
| Watts, GF | 1 |
| Tsimikas, S | 1 |
| Stanković, P | 1 |
| Hoch, S | 1 |
| Rudhart, S | 1 |
| Stojković, S | 1 |
| Wilhelm, T | 1 |
| Kishi, T | 1 |
| Kitajima, A | 1 |
| Yamanouchi, K | 1 |
| Hirooka, Y | 1 |
| Toda, S | 1 |
| Takamori, A | 1 |
| Fujimoto, K | 2 |
| Kishi, C | 1 |
| Tomiyoshi, Y | 1 |
| Miklík, R | 1 |
| Jiravský, O | 1 |
| Kuzel, AJ | 1 |
| Cuellar, A | 1 |
| Nichols, L | 1 |
| Haim-Pinhas, H | 1 |
| Yoskovitz, G | 1 |
| Lishner, M | 1 |
| Pereg, D | 1 |
| Kitay-Cohen, Y | 1 |
| Topaz, G | 1 |
| Sela, Y | 1 |
| Wand, O | 1 |
| Rozenberg, I | 1 |
| Benchetrit, S | 1 |
| Cohen-Hagai, K | 1 |
| Klausner, S | 1 |
| Slawson, DC | 3 |
| Li, DK | 4 |
| Ong, SY | 4 |
| Hughes, ML | 3 |
| Hung, KW | 3 |
| Agarwal, R | 3 |
| Alexis, J | 3 |
| Damianos, J | 3 |
| Sharma, S | 3 |
| Pires, J | 3 |
| Nanna, M | 3 |
| Laine, L | 8 |
| Goel, A | 2 |
| Malik, AH | 2 |
| Russell, B | 1 |
| Morgan Stewart, H | 1 |
| Lau, ES | 1 |
| Miller, WL | 1 |
| Sweeney, SM | 1 |
| Hall, JD | 1 |
| Hemler, JR | 1 |
| Ono, SS | 1 |
| Ezekiel-Herrera, D | 1 |
| Baron, A | 1 |
| Crabtree, BF | 1 |
| Solberg, LI | 2 |
| Drai, E | 1 |
| Marques-Vidal, P | 2 |
| Bochud, M | 1 |
| Vaucher, J | 2 |
| Carlin, S | 2 |
| de Vries, TAC | 2 |
| Budaj, A | 4 |
| Eikelboom, J | 5 |
| Verheugt, FWA | 2 |
| Huber, K | 6 |
| Ferreira Moita, C | 1 |
| Marau, G | 1 |
| Corte-Real, S | 1 |
| Dantas, A | 1 |
| Demirci, E | 1 |
| Celik, O | 1 |
| Cil, C | 1 |
| Tanık, VO | 1 |
| Memic Sancar, K | 1 |
| Orscelik, O | 1 |
| Resulzade, MM | 1 |
| Kaya, C | 1 |
| Kırıs, T | 1 |
| Dogan, V | 1 |
| Basaran, O | 1 |
| Caldeira, D | 3 |
| Alves, M | 3 |
| Ferreira, JJ | 3 |
| Pinto, FJ | 3 |
| Mufarreh, A | 1 |
| Shah, AJ | 1 |
| Vaccarino, V | 1 |
| Kulshreshtha, A | 1 |
| Roshanov, PS | 1 |
| Garg, AX | 1 |
| Bosch, JJ | 1 |
| O'Donnell, MJ | 2 |
| Lopez Jaramillo, P | 1 |
| Liu, S | 5 |
| Eckstein, J | 1 |
| Lam, A | 1 |
| Cheema, AN | 1 |
| Khaled, A | 1 |
| Almaghaslah, D | 1 |
| Nagib, R | 1 |
| Makki, S | 1 |
| Siddiqua, A | 1 |
| Liani, R | 2 |
| Simeone, PG | 1 |
| Tripaldi, R | 1 |
| D'Ardes, D | 1 |
| Creato, V | 1 |
| Pepe, R | 1 |
| Lessiani, G | 1 |
| Bologna, G | 1 |
| Cipollone, F | 2 |
| Marchisio, M | 1 |
| Lanuti, P | 1 |
| Santilli, F | 4 |
| Nay, I | 1 |
| Hutchinson, D | 1 |
| Rondina, M | 2 |
| Kroencke, R | 1 |
| Kirkham, A | 1 |
| Trujillo, T | 1 |
| Tolley, ND | 1 |
| Munger, M | 1 |
| Cortellini, G | 1 |
| Raiteri, A | 1 |
| Galli, M | 3 |
| Lotrionte, M | 2 |
| Piscaglia, F | 1 |
| Romano, A | 2 |
| Dalli, J | 1 |
| Kitch, D | 1 |
| O'Brien, MP | 1 |
| Hunt, PW | 1 |
| Funderburg, N | 1 |
| Moisi, D | 1 |
| Gupta, A | 2 |
| Brown, TT | 1 |
| Tien, PC | 1 |
| Aberg, JA | 1 |
| Shivakoti, R | 1 |
| Zheng, N | 1 |
| Zhong, J | 1 |
| Chen, X | 1 |
| Su, J | 1 |
| Jiang, L | 1 |
| Buck, G | 4 |
| Aung, T | 5 |
| Clark, S | 1 |
| Hill, MR | 1 |
| Collins, R | 9 |
| Silva, GFD | 1 |
| Lopes, BM | 1 |
| Moser, V | 1 |
| Ferreira, LE | 1 |
| Liu, T | 1 |
| Zuo, R | 1 |
| Huangtao, Z | 1 |
| Wang, B | 1 |
| Sun, L | 1 |
| Wang, S | 2 |
| Li, B | 1 |
| Zhu, Z | 1 |
| Pan, Y | 2 |
| Kristensen, AMD | 1 |
| Pareek, M | 2 |
| Kragholm, KH | 1 |
| Torp-Pedersen, C | 6 |
| Prescott, EB | 1 |
| Kim, SP | 1 |
| Ryu, J | 1 |
| Kim, SH | 2 |
| Yoon, HJ | 1 |
| Carr, T | 1 |
| Gillum, R | 1 |
| Scarfo, NL | 1 |
| Thomas, V | 1 |
| Mayboroda, MS | 1 |
| Hewage, U | 1 |
| Zhuge, RQ | 1 |
| Hu, ML | 1 |
| Liu, ML | 4 |
| Pugliese, NR | 1 |
| Taddei, S | 1 |
| Wei, J | 2 |
| Zeng, C | 1 |
| Lane, NE | 1 |
| Lei, G | 1 |
| Zhang, Y | 6 |
| Curtis, AJ | 1 |
| Zhu, C | 1 |
| Carr, PR | 1 |
| Espinoza, SE | 1 |
| Zoungas, S | 3 |
| Mallick, S | 1 |
| Shroff, GR | 1 |
| Linzer, M | 1 |
| Mandell, BF | 1 |
| Brown, MT | 1 |
| Bortfeld, KS | 1 |
| Sperling, LS | 4 |
| Wenger, NK | 4 |
| Sayed, A | 1 |
| Munir, M | 1 |
| Addison, D | 1 |
| Abushouk, AI | 1 |
| Dent, SF | 1 |
| Neilan, TG | 1 |
| Blaes, A | 1 |
| Fradley, MG | 1 |
| Nohria, A | 1 |
| Moustafa, K | 1 |
| Ramandi, A | 1 |
| George, J | 1 |
| Merat, S | 5 |
| Jafari, E | 2 |
| Sharafkhah, M | 2 |
| Radmard, AR | 2 |
| Nateghi Baygi, A | 1 |
| Delavari, A | 1 |
| Mohammadi, Z | 1 |
| Poustchi, H | 5 |
| Gupta, K | 5 |
| Mehta, H | 1 |
| Kim, H | 1 |
| Stebbins, A | 3 |
| Wruck, LM | 4 |
| Muñoz, D | 5 |
| Effron, MB | 5 |
| Anderson, RD | 3 |
| Pepine, CJ | 6 |
| Jain, SK | 4 |
| Girotra, S | 5 |
| DeWalt, DA | 4 |
| Whittle, J | 4 |
| Benziger, CP | 5 |
| Farrehi, P | 3 |
| Zhou, L | 2 |
| Knowlton, KU | 3 |
| Polonsky, TS | 5 |
| Bradley, SM | 3 |
| Harrington, RA | 6 |
| Rothman, RL | 4 |
| Jones, WS | 10 |
| Hernandez, AF | 6 |
| Oynotkinova, OS | 1 |
| Matskeplishvili, ST | 1 |
| Maslennikova, OM | 1 |
| Pavlov, AI | 1 |
| Poberezhskaya, AG | 1 |
| Kim, JH | 6 |
| Park, D | 1 |
| Lim, HS | 2 |
| Kang, MJ | 1 |
| Lee, JH | 3 |
| Yoon, SY | 2 |
| Kim, HS | 2 |
| Mystakelis, HA | 1 |
| Wilson, E | 1 |
| Laidlaw, E | 1 |
| Poole, A | 1 |
| Krishnan, S | 1 |
| Rupert, A | 1 |
| Welker, JL | 1 |
| Gorelick, RJ | 1 |
| Lisco, A | 1 |
| Manion, M | 1 |
| Baker, JV | 1 |
| Migueles, SA | 1 |
| Sereti, I | 1 |
| Adame, MJ | 1 |
| Raji, M | 1 |
| Shan, Y | 1 |
| Kuo, YF | 1 |
| Tripple, JW | 1 |
| Tran, RJC | 1 |
| Roberts, MM | 1 |
| Wells, R | 1 |
| Atem, FD | 1 |
| Sepanlou, SG | 2 |
| Mann, JFE | 1 |
| Yoo, SGK | 1 |
| Chung, GS | 1 |
| Bahendeka, SK | 1 |
| Sibai, AM | 1 |
| Damasceno, A | 1 |
| Farzadfar, F | 2 |
| Rohloff, P | 1 |
| Houehanou, C | 1 |
| Norov, B | 1 |
| Karki, KB | 1 |
| Azangou-Khyavy, M | 1 |
| Marcus, ME | 1 |
| Aryal, KK | 1 |
| Brant, LCC | 1 |
| Theilmann, M | 1 |
| Cífková, R | 1 |
| Lunet, N | 1 |
| Gurung, MS | 1 |
| Mwangi, JK | 1 |
| Martins, J | 1 |
| Haghshenas, R | 1 |
| Sturua, L | 1 |
| Vollmer, S | 1 |
| Bärnighausen, T | 1 |
| Atun, R | 1 |
| Sussman, JB | 2 |
| Singh, K | 2 |
| Saeedi Moghaddam, S | 1 |
| Guwatudde, D | 1 |
| Geldsetzer, P | 1 |
| Manne-Goehler, J | 1 |
| Davies, JI | 1 |
| Flood, D | 1 |
| Wongcharoen, W | 1 |
| Osataphan, N | 1 |
| Prasertwitayakij, N | 1 |
| Suwannasom, P | 1 |
| Suraamornkul, S | 1 |
| Wongtheptian, W | 1 |
| Gunaparn, S | 1 |
| Sirikul, W | 1 |
| Phrommintikul, A | 1 |
| Shung, DL | 1 |
| De Luca, L | 1 |
| Sleem, A | 1 |
| Re, RN | 2 |
| Farrehi, PM | 1 |
| Roe, MT | 7 |
| Wang, Y | 2 |
| Tian, A | 1 |
| Wu, C | 2 |
| Lu, J | 2 |
| Chen, B | 1 |
| Zhang, X | 3 |
| Cui, J | 1 |
| Xu, W | 1 |
| Song, L | 1 |
| Guo, W | 2 |
| Hu, S | 2 |
| Wruck, L | 1 |
| Kripalani, S | 3 |
| Ahmad, FS | 3 |
| Brooker, C | 1 |
| Compton, R | 1 |
| Babineau, T | 1 |
| Normeshie, CA | 1 |
| Blackstone, SR | 1 |
| Schrör, K | 4 |
| Storey, RF | 8 |
| Paseban, M | 1 |
| Marjaneh, RM | 1 |
| Banach, M | 3 |
| Riahi, MM | 1 |
| Bo, S | 1 |
| Sahebkar, A | 2 |
| Uchiyama, S | 4 |
| Goto, S | 2 |
| Origasa, H | 1 |
| Uemura, N | 1 |
| Sugano, K | 1 |
| Hiraishi, H | 2 |
| Shimada, K | 3 |
| Okada, Y | 1 |
| Ikeda, Y | 4 |
| Webster, R | 10 |
| Grobbee, D | 1 |
| Khoshnia, M | 4 |
| Hemming, K | 3 |
| Kamangar, F | 1 |
| Gharavi, A | 1 |
| Ostovaneh, MR | 2 |
| Nateghi, A | 4 |
| Majed, M | 2 |
| Navabakhsh, B | 2 |
| Pourshams, A | 3 |
| Nalini, M | 1 |
| Malekzadeh, F | 5 |
| Naemi-Tabiei, M | 1 |
| Fazel, A | 1 |
| Brennan, P | 1 |
| Etemadi, A | 2 |
| Boffetta, P | 1 |
| Thomas, N | 2 |
| Marshall, T | 8 |
| Cheng, KK | 4 |
| Rosenberg, K | 3 |
| Salam, A | 1 |
| Praveen, D | 1 |
| Patel, A | 11 |
| Tewari, A | 1 |
| Cavalcoli, F | 1 |
| Pusceddu, S | 1 |
| Zilli, A | 1 |
| Tamagno, G | 1 |
| Femia, D | 1 |
| Prinzi, N | 1 |
| Travers, J | 1 |
| Consonni, D | 1 |
| Ciafardini, C | 1 |
| Conte, D | 1 |
| Massironi, S | 1 |
| Zhang, XF | 1 |
| Wang, X | 1 |
| Hu, DY | 3 |
| Vidyanti, AN | 1 |
| Chan, L | 1 |
| Lin, CL | 1 |
| Muo, CH | 1 |
| Hsu, CY | 1 |
| Chen, YC | 1 |
| Wu, D | 2 |
| Hu, CJ | 1 |
| McClure, GR | 1 |
| Kaplovitch, E | 2 |
| Narula, S | 1 |
| Bhagirath, VC | 2 |
| Anand, SS | 14 |
| Shi, Y | 2 |
| Li, J | 5 |
| Zhang, Z | 2 |
| Yan, Z | 1 |
| Liu, Y | 1 |
| Ruze, R | 1 |
| Xiong, Y | 1 |
| Han, H | 2 |
| Zhan, H | 1 |
| Zhang, G | 1 |
| Saad, M | 2 |
| Abdelaziz, HK | 2 |
| Mehta, JL | 2 |
| Andreotti, F | 4 |
| D'Amario, D | 1 |
| Vergallo, R | 1 |
| Montone, RA | 1 |
| Porto, I | 1 |
| Crea, F | 2 |
| de Vries, TI | 1 |
| Eikelboom, JW | 28 |
| Westerink, J | 1 |
| Dorresteijn, JAN | 2 |
| Alings, M | 5 |
| Dyal, L | 6 |
| Berkowitz, SD | 5 |
| van der Graaf, Y | 7 |
| Fox, KAA | 9 |
| Visseren, FLJ | 2 |
| Kozieł, M | 1 |
| Lip, GYH | 2 |
| Jiménez-García, N | 1 |
| de la Torre Lima, J | 1 |
| García Alegría, J | 1 |
| Selak, V | 9 |
| Jackson, R | 5 |
| Poppe, K | 4 |
| Wu, B | 3 |
| Harwood, M | 4 |
| Grey, C | 3 |
| Pylypchuk, R | 2 |
| Mehta, S | 2 |
| Choi, YH | 1 |
| Kerr, A | 4 |
| Wells, S | 5 |
| Simeone, P | 1 |
| Al-Sofiani, ME | 2 |
| Derenbecker, R | 1 |
| Quartuccio, M | 1 |
| Kalyani, RR | 3 |
| Pierce, JB | 1 |
| Feinberg, MW | 1 |
| Mahmoud, AN | 3 |
| Elgendy, IY | 3 |
| Soejima, H | 6 |
| Ogawa, H | 11 |
| Morimoto, T | 11 |
| Okada, S | 5 |
| Matsumoto, C | 2 |
| Nakayama, M | 6 |
| Masuda, I | 3 |
| Jinnouchi, H | 5 |
| Waki, M | 4 |
| Saito, Y | 7 |
| Qiu, J | 1 |
| Ke, X | 1 |
| Yang, G | 1 |
| Thobani, A | 1 |
| Dhindsa, DS | 1 |
| DeMoss, BD | 1 |
| Raad, M | 1 |
| Sandesara, PB | 1 |
| Baer, JT | 1 |
| Lewis, J | 1 |
| Bethishou, L | 1 |
| Tsu, LV | 1 |
| Grant, PJ | 1 |
| Cosentino, F | 1 |
| Bello, NA | 1 |
| Miller, EC | 1 |
| Cleary, KL | 1 |
| Rosberg, V | 1 |
| Grove, EL | 10 |
| Bøtker, HE | 2 |
| McLaughlin, E | 1 |
| Leggett, S | 1 |
| Kelsberg, G | 2 |
| Safranek, S | 1 |
| Belcaro, G | 2 |
| Cesarone, MR | 2 |
| Scipione, C | 2 |
| Scipione, V | 2 |
| Dugall, M | 2 |
| Shu, H | 1 |
| Peterzan, P | 1 |
| Corsi, M | 1 |
| Luzzi, R | 1 |
| Hosoi, M | 1 |
| Feragalli, B | 2 |
| Cotellese, R | 2 |
| Maione, C | 1 |
| Koilpillai, P | 1 |
| Nishtala, NS | 1 |
| Gelbenegger, G | 1 |
| Postula, M | 2 |
| Pecen, L | 1 |
| Halvorsen, S | 4 |
| Lesiak, M | 1 |
| Schoergenhofer, C | 1 |
| Jilma, B | 5 |
| Hengstenberg, C | 2 |
| Siller-Matula, JM | 3 |
| Ramacciotti, E | 1 |
| Weitz, JI | 3 |
| De Backer, O | 2 |
| Dangas, GD | 4 |
| Jilaihawi, H | 1 |
| Leipsic, JA | 1 |
| Terkelsen, CJ | 1 |
| Makkar, R | 1 |
| Kini, AS | 2 |
| Veien, KT | 1 |
| Abdel-Wahab, M | 1 |
| Kim, WK | 1 |
| Balan, P | 1 |
| Van Mieghem, N | 1 |
| Mathiassen, ON | 1 |
| Jeger, RV | 3 |
| Arnold, M | 1 |
| Mehran, R | 5 |
| Guimarães, AHC | 2 |
| Nørgaard, BL | 1 |
| Kofoed, KF | 1 |
| Blanke, P | 1 |
| Windecker, S | 6 |
| Søndergaard, L | 2 |
| Tijssen, JGP | 1 |
| Wöhrle, J | 1 |
| Gilard, M | 1 |
| Möllmann, H | 1 |
| Makkar, RR | 1 |
| Herrmann, HC | 1 |
| Giustino, G | 2 |
| Baldus, S | 1 |
| Gullestad, L | 1 |
| Kini, A | 1 |
| von Lewinski, D | 2 |
| Mack, M | 1 |
| Moreno, R | 1 |
| Schäfer, U | 1 |
| Seeger, J | 1 |
| Tchétché, D | 1 |
| Thomitzek, K | 2 |
| Valgimigli, M | 5 |
| Vranckx, P | 3 |
| Welsh, RC | 2 |
| Wildgoose, P | 2 |
| Volkl, AA | 2 |
| Zazula, A | 2 |
| van Amsterdam, RGM | 1 |
| Gallus, A | 1 |
| Jain, M | 1 |
| Childers, C | 1 |
| Moriarty, F | 2 |
| Ebell, MH | 2 |
| Jung, M | 1 |
| Lee, S | 2 |
| Roderick, P | 2 |
| Mafham, MM | 1 |
| Bowman, LJ | 1 |
| Haynes, RJ | 1 |
| Armitage, JM | 1 |
| Jiang, M | 1 |
| Li, P | 2 |
| You, JH | 1 |
| Zheng, X | 1 |
| Deng, J | 1 |
| Zhao, M | 1 |
| Feng, L | 1 |
| Fang, Y | 1 |
| David, C | 1 |
| Costa, J | 1 |
| Qu, B | 1 |
| He, Y | 1 |
| Wu, L | 1 |
| Lu, H | 1 |
| Wu, H | 1 |
| Li, M | 1 |
| Fernandez-Jimenez, R | 1 |
| Wang, TJ | 1 |
| Blot, WJ | 1 |
| Luo, Y | 1 |
| Zhu, Y | 1 |
| Chen, J | 6 |
| Gao, X | 1 |
| Yang, W | 2 |
| Zou, X | 1 |
| Zhou, X | 2 |
| Ji, L | 1 |
| Schneider, DJ | 2 |
| McMahon, SR | 1 |
| Ehle, GL | 1 |
| Chava, S | 1 |
| Taatjes-Sommer, HS | 1 |
| Meagher, S | 1 |
| Chabior, A | 1 |
| Pordzik, J | 1 |
| Mirowska-Guzel, D | 1 |
| Postuła, M | 2 |
| Aimo, A | 4 |
| Ridker, PM | 25 |
| Zhao, Y | 1 |
| Jeyaraman, K | 1 |
| Burgess, P | 1 |
| Connors, C | 1 |
| Guthridge, S | 1 |
| Maple-Brown, L | 1 |
| Falhammar, H | 1 |
| Pfrepper, C | 1 |
| Dietze, C | 1 |
| Remane, Y | 1 |
| Bertsche, T | 1 |
| Schiek, S | 1 |
| Kaiser, T | 2 |
| Gockel, I | 1 |
| Josten, C | 1 |
| Petros, S | 1 |
| Tofler, GH | 3 |
| Morel-Kopp, MC | 2 |
| Spinaze, M | 1 |
| Dent, J | 1 |
| Ward, C | 1 |
| McKinley, S | 1 |
| Mihailidou, AS | 1 |
| Havyatt, J | 1 |
| Whitfield, V | 1 |
| Bartrop, R | 1 |
| Fethney, J | 1 |
| Prigerson, HG | 1 |
| Buckley, T | 2 |
| Rocca, B | 4 |
| Kwon, S | 1 |
| Chan, AT | 2 |
| Schamroth Pravda, M | 1 |
| Schamroth Pravda, N | 1 |
| Beigel, Y | 1 |
| Matetzky, S | 2 |
| Beigel, R | 2 |
| Camara Planek, MI | 1 |
| Silver, AJ | 1 |
| Volgman, AS | 1 |
| Okwuosa, TM | 1 |
| González-Juanatey, JR | 2 |
| Tamargo, J | 2 |
| Torres, F | 2 |
| Weisser, B | 1 |
| Oudovenko, N | 1 |
| Khezrian, M | 1 |
| Waymont, JMJ | 1 |
| Myint, PK | 1 |
| McNeil, CJ | 1 |
| Whalley, LJ | 2 |
| Staff, R | 1 |
| Murray, AD | 1 |
| Yang, C | 1 |
| Fan, Z | 1 |
| Yang, J | 1 |
| Shi, Q | 2 |
| Shambhu, S | 2 |
| Marshall, A | 1 |
| Rose-Kennedy, E | 1 |
| Robertson, H | 2 |
| Paullin, M | 1 |
| Cziraky, M | 2 |
| Haynes, K | 4 |
| Lopau, K | 1 |
| Wanner, C | 2 |
| Shelley, DR | 1 |
| Gepts, T | 1 |
| Siman, N | 2 |
| Nguyen, AM | 1 |
| Cleland, C | 2 |
| Cuthel, AM | 1 |
| Rogers, ES | 1 |
| Ogedegbe, O | 1 |
| Pham-Singer, H | 1 |
| Wu, W | 2 |
| Berry, CA | 1 |
| Peters, AT | 1 |
| Mutharasan, RK | 1 |
| Misialek, JR | 5 |
| Oldenburg, NC | 6 |
| Jones, C | 3 |
| Alvikas, J | 1 |
| Myers, SP | 1 |
| Wessel, CB | 1 |
| Okonkwo, DO | 1 |
| Joseph, B | 1 |
| Pelaez, C | 1 |
| Doberstein, C | 1 |
| Guillotte, AR | 1 |
| Rosengart, MR | 1 |
| Neal, MD | 1 |
| Ravach, G | 1 |
| Fournier, S | 1 |
| Mazzolai, L | 2 |
| Nanchen, D | 1 |
| Sagar, RC | 1 |
| Naseem, KM | 1 |
| Ajjan, RA | 2 |
| Gowda, SN | 1 |
| Bell, M | 1 |
| Jahraus, M | 1 |
| Fanciullo, J | 1 |
| Gelosa, P | 1 |
| Castiglioni, L | 1 |
| Camera, M | 1 |
| Sironi, L | 1 |
| Lombardi, N | 1 |
| Crescioli, G | 1 |
| Simonetti, M | 3 |
| Marconi, E | 1 |
| Vannacci, A | 1 |
| Bettiol, A | 1 |
| Parretti, D | 3 |
| Cricelli, C | 4 |
| Lapi, F | 3 |
| Zhang, P | 3 |
| Wang, H | 3 |
| Chen, XH | 3 |
| Liang, WY | 2 |
| Liu, WW | 3 |
| Bonaca, MP | 3 |
| Bauersachs, RM | 1 |
| Debus, ES | 2 |
| Nehler, MR | 1 |
| Patel, MR | 2 |
| Fanelli, F | 1 |
| Capell, WH | 1 |
| Diao, L | 1 |
| Jaeger, N | 1 |
| Hess, CN | 1 |
| Pap, AF | 1 |
| Kittelson, JM | 2 |
| Gudz, I | 1 |
| Mátyás, L | 1 |
| Krievins, DK | 1 |
| Brodmann, M | 1 |
| Muehlhofer, E | 3 |
| Haskell, LP | 1 |
| Hiatt, WR | 6 |
| Connolly, SJ | 7 |
| Steg, PG | 18 |
| Verma, S | 1 |
| Branch, KRH | 5 |
| Probstfield, J | 5 |
| Shestakovska, O | 5 |
| Szarek, M | 1 |
| Maggioni, AP | 6 |
| Widimský, P | 10 |
| Lewis, BS | 5 |
| Ryden, L | 5 |
| Petersohn, S | 1 |
| Pouwels, X | 1 |
| Ramaekers, B | 1 |
| Ten Cate-Hoek, A | 1 |
| Joore, M | 1 |
| Piggott, C | 1 |
| Lyon, C | 1 |
| Clemens, KK | 1 |
| Woodward, M | 2 |
| Neal, B | 4 |
| Zinman, B | 1 |
| Ambrose, JA | 1 |
| Najafi, A | 1 |
| Jain, V | 1 |
| Muller, JE | 2 |
| Ranka, S | 1 |
| Barua, RS | 1 |
| Kanorskii, SG | 1 |
| El Alaoui, MZ | 1 |
| Guy, A | 1 |
| Khalki, L | 1 |
| Limami, Y | 1 |
| Benomar, A | 1 |
| Zaid, N | 1 |
| Cherrah, Y | 1 |
| Mekhfi, H | 2 |
| Cadi, R | 1 |
| Zaid, Y | 1 |
| Schenone, AL | 1 |
| Lincoff, AM | 1 |
| Moyad, MA | 4 |
| Larina, VN | 1 |
| Gaydina, TA | 1 |
| Mkrtychev, DS | 1 |
| Kuznetsova, VA | 1 |
| Snezhko, ZV | 1 |
| Byrne, RA | 1 |
| Colleran, R | 1 |
| Wein, T | 1 |
| Lindsay, MP | 1 |
| Gladstone, DJ | 1 |
| Poppe, A | 1 |
| Bell, A | 2 |
| Casaubon, LK | 1 |
| Foley, N | 1 |
| Coutts, SB | 1 |
| Cox, J | 4 |
| Douketis, J | 1 |
| Field, T | 1 |
| Gioia, L | 1 |
| Habert, J | 1 |
| Lang, E | 1 |
| Mehta, SR | 8 |
| Papoushek, C | 1 |
| Semchuk, W | 1 |
| Sharma, M | 2 |
| Udell, JA | 2 |
| Lawrence, S | 1 |
| Mountain, A | 1 |
| Gubitz, G | 1 |
| Dowlatshahi, D | 1 |
| Simard, A | 1 |
| de Jong, A | 1 |
| Smith, EE | 1 |
| Elsonbaty, A | 1 |
| Serag, A | 1 |
| Abdulwahab, S | 1 |
| Hassan, WS | 1 |
| Eissa, MS | 1 |
| Gresele, P | 2 |
| Paciullo, F | 1 |
| Migliacci, R | 1 |
| Li, XY | 2 |
| Shi, ZW | 1 |
| Zhao, D | 3 |
| Yin, DW | 1 |
| Cainzos-Achirica, M | 2 |
| Bilal, U | 1 |
| Magness, JW | 1 |
| Arnwine, C | 1 |
| Lockwood, K | 1 |
| Reinert, A | 1 |
| Synnott, PG | 1 |
| McQueen, RB | 1 |
| Ollendorf, DA | 1 |
| Campbell, JD | 1 |
| Pearson, SD | 1 |
| Ricket, IM | 1 |
| Hammill, BG | 2 |
| Eskenazi, L | 1 |
| Robertson, HR | 2 |
| Curtis, LH | 2 |
| Dobi, CD | 1 |
| Kizer, JR | 1 |
| Roumie, CL | 1 |
| Waitman, R | 1 |
| Weiner, MG | 1 |
| Nyambuya, TM | 1 |
| Dludla, PV | 1 |
| Mxinwa, V | 1 |
| Mokgalaboni, K | 1 |
| Ngcobo, SR | 1 |
| Tiano, L | 1 |
| Nkambule, BB | 1 |
| Spiegel, R | 1 |
| Schjerning, AM | 1 |
| McGettigan, P | 1 |
| Gislason, GH | 2 |
| Patel, NJ | 1 |
| Baliga, RR | 1 |
| Gager, GM | 1 |
| Winter, MP | 1 |
| Lang, IM | 1 |
| Toma, A | 1 |
| Prüller, F | 2 |
| Wallner, M | 1 |
| Kolesnik, E | 1 |
| Chung, YH | 1 |
| Lee, KA | 1 |
| Cho, M | 1 |
| Shin, S | 2 |
| Lee, BK | 1 |
| Cho, YH | 1 |
| Yun, KH | 1 |
| Kim, YH | 2 |
| Suh, Y | 1 |
| Cho, JY | 1 |
| Her, AY | 1 |
| Cho, S | 1 |
| Jeon, DW | 1 |
| Yoo, SY | 1 |
| Cho, DK | 1 |
| Hong, BK | 1 |
| Kwon, H | 1 |
| Nam, CM | 1 |
| Sulaica, EM | 1 |
| Asias-Dinh, BD | 1 |
| Wanat, MA | 1 |
| Birtcher, KK | 1 |
| Lewis, JP | 2 |
| Xie, S | 1 |
| Nelson, M | 2 |
| Shuldiner, AR | 3 |
| Soodi, D | 2 |
| VanWormer, JJ | 6 |
| Rezkalla, SH | 3 |
| Mahady, SE | 3 |
| Hosokawa, K | 2 |
| Ohnishi-Wada, T | 1 |
| Nagasato, T | 1 |
| Sameshima-Kaneko, H | 1 |
| Oyamada, C | 1 |
| Dahlen, J | 1 |
| Smilowitz, NR | 3 |
| Homco, J | 1 |
| Carabin, H | 1 |
| Nagykaldi, Z | 1 |
| Garwe, T | 1 |
| Duffy, FD | 1 |
| Kendrick, D | 1 |
| Martinez, S | 1 |
| Zhao, YD | 1 |
| Stoner, J | 1 |
| Fiala, C | 1 |
| Pasic, MD | 1 |
| Pafundi, PC | 1 |
| Galiero, R | 1 |
| Caturano, A | 1 |
| Acierno, C | 1 |
| de Sio, C | 1 |
| Vetrano, E | 1 |
| Nevola, R | 1 |
| Gelso, A | 1 |
| Bono, V | 1 |
| Costagliola, C | 1 |
| Marfella, R | 2 |
| Sardu, C | 1 |
| Rinaldi, L | 1 |
| Salvatore, T | 1 |
| Adinolfi, LE | 1 |
| Sasso, FC | 2 |
| Fras, Z | 1 |
| van Diemen, JJK | 1 |
| Madsen, MC | 1 |
| Vrancken, P | 1 |
| de Bie, K | 1 |
| van der Bom, JG | 2 |
| Veen, G | 2 |
| Bonten, TN | 2 |
| Fuijkschot, WW | 2 |
| Smulders, YM | 2 |
| Thijs, A | 2 |
| Brouwer, J | 1 |
| Nijenhuis, VJ | 1 |
| Delewi, R | 1 |
| Hermanides, RS | 1 |
| Holvoet, W | 1 |
| Dubois, CLF | 1 |
| Frambach, P | 1 |
| De Bruyne, B | 1 |
| van Houwelingen, GK | 1 |
| Van Der Heyden, JAS | 1 |
| Toušek, P | 1 |
| van der Kley, F | 1 |
| Buysschaert, I | 1 |
| Schotborgh, CE | 1 |
| Ferdinande, B | 1 |
| van der Harst, P | 1 |
| Roosen, J | 1 |
| Peper, J | 1 |
| Thielen, FWF | 1 |
| Veenstra, L | 1 |
| Chan Pin Yin, DRPP | 1 |
| Swaans, MJ | 1 |
| Rensing, BJWM | 1 |
| van 't Hof, AWJ | 1 |
| Timmers, L | 1 |
| Kelder, JC | 1 |
| Stella, PR | 1 |
| Baan, J | 1 |
| Mahtta, D | 1 |
| Akeroyd, JM | 1 |
| Spertus, JA | 1 |
| Petersen, LA | 2 |
| Ballantyne, CM | 3 |
| Patti, G | 2 |
| Sticchi, A | 1 |
| Verolino, G | 1 |
| Pasceri, V | 1 |
| Vizzi, V | 1 |
| Brscic, E | 1 |
| Casu, G | 1 |
| Golino, P | 1 |
| Russo, V | 1 |
| Rapacciuolo, A | 1 |
| Boccuzzi, G | 1 |
| Mangieri, A | 1 |
| Pagnotta, PA | 1 |
| Colombo, A | 2 |
| Gandomkar, A | 1 |
| Malekzadeh, Z | 1 |
| Moghadami, M | 1 |
| Fattahi, MR | 1 |
| Moini, M | 1 |
| Anushiravani, A | 1 |
| Mortazavi, R | 1 |
| Sadeghi Boogar, S | 1 |
| Mohammadkarimi, V | 1 |
| Abtahi, F | 1 |
| Keikhosravi, N | 1 |
| Mirdamadian, SZ | 1 |
| Varshosaz, J | 1 |
| Taheri, A | 1 |
| Lee, MC | 1 |
| Liao, CT | 1 |
| Toh, HS | 1 |
| Chou, CC | 1 |
| Chang, WT | 1 |
| Chen, ZC | 1 |
| Wu, WS | 1 |
| Yu, T | 4 |
| Strong, C | 1 |
| Scott, LJ | 2 |
| Batais, MA | 1 |
| Almutairi, KM | 1 |
| Almigbal, TH | 1 |
| Alodhayani, A | 1 |
| Alonazi, WB | 1 |
| Vinluan, JM | 1 |
| Asnar, JB | 1 |
| Salem, RE | 1 |
| Aljubab, RA | 1 |
| Walker, R | 1 |
| Abhayaratna, WP | 4 |
| Gibbs, P | 3 |
| Wood, EM | 2 |
| Williamson, JD | 3 |
| Donnan, GA | 8 |
| Cloud, GC | 1 |
| Mogul, A | 1 |
| Leppien, EE | 1 |
| Laughlin, E | 1 |
| Spinler, SA | 2 |
| Do, CT | 1 |
| Manjaly, ZM | 1 |
| Heinzle, J | 1 |
| Schöbi, D | 1 |
| Kasper, L | 1 |
| Pruessmann, KP | 1 |
| Stephan, KE | 1 |
| Frässle, S | 1 |
| Molinero, G | 1 |
| Chui, P | 1 |
| Bhargava, A | 1 |
| Justice, A | 1 |
| Hauser, RG | 1 |
| Aboyans, V | 5 |
| Abola, MT | 1 |
| Ashkenazi, I | 1 |
| Schermann, H | 1 |
| Gold, A | 1 |
| Gurel, R | 1 |
| Chechik, O | 1 |
| Warschawski, Y | 1 |
| Schwarzkopf, R | 1 |
| Snir, N | 1 |
| Antunes, MM | 1 |
| Haley, SP | 1 |
| Chessman, A | 1 |
| Broder, JC | 1 |
| Stocks, NP | 2 |
| Liew, D | 4 |
| Peters, CD | 1 |
| Kjaergaard, KD | 1 |
| Christensen, KL | 1 |
| Bibby, BM | 1 |
| Jespersen, B | 1 |
| Jensen, JD | 1 |
| Chowdhury, EK | 1 |
| Beilin, LJ | 4 |
| Margolis, KL | 3 |
| Poplawski, M | 1 |
| Nelson, NK | 1 |
| Earwood, JS | 1 |
| Yusoff, K | 6 |
| Christou, C | 1 |
| Girish, P | 1 |
| Yeates, K | 1 |
| Xavier, F | 1 |
| Dagenais, G | 3 |
| Rocha, C | 1 |
| McCready, T | 3 |
| Tyrwhitt, J | 1 |
| Eichelberger, B | 1 |
| Kopp, CW | 6 |
| Panzer, S | 6 |
| Gremmel, T | 7 |
| Dasa, O | 1 |
| Pearson, TA | 3 |
| Robson, A | 1 |
| Yang, SC | 1 |
| Wu, CK | 1 |
| Tai, WC | 1 |
| Liang, CM | 1 |
| Yao, CC | 1 |
| Wu, KL | 1 |
| Hsu, CN | 1 |
| Chuah, SK | 1 |
| Oh, TK | 1 |
| Song, IA | 1 |
| Kay, VR | 1 |
| Wedel, N | 1 |
| Smith, GN | 1 |
| Barnes, GD | 1 |
| Peery, AF | 1 |
| Shaukat, A | 2 |
| Strate, LL | 1 |
| Chen, Y | 1 |
| Ou, Z | 1 |
| Ouyang, F | 1 |
| Liang, J | 1 |
| Jiang, Z | 1 |
| Chen, C | 3 |
| Zeng, J | 1 |
| Desai, N | 1 |
| Wilson, B | 1 |
| Bond, M | 1 |
| Conant, A | 1 |
| Rahman, M | 1 |
| Zhirov, IV | 1 |
| Bhat, G | 1 |
| Shetty, A | 1 |
| Schade, DS | 1 |
| Burchiel, S | 1 |
| Eaton, RP | 1 |
| Liang, W | 1 |
| Liu, M | 2 |
| Davis, KAS | 1 |
| Bishara, D | 1 |
| Molokhia, M | 1 |
| Mueller, C | 1 |
| Perera, G | 1 |
| Stewart, RJ | 1 |
| Ricciotti, E | 2 |
| FitzGerald, GA | 8 |
| Major, RW | 3 |
| Burton, JO | 2 |
| Kochar, A | 1 |
| Summers, MB | 1 |
| Lampert, BC | 1 |
| Breiburg, A | 1 |
| Kuschner, WG | 1 |
| Lee, CY | 1 |
| Liu, KT | 1 |
| Lu, HT | 1 |
| Mohd Ali, R | 1 |
| Fong, AYY | 1 |
| Wan Ahmad, WA | 1 |
| Kim, SJ | 1 |
| Kwon, OD | 1 |
| Choi, HC | 1 |
| Lee, EJ | 2 |
| Cho, B | 1 |
| Kolditz, M | 1 |
| Welte, T | 1 |
| Mathews, L | 1 |
| Han, D | 1 |
| Evans, MK | 1 |
| Zonderman, AB | 1 |
| Ndumele, CE | 1 |
| Crews, DC | 1 |
| Rhee, TG | 1 |
| Kumar, M | 1 |
| Ross, JS | 1 |
| Coll, PP | 1 |
| Merzon, E | 1 |
| Green, I | 1 |
| Vinker, S | 1 |
| Golan-Cohen, A | 1 |
| Gorohovski, A | 1 |
| Avramovich, E | 1 |
| Frenkel-Morgenstern, M | 1 |
| Magen, E | 1 |
| Perrone-Filardi, P | 2 |
| Minghetti, P | 1 |
| Menditto, E | 1 |
| Bianchi, S | 1 |
| Scaglione, F | 1 |
| Trifirò, G | 1 |
| Piccinocchi, G | 1 |
| Corona, T | 1 |
| Gambarelli, G | 1 |
| Izzi, C | 1 |
| Misciagna, V | 1 |
| Putignano, D | 1 |
| Lopatriello, S | 1 |
| Cafiero, D | 1 |
| Barry, A | 1 |
| Kenny, RA | 1 |
| Fahey, T | 2 |
| Kalashnikov, VY | 1 |
| Michurova, MS | 1 |
| Pollack, CV | 3 |
| Wang, TY | 3 |
| Angiolillo, DJ | 7 |
| Oh, YJ | 1 |
| Kim, AJ | 2 |
| Ro, H | 2 |
| Chang, JH | 2 |
| Lee, HH | 2 |
| Chung, W | 2 |
| Hyun, YY | 1 |
| Lee, J | 2 |
| Han, SH | 1 |
| Chae, DW | 1 |
| Ahn, C | 1 |
| Oh, KH | 1 |
| Jung, JY | 2 |
| Horvath, KJ | 1 |
| Van't Hof, J | 1 |
| Hirsch, AT | 6 |
| Tanner, M | 1 |
| Tervonen, T | 1 |
| Seo, J | 1 |
| Krucien, N | 1 |
| Marsh, K | 1 |
| Wissinger, U | 1 |
| Soriano Gabarró, M | 1 |
| Kamran, H | 1 |
| Kayani, WT | 1 |
| Levine, GN | 1 |
| Nambi, V | 2 |
| Khalid, U | 1 |
| Siegel, AJ | 2 |
| Cooper, J | 1 |
| Foy, AJ | 1 |
| Gallieni, M | 1 |
| Paik, JM | 1 |
| Fiorina, P | 1 |
| Alam, A | 1 |
| Carey, SA | 1 |
| Hall, SA | 1 |
| Messerli, FH | 2 |
| Brguljan, J | 1 |
| Bangalore, S | 1 |
| Wald, N | 1 |
| Wald, D | 1 |
| Law, M | 1 |
| Eder, MM | 1 |
| Jhaveri, A | 1 |
| Sibley, RA | 1 |
| Spatz, ES | 1 |
| Dodson, J | 1 |
| Holzgreve, H | 1 |
| Block, RC | 2 |
| Shearer, GC | 1 |
| Holub, A | 1 |
| Tu, XM | 1 |
| Mousa, S | 1 |
| Brenna, JT | 1 |
| Harris, WS | 1 |
| Tintle, N | 1 |
| Heide-Jørgensen, U | 1 |
| Thim, T | 2 |
| Thomsen, RW | 1 |
| Sørensen, HT | 1 |
| Baigent, C | 14 |
| Mulder, H | 1 |
| Pencina, MJ | 1 |
| Crenshaw, DL | 1 |
| Handberg, EM | 1 |
| Manning, BR | 1 |
| Riley, D | 1 |
| Goldberg, YH | 1 |
| Roger, VL | 1 |
| Hess, R | 1 |
| Ford, DE | 1 |
| Kraschnewski, JL | 1 |
| Fintel, DJ | 1 |
| McClay, JC | 1 |
| Campbell, JR | 1 |
| Bell, DS | 3 |
| Fonarow, GC | 2 |
| Paranjape, A | 1 |
| Sharlow, AG | 1 |
| Berdan, LG | 1 |
| Harris, DF | 1 |
| Qualls, LG | 1 |
| Modrow, MF | 1 |
| Marcus, GM | 1 |
| Carton, TW | 1 |
| Nauman, E | 1 |
| Waitman, LR | 1 |
| Kho, AN | 2 |
| Shenkman, EA | 1 |
| McTigue, KM | 1 |
| Kaushal, R | 1 |
| Masoudi, FA | 1 |
| Antman, EM | 4 |
| Davidson, DR | 1 |
| Edgley, K | 1 |
| Merritt, JG | 1 |
| Brown, LS | 1 |
| Zemon, DN | 1 |
| McCormick, TE | 1 |
| Alikhaani, JD | 1 |
| Gregoire, KC | 1 |
| Minhas, S | 1 |
| Khan, A | 1 |
| Naids, S | 1 |
| Patel, JR | 1 |
| Seitz, MP | 1 |
| Khouzam, RN | 1 |
| Hamburg, NM | 1 |
| Creager, MA | 4 |
| Du, L | 1 |
| Kong, L | 1 |
| Zhang, S | 2 |
| Li, S | 4 |
| Du, G | 1 |
| Liu, EY | 1 |
| Yeh, HC | 1 |
| Echouffo-Tcheugui, JB | 1 |
| Joseph, JJ | 2 |
| Tan, SY | 1 |
| Cronin, H | 1 |
| Byrne, S | 1 |
| O'Donovan, A | 1 |
| Tuthill, A | 1 |
| Xu, H | 2 |
| Geng, Q | 1 |
| Mak, WH | 1 |
| Ling, F | 1 |
| Su, Z | 1 |
| Yang, F | 2 |
| Zhang, T | 1 |
| Yang, H | 1 |
| Xu, X | 1 |
| Jia, H | 1 |
| Zhong, S | 1 |
| Christensen, MB | 1 |
| Jimenez-Solem, E | 1 |
| Ernst, MT | 1 |
| Schmidt, M | 1 |
| Pottegård, A | 1 |
| Wang, IE | 1 |
| Yi, S | 1 |
| Mousa, SA | 2 |
| Pyarali, F | 1 |
| Iordanov, R | 1 |
| Ebner, B | 1 |
| Grant, J | 1 |
| Vincent, L | 1 |
| Toirac, A | 1 |
| Haque, T | 1 |
| Zablah, G | 1 |
| Kapoor, K | 1 |
| Powell, A | 1 |
| Boulanger, C | 1 |
| Hurwitz, B | 1 |
| Alcaide, M | 1 |
| Martinez, C | 1 |
| Naguib, D | 2 |
| Helten, C | 2 |
| Zako, S | 1 |
| Mourikis, P | 1 |
| M'Pembele, R | 1 |
| Trojovsky, K | 1 |
| Ahlbrecht, S | 1 |
| Zikeli, D | 1 |
| Zeus, T | 4 |
| Kelm, M | 4 |
| Dannenberg, L | 3 |
| Polzin, A | 4 |
| Sacristán, JA | 1 |
| Monach, PA | 1 |
| Branch-Elliman, W | 1 |
| Javor, E | 1 |
| Skelin, M | 1 |
| Lucijanić, M | 1 |
| Weisman, SM | 5 |
| Brunton, S | 1 |
| Luo, SD | 1 |
| Wu, SC | 1 |
| Chen, WC | 3 |
| Wu, CN | 1 |
| Chiu, TJ | 1 |
| Yang, YH | 1 |
| Li, SH | 1 |
| Fang, FM | 1 |
| Huang, TL | 1 |
| Hsiao, CC | 1 |
| Chen, CH | 1 |
| Pallikadavath, S | 1 |
| Ashton, L | 1 |
| Brunskill, NJ | 2 |
| Gray, LJ | 2 |
| Wolfe, RS | 1 |
| Newman, AB | 1 |
| Trevaks, RE | 3 |
| Johnston, CI | 3 |
| Grimm, RH | 1 |
| Frouws, MA | 1 |
| van Herk-Sukel, MPP | 1 |
| Maas, HA | 1 |
| Van de Velde, CJH | 1 |
| Portielje, JEA | 1 |
| Liefers, GJ | 1 |
| Bastiaannet, E | 1 |
| Lavie, CJ | 3 |
| Howden, CW | 1 |
| Scheiman, J | 5 |
| Tursi, J | 1 |
| Ventura, H | 1 |
| Woods, R | 3 |
| McNeil, J | 2 |
| Chan, FKL | 1 |
| Ching, JYL | 1 |
| Tse, YK | 2 |
| Lam, K | 1 |
| Wong, GLH | 1 |
| Ng, SC | 4 |
| Lee, V | 1 |
| Au, KWL | 1 |
| Cheong, PK | 1 |
| Suen, BY | 1 |
| Chan, H | 1 |
| Kee, KM | 1 |
| Lo, A | 1 |
| Wong, VWS | 1 |
| Wu, JCY | 1 |
| Kyaw, MH | 1 |
| Lafeber, M | 4 |
| Spiering, W | 4 |
| Visseren, FL | 6 |
| Grobbee, DE | 7 |
| Bots, ML | 7 |
| Stanton, A | 5 |
| Thom, S | 7 |
| Skolnik, N | 1 |
| Jaffa, FM | 1 |
| Johnson, E | 1 |
| Shubrook, JH | 1 |
| García-Rayado, G | 1 |
| Sostres, C | 6 |
| Lanas, A | 21 |
| Monden, K | 1 |
| Sadamori, H | 1 |
| Hioki, M | 1 |
| Ohno, S | 1 |
| Saneto, H | 1 |
| Ueki, T | 1 |
| Yabushita, K | 1 |
| Ono, K | 1 |
| Sakaguchi, K | 1 |
| Takakura, N | 1 |
| Fasano, S | 3 |
| Pierro, L | 2 |
| Pantano, I | 3 |
| Iudici, M | 2 |
| Valentini, G | 3 |
| Yang, YS | 1 |
| Kornelius, E | 1 |
| Chiou, JY | 1 |
| Lai, YR | 1 |
| Lo, SC | 1 |
| Peng, CH | 1 |
| Huang, CN | 1 |
| Volpe, M | 3 |
| Battistoni, A | 2 |
| Gallo, G | 1 |
| Coluccia, R | 1 |
| Richman, IB | 1 |
| Owens, DK | 2 |
| Piccolo, R | 1 |
| Gargiulo, G | 2 |
| Franzone, A | 1 |
| Santucci, A | 1 |
| Ariotti, S | 1 |
| Baldo, A | 1 |
| Tumscitz, C | 1 |
| Moschovitis, A | 1 |
| Sun, Q | 1 |
| Chang, S | 1 |
| Lu, S | 1 |
| Chang, Y | 1 |
| Small, KW | 1 |
| Garabetian, CA | 1 |
| Shaya, FS | 1 |
| Buhatem Medeiros, F | 1 |
| Pepe Medeiros de Rezende, N | 1 |
| Bertoldi Franco, J | 1 |
| Porrio de Andrade, AC | 1 |
| Timerman, L | 1 |
| Gallottini, M | 1 |
| Itagiba Neves, IL | 1 |
| Ortega, KL | 1 |
| Pagidipati, NJ | 1 |
| Navar, AM | 1 |
| Pieper, KS | 1 |
| Green, JB | 1 |
| Bethel, MA | 2 |
| Armstrong, PW | 4 |
| Josse, RG | 1 |
| McGuire, DK | 5 |
| Lokhnygina, Y | 2 |
| Cornel, JH | 2 |
| Strandberg, TE | 1 |
| Delibasi, T | 1 |
| Holman, RR | 4 |
| Peterson, ED | 1 |
| Wiernek, SL | 1 |
| Cavender, MA | 1 |
| Ardoino, I | 1 |
| Rossio, R | 1 |
| Di Blanca, D | 1 |
| Nobili, A | 1 |
| Pasina, L | 1 |
| Mannucci, PM | 1 |
| Peyvandi, F | 1 |
| Franchi, C | 1 |
| Dalal, KS | 1 |
| Bridgeman, MB | 1 |
| Subramanyam, P | 1 |
| Gianos, E | 1 |
| Reynolds, HR | 1 |
| Shah, B | 1 |
| Sedlis, SP | 1 |
| van Capelleveen, JC | 1 |
| Bochem, AE | 1 |
| Boekholdt, SM | 1 |
| Hoogeveen, RC | 1 |
| Sun, W | 1 |
| Barter, PJ | 1 |
| Tall, AR | 1 |
| Zwinderman, AH | 1 |
| Kastelein, JJP | 1 |
| Wareham, NJ | 1 |
| Khaw, KT | 1 |
| Hovingh, GK | 1 |
| Margiotta, DP | 1 |
| Navarini, L | 1 |
| Riccardi, A | 1 |
| Afeltra, A | 1 |
| Yee, J | 1 |
| Kumar, V | 1 |
| Anuwatworn, A | 1 |
| Petrasko, M | 1 |
| Stys, A | 1 |
| Gillani, SW | 1 |
| Sulaiman, SAS | 1 |
| Abdul, MIM | 1 |
| Baig, MR | 1 |
| Sakulchit, T | 1 |
| Benseler, SM | 1 |
| Goldman, RD | 1 |
| Murphy, L | 1 |
| Brown, C | 1 |
| Smith, A | 2 |
| Cranfield, F | 1 |
| Sharp, L | 1 |
| Visvanathan, K | 1 |
| Bennett, K | 2 |
| Barron, TI | 1 |
| Hart, RG | 6 |
| Lonn, EM | 3 |
| Hori, M | 5 |
| Piegas, LS | 3 |
| O'Donnell, M | 5 |
| Kakkar, AK | 3 |
| Parkhomenko, AN | 4 |
| Ertl, G | 3 |
| Störk, S | 4 |
| Keltai, M | 4 |
| Pogosova, N | 4 |
| Lanas, F | 6 |
| Commerford, PJ | 5 |
| Guzik, TJ | 3 |
| Verhamme, PB | 3 |
| Vinereanu, D | 5 |
| Felix, C | 4 |
| Metsarinne, KP | 2 |
| Cook Bruns, N | 4 |
| Misselwitz, F | 2 |
| Chen, E | 2 |
| Leong, D | 3 |
| Stylos, E | 1 |
| Chatziathanasiadou, MV | 1 |
| Tsiailanis, A | 1 |
| Kellici, TF | 1 |
| Tsoumani, M | 1 |
| Kostagianni, AD | 1 |
| Deligianni, M | 1 |
| Tselepis, AD | 2 |
| Tzakos, AG | 1 |
| Brass, EP | 1 |
| Zhang, JW | 1 |
| McCaffrey, TA | 2 |
| He, XQ | 1 |
| Feng, XR | 1 |
| Fu, SW | 2 |
| Huang, WY | 1 |
| Daugherty, SE | 1 |
| Shiels, MS | 1 |
| Purdue, MP | 1 |
| Freedman, ND | 1 |
| Abnet, CC | 1 |
| Hollenbeck, AR | 1 |
| Hayes, RB | 1 |
| Silverman, DT | 1 |
| Berndt, SI | 1 |
| Desormais, I | 1 |
| Jarlan, L | 1 |
| Teissier, MP | 1 |
| Lacroix, P | 1 |
| Mendy, VL | 1 |
| Vargas, R | 1 |
| Lim, GB | 1 |
| Jawaid, H | 1 |
| Hussain, A | 1 |
| Imtiaz, F | 1 |
| Toyota, T | 1 |
| Shiomi, H | 1 |
| Natsuaki, M | 1 |
| Kimura, T | 3 |
| Sundström, J | 2 |
| Hedberg, J | 1 |
| Thuresson, M | 1 |
| Aarskog, P | 1 |
| Johannesen, KM | 1 |
| Oldgren, J | 3 |
| Walts, A | 1 |
| Kopecky, SL | 1 |
| Huynh, K | 3 |
| Chen, HY | 1 |
| Chou, P | 1 |
| Hawks, MK | 1 |
| Dixon, MA | 1 |
| Gilbertson, D | 1 |
| Lockery, J | 1 |
| Williamson, J | 1 |
| Krasińska, B | 1 |
| Osińska, A | 1 |
| Krasińska, A | 1 |
| Osiński, M | 1 |
| Rzymski, P | 1 |
| Tykarski, A | 1 |
| Krasiński, Z | 1 |
| Metsarinne, K | 2 |
| Ha, JW | 1 |
| Avezum, AA | 3 |
| Lisheng, L | 1 |
| Keltai, K | 2 |
| Varigos, JD | 2 |
| Vanassche, T | 1 |
| Branch, K | 1 |
| Leong, DP | 1 |
| Kohlman-Trigoboff, D | 1 |
| Iwasawa, M | 1 |
| Wada, K | 1 |
| Takada, M | 2 |
| Kim, JB | 2 |
| Choi, BG | 1 |
| Rha, SW | 1 |
| Seo, HS | 1 |
| Choi, SY | 1 |
| Byun, JK | 1 |
| Na, JO | 1 |
| Choi, CU | 1 |
| Kim, EJ | 1 |
| Park, CG | 1 |
| Oh, DJ | 1 |
| Park, SK | 1 |
| Jung, DE | 1 |
| Jung, SA | 2 |
| Kim, WH | 2 |
| Bahk, JH | 1 |
| Ladapo, JA | 1 |
| Chokshi, DA | 1 |
| Graham, K | 1 |
| Sawhney, MS | 1 |
| Reynolds, EE | 1 |
| Wagner, J | 1 |
| Lock, JF | 1 |
| Luber, V | 1 |
| Dietz, UA | 1 |
| Lichthardt, S | 1 |
| Matthes, N | 1 |
| Krajinovic, K | 1 |
| Germer, CT | 1 |
| Knop, S | 1 |
| Wiegering, A | 1 |
| Squizzato, A | 4 |
| Bellesini, M | 2 |
| Takeda, A | 1 |
| Middeldorp, S | 3 |
| Donadini, MP | 2 |
| Leggio, M | 2 |
| Bendini, MG | 1 |
| Caldarone, E | 1 |
| Lombardi, M | 1 |
| Severi, P | 1 |
| D'Emidio, S | 1 |
| Stavri, DC | 1 |
| Armeni, M | 1 |
| Bravi, V | 1 |
| Mazza, A | 2 |
| McCarthy, NS | 1 |
| Vangjeli, C | 2 |
| Surendran, P | 1 |
| Treumann, A | 1 |
| Rooney, C | 1 |
| Ho, E | 1 |
| Hughes, AD | 2 |
| Munroe, PB | 1 |
| Howard, P | 1 |
| Johnson, T | 1 |
| Caulfield, M | 1 |
| Shields, DC | 3 |
| O'Brien, E | 1 |
| Fitzgerald, DJ | 8 |
| Stanton, AV | 1 |
| Ruivo, C | 1 |
| Sá, FM | 1 |
| Santos, LG | 1 |
| Correia, J | 1 |
| Belo, A | 1 |
| Morais, J | 3 |
| Guercio, V | 1 |
| Turati, F | 1 |
| Bosetti, C | 2 |
| Polesel, J | 1 |
| Serraino, D | 1 |
| Montella, M | 1 |
| Libra, M | 1 |
| Galfano, A | 1 |
| La Vecchia, C | 2 |
| Tavani, A | 1 |
| Xing, M | 1 |
| Zhu, X | 1 |
| Liu, Q | 1 |
| Wingrove, JA | 1 |
| Fitch, K | 1 |
| Rhees, B | 1 |
| Rosenberg, S | 1 |
| Voora, D | 3 |
| Kruger, PC | 2 |
| Liu, SM | 1 |
| Zhao, WL | 1 |
| Song, HQ | 1 |
| Meng, R | 1 |
| Li, SJ | 1 |
| Ren, CH | 1 |
| Ovbiagele, B | 1 |
| Ji, XM | 1 |
| Feng, WW | 1 |
| Kańtoch, A | 1 |
| Gryglewska, B | 1 |
| Wójkowska-Mach, J | 1 |
| Heczko, P | 1 |
| Grodzicki, T | 1 |
| Majithia, A | 1 |
| Tang, YD | 1 |
| Wang, W | 3 |
| Yang, M | 1 |
| Zhang, K | 1 |
| Qiao, S | 1 |
| Yan, H | 1 |
| Wu, Y | 2 |
| Huang, X | 1 |
| Xu, B | 2 |
| Gao, R | 2 |
| de Carvalho, LP | 1 |
| Fong, A | 1 |
| Troughton, R | 1 |
| Yan, BP | 1 |
| Chin, CT | 1 |
| Poh, SC | 1 |
| Mejin, M | 1 |
| Huang, N | 1 |
| Seneviratna, A | 1 |
| Lee, CH | 1 |
| Low, AF | 1 |
| Tan, HC | 1 |
| Chan, SP | 1 |
| Frampton, C | 1 |
| Richards, AM | 1 |
| Chan, MY | 1 |
| Ediriweera, DS | 1 |
| Dilina, N | 1 |
| Saparamadu, V | 1 |
| Fernando, I | 1 |
| Kurukulasuriya, B | 1 |
| Fernando, D | 1 |
| Kurera, J | 1 |
| Perepech, NB | 1 |
| Mikhaylova, IE | 1 |
| Grenier, J | 1 |
| Leiter, LA | 2 |
| Langer, A | 2 |
| Goldin, L | 1 |
| Teoh, H | 1 |
| Connelly, KA | 1 |
| Cheng, AYY | 1 |
| Tan, MK | 1 |
| Fitchett, D | 1 |
| Goodman, SG | 3 |
| Yan, AT | 1 |
| Gregg, LP | 1 |
| Hedayati, SS | 1 |
| Pöhl, M | 1 |
| Ayhan, A | 1 |
| Hohlfeld, T | 5 |
| Levkau, B | 2 |
| Bouida, W | 1 |
| Beltaief, K | 1 |
| Baccouche, H | 1 |
| Sassi, M | 1 |
| Dridi, Z | 1 |
| Trabelsi, I | 1 |
| Laaouiti, K | 1 |
| Chakroun, T | 2 |
| Hellara, I | 1 |
| Boukef, R | 1 |
| Sakly, N | 1 |
| Hassine, M | 1 |
| Added, F | 1 |
| Razgallah, R | 1 |
| Najjar, F | 1 |
| Nouira, S | 1 |
| Basu, A | 1 |
| Meltzer, D | 1 |
| Wolff, G | 1 |
| Navarese, EP | 1 |
| Brockmeyer, M | 1 |
| Lin, Y | 1 |
| Karathanos, A | 1 |
| Kołodziejczak, M | 1 |
| Kubica, J | 1 |
| Westenfeld, R | 1 |
| Schulze, V | 1 |
| Srivastava, P | 1 |
| Shroyer, AL | 1 |
| Lacey, M | 1 |
| Parikh, PB | 1 |
| Mutter, J | 1 |
| Grandy, R | 1 |
| Hulkower, S | 1 |
| Stigleman, S | 1 |
| Shelley, D | 1 |
| Blechter, B | 1 |
| Jiang, N | 1 |
| Williams, S | 3 |
| Rogers, E | 1 |
| Berry, C | 2 |
| Chen, F | 3 |
| Lader, E | 1 |
| Solomon, DH | 1 |
| Libby, P | 1 |
| Yeomans, ND | 2 |
| Wolski, KE | 1 |
| Nissen, SE | 2 |
| Husni, ME | 1 |
| Ibrahim, H | 2 |
| Welt, FGP | 1 |
| Parasuraman, S | 1 |
| Yu, J | 1 |
| Paranagama, D | 1 |
| Shrestha, S | 1 |
| Wang, L | 2 |
| Baser, O | 1 |
| Scherber, R | 1 |
| Zolezzi, M | 1 |
| Abdallah, O | 1 |
| Kheir, N | 1 |
| Abdelsalam, AG | 1 |
| Kim, BJ | 1 |
| Kwon, SU | 1 |
| Park, JH | 1 |
| Kim, YJ | 1 |
| Hong, KS | 1 |
| Wong, LKS | 1 |
| Yu, S | 1 |
| Hwang, YH | 1 |
| Lee, JS | 1 |
| Rha, JH | 1 |
| Heo, SH | 1 |
| Ahn, SH | 1 |
| Seo, WK | 1 |
| Park, JM | 1 |
| Kwon, JH | 1 |
| Sohn, SI | 1 |
| Jung, JM | 1 |
| Navarro, JC | 1 |
| Kang, DW | 1 |
| Yi-Tong, W | 1 |
| Cournot, M | 1 |
| Lairez, O | 1 |
| Medzech, B | 1 |
| Ciolino, JD | 1 |
| Jackson, KL | 1 |
| Liss, DT | 1 |
| Brown, T | 1 |
| Walunas, TL | 1 |
| Murakami, L | 1 |
| Chung, I | 2 |
| Persell, SD | 1 |
| Alqahtani, Z | 1 |
| Jamali, F | 1 |
| Sakuma, M | 4 |
| Doi, N | 4 |
| Erturk, I | 1 |
| Yesildal, F | 1 |
| Acar, R | 1 |
| Ozgurtas, T | 1 |
| Saglam, K | 1 |
| Mathew, RO | 1 |
| Gosmanova, EO | 1 |
| Sidhu, MS | 1 |
| Victor, K | 1 |
| Skelly, M | 1 |
| Mulcahy, K | 1 |
| Demler, TL | 1 |
| Trigoboff, E | 1 |
| Goicoechea, M | 1 |
| de Vinuesa, SG | 1 |
| Quiroga, B | 1 |
| Verde, E | 1 |
| Bernis, C | 1 |
| Morales, E | 1 |
| Fernández-Juárez, G | 1 |
| de Sequera, P | 1 |
| Verdalles, U | 1 |
| Delgado, R | 1 |
| Torres, A | 1 |
| Arroyo, D | 1 |
| Abad, S | 1 |
| Ortiz, A | 1 |
| Luño, J | 1 |
| Almas, A | 1 |
| Ghazni, MS | 1 |
| Hashmani, S | 1 |
| Mushtaq, Z | 1 |
| Stepien, S | 1 |
| Bullen, C | 3 |
| Arroll, B | 1 |
| Brown, A | 2 |
| Crengle, S | 2 |
| Dorairaj, P | 1 |
| Elley, CR | 4 |
| Hillis, GS | 3 |
| Laba, TL | 2 |
| Peiris, D | 2 |
| Rafter, N | 5 |
| Reid, C | 3 |
| Tonkin, A | 6 |
| Usherwood, T | 4 |
| Wadham, A | 2 |
| Baber, U | 3 |
| Dangas, G | 1 |
| Rollini, F | 2 |
| Collet, JP | 3 |
| Gibson, CM | 3 |
| Lopes, RD | 3 |
| Gwon, HC | 1 |
| Serruys, PW | 2 |
| Foster, JG | 1 |
| Garber, A | 1 |
| Cook, NR | 17 |
| Theken, KN | 1 |
| Grosser, T | 3 |
| Rothwell, PM | 5 |
| Price, JF | 2 |
| Belch, JFF | 1 |
| Mehta, Z | 1 |
| Mazlan-Kepli, W | 1 |
| Dawson, J | 1 |
| Walters, M | 1 |
| Ruiz Arzalluz, MV | 1 |
| Burgos-Alonso, N | 1 |
| Garcia-Alvarez, A | 1 |
| Gomez Fernandez, MC | 1 |
| Vinyoles, E | 1 |
| Grandes, G | 1 |
| Niessner, A | 1 |
| Agewall, S | 3 |
| Barton, J | 3 |
| Murphy, K | 3 |
| Murawska, A | 3 |
| Young, A | 2 |
| Lay, M | 3 |
| Sammons, E | 2 |
| Waters, E | 2 |
| Adler, A | 2 |
| Bodansky, J | 2 |
| Farmer, A | 2 |
| McPherson, R | 2 |
| Neil, A | 2 |
| Simpson, D | 2 |
| Peto, R | 7 |
| Zhang, XL | 1 |
| Fu, HJ | 1 |
| Yang, GR | 1 |
| Wan, G | 1 |
| Li, D | 1 |
| Zhu, LX | 1 |
| Xie, RR | 1 |
| Lv, YJ | 1 |
| Zhang, JD | 1 |
| Li, YL | 1 |
| Dai, QF | 1 |
| Ji, Y | 1 |
| Gao, DY | 1 |
| Cui, XL | 1 |
| Liu, DY | 1 |
| Yuan, SY | 1 |
| Yuan, MX | 1 |
| Ademi, Z | 3 |
| Zomer, E | 2 |
| Radziszewska, B | 1 |
| Jelinek, M | 1 |
| Malik, M | 1 |
| Eaton, CB | 1 |
| Brauer, D | 1 |
| Cloud, G | 1 |
| Satterfield, S | 1 |
| Grimm, R | 1 |
| Fernández-Ruiz, I | 1 |
| Gómez-Acebo, I | 1 |
| Dierssen-Sotos, T | 1 |
| de Pedro, M | 1 |
| Pérez-Gómez, B | 1 |
| Castaño-Vinyals, G | 1 |
| Fernández-Villa, T | 1 |
| Palazuelos-Calderón, C | 1 |
| Amiano, P | 1 |
| Etxeberria, J | 1 |
| Benavente, Y | 1 |
| Fernández-Tardón, G | 1 |
| Salcedo-Bellido, I | 1 |
| Capelo, R | 1 |
| Peiró, R | 1 |
| Marcos-Gragera, R | 1 |
| Huerta, JM | 1 |
| Tardón, A | 1 |
| Barricarte, A | 1 |
| Altzibar, JM | 1 |
| Alonso-Molero, J | 1 |
| Dávila-Batista, V | 1 |
| Aragonés, N | 1 |
| Pollán, M | 1 |
| Kogevinas, M | 1 |
| Llorca, J | 1 |
| Prozzi, GR | 1 |
| Cañás, M | 1 |
| Urtasun, MA | 1 |
| Buschiazzo, HO | 1 |
| Dorati, CM | 1 |
| Mordujovich-Buschiazzo, P | 1 |
| Ederhy, S | 1 |
| Ancedy, Y | 1 |
| Soulat-Dufour, L | 1 |
| Chauvet-Droit, M | 1 |
| Cohen, A | 1 |
| Franczyk, B | 1 |
| Gluba-Brzózka, A | 1 |
| Jurkiewicz, Ł | 1 |
| Penson, P | 1 |
| Rysz, J | 1 |
| Stamenovic, D | 1 |
| Schneider, T | 2 |
| Messerschmidt, A | 1 |
| Lippi, G | 1 |
| Danese, E | 1 |
| Favaloro, EJ | 1 |
| Wilson, N | 2 |
| Jones, AC | 1 |
| Nghiem, N | 2 |
| Blakely, T | 2 |
| Carlton, R | 1 |
| Coppolecchia, R | 1 |
| Khalaf-Gillard, K | 1 |
| Lennert, B | 1 |
| Moradi, A | 1 |
| Williamson, T | 1 |
| Cameron, J | 1 |
| Millard, MA | 1 |
| Hernandez-Vila, EA | 1 |
| Gawrys, J | 1 |
| Gawrys, K | 1 |
| Szahidewicz-Krupska, E | 1 |
| Derkacz, A | 1 |
| Mochol, J | 1 |
| Doroszko, A | 1 |
| Gurbel, P | 1 |
| Tantry, U | 3 |
| Weisman, S | 2 |
| Thabah, MM | 1 |
| Sharma, R | 1 |
| Gad, MM | 2 |
| Elgendy, AY | 2 |
| Bavry, AA | 4 |
| Sugawara, M | 2 |
| Goto, Y | 1 |
| Yamazaki, T | 2 |
| Teramoto, T | 2 |
| Oikawa, S | 3 |
| Ando, K | 2 |
| Ishizuka, N | 2 |
| Murata, M | 2 |
| Yokoyama, K | 3 |
| Uemura, Y | 1 |
| Somuncu, MU | 1 |
| Demir, AR | 1 |
| Karakurt, ST | 1 |
| Karakurt, H | 1 |
| Karabag, T | 1 |
| Kuehn, BM | 1 |
| Montalescot, G | 9 |
| Abi Khalil, C | 1 |
| Omar, OM | 1 |
| Al Suwaidi, J | 2 |
| Taheri, S | 1 |
| Tsilimigras, DI | 1 |
| Moris, D | 1 |
| Karaolanis, G | 1 |
| Kakkos, SK | 1 |
| Filis, K | 1 |
| Sigala, F | 1 |
| Berkelmans, GFN | 1 |
| Gudbjörnsdottir, S | 1 |
| Wild, SH | 1 |
| Franzen, S | 1 |
| Chalmers, J | 2 |
| Davis, BR | 1 |
| Poulter, NR | 3 |
| Spijkerman, AM | 1 |
| Pressel, SL | 1 |
| Gupta, AK | 1 |
| van der Schouw, YT | 1 |
| Svensson, AM | 1 |
| Read, SH | 1 |
| Eliasson, B | 1 |
| Xing, Y | 1 |
| Tan, KC | 1 |
| Hirsch, C | 2 |
| Carson, E | 1 |
| Hemenway, AN | 1 |
| Zheng, SL | 2 |
| Roddick, AJ | 2 |
| Tousoulis, D | 2 |
| Allen, N | 1 |
| Guo, Y | 1 |
| Nardi, M | 1 |
| Ramkhelawon, B | 1 |
| Rockman, CB | 1 |
| Hochman, JS | 4 |
| Nelson, AJ | 1 |
| Barmanray, R | 1 |
| Hamblin, PS | 1 |
| Song, N | 1 |
| French, JK | 1 |
| Khan, SU | 1 |
| Ul Abideen Asad, Z | 1 |
| Khan, MU | 1 |
| Talluri, S | 1 |
| Ali, F | 1 |
| Shahzeb Khan, M | 1 |
| Lone, AN | 1 |
| Mookadam, F | 1 |
| Krasuski, RA | 1 |
| Kaluski, E | 3 |
| Andrews, GP | 1 |
| Almajaan, A | 1 |
| Martini, L | 1 |
| Healy, A | 1 |
| Jones, DS | 1 |
| Coppens, M | 1 |
| Eikelboom, JWA | 1 |
| Pastori, D | 1 |
| Tanguay, JF | 3 |
| Ricco, JB | 1 |
| Bauersachs, R | 1 |
| Nikol, S | 1 |
| Nehler, M | 1 |
| Violi, F | 4 |
| Schuttenberg, N | 1 |
| O'Sullivan, JW | 1 |
| Fortuni, F | 1 |
| Crimi, G | 1 |
| Gritti, V | 1 |
| Mirizzi, AM | 1 |
| Leonardi, S | 1 |
| Ferrari, GM | 1 |
| Urbinati, S | 1 |
| Vouillarmet, J | 1 |
| Whitlock, EP | 6 |
| Johnson, ES | 2 |
| Kogan, A | 1 |
| Tu, SW | 1 |
| Peleg, M | 1 |
| Ye, S | 1 |
| Lee, M | 1 |
| Lee, D | 1 |
| Ha, EH | 1 |
| Chun, EM | 1 |
| Wessels, F | 1 |
| Kriegmair, MC | 1 |
| Oehme, A | 1 |
| Rassweiler-Seyfried, MC | 1 |
| Erben, P | 1 |
| Oberneder, R | 1 |
| Kriegmair, M | 1 |
| Ritter, M | 1 |
| Michel, MS | 1 |
| Honeck, P | 1 |
| Collyer, TA | 1 |
| Sumaya, W | 1 |
| Geisler, T | 2 |
| Upadhaya, S | 1 |
| Madala, S | 1 |
| Baniya, R | 1 |
| Saginala, K | 1 |
| Khan, J | 1 |
| Nicolini, F | 1 |
| Murphy, S | 1 |
| McCarthy, CP | 2 |
| Bittner, V | 1 |
| Barbosa, E | 1 |
| Molina, DI | 1 |
| Sanchez, R | 1 |
| Diaz, M | 1 |
| Camacho, PA | 1 |
| Pasquel, M | 1 |
| Accini, JL | 1 |
| Ponte-Negretti, CI | 1 |
| Alcocer, L | 1 |
| Cobos, L | 1 |
| Wyss, F | 1 |
| Sebba-Barroso, W | 1 |
| Coca, A | 1 |
| Zanchetti, A | 9 |
| Tsujimoto, T | 1 |
| Kajio, H | 1 |
| Tiberti, C | 1 |
| Reddy, S | 1 |
| Jim, B | 1 |
| Piepoli, MF | 1 |
| Hickner, J | 1 |
| Smith, DK | 1 |
| Demetriou, T | 1 |
| Weber, C | 1 |
| Shu, C | 1 |
| Xin, Q | 1 |
| Cong, W | 1 |
| Chen, K | 1 |
| McCaw, ZR | 1 |
| Wei, LJ | 1 |
| Kim, DH | 1 |
| Moayyedi, P | 3 |
| Kakkar, A | 1 |
| Guzik, T | 1 |
| Ma, Q | 1 |
| Chung, H | 1 |
| Roe, M | 1 |
| Fernandes, A | 1 |
| Devereaux, PJ | 1 |
| Szczeklik, W | 1 |
| Christiansen, M | 1 |
| Hvas, AM | 2 |
| Shanker, A | 1 |
| Bhupathi, V | 1 |
| Faggiano, P | 1 |
| Fattirolli, F | 2 |
| Frisinghelli, A | 1 |
| Piccioli, L | 1 |
| Dasseni, N | 1 |
| Silverii, MV | 1 |
| Albricci, L | 1 |
| D'Ambrosio, G | 1 |
| Garrì, R | 1 |
| Esposito, L | 1 |
| Giallauria, F | 1 |
| Atencio, A | 1 |
| Cardoso, R | 1 |
| Nasir, K | 1 |
| Maggi, P | 3 |
| De Socio, GV | 3 |
| Cicalini, S | 2 |
| D'Abbraccio, M | 2 |
| Dettorre, G | 2 |
| Di Biagio, A | 2 |
| Martinelli, C | 3 |
| Nunnari, G | 2 |
| Rusconi, S | 2 |
| Sighinolfi, L | 2 |
| Spagnuolo, V | 2 |
| Squillace, N | 2 |
| Cairns, JA | 2 |
| DeMets, D | 2 |
| Chow, CK | 1 |
| Meng, Q | 1 |
| Lin, KW | 2 |
| Middleton, J | 1 |
| Bruns, NC | 1 |
| Shah, R | 2 |
| Khan, B | 1 |
| Latham, SB | 1 |
| Khan, SA | 1 |
| Rao, SV | 1 |
| Thompson, D | 1 |
| Seidu, S | 2 |
| Kunutsor, SK | 2 |
| Sesso, HD | 6 |
| Buring, JE | 50 |
| Khunti, K | 2 |
| Thürmann, PA | 1 |
| Kleinerüschkamp, AG | 1 |
| Boehme, P | 1 |
| Gaziano, TA | 3 |
| Pandya, A | 1 |
| Sy, S | 1 |
| Jardim, TV | 1 |
| Ogden, JM | 1 |
| Weinstein, MC | 2 |
| Syn, NL | 1 |
| Wee, IJY | 1 |
| Pothineni, NVK | 1 |
| Megaly, M | 1 |
| Potluri, R | 1 |
| Saleh, M | 1 |
| Kon, DLC | 1 |
| Roberts, DH | 1 |
| Aronow, HD | 1 |
| Abbott, JD | 1 |
| Knickelbine, T | 1 |
| Raber, I | 1 |
| Vaduganathan, M | 3 |
| Wood, DA | 1 |
| Hall, KT | 2 |
| Kessler, T | 1 |
| Passow, D | 1 |
| Zee, RYL | 1 |
| Chasman, DI | 4 |
| Schunkert, H | 2 |
| Judge, C | 1 |
| Ruttledge, S | 1 |
| Murphy, R | 1 |
| Loughlin, E | 1 |
| Gorey, S | 1 |
| Costello, M | 1 |
| Nolan, A | 1 |
| Ferguson, J | 1 |
| Halloran, MO | 1 |
| O'Canavan, M | 1 |
| Neumann, C | 1 |
| Sharma, AN | 1 |
| Deyell, JS | 1 |
| Sharma, SN | 1 |
| Barseghian, A | 1 |
| Sanmartín, M | 1 |
| Bellmunt, S | 1 |
| Cosín-Sales, J | 2 |
| García-Moll, X | 1 |
| Riera-Mestre, A | 1 |
| Almendro-Delia, M | 1 |
| Hernández, JL | 1 |
| Lozano, F | 1 |
| Mazón, P | 1 |
| Suarez Fernández, C | 1 |
| Holmes, MV | 1 |
| Zayed, Y | 1 |
| Gakhal, I | 1 |
| Barbarawi, O | 1 |
| Rashdan, L | 1 |
| Rizk, F | 1 |
| Bachuwa, G | 1 |
| Alkotob, ML | 1 |
| Fritsch, P | 1 |
| Kolber, MR | 2 |
| Truong, C | 2 |
| Plazak, ME | 1 |
| Mouradjian, MT | 1 |
| Watson, K | 1 |
| Reed, BN | 2 |
| Noel, ZR | 1 |
| Devabhakthuni, S | 1 |
| Gale, SE | 1 |
| Tscharre, M | 1 |
| Farhan, S | 3 |
| Bruno, V | 1 |
| Rohla, M | 1 |
| Egger, F | 1 |
| Weiss, TW | 1 |
| Hübl, W | 1 |
| Willheim, M | 1 |
| Wojta, J | 2 |
| Geppert, A | 2 |
| Freynhofer, MK | 1 |
| O'Brien, CW | 1 |
| Juraschek, SP | 1 |
| Wee, CC | 1 |
| Kaikita, K | 3 |
| Dahlen, JR | 1 |
| Ajrouche, A | 1 |
| Estellat, C | 1 |
| De Rycke, Y | 1 |
| Tubach, F | 1 |
| Parchman, ML | 1 |
| Anderson, ML | 2 |
| Coleman, K | 1 |
| Michaels, LA | 1 |
| Schuttner, L | 1 |
| Conway, C | 1 |
| Hsu, C | 1 |
| Fagnan, LJ | 1 |
| Vogel, B | 1 |
| Chandrasekhar, J | 1 |
| Mastoris, I | 1 |
| Sartori, S | 1 |
| Aquino, M | 1 |
| Krucoff, MW | 1 |
| Moliterno, DJ | 1 |
| Henry, TD | 1 |
| Weisz, G | 1 |
| Iakovou, I | 1 |
| Sorrentino, S | 1 |
| Faggioni, M | 1 |
| Witzenbichler, B | 1 |
| Chieffo, A | 1 |
| Stuckey, T | 1 |
| Ariti, C | 1 |
| Pocock, S | 1 |
| Laidman, J | 1 |
| Polo-Tomás, M | 2 |
| Casado-Arroyo, R | 6 |
| Cattaneo, M | 5 |
| Lip, GY | 7 |
| Verheugt, FW | 10 |
| Husted, S | 2 |
| Wassmann, S | 1 |
| Rosano, G | 1 |
| Atar, D | 2 |
| Pathak, A | 1 |
| Kjeldsen, K | 1 |
| Remková, A | 1 |
| Janušicová, A | 1 |
| Remko, M | 1 |
| Hayasaka, M | 1 |
| Takahashi, Y | 1 |
| Nishida, Y | 1 |
| Yoshida, Y | 1 |
| Hidaka, S | 1 |
| Asai, S | 1 |
| Raichand, S | 2 |
| Moore, D | 5 |
| Riley, RD | 3 |
| Dretzke, J | 5 |
| O'Donnell, J | 2 |
| Jowett, S | 2 |
| Bayliss, S | 5 |
| Fitzmaurice, DA | 1 |
| Mischnik, M | 1 |
| Boyanova, D | 1 |
| Hubertus, K | 1 |
| Geiger, J | 1 |
| Philippi, N | 1 |
| Dittrich, M | 1 |
| Wangorsch, G | 1 |
| Timmer, J | 1 |
| Dandekar, T | 1 |
| Capranzano, P | 4 |
| Dragani, A | 1 |
| Pagliaccia, F | 1 |
| Poredos, P | 2 |
| Jezovnik, MK | 2 |
| Cheung, N | 1 |
| Tay, WT | 1 |
| Cheung, GC | 1 |
| Wang, JJ | 3 |
| Mitchell, P | 2 |
| Wong, TY | 2 |
| Dalen, JE | 7 |
| Valkhoff, VE | 2 |
| Sturkenboom, MC | 2 |
| Hill, C | 3 |
| Veldhuyzen van Zanten, S | 1 |
| Kuipers, EJ | 2 |
| Mogabgab, O | 1 |
| Wiviott, SD | 3 |
| Foody, JM | 1 |
| Sabatine, MS | 2 |
| Cannon, CP | 5 |
| Giugliano, RP | 1 |
| Cragg, JJ | 1 |
| Schulzer, M | 1 |
| Mancini, GB | 1 |
| Smith, R | 3 |
| Magliano, DJ | 1 |
| Attia, JR | 1 |
| Pearce, R | 1 |
| Manolis, AS | 2 |
| Manolis, TA | 1 |
| Papadimitriou, P | 1 |
| Koulouris, S | 2 |
| Melita, H | 2 |
| Algra, AM | 2 |
| Matthys, F | 1 |
| De Backer, T | 1 |
| De Backer, G | 1 |
| Stichele, RV | 1 |
| Seidinger, D | 4 |
| Koppensteiner, R | 5 |
| Steiner, S | 5 |
| Nortier, JW | 1 |
| Park, K | 1 |
| Woessner, KM | 1 |
| Simon, RA | 1 |
| Iida, O | 1 |
| Yokoi, H | 1 |
| Soga, Y | 1 |
| Inoue, N | 1 |
| Suzuki, K | 1 |
| Yokoi, Y | 1 |
| Kawasaki, D | 1 |
| Zen, K | 1 |
| Urasawa, K | 1 |
| Shintani, Y | 2 |
| Miyamoto, A | 1 |
| Hirano, K | 1 |
| Miyashita, Y | 1 |
| Tsuchiya, T | 1 |
| Shinozaki, N | 1 |
| Nakamura, M | 1 |
| Isshiki, T | 2 |
| Hamasaki, T | 1 |
| Nanto, S | 1 |
| Zantek, ND | 3 |
| Miller, K | 1 |
| Crooks, CJ | 1 |
| West, J | 1 |
| Card, TR | 1 |
| Bassuk, SS | 1 |
| Sylvester, KW | 1 |
| Cheng, JW | 2 |
| Mehra, MR | 1 |
| Kautzky-Willer, A | 1 |
| Stich, K | 1 |
| Hintersteiner, J | 1 |
| Kautzky, A | 1 |
| Kamyar, MR | 1 |
| Saukel, J | 1 |
| Johnson, J | 1 |
| Lemmens-Gruber, R | 1 |
| Zhou, Y | 1 |
| Boudreau, DM | 1 |
| Freedman, AN | 1 |
| Cartledge, B | 1 |
| Day, RO | 1 |
| Graham, GG | 1 |
| Ramaswamy, SG | 1 |
| Greenberg, PB | 1 |
| Krzystolik, MG | 1 |
| Soubrier, M | 1 |
| Rosenbaum, D | 1 |
| Tatar, Z | 1 |
| Lahaye, C | 1 |
| Dubost, JJ | 1 |
| Mathieu, S | 1 |
| Huang, WK | 2 |
| Chiou, MJ | 1 |
| Yu, KH | 1 |
| Lin, YC | 1 |
| Yang, TS | 1 |
| Chen, JS | 1 |
| Kuo, CF | 1 |
| See, LC | 2 |
| Würtz, M | 3 |
| Grinshtein, YI | 1 |
| Kosinova, AA | 1 |
| Grinshtein, IY | 1 |
| Cyr, D | 1 |
| Lucas, J | 1 |
| Chi, JT | 1 |
| Dungan, J | 1 |
| Katz, R | 1 |
| Newby, LK | 1 |
| Kraus, WE | 1 |
| Becker, RC | 4 |
| Ortel, TL | 2 |
| Ginsburg, GS | 2 |
| Martín Merino, E | 1 |
| Johansson, S | 8 |
| Nagy, P | 7 |
| Bishopric, NH | 1 |
| López, J | 1 |
| Morales, C | 1 |
| Avanzas, P | 1 |
| Callejo, F | 1 |
| Hernández-Vaquero, D | 1 |
| Llosa, JC | 1 |
| Yerges-Armstrong, LM | 1 |
| Ellero-Simatos, S | 1 |
| Georgiades, A | 1 |
| Kaddurah-Daouk, R | 1 |
| Hankemeier, T | 1 |
| Bryant, L | 2 |
| Nathoe, H | 1 |
| Cleland, JG | 4 |
| Gadzhanova, SV | 1 |
| Roughead, EE | 1 |
| Bartlett, MJ | 1 |
| Thornley, SJ | 1 |
| Barzi, F | 1 |
| El-Menyar, A | 1 |
| Ahmed, E | 1 |
| Albinali, H | 1 |
| Al-Thani, H | 1 |
| Gehani, A | 1 |
| Singh, R | 1 |
| Nishino, M | 1 |
| Sugimoto, M | 1 |
| Uotani, T | 1 |
| Yamade, M | 1 |
| Sahara, S | 1 |
| Ichikawa, H | 1 |
| Sugimoto, K | 1 |
| Umemura, K | 2 |
| Watanabe, H | 2 |
| Miyajima, H | 1 |
| Furuta, T | 1 |
| Burr, N | 1 |
| Hull, MA | 1 |
| Wilhelm, TJ | 1 |
| Post, S | 1 |
| Dalton, AR | 1 |
| Naderi, S | 1 |
| Cho, LS | 1 |
| Poulter, N | 4 |
| Field, J | 3 |
| Reddy, KS | 4 |
| Cidambi, R | 2 |
| Bompoint, S | 2 |
| Billot, L | 3 |
| Picozzi, S | 2 |
| Marenghi, C | 1 |
| Ricci, C | 2 |
| Bozzini, G | 2 |
| Casellato, S | 1 |
| Carmignani, L | 2 |
| Lin, JS | 1 |
| Olson, CM | 1 |
| Moyer, VA | 1 |
| Sugiyama, S | 2 |
| Horii, M | 1 |
| Kawata, H | 1 |
| Somekawa, S | 1 |
| Soeda, T | 1 |
| Uemura, S | 2 |
| Sifferlin, A | 1 |
| Gaglia, MA | 1 |
| Clavijo, L | 1 |
| Kapłon-Cieślicka, A | 1 |
| Rosiak, M | 2 |
| Serafin, A | 1 |
| Kondracka, A | 2 |
| Opolski, G | 2 |
| Filipiak, KJ | 3 |
| Sutcliffe, P | 1 |
| Connock, M | 1 |
| Gurung, T | 1 |
| Freeman, K | 1 |
| Johnson, S | 1 |
| Kandala, NB | 1 |
| Grove, A | 1 |
| Gurung, B | 1 |
| Morrow, S | 1 |
| Clarke, A | 1 |
| Dovizio, M | 1 |
| Alberti, S | 1 |
| Guillem-Llobat, P | 1 |
| Patrignani, P | 6 |
| Fischer, C | 1 |
| Lümmen, G | 1 |
| Rubboli, A | 1 |
| Marìn, F | 1 |
| Lip, G | 1 |
| Aksu, HU | 1 |
| Oner, E | 1 |
| Erturk, M | 2 |
| Aksu, H | 2 |
| Isıksacan, N | 1 |
| Ozalp, B | 1 |
| Akture, G | 1 |
| Akbay, E | 1 |
| Ozer, L | 1 |
| Erol, MK | 1 |
| Cass, A | 4 |
| Burch, C | 2 |
| Berwanger, O | 1 |
| de Jong, PT | 3 |
| Fletcher, AE | 2 |
| Bliden, KP | 6 |
| Brener, M | 1 |
| Gesheff, MG | 2 |
| Franzese, CJ | 2 |
| Tabrizchi, A | 1 |
| Gurbel, PA | 9 |
| Song, M | 1 |
| Jian, Z | 1 |
| Chen, G | 1 |
| Jiang, G | 1 |
| Wu, X | 1 |
| Huang, L | 1 |
| Korownyk, C | 1 |
| Heptinstall, S | 2 |
| Lin, KJ | 1 |
| Calderaro, D | 2 |
| Pastana, AF | 1 |
| Flores da Rocha, TR | 1 |
| Yu, PC | 1 |
| Gualandro, DM | 2 |
| DeLuccia, N | 1 |
| D' Amico, EA | 1 |
| Caramelli, B | 2 |
| Jeong, YH | 1 |
| Tantry, US | 6 |
| del Castillo-Carnevali, H | 1 |
| Barrios Alonso, V | 1 |
| Zamorano Gómez, JL | 1 |
| DeFilippis, AP | 2 |
| Rai, SN | 1 |
| Cambon, A | 1 |
| Miles, RJ | 1 |
| Jaffe, AS | 1 |
| Moser, AB | 1 |
| Jones, RO | 1 |
| Bolli, R | 1 |
| Schulman, SP | 1 |
| Simpson, SH | 2 |
| Abdelmoneim, AS | 1 |
| Omran, D | 1 |
| Featherstone, TR | 1 |
| Duffy, D | 2 |
| Kelly, E | 1 |
| Trang, A | 1 |
| Whellan, D | 1 |
| Mills, G | 1 |
| Peura, DA | 1 |
| Wilcox, CM | 3 |
| Nomura, K | 1 |
| Xhelili, E | 1 |
| Goltz, L | 1 |
| Bodechtel, U | 1 |
| Siepmann, T | 1 |
| Bunimov, N | 2 |
| Laneuville, O | 2 |
| Pinto, A | 1 |
| Di Raimondo, D | 1 |
| Tuttolomondo, A | 1 |
| Buttà, C | 1 |
| Licata, G | 1 |
| Kanzaki, R | 1 |
| Inoue, M | 1 |
| Minami, M | 1 |
| Nakagiri, T | 1 |
| Funaki, S | 1 |
| Sawabata, N | 1 |
| Okumura, M | 1 |
| Roth, GA | 1 |
| Gillespie, CW | 1 |
| Mokdad, AA | 1 |
| Shen, DD | 1 |
| Fleming, DW | 1 |
| Stergachis, A | 1 |
| Murray, CJ | 1 |
| Mokdad, AH | 2 |
| Simão, AF | 1 |
| Precoma, DB | 1 |
| Andrade, JP | 1 |
| Correa, FH | 1 |
| Saraiva, JF | 1 |
| Oliveira, GM | 1 |
| Murro, AL | 1 |
| Campos, A | 1 |
| Alessi, A | 1 |
| Achutti, AC | 1 |
| Miguel, AC | 1 |
| Sousa, AC | 1 |
| Lotemberg, AM | 1 |
| Lins, AP | 1 |
| Falud, AA | 1 |
| Brandão, AA | 1 |
| Sanjuliani, AF | 1 |
| Sbissa, AS | 1 |
| Alencar, FA | 1 |
| Herdy, AH | 1 |
| Polanczyk, CA | 1 |
| Lantieri, CJ | 1 |
| Machado, CA | 1 |
| Scherr, C | 1 |
| Stoll, C | 1 |
| Amodeo, C | 1 |
| Araújo, CG | 1 |
| Saraiva, D | 1 |
| Moriguchi, EH | 1 |
| Mesquita, ET | 1 |
| Fonseca, FA | 1 |
| Campos, GP | 1 |
| Soares, GP | 1 |
| Feitosa, GS | 1 |
| Xavier, HT | 1 |
| Castro, I | 1 |
| Giuliano, IC | 1 |
| Rivera, IV | 1 |
| Guimaraes, IC | 1 |
| Issa, JS | 1 |
| Souza, JR | 1 |
| Faria, NJ | 1 |
| Cunha, LB | 1 |
| Pellanda, LC | 2 |
| Bortolotto, LA | 2 |
| Bertolami, MC | 1 |
| Miname, MH | 1 |
| Gomes, MA | 1 |
| Tambascia, M | 1 |
| Malachias, MV | 1 |
| Silva, MA | 1 |
| Izar, MC | 1 |
| Magalhães, ME | 1 |
| Bacellar, MS | 1 |
| Milani, M | 2 |
| Wajngarten, M | 1 |
| Ghorayeb, N | 1 |
| Coelho, OR | 1 |
| Villela, PB | 1 |
| Jardim, PC | 1 |
| Santos Filho, RD | 1 |
| Stein, R | 1 |
| Cassani, RS | 1 |
| D'Avila, RI | 1 |
| Ferreira, RM | 1 |
| Barbosa, RB | 1 |
| Povoa, RM | 1 |
| Kaiser, SE | 1 |
| Ismael, SC | 1 |
| Carvalho, T | 1 |
| Giraldez, VZ | 1 |
| Coutinho, W | 1 |
| Souza, WK | 1 |
| Golden, SH | 2 |
| Ittaman, SV | 1 |
| Waeber, G | 1 |
| Vollenweider, P | 1 |
| Wisman, PP | 2 |
| Roest, M | 2 |
| Asselbergs, FW | 1 |
| de Groot, PG | 1 |
| Moll, FL | 2 |
| Lugo, A | 1 |
| Asciutto, R | 1 |
| Parazzini, F | 2 |
| Gallus, S | 1 |
| Kim, JD | 1 |
| Ahn, KJ | 1 |
| Cho, JH | 1 |
| Choi, KM | 1 |
| Kang, JG | 1 |
| Lee, KY | 1 |
| Lee, BW | 1 |
| Mok, JO | 1 |
| Moon, MK | 1 |
| Park, JY | 2 |
| Park, SW | 1 |
| McGrogan, D | 1 |
| Mark, D | 1 |
| Lee, B | 1 |
| O'Donnell, ME | 1 |
| Sandli, OK | 1 |
| Spigset, O | 1 |
| Slørdal, L | 1 |
| Reina-Couto, M | 1 |
| Carvalho, J | 1 |
| Valente, MJ | 1 |
| Vale, L | 1 |
| Afonso, J | 1 |
| Carvalho, F | 1 |
| Bettencourt, P | 1 |
| Sousa, T | 1 |
| Albino-Teixeira, A | 1 |
| Jan, S | 2 |
| Burke, H | 1 |
| Hayman, N | 1 |
| Molanus, B | 1 |
| Shiel, L | 1 |
| Togni, S | 1 |
| Frisch, S | 1 |
| Zsíros, N | 1 |
| Paragh, G | 1 |
| Harangi, M | 1 |
| de Cates, AN | 2 |
| Farr, MR | 1 |
| Wright, N | 1 |
| Jarvis, MC | 1 |
| Rees, K | 2 |
| Ebrahim, S | 6 |
| Torjesen, I | 1 |
| Yamamoto, K | 1 |
| Wada, H | 2 |
| Sakakura, K | 1 |
| Ikeda, N | 1 |
| Yamada, Y | 1 |
| Katayama, T | 1 |
| Sugawara, Y | 1 |
| Mitsuhashi, T | 1 |
| Ako, J | 1 |
| Momomura, S | 1 |
| Endo, H | 1 |
| Sakai, E | 1 |
| Taniguchi, L | 1 |
| Kessoku, T | 1 |
| Komiya, Y | 1 |
| Ezuka, A | 1 |
| Kawamura, H | 1 |
| Taguri, M | 1 |
| Higurashi, T | 1 |
| Ohkubo, H | 1 |
| Yamada, E | 1 |
| Takahashi, H | 1 |
| Inamori, M | 1 |
| Maeda, S | 1 |
| Sakaguchi, T | 1 |
| Hata, Y | 1 |
| Nagase, H | 1 |
| Nakajima, A | 1 |
| LaMarre, H | 1 |
| Peterson, KA | 1 |
| Jacobs, G | 1 |
| Straka, RJ | 1 |
| Miller, KH | 1 |
| Schnabel, MJ | 1 |
| Gierth, M | 1 |
| Bründl, J | 1 |
| Chaussy, CG | 1 |
| Burger, M | 1 |
| Fritsche, HM | 1 |
| Ritchey, MD | 1 |
| Wall, HK | 2 |
| Gillespie, C | 1 |
| George, MG | 2 |
| Jamal, A | 1 |
| Barry, AR | 1 |
| Koshman, SL | 1 |
| Norris, CM | 1 |
| Ross, DB | 1 |
| Pearson, GJ | 1 |
| Fond, G | 1 |
| Leboyer, M | 1 |
| Macgregor, A | 1 |
| Girerd, N | 1 |
| Pines, A | 1 |
| Diaz, VA | 1 |
| Dickerson, LM | 1 |
| Smith, LL | 1 |
| Seawright, K | 1 |
| Wessell, A | 1 |
| Gavin, JK | 1 |
| Chirina, S | 1 |
| Knoll, M | 1 |
| Player, MS | 1 |
| McCutcheon, A | 1 |
| Mainous, AG | 2 |
| Tanner, RJ | 1 |
| Shorr, RI | 1 |
| Limacher, MC | 1 |
| Martín-Merino, E | 1 |
| Coccheri, S | 1 |
| Marchioli, R | 3 |
| Nelson, CP | 1 |
| Davis, RB | 1 |
| Kirsch, I | 1 |
| Mittleman, MA | 1 |
| Loscalzo, J | 1 |
| Samani, NJ | 1 |
| Kaptchuk, TJ | 1 |
| Lattanzio, S | 1 |
| Vazzana, N | 1 |
| Ueland, T | 1 |
| Di Fulvio, P | 1 |
| Formoso, G | 1 |
| Consoli, A | 1 |
| Aukrust, P | 1 |
| Davì, G | 4 |
| Gargallo, CJ | 2 |
| Sandri, A | 1 |
| Tassone, EJ | 1 |
| Perticone, M | 1 |
| Sciacqua, A | 1 |
| Mafrici, SF | 1 |
| Settino, C | 1 |
| Malara, N | 1 |
| Mollace, V | 1 |
| Sesti, G | 1 |
| Perticone, F | 1 |
| Fiscella, K | 1 |
| Winters, PC | 1 |
| Mendoza, M | 1 |
| Noronha, GJ | 1 |
| Swanger, CM | 1 |
| Bisognano, JD | 1 |
| Fortuna, RJ | 1 |
| Lim, HJ | 1 |
| Ko, KP | 1 |
| Han, SY | 1 |
| Contino, CJ | 1 |
| Rafeedheen, R | 1 |
| Pagano, A | 1 |
| Porta, G | 1 |
| Signoriello, G | 1 |
| Lascar, N | 1 |
| Minutolo, R | 1 |
| Carbonara, O | 1 |
| Persico, M | 1 |
| Piscione, F | 1 |
| De Nicola, L | 1 |
| Torella, R | 1 |
| Paolisso, G | 1 |
| Sáez, ME | 2 |
| González-Pérez, A | 2 |
| Achuthan, S | 1 |
| Ahluwalia, J | 1 |
| Shafiq, N | 1 |
| Bhalla, A | 1 |
| Pareek, A | 1 |
| Chandurkar, N | 1 |
| Malhotra, S | 1 |
| Daels, FP | 1 |
| Gaizauskas, A | 1 |
| Rioja, J | 1 |
| Varshney, AK | 1 |
| Erkan, E | 1 |
| Ozgok, Y | 1 |
| Melekos, M | 1 |
| de la Rosette, JJ | 1 |
| Longo, G | 1 |
| Tamburino, C | 1 |
| Marjani, H | 1 |
| Jaafari, E | 1 |
| Naemi, M | 1 |
| Thomas, GN | 3 |
| Wang, PY | 1 |
| Chen, HP | 1 |
| Chen, A | 1 |
| Tsay, FW | 1 |
| Lai, KH | 2 |
| Kao, SS | 1 |
| Kuo, CH | 1 |
| Peng, NJ | 1 |
| Tseng, HH | 1 |
| Hsu, PI | 3 |
| Whellan, DJ | 4 |
| Goldstein, JL | 4 |
| Cryer, BL | 3 |
| Eisen, GM | 2 |
| Miller, AB | 1 |
| Scheiman, JM | 9 |
| Fort, JG | 4 |
| O'Connor, C | 1 |
| Fosmire Rundgren, EW | 1 |
| Anderson, SL | 1 |
| Marrs, JC | 1 |
| Patel, PA | 1 |
| Fleisher, LA | 1 |
| Goldsweig, AM | 1 |
| Reid, KJ | 1 |
| Gosch, K | 1 |
| Tang, F | 1 |
| Fang, MC | 1 |
| Chan, PS | 1 |
| Miyares, MA | 1 |
| Davis, KA | 1 |
| Rooney, B | 1 |
| Adams, S | 1 |
| Pinnarelli, L | 1 |
| Mayer, F | 1 |
| Bauleo, L | 1 |
| Agabiti, N | 1 |
| Kirchmayer, U | 1 |
| Belleudi, V | 1 |
| Di Martino, M | 1 |
| Autore, C | 1 |
| Ricci, R | 1 |
| Violini, R | 1 |
| Fusco, D | 1 |
| Davoli, M | 1 |
| Perucci, CA | 1 |
| Li, XC | 1 |
| Lu, L | 1 |
| Cao, Y | 1 |
| Sun, RR | 1 |
| Chen, S | 2 |
| Zhang, PY | 1 |
| Bjorkman, DJ | 3 |
| Davila, CD | 1 |
| Vargas, F | 1 |
| Huang, KH | 1 |
| Monaco, T | 1 |
| Dimou, A | 1 |
| Rangaswami, J | 1 |
| Figueredo, VM | 1 |
| Xie, M | 1 |
| Shan, Z | 1 |
| Bao, W | 1 |
| Rong, Y | 1 |
| Yu, X | 1 |
| Hu, FB | 1 |
| Huang, QY | 1 |
| Yang, RQ | 1 |
| Leavitt, DA | 2 |
| Theckumparampil, N | 2 |
| Moreira, DM | 2 |
| Elsamra, SE | 2 |
| Waingankar, N | 1 |
| Hoenig, DM | 2 |
| Smith, AD | 2 |
| Okeke, Z | 2 |
| Morganstern, B | 1 |
| Singh, S | 2 |
| Kullo, IJ | 1 |
| Pardi, DS | 1 |
| Loftus, EV | 1 |
| Psotka, MA | 1 |
| Fleischmann, KE | 1 |
| Ensor, J | 3 |
| Hodgkinson, J | 4 |
| Patai, Á | 1 |
| Solymosi, N | 1 |
| Patai, ÁV | 1 |
| van Kruijsdijk, RC | 2 |
| Dorresteijn, JA | 3 |
| Ruigómez, A | 1 |
| Martín-Pérez, M | 2 |
| Rodríguez, LA | 1 |
| Hayes, A | 1 |
| Lo, S | 1 |
| Peiris, DP | 1 |
| Neal, BC | 1 |
| Wise, J | 2 |
| Brotons, C | 2 |
| Benamouzig, R | 2 |
| Limmroth, V | 1 |
| Borghi, C | 2 |
| Cohen, AT | 1 |
| Imfeld, S | 1 |
| Markham, J | 1 |
| Granziera, S | 1 |
| Sun, Y | 2 |
| Hu, D | 1 |
| Schwartz, JB | 1 |
| Wu, IC | 2 |
| Hsieh, HM | 2 |
| Wu, MT | 2 |
| Serrano, CV | 2 |
| Frati, G | 1 |
| Agostoni, P | 1 |
| Abbate, A | 1 |
| Kennedy, K | 1 |
| Alam, M | 1 |
| Basra, SS | 1 |
| Ho, PM | 1 |
| Deswal, A | 1 |
| Liu, J | 5 |
| Qi, Y | 2 |
| Sun, J | 2 |
| Markun, S | 1 |
| Desai, D | 1 |
| Ahmed, HM | 1 |
| Snoep, JD | 2 |
| Assendelft, WJ | 1 |
| Zwaginga, JJ | 1 |
| Eikenboom, J | 1 |
| Huisman, MV | 1 |
| Rosendaal, FR | 1 |
| Gerstein, NS | 2 |
| Carey, MC | 1 |
| Cigarroa, JE | 1 |
| Schulman, PM | 2 |
| Cegarra-Sanmartin, V | 1 |
| Paniagua-Iglesias, P | 1 |
| Popova, E | 1 |
| de Nadal Clanchet, M | 1 |
| Alonso-Coello, P | 1 |
| Plou, P | 1 |
| Mata Mena, E | 1 |
| Fernández-Riveira, C | 1 |
| García del Valle, S | 1 |
| Tena Blanco, B | 1 |
| Sabaté Tenas, S | 1 |
| Font Gual, A | 1 |
| Maestre Hittinger, ML | 1 |
| González Rodríguez, R | 1 |
| Wehbeh, A | 2 |
| Tamim, HM | 1 |
| Abu Daya, H | 1 |
| Abou Mrad, R | 1 |
| Badreddine, RJ | 1 |
| Eloubeidi, MA | 1 |
| Rockey, DC | 3 |
| Barada, K | 2 |
| Miller, AW | 1 |
| Rezkalla, H | 1 |
| Cohen, M | 4 |
| Jensen, EC | 1 |
| Magnani, G | 2 |
| Bansilal, S | 3 |
| Fish, MP | 1 |
| Im, K | 1 |
| Bengtsson, O | 1 |
| Oude Ophuis, T | 1 |
| Theroux, P | 1 |
| Ruda, M | 1 |
| Hamm, C | 4 |
| Spinar, J | 1 |
| Nicolau, JC | 2 |
| Kiss, RG | 2 |
| Murphy, SA | 3 |
| Held, P | 1 |
| Braunwald, E | 2 |
| Opie, LH | 3 |
| Lopaschuk, GD | 1 |
| Christen, WG | 9 |
| Kereiakes, DJ | 1 |
| Massaro, JM | 1 |
| Driscoll-Shempp, P | 1 |
| Cutlip, DE | 1 |
| Gershlick, AH | 1 |
| Darius, H | 1 |
| Meredith, IT | 1 |
| Ormiston, J | 1 |
| Garratt, KN | 1 |
| Kandzari, DE | 1 |
| Lee, DP | 1 |
| Simon, DI | 1 |
| Iancu, AC | 1 |
| Trebacz, J | 1 |
| Mauri, L | 1 |
| Horváth, VJ | 1 |
| Tabák, GÁ | 1 |
| Szabó, G | 1 |
| Putz, Z | 1 |
| Koós, CG | 1 |
| Lakatos, P | 1 |
| Onuchina, EV | 1 |
| Desai, H | 1 |
| Hollingsworth, PW | 1 |
| Chugh, AR | 1 |
| Eliraqi, GM | 1 |
| Vistisen, D | 1 |
| Lauritzen, T | 1 |
| Sandbaek, A | 1 |
| Jørgensen, ME | 1 |
| Faerch, K | 1 |
| Argulian, E | 1 |
| Conen, D | 1 |
| Tran-Duy, A | 1 |
| Vanmolkot, FH | 1 |
| Joore, MA | 1 |
| Hoes, AW | 1 |
| Stehouwer, CD | 3 |
| Armstrong, EJ | 1 |
| Anderson, DR | 1 |
| Yeo, KK | 1 |
| Singh, GD | 1 |
| Bang, H | 1 |
| Amsterdam, EA | 4 |
| Freischlag, JA | 1 |
| Laird, JR | 1 |
| Spence, JD | 1 |
| Murali, SB | 1 |
| Mastromarino, V | 1 |
| Hokimoto, S | 2 |
| Akasaka, T | 1 |
| Tabata, N | 1 |
| Arima, Y | 1 |
| Sakamoto, K | 1 |
| Morita, K | 1 |
| Kumagae, N | 1 |
| Yamamoto, E | 1 |
| Oniki, K | 1 |
| Nakagawa, K | 1 |
| Depta, JP | 1 |
| Vlachopoulos, C | 1 |
| Aznaouridis, K | 1 |
| Bratsas, A | 1 |
| Ioakeimidis, N | 1 |
| Dima, I | 1 |
| Xaplanteris, P | 1 |
| Stefanadis, C | 1 |
| Danelich, IM | 1 |
| Wright, SS | 1 |
| Lose, JM | 1 |
| Tefft, BJ | 1 |
| Cicci, JD | 1 |
| Jacoby, D | 1 |
| Hajj, J | 1 |
| Javaheri, A | 1 |
| deGoma, E | 1 |
| Lin, A | 1 |
| Ahn, P | 1 |
| Quon, H | 1 |
| Moloney, E | 1 |
| Price, M | 1 |
| Parhofer, KG | 1 |
| Harrison, P | 1 |
| Sourij, H | 1 |
| Tucker, L | 1 |
| Kennedy, I | 1 |
| White, S | 1 |
| Hill, L | 1 |
| Oulhaj, A | 1 |
| Coleman, RL | 1 |
| Gold, R | 2 |
| Nelson, C | 1 |
| Cowburn, S | 1 |
| Bunce, A | 1 |
| Hollombe, C | 2 |
| Davis, J | 1 |
| Muench, J | 1 |
| Mital, M | 1 |
| Puro, J | 1 |
| Perrin, N | 1 |
| Nichols, G | 1 |
| Turner, A | 1 |
| Mercer, M | 1 |
| Jaworski, V | 1 |
| Howard, C | 1 |
| Abiles, E | 1 |
| Shah, A | 2 |
| Dudl, J | 1 |
| Chan, W | 1 |
| DeVoe, J | 1 |
| Everett, BM | 2 |
| Pradhan, AD | 3 |
| Chow, KY | 1 |
| Liu, SE | 1 |
| Irwin, MG | 1 |
| Bem, D | 2 |
| Stevens, S | 2 |
| Paixao, AR | 1 |
| Enriquez, JR | 1 |
| Berry, JD | 1 |
| Khera, A | 1 |
| Das, SR | 2 |
| de Lemos, JA | 2 |
| Kontos, MC | 1 |
| Teraa, M | 1 |
| Verhaar, MC | 2 |
| Stegeman, I | 2 |
| Bossuyt, PM | 1 |
| Boyd, C | 1 |
| Puhan, MA | 2 |
| Castiglioni, B | 1 |
| Li, XX | 1 |
| Zhang, YG | 1 |
| Wang, D | 1 |
| Chen, YF | 1 |
| Shan, YH | 1 |
| Derosa, G | 1 |
| Mugellini, A | 1 |
| Pesce, RM | 1 |
| D'Angelo, A | 1 |
| Maffioli, P | 1 |
| Frelinger, AL | 3 |
| Michelson, AD | 4 |
| Pignatelli, P | 2 |
| Kim, KJ | 1 |
| Cho, IJ | 1 |
| Hong, GR | 1 |
| Chung, N | 1 |
| Rah, YM | 1 |
| Chang, HJ | 1 |
| Sudoyo, AW | 1 |
| Shiravi Khuzani, A | 1 |
| Brun, C | 1 |
| Daali, Y | 1 |
| Combescure, C | 2 |
| Zufferey, A | 2 |
| Fontana, P | 6 |
| Reny, JL | 5 |
| Welsh, KJ | 1 |
| Dasgupta, A | 2 |
| Nguyen, AN | 1 |
| Wahed, A | 1 |
| Roberto, G | 1 |
| Cricelli, I | 2 |
| Giustini, SE | 1 |
| Sibbing, D | 2 |
| Gross, L | 1 |
| Aradi, D | 1 |
| Pelliccia, F | 1 |
| Marazzi, G | 1 |
| Greco, C | 1 |
| Gaudio, C | 2 |
| Noubiap, JJ | 1 |
| Nansseu, JR | 1 |
| Patrick, J | 1 |
| Pennell, AT | 1 |
| Rossello, X | 1 |
| Julian, DG | 1 |
| Tu, HT | 1 |
| Brugada, P | 2 |
| McCarthy, M | 2 |
| Varadhan, R | 1 |
| Boyd, CM | 1 |
| Pang, S | 1 |
| Shi, SY | 1 |
| Zhang, YJ | 1 |
| Iqbal, J | 1 |
| Chen, XY | 1 |
| Ren, XM | 1 |
| Zhu, H | 1 |
| Zeng, YP | 1 |
| Bioh, G | 1 |
| Bourantas, CV | 1 |
| Chen, SL | 1 |
| Naimo, PS | 1 |
| McGiffin, D | 1 |
| Konstantinov, IE | 1 |
| Adams, MA | 1 |
| Khatib, R | 1 |
| McKee, M | 1 |
| Shannon, H | 1 |
| Chow, C | 1 |
| Rangarajan, S | 1 |
| Wei, L | 4 |
| Mony, P | 1 |
| Mohan, V | 2 |
| Gupta, R | 2 |
| Kumar, R | 1 |
| Vijayakumar, K | 1 |
| Lear, SA | 1 |
| Ismail, N | 1 |
| Kazmi, K | 1 |
| Rahman, O | 1 |
| Rosengren, A | 1 |
| Monsef, N | 1 |
| Kelishadi, R | 1 |
| Kruger, A | 1 |
| Puoane, T | 1 |
| Szuba, A | 1 |
| Chifamba, J | 1 |
| Temizhan, A | 2 |
| Gafni, A | 1 |
| Jalil, NJ | 1 |
| Bannur, Z | 1 |
| Derahman, A | 1 |
| Maskon, O | 1 |
| Darinah, N | 1 |
| Hamidi, H | 1 |
| Gunasekaran, OA | 1 |
| Rafizi, M | 1 |
| Azreen, NI | 1 |
| Kek, TL | 1 |
| Salleh, MZ | 1 |
| Ying, GS | 1 |
| Maguire, MG | 1 |
| Daniel, E | 1 |
| Grunwald, JE | 1 |
| Ahmed, O | 1 |
| Martin, DF | 1 |
| Cai, G | 1 |
| Zhou, W | 1 |
| Lu, Y | 2 |
| Chen, P | 1 |
| Lu, Z | 1 |
| Fu, Y | 1 |
| van Diemen, JJ | 1 |
| Wessels, TJ | 1 |
| Fraison, JB | 1 |
| Sève, P | 1 |
| Dauphin, C | 1 |
| Mahr, A | 1 |
| Gomard-Mennesson, E | 1 |
| Varron, L | 1 |
| Pugnet, G | 1 |
| Landron, C | 1 |
| Roblot, P | 1 |
| Oziol, E | 1 |
| Chalhoub, G | 1 |
| Galempoix, JM | 1 |
| Humbert, S | 1 |
| Humbert, P | 1 |
| Sbidian, E | 1 |
| Grange, F | 1 |
| Bayrou, O | 1 |
| Cathebras, P | 1 |
| Morlat, P | 1 |
| Epaulard, O | 1 |
| Pavese, P | 1 |
| Huong, du LT | 1 |
| Zoulim, A | 1 |
| Stankovic, K | 1 |
| Bachelez, H | 1 |
| Smail, A | 1 |
| Bachmeyer, C | 1 |
| Granel, B | 1 |
| Serratrice, J | 1 |
| Brinchault, G | 1 |
| Mekinian, A | 1 |
| Costedoat-Chalumeau, N | 1 |
| Bourgarit-Durand, A | 1 |
| Puéchal, X | 1 |
| Guillevin, L | 1 |
| Piram, M | 1 |
| Koné-Paut, I | 1 |
| Fain, O | 1 |
| Yu, FJ | 1 |
| Wu, MC | 1 |
| Wu, TS | 1 |
| Dobesh, PP | 1 |
| Varnado, S | 1 |
| Doyle, M | 1 |
| Sansone, R | 1 |
| Barrios, V | 2 |
| Escobar, C | 1 |
| Grimes, RT | 1 |
| Henman, MC | 1 |
| Steffen, LM | 1 |
| Michaud, TL | 1 |
| Abraham, J | 1 |
| Jalal, H | 1 |
| Huebert, I | 1 |
| Heinicke, N | 1 |
| Kook, D | 1 |
| Boost, KA | 1 |
| Miller, CV | 1 |
| Mayer, WJ | 1 |
| Haritoglou, C | 1 |
| Kampik, A | 1 |
| Gandorfer, A | 1 |
| Hintschich, C | 1 |
| Wolf, A | 1 |
| Kim, J | 1 |
| Srivastava, PK | 1 |
| Goeddeke-Merickel, CM | 1 |
| Huguelet, J | 1 |
| Omboni, S | 1 |
| Novo, S | 1 |
| Ambrosio, G | 1 |
| Ambrosioni, E | 1 |
| Sarbacker, GB | 1 |
| Lusk, KA | 1 |
| Flieller, LA | 1 |
| Van Liew, JR | 1 |
| Bhatia, N | 1 |
| Santos, M | 1 |
| Jones, LW | 1 |
| Beckman, JA | 3 |
| Penson, DF | 1 |
| Morgans, AK | 1 |
| Moslehi, J | 1 |
| Katare, PB | 1 |
| Banerjee, SK | 1 |
| Levi, M | 1 |
| Cancian, M | 1 |
| Sobrero, A | 1 |
| Chen, L | 1 |
| Qiao, QY | 1 |
| Pan, LH | 1 |
| Gu, YH | 1 |
| Gu, HF | 1 |
| Fu, SK | 1 |
| Jin, HM | 1 |
| Sanin, V | 1 |
| Pfetsch, V | 1 |
| Koenig, W | 1 |
| Dad, T | 1 |
| Tighiouart, H | 1 |
| Joseph, A | 1 |
| Bostom, A | 1 |
| Carpenter, M | 1 |
| Hunsicker, L | 2 |
| Kusek, JW | 1 |
| Pfeffer, M | 1 |
| Levey, AS | 2 |
| Weiner, DE | 1 |
| Leung, W | 1 |
| Clarke, P | 1 |
| Knight, J | 1 |
| Lee, TH | 3 |
| Lee, RT | 1 |
| Fanaroff, AC | 1 |
| Kaasenbrood, L | 1 |
| Qato, DM | 2 |
| Lee, TA | 1 |
| Durazo-Arvizu, R | 1 |
| Wilder, J | 1 |
| Reina, SA | 1 |
| Cai, J | 1 |
| Gonzalez, F | 1 |
| Talavera, GA | 1 |
| Ostfeld, RJ | 1 |
| Daviglus, ML | 1 |
| Sun, JY | 1 |
| Ricci, E | 1 |
| Parruti, G | 1 |
| Calza, L | 1 |
| Celesia, BM | 1 |
| Orofino, G | 1 |
| Madeddu, G | 1 |
| Menzaghi, B | 1 |
| Taramasso, L | 1 |
| Penco, G | 1 |
| Carenzi, L | 1 |
| Franzetti, M | 1 |
| Bonfanti, P | 1 |
| Ayub, A | 1 |
| Parkash, O | 1 |
| Naeem, B | 1 |
| Murtaza, D | 1 |
| Khan, AH | 1 |
| Jafri, W | 1 |
| Hamid, S | 1 |
| Mostaza, JM | 1 |
| Lobos, JM | 1 |
| Abarca, B | 1 |
| Llisterri, JL | 1 |
| Burda, BU | 2 |
| Williams, SB | 2 |
| O'Connor, EA | 1 |
| Chubak, J | 1 |
| Kamineni, A | 1 |
| Buist, DS | 1 |
| Flottemesch, TJ | 2 |
| LaFrance, AB | 1 |
| Bibbins-Domingo, K | 1 |
| Hedner, T | 1 |
| Kjeldsen, SE | 2 |
| Narkiewicz, K | 1 |
| Oparil, S | 1 |
| Nagatsuka, K | 2 |
| Miyata, S | 2 |
| Kada, A | 2 |
| Kawamura, A | 1 |
| Nakagawara, J | 1 |
| Furui, E | 1 |
| Takiuchi, S | 1 |
| Taomoto, K | 1 |
| Kario, K | 1 |
| Saito, K | 1 |
| Nagao, T | 1 |
| Kitagawa, K | 1 |
| Hosomi, N | 1 |
| Tanaka, K | 1 |
| Katayama, Y | 1 |
| Abumiya, T | 1 |
| Nakane, H | 1 |
| Hattori, A | 1 |
| Kimura, K | 1 |
| Nishikawa, M | 1 |
| Yamawaki, T | 1 |
| Yonemoto, N | 1 |
| Okada, H | 1 |
| Minematsu, K | 1 |
| Miyata, T | 3 |
| Egholm, G | 1 |
| Olesen, KK | 1 |
| Madsen, M | 1 |
| Sorensen, HT | 1 |
| Jensen, SE | 1 |
| Jensen, LO | 1 |
| Botker, HE | 1 |
| Chiva-Blanch, G | 1 |
| Suades, R | 1 |
| Padró, T | 1 |
| Vilahur, G | 1 |
| Peña, E | 1 |
| Ybarra, J | 1 |
| Pou, JM | 1 |
| Badimon, L | 2 |
| Ikeda, S | 1 |
| Okumura, K | 1 |
| Matsuda, S | 1 |
| Koretsune, Y | 1 |
| Montouchet, C | 1 |
| Watanabe-Fujinuma, E | 1 |
| Evers, T | 5 |
| Rossi, B | 1 |
| Ruff, L | 1 |
| Briere, JB | 1 |
| Bunce, AE | 1 |
| Nelson, CA | 1 |
| Proctor, EK | 1 |
| Pope, JA | 1 |
| DeVoe, JE | 1 |
| Raju, N | 1 |
| Sobieraj-Teague, M | 2 |
| Chan, FK | 9 |
| Leung Ki, EL | 1 |
| Wong, GL | 1 |
| Ching, JY | 3 |
| Au, KW | 1 |
| Wu, JC | 3 |
| Ngalesoni, FN | 1 |
| Ruhago, GM | 1 |
| Mori, AT | 1 |
| Robberstad, B | 1 |
| Norheim, OF | 1 |
| Chaudhary, R | 2 |
| Byun, S | 1 |
| Soeiro, Ade M | 1 |
| Mansur, Ade P | 1 |
| Schaan, BD | 1 |
| Rochitte, CE | 1 |
| Garzillo, CL | 1 |
| Lima, EG | 1 |
| Marcondes-Braga, FG | 1 |
| Lima, FG | 1 |
| Oliveira, FM | 1 |
| Azevedo, FR | 1 |
| Chauhan, H | 1 |
| Salles, JE | 1 |
| Soares, J | 1 |
| Cardoso, JN | 1 |
| Sacilotto, L | 1 |
| Baracioli, L | 1 |
| César, LA | 1 |
| Ochiai, ME | 1 |
| Minami, MH | 1 |
| Pinheiro, MB | 1 |
| Moretti, MA | 1 |
| Oliveira, MT | 1 |
| Rezende, PC | 1 |
| Lemos, PA | 1 |
| Admoni, SN | 1 |
| Lottenberg, SA | 1 |
| Rocha, VZ | 1 |
| Hueb, W | 1 |
| Mathias, W | 1 |
| Smith, DL | 1 |
| Horn, GP | 1 |
| Woods, J | 1 |
| Ploutz-Snyder, R | 1 |
| Fernhall, B | 1 |
| Gabriele Falcone, L | 1 |
| La Montagna, G | 1 |
| Migliaresi, S | 1 |
| Dillinger, JG | 1 |
| Saeed, A | 1 |
| Spagnoli, V | 1 |
| Sollier, CB | 1 |
| Sideris, G | 1 |
| Silberman, SM | 1 |
| Voicu, S | 1 |
| Drouet, L | 2 |
| Henry, P | 2 |
| Shimada, YJ | 1 |
| Himmelmann, A | 1 |
| Neely, B | 1 |
| James, SK | 1 |
| Katus, HA | 2 |
| Wallentin, L | 1 |
| Ames, JM | 1 |
| Timmis, A | 1 |
| Rapsomaniki, E | 1 |
| Chung, SC | 2 |
| Pujades-Rodriguez, M | 1 |
| Moayyeri, A | 1 |
| Stogiannis, D | 1 |
| Shah, AD | 1 |
| Pasea, L | 1 |
| Denaxas, S | 1 |
| Emmas, C | 1 |
| Hemingway, H | 1 |
| Huang, WT | 1 |
| Erickson, SR | 1 |
| Hansen, RA | 1 |
| Wu, CH | 1 |
| Oozeerally, I | 1 |
| Dawson, S | 1 |
| Riddleston, H | 1 |
| Di Tullio, MR | 1 |
| Qian, M | 1 |
| Thompson, JL | 1 |
| Labovitz, AJ | 1 |
| Mann, DL | 1 |
| Sacco, RL | 2 |
| Pullicino, PM | 1 |
| Freudenberger, RS | 1 |
| Teerlink, JR | 1 |
| Graham, S | 1 |
| Levin, B | 2 |
| Mohr, JP | 1 |
| Buchsbaum, R | 1 |
| Estol, CJ | 1 |
| Lok, DJ | 1 |
| Anker, SD | 1 |
| Homma, S | 1 |
| Gu, Y | 1 |
| Kerr, AJ | 1 |
| Terrosu, P | 1 |
| Thorat, MA | 1 |
| Karmali, KN | 1 |
| Lloyd-Jones, DM | 1 |
| Berendsen, MA | 1 |
| Goff, DC | 1 |
| Sanghavi, DM | 1 |
| Brown, NC | 1 |
| Korenovska, L | 1 |
| Packard, KA | 1 |
| Hilleman, DE | 1 |
| Kaskens, L | 1 |
| Ruiz, JE | 1 |
| Zsolt, I | 1 |
| Gracia, A | 1 |
| Kokoska, LA | 1 |
| Wilhelm, SM | 1 |
| Garwood, CL | 1 |
| Berlie, HD | 1 |
| Fortuna, LA | 1 |
| Pawloski, PA | 1 |
| Parker, ED | 1 |
| Trower, NK | 1 |
| Kottke, TE | 1 |
| Sasaki, K | 1 |
| Ueno, T | 1 |
| Kamenova, M | 2 |
| Lutz, K | 2 |
| Schaedelin, S | 1 |
| Fandino, J | 2 |
| Mariani, L | 2 |
| Soleman, J | 2 |
| Godley, RW | 1 |
| Hernandez-Vila, E | 1 |
| Rao, AK | 1 |
| Jalagadugula, GS | 1 |
| Myers, R | 1 |
| Harris, E | 1 |
| de Waha, A | 1 |
| Sandner, S | 1 |
| Boening, A | 1 |
| Koch-Buettner, K | 1 |
| Hammel, D | 1 |
| Hambrecht, R | 1 |
| Danner, BC | 1 |
| Schöndube, FA | 1 |
| Goerlach, G | 1 |
| Fischlein, T | 1 |
| Schmoeckel, M | 1 |
| Oberhoffer, M | 1 |
| Schulz, R | 1 |
| Walther, T | 1 |
| Ziegelhöffer, T | 1 |
| Knosalla, C | 1 |
| Schönrath, F | 1 |
| Beyersdorf, F | 1 |
| Siepe, M | 1 |
| Attmann, T | 1 |
| Misfeld, M | 1 |
| Mohr, FW | 1 |
| Sievers, HH | 1 |
| Joost, A | 1 |
| Putman, LM | 1 |
| Laufer, G | 1 |
| Zeymer, U | 1 |
| Kastrati, A | 2 |
| Radke, PW | 1 |
| Lange, R | 1 |
| Cremer, J | 1 |
| Bajrangee, A | 1 |
| Ryan, N | 1 |
| Brennan, M | 1 |
| Cox, D | 5 |
| Fitzgerald, D | 1 |
| Maree, A | 1 |
| Latorre, A | 1 |
| Moscardó, A | 1 |
| Meier, R | 1 |
| Marthy, R | 1 |
| Saely, CH | 1 |
| Kuster, MS | 1 |
| Giesinger, K | 1 |
| Rickli, H | 1 |
| Malayala, SV | 1 |
| Raza, A | 1 |
| Zaiou, M | 1 |
| El Amri, H | 1 |
| Liu, Z | 1 |
| Moorin, R | 1 |
| Worthington, J | 1 |
| Tofler, G | 1 |
| Bartlett, M | 1 |
| Khan, R | 1 |
| Zuo, Y | 1 |
| Praksch, D | 1 |
| Sandor, B | 1 |
| Nagy, KK | 1 |
| Viola, M | 1 |
| Toth, A | 1 |
| Toth, K | 2 |
| Szakaly, P | 1 |
| Varga, A | 1 |
| Faucon, AL | 1 |
| Madjalian, AM | 1 |
| Bobrie, G | 1 |
| Amar, L | 1 |
| Azizi, M | 1 |
| Murff, HJ | 1 |
| Ventura, L | 1 |
| Miccinesi, G | 1 |
| Barchielli, A | 1 |
| Manneschi, G | 1 |
| Puliti, D | 1 |
| Mantellini, P | 1 |
| Orso, F | 1 |
| Zappa, M | 1 |
| Hsiao, KC | 1 |
| Huang, JY | 1 |
| Lee, CT | 1 |
| Hung, TW | 1 |
| Liaw, YP | 1 |
| Chang, HR | 1 |
| Olechowski, B | 1 |
| Ashby, A | 1 |
| Mariathas, M | 1 |
| Khanna, V | 1 |
| Mahmoudi, M | 1 |
| Curzen, N | 2 |
| Tijssen, J | 1 |
| Guimarães, AH | 1 |
| van Es, GA | 1 |
| Hemmrich, M | 1 |
| Moro, MG | 1 |
| Sanchez, PK | 1 |
| Gevert, MV | 1 |
| Baller, EM | 1 |
| Tostes, AF | 1 |
| Lupepsa, AC | 1 |
| Baglie, S | 1 |
| Franco, GC | 1 |
| Agus, DB | 1 |
| Gaudette, É | 1 |
| Goldman, DP | 1 |
| Messali, A | 1 |
| Guyatt, G | 1 |
| Jaeschke, R | 2 |
| Stovitz, SD | 1 |
| Satin, DJ | 1 |
| Shrier, I | 1 |
| McNellis, RJ | 1 |
| Beswick-Escanlar, V | 1 |
| Sharma, T | 1 |
| Bliden, K | 1 |
| Chao, J | 1 |
| Brandi, G | 1 |
| De Lorenzo, S | 1 |
| Palloni, A | 1 |
| Biasco, G | 1 |
| Tovoli, F | 1 |
| Desborough, MJR | 1 |
| Keeling, DM | 1 |
| Raschi, E | 1 |
| Bianchin, M | 1 |
| Poluzzi, E | 1 |
| De Ponti, F | 1 |
| Nevzati, E | 1 |
| Dolp, A | 1 |
| Han, Y | 1 |
| Schofield, D | 1 |
| Tursi, JP | 1 |
| Sperl-Hillen, J | 1 |
| Margolis, K | 1 |
| Crain, L | 1 |
| Sehgal, M | 1 |
| Ouslander, JG | 1 |
| Mosca, L | 1 |
| Crescente, M | 2 |
| Di Castelnuovo, A | 2 |
| Iacoviello, L | 1 |
| de Gaetano, G | 3 |
| Cerletti, C | 2 |
| Sullivan, J | 1 |
| Amarshi, N | 1 |
| Talbert, RL | 2 |
| Romero, SC | 1 |
| Dela Rosa, KM | 1 |
| Linz, PE | 1 |
| Finks, SW | 1 |
| Fisher, M | 4 |
| Cushman, M | 4 |
| Knappertz, V | 3 |
| Howard, G | 3 |
| Kauffman, AB | 1 |
| Delate, T | 1 |
| Olson, KL | 1 |
| Cymbala, AA | 1 |
| Hutka, KA | 1 |
| Kasten, SL | 1 |
| Rasmussen, JR | 1 |
| Driver, JA | 2 |
| Kurth, T | 11 |
| Logroscino, G | 1 |
| Sousa, CS | 1 |
| Fonseca, T | 1 |
| Clara, JG | 1 |
| Clappers, N | 1 |
| van Oijen, MG | 3 |
| Sundaresan, S | 1 |
| Brouwer, MA | 1 |
| Te Morsche, RH | 1 |
| Keuper, W | 1 |
| Peters, WH | 3 |
| Drenth, JP | 2 |
| Riondino, S | 4 |
| Petrini, N | 1 |
| Donato, L | 1 |
| Torromeo, C | 1 |
| Tanzilli, G | 1 |
| Pulcinelli, FM | 3 |
| Barillà, F | 1 |
| Ames, DA | 1 |
| Krum, H | 2 |
| Kahn, R | 1 |
| Robertson, RM | 1 |
| Eddy, D | 1 |
| Todd, DJ | 1 |
| Schürks, M | 1 |
| Zee, RY | 3 |
| Blaha, MJ | 1 |
| Bansal, S | 1 |
| Rouf, R | 1 |
| Swaim, L | 1 |
| Hillman, RS | 1 |
| Saini, SD | 2 |
| Schoenfeld, P | 1 |
| Fendrick, AM | 3 |
| Mardikar, H | 1 |
| Deo, D | 1 |
| Deshpande, N | 1 |
| Mardikar, M | 1 |
| Ghosh, A | 1 |
| Munot, K | 1 |
| Steinhubl, S | 2 |
| Mukherjee, D | 4 |
| Hellstrom, HR | 1 |
| Jankowski, J | 2 |
| Hunt, R | 3 |
| Bulugahapitiya, U | 1 |
| Siyambalapitiya, S | 1 |
| Sithole, J | 1 |
| Fernando, DJ | 1 |
| Idris, I | 1 |
| Gibbings, G | 1 |
| Woollard, M | 1 |
| Elwood, PC | 3 |
| Bousser, MG | 2 |
| Alves, JD | 1 |
| Steinhagen-Thiessen, E | 1 |
| Darioli, R | 1 |
| Hostalek, U | 1 |
| Vogt, A | 1 |
| Shantsila, E | 3 |
| Falk, GW | 1 |
| Hur, C | 1 |
| Broughton, DE | 1 |
| Ozanne, E | 1 |
| Yachimski, P | 1 |
| Nishioka, NS | 1 |
| Gazelle, GS | 1 |
| Shiffman, D | 2 |
| Louie, JZ | 1 |
| Luke, MM | 1 |
| Rowland, CM | 1 |
| Catanese, JJ | 1 |
| Devlin, JJ | 2 |
| Norkus, EP | 1 |
| Rosenson, RS | 4 |
| Engberding, N | 1 |
| de Liefde, II | 2 |
| Hoeks, SE | 2 |
| van Gestel, YR | 2 |
| Bax, JJ | 2 |
| Klein, J | 2 |
| van Domburg, RT | 2 |
| Poldermans, D | 3 |
| Márk, L | 1 |
| Dani, G | 1 |
| Kiss, Z | 1 |
| Katona, A | 1 |
| Mueller, T | 1 |
| Dieplinger, B | 1 |
| Poelz, W | 1 |
| Haltmayer, M | 1 |
| Maegdefessel, L | 1 |
| Schlitt, A | 1 |
| Faerber, J | 1 |
| Bond, SP | 1 |
| Messow, CM | 1 |
| Buerke, M | 1 |
| Raaz, U | 1 |
| Werdan, K | 1 |
| Muenzel, T | 1 |
| Weiss, C | 1 |
| Rajec, J | 1 |
| Kriska, M | 1 |
| Vojtko, R | 1 |
| Dukat, A | 1 |
| Risnyovszki, Z | 1 |
| Sapak, M | 1 |
| Ferroni, P | 1 |
| Martini, F | 1 |
| La Farina, F | 1 |
| Magnapera, A | 1 |
| Ciatti, F | 1 |
| Guadagni, F | 1 |
| Hankey, GJ | 11 |
| Thom, J | 1 |
| Johnston, SC | 3 |
| Steinhubl, SR | 8 |
| Mak, KH | 5 |
| Easton, JD | 2 |
| Hu, T | 1 |
| Fox, KA | 9 |
| Topol, EJ | 13 |
| Fortuna, GR | 1 |
| Mueller, EW | 1 |
| James, LE | 1 |
| Shutter, LA | 1 |
| Butler, KL | 1 |
| Tourmousoglou, CE | 1 |
| Rokkas, CK | 1 |
| Anfossi, G | 1 |
| Russo, I | 1 |
| Trovati, M | 1 |
| Müller-Ehmsen, J | 1 |
| Erdmann, E | 2 |
| Kapoor, JR | 1 |
| Raju, NC | 2 |
| Hirsh, J | 2 |
| Nicolucci, A | 6 |
| Kanauchi, M | 1 |
| Verhagen, HJ | 1 |
| Federman, DG | 1 |
| Shelling, M | 1 |
| Prodanovich, S | 1 |
| Gunderson, CG | 1 |
| Kirsner, RS | 1 |
| Pusch, G | 1 |
| Feher, G | 2 |
| Kotai, K | 1 |
| Tibold, A | 1 |
| Gasztonyi, B | 1 |
| Feher, A | 1 |
| Papp, E | 2 |
| Lupkovics, G | 1 |
| Szapary, L | 1 |
| Forslund, L | 1 |
| Rostom, A | 2 |
| Gorelick, PB | 5 |
| Wong, DK | 1 |
| Lurie, F | 1 |
| Wong, LL | 1 |
| Robinson, JG | 2 |
| Suryadevara, S | 1 |
| Zenni, MZ | 1 |
| Guzman, LA | 1 |
| Bass, TA | 2 |
| Acikel, S | 1 |
| Yildirir, A | 1 |
| Aydinalp, A | 1 |
| Demirtas, K | 1 |
| Bal, U | 1 |
| Kaynar, G | 1 |
| Ozin, B | 1 |
| Karakayali, H | 1 |
| Muderrisoglu, H | 1 |
| Haberal, M | 1 |
| Sigamani, A | 3 |
| Pogue, J | 3 |
| Afzal, R | 4 |
| Serebruany, V | 3 |
| Shalito, I | 1 |
| Kopyleva, O | 1 |
| Calatzis, A | 2 |
| Hobson, A | 1 |
| Cacoub, PP | 1 |
| Price, HC | 1 |
| Oestreich, JH | 1 |
| Smyth, SS | 2 |
| Campbell, CL | 3 |
| Pallares, MJ | 1 |
| Powers, ER | 1 |
| Zwerner, PL | 1 |
| Fowler, A | 1 |
| Reeves, R | 1 |
| Nappi, JM | 1 |
| Ott, P | 1 |
| Benke, I | 1 |
| Stelzer, J | 1 |
| Köhler, C | 1 |
| Bonello, L | 1 |
| De Labriolle, A | 1 |
| Lemesle, G | 1 |
| Steinberg, DH | 1 |
| Roy, P | 1 |
| Torguson, R | 1 |
| Suddath, WO | 1 |
| Satler, LF | 1 |
| Kent, KM | 1 |
| Pichard, AD | 1 |
| Waksman, R | 1 |
| Milani, RV | 1 |
| Wammes-van der Heijden, EA | 1 |
| Tijssen, CC | 1 |
| Egberts, AC | 1 |
| Lancaster, GI | 1 |
| Srinivasan, J | 1 |
| Jain, H | 1 |
| Gibbons, RJ | 1 |
| Schlossberg, D | 1 |
| Kramer, MH | 1 |
| Brennan, DM | 4 |
| Berger, PB | 4 |
| Wolff, T | 1 |
| Miller, T | 1 |
| Ko, S | 1 |
| Conti, CR | 2 |
| Neyt, M | 1 |
| De Laet, C | 1 |
| Van Brabandt, H | 1 |
| Franco, O | 1 |
| Ramaekers, D | 1 |
| Joshi, R | 1 |
| de Galan, B | 1 |
| Colwell, JA | 10 |
| Papathanasiou, A | 1 |
| Goudevenos, J | 1 |
| Ivandic, BT | 1 |
| Sausemuth, M | 1 |
| Giannitsis, E | 1 |
| Gawaz, M | 3 |
| Vernooij, MW | 1 |
| Haag, MD | 1 |
| van der Lugt, A | 1 |
| Hofman, A | 2 |
| Krestin, GP | 1 |
| Stricker, BH | 1 |
| Breteler, MM | 1 |
| Amarenco, P | 1 |
| Chamorro, A | 1 |
| Ford, I | 1 |
| Fox, K | 1 |
| Hennerici, MG | 1 |
| Mattle, HP | 1 |
| Rifai, N | 3 |
| Hjemdahl, P | 1 |
| Brister, SJ | 2 |
| Buchanan, MR | 2 |
| Farkouh, ME | 2 |
| Greenberg, BP | 1 |
| Shaw, E | 1 |
| Bajorek, B | 1 |
| Ward, M | 1 |
| Mathewkutty, S | 1 |
| Shao, M | 1 |
| Weber, MA | 2 |
| Haffner, SM | 2 |
| Dimas, AP | 1 |
| Krantz, MJ | 3 |
| McDermott, MM | 1 |
| Criqui, MH | 1 |
| Iwakiri, R | 1 |
| Hara, M | 1 |
| Ootani, H | 1 |
| Shimoda, R | 1 |
| Tsunada, S | 1 |
| Sakata, H | 1 |
| Fox, SC | 1 |
| May, JA | 1 |
| Neubert, U | 1 |
| Apostolakis, S | 1 |
| Fiorucci, S | 2 |
| Tuleta, I | 1 |
| Bauriedel, G | 2 |
| Hasenbank, I | 1 |
| Andrié, R | 1 |
| Pabst, S | 1 |
| Nickenig, G | 2 |
| Skowasch, D | 2 |
| Cuisset, T | 1 |
| Frere, C | 1 |
| Quilici, J | 1 |
| Morange, PE | 1 |
| Mouret, JP | 1 |
| Bali, L | 1 |
| Moro, PJ | 1 |
| Lambert, M | 1 |
| Alessi, MC | 1 |
| Bonnet, JL | 1 |
| Fung, CY | 1 |
| Marcus, AJ | 1 |
| Broekman, MJ | 1 |
| Mahaut-Smith, MP | 1 |
| Blackwell, L | 1 |
| Emberson, J | 1 |
| Godwin, J | 1 |
| Buring, J | 1 |
| Hennekens, C | 3 |
| Kearney, P | 1 |
| Meade, T | 2 |
| Britt, HC | 1 |
| Dunn, ES | 1 |
| Shi, C | 1 |
| Caro, JJ | 1 |
| Mahoney, EM | 1 |
| Gabriel, S | 1 |
| Jackson, JD | 1 |
| Nazarian, SM | 1 |
| Thompson, JB | 1 |
| Gluckman, TJ | 1 |
| Laws, K | 1 |
| Jani, JT | 1 |
| Kickler, TS | 1 |
| Rade, JJ | 1 |
| Gaston, RS | 1 |
| Kasiske, BL | 1 |
| Fieberg, AM | 1 |
| Leduc, R | 1 |
| Cosio, FC | 1 |
| Gourishankar, S | 1 |
| Halloran, P | 1 |
| Rush, D | 1 |
| Matas, AJ | 1 |
| Younis, N | 2 |
| Soran, H | 2 |
| Aslam, F | 1 |
| Waheed, A | 1 |
| Adamopoulos, AB | 1 |
| Sakizlis, GN | 1 |
| Nasothimiou, EG | 1 |
| Anastasopoulou, I | 1 |
| Anastasakou, E | 1 |
| Kotsi, P | 1 |
| Karafoulidou, A | 1 |
| Stergiou, GS | 1 |
| Chandra, S | 1 |
| Lenihan, DJ | 1 |
| Wei, W | 1 |
| Yusuf, SW | 1 |
| Tong, AT | 1 |
| Bloom, JM | 1 |
| Taha, AS | 1 |
| McCloskey, C | 1 |
| Prasad, R | 1 |
| Bezlyak, V | 1 |
| Shakib, S | 1 |
| Hall, CJ | 1 |
| Metzler, H | 1 |
| Münch, A | 1 |
| Primus, G | 1 |
| Kainz, J | 1 |
| Hödl, R | 1 |
| Rehak, P | 1 |
| Bonvini, RF | 1 |
| Barazer, I | 2 |
| Berdagué, P | 2 |
| de Moerloose, P | 6 |
| Schved, JF | 2 |
| Gris, JC | 1 |
| Samama, MM | 2 |
| Elalamy, I | 2 |
| Gardner, M | 1 |
| Palmer, J | 1 |
| Manrique, C | 1 |
| Lastra, G | 1 |
| Gardner, DW | 1 |
| Sowers, JR | 2 |
| Torres Baile, JL | 1 |
| Ortega Sánchez, G | 1 |
| Chalupka, S | 1 |
| Voelker, R | 1 |
| Welin, L | 1 |
| Wilhelmsen, L | 2 |
| Björnberg, A | 1 |
| Odén, A | 1 |
| Lièvre, M | 1 |
| Cucherat, M | 1 |
| Kasotakis, G | 1 |
| Pipinos, II | 1 |
| Lynch, TG | 1 |
| Sakariassen, KS | 1 |
| Alberts, P | 1 |
| Mann, J | 1 |
| Bounameaux, H | 3 |
| Sorensen, AS | 1 |
| Unger, EF | 1 |
| Calvin, AD | 1 |
| Aggarwal, NR | 1 |
| Murad, MH | 1 |
| Elamin, MB | 1 |
| Geske, JB | 1 |
| Fernandez-Balsells, MM | 1 |
| Albuquerque, FN | 1 |
| Lampropulos, JF | 1 |
| Erwin, PJ | 1 |
| Smith, SA | 3 |
| Montori, VM | 3 |
| Ambrosi, P | 2 |
| Takagi, H | 1 |
| Umemoto, T | 1 |
| Davis, TM | 2 |
| Sillars, BA | 1 |
| Davis, WA | 2 |
| Hebert, PR | 5 |
| Schneider, WR | 3 |
| Cooney, MT | 1 |
| Dudina, A | 1 |
| Whincup, P | 2 |
| Capewell, S | 1 |
| Menotti, A | 1 |
| Jousilahti, P | 1 |
| Njølstad, I | 1 |
| Oganov, R | 1 |
| Thomsen, T | 1 |
| Tverdal, A | 1 |
| Wedel, H | 3 |
| Graham, I | 1 |
| Shaw, LJ | 1 |
| Min, JK | 1 |
| Budoff, M | 1 |
| Gransar, H | 1 |
| Rozanski, A | 1 |
| Hayes, SW | 1 |
| Friedman, JD | 1 |
| Miranda, R | 1 |
| Wong, ND | 2 |
| Berman, DS | 1 |
| Klomp, CM | 1 |
| ten Cate, H | 1 |
| Schaper, NC | 1 |
| Watson, PD | 1 |
| Joy, PS | 1 |
| Nkonde, C | 1 |
| Hessen, SE | 1 |
| Karalis, DG | 1 |
| Glynn, RJ | 13 |
| Chew, EY | 3 |
| Sudlow, CL | 2 |
| Mason, G | 1 |
| Maurice, JB | 1 |
| Wedderburn, CJ | 1 |
| Benhamou, Y | 1 |
| Lévesque, H | 2 |
| Mohan, AV | 1 |
| Mohan, CP | 1 |
| Balaban, R | 1 |
| Budhraja, V | 1 |
| Hsiao, FY | 3 |
| Tsai, YW | 3 |
| Huang, WF | 3 |
| Wen, YW | 3 |
| Chen, PF | 3 |
| Chang, PY | 1 |
| Kuo, KN | 2 |
| Ghisdal, L | 1 |
| Broeders, N | 1 |
| Wissing, KM | 1 |
| Saidi, A | 1 |
| Bensalem, T | 1 |
| Mbaba Mena, J | 1 |
| Lemy, A | 1 |
| Pradier, O | 1 |
| Hoang, AD | 1 |
| Mikhalski, D | 1 |
| Donckier, V | 1 |
| Cochaux, P | 1 |
| El Housni, H | 1 |
| Abramowicz, M | 1 |
| Vereerstraeten, P | 1 |
| Abramowicz, D | 1 |
| Singla, A | 1 |
| Antonino, MJ | 1 |
| Zhang, C | 1 |
| Sun, A | 1 |
| Fu, M | 1 |
| Wang, K | 1 |
| Zou, Y | 1 |
| Ge, J | 1 |
| Seet, RC | 1 |
| Chen, CP | 1 |
| Leung, WY | 1 |
| So, WY | 1 |
| Stewart, D | 1 |
| Lui, A | 1 |
| Tong, PC | 1 |
| Ko, GT | 1 |
| Kong, AP | 1 |
| Ma, RC | 1 |
| Yang, X | 1 |
| Chiang, SC | 1 |
| Chan, JC | 1 |
| Helft, G | 1 |
| Gao, XR | 1 |
| Adhikari, CM | 1 |
| Peng, LY | 1 |
| Guo, XG | 1 |
| Zhai, YS | 1 |
| He, XY | 1 |
| Zhang, LY | 1 |
| Lin, J | 2 |
| Zuo, ZY | 1 |
| Ong, G | 1 |
| Kappagoda, CT | 2 |
| Barkun, AN | 2 |
| Bardou, M | 2 |
| Sung, JJ | 2 |
| Lau, JY | 2 |
| Lee, YT | 2 |
| Chiu, PW | 1 |
| Leung, VK | 2 |
| Wong, VW | 2 |
| Varon, D | 2 |
| Spectre, G | 2 |
| Rifai, L | 1 |
| Khan, BV | 1 |
| Brown, DL | 4 |
| Burke, GL | 1 |
| Oberman, A | 1 |
| Kostis, JB | 1 |
| Langer, RD | 1 |
| Wassertheil-Smoller, S | 1 |
| Preobrazhenskiĭ, DV | 2 |
| Sidorenko, BA | 3 |
| Batyraliev, TA | 2 |
| Vural, A | 1 |
| Islek, M | 1 |
| Avsar, O | 1 |
| Fettser, DV | 2 |
| Shai, E | 1 |
| Krupa, M | 1 |
| Moskała, M | 1 |
| Składzień, T | 1 |
| Grzywna, E | 1 |
| Hasford, J | 2 |
| Lehmacher, W | 2 |
| Kidson-Gerber, G | 1 |
| Weaver, J | 1 |
| Gemmell, R | 1 |
| Prasan, AM | 1 |
| Chong, BH | 1 |
| Oscarsson, A | 1 |
| Fredrikson, M | 1 |
| Järhult, J | 1 |
| Nyström, M | 1 |
| Pettersson, E | 1 |
| Darvish, B | 1 |
| Krook, H | 1 |
| Swahn, E | 1 |
| Eintrei, C | 1 |
| Bramlage, P | 2 |
| Koch, G | 1 |
| Einhäupl, K | 1 |
| Montine, TJ | 1 |
| Sonnen, JA | 1 |
| Milne, G | 1 |
| Baker, LD | 1 |
| Breitner, JC | 1 |
| Laufs, U | 1 |
| Hoppe, UC | 1 |
| Rosenkranz, S | 1 |
| Kirchhof, P | 1 |
| Böhm, M | 1 |
| Endres, M | 1 |
| Grond, M | 1 |
| Hacke, W | 3 |
| Meinertz, T | 1 |
| Ringelstein, EB | 1 |
| Röther, J | 1 |
| Dichgans, M | 1 |
| Bupha-Intr, O | 1 |
| Rose, SB | 1 |
| Lawton, BA | 1 |
| Dowell, AC | 1 |
| Fowkes, FG | 1 |
| Stewart, MC | 1 |
| Butcher, I | 1 |
| Leng, GC | 1 |
| Pell, AC | 1 |
| Sandercock, PA | 1 |
| Lowe, GD | 2 |
| Murray, GD | 1 |
| Nichols, GA | 1 |
| Wang, F | 1 |
| Pedula, KL | 1 |
| Løchen, ML | 1 |
| Kvan, E | 1 |
| Borrás, X | 1 |
| Murga, N | 1 |
| Fiol, M | 1 |
| Pedreira, M | 1 |
| Fumeaux, D | 1 |
| Becerra, ME | 1 |
| Philippe, J | 2 |
| Louis-Simonet, M | 1 |
| Shah, G | 1 |
| Jha, V | 1 |
| Ghosh, C | 1 |
| Desai, J | 1 |
| Khamar, B | 1 |
| Chakraborty, BS | 1 |
| Gebel, JM | 1 |
| Herlitz, J | 2 |
| Tóth, PP | 1 |
| Naesdal, J | 2 |
| Dickson, I | 1 |
| Uchida, Y | 1 |
| Mori, F | 1 |
| Takagi, A | 1 |
| Hagiwara, N | 1 |
| Shigematsu, H | 1 |
| Nishibe, T | 1 |
| Obitsu, Y | 1 |
| Matsuzaki, K | 1 |
| Ishida, A | 1 |
| Shindo, S | 1 |
| Hida, K | 1 |
| Ohta, T | 1 |
| Ando, M | 1 |
| Kawasaki, T | 1 |
| Yasugi, T | 1 |
| Matsumoto, T | 1 |
| Bordeaux, BC | 1 |
| Qayyum, R | 2 |
| Yanek, LR | 4 |
| Vaidya, D | 4 |
| Becker, LC | 4 |
| Faraday, N | 4 |
| Becker, DM | 4 |
| Barnett, H | 1 |
| Burrill, P | 1 |
| Iheanacho, I | 1 |
| Chang, SM | 1 |
| Granger, CB | 3 |
| Johansson, PA | 1 |
| Kosolcharoen, P | 1 |
| McMurray, JJ | 1 |
| Michelson, EL | 1 |
| Murray, DR | 1 |
| Olofsson, B | 1 |
| Solomon, SD | 3 |
| Swedberg, K | 1 |
| Dunlap, ME | 1 |
| Vannucchi, AM | 1 |
| Ammori, B | 1 |
| Gasparyan, AY | 3 |
| Melnyk, BM | 1 |
| Brotons Cuixart, C | 2 |
| Moral Peláez, I | 1 |
| Ueno, M | 1 |
| Bainey, KR | 1 |
| Mourad, JJ | 1 |
| Kotani, K | 1 |
| Caccavello, R | 1 |
| Hermo, R | 1 |
| Yamada, T | 1 |
| Taniguchi, N | 1 |
| Gugliucci, A | 1 |
| Parsons, J | 1 |
| Alberts, MJ | 3 |
| Inzucchi, SE | 3 |
| Williams, CD | 4 |
| Wilson, PW | 4 |
| Kirkman, MS | 3 |
| Minar, E | 1 |
| Yung, R | 1 |
| Lee, HY | 2 |
| Tong, YP | 1 |
| Xing, S | 1 |
| Cooke, CE | 1 |
| Norgren, L | 1 |
| Bergqvist, D | 1 |
| Pärsson, H | 1 |
| Allan, GM | 1 |
| Ivers, N | 1 |
| McCormack, J | 1 |
| Annemans, L | 5 |
| Wittrup-Jensen, K | 1 |
| Tornero, C | 1 |
| Ventura, A | 1 |
| Mafe, M | 1 |
| Gharravi, M | 1 |
| Aslani, A | 1 |
| Rastegarpanah, M | 2 |
| Semnani, S | 1 |
| Salahi, R | 1 |
| Larijani, B | 1 |
| Peace, A | 1 |
| McCall, M | 1 |
| Tedesco, T | 1 |
| Kenny, D | 1 |
| Conroy, RM | 2 |
| Foley, D | 1 |
| Tang, HQ | 1 |
| Yang, LL | 1 |
| Hu, SL | 1 |
| Shen, G | 1 |
| Sun, YH | 1 |
| Huang, XH | 1 |
| Li, JH | 1 |
| Xu, TJ | 1 |
| Morgan, GP | 2 |
| Pratt, S | 2 |
| Thompson, VJ | 1 |
| Elkin, EP | 1 |
| Næsdal, J | 2 |
| Sörstadius, E | 2 |
| Martin-Carrillo, P | 1 |
| Añino, A | 1 |
| Pinar, O | 1 |
| Fernandez, I | 1 |
| Saenz, A | 1 |
| Ausejo, M | 1 |
| Hezard, N | 1 |
| Tessier-Marteau, A | 1 |
| Macchi, L | 1 |
| Lindau, ST | 1 |
| Conti, RM | 1 |
| Schumm, LP | 1 |
| Alexander, GC | 1 |
| Goodyear-Smith, F | 1 |
| Sharpe, N | 1 |
| Hudson, B | 1 |
| Mangin, D | 1 |
| Hong, JB | 1 |
| Hoem, JB | 1 |
| Kerse, N | 1 |
| Scahill, S | 1 |
| Moyes, S | 1 |
| Peri, K | 1 |
| Hughes, C | 2 |
| Cesari, F | 1 |
| Marcucci, R | 2 |
| Gori, AM | 2 |
| Caporale, R | 1 |
| Fanelli, A | 1 |
| Paniccia, R | 2 |
| Zanazzi, M | 1 |
| Bertoni, E | 1 |
| Larti, A | 1 |
| Salvadori, M | 1 |
| Gensini, GF | 3 |
| Abbate, R | 2 |
| Gray, B | 1 |
| Müller, K | 1 |
| Aichele, S | 1 |
| Herkommer, M | 1 |
| Bigalke, B | 1 |
| Stellos, K | 1 |
| Htun, P | 2 |
| Fateh-Moghadam, S | 2 |
| May, AE | 1 |
| Flather, M | 1 |
| Manson, SC | 1 |
| Benedict, A | 1 |
| Pan, F | 1 |
| Wittrup-Jensen, KU | 1 |
| Dineen, PF | 1 |
| Curtin, RJ | 3 |
| Harty, JA | 1 |
| Jolly, SS | 1 |
| Joyner, CD | 2 |
| Faxon, DP | 1 |
| Rupprecht, HJ | 2 |
| Bassand, JP | 2 |
| Macaya, C | 1 |
| Di Pasquale, G | 1 |
| Niemela, K | 1 |
| Ajani, AE | 1 |
| White, HD | 2 |
| Chrolavicius, S | 3 |
| Jolly, S | 1 |
| Jardine, MJ | 1 |
| Ninomiya, T | 1 |
| Perkovic, V | 1 |
| Turnbull, F | 1 |
| Gallagher, MP | 1 |
| Lambers Heerspink, HJ | 1 |
| Wali, RK | 1 |
| Niiazova-Karben, ZA | 1 |
| Besnili, F | 1 |
| Braun, S | 1 |
| Morath, T | 1 |
| Jaitner, J | 1 |
| Stegherr, J | 1 |
| Mehilli, J | 1 |
| von Beckerath, N | 1 |
| Schömig, A | 2 |
| Al-Azzam, SI | 2 |
| AlMahasneh, F | 1 |
| Mhaidat, N | 1 |
| Alzoubi, KH | 2 |
| Khader, YS | 1 |
| Desai, HV | 1 |
| Aronow, WS | 3 |
| Gandhi, K | 1 |
| Bakerywala, S | 1 |
| Laimuanpuii, J | 1 |
| Peterson, SJ | 1 |
| Castelli, C | 1 |
| Nolli, S | 1 |
| Fabbro-Peray, P | 1 |
| Mach, F | 1 |
| Contant, CF | 1 |
| Schnitzer, TJ | 1 |
| Shook, TL | 1 |
| Lapuerta, P | 1 |
| Goldsmith, MA | 1 |
| Scirica, BM | 2 |
| Song, Y | 3 |
| Klevak, A | 1 |
| Bender, R | 1 |
| Koch, A | 1 |
| Skipka, G | 1 |
| Lange, S | 1 |
| Sheridan, SL | 1 |
| Edwards, T | 1 |
| Soliman, EZ | 2 |
| Harris, R | 3 |
| Furberg, CD | 5 |
| Rhee, SY | 1 |
| Kim, YS | 1 |
| Chon, S | 1 |
| Oh, S | 1 |
| Woo, JT | 1 |
| Kim, SW | 1 |
| Kim, JW | 1 |
| Pokov, A | 1 |
| Hetzel, S | 1 |
| Schröder, H | 1 |
| Tentzeris, I | 1 |
| Jarai, R | 1 |
| Brozovic, I | 1 |
| Smetana, P | 1 |
| Siller-Matula, J | 1 |
| Oliveira, DC | 1 |
| Silva, RF | 1 |
| Silva, DJ | 1 |
| Lima, VC | 1 |
| Warner, TD | 1 |
| Armstrong, PC | 1 |
| Curzen, NP | 1 |
| Mitchell, JA | 1 |
| Wilson, M | 1 |
| Elwin, CE | 1 |
| Norrving, B | 1 |
| Algra, A | 2 |
| Warlow, CP | 1 |
| Meade, TW | 4 |
| Sanchez-Ross, M | 1 |
| Waller, AH | 1 |
| Maher, J | 1 |
| Klapholz, M | 1 |
| Haider, B | 1 |
| Undas, A | 5 |
| Siudak, Z | 1 |
| Topór-Mądry, R | 1 |
| Leśniak, M | 1 |
| Tracz, W | 2 |
| Musallam, KM | 1 |
| Charafeddine, K | 1 |
| Bitar, A | 1 |
| Khoury, M | 1 |
| Assaad, S | 1 |
| Beresian, J | 1 |
| Alam, S | 1 |
| Taher, AT | 1 |
| Abraham, NS | 2 |
| Hlatky, MA | 2 |
| Clark, CB | 2 |
| Johnson, DA | 3 |
| Kahi, CJ | 2 |
| Mahaffey, KW | 2 |
| Quigley, EM | 2 |
| Tomaselli, GF | 2 |
| Spite, M | 1 |
| Serhan, CN | 1 |
| Gilpin, VL | 1 |
| Pakhomov, SV | 1 |
| Shah, ND | 3 |
| Hanson, P | 1 |
| Balasubramaniam, SC | 1 |
| Mazinani, B | 1 |
| Plange, N | 1 |
| Walter, P | 1 |
| Galloway, CF | 1 |
| Stevenson, JC | 1 |
| Garg, MK | 1 |
| Komarov, AL | 1 |
| Huy, C | 1 |
| Litaker, D | 1 |
| Wald, DS | 2 |
| Wald, NJ | 2 |
| Hughes, GR | 1 |
| Ahmad, T | 1 |
| Paré, G | 1 |
| Lee, IM | 3 |
| Yiannakopoulou, EC | 1 |
| Stavrakis, S | 1 |
| Stoner, JA | 1 |
| Azar, M | 1 |
| Wayangankar, S | 1 |
| Thadani, U | 1 |
| Mendis, S | 1 |
| Dissanayake, WP | 1 |
| Somasundaram, NP | 1 |
| Gunaratne, PS | 1 |
| Jayasingne, IK | 1 |
| Bramlage, C | 1 |
| Cuneo, A | 1 |
| Härtel, D | 1 |
| Jung, K | 1 |
| Witteck, CH | 1 |
| Högel, R | 1 |
| Müller, GA | 1 |
| Tebbe, U | 1 |
| Bal dit Sollier, C | 1 |
| Keller, T | 1 |
| Romualdi, E | 1 |
| Balmor, GR | 1 |
| Shoenfeld, Y | 1 |
| Vassiliou, V | 1 |
| Palumbo, A | 1 |
| Cavo, M | 1 |
| Bringhen, S | 1 |
| Zamagni, E | 1 |
| Patriarca, F | 1 |
| Rossi, D | 1 |
| Gentilini, F | 1 |
| Crippa, C | 1 |
| Nozzoli, C | 1 |
| Ria, R | 1 |
| Marasca, R | 1 |
| Montefusco, V | 1 |
| Baldini, L | 1 |
| Elice, F | 1 |
| Callea, V | 1 |
| Pulini, S | 1 |
| Carella, AM | 1 |
| Zambello, R | 1 |
| Benevolo, G | 1 |
| Magarotto, V | 1 |
| Tacchetti, P | 1 |
| Pescosta, N | 1 |
| Cellini, C | 1 |
| Polloni, C | 1 |
| Evangelista, A | 1 |
| Caravita, T | 1 |
| Morabito, F | 1 |
| Offidani, M | 1 |
| Tosi, P | 1 |
| Boccadoro, M | 1 |
| Mezzasoma, AM | 1 |
| Del Pinto, M | 1 |
| Palmerini, F | 1 |
| Windgassen, EB | 1 |
| Funtowicz, L | 1 |
| Lunsford, TN | 1 |
| Harris, LA | 1 |
| Mulvagh, SL | 1 |
| Fitzgerald, R | 1 |
| Pirmohamed, M | 1 |
| Shanker, J | 1 |
| Kitas, GD | 1 |
| Kakkar, VV | 1 |
| Sweeny, JM | 1 |
| Park, KW | 1 |
| Park, JJ | 1 |
| Lee, SP | 1 |
| Oh, IY | 1 |
| Suh, JW | 1 |
| Yang, HM | 1 |
| Kang, HJ | 1 |
| Cho, YS | 1 |
| Koo, BK | 2 |
| Youn, TJ | 1 |
| Chae, IH | 1 |
| Choi, DJ | 1 |
| Oh, BH | 1 |
| Park, YB | 1 |
| Zhang, YH | 1 |
| Peng, SX | 1 |
| Fried, TR | 1 |
| Tinetti, ME | 1 |
| Towle, V | 1 |
| O'Leary, JR | 1 |
| Iannone, L | 1 |
| Maeda, M | 1 |
| Sasai, T | 1 |
| Kanke, K | 1 |
| Shimada, T | 1 |
| Weber, M | 1 |
| Easton, DJ | 1 |
| Hamm, CW | 2 |
| Chan, YH | 1 |
| Schooling, CM | 1 |
| Filippi, A | 1 |
| Bianchi, C | 1 |
| Sessa, E | 1 |
| Mazzaglia, G | 1 |
| Lim, MY | 1 |
| Pruthi, RK | 1 |
| Butalia, S | 1 |
| Leung, AA | 1 |
| Ghali, WA | 1 |
| Rabi, DM | 1 |
| Di Minno, MN | 1 |
| Tufano, A | 1 |
| Ageno, W | 1 |
| Prandoni, P | 1 |
| Di Minno, G | 1 |
| Bartolucci, AA | 2 |
| Tendera, M | 1 |
| Vijan, S | 2 |
| Choi, H | 2 |
| Hayward, RA | 2 |
| Hirata, Y | 1 |
| Kataoka, H | 1 |
| Shimura, T | 1 |
| Mizushima, T | 1 |
| Mizoshita, T | 1 |
| Tanida, S | 1 |
| Kamiya, T | 1 |
| Joh, T | 1 |
| Bae, SE | 1 |
| Kim, SE | 1 |
| Shim, KN | 1 |
| Jung, HK | 1 |
| Kim, TH | 1 |
| Yoo, K | 1 |
| Moon, IH | 1 |
| Standl, E | 2 |
| Ardissino, D | 2 |
| Mantovani, F | 1 |
| Demola, MA | 1 |
| Charlot, M | 1 |
| Hansen, PR | 1 |
| Olesen, JB | 1 |
| Ahlehoff, O | 1 |
| Selmer, C | 1 |
| Lindhardsen, J | 1 |
| Madsen, JK | 1 |
| Køber, L | 1 |
| Morris, JK | 1 |
| Law, MR | 1 |
| Kent, DM | 1 |
| Adelman, EE | 1 |
| Lisabeth, L | 1 |
| Lischke, S | 1 |
| Mereu, L | 1 |
| Chambers, T | 1 |
| Miser, WF | 2 |
| Bailey, AL | 1 |
| Yates, RA | 1 |
| Pande, RL | 1 |
| Perlstein, TS | 1 |
| Folks, B | 1 |
| Leblanc, WG | 1 |
| Staton, EW | 1 |
| Pace, WD | 1 |
| Shrestha, K | 1 |
| Hughes, JD | 1 |
| Lee, YP | 1 |
| Parsons, R | 1 |
| Sanchez, JC | 1 |
| Burkard, T | 1 |
| Kaiser, CA | 1 |
| Brunner-La Rocca, H | 1 |
| Osswald, S | 1 |
| Pfisterer, ME | 1 |
| Lala, A | 1 |
| Baker, GS | 1 |
| Moberg, C | 1 |
| Svedberg, LE | 2 |
| Duchateau, D | 1 |
| Harte, N | 1 |
| Landoni, G | 1 |
| Albaladejo, P | 1 |
| Marret, E | 1 |
| Samama, CM | 1 |
| Abhay, K | 1 |
| Loutrel, O | 1 |
| Charbonneau, H | 1 |
| Jaber, S | 1 |
| Thoret, S | 1 |
| Bosson, JL | 1 |
| Piriou, V | 1 |
| Bollati, M | 1 |
| Giraudi, E | 1 |
| Moretti, C | 1 |
| Millesimo, G | 1 |
| Sciuto, F | 1 |
| Omedè, P | 1 |
| Biondi Zoccai, G | 1 |
| Sheiban, I | 1 |
| Rose, PW | 1 |
| Watson, EK | 1 |
| Jenkins, LS | 1 |
| Verschuren, JJ | 1 |
| Trompet, S | 1 |
| Wessels, JA | 1 |
| Guchelaar, HJ | 1 |
| de Maat, MP | 1 |
| Simoons, ML | 1 |
| Jukema, JW | 2 |
| Mullins, CD | 1 |
| Lomakin, NV | 1 |
| Gruzdev, AK | 1 |
| Hollingsworth, B | 1 |
| Jackson, AN | 1 |
| Hume, AL | 2 |
| Chakravarthy, U | 1 |
| Rahu, M | 1 |
| Seland, J | 1 |
| Soubrane, G | 1 |
| Topouzis, F | 1 |
| Vingerling, JR | 1 |
| Vioque, J | 1 |
| Young, I | 1 |
| Fürstenwerth, H | 1 |
| Abdul Hadi, M | 1 |
| Ming, LC | 1 |
| Awaisu, A | 1 |
| Guggilla, RK | 1 |
| Patil, V | 1 |
| Negri, E | 1 |
| Gaeta, M | 1 |
| Pavesi, M | 1 |
| Antonoff, MB | 1 |
| D'Cunha, J | 1 |
| Taylor, K | 1 |
| Filgate, R | 1 |
| Guo, DY | 1 |
| Macneil, F | 1 |
| Gohlke, H | 2 |
| Paynter, NP | 1 |
| Wassink, AM | 1 |
| Sanz, G | 1 |
| Guzmán, L | 1 |
| Guglietta, A | 1 |
| Arnáiz, JA | 1 |
| Martínez, F | 2 |
| Sarria, A | 1 |
| Taubert, K | 1 |
| Pirker, S | 1 |
| Baumgartner, C | 1 |
| Seshasai, SR | 1 |
| Wijesuriya, S | 1 |
| Sivakumaran, R | 1 |
| Nethercott, S | 1 |
| Erqou, S | 1 |
| Sattar, N | 1 |
| Ray, KK | 1 |
| Mayor, S | 1 |
| Lemkes, BA | 1 |
| Bähler, L | 1 |
| Kamphuisen, PW | 1 |
| Stroobants, AK | 1 |
| Van Den Dool, EJ | 1 |
| Hoekstra, JB | 1 |
| Nieuwland, R | 1 |
| Gerdes, VE | 1 |
| Holleman, F | 1 |
| Cho, SJ | 1 |
| Choi, IJ | 1 |
| Kim, CG | 1 |
| Lee, JY | 1 |
| Nam, BH | 1 |
| Kwak, MH | 1 |
| Kim, HJ | 1 |
| Ryu, KW | 1 |
| Kim, YW | 1 |
| Frieden, TR | 1 |
| Blakeman, DE | 1 |
| Jauch, EC | 1 |
| Mohl, S | 1 |
| Rivera, CM | 1 |
| Song, J | 1 |
| Copeland, L | 1 |
| Buirge, C | 1 |
| Ory, M | 1 |
| McNeal, CJ | 1 |
| Martsevich, SIu | 1 |
| Tolpygina, SN | 1 |
| Lukina, IuV | 1 |
| Voronina, VP | 1 |
| Kiseleva, NV | 1 |
| Boĭchenko, ES | 1 |
| Dubinskaia, RÉ | 1 |
| Khoseva, EN | 1 |
| Pentecost, MJ | 1 |
| Delle-Karth, G | 1 |
| Christ, G | 1 |
| Neunteufl, T | 1 |
| Maurer, G | 1 |
| Tolios, A | 1 |
| Drucker, C | 1 |
| Hartanto, MD | 1 |
| Arieselia, Z | 1 |
| Setiabudy, R | 1 |
| Setiawati, A | 1 |
| Baziad, A | 1 |
| Smith, JP | 1 |
| Haddad, EV | 1 |
| Taylor, MB | 1 |
| Oram, D | 1 |
| Blakemore, D | 1 |
| Chen, Q | 2 |
| Boutaud, O | 1 |
| Oates, JA | 1 |
| Avivi, D | 1 |
| Moshkowitz, M | 1 |
| Detering, E | 1 |
| Arber, N | 2 |
| Cao, L | 1 |
| Silvestry, S | 1 |
| Zhao, N | 1 |
| Diehl, J | 1 |
| Zhou, YH | 1 |
| Wei, X | 1 |
| Ye, XF | 1 |
| Wu, MJ | 1 |
| Xu, JF | 1 |
| Qin, YY | 1 |
| He, J | 1 |
| Strully, KW | 1 |
| Fowler, JH | 1 |
| Murabito, JM | 1 |
| Benjamin, EJ | 1 |
| Levy, D | 1 |
| Christakis, NA | 1 |
| Sadilkova, L | 1 |
| Paluch, Z | 4 |
| Mottlova, J | 1 |
| Bednar, F | 2 |
| Alusik, S | 3 |
| Burness, CB | 1 |
| Struijk, M | 1 |
| Postma, DF | 1 |
| van Tuyl, SA | 1 |
| van de Ree, MA | 1 |
| Binhas, M | 1 |
| Salomon, L | 1 |
| Roudot-Thoraval, F | 1 |
| Armand, C | 1 |
| Plaud, B | 1 |
| Marty, J | 1 |
| Paikin, JS | 1 |
| Westgate, PM | 1 |
| Braun, TM | 1 |
| Cao, J | 3 |
| Fan, L | 3 |
| Chen, T | 1 |
| Hu, G | 2 |
| Hu, Y | 2 |
| Zhu, B | 2 |
| Fukuda, S | 1 |
| Hosaka, S | 1 |
| Ozawa, N | 1 |
| Akita, S | 1 |
| Kashima, T | 1 |
| Kimura, S | 1 |
| Akiyama, J | 1 |
| Mizoue, T | 1 |
| Demos, L | 1 |
| Workman, B | 1 |
| Gerstein, WH | 1 |
| Petersen, TR | 1 |
| Tawil, I | 1 |
| Macchia, A | 1 |
| Laffaye, N | 1 |
| Comignani, PD | 1 |
| Cornejo Pucci, E | 1 |
| Igarzabal, C | 1 |
| Scazziota, AS | 1 |
| Herrera, L | 1 |
| Mariani, JA | 1 |
| Bragagnolo, JC | 1 |
| Catalano, H | 1 |
| Tognoni, G | 9 |
| Chopra, V | 1 |
| Almeida, B | 1 |
| Gleeson, P | 1 |
| Chawla, K | 1 |
| Brogan, P | 1 |
| Liu, CP | 1 |
| Mar, GY | 1 |
| Lin, SY | 1 |
| Ger, LP | 1 |
| Schnell, O | 2 |
| Erbach, M | 1 |
| Hummel, M | 1 |
| Sanuki, T | 1 |
| Fujita, T | 1 |
| Kutsumi, H | 1 |
| Hayakumo, T | 1 |
| Yoshida, S | 1 |
| Inokuchi, H | 1 |
| Murakami, M | 1 |
| Matsubara, Y | 1 |
| Kuwayama, H | 1 |
| Miyaji, H | 1 |
| Fujisawa, T | 1 |
| Terao, S | 1 |
| Yamazaki, Y | 1 |
| Azuma, T | 1 |
| Bayrak, F | 1 |
| Sarkozy, A | 1 |
| Chierchia, GB | 1 |
| de Asmundis, C | 1 |
| Gargallo, C | 1 |
| Lanas Arbeloa, A | 1 |
| Thiagarajan, P | 1 |
| Jankowski, JA | 1 |
| Pogatzki-Zahn, EM | 1 |
| Schnabel, A | 1 |
| Zahn, PK | 1 |
| Monaco, M | 1 |
| Di Tommaso, L | 1 |
| Pinna, GB | 1 |
| Lillo, S | 1 |
| Schiavone, V | 1 |
| Stassano, P | 1 |
| Slawsky, K | 1 |
| Fusfeld, L | 1 |
| Goss, TF | 1 |
| Carey, KM | 1 |
| Comee, MR | 1 |
| Donovan, JL | 1 |
| Kanaan, AO | 1 |
| Wick, JY | 1 |
| Drepper, MD | 1 |
| Spahr, L | 1 |
| Frossard, JL | 1 |
| LeBlanc, A | 1 |
| Ruud, KL | 1 |
| Branda, ME | 1 |
| Tiedje, K | 1 |
| Boehmer, KR | 1 |
| Pencille, LJ | 1 |
| Van Houten, H | 1 |
| Matthews, M | 1 |
| May, CR | 1 |
| Yawn, BP | 1 |
| Vianna, CA | 1 |
| González, DA | 1 |
| Matijasevich, A | 1 |
| Tagliabue, L | 1 |
| Dipaola, F | 1 |
| Perego, F | 1 |
| Podda, GM | 1 |
| Tong, X | 1 |
| Sonnenfeld, N | 1 |
| Hong, Y | 2 |
| Cole, SR | 2 |
| De Berardis, G | 2 |
| Lucisano, G | 1 |
| D'Ettorre, A | 1 |
| Pellegrini, F | 2 |
| Lepore, V | 1 |
| Longley, M | 1 |
| Sakurai, R | 1 |
| Kaneda, H | 1 |
| Bonneau, HN | 1 |
| Nagai, R | 1 |
| Naderi, SH | 1 |
| Bestwick, JP | 1 |
| Raz, I | 1 |
| Davidson, J | 1 |
| Hirshberg, B | 1 |
| Spangler, J | 1 |
| Teo, KK | 1 |
| Hawkes, N | 1 |
| Bikdeli, B | 1 |
| Barreto-Filho, JA | 1 |
| Drozda, JP | 1 |
| Holmes, DP | 1 |
| Wright, JS | 2 |
| Briss, PA | 1 |
| Schooley, M | 1 |
| Hamza, S | 1 |
| Le Ray, I | 1 |
| Goirand, F | 1 |
| Cattano, D | 1 |
| Altamirano, AV | 1 |
| Kaynak, HE | 1 |
| Seitan, C | 1 |
| Chen, Z | 1 |
| Huang, H | 1 |
| Prisco, D | 1 |
| Hagberg, CA | 1 |
| Pivalizza, EG | 1 |
| Farooq, MU | 1 |
| Kourlaba, G | 1 |
| Fragoulakis, V | 1 |
| Maniadakis, N | 1 |
| Ye, L | 1 |
| Cui, CP | 1 |
| Zhou, FC | 1 |
| Sallum, RH | 1 |
| Katona, B | 1 |
| Maya, J | 1 |
| Ranganathan, G | 1 |
| Xu, Y | 1 |
| Mwamburi, M | 1 |
| Yamane, K | 1 |
| Ikeda, T | 1 |
| Taniguchi, R | 1 |
| Watanabe, S | 1 |
| Kawato, M | 1 |
| Kondo, H | 1 |
| Shirakawa, R | 1 |
| Higashi, T | 1 |
| Toma, M | 1 |
| Tabuchi, A | 1 |
| Tamura, T | 1 |
| Takahashi, K | 1 |
| Yoshikawa, Y | 1 |
| Kita, T | 1 |
| Horiuchi, H | 1 |
| Gasparovic, H | 1 |
| Petricevic, M | 1 |
| Kopjar, T | 1 |
| Djuric, Z | 1 |
| Svetina, L | 1 |
| Biocina, B | 1 |
| Clemmensen, P | 1 |
| Boden, WE | 3 |
| Ruzyllo, W | 1 |
| Dalby, AJ | 1 |
| Leiva-Pons, JL | 1 |
| Parkhomenko, A | 1 |
| Gottlieb, S | 2 |
| Topacio, GO | 1 |
| Pavlides, G | 1 |
| Goudev, AR | 1 |
| Oto, A | 1 |
| Tseng, CD | 1 |
| Gasparovic, V | 1 |
| Corbalan, R | 1 |
| Cinteză, M | 1 |
| McLendon, RC | 1 |
| Winters, KJ | 1 |
| Brown, EB | 1 |
| Aylward, PE | 1 |
| Ohman, EM | 1 |
| Divisón, JA | 1 |
| Galgo, A | 1 |
| Polo, J | 1 |
| Durá, R | 1 |
| Derogar, M | 1 |
| Sandblom, G | 1 |
| Lundell, L | 1 |
| Orsini, N | 1 |
| Bottai, M | 1 |
| Sadr-Azodi, O | 1 |
| Lobos Bejarano, JM | 1 |
| Martín Rioboó, E | 1 |
| Galán, AM | 1 |
| McMullan, KL | 1 |
| Wedner, HJ | 1 |
| Khabour, O | 1 |
| Alowidi, A | 1 |
| Tawalbeh, D | 1 |
| Greenlee, RT | 1 |
| McBride, PE | 1 |
| Peppard, PE | 1 |
| Malecki, KC | 1 |
| Che, J | 1 |
| Nieto, FJ | 1 |
| Nemerovski, CW | 1 |
| Salinitri, FD | 1 |
| Morbitzer, KA | 1 |
| Moser, LR | 1 |
| Hermann, M | 1 |
| Franco, OH | 2 |
| Kaplon-Cieslicka, A | 1 |
| Trzepla, E | 1 |
| Czlonkowski, A | 1 |
| Wagenaar, P | 1 |
| Tan, HJ | 1 |
| Mahadeva, S | 1 |
| Menon, J | 1 |
| Ng, WK | 1 |
| Zainal Abidin, I | 1 |
| Goh, KL | 1 |
| Cacciapuoti, F | 1 |
| Abourjaili, G | 1 |
| Said, R | 1 |
| Khoueiry, G | 1 |
| Waked, A | 1 |
| Nagrani, T | 1 |
| Lakhani, M | 1 |
| Aboujaoude, D | 1 |
| Damaa, G | 1 |
| Lafferty, J | 1 |
| Valentine, N | 1 |
| Van de Laar, FA | 1 |
| van Driel, ML | 1 |
| Tomaszuk-Kazberuk, A | 1 |
| Kozuch, M | 1 |
| Malyszko, J | 1 |
| Bachorzewska-Gajewska, H | 1 |
| Dobrzycki, S | 1 |
| Musial, WJ | 1 |
| Ozturk, S | 1 |
| Karadag, S | 1 |
| Yegen, M | 1 |
| Gursu, M | 1 |
| Uzun, S | 1 |
| Aydin, Z | 1 |
| Gurdal, A | 1 |
| Koldas, M | 1 |
| Kumbasar, B | 1 |
| Kazancioglu, R | 1 |
| Veldhuyzen van Zanten, SJ | 1 |
| Nauclér, EC | 1 |
| Yi, X | 1 |
| Zhou, Q | 1 |
| Chi, L | 1 |
| Einecke, D | 1 |
| Saxena, A | 1 |
| Chiang, CE | 1 |
| Wang, KL | 1 |
| Willder, JM | 1 |
| Walker, VC | 1 |
| Halbert, GL | 1 |
| Dick, CP | 1 |
| Orange, C | 1 |
| Qayyum, T | 1 |
| Horgan, PG | 1 |
| Underwood, MA | 1 |
| Edwards, J | 1 |
| Ding, XL | 1 |
| Xie, C | 2 |
| Jiang, B | 1 |
| Gao, J | 1 |
| Zhang, LL | 1 |
| Zhang, JJ | 1 |
| Miao, LY | 1 |
| McCarty, MF | 1 |
| Roubille, C | 1 |
| Martel-Pelletier, J | 1 |
| Davy, JM | 1 |
| Haraoui, B | 1 |
| Pelletier, JP | 1 |
| Bautista, LE | 1 |
| Vera-Cala, LM | 1 |
| Ferrante, D | 1 |
| Herrera, VM | 1 |
| Miranda, JJ | 1 |
| Pichardo, R | 1 |
| Sánchez Abanto, JR | 1 |
| Ferreccio, C | 1 |
| Silva, E | 1 |
| Oróstegui Arenas, M | 1 |
| Chirinos, JA | 1 |
| Medina-Lezama, J | 1 |
| Pérez, CM | 1 |
| Schapochnik, N | 1 |
| Casas, JP | 1 |
| Bytzer, P | 1 |
| Elkin, E | 1 |
| Parekh, AK | 1 |
| Galloway, JM | 1 |
| Liew, G | 1 |
| Rochtchina, E | 1 |
| Kolber, M | 1 |
| Sharif, N | 1 |
| Marceau, R | 1 |
| Szafran, O | 1 |
| Neogi, T | 1 |
| Chaisson, C | 1 |
| Hunter, DJ | 1 |
| Feng, CH | 1 |
| White, AA | 1 |
| Stevenson, DD | 1 |
| Adly, G | 1 |
| Plakogiannis, R | 1 |
| Sleeper, RB | 1 |
| Rojas-Fernandez, C | 1 |
| Gajewski, P | 1 |
| Brozek, J | 1 |
| Lychakov, AV | 1 |
| Shevchuk, MK | 1 |
| Savateeva, TN | 1 |
| Kolbasov, SE | 1 |
| Kovalenko, AL | 1 |
| McCullough, PA | 1 |
| Sandberg, KR | 1 |
| Borzak, S | 1 |
| Hudson, MP | 1 |
| Garg, M | 1 |
| Manley, HJ | 1 |
| Boltri, JM | 1 |
| Akerson, MR | 1 |
| Vogel, RL | 1 |
| Lorell, BH | 1 |
| Nissen, S | 1 |
| Borer, J | 1 |
| Murphy, M | 3 |
| Foster, C | 2 |
| Sudlow, C | 2 |
| Nicholas, J | 2 |
| Mulrow, C | 2 |
| Ness, A | 2 |
| McLaughlin, GE | 1 |
| Aroney, CN | 1 |
| Graham, DY | 2 |
| Serrano, P | 1 |
| Arroyo, MT | 1 |
| Ferreira, IJ | 1 |
| Vainio, H | 2 |
| McKee, SA | 1 |
| Sane, DC | 1 |
| Deliargyris, EN | 1 |
| Szczeklik, A | 4 |
| Musiał, J | 3 |
| Nowak, SN | 1 |
| Jaber, LA | 1 |
| VanDenburgh, M | 1 |
| Cryer, B | 5 |
| Faragon, JJ | 1 |
| Waite, NM | 1 |
| Hobson, EH | 1 |
| Seoldo, N | 1 |
| VanAmburgh, JA | 1 |
| Migden, H | 1 |
| Lawlor, DA | 3 |
| Bedford, C | 2 |
| Taylor, M | 2 |
| Riley, SJ | 1 |
| Stouffer, GA | 1 |
| Donahue, K | 1 |
| Rathore, SS | 1 |
| Frame, P | 1 |
| Woolf, SH | 1 |
| Lohr, KN | 1 |
| O'Keefe, JH | 1 |
| Lurk, JT | 1 |
| Kahatapitiya, RC | 1 |
| Haskin, JA | 1 |
| Gaede, P | 2 |
| Hansen, HP | 1 |
| Parving, HH | 2 |
| Pedersen, O | 2 |
| Joost, HG | 1 |
| MacDonald, TM | 3 |
| Panichi, V | 1 |
| Taccola, D | 1 |
| Migliori, M | 1 |
| Consani, C | 1 |
| Giovannini, L | 1 |
| Tetta, C | 1 |
| Pearson, WS | 1 |
| Loke, YK | 1 |
| Derry, S | 1 |
| Eichenberger, A | 1 |
| Pontiggia, L | 1 |
| Beer, JH | 1 |
| Meyer, BJ | 1 |
| Tsakiris, DA | 1 |
| Matías-Guiu, J | 2 |
| Ferro, JM | 1 |
| Alvarez-Sabín, J | 2 |
| Jiménez, MD | 1 |
| Lago, A | 1 |
| Melo, T | 1 |
| Gum, PA | 2 |
| Kottke-Marchant, K | 3 |
| Welsh, PA | 2 |
| White, J | 1 |
| Kase, CS | 1 |
| Berger, K | 2 |
| Schaeffner, ES | 2 |
| Bennett, KE | 1 |
| Williams, D | 2 |
| Feely, J | 1 |
| Berenbaum, F | 1 |
| López De La Iglesia, J | 1 |
| Escudero Alvarez, S | 1 |
| González García, AM | 1 |
| Mencía Mieres, A | 1 |
| García Andrés, LE | 1 |
| Morán Fernández, B | 1 |
| Levenson, D | 1 |
| Etminan, M | 1 |
| Samii, A | 1 |
| Smout, J | 2 |
| Cleanthis, M | 1 |
| Stansby, G | 2 |
| Jerie, P | 2 |
| Weiss, HJ | 2 |
| Curtis, JP | 1 |
| Krumholz, HM | 1 |
| Cross, PL | 1 |
| Hartness, S | 1 |
| Chiroli, V | 1 |
| Benedini, F | 1 |
| Ongini, E | 1 |
| Del Soldato, P | 1 |
| Ali Raza, J | 1 |
| Movahed, A | 1 |
| Sellmayer, A | 1 |
| Limmert, T | 1 |
| Hoffmann, U | 1 |
| Tracy, RP | 1 |
| McKeogh, DF | 1 |
| Reikvam, A | 1 |
| Madsen, S | 1 |
| Landmark, K | 2 |
| Nesto, RW | 1 |
| Adler, AI | 1 |
| Schaumberg, DA | 4 |
| Sullivan, DA | 1 |
| Dana, MR | 1 |
| Armstrong, TA | 1 |
| Walker, AM | 1 |
| Rexrode, KM | 1 |
| Stampfer, MJ | 4 |
| Chiolero, A | 1 |
| Maillard, MP | 1 |
| Burnier, M | 1 |
| Schafer, AI | 1 |
| McCall, AL | 1 |
| BUFF, IE | 1 |
| Gere, J | 1 |
| Minier, D | 1 |
| Osseby, GV | 1 |
| Couvreur, G | 1 |
| Moreau, T | 1 |
| Giroud, M | 1 |
| Eidelman, RS | 1 |
| Abraha, I | 1 |
| Montedori, A | 1 |
| Stracci, F | 1 |
| Rossi, M | 1 |
| Romagnoli, C | 1 |
| Fiotti, N | 1 |
| Altamura, N | 1 |
| Cappelli, C | 1 |
| Schillan, M | 1 |
| Guarnieri, G | 1 |
| Giansante, C | 1 |
| Bryant, SC | 1 |
| O'Connor, AM | 1 |
| Jorgensen, NW | 1 |
| Walsh, EE | 1 |
| Varanasi, JS | 1 |
| Goldberg, L | 1 |
| Varinasi, JS | 1 |
| Lisse, JR | 1 |
| Perlman, M | 1 |
| Johansson, G | 1 |
| Shoemaker, JR | 1 |
| Schechtman, J | 1 |
| Skalky, CS | 1 |
| Dixon, ME | 1 |
| Polis, AB | 1 |
| Mollen, AJ | 1 |
| Geba, GP | 1 |
| Lee, HL | 1 |
| Han, DS | 1 |
| Sohn, JH | 1 |
| Hahm, JS | 1 |
| Ahn, YH | 1 |
| Mahé, I | 1 |
| Leizorovicz, A | 1 |
| Caulin, C | 1 |
| Bergmann, JF | 1 |
| Donnan, G | 1 |
| Johnston, C | 1 |
| Di Napoli, M | 2 |
| Papa, F | 2 |
| Scheen, AJ | 5 |
| Lefèbvre, PJ | 1 |
| Kulbertus, H | 3 |
| Spivak, JL | 1 |
| Barosi, G | 1 |
| Barbui, T | 2 |
| Finazzi, G | 1 |
| Marchetti, M | 1 |
| Sacco, M | 1 |
| Avanzini, F | 3 |
| Pluhar, WM | 1 |
| Rabelink, TJ | 1 |
| Gerotziafas, G | 1 |
| Robert, F | 1 |
| Lecrubier, C | 1 |
| Hatmi, M | 1 |
| Williams, A | 1 |
| Reilly, V | 1 |
| Cavanagh, M | 1 |
| Landolfi, R | 1 |
| Kutti, J | 1 |
| Gisslinger, H | 1 |
| Weston, C | 1 |
| Rao, U | 1 |
| Passamonti, M | 1 |
| Pigni, M | 1 |
| Testolin, E | 1 |
| Sacks, FM | 1 |
| Byington, RP | 1 |
| Pitt, B | 1 |
| Berry, DA | 1 |
| Berry, SM | 1 |
| Ford, NF | 1 |
| Walker, AJ | 1 |
| Natarajan, K | 1 |
| Sheng-Lin, C | 1 |
| Fiedorek, FT | 1 |
| Belder, R | 1 |
| Janssen, JH | 1 |
| Henshaw, D | 1 |
| Joshipura, KJ | 1 |
| Wand, HC | 1 |
| Merchant, AT | 1 |
| Rimm, EB | 1 |
| Esmatjes, E | 1 |
| Castell, C | 1 |
| Franch, J | 1 |
| Puigoriol, E | 1 |
| Hernáez, R | 1 |
| Mohler, P | 1 |
| Cotter, G | 1 |
| Shemesh, E | 1 |
| Zehavi, M | 1 |
| Dinur, I | 1 |
| Rudnick, A | 1 |
| Milo, O | 1 |
| Vered, Z | 1 |
| Krakover, R | 1 |
| Kornberg, A | 1 |
| Werner, M | 1 |
| Weismantel, AM | 1 |
| Aitken, PV | 1 |
| Schröder, S | 1 |
| Cradick, NH | 1 |
| Ruef, J | 1 |
| Banerjee, S | 1 |
| Denniston, AK | 1 |
| Gibson, JM | 1 |
| Dodson, PM | 1 |
| Williams, B | 2 |
| Brown, MJ | 1 |
| Davis, M | 1 |
| McInnes, GT | 1 |
| Potter, JF | 2 |
| Sever, PS | 1 |
| Thom, SM | 1 |
| Behan, MW | 1 |
| Chaussade, S | 2 |
| Rollet, J | 1 |
| Tonstad, S | 1 |
| Rosvold, EO | 1 |
| Furu, K | 1 |
| Skurtveit, S | 1 |
| Li, JJ | 1 |
| Fang, CH | 1 |
| Mudaliar, S | 1 |
| Betteridge, DJ | 1 |
| Belch, J | 1 |
| Brown, MM | 1 |
| Gent, M | 1 |
| Julian, D | 1 |
| Long, S | 1 |
| Morris, S | 1 |
| Pittard, J | 1 |
| Pye, M | 1 |
| Camerini, A | 1 |
| Chieffo, C | 1 |
| Griffo, R | 1 |
| Comaschi, M | 1 |
| Gattone, M | 1 |
| Mannucci, E | 1 |
| Faglia, E | 1 |
| Giorda, C | 1 |
| Biorci, ML | 1 |
| Fukumoto, K | 1 |
| Shibakawa, M | 1 |
| Denes, AE | 1 |
| Martin-Du Pan, RC | 1 |
| Klinke, JA | 1 |
| Johnson, JA | 1 |
| Guirguis, LM | 1 |
| Toth, EL | 1 |
| Lee, TK | 1 |
| Lewanczuk, RZ | 1 |
| Majumdar, SR | 1 |
| Rosner, B | 5 |
| Kong, DF | 1 |
| Blann, AD | 2 |
| Mueller, RL | 1 |
| McElduff, P | 1 |
| Lyratzopoulos, G | 1 |
| Edwards, R | 1 |
| Heller, RF | 1 |
| Shekelle, P | 1 |
| Roland, M | 1 |
| Gaspoz, JM | 1 |
| Claudi, T | 2 |
| Cooper, JG | 1 |
| Hausken, MF | 1 |
| Michaelsen, T | 1 |
| Harboe, K | 1 |
| Ingskog, W | 1 |
| ØStrem, A | 1 |
| Bredie, SJ | 1 |
| Wollersheim, H | 1 |
| Thien, T | 1 |
| Kim, C | 1 |
| Beckles, GL | 1 |
| Dressler, R | 1 |
| Tarnawski, AS | 1 |
| Caves, TC | 1 |
| Sicras Mainar, A | 1 |
| Ruiz Riera, R | 1 |
| Frías Garrido, X | 1 |
| Navarro Artieda, R | 1 |
| Barquero Romero, J | 1 |
| Masero Carretero, A | 1 |
| Pérez Miranda, M | 1 |
| González-Clemente, JM | 1 |
| Barahona, MJ | 1 |
| Giménez-Pérez, G | 1 |
| Mauricio, D | 1 |
| Diogène, E | 1 |
| Agustí, A | 1 |
| Roberts, SS | 1 |
| Stiefelhagen, P | 1 |
| Mason, PJ | 1 |
| Freedman, JE | 2 |
| Jacobs, AK | 2 |
| Hirmerová, J | 1 |
| Filipovský, J | 1 |
| Bell, NP | 1 |
| Orengo-Nania, S | 1 |
| Pietz, K | 1 |
| Gross, RL | 1 |
| Simons, J | 1 |
| Emberson, JR | 1 |
| Walker, M | 2 |
| Fulcher, GR | 1 |
| Amarena, JV | 1 |
| Conner, GW | 1 |
| Gilbert, RE | 1 |
| Laheij, RJ | 2 |
| Jansen, JB | 2 |
| Fukui, T | 1 |
| Matsui, K | 2 |
| Rodondi, N | 3 |
| Bauer, DC | 2 |
| Kimmey, MB | 1 |
| de Lange, DW | 1 |
| Fiets, WE | 1 |
| Banga, JD | 1 |
| Nobles-James, C | 1 |
| James, EA | 1 |
| Knatterud, GL | 1 |
| Smaha, LA | 1 |
| Damci, T | 1 |
| Kultursay, H | 1 |
| Oguz, A | 1 |
| Pehlivanoglu, S | 1 |
| Tokgozoglu, L | 1 |
| Campbell, N | 1 |
| Hovens, MM | 1 |
| Cannegieter, SC | 1 |
| Malcolm, J | 3 |
| Meggison, H | 2 |
| Sigal, R | 3 |
| Cull, CA | 1 |
| Neil, HA | 1 |
| Hillarp, A | 1 |
| Peter, K | 1 |
| Bode, C | 1 |
| Wolfe, MM | 1 |
| Evangelista, V | 1 |
| Totani, L | 1 |
| Rotondo, S | 1 |
| Lorenzet, R | 1 |
| El-Sayed, MS | 1 |
| Ali, N | 1 |
| El-Sayed Ali, Z | 1 |
| Hung, LC | 1 |
| Kung, NN | 1 |
| Hui, AJ | 1 |
| Lee, VW | 1 |
| Lee, KK | 1 |
| To, KF | 1 |
| Chan, HL | 1 |
| Maheshwari, N | 1 |
| Moussouttas, M | 1 |
| Papamitsakis, N | 1 |
| Nguyen, KX | 1 |
| Marinac, JS | 1 |
| Sun, C | 1 |
| Greenberg, JD | 2 |
| Bingham, CO | 1 |
| Abramson, SB | 2 |
| Reed, G | 1 |
| Sebaldt, RJ | 1 |
| Kremer, J | 1 |
| Smith, PS | 1 |
| Schleinitz, MD | 1 |
| Heidenreich, PA | 1 |
| Bresalier, RS | 1 |
| Sandler, RS | 2 |
| Quan, H | 1 |
| Bolognese, JA | 1 |
| Oxenius, B | 1 |
| Horgan, K | 1 |
| Lines, C | 1 |
| Riddell, R | 1 |
| Morton, D | 1 |
| Konstam, MA | 2 |
| Baron, JA | 2 |
| Abdella, NA | 1 |
| Mojiminiyi, OA | 1 |
| Moussa, MA | 1 |
| Zaki, M | 1 |
| Al Mohammedi, H | 1 |
| Al Ozairi, ES | 1 |
| Al Jebely, S | 1 |
| Arellano, FM | 1 |
| Daurbekova, LV | 1 |
| Orlov, VA | 1 |
| Giliarevskiĭ, SR | 1 |
| Abirova, ES | 1 |
| Murzabekova, LI | 1 |
| Oliveira, GH | 1 |
| Sanderson, S | 1 |
| Emery, J | 1 |
| Baglin, T | 1 |
| Kinmonth, AL | 1 |
| Chagan, L | 1 |
| Bernstein, D | 1 |
| Kirschenbaum, HL | 1 |
| Rozenfeld, V | 1 |
| Caliendo, GC | 1 |
| Meyer, J | 1 |
| Mehl, B | 1 |
| Gordon, D | 2 |
| Landray, M | 1 |
| Leaper, C | 1 |
| Altmann, P | 1 |
| Baxter, A | 1 |
| Cairns, HS | 1 |
| Foley, RN | 1 |
| Frighi, V | 1 |
| Kourellias, K | 1 |
| Ratcliffe, PJ | 1 |
| Rogerson, M | 1 |
| Scoble, JE | 1 |
| Tomson, CR | 1 |
| Warwick, G | 1 |
| Wheeler, DC | 1 |
| Krane, V | 1 |
| Levin, RI | 1 |
| Kriszbacher, I | 2 |
| Koppán, M | 2 |
| Bódis, J | 2 |
| Martin, TN | 1 |
| Irving, RJ | 1 |
| Sutherland, M | 1 |
| Sutherland, K | 1 |
| Bloomfield, P | 1 |
| Yan, Y | 1 |
| Phillips, DR | 1 |
| Soedamah-Muthu, SS | 1 |
| Chimowitz, MI | 1 |
| Lynn, MJ | 1 |
| Howlett-Smith, H | 1 |
| Stern, BJ | 1 |
| Hertzberg, VS | 1 |
| Frankel, MR | 1 |
| Levine, SR | 1 |
| Chaturvedi, S | 1 |
| Kasner, SE | 1 |
| Benesch, CG | 1 |
| Sila, CA | 1 |
| Jovin, TG | 1 |
| Romano, JG | 1 |
| Maywald, U | 1 |
| Schindler, C | 1 |
| Burger, W | 1 |
| Chemnitius, JM | 1 |
| Kneissl, GD | 1 |
| Rücker, G | 1 |
| Capone, ML | 2 |
| Sciulli, MG | 1 |
| Tacconelli, S | 2 |
| Grana, M | 1 |
| Renda, G | 1 |
| Di Gregorio, P | 1 |
| Merciaro, G | 1 |
| Wolk, MJ | 1 |
| Shanks, M | 1 |
| Holmes, DT | 1 |
| Cermakova, L | 1 |
| Frohlich, J | 1 |
| Ouyang, XL | 1 |
| Lin, ZL | 1 |
| Wang, HB | 1 |
| Ma, SX | 1 |
| Li, H | 2 |
| Yu, Y | 1 |
| Liu, JH | 1 |
| Li, XJ | 1 |
| Lu, FX | 1 |
| Bondman, DP | 1 |
| Bates, ER | 1 |
| Lau, WC | 1 |
| Corman, SL | 1 |
| Fedutes, BA | 1 |
| Ansani, NT | 1 |
| Bruno, A | 1 |
| Grassi, G | 1 |
| Dani, F | 1 |
| Degiovanni, M | 1 |
| Maghenzani, G | 1 |
| Pagano, G | 1 |
| Schwaninger, M | 1 |
| Cappelli, R | 1 |
| Ceccarelli, E | 1 |
| Di Gianfilippo, G | 1 |
| Donati, C | 1 |
| Emsley, HC | 1 |
| Forconi, S | 1 |
| Hopkins, SJ | 1 |
| Masotti, L | 1 |
| Muir, KW | 1 |
| Paciucci, A | 1 |
| Roncacci, S | 1 |
| Sander, D | 1 |
| Sander, K | 1 |
| Smith, CJ | 1 |
| Stefanini, A | 1 |
| Weber, D | 1 |
| Joshi, SR | 1 |
| Sofer, D | 1 |
| Harris, M | 1 |
| Wan, Q | 1 |
| Plöckinger, U | 1 |
| Cabeza, N | 1 |
| Reuter, T | 1 |
| Ersel, S | 1 |
| Dietz, R | 1 |
| Bocksch, W | 1 |
| Konstantinopoulos, PA | 2 |
| Lehmann, DF | 1 |
| Dussaillant N, G | 1 |
| Zapata M, M | 1 |
| Fardella B, P | 1 |
| Conte L, G | 1 |
| Cuneo V, M | 1 |
| Saseen, JJ | 1 |
| Muzyka, BC | 1 |
| Tzeis, S | 1 |
| Andrikopoulos, G | 1 |
| Schaerlig, E | 1 |
| Das, UN | 2 |
| Jochmann, N | 1 |
| Stangl, K | 1 |
| Garbe, E | 1 |
| Baumann, G | 1 |
| Stangl, V | 1 |
| Jacobs, EJ | 1 |
| Thun, MJ | 1 |
| Pinto Pereira, LM | 1 |
| Iredale, RT | 1 |
| McMullen, M | 1 |
| Dhatariya, KK | 1 |
| Svenstrup Poulsen, T | 1 |
| Kristensen, SR | 2 |
| Mickley, H | 2 |
| Monesi, L | 1 |
| Barlera, S | 1 |
| Caimi, V | 1 |
| Lauri, D | 1 |
| Longoni, P | 1 |
| Roccatagliata, D | 1 |
| Tombesi, M | 1 |
| Righetti, A | 1 |
| Aranki, SF | 1 |
| Green, LW | 1 |
| Hobikoglu, GF | 1 |
| Norgaz, T | 1 |
| Ozer, O | 1 |
| Nurkalem, Z | 1 |
| Narin, A | 1 |
| Ajtay, Z | 1 |
| Sanak, M | 2 |
| Cornuz, J | 2 |
| Nathoe, HM | 1 |
| Doevendans, PA | 1 |
| Westerweel, PE | 1 |
| van Wijk, JP | 1 |
| Bolten, WW | 1 |
| Cieślik-Bielewska, A | 1 |
| Pelc, R | 1 |
| Cieślik, T | 1 |
| Feuring, M | 1 |
| Schultz, A | 1 |
| Losel, R | 1 |
| Wehling, M | 1 |
| Maree, AO | 4 |
| Chubb, A | 1 |
| Dolan, C | 1 |
| O'Brien, J | 1 |
| Crean, P | 2 |
| Bruce, IN | 1 |
| Kannan, S | 1 |
| Eriksson, P | 1 |
| Rothberg, M | 1 |
| Kim, JA | 1 |
| Choi, YS | 1 |
| Smith, SC | 1 |
| Dooley, M | 1 |
| Narayanan, SN | 1 |
| Ahamed, MZ | 1 |
| Safia, M | 1 |
| Pijak, MR | 1 |
| Huzicka, I | 1 |
| Gazdik, F | 1 |
| Allen, MJ | 1 |
| McLean-Veysey, P | 1 |
| Fleming, I | 1 |
| Nitschmann, S | 1 |
| Mössner, J | 1 |
| Diehl, KA | 1 |
| Kudriashov, OIu | 1 |
| Zateĭshchikov, DA | 1 |
| Gelber, RP | 2 |
| Kausz, AT | 1 |
| Brandt, D | 1 |
| Charpentier, G | 1 |
| Puel, J | 1 |
| Rossini, R | 1 |
| Lucà, MG | 1 |
| Scuri, P | 1 |
| Invernizzi, P | 1 |
| Strazzabosco, M | 1 |
| Gavazzi, A | 1 |
| Stafford, RS | 1 |
| Monti, V | 1 |
| Ma, J | 2 |
| Williams, GW | 1 |
| Fries, S | 1 |
| Huybers, S | 1 |
| Dempster, DW | 1 |
| Rosenstock, JL | 1 |
| Schwimmer, JA | 1 |
| Panagopoulos, G | 1 |
| DeVita, MV | 1 |
| Michelis, MF | 1 |
| Waltering, A | 1 |
| Hemkens, L | 1 |
| Florack, C | 1 |
| Naunton, M | 1 |
| Duyvendak, M | 1 |
| Manes, C | 1 |
| Giacci, L | 1 |
| Sciartilli, A | 1 |
| D'Alleva, A | 1 |
| Celestini, A | 1 |
| Trifirò, E | 2 |
| Di Renzo, L | 3 |
| Wang, TH | 2 |
| Shin, SJ | 1 |
| Kim, BC | 1 |
| Park, S | 1 |
| Kim, S | 1 |
| Kim, TI | 1 |
| Wu, R | 1 |
| Laplante, MA | 1 |
| de Champlain, J | 1 |
| Mitka, M | 1 |
| Hollar, D | 2 |
| Rajagopal, AS | 1 |
| Shinkfield, M | 1 |
| Voight, S | 1 |
| Hamdan, K | 1 |
| Ajani, UA | 4 |
| Ford, ES | 1 |
| Greenland, KJ | 1 |
| Giles, WH | 1 |
| Artz, MB | 1 |
| Harnack, LJ | 1 |
| Duval, SJ | 1 |
| Armstrong, C | 1 |
| Arnett, DK | 1 |
| Nizankowski, R | 1 |
| Pangrazzi, I | 1 |
| Lamotte, M | 4 |
| Kubin, M | 4 |
| Mehta, SS | 1 |
| Silver, RJ | 1 |
| Aaronson, A | 1 |
| Abrahamson, M | 1 |
| Goldfine, AB | 1 |
| Njaman, W | 1 |
| Miyauchi, K | 1 |
| Kasai, T | 1 |
| Kurata, T | 1 |
| Satoh, H | 1 |
| Ohta, H | 1 |
| Okazaki, S | 1 |
| Kojima, T | 1 |
| Akimoto, Y | 1 |
| Daida, H | 1 |
| Brown, J | 1 |
| Gogia, A | 1 |
| Agarwal, PK | 1 |
| Brügemann, J | 1 |
| van Gelder, IC | 1 |
| van der Meer, J | 1 |
| Zijlstra, F | 1 |
| Chang, FY | 1 |
| Hwang, B | 1 |
| Chen, SJ | 1 |
| Lee, PC | 1 |
| Meng, CC | 1 |
| Lu, JH | 1 |
| Schuler, G | 1 |
| Sawanyawisuth, K | 1 |
| Limpawattana, P | 1 |
| Bumrerraj, S | 1 |
| Thongmee, A | 1 |
| Kosakarn, J | 1 |
| Choenrungroj, T | 1 |
| Pradit, P | 1 |
| Naranunn, P | 1 |
| Punyamee, S | 1 |
| Premgamone, A | 1 |
| Jarcho, JA | 1 |
| Black, HR | 1 |
| Cacoub, P | 1 |
| Cohen, EA | 1 |
| Flather, MD | 2 |
| Mas, JL | 1 |
| Fabry-Ribaudo, L | 1 |
| Booth, J | 1 |
| Murray, S | 1 |
| Hung, J | 1 |
| Williams, WR | 1 |
| Segal, J | 1 |
| Herrera-Galeano, JE | 2 |
| Bray, PF | 2 |
| Moy, TF | 3 |
| Targownik, LE | 2 |
| Al-Mamfud, A | 1 |
| Viktor, A | 1 |
| Schneider-Schmitt, M | 1 |
| Lüderitz, B | 1 |
| Sleight, P | 1 |
| Pouleur, H | 1 |
| Ardehali, R | 1 |
| Lange, RA | 1 |
| Ardehali, H | 1 |
| Antonelli, E | 1 |
| El Haouari, M | 1 |
| Bnouham, M | 1 |
| Bendahou, M | 1 |
| Aziz, M | 1 |
| Ziyyat, A | 1 |
| Legssyer, A | 1 |
| Vaeth, PA | 1 |
| Stanek, HG | 1 |
| Dobbins, RL | 1 |
| Wang, CB | 1 |
| Shi, XB | 1 |
| Zhu, ZY | 1 |
| Zhu, JY | 1 |
| Yang, JG | 1 |
| Whelton, A | 1 |
| van de Pol, MA | 1 |
| van Houdenhoven, M | 1 |
| Hans, EW | 1 |
| Boersma, E | 1 |
| Feringa, HH | 1 |
| Schouten, O | 1 |
| van Sambeek, MR | 1 |
| Ohmori, T | 1 |
| Yatomi, Y | 1 |
| Nonaka, T | 1 |
| Kobayashi, Y | 1 |
| Madoiwa, S | 1 |
| Mimuro, J | 1 |
| Ozaki, Y | 1 |
| Sakata, Y | 1 |
| Drzewoski, J | 1 |
| Sawer-Szewczyk, J | 1 |
| Stepień, A | 1 |
| Olszewski, A | 1 |
| Liniarski, M | 1 |
| Iavelov, IS | 1 |
| Enver, MK | 1 |
| Hoh, I | 1 |
| Chinegwundoh, FI | 1 |
| Wong, S | 1 |
| Appleberg, M | 1 |
| Ward, CM | 1 |
| Lewis, DR | 1 |
| Johns, A | 1 |
| Coffield, AB | 1 |
| Edwards, NM | 1 |
| Goodman, MJ | 1 |
| Ruiz, J | 1 |
| Egli, M | 1 |
| Shah, NR | 1 |
| Ji, KY | 1 |
| Hu, FL | 1 |
| Kumar, N | 1 |
| Jivan, S | 1 |
| Thomas, P | 1 |
| McLure, H | 1 |
| Fosburgh, D | 1 |
| Kakafika, AI | 1 |
| Liberopoulos, EN | 1 |
| Athyros, VG | 1 |
| Mikhailidis, DP | 1 |
| Grewal, J | 1 |
| Tuzcu, EM | 1 |
| Sipahi, I | 1 |
| Schoenhagen, P | 1 |
| Rozenman, Y | 1 |
| Almanaseer, Y | 1 |
| Desai, DM | 1 |
| Kongsaengdao, S | 1 |
| Arayawichanont, A | 1 |
| Kamalesh, M | 1 |
| Allison, J | 1 |
| Benzuly, K | 1 |
| Borum, M | 1 |
| Ladabaum, U | 1 |
| Paulus, H | 1 |
| Regueiro, C | 1 |
| Simon, L | 1 |
| Hammerman-Rozenberg, R | 1 |
| Jacobs, JM | 1 |
| Azoulay, D | 1 |
| Stessman, J | 1 |
| Koltai, K | 1 |
| Alkonyi, B | 1 |
| Solyom, A | 1 |
| Kenyeres, P | 1 |
| Kesmarky, G | 1 |
| Czopf, L | 1 |
| Piñol, C | 1 |
| Guardiola, E | 1 |
| Bertagnolli, MM | 1 |
| Eagle, CJ | 2 |
| Zauber, AG | 2 |
| Redston, M | 1 |
| Tang, J | 2 |
| Rosenstein, RB | 2 |
| Wittes, J | 2 |
| Corle, D | 1 |
| Hess, TM | 1 |
| Woloj, GM | 1 |
| Boisserie, F | 1 |
| Anderson, WF | 1 |
| Viner, JL | 1 |
| Bagheri, D | 1 |
| Burn, J | 1 |
| Chung, DC | 1 |
| Dewar, T | 1 |
| Foley, TR | 1 |
| Hoffman, N | 1 |
| Macrae, F | 1 |
| Pruitt, RE | 1 |
| Saltzman, JR | 1 |
| Salzberg, B | 1 |
| Sylwestrowicz, T | 1 |
| Gordon, GB | 1 |
| Hawk, ET | 1 |
| Spicak, J | 1 |
| Rácz, I | 1 |
| Dite, P | 1 |
| Hajer, J | 1 |
| Zavoral, M | 1 |
| Lechuga, MJ | 1 |
| Gerletti, P | 1 |
| Macdonald, K | 1 |
| Bhadra, P | 1 |
| Fowler, R | 1 |
| Legrand, DA | 3 |
| Arnaout, A | 1 |
| Heeg, B | 1 |
| van Gestel, A | 1 |
| Hout, Bv | 1 |
| Olsen, J | 1 |
| Haghfelt, TH | 1 |
| Weber, AA | 2 |
| Harder, S | 1 |
| Schroeder, WS | 2 |
| Ghobrial, L | 1 |
| Gandhi, PJ | 1 |
| Watson, T | 2 |
| Sechenova, O | 1 |
| Serebruany, VL | 3 |
| Blonde, L | 1 |
| Dempster, J | 1 |
| Gallivan, JM | 1 |
| Warren-Boulton, E | 1 |
| Chapman, MJ | 1 |
| Flipo, RM | 1 |
| Avouac, B | 1 |
| Vicaut, E | 1 |
| Valat, JP | 1 |
| Garcia-Donaire, JA | 1 |
| Ruilope, LM | 2 |
| Kotake, H | 1 |
| Schwartz, KA | 1 |
| Raméntol Teys, S | 1 |
| Pujol Blaya, V | 1 |
| León de la Fuente, M | 1 |
| León-Sanromà, M | 1 |
| Poulsen, TS | 1 |
| Korsholm, L | 1 |
| Haghfelt, T | 1 |
| Jørgensen, B | 1 |
| Licht, PB | 1 |
| Kim, DS | 1 |
| De la Figuera von Wichmann, M | 1 |
| Llisterri Caro, JL | 1 |
| Page, NA | 1 |
| Nascimento-Silva, V | 1 |
| Arruda, MA | 1 |
| Barja-Fidalgo, C | 1 |
| Fierro, IM | 1 |
| Kahraman, G | 1 |
| Sahin, T | 1 |
| Kilic, T | 1 |
| Baytugan, NZ | 1 |
| Agacdiken, A | 1 |
| Ural, E | 1 |
| Ural, D | 1 |
| Komsuoglu, B | 1 |
| Leitão, CB | 1 |
| Krahe, AL | 1 |
| Nabinger, GB | 1 |
| Picon, PX | 1 |
| Pecis, M | 1 |
| Zaslavsky, LM | 1 |
| Gross, JL | 2 |
| Canani, LH | 1 |
| Rottlaender, D | 1 |
| Scherner, M | 1 |
| Tran, HA | 1 |
| Zakharov, OV | 1 |
| Arablinskiĭ, AV | 1 |
| Lev, EI | 1 |
| Ramchandani, M | 1 |
| Garg, R | 1 |
| Wojciechowski, Z | 1 |
| Builes, A | 1 |
| Tripathy, U | 1 |
| Kleiman, NS | 1 |
| Earnshaw, S | 1 |
| Pletcher, MJ | 1 |
| Tice, JA | 1 |
| Hall, MN | 1 |
| Campos, H | 1 |
| Willett, WC | 1 |
| Tsutani, K | 1 |
| Fujikawa, K | 1 |
| Tran, H | 1 |
| Dubé, C | 1 |
| Lewin, G | 1 |
| Tsertsvadze, A | 1 |
| Barrowman, N | 1 |
| Code, C | 1 |
| Sampson, M | 1 |
| Moher, D | 1 |
| Stillman, MJ | 1 |
| Stillman, MT | 1 |
| Choudhury, A | 1 |
| Netzer, G | 1 |
| Maciá Bobes, C | 1 |
| Ronzón Fernández, A | 1 |
| Fernández García, E | 1 |
| Cen, YY | 1 |
| Feskanich, D | 1 |
| Colditz, GA | 1 |
| Fuchs, CS | 1 |
| Yadav, J | 1 |
| Goodman, T | 2 |
| Ramanathan, K | 1 |
| Chesebro, JH | 3 |
| Kirshner, H | 1 |
| Lay, CL | 1 |
| Ruland, S | 1 |
| Mellein, B | 1 |
| Matchaba, PT | 1 |
| Jamieson, MJ | 1 |
| Naghavi, M | 1 |
| Sakai, T | 1 |
| Saku, K | 1 |
| Kang, JH | 1 |
| Cook, N | 3 |
| Manson, J | 2 |
| Grodstein, F | 1 |
| Mathias, R | 1 |
| Fallin, MD | 1 |
| Wilson, AF | 1 |
| Anderson, GK | 1 |
| Binns, K | 1 |
| Tilson, HH | 1 |
| Smyth, S | 1 |
| Fefer, P | 1 |
| Dvir, D | 1 |
| Hod, H | 1 |
| Mowat, DH | 1 |
| Merrick, GS | 1 |
| Meadows, TA | 1 |
| Lima Filho, Mde O | 1 |
| Figueiredo, GL | 1 |
| Haddad, JL | 1 |
| Schmidt, A | 1 |
| Lima, NK | 1 |
| Camargo, EG | 1 |
| Weinert, LS | 1 |
| Lavinsky, J | 1 |
| Silveiro, SP | 1 |
| Placzkiewicz-Jankowska, E | 1 |
| Zieliński, L | 1 |
| Häussler, B | 1 |
| Schiffhorst, G | 1 |
| Gothe, H | 1 |
| Hempel, E | 1 |
| Thatipelli, MR | 1 |
| Pellikka, PA | 1 |
| McBane, RD | 1 |
| Rooke, TW | 1 |
| Rosales, GA | 1 |
| Hodge, D | 1 |
| Herges, RM | 1 |
| Wysokinski, WE | 1 |
| Brennan, MT | 1 |
| Wynn, RL | 1 |
| Miller, CS | 1 |
| Jedlicková, V | 2 |
| Skibova, J | 1 |
| Adamek, T | 1 |
| Anand, S | 1 |
| Sussex, B | 1 |
| Guzman, R | 1 |
| Cina, C | 1 |
| Crowell, R | 1 |
| Gosselin, G | 1 |
| Keller, TT | 1 |
| Tweddell, JS | 1 |
| Born, GV | 2 |
| Wong, GK | 1 |
| Clegg, A | 1 |
| Mosorjakova, D | 1 |
| San Miguel Hernández, A | 1 |
| Inglada-Galiana, L | 1 |
| García Iglesias, R | 1 |
| Alonso Castillejos, N | 1 |
| Martín Gil, FJ | 1 |
| Jiménez, P | 1 |
| García, A | 1 |
| Santander, S | 1 |
| Piazuelo, E | 1 |
| Sopena, F | 1 |
| von Pape, KW | 1 |
| Dzijan-Horn, M | 1 |
| Bohner, J | 1 |
| Spannagl, M | 1 |
| Weisser, H | 1 |
| Helton, TJ | 1 |
| Kumbhani, DJ | 1 |
| Duggal, S | 1 |
| Roukoz, H | 1 |
| Ding, EL | 1 |
| Shaker, M | 1 |
| Lobb, A | 1 |
| Jenkins, P | 1 |
| O'Rourke, D | 1 |
| Takemoto, SK | 1 |
| Sheth, S | 1 |
| Burroughs, T | 1 |
| Dykewicz, MS | 1 |
| Bowman, TS | 2 |
| Celik, U | 1 |
| Alhan, E | 1 |
| Arabaci, F | 1 |
| Karnik, K | 1 |
| Bonneux, L | 1 |
| Christie, DJ | 1 |
| Gorman, RT | 1 |
| von Känel, R | 1 |
| Kudielka, BM | 1 |
| Metzenthin, P | 1 |
| Helfricht, S | 1 |
| Preckel, D | 1 |
| Haeberli, A | 1 |
| Stutz, M | 1 |
| Fischer, JE | 1 |
| Ethier, J | 1 |
| Bragg-Gresham, JL | 1 |
| Piera, L | 1 |
| Akizawa, T | 1 |
| Asano, Y | 1 |
| Mason, N | 1 |
| Gillespie, BW | 1 |
| Young, EW | 1 |
| Motovska, Z | 1 |
| Sujanova, Z | 1 |
| Wimmerova, S | 1 |
| Ardo, J | 1 |
| Skrakova, M | 1 |
| Hinz, B | 1 |
| Renner, B | 1 |
| Brune, K | 1 |
| Atkins, D | 1 |
| Amer, F | 1 |
| Hunt, B | 1 |
| Hsia, J | 1 |
| Tailor, A | 1 |
| Wood, KC | 1 |
| Wallace, JL | 1 |
| Specian, RD | 1 |
| Granger, DN | 1 |
| Sicras-Mainar, A | 1 |
| Navarro-Artieda, R | 1 |
| Rejas-Gutiérrez, J | 1 |
| Fernández-de-Bobadilla, J | 1 |
| Frías-Garrido, X | 1 |
| Ruiz-Riera, R | 1 |
| Sepehri, G | 1 |
| Talebizadeh, N | 1 |
| Mirzazadeh, A | 1 |
| Mohsenbeigi, M | 1 |
| Mood, GR | 1 |
| Dekkers, OM | 1 |
| Vandenbroucke, JP | 1 |
| Lim, SS | 1 |
| Gakidou, E | 1 |
| Lozano, R | 1 |
| Sweileh, WM | 1 |
| Crutcher, JM | 1 |
| Mallonee, S | 1 |
| Daniels, C | 1 |
| Thomas, MC | 1 |
| Colt, E | 1 |
| Strand, V | 1 |
| Türkoğlu, S | 1 |
| Abaci, A | 1 |
| Altin, T | 1 |
| Kiliçkap, M | 1 |
| Törüner, M | 1 |
| Krasopoulos, G | 1 |
| Beattie, WS | 1 |
| Sirotkina, OV | 1 |
| Zabotina, AM | 1 |
| Taraskina, AE | 1 |
| Sivachenko, EB | 1 |
| Zueva, EE | 1 |
| Kadinskaya, MI | 1 |
| Buryachkovskaya, LI | 1 |
| Uchitel', IA | 1 |
| Khaspekova, SG | 1 |
| Vavilova, TV | 1 |
| Shvartsman, AL | 1 |
| Mazurov, AV | 1 |
| Fares, RR | 1 |
| Lansing, LS | 1 |
| Gallati, CA | 1 |
| Coma-Canella, I | 1 |
| Velasc, A | 1 |
| Bulckaen, H | 1 |
| Prévost, G | 1 |
| Boulanger, E | 1 |
| Robitaille, G | 1 |
| Roquet, V | 1 |
| Gaxatte, C | 1 |
| Garçon, G | 1 |
| Corman, B | 1 |
| Gosset, P | 1 |
| Shirali, P | 1 |
| Creusy, C | 1 |
| Puisieux, F | 1 |
| Morel, O | 1 |
| Ohlmann, P | 1 |
| Bareiss, P | 1 |
| Wienbergen, H | 1 |
| Senges, J | 2 |
| Gitt, AK | 1 |
| Stirban, AO | 1 |
| Tschoepe, D | 1 |
| Sofi, F | 1 |
| Lund-Andersen, H | 1 |
| Giliarov, MIu | 1 |
| Noce, A | 1 |
| De Angelis, S | 1 |
| Miani, N | 1 |
| Di Daniele, N | 1 |
| Tozzo, C | 1 |
| De Lorenzo, A | 1 |
| Neubauer, H | 1 |
| Lask, S | 1 |
| Engelhardt, A | 1 |
| Mügge, A | 1 |
| Tseeng, S | 1 |
| Arora, R | 1 |
| Principessa, L | 1 |
| Mascioletti, S | 1 |
| Biasucci, LM | 1 |
| Simpson, CR | 1 |
| Alford, K | 1 |
| Drown, DJ | 1 |
| Purcell, H | 1 |
| Gladding, PA | 1 |
| Webster, MW | 1 |
| Farrell, HB | 1 |
| Zeng, IS | 1 |
| Park, R | 1 |
| Ruijne, N | 1 |
| Karamouzis, MV | 1 |
| Papavassiliou, AG | 1 |
| Metge, CJ | 1 |
| Leung, S | 1 |
| Brodie, BR | 1 |
| Gellatly, RM | 1 |
| Ackman, ML | 1 |
| Mohagheghi, A | 1 |
| Mitchell, BD | 1 |
| McArdle, PF | 1 |
| Shen, H | 1 |
| Rampersaud, E | 1 |
| Pollin, TI | 1 |
| Bielak, LF | 1 |
| Jaquish, C | 1 |
| Douglas, JA | 1 |
| Roy-Gagnon, MH | 1 |
| Sack, P | 1 |
| Naglieri, R | 1 |
| Hines, S | 1 |
| Horenstein, RB | 1 |
| Chang, YP | 1 |
| Post, W | 1 |
| Ryan, KA | 1 |
| Brereton, NH | 1 |
| Pakyz, RE | 1 |
| Sorkin, J | 1 |
| Damcott, CM | 1 |
| O'Connell, JR | 1 |
| Mangano, C | 1 |
| Corretti, M | 1 |
| Vogel, R | 1 |
| Herzog, W | 1 |
| Weir, MR | 2 |
| Peyser, PA | 1 |
| Osmancik, P | 1 |
| Hlavicka, J | 1 |
| Vanek, T | 1 |
| Grima, DT | 1 |
| Attard, CL | 1 |
| Chow, CM | 1 |
| Sirois, C | 1 |
| Poirier, P | 1 |
| Moisan, J | 1 |
| Grégoire, JP | 1 |
| Greving, JP | 1 |
| Buskens, E | 1 |
| Koffijberg, H | 1 |
| Friedewald, WT | 1 |
| Schoenberger, JA | 1 |
| Chabali, R | 1 |
| Haynes, RE | 1 |
| Kubryk, N | 1 |
| Borde, M | 1 |
| Cella, G | 1 |
| Colby, SI | 1 |
| Taylor, AD | 1 |
| McCracken, L | 1 |
| Parisi, AF | 1 |
| Sasahara, AA | 1 |
| Krantz, JC | 2 |
| Weksler, BB | 1 |
| Podell, RN | 1 |
| Viinikka, L | 1 |
| Ek, I | 1 |
| Thunell, S | 1 |
| Blombäck, M | 1 |
| Farah, AE | 1 |
| Rosenberg, F | 1 |
| Birgens, HS | 1 |
| Hansen, MS | 1 |
| Margulies, EH | 1 |
| White, AM | 1 |
| Sherry, S | 1 |
| Vane, JR | 1 |
| Moncada, S | 1 |
| Gunby, P | 2 |
| Turpie, AG | 1 |
| Sullivan, JL | 1 |
| Boeynaems, JM | 1 |
| Gomberg, R | 1 |
| Hamm, P | 1 |
| Martin, A | 1 |
| Fukushige, J | 1 |
| Nihill, MR | 1 |
| McNamara, DG | 1 |
| Bygdeman, M | 1 |
| González, ER | 1 |
| Gysling, E | 1 |
| Catella-Lawson, F | 1 |
| Bernheimer, J | 1 |
| Weil, J | 1 |
| Colin-Jones, D | 1 |
| Langman, M | 1 |
| Lawson, D | 1 |
| Logan, R | 1 |
| Rawlins, M | 1 |
| Vessey, M | 1 |
| Wainwright, P | 1 |
| Moriarty, KT | 1 |
| Hebert, P | 1 |
| Romero, J | 1 |
| Kittross, A | 1 |
| Hansson, L | 6 |
| Leibovici, A | 1 |
| Lavi, N | 1 |
| Wainstok, S | 1 |
| Herman, J | 1 |
| Greene, VW | 1 |
| Janssen, PL | 1 |
| Katan, MB | 1 |
| Hollman, PC | 1 |
| Venema, DP | 1 |
| Blake, C | 1 |
| Bailey, JM | 1 |
| Salata, K | 1 |
| Makheja, AN | 1 |
| Jelnes, R | 1 |
| Hensler, MK | 1 |
| Madsen, PV | 1 |
| Gembitskiĭ, EV | 1 |
| Begunov, AB | 1 |
| Fredholm, B | 1 |
| Husted, SE | 1 |
| Nielsen, HK | 1 |
| Byers, JF | 1 |
| Peterson, B | 1 |
| George, SL | 1 |
| Fredholm, BB | 1 |
| Gray, R | 1 |
| Silagy, CA | 3 |
| Worsam, B | 3 |
| Campion, K | 2 |
| Curb, JD | 1 |
| Couch, JR | 1 |
| Grotemeyer, KH | 1 |
| Scharafinski, HW | 1 |
| Husstedt, IW | 1 |
| Jonas, MA | 1 |
| Aldhous, P | 1 |
| Underwood, MJ | 1 |
| More, RS | 1 |
| Goodnight, SH | 2 |
| Coull, BM | 1 |
| McAnulty, JH | 1 |
| Taylor, LM | 1 |
| Harker, LA | 2 |
| Dyken, ML | 2 |
| Vokonas, PS | 1 |
| Wilkes, HC | 1 |
| Barbour, MM | 1 |
| Lapane, KL | 1 |
| Assaf, AR | 1 |
| Carleton, RA | 1 |
| Kelly, R | 1 |
| Smith, PK | 1 |
| Goldwater, PN | 1 |
| Lodder, J | 1 |
| Boiten, J | 1 |
| Kuhn, W | 1 |
| Müller, T | 1 |
| Büttner, T | 1 |
| Gerlach, M | 1 |
| Greenberg, PD | 1 |
| Cello, JP | 1 |
| Alderman, C | 1 |
| Seddon, JM | 2 |
| Lipinska, I | 1 |
| Hafner, J | 1 |
| De Lorgeril, M | 1 |
| Salen, P | 1 |
| Martin, JL | 1 |
| Mamelle, N | 1 |
| Monjaud, I | 1 |
| Touboul, P | 1 |
| Delaye, J | 1 |
| Malik, AS | 1 |
| Cimminiello, C | 1 |
| Ceriello, A | 1 |
| Motz, E | 1 |
| Yudkin, JS | 1 |
| Wood, SF | 1 |
| Moher, M | 1 |
| Lancaster, T | 1 |
| Camargo, CA | 1 |
| Goldhaber, SZ | 1 |
| O'Donnell, CJ | 1 |
| Ajani, U | 1 |
| Richards, M | 1 |
| Peart, S | 1 |
| Brennan, PJ | 1 |
| Mann, AH | 1 |
| Dippel, DW | 1 |
| Koudstaal, PJ | 1 |
| Schühlen, H | 1 |
| Hadamitzky, M | 1 |
| Walter, H | 1 |
| Ulm, K | 1 |
| Bruno, JJ | 1 |
| Murray, WM | 1 |
| Cahill, MR | 1 |
| Perry, IJ | 1 |
| McCallum, AK | 1 |
| Whincup, PH | 1 |
| Morris, RW | 1 |
| Thomson, A | 1 |
| Sánchez García, P | 1 |
| Gill, S | 1 |
| Majumdar, S | 1 |
| Brown, NE | 1 |
| Mallion, JM | 3 |
| Dahan, R | 1 |
| Boutelant, S | 1 |
| Benkritly, A | 2 |
| Baguet, JP | 2 |
| Noir-Clerc, M | 1 |
| Alessandrini, P | 1 |
| Mezzetti, A | 1 |
| Minotti, G | 1 |
| Bucciarelli, T | 1 |
| Costantini, F | 1 |
| Bon, GB | 1 |
| Ciabattoni, G | 2 |
| Vanchieri, C | 1 |
| Codina, A | 1 |
| Passa, P | 1 |
| Eccles, M | 1 |
| Freemantle, N | 1 |
| Mason, J | 1 |
| Saniabadi, AR | 1 |
| Takeich, S | 1 |
| Yukawa, N | 1 |
| Nakajima, Y | 1 |
| Nakashima, M | 1 |
| Kronmal, RA | 1 |
| Manolio, TA | 1 |
| Beauchamp, NJ | 1 |
| Newman, A | 1 |
| Wolin, MS | 1 |
| Kaplan, N | 1 |
| Carruthers, SG | 1 |
| Dahlöf, B | 1 |
| Elmfeldt, D | 2 |
| Julius, S | 1 |
| Ménard, J | 1 |
| Rahn, KH | 2 |
| Westerling, S | 1 |
| Marchesi, VT | 1 |
| Siché, JP | 1 |
| Kendall, MJ | 2 |
| Toescu, V | 1 |
| Carter, K | 1 |
| Miller, KM | 1 |
| Augustovski, FA | 1 |
| Cantor, SB | 1 |
| Thach, CT | 1 |
| Spann, SJ | 1 |
| Boissel, JP | 1 |
| Strubelt, O | 1 |
| Diederich, KW | 1 |
| Sánchez de Miguel, L | 1 |
| de Frutos, T | 1 |
| González-Fernández, F | 1 |
| del Pozo, V | 1 |
| Lahoz, C | 1 |
| Jiménez, A | 1 |
| Rico, L | 1 |
| García, R | 1 |
| Aceituno, E | 1 |
| Millás, I | 1 |
| Gómez, J | 1 |
| Farré, J | 1 |
| Casado, S | 1 |
| López-Farré, A | 1 |
| Rubin, R | 1 |
| O'Brien, JR | 1 |
| Baker, RI | 1 |
| Mollison, LC | 1 |
| James-Wallace, MJ | 1 |
| Kirke, AB | 1 |
| Stein, GR | 1 |
| Jamrozik, KD | 1 |
| Wesseling, H | 1 |
| D'Agostino, RB | 2 |
| Hanley, DF | 1 |
| Moye, L | 1 |
| Ramsay, LE | 2 |
| Johnston, GD | 1 |
| MacGregor, GA | 1 |
| Poston, L | 1 |
| Russell, G | 1 |
| Quinn, MJ | 1 |
| Rohde, LE | 1 |
| Steiner, M | 1 |
| Ryan, NS | 1 |
| Leung, DY | 1 |
| Meissner, HC | 1 |
| Kajubi, SK | 1 |
| Black, DA | 1 |
| Fraser, CM | 1 |
| Karila-Cohen, D | 1 |
| Gabriel Steg, P | 1 |
| Fry, RA | 1 |
| Dunbabin, DW | 1 |
| Kolloch, RE | 1 |
| Leonetti, G | 2 |
| Warnold, I | 2 |
| Moynihan, R | 1 |
| Bero, L | 1 |
| Ross-Degnan, D | 1 |
| Henry, D | 1 |
| Lee, K | 1 |
| Mah, C | 1 |
| Soumerai, SB | 1 |
| Martín Escalante, MD | 1 |
| Cruz Caparrós, G | 1 |
| Zambrana García, JL | 1 |
| Steinberg, H | 1 |
| Wong, KS | 1 |
| Mok, V | 1 |
| Lam, WW | 1 |
| Kay, R | 1 |
| Tang, A | 1 |
| Chan, YL | 1 |
| Woo, J | 1 |
| Weinsaft, JW | 1 |
| Green, AR | 1 |
| Lotufo, PA | 1 |
| Tenenbaum, A | 2 |
| Grossman, E | 2 |
| Shemesh, J | 1 |
| Fisman, EZ | 2 |
| Nosrati, I | 1 |
| Motro, M | 2 |
| Boles, M | 1 |
| Getchell, WS | 1 |
| Feldman, G | 1 |
| McBride, R | 1 |
| Le, IM | 1 |
| Reverter, JC | 1 |
| Pedersen, OB | 1 |
| Gaede, PH | 1 |
| Masferrer, JL | 1 |
| Needleman, P | 1 |
| Birkeland, KI | 1 |
| Hansteen, V | 1 |
| Hanssen, KF | 1 |
| Hjermann, I | 1 |
| Jenssen, T | 1 |
| Jervell, J | 1 |
| Os, I | 1 |
| Meland, E | 1 |
| Ellekjaer, H | 1 |
| Gjelsvik, B | 1 |
| Kimsås, A | 1 |
| Holmen, J | 1 |
| Hetlevik, I | 1 |
| Stanley, P | 1 |
| Hegedus, R | 1 |
| Bennett, JS | 1 |
| Sanmuganathan, PS | 1 |
| Ghahramani, P | 1 |
| Jackson, PR | 1 |
| Wallis, EJ | 1 |
| Skerrett, PJ | 1 |
| Rosser, WW | 1 |
| Kaplan, RC | 1 |
| Heckbert, SR | 1 |
| Koepsell, TD | 1 |
| Polak, JF | 1 |
| Schoen, RE | 1 |
| Psaty, BM | 1 |
| Cockcroft, JR | 1 |
| Wilkinson, IB | 1 |
| Yki-Järvinen, H | 1 |
| Rolka, DB | 1 |
| Fagot-Campagna, A | 1 |
| Narayan, KM | 1 |
| Berent, R | 1 |
| Weber, T | 1 |
| Porodko, M | 1 |
| Mayr, H | 1 |
| Maurer, E | 1 |
| Eber, B | 1 |
| Duly-Bouhanick, B | 1 |
| Menard, S | 1 |
| Hadjadj, S | 1 |
| Soares-Barbosa, S | 1 |
| Plun-Favreau, J | 1 |
| Guilloteau, G | 1 |
| Andréjak, M | 1 |
| Gayet, JL | 1 |
| Foggensteiner, L | 1 |
| Mulroy, S | 1 |
| Firth, J | 1 |
| Thiéfin, G | 1 |
| Sexton, RC | 1 |
| Chambers, S | 1 |
| Evans, L | 1 |
| Krishnan, A | 1 |
| Conti, AA | 1 |
| Micheletta, F | 1 |
| Luliano, L | 1 |
| Hooper, L | 1 |
| Ness, AR | 1 |
| Smith, GD | 1 |
| Dylewska, K | 1 |
| Maćkowska, K | 1 |
| Masłowska, E | 1 |
| Kojro-Wojcieszonek, A | 1 |
| Balcar-Boroń, A | 1 |
| Hien, P | 1 |
| Morr, H | 1 |
| Poggio, ED | 1 |
| Gurm, H | 1 |
| Brooks, L | 1 |
| Sapp, SK | 1 |
| Zhao, F | 1 |
| Fox, KK | 1 |
| Hankinson, SE | 1 |
| Stillings, M | 1 |
| Kennedy, J | 1 |
| Mogensen, CE | 1 |
| Ball, SG | 1 |
| Castaigne, AD | 1 |
| Distiller, L | 1 |
| Fisher, BM | 1 |
| Gonzalez-Jaunatey, J | 1 |
| Nosadini, R | 1 |
| Novials, A | 1 |
| Ostergren, J | 1 |
| Palma-Gámiz, J | 1 |
| Schipperheijn, JJ | 1 |
| Trevisan, R | 1 |
| George, PB | 1 |
| Tobin, KJ | 1 |
| Corpus, RA | 1 |
| Devlin, WH | 1 |
| O'Neill, WW | 1 |
| Fox, R | 1 |
| Guijarro, C | 1 |
| Fuchs, I | 1 |
| McGeer, PL | 1 |
| McGeer, EG | 1 |
| Yasojima, K | 1 |
| Coletta, AP | 1 |
| Rich, SA | 1 |
| Bedson, J | 1 |
| Whitehurst, T | 1 |
| Lewis, M | 1 |
| Croft, P | 1 |
| Nordt, T | 1 |
| de Ferranti, S | 1 |
| Chiquette, E | 1 |
| Chilton, R | 1 |
| Alkhenizan, A | 1 |
| DeMaria, AN | 1 |
| Przytulski, B | 1 |
| Schanz, A | 1 |
| Ehlers, R | 1 |
| Felbinger, TW | 1 |
| Eltzschig, HK | 1 |
| Halushka, MK | 1 |
| Halushka, PV | 2 |
| Johnston, M | 1 |
| Yi, Q | 1 |
| SoRelle, R | 1 |
| Bradbury, J | 1 |
| Taubes, G | 1 |
| Sharma, RA | 1 |
| Peters, AJ | 1 |
| Borries, M | 1 |
| Gradaus, F | 1 |
| Jax, TW | 1 |
| Schoebel, FC | 1 |
| Strauer, BE | 1 |
| Ruilope, L | 1 |
| Krein, SL | 1 |
| Pogach, LM | 1 |
| Hogan, MM | 1 |
| Kerr, EA | 1 |
| Geber, J | 1 |
| Parra, D | 1 |
| Beckey, NP | 1 |
| Korman, L | 1 |
| Kiberd, BA | 1 |
| Cohn, PF | 1 |
| Bochenek, G | 1 |
| Swierczyńska, M | 1 |
| Nizankowska-Mogilnicka, E | 1 |
| Vivet, P | 1 |
| Gicquel, M | 1 |
| Jobin, F | 1 |
| Heine, H | 1 |
| Norden, C | 1 |
| Heinemann, L | 1 |
| Stepanauskas, M | 1 |
| Packham, MA | 1 |
| Clagett, GP | 1 |
| Collins, GJ | 1 |
| Gantmacher, ML | 1 |
| Roncucci, R | 1 |
| Deperon, R | 1 |
| Destailleur, J | 1 |
| Doumont, J | 1 |
| Lambelin, G | 1 |
| Lansen, J | 1 |
| Moriau, M | 1 |
| Van Stalle, F | 1 |
| Verhaeghe, R | 1 |
| Benowitz, NL | 1 |
| Rosenberg, J | 1 |
| Becker, CE | 1 |
| Monson, RR | 1 |
| Hall, AP | 1 |
| Langman, MJ | 1 |
| Long, K | 1 |
| Long, R | 1 |
| Baume, P | 1 |
| McAnally, LE | 1 |
| Corn, CR | 1 |
| Hamilton, SF | 1 |
| Gore, JM | 2 |
| Cairns, J | 1 |
| Cohen, L | 1 |
| Colton, T | 1 |
| Deykin, D | 1 |
| Friedman, L | 1 |
| Greenwald, P | 1 |
| Hutchison, GB | 1 |
| Cobb, JL | 1 |
| Wolf, PA | 1 |
| Dorris, RJ | 1 |
| Mahon, J | 1 |
| Steel, K | 1 |
| Feagan, BG | 1 |
| Laupacis, A | 1 |
| Pederson, LL | 1 |
| Willich, SN | 1 |
| Murray, R | 1 |
| Moran, N | 1 |
| Funk, C | 1 |
| Charman, W | 1 |
| Clarke, R | 1 |
| Furci, L | 1 |
| Hirschon Prado, A | 1 |
| Lang, JM | 1 |
| Quyyumi, AA | 1 |
| Dubach, UC | 1 |
| Stürmer, T | 1 |
| Bulpitt, CJ | 1 |
| Castel, JM | 1 |
| Artaza, MA | 1 |
| Laporte, JR | 2 |
| Thorngren, M | 1 |
| Eckert, B | 1 |
| Vinge, E | 1 |
| Bourrillon, A | 1 |
| Seban, E | 1 |
| Vitoux-Brot, C | 1 |
| Aro, JL | 1 |
| Haapiainen, RK | 1 |
| Rannikko, SA | 1 |
| Alfthan, OS | 1 |
| Sandercock, P | 1 |
| Horton, RC | 1 |
| Stein, B | 1 |
| Israel, DH | 1 |
| Badimon, JJ | 1 |
| Mayo, G | 1 |
| Price, P | 1 |
| Takahara, K | 1 |
| Naess, K | 1 |
| Borhani, NO | 1 |
| Dorn, GW | 1 |
| Squires, RW | 2 |
| Gau, GT | 2 |
| Orme, M | 1 |
| Henriksson, P | 1 |
| Green, K | 1 |
| Vesterqvist, O | 1 |
| Edhag, O | 1 |
| Rasmanis, G | 1 |
| Folsom, AR | 1 |
| Iso, H | 1 |
| Sprafka, JM | 1 |
| Edlavitch, SA | 1 |
| Reilly, IA | 1 |
| Spaulding, GL | 1 |
| Houser, HB | 1 |
| Beaufils, P | 1 |
| Warlow, C | 1 |
| Eberlein, K | 1 |
| Courillon-Mallet, A | 1 |
| Wautier, JL | 1 |
| Boyd, NF | 1 |
| Harbro, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Low Dose Aspirin in Type-2 Diabetic Patients With Very High Cardiovascular Risk and Subclinical Inflammation[NCT02164578] | Phase 3 | 179 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| A Study of Cardiovascular Events iN Diabetes - A Randomized 2x2 Factorial Study of Aspirin Versus Placebo, and of Omega-3 Fatty Acid Supplementation Versus Placebo, for Primary Prevention of Cardiovascular Events in People With Diabetes[NCT00135226] | Phase 4 | 15,480 participants (Actual) | Interventional | 2005-03-31 | Active, not recruiting | ||
| Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients[NCT02933788] | Phase 4 | 116 participants (Anticipated) | Interventional | 2016-10-31 | Not yet recruiting | ||
| Aspirin to Target Arterial Events in Chronic Kidney Disease[NCT03796156] | Phase 3 | 25,210 participants (Anticipated) | Interventional | 2019-02-25 | Recruiting | ||
| Testing a Community Intervention to Increase Aspirin Use for Primary Prevention of Cardiovascular Disease[NCT02607917] | 10,800 participants (Actual) | Interventional | 2015-02-16 | Completed | |||
| Secondary Prevention of Cardiovascular Disease in the Elderly Trial[NCT02596126] | Phase 3 | 2,499 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| Developing a Heart Failure Polypill to Improve Outcomes at a Safety Net Hospital: A Pilot Crossover Randomized Controlled Trial[NCT06029712] | Phase 2 | 40 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| Polypill Strategy for Evidence-Based Management of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention in an Underserved Patient Population[NCT05514938] | Phase 2 | 60 participants (Anticipated) | Interventional | 2022-11-30 | Recruiting | ||
| Effectiveness of Polypill for Primary Prevention of Cardiovascular Disease (PolyPars): Study Design and Rationale for a Pragmatic Cluster Randomized Controlled Trial[NCT03459560] | Phase 3 | 4,415 participants (Actual) | Interventional | 2015-12-20 | Active, not recruiting | ||
| Fixed-dose Combination Therapy (PolyPill) in Primary and Secondary Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians[NCT01271985] | Phase 3 | 8,410 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| Polipill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt in Primary Health Care[NCT05155137] | Phase 3 | 12,268 participants (Anticipated) | Interventional | 2021-12-20 | Recruiting | ||
| A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424] | Phase 3 | 27,395 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II[NCT05702463] | Phase 1 | 30 participants (Anticipated) | Interventional | 2023-06-13 | Recruiting | ||
| Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes: APPEASED Study Phase 1[NCT05105919] | Early Phase 1 | 50 participants (Anticipated) | Interventional | 2021-08-26 | Recruiting | ||
| Efficacy of Postoperative Pain Control Between Transarticular VS Periartiucular Multimodal Drug Infiltration in Total Hip Arthroplasty: Double-blinded Randomized Control Trial[NCT05325671] | 120 participants (Anticipated) | Interventional | 2022-04-05 | Not yet recruiting | |||
| Randomized Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography ([NCT02833948] | Phase 3 | 231 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes[NCT02556203] | Phase 3 | 1,653 participants (Actual) | Interventional | 2015-12-16 | Terminated (stopped due to Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator) | ||
| Novel Biomarkers of Thrombotic Risk[NCT02505217] | 200 participants (Actual) | Observational | 2015-07-31 | Completed | |||
| Cross-over Analysis of the Control of Coronary Risk Factors and Level of Platelet Inhibition With a Polypill[NCT05030818] | Phase 4 | 88 participants (Anticipated) | Interventional | 2022-10-14 | Recruiting | ||
| Using Practice Facilitation in Primary Care Settings to Reduce Risk Factors for Cardiovascular Disease[NCT02646488] | 276 participants (Actual) | Interventional | 2015-08-31 | Completed | |||
| An International, Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Thrombotic Vascular Events in Patients With Symptomatic Peripheral Artery Disease Un[NCT02504216] | Phase 3 | 6,564 participants (Actual) | Interventional | 2015-08-18 | Completed | ||
| Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness[NCT02697916] | 15,076 participants (Actual) | Interventional | 2016-04-30 | Completed | |||
| [NCT02494895] | Phase 4 | 3,056 participants (Anticipated) | Interventional | 2015-08-01 | Recruiting | ||
| Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation: Multicenter Randomized Clinical Trial[NCT05283356] | Phase 4 | 1,206 participants (Anticipated) | Interventional | 2022-01-21 | Recruiting | ||
| Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation[NCT02247128] | Phase 4 | 1,016 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Ischemic And Bleeding Risk Assessment After TAVR (FOCUS ONE Registry)[NCT06000943] | 2,500 participants (Anticipated) | Observational [Patient Registry] | 2023-08-01 | Recruiting | |||
| Aspirin in Reducing Events in the Elderly[NCT01038583] | 19,114 participants (Actual) | Observational | 2010-01-31 | Active, not recruiting | |||
| Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan - a Double Blind Randomised Study[NCT00791830] | Phase 3 | 82 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Study of Adherence to Antihypertensive Drugs and Statins in the Population of Subjects With Hypertension Followed at SIIA Centers, Using an Innovative Monitoring Based on Hair Analysis[NCT05347823] | 200 participants (Anticipated) | Observational | 2022-05-15 | Not yet recruiting | |||
| The International Polycap Study 3 (TIPS-3) is a Randomized Double-blind Placebo-controlled Trial for the Evaluation of a Polycap, Low Dose Aspirin and Vitamin D Supplementation in Primary Prevention[NCT01646437] | Phase 3 | 7,793 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| [NCT00005121] | 0 participants | Observational | 1948-07-31 | Completed | |||
| A Double-blind Randomized Comparison of Celecoxib Plus Esomeprazole Versus Naproxen Plus Esomeprazole for Prevention of Recurrent Ulcer Bleeding in Patients With Arthritis and Cardiothrombotic Diseases (NSAID#8 Study)[NCT00153660] | Phase 3 | 514 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286] | Phase 4 | 1,700 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| Randomized 2x2 Factorial Trial Comparing the Cre8 Amphilimus-sirolimus Eluting Stent vs. the Synergy Everolimus-eluting Stent and a Personalized vs. Standard Duration of Dual Antiplatelet Therapy in All-comers Patients Undergoing Percutaneous Coronary Int[NCT04135989] | Phase 4 | 2,106 participants (Anticipated) | Interventional | 2020-01-01 | Active, not recruiting | ||
| TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Sitagliptin in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control[NCT00790205] | Phase 3 | 14,671 participants (Actual) | Interventional | 2008-12-10 | Completed | ||
| Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women[NCT00000479] | Phase 3 | 39,876 participants (Actual) | Interventional | 1992-09-30 | Completed | ||
| Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion[NCT03630055] | Phase 3 | 1,800 participants (Anticipated) | Interventional | 2018-10-03 | Recruiting | ||
| Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients With Chronic Coronary Syndromes[NCT04347200] | 2,000 participants (Anticipated) | Observational [Patient Registry] | 2015-01-15 | Recruiting | |||
| DUAL Pathway Inhibition (Low-dose Rivaroxaban and Aspirin) as Compared to Aspirin Only to Improve Endothelial Function in Peripheral Artery Disease.[NCT04218656] | Phase 4 | 159 participants (Actual) | Interventional | 2020-06-08 | Completed | ||
| Characterisation of a Novel Regimen of Very Low-dose Aspirin Combined With Rivaroxaban in Patients With Chronic Coronary Syndromes: WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes?[NCT04990791] | Phase 4 | 48 participants (Anticipated) | Interventional | 2021-08-26 | Recruiting | ||
| An Exploratory Study of Effectiveness and Safety of Rivaroxaban in Patients With Left Ventricular Thrombus[NCT04970381] | 60 participants (Anticipated) | Interventional | 2021-07-22 | Recruiting | |||
| Influence of Rivaroxaban 2.5 mg Two Times a Day for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic Peripheral Arterial Disease (PAD) - a Randomised Controlled Trial[NCT04305028] | 100 participants (Anticipated) | Observational | 2021-03-10 | Not yet recruiting | |||
| Effects of Edoxaban on Platelet Aggregation in Patients With Stable Coronary Artery Disease[NCT05122455] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2021-09-14 | Recruiting | ||
| Feasibility of Applying Remote Ischemic Conditioning in Secondary Prevention in Patients With Minor Ischemic Stroke or Transient Ischemic Attack -A Single-arm Futility Study[NCT03004820] | 167 participants (Actual) | Interventional | 2016-12-06 | Completed | |||
| Investigator Initiated Prospective Study to Investigate the Best Anti-platelet Treatment in High Thrombotic Risk PCI Patients.[NCT01779401] | 1,078 participants (Actual) | Interventional | 2012-09-30 | Completed | |||
| Ramadan Fasting Effects in Patients With Cardiovascular Risk Factors[NCT02720133] | 500 participants (Actual) | Observational [Patient Registry] | 2013-07-31 | Completed | |||
| A Multicenter, Double Blind, Factorial Design, Phase IV Trial to Compare the Efficacy and Safety of Cilostazol Long-term Treatment With Aspirin in Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage for the Prevention of Cerebral Hemorrhage and[NCT01013532] | Phase 4 | 1,600 participants (Anticipated) | Interventional | 2009-06-30 | Active, not recruiting | ||
| Midwest Small Practice Care Transformation Research Alliance (MSPCTRA)[NCT02598284] | 226 participants (Actual) | Interventional | 2016-01-31 | Completed | |||
| Effect of Aspirin in Primary Prevention of Cardiovascular Risk in Patients With Chronic Kidney Disease (AASER Study)[NCT01709994] | Phase 3 | 97 participants (Anticipated) | Interventional | 2010-05-31 | Recruiting | ||
| Correlation Between Bleeding Complication and Treatment Failure of DOAC and Its Predictions Based on Cipherome's Pharmacogenomic Technology[NCT04597593] | 200 participants (Actual) | Observational | 2020-10-07 | Completed | |||
| Effectiveness of the Timing of the Administration of Aspirin in Hypertensive Patients Treated With Low Doses of Acetyl Salicylic Acid for Secondary Prevention - TAHPS[NCT01741922] | Phase 3 | 230 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| Efficacy and Safety of Clopidogrel for Primary Prevention in Patients With Subclinical Coronary Atherosclerosis Identified on Imaging[NCT05845489] | Phase 4 | 9,930 participants (Anticipated) | Interventional | 2023-03-09 | Recruiting | ||
| Aspirin Discontinuation After Left Atrial Appendage Occlusion in Atrial Fibrillation[NCT03821883] | 1,120 participants (Anticipated) | Interventional | 2020-06-01 | Recruiting | |||
| Study of the Effect of Eicosapentaenoic Acid (EPA) on Markers of Atherothrombosis in Patients With Type-2 Diabetes[NCT06129526] | Phase 4 | 450 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Japanese Primary Prevention Project With Aspirin in the Elderly With One or More Risk Factors of Vascular Events: JPPP[NCT00225849] | Phase 4 | 10,000 participants | Interventional | 2005-03-31 | Recruiting | ||
| A Clinical Multicenter, Prospective, Observational Cohort Study to Validate a Prediction Mobile APP for Perioperative Hypothermia[NCT05333120] | 3,000 participants (Anticipated) | Observational [Patient Registry] | 2021-05-25 | Recruiting | |||
| Influence of Different Inspired Oxygen Fractions on Perioperative Myocardial Biomarkers, Myocardial Strain and Outcome in Patients Undergoing General Anaesthesia for Elective Non-cardiac Surgery: A Prospective Randomized Open-label Single Centre Pilot Stu[NCT04808401] | 110 participants (Anticipated) | Interventional | 2021-05-07 | Recruiting | |||
| Closed Incision Negative Pressure Therapy Compared to Conventional Dressing Following Autologous Abdominal Tissue Breast Reconstruction: A Randomized Control Trial[NCT05907941] | 114 participants (Anticipated) | Interventional | 2023-07-31 | Not yet recruiting | |||
| The Efficacy and Safety of Proton Pump Inhibitor ( in Patients With Moderate Bleeding Risk and Coronary Artery Disease Undergoing Percutaneous Coronary: A Randomised, Open ,Compared With Control[NCT05820048] | Phase 4 | 300 participants (Anticipated) | Interventional | 2023-05-01 | Not yet recruiting | ||
| Multicenter Randomized, Double-blind, Placebo-controlled, Clinical Trial of Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients (Asperum)[NCT04808895] | Phase 3 | 204 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | ||
| Clinical Study Evaluating the Gastroprotective Effect of Carvedilol in Patients With Ischemic Heart Disease on Aspirin Therapy[NCT05553717] | 66 participants (Anticipated) | Interventional | 2022-10-31 | Not yet recruiting | |||
| The Northwest Coalition for Primary Care Practice Support[NCT02839382] | 209 participants (Actual) | Interventional | 2015-05-01 | Completed | |||
| Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment[NCT00912756] | Phase 4 | 200 participants (Anticipated) | Interventional | 2009-03-31 | Recruiting | ||
| Fixed Combination for Lipid and Blood Pressure Control. Randomized Cross-over Study[NCT03047538] | Phase 4 | 0 participants (Actual) | Interventional | 2017-09-01 | Withdrawn (stopped due to Insufficient funds) | ||
| A Randomised Controlled Trial of a Fixed-dose Combination Polypill Medication (the Red Heart Pill) and Usual Care in Those at High Risk of Cardiovascular Disease.[NCT01057537] | Phase 3 | 2,004 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Must Aspirin be Discontinued Prior to TURBT: a Prospective, Randomized, Non-inferiority Trial Comparing Peri-operative Aspirin Continuation Versus Discontinuation.[NCT02350543] | Phase 4 | 50 participants (Actual) | Interventional | 2015-02-28 | Terminated (stopped due to Insufficient recruitment.) | ||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| USE OF KEFIR AS A CO-ADJUVANT IN THE TREATMENT OF METABOLIC SYNDROME COMPONENTS: a Double-blind, Randomized, Placebo Controlled Clinical Trial[NCT03649828] | 48 participants (Actual) | Interventional | 2016-07-01 | Completed | |||
| COMT on Aspirin Platelets Effects (CAPE)[NCT03433586] | Phase 4 | 45 participants (Anticipated) | Interventional | 2020-07-10 | Recruiting | ||
| Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography.[NCT02874287] | Phase 4 | 35 participants (Actual) | Interventional | 2017-10-08 | Completed | ||
| Fixed-dose Combination Therapy (PolyPill) in Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians - Focus on Liver-Related Variables.[NCT01245608] | Phase 3 | 2,400 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Effects of Synbiotics Supplementation on the Concentration of the Uremic Toxin Indoxyl Sulfate, Symptoms of Constipation, and Constipation-related Quality of Life in End-stage Renal Disease Patients Undergoing Hemodialysis[NCT04527640] | 60 participants (Anticipated) | Interventional | 2020-09-15 | Not yet recruiting | |||
| A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM[NCT02334969] | Phase 4 | 2,200 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin[NCT03869268] | Phase 4 | 72 participants (Actual) | Interventional | 2019-04-24 | Completed | ||
| Aspirin Withdrawal and Clinical Outcome in Patients With Moderate to High Cardiovascular Risk But Without Cardiovascular Disease[NCT03757156] | 4,118 participants (Anticipated) | Interventional | 2019-03-31 | Not yet recruiting | |||
| A Different Approach to Preventing Thrombosis (ADAPT): A Randomized Controlled Trial Comparing Low Molecular Weight Heparin to Acetylsalicylic Acid in Orthopedic Trauma Patients[NCT02774265] | Phase 3 | 329 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Pilot Intervention to Improve the Transition From Hospital to Home[NCT01431846] | 19 participants (Actual) | Interventional | 2011-08-31 | Completed | |||
| Association Between Perioperative Bleeding and Aspirin Use in Spine Surgery: A Randomized, Controlled Trial[NCT02807441] | Phase 3 | 0 participants (Actual) | Interventional | 2016-07-31 | Withdrawn | ||
| Personalization of Long-Term Antiplatelet Therapy Using a Novel Combined Demographic/Pharmacogenomic Strategy - The RAPID EXTEND Randomized Study[NCT03729401] | Phase 4 | 390 participants (Anticipated) | Interventional | 2019-08-22 | Suspended (stopped due to Testing supplies unavailable.) | ||
| A Randomized, Single Center Trial to Assess the Endothelial Function With Ticagrelor Monotherapy Compared to Aspirin Monotherapy in Patients With History of Acute Coronary Syndrome[NCT03881943] | Phase 4 | 200 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
| Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg Twice Daily in Elderly Patients With Acute Coronary Syndrome (ACS)[NCT04739384] | Phase 3 | 50 participants (Actual) | Interventional | 2021-04-01 | Completed | ||
| A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myoca[NCT01225562] | Phase 3 | 21,379 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S[NCT00977938] | Phase 4 | 25,682 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Dissemination of CVD Risk Factor Treatment Among Diabetic Patients in Safety Net Clinics[NCT02299791] | 4,856 participants (Actual) | Interventional | 2010-09-30 | Completed | |||
| Allogeneic Mesenchymal Stromal Cells for Angiogenesis and Neovascularization in No-option Ischemic Limbs; A Double-blind, Randomized, Placebo-controlled Trial[NCT03042572] | Phase 2/Phase 3 | 60 participants (Anticipated) | Interventional | 2018-12-31 | Not yet recruiting | ||
| Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Patients With Chronic Critical Limb Ischemia: a Randomized, Placebo-controlled Clinical Trial[NCT00371371] | Phase 1/Phase 2 | 160 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Evaluation of Some Emerging Biomarkers of Cardiovascular Risk Stratification in Hypertensive Patients: a 5-years Follow-up[NCT02064218] | 0 participants | Observational | 2007-11-30 | Recruiting | |||
| BEta Blocker dEprescription Following Coronary Artery Bypass Graft sURGERy: Feasibility and Safety Pilot (BEEFBURGER Trial)[NCT04788186] | Phase 4 | 200 participants (Anticipated) | Interventional | 2021-08-23 | Recruiting | ||
| Prospective Urban Rural Epidemiology Study[NCT03225586] | 200,000 participants (Anticipated) | Observational | 2002-01-01 | Recruiting | |||
| Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)[NCT00593450] | Phase 3 | 1,208 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Aspirin Resistance in Obstructive Sleep Apnea Patients (ARISA Trial)[NCT03930875] | 63 participants (Actual) | Observational | 2017-12-12 | Completed | |||
| A 12-Month, Phase 3, Open-Label, Multi-Center Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers[NCT00995410] | Phase 3 | 380 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Adaptation of an eHealth (Web-application) Platform for Delivery of a Sedentary Behavior Intervention Among Prostate Cancer Patients[NCT03740035] | 4 participants (Actual) | Observational | 2018-08-13 | Terminated (stopped due to Pl left institution) | |||
| The Effect Of Aspirin On Survival in in Patients Undergoing Chronic Hemodialysis[NCT02261025] | 410 participants (Actual) | Interventional | 2008-01-31 | Completed | |||
| The Effect of Remote Ischemic Preconditioning on Myocardial Injury After Noncardiac Surgery in Patients at a High Risk of Cardiac Events[NCT05733208] | 766 participants (Anticipated) | Interventional | 2023-05-06 | Recruiting | |||
| Association of PeriOPerative Aspirin-ResisTance and CardioVascular Outcome[NCT04053894] | 220 participants (Anticipated) | Observational | 2019-08-31 | Not yet recruiting | |||
| Nurses' Health Study (Cardiovascular Component)[NCT00005152] | 121,700 participants (Actual) | Observational | 1980-08-31 | Active, not recruiting | |||
| Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial[NCT00041938] | Phase 3 | 2,305 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial[NCT00110448] | Phase 4 | 2,539 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145] | Phase 4 | 40 participants (Actual) | Interventional | 2020-06-23 | Completed | ||
| Prioritized Clinical Decision Support (CDS) to Reduce Cardiovascular Risk[NCT01420016] | 7,914 participants (Actual) | Interventional | 2012-08-20 | Completed | |||
| Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029] | Phase 3 | 4,881 participants (Actual) | Interventional | 2010-05-28 | Terminated (stopped due to The trial was halted by the DSMB.) | ||
| Influence of Pelacarsen on Arterial Wall Properties and Risk Factors in Patients After Myocardial Infarction With High Lp(a) Values[NCT04993664] | 0 participants (Actual) | Interventional | 2021-10-01 | Withdrawn (stopped due to Administrative reason) | |||
| Genetic, Biochemical and Functional Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment Options[NCT04613167] | 70 participants (Anticipated) | Interventional | 2020-11-10 | Recruiting | |||
| A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low[NCT00050817] | Phase 3 | 15,603 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| The AHEAD Study: Monitoring Anticoagulated Patients Who Suffer Head Injury[NCT02461498] | 3,556 participants (Actual) | Observational | 2011-07-31 | Completed | |||
| Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events[NCT02616497] | Phase 4 | 1,220 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| A Randomized Double Blind Controlled Trial of the Efficacy and Safety of POLYCAP (Quintapill)Versus Its Components in Subjects With at Least One Additional Cardiovascular Risk Factor[NCT00443794] | 2,050 participants (Actual) | Interventional | 2007-03-31 | Completed | |||
| Antithrombotic Drug Use in Patients With Ischemic Stroke and Microbleeds[NCT05032053] | 3,000 participants (Anticipated) | Observational [Patient Registry] | 2022-03-01 | Recruiting | |||
| Pragmatic Randomized Controlled Trial Comparing Treatment Effectiveness of Guideline Indicated Anti-platelet Therapy for Acute Coronary Syndrome in Patients With Chronic Kidney Disease[NCT03150667] | Phase 4 | 220 participants (Anticipated) | Interventional | 2017-04-10 | Recruiting | ||
| HOST-EXAM-Ex : Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - EXtended Antiplatelet Monotherapy - EXtended Follow up[NCT05567536] | 5,530 participants (Actual) | Observational | 2014-03-01 | Active, not recruiting | |||
| Improving Equitable Acces and Adherence to Secondary Prevention Therapy With a Fixed-Dose Combination Drug[NCT01321255] | Phase 3 | 2,118 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| Antiplatlet Effects of Standardized Tomato Extract in Hypertensive Subjects at High Estimated Cardiovascular Risk[NCT03206944] | Phase 4 | 82 participants (Actual) | Interventional | 2015-07-01 | Completed | ||
| Lipid Management in Renal Transplant Recipients: A Pilot Study Evaluating the Use of PCSK-9 Inhibitor, Evolocumab.[NCT04608474] | Phase 4 | 120 participants (Anticipated) | Interventional | 2021-02-17 | Recruiting | ||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization[NCT03953547] | 88 participants (Actual) | Observational | 2018-01-01 | Completed | |||
| DPP-4 Inhibitors in Patients With Type 2 Diabetes and Acute Myocardial Infarction:Effects on Platelet Function[NCT02377388] | Phase 3 | 74 participants (Actual) | Interventional | 2017-02-07 | Completed | ||
| [NCT00153725] | 156 participants | Interventional | 2003-02-28 | Completed | |||
| A Prospective, Nonrandomized, Study Comparing the Use of Aspirin and Intraoperative Blood Loss and Postoperative Complications Following Open Inguinal Hernia Repair.[NCT02084615] | 300 participants (Anticipated) | Interventional | 2014-08-31 | Enrolling by invitation | |||
| Maintenance of an Antiaggregation by Acetylsalicylic Acid, Less or Equal to 250mg While a Extracorporeal Lithotripsy (ECL) Session on a Kidney Stone is Perfomed: Comparative Unicentric Prospective Study[NCT03437057] | 300 participants (Anticipated) | Interventional | 2018-01-08 | Recruiting | |||
| A Prospective Descriptive, Multi-National, Multi-Centre Observational Study of Burden of Upper GI-Symptoms in Subjects With Cardiovascular Risk or Disease Receiving Treatment With Low-Dose Aspirin[NCT00681759] | 1,836 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| Intensified Antiplatelet Therapy in Post-PCI Patients With High On-treatment Platelet Reactivity: the OPTIMA-2 Trial[NCT01955200] | Phase 4 | 1,724 participants (Actual) | Interventional | 2013-10-05 | Completed | ||
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy.[NCT00335452] | Phase 3 | 25,086 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events: A Pilot Study[NCT01945268] | Phase 4 | 107 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events[NCT02762851] | Phase 4 | 5,000 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease[NCT00557921] | Phase 3 | 5,000 participants (Anticipated) | Interventional | 2007-12-31 | Terminated (stopped due to Terminated by Sponsor) | ||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy[NCT02049762] | Phase 4 | 29 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| A Prospective Randomized Control Trial of the Effect of Sorafenib Combined With Aspirin in Preventing the Recurrence in High-risk Patients With Hepatocellular Carcinoma[NCT02748304] | 52 participants (Actual) | Interventional | 2016-04-30 | Terminated (stopped due to The enrollment of this study was slow. With the approval of lenvatinib in HCC,many patients choose the new drug, so subsequent enrollment may be more difficult.) | |||
| Omega EVAR: Use of Fish Oil to Reduce Inflammation During Endovascular Abdominal Aortic Repair.[NCT03208920] | 2 participants (Actual) | Interventional | 2016-12-31 | Completed | |||
| The Feasibility of a Polypill Clinical Trial for Primary Prevention of Cardiovascular Disease: A Pilot Study[NCT00567307] | Phase 2 | 216 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Prognostic Models for People With Stable Coronary Artery Disease[NCT01609465] | 300,000 participants (Anticipated) | Observational | 2010-01-31 | Active, not recruiting | |||
| Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy for Secondary Prevention[NCT01888575] | 35,604 participants (Actual) | Observational | 2012-09-30 | Completed | |||
| The Risk of Uncomplicated Peptic Ulcer in a Cohort of Secondary Prevention Aspirin Users[NCT01814943] | 39,000 participants (Actual) | Observational | 2012-11-30 | Completed | |||
| Thrombosis in Newly Diagnosed Multiple Myeloma Patients: a Clinical Audit of Intermediate Dose Low Molecular Weight Heparin[NCT05541978] | 140 participants (Actual) | Observational | 2022-09-01 | Completed | |||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease[NCT02719665] | 30 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| Assessment of Exercise Capacity, Physical Activity, Pulmonary Function, Peripheric and Respiratory Muscle Strength, Respiratory Muscle Endurance in Patient With Peripheral Artery Disease[NCT03458754] | 35 participants (Actual) | Observational | 2018-01-01 | Completed | |||
| Risk Informed Intervention Development and Implementation of Safe Ambulatory Care[NCT01247454] | 7,000 participants (Actual) | Interventional | 2009-07-31 | Completed | |||
| Antiplatelet Therapy in HIV - Antiplatelet and Immune Modulating Effects of Aspirin or Clopidogrel in Subjects With HIV[NCT02559414] | Phase 2 | 55 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| MONET BRIDGE(Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery) - (Mantenimento Della Terapia Antiaggregante Nei Pazienti Portatori di Stent Coronarico Candidati a Chirurgia)[NCT03862651] | Phase 2 | 140 participants (Anticipated) | Interventional | 2019-06-01 | Not yet recruiting | ||
| Multicenter, Prospective Cohort of Patient With Coronary Stents Undergoing Non Cardiac Surgery or Invasive Procedures.[NCT01045850] | 1,312 participants (Actual) | Observational | 2006-02-28 | Completed | |||
| To Investigate Post-procedure Hemorrhage and Cardiovascular Events in Taiwanese Patients Who Continue or Discontinue Low-Dose Aspirin Before Transrectal Prostate Biopsy: a Prospective Randomized Trial[NCT02744937] | Phase 4 | 150 participants (Anticipated) | Interventional | 2016-04-30 | Not yet recruiting | ||
| Acetylsalicylic Acid Administered in Patients With Type 2 Diabetes Mellitus and Its Effect on the Antioxidant Enzyme System[NCT03341117] | Phase 3 | 21 participants (Actual) | Interventional | 2014-12-02 | Completed | ||
| Evaluation of Aspirin Resistance at a Molecular Level in Aspirin-Treated Patients With Coronary Artery Disease[NCT00753935] | Early Phase 1 | 92 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Steps to Eliminate Postoperative Problems[NCT02880176] | 34 participants (Actual) | Interventional | 2016-08-31 | Completed | |||
| Aspirin Statins Or Both For The Reduction Of Thrombin Generation In Diabetic People[NCT00793754] | Phase 4 | 30 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Wiser Choices for Patients With Type II Diabetes: Diabetes Medication Choice[NCT00388050] | 85 participants (Actual) | Interventional | 2006-07-31 | Completed | |||
| Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting[NCT01159639] | Phase 4 | 200 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed[NCT00699998] | Phase 3 | 9,326 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| A Randomized, Double-blind, Parallel-group, Multicentre, Phase III Study to Assess the Effect of Esomeprazole 20 or 40 mg od Versus Placebo on the Occurrence of Peptic Ulcers During 26 Weeks in Subjects on Continuous Low Dose Acetylsalicylic Acid (ASA)[NCT00441727] | Phase 3 | 2,426 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| A Randomised Controlled Cross-over Trial to Evaluate Evening Versus Morning Administration of a Cardiovascular Polypill[NCT01506505] | 78 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| [NCT00000500] | Phase 3 | 0 participants | Interventional | 1981-09-30 | Completed | ||
| Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.[NCT00222261] | Phase 4 | 1,001 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Impact of Breathing Exercises and Meditation on Health-Related Quality of Life in Dry Eye Disease Patients: A Pilot Study[NCT03345381] | 70 participants (Anticipated) | Interventional | 2019-07-01 | Not yet recruiting | |||
| Automated Morphological Analysis of Meibomian Glands[NCT04052841] | 180 participants (Anticipated) | Interventional | 2020-10-12 | Recruiting | |||
| Automatic Self Transcending Meditation (ASTM) Plus Treatment As Usual (TAU) Versus TAU Alone in Patients With Dry Eye Disease (DED): a Single Blind Randomized Controlled Longitudinal Study[NCT03087006] | 256 participants (Anticipated) | Interventional | 2018-07-01 | Not yet recruiting | |||
| Study on the Effectiveness of Eye-drops Containing Cross-linked Hyaluronic Acid and Coenzyme Q10 in the Treatment of Patients With Mild to Moderate Dry Eye[NCT03074344] | 40 participants (Actual) | Interventional | 2016-05-31 | Completed | |||
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome)[NCT00272311] | Phase 4 | 70 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation & Endothelial Function in Secondary Prevention (Pts w/Chronic Stable Coronary Disease)[NCT00272337] | Phase 4 | 37 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| [NCT00005182] | 50,000 participants (Actual) | Observational | 1985-12-31 | Completed | |||
| Treatment of Periodontal Disease in Patients With Acute Myocardial Infarction: Randomized Controlled Trial[NCT02543502] | 54 participants (Actual) | Interventional | 2012-08-31 | Completed | |||
| Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention[NCT00413309] | 30 participants (Anticipated) | Interventional | 2006-04-30 | Completed | |||
| A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study With In-House Blinding to Determine the Effect of 156 Weeks of Treatment With MK0966 on the Recurrence of Neoplastic Polyps of the Large Bowel in Patients With a History of [NCT00282386] | Phase 3 | 2,586 participants (Actual) | Interventional | 1999-12-23 | Completed | ||
| The Effect of Serum LDL Lowering on Aspirin Resistance[NCT00466154] | 40 participants | Interventional | 2005-07-31 | Completed | |||
| Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
| Study of Heart and Renal Protection (SHARP): The Effects of Lowering LDL-cholesterol With Simvastatin 20mg Plus Ezetimibe 10mg in Patients With Chronic Kidney Disease: a Randomized Placebo-controlled Trial[NCT00125593] | Phase 4 | 9,438 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Clinical Registration Trial of Intracranial Stenting for Patients With Symptomatic Intracranial Artery Stenosis:A Prospective Multi-center, Registry Trial[NCT01994161] | 840 participants (Anticipated) | Observational [Patient Registry] | 2012-12-31 | Recruiting | |||
| Phase III Study of Pharos Vitesse Neurovascular Stent System Compared to Best Medical Therapy for the Treatment of Ischemic Disease[NCT00816166] | Phase 2/Phase 3 | 125 participants (Actual) | Interventional | 2008-10-31 | Terminated | ||
| Registry of Emergent Large veSsel oCclUsion duE to IntraCranial AtherosclerosiS[NCT05403593] | 600 participants (Anticipated) | Observational [Patient Registry] | 2021-12-15 | Recruiting | |||
| An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis[NCT00929383] | 82 participants (Actual) | Observational | 2009-02-28 | Completed | |||
| A Prospective, Multi-center, Randomized Controlled Study to Evaluate the Safety and Efficacy of the Maurora® Sirolimus-Eluting Stent Versus the Apollo Stent in Intracranial Atherosclerotic Stenosis(Maurora ICAS Trial)[NCT05719883] | 156 participants (Anticipated) | Interventional | 2023-02-20 | Recruiting | |||
| The Role of Additional Antiplatelet Therapy in the Ischemic Stroke With Atrial Fibrillation and Co-morbiD Atherosclerosis During edOxaban treatmeNt. (ADD-ON) Study, Multicenter Registry-based Analysis[NCT04010955] | 1,200 participants (Anticipated) | Observational [Patient Registry] | 2019-10-01 | Recruiting | |||
| Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial: a Prospective, Randomized, Open-labelled, Blinded End-point Trial (DREAM-PRIDE)[NCT04948749] | 792 participants (Anticipated) | Interventional | 2021-07-02 | Recruiting | |||
| PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis[NCT03507374] | Early Phase 1 | 20 participants (Actual) | Interventional | 2018-10-30 | Terminated (stopped due to Funding withdrawn) | ||
| Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging[NCT05907629] | 300 participants (Anticipated) | Observational | 2023-12-30 | Not yet recruiting | |||
| China Angioplasty & Stenting for Symptomatic Intracranial Severe Stenosis (CASSISS): a New, Prospective, Multi-center, Randomized Controlled Trial in China[NCT01763320] | Phase 3 | 380 participants (Actual) | Interventional | 2014-03-05 | Completed | ||
| Effect of Low Molecular Weight Heparin vs Unfractionated Heparin on Bleeding After Cardiac Surgery[NCT00420667] | 43 participants (Actual) | Interventional | 2004-11-30 | Completed | |||
| Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273] | 1,800 participants (Anticipated) | Observational [Patient Registry] | 2018-11-21 | Not yet recruiting | |||
| Prevalence of Aspirin Resistance in Ischemic Stroke Patients at Assiut University Hospital[NCT05151263] | 133 participants (Anticipated) | Observational | 2023-11-01 | Not yet recruiting | |||
| Effects of Coenzyme Q10 in Parkinson Disease - Phase III[NCT00740714] | Phase 3 | 600 participants (Actual) | Interventional | 2008-12-31 | Terminated (stopped due to The investigational drug is unlikely to demonstrate efficacy over placebo for this indication. However, no safety issues were discovered.) | ||
| Effect of Aspirin Intake on Awakening Versus at Bedtime on Circadian Rhythm of Platelet Reactivity in Healthy Subjects[NCT01900639] | Phase 4 | 14 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| Antiplatelet Activity of Aspirin in Infants After Aortopulmonary and Cavopulmonary Shunts[NCT01656993] | 25 participants (Actual) | Observational | 2012-11-30 | Completed | |||
| Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke (ATAMIS): a Parallel Randomized, Open-label, Multicenter, Prospective Study[NCT02869009] | Phase 3 | 3,000 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| The Effect of Inducing the Cytochrome P450 System on the Pharmacodynamic Efficacy of Clopidogrel[NCT01330589] | 0 participants (Actual) | Interventional | 2011-04-30 | Withdrawn (stopped due to Inability to enroll subjects and changes in standard of care for PCI) | |||
| A Prospective, Multicentre, Open-label, Single-arm Interventional Study of Bisoprolol (Nerkardou) (Between Low Dose and High Dose) 5 and 10 mg ODF Treatment In Egyptian Patients With Essential Hypertension[NCT05880056] | Phase 4 | 827 participants (Anticipated) | Interventional | 2023-07-15 | Not yet recruiting | ||
| Prevention of Sporadic Colorectal Adenomas With Celecoxib[NCT00005094] | Phase 3 | 1,170 participants (Anticipated) | Interventional | 2000-03-31 | Completed | ||
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614] | Phase 2 | 58 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)[NCT00141193] | Phase 3 | 1,561 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| [NCT00000152] | Phase 3 | 0 participants | Interventional | 1982-04-30 | Active, not recruiting | ||
| A Phase III Randomized Trial of Warfarin Plus Antiplatelet Therapy Versus Antiplatelet Therapy Alone in Patients With Peripheral Vascular Disease[NCT00125671] | Phase 3 | 2,400 participants | Interventional | 2000-01-31 | Active, not recruiting | ||
| Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in Subjects With Symptomatic Peripheral Artery Disease (PAD) Undergoing Infrapopliteal Endovascular Peripheral Revascularization Procedures in Patients With Critical Limb[NCT04229264] | Phase 3 | 200 participants (Anticipated) | Interventional | 2020-01-09 | Recruiting | ||
| Effect of Low Dose of Colchicine on Platelet Reactivty in Patients With Chronic Coronary Disease[NCT05956145] | Phase 3 | 80 participants (Anticipated) | Interventional | 2021-06-17 | Recruiting | ||
| A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of Lansoprazole 30 mg QD and Naproxen 500 mg BID Versus Celecoxib 200 mg QD in Risk Reduction of Non Steroidal Anti-Inflammatory-Associated Ulcers in Osteoarthritis Subjects Taki[NCT00175032] | Phase 3 | 1,045 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| The Impact of Novel Strategies to Improve Cardiometabolic Status and Adherence to Exercise Regimens in Patients at High Risk for Cardiovascular Disease[NCT03103854] | 500 participants (Anticipated) | Interventional | 2014-01-01 | Recruiting | |||
| Intensified Multifactorial Intervention in Patients With Type 2 Diabetes and Microalbuminuria[NCT00320008] | 160 participants (Actual) | Interventional | 1992-01-31 | Active, not recruiting | |||
| A Randomised Controlled Trial of a Duodenal Sleeve Bypass Device (EndoBarrier)Compared With Standard Medical Therapy for the Management of Obese Subjects With Type 2 Diabetes[NCT02459561] | 170 participants (Actual) | Interventional | 2015-03-31 | Active, not recruiting | |||
| Optimized Antiplatelet Therapy With Aspirin and Clopidogrel Improves Mortality Compared to Standard Treatment.[NCT01796691] | 600 participants (Actual) | Observational | 2009-01-31 | Completed | |||
| Optimizing Therapy With Aspirin and Clopidogrel. The BOchum CLopidogrel and Aspirin Plan to Improve Dual Antiplatelet Therapy.[NCT01212302] | 500 participants (Actual) | Interventional | 2008-10-31 | Completed | |||
| PPD Trial Pilot Study: Plavix, Prasugrel and Drug Eluting Stents[NCT01103843] | 1,000 participants (Anticipated) | Interventional | 2010-04-30 | Recruiting | |||
| Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes: Role of Inflammation, Kynurenine Pathway, and Structural and Functional Brain Connectivity as Biomarkers[NCT03580967] | Phase 4 | 0 participants (Actual) | Interventional | 2019-07-01 | Withdrawn (stopped due to COVID-19 Pandemic interfered with Pt recruitment) | ||
| Phase II Study of Heart Polypill in Primary Prevention of Cardiovascular Disease - Safety and Efficacy[NCT00603590] | Phase 2 | 475 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| [NCT00000491] | Phase 3 | 0 participants | Interventional | 1974-10-31 | Completed | ||
| [NCT00000157] | Phase 3 | 0 participants | Interventional | 1982-04-30 | Terminated | ||
| Does Acetaminophen Potentiate the Gastroduodenal Mucosal Injury of Aspirin? A Prospective, Randomized, Pilot Study.[NCT00594867] | Phase 4 | 94 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension: A Pilot Study[NCT04908982] | Phase 4 | 60 participants (Anticipated) | Interventional | 2021-05-28 | Recruiting | ||
| [NCT00005151] | 0 participants | Observational | 1980-08-31 | Completed | |||
| Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease[NCT00874432] | Phase 2 | 43 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Pivotal Study To Evaluate The Effectiveness of Isometric Handgrip Therapy In Prehypertensive And Hypertensive Patients[NCT04467879] | 146 participants (Actual) | Interventional | 2020-06-01 | Terminated (stopped due to New Protocol and Outcome Measures in Review) | |||
| Influence of SPRINT Trial Type Blood Pressure Measurements on Hypertension Diagnosis in Patients After Kidney Transplantation[NCT03094702] | 120 participants (Actual) | Observational | 2017-01-01 | Completed | |||
| Efficacy and Tolerability of Combination Antihypertensive Drug in Non-Responders to Angiotensin Receptor Blocker(ARB) monoTHerapy Using 24h ABPM.[NCT01713920] | Phase 4 | 68 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| [NCT00005493] | 0 participants | Observational | 1998-04-30 | Completed | |||
| The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093] | 280 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913] | Phase 3 | 300 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Comparative Study of Clinical Efficacy and Safety of Different Clopidogrel Salts in Patients With Cardiovascular Disease. A Multi-center Non-interventional Clinical Trial.[NCT02126982] | 1,500 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| The Association Between Plasma or Platelet microRNAs and Clopidogrel Low Response and Its Mechanism[NCT02447809] | Phase 4 | 400 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| The Evaluation of Nutrition Status in Persons With Age-Related Macular Degeneration[NCT03326401] | 200 participants (Actual) | Observational | 2015-07-01 | Completed | |||
| Do Innovative Strategies Complement Medical Management to Reduce Cardiovascular Risk Factors Following Coronary Artery Bypass Graft Surgery?[NCT00462436] | Phase 2 | 35 participants (Anticipated) | Interventional | 2007-02-28 | Completed | ||
| Prevention of Ischemic Events in Patients With Peripheral Arterial Disease by the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice[NCT00761969] | 1,455 participants (Actual) | Observational | 2004-12-31 | Completed | |||
| Evaluation of Platelet Aggregation and Adenosine Levels in Patients With Coronary Artery Disease and Chronic Kidney Dysfunction Taking Dual Antiplatelet Therapy With Aspirin and Clopidogrel or Ticagrelor[NCT03039205] | Phase 2 | 90 participants (Actual) | Interventional | 2017-11-07 | Completed | ||
| Efficacy of Medifast's 5 & 1 Program Compared to a Food-based Diet After a Period of Weight Loss and Weight Maintenance[NCT01011491] | 90 participants (Actual) | Interventional | 2008-03-31 | Completed | |||
| Renal and Cardiovascular Impairment in WTC Responders: Implications for Diagnosis and Treatment[NCT02246101] | 406 participants (Actual) | Observational | 2014-07-31 | Completed | |||
| Study of Trends in Cardiovascular Risk Factors in an Urban Population.[NCT00005145] | 0 participants | Observational | 1979-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Change of maximal postischemic forearm blood flow during reactive hyperaemia after 5 min of forearm ischemia (FBF max. ml/100ml).~Difference of change in post-ischemic forearm blood flow measured by venous occlusion plethysmography at baseline and after 20 weeks treatment with rivaroxaban or aspirin." (NCT02164578)
Timeframe: Baseline and week 20
| Intervention | ml/100ml (Mean) |
|---|---|
| Rivaroxaban | 3.60 |
| Aspirin | 1.00 |
Difference of change in post-ischemic forearm blood flow measured by venous occlusion plethysmography at baseline and after 52 weeks treatment with rivaroxaban or aspirin. (NCT02164578)
Timeframe: Baseline and week 52
| Intervention | ml/100ml (Mean) |
|---|---|
| Rivaroxaban | 6.11 |
| Aspirin | 1.56 |
Change in pulse wave velocity as a marker for arterial stiffness (measured by IEM Mobil-O-Graph) (NCT02164578)
Timeframe: Baseline to week 20
| Intervention | m/s (Mean) |
|---|---|
| Rivaroxaban | 0.02 |
| Aspirin | 0.14 |
Change in pulse wave velocity as a marker of arterial stiffness (measured by IEM Mobil-O-Graph) (NCT02164578)
Timeframe: Baseline and week 52
| Intervention | m/s (Mean) |
|---|---|
| Rivaroxaban | 0.24 |
| Aspirin | 0.51 |
Change in skin blood flow for assessment of peripheral skin microcirculatory function (measured by laserdopplerfluxmetry; LDF) (NCT02164578)
Timeframe: Baseline to week 20
| Intervention | arbitrary units (Mean) |
|---|---|
| Rivaroxaban | 3.47 |
| Aspirin | -6.01 |
Change in skin blood flow for assessment of peripheral skin microcirculatory function (measured by laserdopplerfluxmetry; LDF) (NCT02164578)
Timeframe: Baseline to week 52
| Intervention | arbitrary units (Mean) |
|---|---|
| Rivaroxaban | -7.3 |
| Aspirin | 5.8 |
"Clinically relevant non-major (CRNM) bleeding defined as at least one of the following:~spontaneous skin hematoma of at least 25 cm~spontaneous nose bleeding of more than 5 minutes duration~macroscopic hematuria, either spontaneous or, if associated with an intervention, lasting more than 24 hours~spontaneous rectal bleeding (more than spotting on toilet paper)~gingival bleeding for more than 5 minutes~bleeding leading to hospitalization and/or requiring surgical treatment~bleeding leading to a transfusion of less than 2 units of whole blood or red cells~any other bleeding event considered clinically relevant by the investigator" (NCT02164578)
Timeframe: Week 1 to week 20
| Intervention | events (Number) |
|---|---|
| Rivaroxaban | 11 |
| Aspirin | 1 |
"Clinically relevant non-major (CRNM) bleeding defined as at least one of the following:~spontaneous skin hematoma of at least 25 cm~spontaneous nose bleeding of more than 5 minutes duration~macroscopic hematuria, either spontaneous or, if associated with an intervention, lasting more than 24 hours~spontaneous rectal bleeding (more than spotting on toilet paper)~gingival bleeding for more than 5 minutes~bleeding leading to hospitalization and/or requiring surgical treatment~bleeding leading to a transfusion of less than 2 units of whole blood or red cells~any other bleeding event considered clinically relevant by the investigator" (NCT02164578)
Timeframe: Week 1 to week 52
| Intervention | events (Number) |
|---|---|
| Rivaroxaban | 6 |
| Aspirin | 1 |
Major bleeding defined as clinically overt and associated with one of the following: 1) reduction of hemoglobin level of 2 g/L or 2) required transfusion of at least 2 units of red cells or, involved a critical organ or was fatal, in accordance with the recommendation of the International Society on Thrombosis and Hemostasis (ISTH). (NCT02164578)
Timeframe: Week 1 to week 20
| Intervention | events (Number) |
|---|---|
| Rivaroxaban | 1 |
| Aspirin | 0 |
Major bleeding defined as clinically overt and associated with one of the following: 1) reduction of hemoglobin level of 2 g/L or 2) required transfusion of at least 2 units of red cells or, involved a critical organ or was fatal, in accordance with the recommendation of the International Society on Thrombosis and Hemostasis (ISTH). (NCT02164578)
Timeframe: Week 1 to week 52
| Intervention | events (Number) |
|---|---|
| Rivaroxaban | 0 |
| Aspirin | 0 |
"Secondary efficacy assessments of aspirin involve intention-to-treat comparisons during the scheduled treatment period among all randomized participants on the first occurrence of:~Any incident gastrointestinal (GI) tract cancer (i.e. any GI cancer excluding pancreas and hepatobiliary), overall and after exclusion of the first three years of follow-up." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 157 |
| Placebo Aspirin | 158 |
"Secondary efficacy assessments involve intention-to-treat comparisons among all randomized participants of allocation to aspirin versus placebo and, separately, of omega-3 versus placebo on the first occurrence of the expanded vascular endpoint of SVE or revascularization (including coronary and non-coronary revascularizations)." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 833 |
| Placebo Aspirin | 936 |
| Omega-3 | 882 |
| Placebo Omega-3 | 887 |
"Incidence of fatal or non-fatal cancers. Any cancer excludes non-fatal non-melanoma skin cancer and non-fatal recurrence of a cancer that had occurred before randomization.~A single participant may have had multiple cancers." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 897 |
| Placebo Aspirin | 887 |
| Omega-3 | 894 |
| Placebo Omega-3 | 890 |
Includes fatal and non-fatal events. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Omega-3 | 166 |
| Placebo Omega-3 | 135 |
Includes fatal and non-fatal cancers. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 97 |
| Placebo Aspirin | 96 |
| Omega-3 | 103 |
| Placebo Omega-3 | 90 |
Includes fatal and non-fatal renal, bladder, prostate, gynaecological and other GU cancers (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 332 |
| Placebo Aspirin | 294 |
| Omega-3 | 323 |
| Placebo Omega-3 | 303 |
Includes fatal and non-fatal cancers. Includes leukaemia and lymphoma. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 88 |
| Placebo Aspirin | 86 |
| Omega-3 | 94 |
| Placebo Omega-3 | 80 |
Includes fatal and non-fatal melanomas. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 50 |
| Placebo Aspirin | 59 |
| Omega-3 | 55 |
| Placebo Omega-3 | 54 |
Includes fatal and non-fatal events, excludes atrial fibrillation. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Omega-3 | 83 |
| Placebo Omega-3 | 99 |
Includes fatal and non-fatal cancers not included elsewhere (where the type of cancer is known). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 25 |
| Placebo Aspirin | 30 |
| Omega-3 | 23 |
| Placebo Omega-3 | 32 |
Includes fatal and non-fatal cancers. Excludes cancers reported in the gastrointestinal tract category (see secondary outcome measure #4), and includes hepatobiliary and pancreatic cancers. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 87 |
| Placebo Aspirin | 82 |
Includes fatal and non-fatal cancers. Includes lung and larynx cancer. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 101 |
| Placebo Aspirin | 103 |
| Omega-3 | 104 |
| Placebo Omega-3 | 100 |
Includes fatal and non-fatal cancers of unknown type. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 26 |
| Placebo Aspirin | 31 |
| Omega-3 | 25 |
| Placebo Omega-3 | 32 |
Fatal 'All stroke' events include deaths from: Haemorrhagic stroke (Intracerebral haemorrhage; Subarachnoid haemorrhage); Non-haemorrhagic stroke (Cerebral infarction; Stroke not specified as haemorrhage or infarction). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 38 |
| Placebo Aspirin | 34 |
| Omega-3 | 35 |
| Placebo Omega-3 | 37 |
'All-cause mortality' includes all recorded deaths. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 748 |
| Placebo Aspirin | 792 |
| Omega-3 | 752 |
| Placebo Omega-3 | 788 |
Fatal 'Cancer' events include any death attributed to cancer. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 309 |
| Placebo Aspirin | 315 |
| Omega-3 | 305 |
| Placebo Omega-3 | 319 |
Fatal 'Coronary' events include deaths from: Acute MI and other CHD (unspecified Acute ischaemic heart disease; Atherosclerotic heart disease; Ischaemic cardiomyopathy; unspecified Chronic ischaemic heart disease). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 105 |
| Placebo Aspirin | 122 |
| Omega-3 | 100 |
| Placebo Omega-3 | 127 |
Fatal 'External cause' events include deaths from: Injury; Fracture; Self harm; and Medical and surgical complications (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 18 |
| Placebo Aspirin | 21 |
| Omega-3 | 17 |
| Placebo Omega-3 | 22 |
Fatal 'Other medical' events include deaths from: Non-vascular medical causes (excluding cancer and respiratory, including Fatal GI bleed or perforation); and deaths from Renal disease and Diabetes. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 126 |
| Placebo Aspirin | 157 |
| Omega-3 | 158 |
| Placebo Omega-3 | 125 |
Fatal 'Other vascular' events include deaths from: Heart failure (excluding ischaemic cardiomyopathy); Other vascular death (excluding stroke; and Cardiac death (excluding CHD). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 67 |
| Placebo Aspirin | 70 |
| Omega-3 | 61 |
| Placebo Omega-3 | 76 |
Fatal 'Respiratory' events include any death attributed to respiratory causes. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 82 |
| Placebo Aspirin | 69 |
| Omega-3 | 73 |
| Placebo Omega-3 | 78 |
Any death for which the cause is not known. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 3 |
| Placebo Aspirin | 4 |
| Omega-3 | 3 |
| Placebo Omega-3 | 4 |
"The primary safety assessments involve intention-to-treat comparisons among all randomized patients of allocation to aspirin versus placebo on the first occurrence of any major bleed, defined as:~any confirmed intracranial hemorrhage (including intracerebral, subarachnoid, subdural or any other intracranial hemorrhage); or~sight-threatening eye bleeding; or~any other serious bleeding episode." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 314 |
| Placebo Aspirin | 245 |
"The primary efficacy assessments involve intention-to-treat comparisons among all randomized participants of allocation to aspirin versus placebo and, separately, of omega-3 fatty acids versus placebo on the first occurrence of any Serious Vascular Event (SVE), defined as:~non-fatal myocardial infarction; or~non-fatal stroke (excluding confirmed intracranial hemorrhage) or TIA; or~vascular death excluding confirmed intracranial hemorrhage (defined as International Classification of Diseases 10th revision [ICD-10] I00-52 or I63-99, i.e. excluding subarachnoid hemorrhage [I60], intracerebral hemorrhage [I61], and other non-traumatic intracranial hemorrhage [I62])." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 658 |
| Placebo Aspirin | 743 |
| Omega-3 | 689 |
| Placebo Omega-3 | 712 |
Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 313 |
| Rivaroxaban 5mg + Aspirin Placebo | 366 |
| Rivaroxaban Placebo + Aspirin 100mg | 378 |
Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 282 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 389 |
| Rivaroxaban 5mg + Aspirin Placebo | 453 |
| Rivaroxaban Placebo + Aspirin 100mg | 516 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 329 |
| Rivaroxaban 5mg + Aspirin Placebo | 397 |
| Rivaroxaban Placebo + Aspirin 100mg | 450 |
Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 379 |
| Rivaroxaban 5mg + Aspirin Placebo | 448 |
| Rivaroxaban Placebo + Aspirin 100mg | 496 |
Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 353 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 288 |
| Rivaroxaban 5mg + Aspirin Placebo | 255 |
| Rivaroxaban Placebo + Aspirin 100mg | 170 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 138 |
"Transprosthetic mean pressure gradiënt as determined by transthoracic echocardiography at three months after randomization.~scale [0-100]" (NCT02833948)
Timeframe: 3 months
| Intervention | mm Hg (Mean) |
|---|---|
| ASA + Clopidogrel | 10 |
| Rivaroxaban + ASA | 10 |
Death, Dichotomization by HALT (NCT02833948)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| HALT (-) | 0 |
| HALT (+) | 0 |
Death, Dichotomization by RLM (NCT02833948)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| RLM>2 (-) | 0 |
| RLM(+) | 0 |
"Effective orifice area (cm2) as determined by transthoracic echocardiography at three months after randomization.~scale [0.1-4.0]" (NCT02833948)
Timeframe: 3 months
| Intervention | cm2 (Mean) |
|---|---|
| ASA + Clopidogrel | 1.8 |
| Rivaroxaban + ASA | 1.8 |
Reduced systolic leaflet excursion is classified as: (I) normal, (II) mildly reduced (<50%), (III) moderate to severely reduced (>50%), and (IV) immobile. Reduced systolic leaflet excursion is considered significant when it is > 50% or immobile. Quantitative assessment of leaflet motion is performed with a blood pool inversion volume rendered cine reconstruction throughout the cardiac cycle evaluating the bioprosthetic leaflets. (NCT02833948)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA + Clopidogrel | 11 |
| Rivaroxaban + ASA | 2 |
The rate of patients with at least one prosthetic leaflet with hypoattenuated leaflet thickening (HALT) as assessed by cardiac 4DCT. (NCT02833948)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA + Clopidogrel | 33 |
| Rivaroxaban + ASA | 12 |
The rate of prosthetic leaflets with RLM> grade 3 as assessed by cardiac 4DCT (NCT02833948)
Timeframe: 3 months
| Intervention | leaflets (Number) |
|---|---|
| ASA + Clopidogrel | 14 |
| Rivaroxaban + ASA | 3 |
The rate of prosthetic leaflet with HALT as assessed by cardiac 4DCT-scan (NCT02833948)
Timeframe: 3 months
| Intervention | Leaflets (Number) |
|---|---|
| ASA + Clopidogrel | 53 |
| Rivaroxaban + ASA | 16 |
Thromboembolic event, Dichotomization by HALT (NCT02833948)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| HALT (-) | 2 |
| HALT (+) | 0 |
Thromboembolic event, Dichotomization by RLM (NCT02833948)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| RLM>2 (-) | 2 |
| RLM(+) | 0 |
Composite of CV-death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism (per adjudication). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 83 |
| Antiplatelet | 68 |
Composite of BARC 2,3 or 5 bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 148 |
| Antiplatelet | 85 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 14 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 68 |
| Antiplatelet | 63 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 105 |
| Antiplatelet | 78 |
ISTH major bleeds (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 49 |
| Antiplatelet | 30 |
The net-clinical-benefit defined as the adjudicated composite of all-cause death, any stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep vein thrombosis, non-CNS systemic embolism (efficacy); VARC life-threatening, disabling and VARC major bleeds (safety). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 137 |
| Antiplatelet | 100 |
PBE is defined according to VARC (Valve Academic Research Consortium) definitions as the adjudicated composite of: Life-threatening, disabling or major bleeding. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 46 |
| Antiplatelet | 31 |
Composite of TIMI major and minor bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 42 |
| Antiplatelet | 24 |
number of participants with the occurrence of a bleeding event leading the participant to seek medical attention (NCT02505217)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| High FcγRIIa Expression | 6 |
| Low FcγRIIa Expression | 6 |
number of participants with myocardial infarction, stroke, and/or death (NCT02505217)
Timeframe: average duration of follow-up 19 months
| Intervention | Participants (Count of Participants) |
|---|---|
| High FcγRIIa Expression | 17 |
| Low FcγRIIa Expression | 6 |
(NCT02504216)
Timeframe: For each participant, the first occurrence of the outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1188.48 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 321 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 297 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1062.48 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 584 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 655 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the composite efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1108.29 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 514 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 588 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the composite efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1085.13 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 614 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 679 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the composite efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1108.79 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 433 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 528 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1154.04 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 262 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 356 |
Venous thromboembolic events were reported by investigator only. (NCT02504216)
Timeframe: For each participant, the first occurrence of the outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1187.65 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 25 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 41 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean time in follow-up survival time until ECOD that date was 1109.76 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 508 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 584 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the primary safety outcome after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo).
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 62 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 44 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered (NCT02504216)
Timeframe: For each participant, the first occurrence of the type 3b and above bleeding events according to the BARC classification after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo)
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 93 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 73 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the major bleeding events according to the ISTH classification after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo).
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 140 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 100 |
(NCT02697916)
Timeframe: Time of randomization through study completion, approximately 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA 81mg | 315 |
| ASA 325mg | 357 |
(NCT02697916)
Timeframe: Time of randomization through study completion, approximately 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA 81mg | 590 |
| ASA 325mg | 569 |
(NCT02697916)
Timeframe: Time of randomization through study completion, approximately 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA 81mg | 53 |
| ASA 325mg | 44 |
(NCT02697916)
Timeframe: Time of randomization through study completion, approximately 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA 81mg | 228 |
| ASA 325mg | 213 |
(NCT02697916)
Timeframe: Time of randomization through study completion, approximately 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA 81mg | 102 |
| ASA 325mg | 92 |
(NCT02697916)
Timeframe: Time of randomization through study completion, approximately 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA 81mg | 471 |
| ASA 325mg | 446 |
Quality of life measures are based on an ordinal scale from 1-5, where 1 corresponds to the best outcome and 5 to the worst. Model-based mean score estimates are obtained from mixed models of each quality of life measure. (NCT02697916)
Timeframe: 2 years
| Intervention | score on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Describe Current Health | Able to Run Errands and Shop | In the past 7 Days, Felt Depressed | In the past 7 Days, Felt Fatigued | In the past 7 Days, Problems with Sleep | Trouble doing Regular Activities | In the past 7 Days, Pain interfered | |
| ASA 325mg | 2.8 | 1.66 | 1.7 | 2.27 | 2.10 | 1.88 | 2.02 |
| ASA 81mg | 2.77 | 1.65 | 1.69 | 2.25 | 2.06 | 1.84 | 2.06 |
Percent incidence of all-cause mortality is reported as the percentage of participants who died due to any cause. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 7.5 |
| Placebo | 7.3 |
Percent incidence of all-cause mortality is reported as the percentage of participants who died due to any cause. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 4.7 |
| Placebo | 4.3 |
Percent incidence of CHF requiring hospitalization was reported as the percentage of participants who were admitted to the hospital for CHF. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 3.1 |
| Placebo | 3.1 |
Percent incidence of CHF requiring hospitalization was reported as the percentage of participants who were admitted to the hospital for CHF. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 2.8 |
| Placebo | 2.8 |
Chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 9.7 |
| Placebo | 13.2 |
Chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 8.6 |
| Placebo | 11.9 |
Primary composite CV endpoint of MACE plus which includes CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 9.6 |
| Placebo | 9.6 |
CV composite endpoint of MACE which includes CV-related death, nonfatal MI, or nonfatal stroke. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 10.2 |
| Placebo | 10.2 |
CV composite endpoint of MACE which includes CV-related death, nonfatal MI, or nonfatal stroke. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 8.4 |
| Placebo | 8.3 |
Primary composite CV endpoint of MACE plus which includes CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization. (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 11.4 |
| Placebo | 11.6 |
In participants not receiving insulin at baseline, time to addition of first co-interventional agent (i.e., next oral AHA or chronic insulin, where chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.) (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 21.7 |
| Placebo | 27.9 |
In participants not receiving insulin at baseline, time to addition of first co-interventional agent (i.e., next oral antihyperglycemic agent [AHA] or chronic insulin, where chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.) (NCT00790205)
Timeframe: Up to 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sitagliptin | 18.9 |
| Placebo | 24.5 |
HbA1c is a measure of the percentage of glycated hemoglobin in the blood. Estimated mean difference between sitagliptin and placebo controlling for baseline HbA1c and region. (NCT00790205)
Timeframe: Baseline and up to 4 years
| Intervention | Percentage of HbA1c (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Month 4: Sitagliptin, n= 6772; Placebo, n= 6738 | Month 8: Sitagliptin, n= 6478; Placebo, n= 6414 | Month 12: Sitagliptin, n= 6448; Placebo, n= 6384 | Month 24: Sitagliptin, n= 6105; Placebo, n= 5975 | Month 36: Sitagliptin, n= 3521; Placebo, n= 3439 | Month 48: Sitagliptin, n= 1432; Placebo, n= 1383 | Month 60: Sitagliptin, n= 123; Placebo, n= 128 | |
| Placebo | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
| Sitagliptin | -0.3 | -0.2 | -0.2 | -0.1 | -0.1 | 0.0 | 0.0 |
HbA1c is a measure of the percentage of glycated hemoglobin in the blood. Estimated mean difference between sitagliptin and placebo controlling for baseline HbA1c and region. (NCT00790205)
Timeframe: Baseline and up to 4 years
| Intervention | Percentage of HbA1c (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Month 4; Sitagliptin, n=6632, Placebo, n=6588 | Month 8; Sitagliptin, n=6294, Placebo, n=6197 | Month 12; Sitagliptin, n=6217, Placebo, n=6092 | Month 24; Sitagliptin, n=5668, Placebo, n=5475 | Month 36; Sitagliptin, n=3227, Placebo, n=3083 | Month 48; Sitagliptin, n=1271, Placebo, n=1224 | Month 60; Sitagliptin, n=106, Placebo, n=108 | |
| Placebo | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | 0.0 |
| Sitagliptin | -0.3 | -0.3 | -0.2 | -0.1 | -0.1 | 0.0 | -0.1 |
Change in renal function based on eGFR using the MDRD method. (NCT00790205)
Timeframe: Baseline and up to 5 years
| Intervention | mL/min/1.73 m^2 (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Month 4; Sitagliptin, n=3949; Placebo, n=3977 | Month 8; Sitagliptin, n=3687; Placebo, n=3648 | Month 12; Sitagliptin, n=5082; Placebo, n=5015 | Month 24; Sitagliptin, n=5157; Placebo, n=5071 | Month 36; Sitagliptin, n=3037; Placebo, n=2942 | Month 48; Sitagliptin, n=1237; Placebo, n=1210 | Month 60; Sitagliptin, n=93; Placebo, n=106 | |
| Placebo | -0.8 | -0.9 | -0.5 | -1.7 | -1.6 | -2.8 | -5.7 |
| Sitagliptin | -1.8 | -2.4 | -1.8 | -3.2 | -3.8 | -4.0 | -4.2 |
Change in renal function based on estimated glomerular filtration rate [eGFR] using the Modification of Diet in Renal Disease [MDRD] method. (NCT00790205)
Timeframe: Baseline and up to 5 years
| Intervention | mL/min/1.73 m^2 (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Month 4; Sitagliptin, n= 3859; Placebo, n= 3864 | Month 8; Sitagliptin, n= 3562; Placebo, n= 3501 | Month 12; Sitagliptin, n=4912, Placebo, n=4778 | Month 24; Sitagliptin, n=4782, Placebo, n=4637 | Month 36; Sitagliptin, n=2776, Placebo, n=2614 | Month 48; Sitagliptin, n=1096, Placebo, n=1056 | Month 60; Sitagliptin, n=79, Placebo, n=88 | |
| Placebo | -0.8 | -0.9 | -0.5 | -1.7 | -1.6 | -2.8 | -6.4 |
| Sitagliptin | -1.9 | -2.5 | -1.8 | -3.1 | -3.7 | -3.7 | -3.5 |
Change from baseline reflects the difference between the urine albumin:creatinine ratio reported time point and baseline value. (NCT00790205)
Timeframe: Baseline and up to 5 years
| Intervention | g/mol Creatinine (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Month 4; n=677, n=713 | Month 8; n=658, n=624 | Month 12; n=1167, n=1115 | Month 24; n=1011, n=964 | Month 36; n=537, n=553 | Month 48; n=265, n=256 | Month 60; n=14, n=18 | |
| Placebo | -1.4 | 0.5 | 1.2 | 3.1 | 3.9 | 1.6 | 6.4 |
| Sitagliptin | -2.1 | 2.1 | 1.3 | 0.5 | 2.6 | 1.9 | -2.5 |
Change from baseline reflects the difference between the urine albumin:creatinine ratio reported time point and baseline value. (NCT00790205)
Timeframe: Baseline and up to 5 years
| Intervention | g/mol Creatinine (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Month 4; Sitagliptin, n=664; Placebo, n=688 | Month 8; Sitagliptin, n=635; Placebo, n=597 | Month 12; Sitagliptin, n=1126; Placebo, n=1059 | Month 24; Sitagliptin, n=930; Placebo, n=892 | Month 36; Sitagliptin, n=488; Placebo, n=513 | Month 48; Sitagliptin, n=238; Placebo, n=233 | Month 60; Sitagliptin, n=13; Placebo, n=17 | |
| Placebo | -1.4 | 0.2 | 1.2 | 3.2 | 4.0 | 1.5 | 4.8 |
| Sitagliptin | -2.2 | 1.7 | 0.8 | 0.7 | 2.5 | 1.3 | -2.7 |
(NCT00000479)
Timeframe: Average follow-up 10.1 years
| Intervention | participants (Number) | |
|---|---|---|
| Total invasive cancer | Cancer death | |
| Aspirin + Vitamin E | 716 | 152 |
| Aspirin Only | 722 | 132 |
| Both Placebos | 706 | 143 |
| Vitamin E Only | 721 | 156 |
(NCT00000479)
Timeframe: Average follow-up 10.1 years
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Major cardiovascular event | Stroke | Myocardial infarction | Cardiovascular death | |
| Aspirin + Vitamin E | 232 | 108 | 102 | 54 |
| Aspirin Only | 245 | 113 | 96 | 66 |
| Both Placebos | 272 | 133 | 99 | 74 |
| Vitamin E Only | 250 | 133 | 94 | 52 |
DVT and how the diagnosis was made will be recorded. The number of events in participants in each arm will be compared to evaluate efficacy. (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 5 |
| VTE Prophylaxis With Aspirin 81mg BID | 9 |
Bases on imaging obtained for symptoms. (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 6 |
| VTE Prophylaxis With Aspirin 81mg BID | 2 |
Includes a greater than 2g/dL drop in hemoglobin, blood transfusion, hematoma evacuation, re-operation for a deep surgical site infection or minor procedure for bleeding and GI bleed (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 52 |
| VTE Prophylaxis With Aspirin 81mg BID | 53 |
Follow up appointment within 2 weeks of discharge back to their primary care providers at a primary care facility from a tertiary referral center. (NCT01431846)
Timeframe: Within 2 weeks of discharge
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Subjects Interviewed | Follow-up within 2 weeks of discharge | Medication reconciliation | Discharge Instructions | |
| Arm 1 | 8 | 3 | 4 | 8 |
| Arm 2 | 3 | NA | NA | NA |
| Arm 3 | 8 | 6 | 8 | 8 |
Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 5.1 |
| Ticagrelor 60 mg | 4.7 |
| Placebo | 5.2 |
A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of >= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug (NCT01225562)
Timeframe: First dosing up to 48 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.6 |
| Ticagrelor 60 mg | 2.3 |
| Placebo | 1.1 |
Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.9 |
| Ticagrelor 60 mg | 2.9 |
| Placebo | 3.4 |
Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 7.8 |
| Ticagrelor 60 mg | 7.8 |
| Placebo | 9.0 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 1.70 |
| Propensity-matched BMS | 2.61 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.69 |
| DES 12-month DAPT | 1.45 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.40 |
| DES 12-month DAPT | 1.35 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.03 |
| BMS 12-month DAPT | 0.90 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.09 |
| BMS 12-month DAPT | 1.05 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.74 |
| DES 12-month DAPT | 1.88 |
The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.53 |
| DES 12-month DAPT | 1.57 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 11.37 |
| Propensity-matched BMS | 13.24 |
(NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.04 |
| BMS 12-month DAPT | 4.69 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.68 |
| BMS 12-month DAPT | 5.48 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 5.62 |
| DES 12-month DAPT | 6.49 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 4.34 |
| DES 12-month DAPT | 5.92 |
Number of patients indicated for ACE/ARB and statin who had an active prescription for both, as a proportion of patients indicated for ACE/ARB and statin. (NCT02299791)
Timeframe: Percent of clinic patients prescribed guideline-concordant cardioprotective medications, as of the 1st day of each month, from up to 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Early Intervention | 1279 |
| Late Implementation | 1318 |
(NCT00593450)
Timeframe: at 1 Year
| Intervention | mm^2 (Mean) |
|---|---|
| 1-Lucentis Monthly | 6.6 |
| 2-Avastin Monthly | 6.5 |
| 3-Lucentis as Needed | 7.3 |
| 4-Avastin as Needed | 7.0 |
(NCT00593450)
Timeframe: Baseline and 1 Year
| Intervention | mm^2 (Mean) |
|---|---|
| 1-Lucentis Monthly | -0.1 |
| 2-Avastin Monthly | 0.3 |
| 3-Lucentis as Needed | 0.6 |
| 4-Avastin as Needed | 1.3 |
(NCT00593450)
Timeframe: at 1 Year
| Intervention | US dollars per patient (Mean) |
|---|---|
| 1-Lucentis Monthly | 23400 |
| 2-Avastin Monthly | 595 |
| 3-Lucentis as Needed | 13800 |
| 4-Avastin as Needed | 385 |
"Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly. The VA score change is the difference of the VA score at 1 Year and the VA score at baseline.~In this study, the outcome VA score change is ranged from -71 to 52, with the higher VA score change the better visual acuity improvement." (NCT00593450)
Timeframe: Baseline and 1 Year
| Intervention | No. of Letters (Mean) |
|---|---|
| 1-Lucentis Monthly | 8.5 |
| 2-Avastin Monthly | 8.0 |
| 3-Lucentis as Needed | 6.8 |
| 4-Avastin as Needed | 5.9 |
(NCT00593450)
Timeframe: Baseline and 1 Year
| Intervention | mm Hg (Mean) |
|---|---|
| 1-Lucentis Monthly | -0.9 |
| 2-Avastin Monthly | -1.4 |
| 3-Lucentis as Needed | -1.9 |
| 4-Avastin as Needed | -2.1 |
(NCT00593450)
Timeframe: Baseline and 1 Year
| Intervention | mm Hg (Mean) |
|---|---|
| 1-Lucentis Monthly | -2.1 |
| 2-Avastin Monthly | -5.4 |
| 3-Lucentis as Needed | -5.2 |
| 4-Avastin as Needed | -4.5 |
Cumulative over the 1 year of trial (NCT00593450)
Timeframe: 1 Year
| Intervention | Number of Treatments (Mean) |
|---|---|
| 1-Lucentis Monthly | 11.7 |
| 2-Avastin Monthly | 11.9 |
| 3-Lucentis as Needed | 6.9 |
| 4-Avastin as Needed | 7.7 |
(NCT00593450)
Timeframe: at 1 Year
| Intervention | μm (Mean) |
|---|---|
| 1-Lucentis Monthly | 152 |
| 2-Avastin Monthly | 172 |
| 3-Lucentis as Needed | 166 |
| 4-Avastin as Needed | 172 |
(NCT00593450)
Timeframe: Baseline and 1 Year
| Intervention | μm (Mean) |
|---|---|
| 1-Lucentis Monthly | -100 |
| 2-Avastin Monthly | -79 |
| 3-Lucentis as Needed | -81 |
| 4-Avastin as Needed | -79 |
(NCT00593450)
Timeframe: at 1 Year
| Intervention | μm (Mean) |
|---|---|
| 1-Lucentis Monthly | 266 |
| 2-Avastin Monthly | 300 |
| 3-Lucentis as Needed | 294 |
| 4-Avastin as Needed | 308 |
(NCT00593450)
Timeframe: Baseline and 1 Year
| Intervention | μm (Mean) |
|---|---|
| 1-Lucentis Monthly | -196 |
| 2-Avastin Monthly | -164 |
| 3-Lucentis as Needed | -168 |
| 4-Avastin as Needed | -152 |
"Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly.~In this study, the outcome VA score is ranged from 0 to 97, with the higher score the better visual acuity." (NCT00593450)
Timeframe: at 1 Year
| Intervention | No. of Letters (Mean) |
|---|---|
| 1-Lucentis Monthly | 68.8 |
| 2-Avastin Monthly | 68.4 |
| 3-Lucentis as Needed | 68.4 |
| 4-Avastin as Needed | 66.5 |
(NCT00593450)
Timeframe: Baseline and 1 Year
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Increase of ≥15 letters | Increase of 5-14 letters | Change of ≤4 letters | Decrease of 5-14 letters | Decrease of ≥15 letters | |
| 1-Lucentis Monthly | 97 | 90 | 62 | 19 | 16 |
| 2-Avastin Monthly | 83 | 98 | 50 | 18 | 16 |
| 3-Lucentis as Needed | 71 | 103 | 75 | 23 | 13 |
| 4-Avastin as Needed | 76 | 90 | 59 | 23 | 23 |
(NCT00593450)
Timeframe: at 1 Year
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Absent | Present | Data missing | |
| 1-Lucentis Monthly | 167 | 97 | 20 |
| 2-Avastin Monthly | 153 | 100 | 12 |
| 3-Lucentis as Needed | 133 | 137 | 15 |
| 4-Avastin as Needed | 111 | 145 | 15 |
(NCT00593450)
Timeframe: at 1 Year
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Absent | Present | Data missing | |
| 1-Lucentis Monthly | 124 | 151 | 9 |
| 2-Avastin Monthly | 69 | 188 | 8 |
| 3-Lucentis as Needed | 68 | 203 | 14 |
| 4-Avastin as Needed | 52 | 214 | 5 |
(NCT00593450)
Timeframe: at 1 Year
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| 83-97 letters, 20/12-20 | 68-82 letters, 20/25-40 | 53-67 letters, 20/50-80 | 38-52 letters, 20/100-160 | ≤37 letters, ≤20/200 | |
| 1-Lucentis Monthly | 42 | 149 | 52 | 23 | 18 |
| 2-Avastin Monthly | 45 | 134 | 47 | 21 | 18 |
| 3-Lucentis as Needed | 38 | 141 | 66 | 23 | 17 |
| 4-Avastin as Needed | 40 | 127 | 57 | 24 | 23 |
Incidence of adverse events and monitoring vital signs and clinical laboratory values. All AEs were coded into preferred terms according to MedDRA (Medical Dictionary for Regulatory Activities) and classified by system organ class (SOC). (NCT00995410)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|---|
| PA32540 Tablet | 379 |
Most Frequent (≥ 1%) Treatment Emergent Adverse Events by System Organ Class leading to Discontinuation (NCT00995410)
Timeframe: 12 months
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Subjects with any AE Leading to Discontinuation | Gastrointestinal disorders | Neoplasms benign, malignant and unspecified | Cardiac Disorders | Investigations | |
| PA32540 Tablet | 51 | 15 | 7 | 6 | 6 |
The time, in years, from randomization to the first to occur of ischemic stroke, intracerebral hemorrhage, or death, up to a maximum of 6 years. Event rate per 100 patient years = 100*(number of subjects with event)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization until the date of the first to occur of ischemic stroke, intracerebral hemorrhage, or death, up to 6 years
| Intervention | events per 100 patient-years (Number) |
|---|---|
| Aspirin | 7.93 |
| Warfarin | 7.47 |
Time, in years, from randomization to death component of secondary composite outcome. This measure counts only deaths that were not preceded by heart failure hospitalization, myocardial infarction, ischemic stroke, or intracerebral hemorrhage. Event rate per 100 patient years = 100*(number of subjects who died)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of death component of secondary composite outcome, up to 6 years
| Intervention | events per 100 patient years (Number) |
|---|---|
| Aspirin | 4.41 |
| Warfarin | 4.43 |
Time, in years, from date of randomization to date of heart failure hospitalization, up to 6 years. Includes hospitalizations for heart failure during follow-up that were not preceded by myocardial infarction. Event rate per 100 patient years = 100*(number of subjects with heart failure hospitalization)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of heart failure hospitalization component of secondary composite outcome, up to 6 years
| Intervention | events per 100 patient years (Number) |
|---|---|
| Aspirin | 5.67 |
| Warfarin | 6.79 |
Time, in years, from date of randomization to date of intracerebral hemorrhage component of secondary composite outcome. Includes only intracerebral hemorrhages not preceded by myocardial infarction or heart failure hospitalization. Event rate per 100 patient years = 100*(number of subjects with intracerebral hemorrhage)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of intracerebral hemorrhage component of secondary composite outcome, up to 6 years
| Intervention | events per 100 patient years (Number) |
|---|---|
| Aspirin | 0.06 |
| Warfarin | 0.11 |
Ischemic stroke component of secondary composite endpoint. Includes only ischemic strokes that were not preceded by a myocardial infarction or heart failure hospitalization. The number of ischemic strokes that are components of the secondary outcome does not therefore match the number of ischemic strokes that are components of the primary outcome. Event rate per 100 patient years = 100*(number of subjects with ischemic stroke)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1)of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of ischemic stroke component of secondary composite outcome, up to 6 years
| Intervention | events per 100 patient years (Number) |
|---|---|
| Aspirin | 1.14 |
| Warfarin | 0.57 |
Time, in years, from date of randomization to date of myocardial infarction, up to 6 years. Includes only myocardial infarctions that occurred during follow-up, before any heart failure hospitalization. Event rate per 100 patient years = 100*(number of subjects with myocardial infarction)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of myocardial infarction component of secondary composite outcome, up to 6 years
| Intervention | events per 100 patient years (Number) |
|---|---|
| Aspirin | 0.87 |
| Warfarin | 0.80 |
"The time, in years, from date of randomization to the date of the first to occur of hospitalization for heart failure, myocardial infarction, ischemic stroke, intracerebral hemorrhage, or death, up to 6 years.~Event rate per 100 patient years = 100*(number of subjects with event)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25." (NCT00041938)
Timeframe: From randomization to the first to occur of hospitalization for heart failure, myocardial infarction, ischemic stroke, intracerebral hemorrhage, or death, up to a maximum of 6 years.
| Intervention | events per 100 patient-years (Number) |
|---|---|
| Aspirin | 12.15 |
| Warfarin | 12.70 |
Time, in years, from date of randomization to date of death component of primary composite outcome. Event rate per 100 patient years = 100*(number of subjects who died)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of death component of primary composite outcome, up to 6 years
| Intervention | events per 100 patient-years (Number) |
|---|---|
| Aspirin | 6.52 |
| Warfarin | 6.63 |
Time, in years, from date of randomization to date of intracerebral hemorrhage component of primary composite outcome. Event rate per 100 patient years = 100*(number of subjects with intracerebral hemorrhage)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of intracerebral hemorrhage component of primary composite outcome, up to 6 years
| Intervention | rate per 100 patient years (Number) |
|---|---|
| Aspirin | 0.05 |
| Warfarin | 0.12 |
Time, in years, from date of randomization to date of ischemic stroke component of primary composite outcome, up to 6 years. Event rate per 100 patient years = 100*(number of subjects with ischemic stroke)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of ischemic stroke component of primary composite outcome, up to 6 years
| Intervention | rate per 100 patient years (Number) |
|---|---|
| Aspirin | 1.36 |
| Warfarin | 0.72 |
Rate/100 patient-years of major hemorrhage. Includes all major hemorrhages in any patient. Major hemorrhage was defined as intracerebral, epidural, subdural, subarachnoid, spinal intramedullary, or retinal hemorrhage; any other bleeding causing a decline in the hemoglobin level of more than 2 g per deciliter in 48 hours; or bleeding requiring transfusion of 2 or more units of whole blood, hospitalization, or surgical intervention. Event rate per 100 patient years = 100*(number of major hemorrhage events)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization until end of scheduled follow-up, up to 6 years
| Intervention | events per 100 patient years (Number) |
|---|---|
| Aspirin | 0.87 |
| Warfarin | 1.78 |
Rate per 100 patient years of minor hemorrhage. Includes all minor hemorrhages. Minor hemorrhage was defined as any non-major hemorrhage. Event rate per 100 patient years = 100*(number of minor hemorrhage events)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1)of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization until the end of scheduled follow-up, up to 6 years
| Intervention | events per 100 patient-years (Number) |
|---|---|
| Aspirin | 7.34 |
| Warfarin | 11.6 |
Ten year cardiovascular risk was calculated at each post index visit from the most recent clinical and laboratory values in the EMR. The Framingham lipid equation was used when a lipid value was available in the previous 5 years; otherwise the Framingham BMI equation was used. The primary outcome was the annualized rate of change (slope) in 10-year CVR, estimated for each treatment group from the time and time-by-treatment parameters of a mixed regression model which predicted post-index CVR values from time elapsed since index, treatment group and the time by treatment interaction. (NCT01420016)
Timeframe: Index to 14 months post index
| Intervention | annualized change in 10 year % cv risk (Number) |
|---|---|
| Prioritized Clinical Decision Support | -0.59 |
| Usual Care | 1.66 |
Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 141 |
| Placebo | 167 |
Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 121 |
| Placebo | 160 |
Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 18 |
| Placebo | 12 |
Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 6 |
| Placebo | 4 |
Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 5 |
| Placebo | 3 |
Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 116 |
| Placebo | 156 |
Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 112 |
| Placebo | 155 |
Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 23 |
| Placebo | 10 |
Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 17 |
| Placebo | 7 |
Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 40 |
| Placebo | 13 |
Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 10 |
| Placebo | 7 |
Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 0 |
Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 2 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Clopidogrel 300/75/75 mg + ASA Low Dose | 267 |
| Clopidogrel 300/75/75 mg + ASA High Dose | 290 |
| Clopidogrel 600/150/75 mg + ASA Low Dose | 282 |
| Clopidogrel 600/150/75 mg + ASA High Dose | 240 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel + ASA High Dose | 527 | 211 | 251 | 65 |
| Clopidogrel + ASA Low Dose | 546 | 231 | 260 | 55 |
"The primary endpoint is the first occurrence of any of the following events:~Cardiovascular death (any death with a clear cardiovascular or unknown cause),~Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal)~Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal)~reported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC)." (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel 300/75/75 mg + ASA | 557 | 222 | 274 | 61 |
| Clopidogrel 600/150/75 mg + ASA | 522 | 226 | 237 | 59 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel 300/75/75 mg + ASA | 392 | 132 | 225 | 35 |
| Clopidogrel 600/150/75 mg + ASA | 330 | 130 | 172 | 28 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
| Clopidogrel + ASA High Dose | 282 | 216 | 73 |
| Clopidogrel + ASA Low Dose | 285 | 215 | 74 |
Major bleeding is defined as any severe bleeding (associated with any of the following: death, leading to a drop in hemoglobin ≥ 5 g/dl, significant hypotension with the need for inotropic agents, symptomatic intracranial hemorrhage, requirement for surgery or for a transfusion ≥ 4 units of red blood cells or equivalent whole blood) and other major bleeding (significantly disabling bleeding, or intraocular bleeding leading to significant loss of vision or bleeding requiring transfusion of 2-3 units of red blood cells or equivalent whole blood) after validation by the independent EAC. (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
| Clopidogrel 300/75/75 mg + ASA | 255 | 195 | 65 |
| Clopidogrel 600/150/75 mg + ASA | 313 | 236 | 83 |
This includes definite stent thrombosis (confirmed by angiography or evidence of recent thrombus determined at autopsy or by examination of tissue retrieved following thrombectomy) and probable stent thrombosis (unexplained death having occurred after intracoronary stenting or, MI related to acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any obvious cause) after validation by the EAC. (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Stent trombosis | - Definite | - Probable | |
| Clopidogrel 300/75/75 mg + ASA | 200 | 111 | 89 |
| Clopidogrel 600/150/75 mg + ASA | 135 | 58 | 77 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
Estimated 10-year CVD total risk score were calculated in the field centers and in the Coordinating Center from the measures of blood pressure and total cholesterol and from the medical history data collected during each visit using the WHO CVD prediction chart. The estimated 10-year CVD total risk calculated by the Coordinating Center were used for analysis. the score is based on systolic blood pressure and total cholesterol measures as well as on medical history data (monthly). Each one of these risk factors is assigned a point in the score and then linked to a table that mention the calculated CVD risk (NCT00567307)
Timeframe: Six months
| Intervention | percent (Mean) |
|---|---|
| The Polypill Group (Arm A) | 11.5 |
| Standard Practice Group (Arm B) | 11.1 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to endothelial function. (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 14.06 |
| Placebo Follow up | 13.84 |
| Aspirin Baseline | 11.18 |
| Aspirin Randomization | 12.11 |
| Clopidogrel Baseline | 13.06 |
| Clopidogrel Randomization | 12.29 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to immune activity (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 15.53 |
| Placebo Follow up | 15.43 |
| Aspirin Baseline | 13.15 |
| Aspirin Follow up | 14.96 |
| Clopidogrel Baseline | 16.03 |
| Clopidogrel Follow up | 14.85 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to inflammation (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 69.45 |
| Placebo Follow up | 80.33 |
| Aspirin Baseline | 82.04 |
| Aspirin Randomization | 62.00 |
| Clopidogrel Baseline | 78.86 |
| Clopidogrel Randomization | 39.88 |
(NCT02559414)
Timeframe: Baseline, 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 69.45 |
| Placebo Follow up | 80.33 |
| Aspirin Baseline | 82.04 |
| Aspirin Randomization | 62.00 |
| Clopidogrel Baseline | 78.86 |
| Clopidogrel Randomization | 39.88 |
The primary objective of these analyses will be to compare the effects of aspirin versus control and clopidogrel versus control for the outcome of platelet activity. Aspirin is expected to decrease arachidonic acid-induced platelet aggregation by 50% versus control. Clopidogrel is expected to decrease ADP-induced platelet aggregation by 50% versus control. (NCT02559414)
Timeframe: Baseline, 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 72.35 |
| Placebo Follow up | 79.11 |
| Aspirin Baseline | 72.79 |
| Aspirin Randomization | 26.77 |
| Clopidogrel Baseline | 71.07 |
| Clopidogrel Randomization | 65.00 |
Thromboxane A2, the major product of cyclooxygenase cytochrome oxidase (COX-1) in platelets, induces platelet aggregation. Thromboxane B2 is an inactive metabolite/product of thromboxane A2. This primary outcome measures the extent of inhibition of platelet COX-1 by measuring the amount of the metabolite thromboxane B2 in serum. (NCT00753935)
Timeframe: after 2 weeks on aspirin
| Intervention | ng/mL (Median) |
|---|---|
| Enteric-coated Aspirin | 5.02 |
| Chewable Aspirin | 2.78 |
"30-day postoperative Stanford Health Assessment Questionnaire Disability Index (SHAQ) score, indicating subjects ability to perform daily tasks.~Scores range continuously from 0-4 representing no disability to complete disability respectively. Scores >2 are usually considered severe disability.~The total score is computed as the mean of 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each category consists of a list of 2-3 actions. The participant selects whether they are able to perform each action without any difficulty, with some difficulty, with much difficulty, or unable to do. These selections are scored 0-4 respectively. The category is assigned the maximum score of its component actions. If the subject requires assistance from a person or device for an individual action, the minimum score for that action is 2." (NCT02880176)
Timeframe: 1 months
| Intervention | units on a scale (Median) |
|---|---|
| Financial Incentive | 1.25 |
| Control (Education) | 1.38 |
Number of days during the study period that each subject reaches their step goal (NCT02880176)
Timeframe: 30 days
| Intervention | days (Median) |
|---|---|
| Financial Incentive | 4.5 |
| Control (Education) | 9 |
"Average number of steps taken per day in the 30 day postoperative period. Note that the average number of steps taken per day is calculated separately for each patient as simply (total number of steps taken in the 30 day postoperative period)/30. For the purposes of comparing the two study groups, nonparametric tests and medians are used. Thus the measure type listed in the Outcome Measure Data Table is correctly listed as median. For example, in the Financial Incentive arm, we report a median average number of steps per day as 979, implying that half of the patients walked fewer than 979 steps on an average day and half of the patients walked more than 979 steps on an average day in that group." (NCT02880176)
Timeframe: 30 days
| Intervention | steps per day (Median) |
|---|---|
| Financial Incentive | 979 |
| Control (Education) | 1191 |
The percentage of participants is the total number of participants experiencing an all-cause death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.61 |
| Prasugrel: 75 Years of Age or Older | 27.04 |
| Clopidogrel: <75 Years of Age | 11.12 |
| Clopidogrel: 75 Years of Age or Older | 26.83 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.06 |
| Prasugrel: 75 Years of Age or Older | 24.64 |
| Clopidogrel: <75 Years of Age | 10.96 |
| Clopidogrel: 75 Years of Age or Older | 24.13 |
The percentage of participants is the total number of participants experiencing a CV death or nonfatal MI divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 9.61 |
| Prasugrel: 75 Years of Age or Older | 22.53 |
| Clopidogrel: <75 Years of Age | 10.21 |
| Clopidogrel: 75 Years of Age or Older | 22.69 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, nonfatal stroke or re-hospitalization for a recurrent UA divided by number of participants in the treatment arm. Endpoints events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 12.13 |
| Prasugrel: 75 Years of Age or Older | 26.27 |
| Clopidogrel: <75 Years of Age | 12.83 |
| Clopidogrel: 75 Years of Age or Older | 25.67 |
Brain natriuretic peptide (BNP) is secreted by the ventricles of the heart in response to hemodynamic stress and is a biomarker associated with increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 6 Months
| Intervention | picograms per milliliter (pg/mL) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=725, 125, 701, 174) | |
| Clopidogrel: <75 Years of Age | 319.345 | 250.982 |
| Clopidogrel: 75 Years of Age or Older | 951.359 | 722.750 |
| Prasugrel: <75 Years of Age | 313.494 | 253.434 |
| Prasugrel: 75 Years of Age or Older | 1082.396 | 770.132 |
C-Reactive Protein (CRP) is a biomarker associated with inflammation and increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and Month 6
| Intervention | milligrams per liter (mg/L) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=755, 143, 745, 178) | |
| Clopidogrel: <75 Years of Age | 2.287 | 2.149 |
| Clopidogrel: 75 Years of Age or Older | 2.226 | 1.543 |
| Prasugrel: <75 Years of Age | 2.330 | 2.272 |
| Prasugrel: 75 Years of Age or Older | 2.441 | 1.593 |
Seattle Angina Questionnaire (SAQ) is a validated, disease-specific questionnaire containing 11 questions (Q) yielding 5 summary scales related to angina: physical limitations, angina stability, angina frequency, treatment satisfaction and disease perception. In this study only angina frequency and the physical limitations scales were assessed. Anginal Frequency was assessed using Q3 and Q4 which consists of a Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how often a patient is having symptoms now. Physical limitations was assessed using Q1 which contains 9 items each assessed via Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how much a participant's condition is hampering their ability to do what they want to do. Scale scores are transformed to a 0-100 by subtracting the lowest possible score, dividing by the range of the scale, and multiplying by 100. Higher values equal better quality of life. (NCT00699998)
Timeframe: Baseline and follow-up (24 months)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline, physical limitations | Baseline, angina frequency | 24 Months, physical limitations (n=420, 412) | 24 Months, angina frequency (n=420, 412) | |
| Clopidogrel | 67.0 | 73.1 | 74.5 | 89.5 |
| Prasugrel | 67.8 | 73.6 | 75.1 | 89.7 |
Variation in the genes encoding the cytochrome P450 (CYP) enzymes (CYP2C19) can reduce the ability to metabolize clopidogrel and a reduced platelet response and have been associated with increased rates of CV events including CV death. Participants were classified as extensive metabolizers (EM); reduced metabolizers (RM); or unknown (UNK) metabolizers based on their CYP2C19 genotype. Possible extensive metabolizer (EM) phenotypes include EM=extensive metabolizer, UM=ultra-rapid metabolizer, and EM (non-UM) that are not UM. Possible reduced metabolizer (RM) phenotypes include IM=intermediate metabolizer and PM=poor metabolizer. Genotypes associated with each predicted phenotype are presented; predicted phenotype is presented first followed by the genotype. Percentage=(number of participants with the predicted phenotype and genotype divided by the total number of participants per arm) multiplied by 100. (NCT00699998)
Timeframe: Baseline
| Intervention | percentage participants with geneotype (Number) | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UM, *1/*17 | UM, *17/*17 | EM (non-UM), *1/*1 | IM, *1/*2 | IM, *1/*3 | IM, *1/*4 | IM, *1/*6 | IM, *1/*8 | PM, *2/*2 | PM, *2/*3 | PM, *2/*4 | PM, *2/*6 | PM, *2/*8 | PM, *3/*3 | UNK, *1/*10 | UNK, *1/*13 | UNK, *1/*9 | UNK, *1/*9, *9/*17 | UNK, *13/*17 | UNK, *2/*13 | UNK, *2/*17 | UNK, *2/*9 | UNK, *3/*17 | UNK, *4/*17 | UNK, *4/*9 | UNK, *6/*17 | UNK, *8/*17 | UNK, *9/*17 | UNK, Undefined genotype | |
| Clopidogrel: <75 Years of Age | 25.1 | 5.4 | 35.7 | 19.8 | 0.5 | 0.1 | 0.0 | 0.4 | 4.3 | 0.3 | 0.2 | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.8 | 0.1 | 0.0 | 0.2 | 0.0 | 0.0 | 0.1 | 0.0 | 0.5 |
| Clopidogrel: 75 Years of Age or Older | 21.8 | 4.3 | 41.2 | 19.7 | 0.6 | 0.3 | 0.2 | 0.3 | 3.8 | 0.3 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.2 | 0.0 | 0.3 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.6 |
| Prasugrel: <75 Years of Age | 24.0 | 5.1 | 38.8 | 18.6 | 0.8 | 0.4 | 0.0 | 0.1 | 3.9 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 6.3 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.7 |
| Prasugrel: 75 Years of Age or Older | 25.0 | 3.6 | 42.1 | 18.3 | 0.6 | 0.0 | 0.2 | 0.5 | 2.2 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 6.1 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 |
Platelet aggregation was measured by as measured by Accumetrics Verify Now™ P2Y12. Results were reported in P2Y12 Reaction Units (PRU). PRU represents the rate and extent of adenosine (ADP)-stimulated platelet aggregation. Lower values indicate greater P2Y12 platelet inhibition and lower platelet activity and aggregation. ANCOVA Model was used and values were corrected for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 12 Months
| Intervention | P2Y12 Reaction Units (PRU) (Least Squares Mean) | |
|---|---|---|
| Day 30 | Month 12 (n=386, 76, 400, 103) | |
| Clopidogrel: <75 Years of Age | 193.489 | 199.003 |
| Clopidogrel: 75 Years of Age or Older | 200.285 | 181.360 |
| Prasugrel: <75 Years of Age | 93.280 | 94.529 |
| Prasugrel: 75 Years of Age or Older | 151.872 | 135.096 |
All deaths, regardless of possible relatedness, with the exception of 1 event, were adjudicated by the Clinical Endpoint Committee (CEC) and are reported in this table. The 1 event which was not adjudicated was a result of the revocation of consent by the participant prior to their death. Deaths possibly related to study drug in the opinion of the investigator are also contained in the Serious Adverse Event (SAE) module. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | participants (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Congestive Heart Failure | Cardiogenic Shock | Cardiac Rupture | Myocardial Infarction | Dysrhythmia | Stent Thrombosis | Directly Related to Revascularization-CABG or PCI | Intracranial Hemorrhage | Non-Hemorrhagic Stroke | Sudden death due to cardiovascular event | Pulmonary Embolism | Stroke, unknown type | Other Cardiovascular Event | Cardiovascular event, unknown type | Accidental | Trauma | Hemorrhage, not intracranial | Infection | Malignancy | Suicide | Other Non-Cardiovascular event | Cause unknown (nonadjudicated event) | |
| Clopidogrel: <75 Years of Age | 13 | 10 | 0 | 24 | 6 | 0 | 1 | 4 | 4 | 70 | 2 | 0 | 0 | 45 | 1 | 0 | 0 | 16 | 14 | 0 | 8 | 0 |
| Clopidogrel: 75 Years of Age or Older | 23 | 9 | 0 | 21 | 3 | 0 | 1 | 1 | 3 | 43 | 1 | 0 | 1 | 45 | 1 | 1 | 4 | 17 | 11 | 0 | 6 | 0 |
| Prasugrel: <75 Years of Age | 10 | 8 | 0 | 16 | 5 | 0 | 1 | 2 | 4 | 75 | 0 | 0 | 6 | 40 | 1 | 2 | 1 | 14 | 14 | 1 | 8 | 0 |
| Prasugrel: 75 Years of Age or Older | 21 | 4 | 1 | 24 | 2 | 0 | 1 | 1 | 4 | 39 | 1 | 1 | 1 | 41 | 0 | 3 | 1 | 21 | 7 | 0 | 4 | 1 |
RDQ contains 12 items on a 6-point Likert scale. Six items concern the frequence ('Did not have' to 'Daily') and six items concern the severity ('Did not have' to 'Severe'). The dyspepsia dimension contains the items 'Burning feeling in the center of the upper stomach' and 'Pain in the center of the upper stomach'. Best score possible 0, worst score possible - daily occurrence. (NCT00441727)
Timeframe: RDQ was assessed at baseline, 8 weeks, 16 week, 26 weeks or upon withdrawal.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole 40 mg | 591 |
| Esomeprazole 20 mg | 577 |
| Placbo | 504 |
RDQ contains 12 items on a 6-point Likert scale. Six items concern the frequency ('Did not have' to 'Daily') and six items concern the severity ('Did not have' to 'Severe'). Gastroesophageal reflux disease (GERD) items: 'Acid taste in the mouth', 'Unpleasant movement of materials upward from the stomach', 'Burning feeling behind the breastbone' and 'Pain behind the breastbone'. Best score possible 0, worst score possible - daily occurrence. (NCT00441727)
Timeframe: RDQ was assessed at baseline, 8 weeks, 16 week, 26 weeks or upon withdrawal.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole 40 mg | 554 |
| Esomeproazole 20 mg | 537 |
| Placebo | 451 |
(NCT00441727)
Timeframe: The number of erosions was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole 40 | 214 |
| Esomeproazole 20 | 213 |
| Placebo | 380 |
The occurrence of gastric ulcer (mucosal break measuring >= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal. (NCT00441727)
Timeframe: During 26 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Esomeprazole 40 | 1.1 |
| Esomeproazole 20 | 0.75 |
| Placebo | 4.1 |
The occurrence of ulcer (mucosal break measuring >= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal. (NCT00441727)
Timeframe: During 26 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Esomeprazole 40 | 1.35 |
| Esomeproazole 20 | 1 |
| Placebo | 6.58 |
The occurrence of duodenal ulcer (mucosal break measuring >= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal. (NCT00441727)
Timeframe: During 26 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Esomeprazole 40 | 0.24 |
| Esomeproazole 20 | 0.25 |
| Placebo | 2.73 |
Changes in Heme oxygenase (HO-1) a downstream target of nitric oxide (NO) formation. (NCT00272311)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| Arm 1 of 5 Randomized Treatment Arms | 27.6 |
| Arm 2 of 5 Randomized Treatment Arms | 27.0 |
| Arm 3 of 5 Randomized Treatment Arms | 31.4 |
| Arm 4 of 5 Randomized Treatment Arms | 25.7 |
| Arm 5 of 5 Randomized Treatment Arms | 28.3 |
Heme oxygenase a downstream target of nitric oxide formation (NCT00272337)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| 1 of 5 Randomized Treatment Arms | 10.0 |
| 2 of 5 Randomized Treatment Arms | 11.2 |
| 3 of 5 Randomized Treatment Arms | 10.0 |
| 4 of 5 Randomized Treatment Arms | 11.0 |
| 5 of 5 Randomized Treatment Arms | 9.6 |
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 189 |
| Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1078 |
| Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 78 |
| Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 303 |
| Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 134 |
| Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 141 |
| Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 42 |
| Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 352 |
| Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 264 |
| Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 668 |
| Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1506 |
| Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 214 |
| Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 26 |
| Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 54 |
| Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 9 |
| Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 23 |
| Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 290 |
| Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 8 |
| Placebo Arm | 21 |
Revascularization included any arterial revascularization procedure, whether surgical or percutaneous, but excluded revascularization performed for hemodialysis vascular access (e.g. fistuloplasty) or to the donor kidney transplant artery. Revascularization included amputations for vascular disease (rather than for trauma or infection). All potential revascularization events (including angiography) were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 284 |
| Placebo | 352 |
End-stage renal disease was defined as initiation of maintenance dialysis or renal transplantation. Temporary dialysis was excluded. All potential dialysis and transplant events were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 1057 |
| Placebo | 1084 |
Major atherosclerotic events defined as non-fatal myocardial infarction or coronary death, non-hemorrhagic stroke, or any arterial revascularization procedure (excluding dialysis access procedures). Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 526 |
| Placebo | 619 |
Major coronary events defined as coronary death or non-fatal myocardial infarction. Myocardial infarction adjudicated based on the presence of serial changes in cardiac biomarkers (e.g. troponin, creatine kinase), typical ECG changes and typical cardiac symptoms. If myocardial infarction was fatal and post-mortem examination findings were available, this information was also assessed. All potential coronary events were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 213 |
| Placebo | 230 |
Major vascular events defined as non-fatal myocardial infarction or cardiac death, any stroke, or any arterial revascularization procedure (excluding dialysis access procedures). Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 701 |
| Placebo | 814 |
Major vascular events defined as non-fatal myocardial infarction or cardiac death, any stroke, or any arterial revascularization procedure (excluding dialysis access procedures). Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 639 |
| Placebo | 749 |
Stroke was defined as rapid onset of focal or global neurological deficit, with duration greater than 24 hours. Clinical notes and brain imaging were sought to determine the stroke etiology, and if the stroke was fatal and post-mortem examination findings were available, this information was also assessed. All potential stroke events (including transient ischemic attack and intracerebral hemorrhage) were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 131 |
| Placebo | 174 |
"The primary effectiveness endpoint was a composite of the two following outcomes:~Stroke in the same territory (distal to the target lesion) as the presenting event within 12 months of randomization~Hard Transient Ischemic Attack (TIA) in the same territory (distal to the target lesion) as the presenting event from day 2 through month 12 post-randomization~A subject was deemed to be a primary endpoint success if neither of these outcomes occurred.~The Kaplan-Meier success rate at 12-months post-operatively was calculated with Kaplan-Meier time-to-event methodology, where the time variable for patients who were successful (no stroke within 12 months or hard TIA between 2 days and 12 months) was censored at the time of last follow-up, and the time variable for patients who were not successful (had a stroke within 12 months or hard TIA between 2 days and 12 months) was censored at the time of the first event (stroke with 12 months or hard TIA between 2 days and 12 months)." (NCT00816166)
Timeframe: One Year
| Intervention | percent probability (Number) |
|---|---|
| Stent Group | 62.24 |
| Medical Therapy Group | 83.68 |
"Any stroke or neurological death at NCT00929383)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Patients Treated With a Wingspan Stent | 12 |
The cumulative stroke rate at 12 months (any stroke or neurological death /= 31 days is 15.9% or 13 events per 82 patients (NCT00929383)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|---|
| Patients Treated With a Wingspan Stent | 13 |
The rate of recurrent ischemic stroke from 31 days to 12 months post procedure was 1.3% or 1 event per 77 patients analyzed. (NCT00929383)
Timeframe: 12 Months
| Intervention | participants (Number) |
|---|---|
| Patients Treated With a Wingspan Stent | 1 |
"The rate of restenosis at 12 months was defined as the degree of residual stenosis greater than 50% as determined by the study sites using the WASID method. There was a 10.4% rate of restenosis >50% or 8 patients out of 77 analyzed. The differences in this analysis population N=77 vs. ITT N= 82 populations results from exclusion of N=4 patients with no stent implanted and N=1 patient who died prior to any follow up measures of restenosis.~The WASID method is a standardized protocol for measuring intracranial arterial stenosis.~[1-(Dstenosis/Dnormal)] x100=% stenosis (where D=vessel diameter)" (NCT00929383)
Timeframe: 12 Months
| Intervention | participants (Number) |
|---|---|
| Patients Treated With a Wingspan Stent | 8 |
The number of Wingspan Stents successfully deployed across the target lesion. (NCT00929383)
Timeframe: Peri-procedural
| Intervention | patients w stent implanted (Number) |
|---|---|
| Patients Treated With a Wingspan Stent | 78 |
Number of participants with anxiety (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)
| Intervention | participants (Number) |
|---|---|
| A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day | 12 |
| B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day | 13 |
| C. Placebo With Vitamin E 1200 IU/Day | 14 |
Number of participants with moderate/severe anxiety (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)
| Intervention | participants (Number) |
|---|---|
| A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day | 9 |
| B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day | 9 |
| C. Placebo With Vitamin E 1200 IU/Day | 7 |
Number of participants with back pain (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)
| Intervention | participants (Number) |
|---|---|
| A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day | 9 |
| B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day | 13 |
| C. Placebo With Vitamin E 1200 IU/Day | 9 |
Number of participants with moderate/severe back pain (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)
| Intervention | participants (Number) |
|---|---|
| A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day | 7 |
| B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day | 9 |
| C. Placebo With Vitamin E 1200 IU/Day | 7 |
Number of participants with constipation (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)
| Intervention | participants (Number) |
|---|---|
| A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day | 7 |
| B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day | 13 |
| C. Placebo With Vitamin E 1200 IU/Day | 7 |
Number of participants with moderate/severe constipation (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)
| Intervention | participants (Number) |
|---|---|
| A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day | 3 |
| B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day | 10 |
| C. Placebo With Vitamin E 1200 IU/Day | 3 |
Number of participants with depression (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)
| Intervention | participants (Number) |
|---|---|
| A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day | 9 |
| B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day | 6 |
| C. Placebo With Vitamin E 1200 IU/Day | 14 |
Number of participants with diarrhoea (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)
| Intervention | participants (Number) |
|---|---|
| A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day | 6 |
| B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day | 9 |
| C. Placebo With Vitamin E 1200 IU/Day | 11 |
Number of participants with headache (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)
| Intervention | participants (Number) |
|---|---|
| A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day | 9 |
| B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day | 8 |
| C. Placebo With Vitamin E 1200 IU/Day | 11 |
Number of participants with hypertension (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)
| Intervention | participants (Number) |
|---|---|
| A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day | 5 |
| B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day | 7 |
| C. Placebo With Vitamin E 1200 IU/Day | 0 |
Number of participants with insomnia (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)
| Intervention | participants (Number) |
|---|---|
| A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day | 6 |
| B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day | 13 |
| C. Placebo With Vitamin E 1200 IU/Day | 6 |
Number of participants with moderate/severe insomnia (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)
| Intervention | participants (Number) |
|---|---|
| A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day | 2 |
| B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day | 9 |
| C. Placebo With Vitamin E 1200 IU/Day | 0 |
Number of participants with nasopharyngitis (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)
| Intervention | participants (Number) |
|---|---|
| A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day | 7 |
| B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day | 9 |
| C. Placebo With Vitamin E 1200 IU/Day | 3 |
Number of participants with nausea (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)
| Intervention | participants (Number) |
|---|---|
| A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day | 7 |
| B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day | 7 |
| C. Placebo With Vitamin E 1200 IU/Day | 10 |
Number of participants with tremor (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)
| Intervention | participants (Number) |
|---|---|
| A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day | 10 |
| B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day | 13 |
| C. Placebo With Vitamin E 1200 IU/Day | 8 |
Number of patients with urinary tract infections (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)
| Intervention | participants (Number) |
|---|---|
| A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day | 6 |
| B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day | 8 |
| C. Placebo With Vitamin E 1200 IU/Day | 3 |
The Modified Hoehn and Yahr Scale is an 8-level Parkinson disease staging instrument. The investigator will assess disease stage at each level. The disease stages range from the best outcome of 0 (no signs of disease) to the worst outcome of 5 (wheelchair bound or bedridden unless aided). (NCT00740714)
Timeframe: Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day | .21 |
| B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day | .20 |
| C. Placebo With Vitamin E 1200 IU/Day | .16 |
The Modified Rankin Scale is a global functional health index with a strong accent on physical disability. Subjects are scored on a scale of 0 (no symptoms at all) to 5 (severe disability: bedridden incontinent, and requiring constant nursing care and attention. (NCT00740714)
Timeframe: Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day | .38 |
| B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day | .31 |
| C. Placebo With Vitamin E 1200 IU/Day | .40 |
This scale measures activities of daily living. This is an investigator and subject assessment of the subject's level of independence at all scheduled visits. The subject is scored on a percentage scale reflective of his/her ability to perform acts of daily living in relation to pre-Parkinson disease ability. Scores range in increments of 10%: 100% for normal (subject is completely independent; essentially normal) to 0% (vegetative functions such as swallowing, bladder and bowel functions are not functioning; bedridden). (NCT00740714)
Timeframe: Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day | -4.94 |
| B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day | -4.29 |
| C. Placebo With Vitamin E 1200 IU/Day | -4.07 |
The subject will complete a questionnaire that will evaluate how Parkinson disease has affected their health and overall quality of life at each visit. The total quality of life scale measures a total of 33 aspects of quality of life. Each aspect is rated on scale of 0 (best outcome) to 4 (worst outcome). Total score range is 0-132. A higher score or increased score compared to a previous visit indicates a lowered quality of life. (NCT00740714)
Timeframe: Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day | 5.06 |
| B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day | 6.12 |
| C. Placebo With Vitamin E 1200 IU/Day | 5.57 |
The Symbol Digit Modalities Test screens cognitive impairment by using a simple substitution tasks that individuals with normal functioning can easily perform. The test score range is from 0(worst outcome) to 110 (best outcome). (NCT00740714)
Timeframe: Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day | -3.36 |
| B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day | -0.49 |
| C. Placebo With Vitamin E 1200 IU/Day | -3.02 |
Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline visit and month 16 or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first. The UPDRS score has three components, each consisting of questions answered on a 0-4 point scale. Part I assesses mentation, behavior and mood; Part II assesses activities of daily living in the week prior to the designated visit; and Part III assesses motor abilities at the time of the visit. A total of 31 items are included in Parts I, II and III. Each item will receive a score ranging from 0 to 4 where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total score ranges from 0-176. (NCT00740714)
Timeframe: Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day | 8.01 |
| B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day | 7.50 |
| C. Placebo With Vitamin E 1200 IU/Day | 6.92 |
Based on samples analyzed to date (NCT00740714)
Timeframe: Baseline, 1, 8 and 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first
| Intervention | ug/ml (Mean) | ||
|---|---|---|---|
| 1 month visit | 8 month visit | 16 month visit | |
| A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day | 3.55 | 3.32 | 2.88 |
| B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day | 2.57 | 2.67 | 2.17 |
| C. Placebo With Vitamin E 1200 IU/Day | .75 | 1.07 | .63 |
"In patients treated with aspirin and clopidogrel aggregometry was performed and depending on the results the patients were either responder or low-responder of antiplatelet therapy.~The following definitions were used for clopidogrel low response (CLR: >5 ohm when stimulated with adenosine diphosphate (ADP) 5 μM) and ASA low response (ALR: >0 ohm;stimulated with arachidonic acid 10 μM) with the ChronoLog 590 aggregometer. In the case of low-response alternative antiplatelet therapy was modified according to the study plan (see protocol section)." (NCT01212302)
Timeframe: 2 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel Low Response | 155 |
Mean of two seated diastolic blood pressures (NCT00603590)
Timeframe: One year
| Intervention | mm Hg (Mean) |
|---|---|
| Polypill | 77.6 |
| Control | 81.3 |
Serum LDL cholesterol (NCT00603590)
Timeframe: One year
| Intervention | mg/dL (Mean) |
|---|---|
| Polypill | 87.8 |
| Control | 112.0 |
Systolic blood pressure. Mean of two seated measurements. (NCT00603590)
Timeframe: One year
| Intervention | mm Hg (Mean) |
|---|---|
| Polypill | 121.7 |
| Control | 129.7 |
PWV will be measured in patients over age 60 with stage 3 CKD and age matched controls without CKD. (NCT00874432)
Timeframe: up to 12 months
| Intervention | m/s (Mean) | ||
|---|---|---|---|
| Carotid-Femoral Pulse Wave Velocity | Carotid-Brachial Pulse Wave Velocity | Carotid-Radial Pulse Wave Velocity | |
| Age Matched Control | 9.96 | 8.57 | 8.38 |
| Chronic Kidney Disease | 9.90 | 7.62 | 9.03 |
"Comparison between Participants with Stage 3 Chronic Kidney Disease (CKD) and age matched Controls without CKD. The numbers reported are the mean of all the participants in the group at two points in time - the baseline and at 12 months for CFPWV, CBPWV, and CRPWV.~Carotid-Femoral Pulse Wave Velocity (CFPWV) Carotid-Brachial Pulse Wave Velocity (CBPWV) Carotid-Radial Pulse Wave Velocity (CRPWV)" (NCT00874432)
Timeframe: baseline and 12 months
| Intervention | m/s (Mean) | |||||
|---|---|---|---|---|---|---|
| CBPWV Baseline | CBPWV 12 months | CRPWV Baseline | CRPWV 12 months | CFPWV Baseline | CFPWV 12 months | |
| Age Matched Control | 8.17 | 8.06 | 8.95 | 9.43 | 9.55 | 9.79 |
| Age Matched Control-ACE-I | 9.14 | 8.65 | 9.75 | 8.16 | 9.96 | 8.33 |
| Chronic Kidney Disease | 6.28 | 8.28 | 4.80 | 8.66 | 7.95 | 10.66 |
| Chronic Kidney Disease-ACE-I | 7.87 | 8.40 | 9.03 | 8.57 | 10.20 | 11.07 |
Total number of deaths, cardiovascular deaths, non-fatal myocardial infarctions, ischemic strokes and critical limb ischemia. (NCT00761969)
Timeframe: 5 years:
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Death of all causes | Cardiovascular death | Non-fatal myocardial infarction | Non-fatal ischemic stroke | Critical limb ischemia | |
| Control | 47 | 17 | 21 | 14 | 0 |
| Peripheral Arterial Disease | 112 | 51 | 50 | 22 | 11 |
Incidence of coronary, carotid and peripheral arterial revascularization procedures (NCT00761969)
Timeframe: 5 years
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Peripheral arterial revascularization | Coronary revascularization | carotid revascularization | Abdominal aortic revascularization | |
| Control | 2 | 20 | 8 | 0 |
| Peripheral Arterial Disease | 183 | 64 | 31 | 6 |
719 reviews available for aspirin and Cardiovascular Diseases
| Article | Year |
|---|---|
Human disorders associated with inflammation and the evolving role of natural products to overcome.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biological Products; Cardiovascular | 2019 |
Benefits and Risks Associated With Aspirin Use in Patients With Diabetes for the Primary Prevention of Cardiovascular Events and Mortality: A Meta-Analysis.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetic Angiopathies; Diabetic Cardiomyop | 2021 |
Efficacy and Safety of Aspirin for Primary Cardiovascular Risk Prevention in Younger and Older Age: An Updated Systematic Review and Meta-analysis of 173,810 Subjects from 21 Randomized Studies.
Topics: Age Factors; Aspirin; Cardiovascular Diseases; Heart Disease Risk Factors; Hemorrhage; Humans; Morta | 2022 |
[Aspirin in primary prevention of cardiovascular and cerebrovascular diseases].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders | 2021 |
Aspirin and statin therapy for primary prevention of cardiovascular disease in older adults.
Topics: Aged; Aspirin; Cardiovascular Diseases; Frailty; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibit | 2022 |
The Role of Thromboxane in the Course and Treatment of Ischemic Stroke: Review.
Topics: Animals; Aspirin; Cardiovascular Diseases; Fibrinolytic Agents; Humans; Ischemic Stroke; Thromboxane | 2021 |
Aspirin use is associated with increased risk for incident heart failure: a patient-level pooled analysis.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Heart Failure; Humans; Incidence; Male; Middle Aged; | 2022 |
Aspirin in the Modern Era of Cardiovascular Disease Prevention.
Topics: Aspirin; Cardiovascular Diseases; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; | 2021 |
Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit-risk ratio, not age.
Topics: Aged; Aspirin; Cardiovascular Diseases; Humans; Middle Aged; Odds Ratio; Primary Health Care; Risk A | 2021 |
Antiplatelet therapy in cardiovascular disease: Current status and future directions.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Platelet | 2022 |
Cardiovascular Outcomes in Systemic Lupus Erythematosus.
Topics: Aspirin; Cardiovascular Diseases; Disease Progression; Humans; Inflammation; Lupus Erythematosus, Sy | 2022 |
Low-doses aspirin in the primary prevention of cardiovascular disease in patients with diabetes: Meta-analysis stratified by baseline cardiovascular risk.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Heart Disease Risk Factors; Humans; Primary Pre | 2022 |
Aspirin for Primary Cardiovascular Prevention in Patients with Diabetes: Uncertainties and Opportunities.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Diabetes Mellitus; Humans; Platelet Aggregation I | 2022 |
Role of Reticulated Platelets in Cardiovascular Disease.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Platelet | 2022 |
Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement.
Topics: Adult; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Computer Simulation; Hemorrhage; Huma | 2022 |
Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Hemorrhage; Humans; Primary Prevention; Rand | 2022 |
The Era of Polypills in the Management of Cardiovascular Diseases: Are We There Yet?
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Drug Combinations; | 2023 |
Benefits and Risks Associated with Low-Dose Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Control Trials and Trial Sequential Analysis.
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Gastrointestinal Hemorrhage; Humans; Intr | 2022 |
Clopidogrel Monotherapy versus Aspirin Monotherapy in Patients with Established Cardiovascular Disease: Systematic Review and Meta-Analysis.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platel | 2022 |
Polypill for cardiovascular disease prevention: Systematic review and meta-analysis of randomized controlled trials.
Topics: Aged; Antihypertensive Agents; Aspirin; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; H | 2022 |
P2Y12 Inhibitors versus Aspirin Monotherapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Disease Events: A Systematic Review and Meta-analysis.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Infarction; Percut | 2022 |
Aspirin for Primary Prevention of Cardiovascular Diseases: "WALTZ" with the Evidence.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Primary Prevention; Risk Factors | 2022 |
Questions and answers on the use of aspirin for primary prevention of cardiovascular disease in diabetes.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Primary Prevention; Risk Assessment | 2022 |
Aspirin and cancer: biological mechanisms and clinical outcomes.
Topics: Aspirin; Cardiovascular Diseases; Humans; Neoplasms | 2022 |
[Aspirin in primary cardiovascular prevention - a 2022 update].
Topics: Aged; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Primary | 2022 |
Acetylsalicylic acid in primary prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Drugs, Essential; Humans; Platelet Aggregation Inhibitors; Primary | 2022 |
Acetylsalicylic Acid (Aspirin) for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Hemorrhage; Humans; Myocardial Infarction; Prim | 2023 |
Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis.
Topics: Aspirin; Atherosclerosis; Bayes Theorem; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combina | 2023 |
Impact of pharmacogenetics on aspirin resistance: a systematic review.
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase 2; Drug Resistance; Humans; Pharmacogenetics; Plate | 2023 |
Fixed dose combination therapies in primary cardiovascular disease prevention in different groups: an individual participant meta-analysis.
Topics: Aged; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Combinations; Hemorrhage; Huma | 2023 |
Aspirin and lipoprotein(a) in primary prevention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Heterozygote; Humans; Lipoprotein(a); Primary Preven | 2023 |
Fixed-Dose Combination Therapy for the Prevention of Cardiovascular Diseases in CKD: An Individual Participant Data Meta-Analysis.
Topics: Aspirin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial | 2023 |
Who may benefit from low-dose rivaroxaban plus aspirin? Practical implications for outpatients with cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Ischemia; | 2023 |
Aspirin and Primary Prevention in Patients with Diabetes-A Critical Evaluation of Available Randomized Trials and Meta-Analyses.
Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Diabetes Complications; D | 2019 |
Modulation of microRNAs by aspirin in cardiovascular disease.
Topics: Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Docosahexaenoic Acids; Drug Resistance; | 2020 |
Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios.
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Factor Xa Inhibitors; F | 2019 |
Aspirin in primary prevention of cardiovascular disease in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascul | 2020 |
The role of aspirin as antiaggregant therapy in primary prevention. An update.
Topics: Aspirin; Cardiovascular Diseases; Clinical Decision-Making; Hemorrhage; Humans; Platelet Aggregation | 2019 |
Aspirin in primary prevention: the triumph of clinical judgement over complex equations.
Topics: Aspirin; Cardiovascular Diseases; Clinical Competence; Humans; Platelet Aggregation Inhibitors; Prim | 2019 |
Aspirin for Primary Prevention of Cardiovascular Disease in Diabetes: a Review of the Evidence.
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Diabetes Complications; Humans; Primary Pre | 2019 |
Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clinical Decision-Making; Clinical Protocols; Clinical Trial | 2019 |
Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clinical Decision-Making; Clinical Protocols; Clinical Trial | 2019 |
Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clinical Decision-Making; Clinical Protocols; Clinical Trial | 2019 |
Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clinical Decision-Making; Clinical Protocols; Clinical Trial | 2019 |
Usefulness of Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Dose-Response Relationship, Drug; Humans; Platele | 2019 |
Aspirin Use for Primary Prevention of Cardiovascular Disease in Older Patients: A Review of Clinical Guidelines and Updated Evidence.
Topics: Aged; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention; Risk Factors | 2019 |
[Acetylsalicylic acid for primary prevention of cardiovascular events in patients with Type 2 diabetes mellitus].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Platelet Aggregation Inhibitors | 2019 |
Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Female; Humans; Hydroxymethylglutaryl-CoA | 2019 |
Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition.
Topics: Aspirin; Cardiovascular Diseases; Factor Xa Inhibitors; Female; Humans; Male; Platelet Activation; P | 2019 |
Aspirin for CVD, Scabies, Intimate Partner Violence, Maternal Vaccines, Caregiver Burden.
Topics: Adaptation, Psychological; Aspirin; Cardiovascular Diseases; Caregivers; Cyclooxygenase Inhibitors; | 2019 |
A comparison of contemporary versus older studies of aspirin for primary prevention.
Topics: Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Neo | 2020 |
Streamlined mail-based methods for large randomised trials: lessons learnt from the ASCEND study.
Topics: Animals; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Fatty Acids, Omega-3; Female; Humans; | 2020 |
Aspirin in the primary prevention of cardiovascular disease on diabetic patients: Systematic review and meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors; Primar | 2020 |
Is there a cardiovascular protective effect of aspirin in chronic kidney disease patients? A systematic review and meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Renal Insuffi | 2020 |
The role of acetylsalicylic acid and circulating microRNAs in primary prevention of cardiovascular events in patients with Diabetes Mellitus Type 2 - A Review.
Topics: Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Circulating MicroRNA; Diabetes Mellitus, | 2019 |
Aspirin Therapy for Primary Prevention: The Case for Continuing Prescribing to Patients at High Cardiovascular Risk-A Review.
Topics: Aged; Aspirin; Cardiology; Cardiovascular Diseases; Cardiovascular System; Diabetes Complications; H | 2020 |
Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, | 2020 |
The Aspirin Primary Prevention Conundrum.
Topics: Aspirin; Cardiovascular Diseases; Fibrinolytic Agents; Humans; Practice Guidelines as Topic; Primary | 2020 |
Exploratory Review of the Role of Statins, Colchicine, and Aspirin for the Prevention of Radiation-Associated Cardiovascular Disease and Mortality.
Topics: Animals; Aspirin; Cardiotoxicity; Cardiovascular Diseases; Colchicine; Heart Disease Risk Factors; H | 2020 |
Aspirin for primary prevention of cardiovascular disease: Advice for a decisional strategy based on risk stratification.
Topics: Aspirin; Cardiovascular Diseases; Decision Support Techniques; Humans; Platelet Aggregation Inhibito | 2020 |
[Treatment of coronary artery disease in renal insufficiency].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Aspirin; Cardiovascular Diseases; Cor | 2020 |
Aspirin for primary cardiovascular prevention: why the wonder drug should not be precipitously dismissed.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; Meta-Analysis as To | 2020 |
A systematic review and meta-analysis of traumatic intracranial hemorrhage in patients taking prehospital antiplatelet therapy: Is there a role for platelet transfusions?
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Disease Progression; Humans; Intracranial Hemorrhage, | 2020 |
[Aspirin for primary cardiovascular prevention : the end of an era ?]
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention; Risk Assessment | 2020 |
Antiplatelet therapies in diabetes.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus; Humans; Platelet Aggregation Inhib | 2020 |
Repurposing of drugs approved for cardiovascular diseases: Opportunity or mirage?
Topics: Acute Kidney Injury; Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Conv | 2020 |
Sex Disparities in Cardiovascular Outcome Trials of Populations With Diabetes: A Systematic Review and Meta-analysis.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Dis | 2020 |
Reducing Tobacco-Related Disability in Chronic Smokers.
Topics: Aortic Aneurysm, Abdominal; Aspirin; Cardiovascular Diseases; Cigarette Smoking; Early Detection of | 2020 |
[Current antiplatelet agents, new inhibitors and therapeutic targets].
Topics: Aspirin; Blood Coagulation; Blood Platelets; Cardiovascular Diseases; Hemorrhage; Humans; Molecular | 2020 |
Aspirin for primary prevention of atherosclerotic cardiovascular events.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Heart Disease Risk Factors; Humans; Platelet Aggr | 2020 |
Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part III.
Topics: Adult; Aspirin; Cardiovascular Diseases; Child; Diet; Dietary Supplements; Humans; Hydroxymethylglut | 2020 |
Antithrombotic treatment of asymptomatic carotid atherosclerosis: a medical dilemma.
Topics: Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Cerebrovascular Disorders; Fibrinolytic A | 2020 |
The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease.
Topics: Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Cost | 2020 |
The impact of metformin and aspirin on T-cell mediated inflammation: A systematic review of in vitro and in vivo findings.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Diabetes Mellitu | 2020 |
Role of Aspirin for Primary Prevention in Persons with Diabetes Mellitus and in the Elderly.
Topics: Aged; Aspirin; Cardiovascular Diseases; Case-Control Studies; Diabetes Complications; Diabetes Melli | 2020 |
Is There Still a Role for Aspirin in Primary Prevention in Women in 2020?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; | 2020 |
Aspirin in Primary Prevention of Cardiovascular Events.
Topics: Aspirin; Cardiovascular Diseases; Humans; Primary Prevention; Risk Factors | 2020 |
Perioperative Cardiovascular Risk Assessment and Management for Noncardiac Surgery: A Review.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagul | 2020 |
Aspirin: Bitter pill or miracle drug?
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Female; Hemorrhage; Humans; Male; Platel | 2020 |
The Use of Aspirin in Contemporary Primary Prevention of Atherosclerotic Cardiovascular Diseases Revisited: The Increasing Need and Call for a Personalized Therapeutic Approach.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus; Dose-Response Relationship, Dr | 2021 |
Rivaroxaban: A Review for Secondary CV Prevention in CAD and PAD.
Topics: Administration, Oral; Anticoagulants; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; H | 2020 |
Aspirin for primary prevention of cardiovascular disease: a review of recent literature and updated guideline recommendations.
Topics: Adult; Aged; American Heart Association; Aspirin; Cardiovascular Diseases; Humans; Middle Aged; Prim | 2021 |
Aspirin in primary prevention. Meta-analysis stratified by baseline cardiovascular risk.
Topics: Aspirin; Cardiovascular Diseases; Heart Disease Risk Factors; Hemorrhage; Humans; Ischemic Stroke; M | 2020 |
Aspirin for Primary Cardiovascular Prevention in Patients with Family History of Cardiovascular Disease: Meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Humans; Medical History Taking; Platelet Aggregation Inhibitors; P | 2021 |
Aspirin in Primary Prevention: What Changed? A Critical Appraisal of Current Evidence.
Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Evidence-Based Medicine; Heart Disease Ri | 2021 |
Family History of Hypertension, Cardiovascular Disease, or Diabetes and Risk of Developing Preeclampsia: A Systematic Review.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Female; Humans; Hypertension; Pre-Eclam | 2021 |
AGA Clinical Practice Update on Medical Management of Colonic Diverticulitis: Expert Review.
Topics: Anti-Bacterial Agents; Aspirin; Cardiovascular Diseases; Colon; Colonoscopy; Diagnosis, Differential | 2021 |
Aspirin Therapy in Cardiovascular Disease with Glucose-6-Phosphate Dehydrogenase Deficiency, Safe or Not?
Topics: Aspirin; Cardiovascular Diseases; Glucosephosphate Dehydrogenase Deficiency; Hemoglobins; Hemolysis; | 2021 |
Aspirin use in elderly for primary prevention of Cardiovascular Disease: Double edged.
Topics: Aged; Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention; | 2020 |
Aspirin in people with dementia, long-term benefits, and harms: a systematic review.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardio | 2021 |
Aspirin in the Prevention of Cardiovascular Disease and Cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Global Health; Humans; In | 2021 |
Evolution of Clinical Thinking and Practice Regarding Aspirin: What Has Changed and Why?
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Humans; Platelet Aggregation Inhibit | 2021 |
Aspirin for Primary Prevention of Cardiovascular Disease in the 21
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention | 2021 |
The Future of Aspirin Therapy in Cardiovascular Disease.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Risk Assessment | 2021 |
Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2021 |
Aspirin, Statins, and Primary Prevention: Opportunities for Shared Decision Making in the Face of Uncertainty.
Topics: Aged; Aspirin; Cardiovascular Diseases; Decision Making; Decision Making, Shared; Humans; Hydroxymet | 2021 |
Topics: Aspirin; Cardiovascular Diseases; Health Status; Humans | 2021 |
Cardiovascular Events After Partner Bereavement, What is the Role of Low Dose Aspirin and Beta-Blockers?
Topics: Adrenergic beta-Antagonists; Aspirin; Bereavement; Cardiovascular Diseases; Humans; Morbidity | 2022 |
Contemporary Medical Management of Peripheral Artery Disease.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Chronic Limb-Threatening Ischemia; Exercise; Fibr | 2021 |
Differences in the prevention and control of cardiovascular and cerebrovascular diseases.
Topics: Animals; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Humans; | 2021 |
New genetic variants associated with major adverse cardiovascular events in patients with acute coronary syndromes and treated with clopidogrel and aspirin.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Dual Anti-Platelet The | 2021 |
Aspirin and omega-3 polyunsaturated fatty acid use and their interaction in cardiovascular diseases and colorectal adenomas.
Topics: Adenoma; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Dietary Supplements; Docosahexaenoi | 2022 |
Primary Prevention of CVD with Aspirin: Benefits vs Risks.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Gastrointestinal Hemorrhage; Humans; Met | 2021 |
Aspirin for the primary prevention of cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis.
Topics: Adult; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention; Renal Insufficiency | 2022 |
The mortality reducing effect of aspirin in colorectal cancer patients: Interpreting the evidence.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; Cardiovascular Diseases; Colorectal Neoplasm | 2017 |
Upper Gastrointestinal Toxicity Associated With Long-Term Aspirin Therapy: Consequences and Prevention.
Topics: Aspirin; Cardiovascular Diseases; Gastrointestinal Diseases; Gastrointestinal Tract; Global Health; | 2017 |
Aspirin and omeprazole for secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers.
Topics: Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Humans; Omepr | 2017 |
Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk.
Topics: Aspirin; Cardiology; Cardiovascular Agents; Cardiovascular Diseases; Hemorrhage; Humans; Patient Sel | 2017 |
Aspirin for Primary Prevention.
Topics: Age Factors; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Diabetes Mellitus; Gastrointest | 2017 |
The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis.
Topics: Anticoagulants; Aspirin; Bayes Theorem; Cardiovascular Diseases; Clopidogrel; Dabigatran; Dipyridamo | 2017 |
MACULAR DEGENERATION AND ASPIRIN USE.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Fibrinolytic Agents; Huma | 2017 |
Effect of non-insulin-based glucose-lowering therapies on cardiovascular outcomes in patients with type 2 diabetes.
Topics: Adult; Aged; Aspirin; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Hum | 2017 |
Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review.
Topics: Adult; Antibodies, Antiphospholipid; Aspirin; Cardiovascular Diseases; Female; Humans; Hydroxychloro | 2017 |
A Primer on Bleeding Risk and Management Strategies of Newer Oral Anti Platelet Agents in Cardiovascular Disease.
Topics: Adenosine; Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Gastrointestinal Hem | 2016 |
Acetylsalicylic acid for children with Kawasaki disease.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Child; Fev | 2017 |
Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: A comparison between the DAPT study and 9 other trials evaluating DAPT duration.
Topics: Aspirin; Cardiovascular Diseases; Databases, Factual; Drug-Eluting Stents; Hemorrhage; Humans; Myoca | 2017 |
Prolonged Dual Antiplatelet Therapy After MI Reduces Major Adverse Cardiac Events.
Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Hemorrhage; Humans; Mortality; Myocardi | 2017 |
[The use of platelet aggregation inhibitors in the perioperative period].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Germany; Humans; Perioperative Period; Platelet Aggre | 2018 |
Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platel | 2017 |
Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: Benefit or risk?
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Fibrinolytic Agents; Humans; Primary Preve | 2018 |
Antiplatelet Therapy in Diabetes.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Humans; Platelet Aggregation Inhibitors | 2018 |
[Antiaggregants in Primary Prevention of Cardiovascular Diseases and Prevention of Atherothrombosis in Patients With Stable Ischemic Heart Disease: Aspects of Efficacy and Safety].
Topics: Aspirin; Cardiovascular Diseases; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Prim | 2018 |
Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data?
Topics: Age Factors; Aspirin; Cardiovascular Diseases; Comorbidity; Disease Management; Disease Progression; | 2018 |
Perioperative aspirin therapy in non-cardiac surgery: A systematic review and meta-analysis of randomized controlled trials.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Mortality; Perioperative Care; Platelet Aggreg | 2018 |
Clinical Inquiries: What are the benefits and risks of daily low-dose aspirin for primary prevention of CV events?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Gastrointestinal Hemorrhag | 2018 |
Antithrombotic drugs in cardiovascular medicine: a year in review.
Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agen | 2018 |
[Preeclampsia: A challenge also for cardiologists].
Topics: Anticoagulants; Aspirin; Biomarkers; Cardiovascular Diseases; Exercise; Female; Heparin, Low-Molecul | 2018 |
Clinical Outcomes of Aspirin Interaction with Other Non-Steroidal Anti-Inflammatory Drugs: A Systematic Review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregat | 2018 |
A review and study of aspirin utilization for the primary prevention of cardiovascular events in a psychiatric population.
Topics: Aged; Aspirin; Cardiovascular Diseases; Humans; Mental Disorders; Middle Aged; Primary Prevention; R | 2018 |
Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials.
Topics: Antihypertensive Agents; Aspirin; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Drug Th | 2019 |
Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention.
Topics: Aspirin; Cardiovascular Diseases; Fibrinolytic Agents; Humans; Stroke | 2018 |
[Cardiovascular risk of non-steroidal anti-inflammatory drugs].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Drug Interacti | 2018 |
[Is cancer a factor or a marker of cardiovascular risk in women?]
Topics: Aspirin; Biomarkers; Cardiovascular Diseases; Chemoprevention; Female; Humans; Hydroxymethylglutaryl | 2018 |
Harms and Benefits of Using Aspirin for Primary Prevention of Cardiovascular Disease: A Narrative Overview.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Neoplasms; Platelet Aggregation Inhibitors; Pr | 2019 |
Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part I.
Topics: Aspirin; Cardiovascular Diseases; Diet; Dietary Supplements; Humans; Hydroxymethylglutaryl-CoA Reduc | 2018 |
What Do the Guidelines Really Say About Aspirin?
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as To | 2018 |
Interactions between the Cyclooxygenase Metabolic Pathway and the Renin-Angiotensin-Aldosterone Systems: Their Effect on Cardiovascular Risk, from Theory to the Clinical Practice.
Topics: Animals; Aspirin; Cardiotonic Agents; Cardiovascular Diseases; Humans; Muscle, Smooth, Vascular; Myo | 2018 |
A narrative review of the cardiovascular risks associated with concomitant aspirin and NSAID use.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Interactions; | 2019 |
Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Tri | 2019 |
A farewell to aspirin in primary prevention?
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors | 2019 |
Rivaroxaban versus Clopidogrel for Peripheral Artery Disease: A Clinico-Economic Approach of the COMPASS Trial.
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, | 2018 |
Recent Evidence Examining Efficacy and Safety of Aspirin for Primary Cardiovascular Disease Prevention.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as To | 2019 |
Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Female; Hemorrhage; Hum | 2019 |
Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseases; Drug Therapy, Combination; Factor | 2019 |
Aspirin for primary prevention of cardiovascular outcomes in diabetes mellitus: An updated systematic review and meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Humans; Platelet Aggrega | 2020 |
Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy.
Topics: Aged; Anticoagulants; Aspirin; Atherosclerosis; Cardiology; Cardiovascular Diseases; Carotid Arterie | 2019 |
Prescription of Aspirin and Statins in Primary Prevention.
Topics: Aspirin; Cardiovascular Diseases; Female; Healthy Lifestyle; Humans; Hydroxymethylglutaryl-CoA Reduc | 2019 |
Aspirin for the primary prevention of cardiovascular disease in the elderly.
Topics: Aged; Aspirin; Cardiovascular Diseases; Humans; Morbidity; Primary Prevention; Risk Factors | 2019 |
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus; Humans; Platelet Aggregation In | 2019 |
Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease?
Topics: Acute Coronary Syndrome; Aged; Algorithms; Aspirin; Cardiovascular Diseases; Coronary Artery Disease | 2019 |
Impact of acetylsalicylic acid on primary prevention of cardiovascular diseases: A meta-analysis of randomized trials.
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention; Pro | 2019 |
Hypertension and Pregnancy: Management and Future Risks.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Chronic Disease; Diuretics; Female; Human | 2019 |
Aspirin for primary prevention: USPSTF recommendations for CVD and colorectal cancer.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clinical Decision-Making; Colorectal Neoplasms; Dose-Respons | 2019 |
Primary Prevention of Cardiovascular Events with Aspirin: Toward More Harm than Benefit-A Systematic Review and Meta-Analysis.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Risk Assessment | 2019 |
Secondary Prevention with Antithrombotic Therapies in Stable Ischemic Heart Disease Patients: a Review.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Human | 2019 |
Statins and aspirin in the prevention of cardiovascular disease among HIV-positive patients between controversies and unmet needs: review of the literature and suggestions for a friendly use.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Red | 2019 |
Polypills for primary prevention of cardiovascular disease.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Coronary Disease; Drug Combinations; Huma | 2019 |
A Meta-Analysis of Aspirin for the Primary Prevention of Cardiovascular Diseases in the Context of Contemporary Preventive Strategies.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Intracranial Hemorrhages; Platelet Aggregation | 2019 |
Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; | 2019 |
Aspirin for Primary Prevention of Cardiovascular Events.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrha | 2019 |
Aspirin for primary prevention of cardiovascular disease: is it time to move on?
Topics: Adult; Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Hemorrhage; Humans; Middle Aged; Pla | 2019 |
The rise and fall of aspirin in the primary prevention of cardiovascular disease.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxy | 2019 |
Aspirin for primary prevention of stroke in individuals without cardiovascular disease-A meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Humans; Primary Prevention; Stroke | 2020 |
Role of aspirin in primary prevention of cardiovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag | 2019 |
Role of aspirin in primary prevention of cardiovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag | 2019 |
Role of aspirin in primary prevention of cardiovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag | 2019 |
Role of aspirin in primary prevention of cardiovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag | 2019 |
Role of and Recent Evidence for Antiplatelet Therapy in Prevention of Cardiovascular Disease in Diabetes.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Perc | 2019 |
Role of rivaroxaban in the prevention of atherosclerotic events.
Topics: Animals; Aspirin; Atherosclerosis; Cardiovascular Diseases; Drug Therapy, Combination; Factor Xa Inh | 2019 |
Aspirin Efficacy in Primary Prevention: A Meta-analysis of Randomized Controlled Trials.
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Clinical Decision-Making; Hemorrhage; Human | 2019 |
An aspirin a day? Clinical utility of aspirin therapy for the primary prevention of cardiovascular disease.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Hemorrhage; Humans; Practice Guide | 2019 |
Total Thrombus-Formation Analysis System (T-TAS): Clinical Application of Quantitative Analysis of Thrombus Formation in Cardiovascular Disease.
Topics: Anticoagulants; Area Under Curve; Aspirin; Blood Platelets; Cardiovascular Diseases; Catheter Ablati | 2019 |
Caution Regarding Low-Dose Aspirin for Primary Prevention of Cardiovascular Events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Humans; Intracranial Hemor | 2019 |
Aspirin for the primary prevention of cardiovascular disease: latest evidence.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Decision Making; Hemorrhage; Humans; Hydroxymethy | 2019 |
Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy.
Topics: Adenosine; Aspirin; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; | 2013 |
Dual antiplatelet therapy in patients with diabetes mellitus: special considerations.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus; Diabetic Angiopat | 2013 |
Identifying determinants of variability to tailor aspirin therapy.
Topics: Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug I | 2013 |
Is aspirin still the drug of choice for management of patients with peripheral arterial disease?
Topics: Aspirin; Cardiovascular Diseases; Disease Progression; Fibrinolytic Agents; Humans; Peripheral Arter | 2013 |
Aspirin in the treatment and prevention of cardiovascular disease: past and current perspectives and future directions.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Primary Preventio | 2013 |
Low-dose acetylsalicylic acid use and the risk of upper gastrointestinal bleeding: a meta-analysis of randomized clinical trials and observational studies.
Topics: Aspirin; Cardiovascular Diseases; Duodenal Diseases; Esophageal Diseases; Gastrointestinal Hemorrhag | 2013 |
Combined antiplatelet therapy: still a sweeping combination in cardiology.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Clinical Trials as Topic; Drug Therapy, Combinati | 2013 |
Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?
Topics: Aspirin; Cardiology; Cardiovascular Agents; Cardiovascular Diseases; Diabetes Mellitus; Evidence-Bas | 2014 |
[Aspirin and cancer: evidence of a prophylactic effect].
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Aspirin; Cardiovascular Diseases; Cost-Benefit Analy | 2013 |
Aspirin: its risks, benefits, and optimal use in preventing cardiovascular events.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Middle Aged; Platelet Aggregation Inhibitors; Prim | 2013 |
Cardiovascular prophylaxis and aspirin "allergy".
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Desensitization, Immunolo | 2013 |
Optimizing the use of aspirin for cardiovascular prevention.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Dose-Response Relationshi | 2013 |
Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Combin | 2013 |
Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?
Topics: Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Cyclooxygenase 1; Cyclooxygenase 2; Epide | 2013 |
Vascular effects of nonsteroidal antiinflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Diclofenac; Humans; Napro | 2013 |
[Aspirin resistance candidate genes and their association with the risk of fatal cardiovascular events].
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Polymorp | 2013 |
Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy.
Topics: Aspirin; Cardiovascular Diseases; Humans; Metabolomics; Pharmacogenetics; Platelet Aggregation; Plat | 2013 |
Is aspirin useful in primary prevention?
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; Meta-Analysis as Topic; Platele | 2013 |
[The most important aspects of risk assessment].
Topics: Algorithms; Aspirin; Cardiovascular Diseases; Clopidogrel; Digestive System Surgical Procedures; Dru | 2013 |
Prevention of cardiovascular disease in women: highlights for the clinician of the 2011 American Heart Association Guidelines.
Topics: American Heart Association; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Cardiovascul | 2013 |
Cardiovascular disease in women: prevention, symptoms, diagnosis, pathogenesis.
Topics: Aspirin; Cardiovascular Diseases; Estrogens; Female; Fibrinolytic Agents; Hormone Replacement Therap | 2013 |
The ankle-brachial index for peripheral artery disease screening and cardiovascular disease prediction among asymptomatic adults: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Adult; Ankle Brachial Index; Aspirin; Asymptomatic Diseases; Cardiovascular Diseases; Fibrinolytic A | 2013 |
Cardiovascular pharmacology core reviews: aspirin.
Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, D | 2013 |
Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Confidence Intervals; Female; G | 2013 |
Role of platelets in inflammation and cancer: novel therapeutic strategies.
Topics: Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Colorectal Neoplasms; Cyclooxygenase 2; | 2014 |
Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard?
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Cardiovascular Diseases; Cli | 2013 |
Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: the SPACE Collaboration.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Cooperative Behavior; Drug Combinations; | 2013 |
PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection.
Topics: Administration, Oral; Aspirin; Biological Availability; Cardiovascular Diseases; Delayed-Action Prep | 2013 |
[Antiplatelet therapy: resistance to traditional antiaggregation drugs and role of new antiplatelet agents].
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Dr | 2014 |
Prevalence of high on-treatment platelet reactivity in diabetic patients treated with aspirin.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Diabetes Complications; Dose-Response Relationshi | 2014 |
Aspirin for cardioprotection and strategies to improve patient adherence.
Topics: Age Factors; Aspirin; Cardiovascular Diseases; Comorbidity; Health Behavior; Humans; Medication Adhe | 2014 |
Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus.
Topics: Aspirin; Barrett Esophagus; Cardiovascular Diseases; Colorectal Neoplasms; Drug Combinations; Gastro | 2014 |
[Cardiovascular event in elderly patients with diabetes mellitus].
Topics: Antihypertensive Agents; Aspirin; Atherosclerosis; Cardiovascular Diseases; Cause of Death; Clinical | 2013 |
[Statins and ASS for primary prevention of cardiovascular and cerebrovascular disease].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiotonic Agents; Cardiovascular Diseases; Cereb | 2014 |
Antiplatelets in stroke prevention.
Topics: Animals; Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Preventi | 2013 |
Type 2 diabetes and cardiovascular disease: what next?
Topics: Anticholesteremic Agents; Aspirin; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2 | 2014 |
The role of aspirin in the prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as To | 2014 |
Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Humans; Pla | 2014 |
[The polypill as cardiovascular prophylactic: clinical trials].
Topics: Antihypertensive Agents; Aspirin; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Clinica | 2014 |
[Clinical significance of and treatment options for increased lipoprotein(a)].
Topics: Aspirin; Biomarkers; Blood Component Removal; Cardiovascular Diseases; Carrier Proteins; Cholesterol | 2014 |
Fixed-dose combination therapy for the prevention of cardiovascular disease.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Combinatio | 2014 |
Antiplatelet and anticoagulative medication during shockwave lithotripsy.
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Contraindications; Disease Susceptibility; Hemorrh | 2014 |
Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis.
Topics: Aspirin; Cardiology; Cardiovascular Diseases; Europe; Humans; Primary Prevention; Societies, Medical | 2014 |
Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: old question new insights.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Helicobacter Inf | 2014 |
Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin.
Topics: Aspirin; Cardiovascular Diseases; Drug Combinations; Drug Therapy, Combination; Humans; Medication A | 2014 |
Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; | 2014 |
Aspirin, clopidogrel, and the surgeon.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Humans; Platelet Aggregati | 2014 |
PA32540 for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers.
Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors | 2014 |
Cardiovascular disease and its relationship with chronic kidney disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aspirin; Blood Pressure; Cardiovascular Diseases; | 2014 |
Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Male; Placebos; Publication Bia | 2014 |
Aspirin in the primary prevention of cardiovascular disease: current knowledge and future research needs.
Topics: Aspirin; Cardiovascular Diseases; Female; Fibrinolytic Agents; Health Knowledge, Attitudes, Practice | 2014 |
Epidemiology, risk factors and management of cardiovascular diseases in IBD.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clopidogrel; Endothelium, | 2015 |
Methodological issues and recommendations for systematic reviews of prognostic studies: an example from cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Prognosis; Review Literature as Topic | 2014 |
A systematic review of aspirin in primary prevention: is it time for a new approach?
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention; Prosp | 2015 |
The use of aspirin for primary and secondary prevention in venous thromboembolism and other cardiovascular disorders.
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary P | 2015 |
Primary prevention: do the very elderly require a different approach?
Topics: Aged, 80 and over; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Dementia; Humans; Hydr | 2015 |
Aspirin underuse, non-compliance or cessation: definition, extent, impact and potential solutions in the primary and secondary prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Health Services Misuse; Humans; Patient Compliance; Platelet Aggre | 2015 |
Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combi | 2015 |
Preventing cardiovascular disease in patients with diabetes: use of aspirin for primary prevention.
Topics: Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Evidence-Based Medicine; Humans; Patient Se | 2015 |
Perioperative aspirin management after POISE-2: some answers, but questions remain.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Fibrinolytic Agents; Humans; Periope | 2015 |
What is good for the circulation also lessens cancer risk.
Topics: Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Epidemiologic Methods; Humans; Hydroxymet | 2015 |
[Cardiovascular side effects of non-steroidal anti-inflammatory drugs in the light of recent recommendations. Diclofenac is not more dangerous].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cardiovascular System; Di | 2015 |
[Antiplatelet therapy with acetylsalicylic acid: approaches to reducing the frequency of gastrointenstinal adverse reactions].
Topics: Aspirin; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Platelet Aggregation Inhibitors | 2014 |
Statins and aspirin: do they really work in women?
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ma | 2015 |
Misconceptions and Facts About Atrial Fibrillation.
Topics: Administration, Oral; Alcohol Drinking; Anticoagulants; Aspirin; Asymptomatic Diseases; Atrial Fibri | 2015 |
Should patients prescribed long-term low-dose aspirin receive proton pump inhibitors? A systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Dose-Response Relationshi | 2015 |
Reducing Cardiovascular and Cancer Risk: How to Address Global Primary Prevention in Clinical Practice.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Global Health; Humans; Ne | 2015 |
Should patients stop taking aspirin for primary prevention?
Topics: Aspirin; Cardiovascular Diseases; Decision Making; Gastrointestinal Hemorrhage; Humans; Platelet Agg | 2015 |
Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Pressur | 2015 |
The prognostic utility of tests of platelet function for the detection of 'aspirin resistance' in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cost-Benefit Analysis; Drug Resistance; | 2015 |
[Aspirin and statins for every diabetic?].
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Ther | 2015 |
New therapy in cardioprotection.
Topics: Adrenergic beta-Antagonists; Anesthetics, Inhalation; Aspirin; Cardiotonic Agents; Cardiovascular Di | 2015 |
Aspirin for primary prevention in diabetes mellitus: from the calculation of cardiovascular risk and risk/benefit profile to personalised treatment.
Topics: Animals; Aspirin; Biomarkers, Pharmacological; Blood Platelets; Cardiovascular Diseases; Cyclooxygen | 2015 |
Drug-drug interactions between clopidogrel and novel cardiovascular drugs.
Topics: Animals; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Hu | 2015 |
Drug delivery and therapeutic impact of extended-release acetylsalicylic acid.
Topics: Aspirin; Cardiovascular Diseases; Delayed-Action Preparations; Dose-Response Relationship, Drug; Dru | 2016 |
Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Biomedical Research; | 2015 |
Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colorectal Neopl | 2015 |
A Balanced View of Efficacy and Safety of Aspirin in Cardiovascular Diseases.
Topics: Animals; Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; Humans; Platelet Aggregation | 2015 |
Epidemiology of Low Dose Aspirin Damage in the Lower Gastrointestinal Tract.
Topics: Animals; Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Endoscopy, Gastrointest | 2015 |
The impact of dual antiplatelet therapy duration on primary composite endpoint after drug-eluting stent implantation: A meta-analysis of 10 randomized trials.
Topics: Aspirin; Cardiovascular Diseases; Drug-Eluting Stents; Endpoint Determination; Humans; Platelet Aggr | 2016 |
Polypill: Progress and Challenges to Global Use--Update on the Trials and Policy Implementation.
Topics: Antihypertensive Agents; Aspirin; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Health | 2015 |
Aspirin resistance and other aspirin-related concerns.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; | 2016 |
Kawasaki disease in adults: Observations in France and literature review.
Topics: Adult; Aspirin; Cardiovascular Diseases; France; Humans; Immunoglobulins, Intravenous; Mucocutaneous | 2016 |
Antiplatelet Agents in Cardiology: A Report on Aspirin, Clopidogrel, Prasugrel, and Ticagrelor.
Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggregation Inhibitors; P | 2016 |
Improving cardiovascular protection: focus on a cardiovascular polypill.
Topics: Antihypertensive Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Humans; | 2016 |
Aspirin dosing frequency in the primary and secondary prevention of cardiovascular events.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Humans | 2016 |
The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.
Topics: Aspirin; Atorvastatin; Cardiovascular Agents; Cardiovascular Diseases; Drug Combinations; Humans; Ra | 2015 |
Aspirin for the Primary Prevention of Cardiovascular Disease: In Need of Clarity.
Topics: Aspirin; Cardiovascular Diseases; Humans; Primary Prevention; Randomized Controlled Trials as Topic; | 2016 |
Aspirin Use for the Primary Prevention of Cardiovascular Disease in the Elderly.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Primar | 2016 |
Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer.
Topics: Aged; Androgen Antagonists; Aspirin; Blood Pressure; Cardiovascular Diseases; Cholesterol; Diabetes | 2016 |
Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibito | 2016 |
Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario.
Topics: Allopurinol; Aspirin; Bromocriptine; Cardiovascular Diseases; Clonidine; Colesevelam Hydrochloride; | 2016 |
[ASA - from cardiovascular to cancer prevention].
Topics: Aspirin; Carcinoma; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Male; Proton | 2016 |
Perioperative Management to Reduce Cardiovascular Events.
Topics: Adrenergic beta-Antagonists; Aged; Anesthesia; Anticoagulants; Arthroplasty, Replacement, Knee; Aspi | 2016 |
Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Percu | 2016 |
Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force.
Topics: Adult; Aspirin; Cardiovascular Diseases; Fibrinolytic Agents; Gastrointestinal Hemorrhage; Hemorrhag | 2016 |
Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force.
Topics: Adult; Aspirin; Cardiovascular Diseases; Cause of Death; Fibrinolytic Agents; Humans; Primary Preven | 2016 |
Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the U.S. Preventive Services Task Force.
Topics: Adult; Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Humans; Inci | 2016 |
Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials.
Topics: Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Diabetic Cardiomyopathies; Evidence-Based M | 2017 |
Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events.
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Secondary | 2016 |
Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease: Advances in Diagnosis and Treatment.
Topics: Aspirin; Cardiovascular Diseases; Chemoprevention; Colorectal Neoplasms; Evidence-Based Medicine; Fe | 2016 |
Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis.
Topics: Adult; Aspirin; Blood Pressure; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as T | 2016 |
Aspirin use for primary prevention in elderly patients.
Topics: Aged; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregat | 2016 |
Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews.
Topics: Aspirin; Blood Pressure; Cardiovascular Diseases; Coronary Artery Disease; Humans; Hydroxymethylglut | 2016 |
The Effects of Different Aspirin Dosing Frequencies and the Timing of Aspirin Intake in Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Chronotherapy; Humans; Primary | 2016 |
Adherence to therapies for secondary prevention of cardiovascular disease: a focus on aspirin.
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Humans; Medication Adherence; Recurrence; R | 2016 |
Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clopidogrel; Databases, F | 2016 |
Aspirin for primary prevention of cardiovascular disease in patients with diabetes: A meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Diabetes Complications; D | 2016 |
Aspirin and Cancer.
Topics: Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Dose-Response Relationship, Drug; Humans; Pl | 2016 |
Regulation of Platelet Function by Acetylation/Deacetylation Mechanisms.
Topics: Acetylation; Aspirin; Blood Platelets; Cardiovascular Diseases; Epigenesis, Genetic; Histone Acetylt | 2016 |
Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs.
Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Administration Schedule; Drug Dosage | 2017 |
[Direct oral anticoagulants in cardiology].
Topics: Administration, Oral; Anticoagulants; Aspirin; Cardiology; Cardiovascular Diseases; Clopidogrel; Fib | 2016 |
Cardiovascular pharmacogenetics: a promise for genomically-guided therapy and personalized medicine.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Genetic Predisposition to Disease; Genetic Variation; | 2017 |
Is arachidonic acid stimulation really a test for the response to aspirin? Time to think again?
Topics: Arachidonic Acid; Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Humans; Platel | 2017 |
Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease.
Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Gastrointestinal Diseases; Gastrointestin | 2017 |
The aspirin story - from willow to wonder drug.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Aspirin; Cardiovascular Diseases; Drug Discov | 2017 |
Yosprala - a combination of aspirin and omeprazole.
Topics: Animals; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Dela | 2017 |
Aspirin in Older Adults: Need for Wider Utilization in Secondary Prevention and Individual Clinical Judgments in Primary Prevention.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; | 2017 |
Aspirin chemoprevention: one size does not fit all.
Topics: Aspirin; Cardiovascular Diseases; Chemoprevention; Female; Humans; Male; Practice Guidelines as Topi | 2008 |
PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a meta-analysis of 19 studies comprising 3,003 patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Odds Ratio; Platelet Aggregation; Platele | 2008 |
Dual antiplatelet therapy with clopidogrel and aspirin.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Contraindications; Coronary Artery Bypass; Hemorrhage | 2008 |
Antiplatelet therapy and cardiovascular primary prevention: influence of gender, age and other risk factors.
Topics: Age Factors; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Female; Humans; Male; Plate | 2008 |
The impact of prevention on reducing the burden of cardiovascular disease.
Topics: Adult; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Cost of Illness; Costs and Cost A | 2008 |
A practical "ABCDE" approach to the metabolic syndrome.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diet Therapy; Early Diagnosis; Evidence-Based M | 2008 |
Cyclooxygenase-2 inhibitors in colorectal cancer prevention: counterpoint.
Topics: Animals; Aspirin; Cardiovascular Diseases; Chemoprevention; Clinical Trials as Topic; Colorectal Neo | 2008 |
Some translations in vascular neurology. The Johann Jacob Wepfer Award 2008.
Topics: Aspirin; Awards and Prizes; Biomedical Research; CADASIL; Cardiovascular Agents; Cardiovascular Dise | 2008 |
Cardiovascular disease prevention tailored for women.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Cardiovascular Diseases; Choleste | 2008 |
[A change of attitude in lipidology, achievement of target levels. What comes next?].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremi | 2008 |
Clopidogrel and aspirin in cardiovascular medicine: responders or not--current best available evidence.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disea | 2008 |
Resistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndrome.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Drug Resistance; Humans; Metabolic Syndrome; Pl | 2008 |
Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cardio | 2008 |
Psoriasis: an opportunity to identify cardiovascular risk.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; F | 2009 |
Aspirin resistance: focus on clinical endpoints.
Topics: Aspirin; Bleeding Time; Cardiovascular Diseases; Drug Resistance; Evidence-Based Medicine; Humans; P | 2008 |
[Aspirin resistance].
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Resistance; Huma | 2008 |
Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cardiovascular P | 2008 |
Is a statin as part of a polypill the answer?
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topi | 2009 |
Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Resistance; Drug | 2009 |
Prasugrel development - claims and achievements.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Platelets; Cardiovascu | 2009 |
Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Cardiovascular Diseas | 2009 |
Aspirin resistance: an update.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Humans | 2009 |
Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force.
Topics: Age Factors; Aged; Aspirin; Cardiovascular Diseases; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2009 |
Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibito | 2009 |
Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium.
Topics: Aspirin; Belgium; Cardiovascular Diseases; Cost-Benefit Analysis; Health Policy; Humans; Hydroxymeth | 2009 |
Trials of cardiovascular risk factor management in type 2 diabetes.
Topics: Aspirin; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes | 2009 |
Aspirin resistance in cardiovascular disease: pathogenesis, diagnosis and clinical impact.
Topics: Acute Coronary Syndrome; Animals; Aspirin; Cardiovascular Diseases; Drug Interactions; Drug Resistan | 2009 |
An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibito | 2009 |
Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Platelet Activ | 2009 |
Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.
Topics: Aspirin; Cardiovascular Diseases; Dipyridamole; Humans; Peripheral Vascular Diseases; Platelet Aggre | 2009 |
Prevention of nonsteroidal anti-inflammatory drug-induced ulcer: looking to the future.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibito | 2009 |
P2X(1) receptor inhibition and soluble CD39 administration as novel approaches to widen the cardiovascular therapeutic window.
Topics: Adenosine Triphosphate; Antigens, CD; Apyrase; Aspirin; Biomedical Research; Cardiovascular Diseases | 2009 |
Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond.
Topics: American Heart Association; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopid | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitus.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Female; Fibrinolytic Age | 2009 |
Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Hemorrhage; H | 2009 |
Aspirin for primary prevention: do potential benefits outweigh the risks?
Topics: Animals; Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; Humans; Neoplasms; Primary P | 2009 |
[Study of variability in response to aspirin and clopidogrel: clinical and/or biological resistance?].
Topics: Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Resistance; Humans; Pl | 2009 |
Utility of aspirin therapy in patients with the cardiometabolic syndrome and diabetes.
Topics: Aspirin; Blood Coagulation; Blood Glucose; Blood Platelets; Cardiovascular Agents; Cardiovascular Di | 2009 |
Aspirin in the secondary prevention of cardiovascular disease: an update of the APTC meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Tri | 2010 |
Current evidence and clinical implications of aspirin resistance.
Topics: Aspirin; Bleeding Time; Cardiovascular Diseases; Drug Resistance; Evidence-Based Medicine; Fibrinoly | 2009 |
Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Humans; | 2009 |
Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes.
Topics: Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Female; Fibrinolytic Agents; Humans; Hypert | 2009 |
Use of aspirin among diabetics in the primary prevention of cardiovascular disease: need for reliable randomized evidence and astute clinical judgment.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Judgment; Male; Primary Prevent | 2009 |
[Acetylsalicylic acid in patients with diabetes mellitus: can be used for secondary but not primary prevention of cardiovascular events].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Humans; Platelet Aggregation Inhibitors; P | 2009 |
Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation I | 2009 |
Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; | 2010 |
Optimizing antiplatelet therapy in high-risk patients with atrial fibrillation: insights from Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE A).
Topics: Antihypertensive Agents; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Cardiovascular Diseases; | 2009 |
[Long-term use of oral antiplatelet therapy: from studies to practice].
Topics: Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Combinations; Fibrinolytic | 2010 |
Polypill: the evidence and the promise.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Combinations; Humans; Hydroxymethylg | 2009 |
[Antiplatelet therapy and gastrointestinal complications].
Topics: Aspirin; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Platelet Aggregation Inhibitors | 2009 |
Antiplatelet agents.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Dose-Response Relationship, | 2009 |
[Thienopyridines in the treatment and prevention of cardiovascular diseases. III. therapeutic application of clopidogrel as monotherapy (without acetylsalicylic acid)].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platel | 2009 |
[Sex differences and cardiovascular drugs].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Asp | 2010 |
[Progress in clinical cardiology: surface electrocardiography, cardiovascular disease in women, and novel therapies].
Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolyt | 2010 |
Antiplatelet and antithrombotic treatment of patients with peripheral arterial disease.
Topics: Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Disease Progression; Dose-Respo | 2010 |
Heterogeneity of efficacy and safety of antiplatelet therapy in cardiovascular and cerebrovascular disease.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Trial | 2010 |
Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation.
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Female; Humans; Male; Medication | 2010 |
Identifying and assessing benefit-risk in primary care--a family physician's perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cardiovascular Diseases; Drug Interacti | 2010 |
Don't use aspirin for primary prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Fibrinolytic Agents; Humans; Off-Label Use; Practice Guidelines as | 2010 |
JAK2 mutation and thrombosis in the myeloproliferative neoplasms.
Topics: Amino Acid Substitution; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Fibrinolytic Ag | 2010 |
Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Primary Prevention | 2010 |
Aspirin and clopidogrel resistance: methodological challenges and opportunities.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Resistance; Humans; Platelet Ag | 2010 |
Late-breaking systematic reviews to inform evidence-based practice.
Topics: Aspirin; Cardiac Rehabilitation; Cardiovascular Diseases; Constipation; Evidence-Based Practice; Hum | 2010 |
Point-of-care testing for assessment of adequacy of oral antiplatelet therapy in patients with cardiovascular disease.
Topics: Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Drug Res | 2010 |
[Primary prevention of cardiovascular disease with aspirin: what do the guidelines say?].
Topics: Aspirin; Cardiovascular Diseases; Humans; Practice Guidelines as Topic; Primary Prevention | 2010 |
Aspirin for acute coronary syndromes: have we learned the correct dose yet?
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Cardiovascular Diseases; Humans; Platelet Aggrega | 2010 |
Aspirin for primary prevention of cardiovascular events in people with diabetes.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiop | 2010 |
A review of international pharmacoeconomic models assessing the use of aspirin in primary prevention.
Topics: Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Economics, Pharmaceutical; Female; Humans; | 2010 |
[Effects of low-dose aspirin on primary prevention of cardiovascular events: a systematic review].
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention; Rando | 2010 |
New insight in antiplatelet therapy monitoring in cardiovascular patients: from aspirin to thienopyridine.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Pyridines | 2010 |
A review of the use of common antiplatelet agents in orthopaedic practice.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combina | 2010 |
[Thienopyridines in the treatment and prevention of cardiovascular diseases. Part V. Combination of clopidogrel and acetylsalicylic acid in the treatment of stable patients with atherothrombotic cardiovascular diseases].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Cardiovascular D | 2010 |
Aspirin for primary prevention of cardiovascular disease in diabetes mellitus.
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Complications; Drug Resistance; Female; Gastrointes | 2010 |
Aspirin resistance: fact or fiction?
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Platelet Aggregation; Platelet Aggregatio | 2010 |
NSAID-induced gastrointestinal and cardiovascular injury.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clopidogrel; Cyc | 2010 |
Aspirin for the prevention of cardiovascular morbidity.
Topics: Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Female; Humans; Male; Myocardial Infarction | 2010 |
ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Dise | 2010 |
Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 | 2010 |
[Efficacy and safety of various doses of acetylsalicylic Acid in prevention of complications of atherothrombosis].
Topics: Aspirin; Blood Platelets; Blood Vessels; Cardiovascular Diseases; Cerebrovascular Disorders; Clinica | 2010 |
ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Dise | 2010 |
Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Dose-Response Relationship, Drug; Hemorrha | 2011 |
Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregati | 2011 |
Aspirin and primary cardiovascular prevention. Uncertain balance between benefits and risks.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Platelet Aggregation Inhibitors; Randomized | 2010 |
C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians.
Topics: Aspirin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Communicable Diseases; Gastrointes | 2011 |
Aspirin resistance: effect of clinical, biochemical and genetic factors.
Topics: Aspirin; Cardiovascular Diseases; Drug Evaluation; Drug Resistance; Humans; Models, Biological; Plat | 2011 |
Platelet function and antiplatelet therapy in cardiovascular disease: implications of genetic polymorphisms.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Genetic Variation; Genotype; Haploty | 2011 |
Antiplatelet agents in cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2011 |
[Advances in the study of nitric oxide-donating drugs].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Azo Compounds; Car | 2009 |
[Strategy to manage low dose aspirin-induced gastrointestinal injury].
Topics: Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Famotid | 2011 |
Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis.
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Diabetes Complications; Evidence-Based Medi | 2011 |
Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update.
Topics: Arterial Occlusive Diseases; Aspirin; Cardiovascular Diseases; Comorbidity; Female; Humans; Incidenc | 2012 |
Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin.
Topics: Aspirin; Cardiovascular Diseases; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Pr | 2011 |
Gender differences in the primary prevention of stroke with aspirin.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Female; Fibrinolytic Agents; Humans; Male; Meta-An | 2011 |
Recent developments in the use of antiplatelet agents to prevent cardiovascular events.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding C | 2011 |
Gastrointestinal effects of aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Gastric Mucosa; Gastroint | 2011 |
Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors; Primar | 2011 |
The polypill to prevent cardiovascular disease: physicians' perspectives.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Attitude of Health Person | 2011 |
Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials.
Topics: Aspirin; Cardiovascular Diseases; Global Health; Hemorrhage; Humans; Morbidity; Platelet Aggregation | 2011 |
Reducing the risk of gastroduodenal ulcers with a fixed combination of esomeprazole and low-dose acetyl salicylic acid.
Topics: Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Drug Therapy, Combin | 2011 |
A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?
Topics: Adrenergic alpha-Antagonists; Anticoagulants; Apolipoproteins E; Aspirin; Cardiovascular Agents; Car | 2012 |
[Cyclooxygenase inhibitors and antiplatelet effect of acetylsalicylic acid. selective approach to nonsteroidal anti-inflammatory drugs in cardiological practice].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cardiovascular Diseases; Cardiova | 2011 |
The cardiovascular polypill in high-risk patients.
Topics: Administration, Oral; Antihypertensive Agents; Aspirin; Cardiovascular Agents; Cardiovascular Diseas | 2012 |
Transrectal ultrasound-guided prostate biopsies in patients taking aspirin for cardiovascular disease: A meta-analysis.
Topics: Aspirin; Biopsy; Cardiovascular Diseases; Hematuria; Hemorrhage; Hemospermia; Humans; Male; Platelet | 2011 |
Is it worth offering cardiovascular disease prevention to the elderly?
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Diet; Exercise; Hu | 2013 |
Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials.
Topics: Aspirin; Cardiovascular Diseases; Humans; Primary Prevention; Randomized Controlled Trials as Topic; | 2012 |
The role of low-dose aspirin in the prevention of colorectal cancer.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Cardiova | 2012 |
Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocar | 2012 |
Acetylsalicylic acid/esomeprazole fixed-dose combination.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Capsules; Cardiovascular Diseas | 2012 |
Optimal drug therapy after aspirin-induced upper gastrointestinal bleeding.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Peptic Ulcer; Pl | 2012 |
Aspirin for primary prevention of cardiovascular events in the elderly: current status and future directions.
Topics: Aged; Aspirin; Cardiovascular Diseases; Humans; Practice Guidelines as Topic; Randomized Controlled | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Primary and secondary prevention of cardiovascular disease in diabetes with aspirin.
Topics: Animals; Anticarcinogenic Agents; Aspirin; Blood Platelets; Cardiovascular Diseases; Diabetes Compli | 2012 |
Role of ASA in the primary and secondary prevention of cardiovascular events.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention; Secon | 2012 |
Risk factors for gastrointestinal bleeding associated with low-dose aspirin.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cardiovascular Diseas | 2012 |
Prevention of damage induced by aspirin in the GI tract.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Drug S | 2012 |
Balancing the risk and benefits of low-dose aspirin in clinical practice.
Topics: Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Gastrointestinal Hemorrhage; Hemorrhage; Hum | 2012 |
Aspirin and NSAIDs; benefits and harms for the gut.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Cardiovascular Disease | 2012 |
Room for improvement: unmet needs in postoperative pain management.
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; | 2012 |
A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
Topics: Antihypertensive Agents; Aspirin; Atenolol; Cardiovascular Diseases; Drug Combinations; Humans; Hydr | 2012 |
Aspirin: a history, a love story.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Benzyl Alcohols; Cardiovascul | 2012 |
Clopidogrel and proton pump inhibitors--where do we stand in 2012?
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Cardiovascular Diseases; Clopido | 2012 |
Aspirin for the primary prevention of cardiovascular diseases.
Topics: Aspirin; Cardiovascular Diseases; Confidence Intervals; Humans; Platelet Aggregation Inhibitors; Pri | 2012 |
Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance.
Topics: Administration, Oral; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Comorbidity; D | 2012 |
Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials.
Topics: Aspirin; Cardiovascular Diseases; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Therapy, Combin | 2013 |
Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients.
Topics: Adrenergic beta-Antagonists; Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting E | 2012 |
Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reduc | 2012 |
Pharmacokinetic and clinical evaluation of esomeprazole and ASA for the prevention of gastroduodenal ulcers in cardiovascular patients.
Topics: Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Drug Interactions; Esomeprazole; Humans; Peptic | 2012 |
The aspirin controversy in primary prevention.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Meta-Analysis as Topic; Myocardial Infarction; | 2012 |
Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Coronary Art | 2012 |
Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Ischemia; Myocardia | 2012 |
Aspirin for primary prevention of cardiovascular disease events.
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Evidence-Based Medicine; Female; Hemorr | 2012 |
[Cardiovascular risk of non-steroidal anti-inflammatory drugs].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Cardiovascular Diseases; Cy | 2012 |
Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus, Type 2; Dipyridamole; Drug Therapy | 2012 |
High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs--pharmacological mechanisms and clinical relevance.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase I | 2013 |
Efficacy and safety of adjunctive cilostazol to dual antiplatelet therapy after stent implantation: an updated meta-analysis of randomized controlled trials.
Topics: Aspirin; Cardiovascular Diseases; Cilostazol; Combined Modality Therapy; Cyclooxygenase Inhibitors; | 2013 |
Cardiovascular adverse effects of anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cardiovascular System; Cl | 2013 |
Reinitiating aspirin therapy for primary prevention of cardiovascular events in a patient post-aspirin-induced upper gastrointestinal bleed: a case report and review of literature.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Car | 2013 |
Aspirin prophylaxis in patients at low risk for cardiovascular disease: a systematic review of all-cause mortality.
Topics: Aspirin; Cardiovascular Diseases; Humans; Risk Assessment | 2002 |
Cardiovascular disorders. Primary prevention.
Topics: Aspirin; Benzofurans; Cardiovascular Diseases; Combined Modality Therapy; Exercise; Feeding Behavior | 2002 |
Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Gastrointestinal Hemorrhage; Humans; My | 2002 |
The public health potential of aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colonic Neoplasms; Female | 2002 |
Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance.
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Resistance; Humans; Platelet Aggre | 2002 |
Aspirin dose for prevention of cardiovascular disease in diabetics.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response | 2003 |
Scientific and therapeutic advances in antiplatelet therapy.
Topics: Adenosine Diphosphate; Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Humans; Platelet | 2003 |
Update on aspirin in the treatment and prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation | 2002 |
Gastrointestinal safety of low-dose aspirin.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Consumer Product Sa | 2002 |
[Aspirin for primary prevention of asymptomatic atherosclerosis].
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Mid | 2002 |
Aspirin. New uses for an old standby.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Fibrinolytic Agents; Huma | 2002 |
Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2; Cycloox | 2003 |
Cardiology Grand Rounds from the University of North Carolina at Chapel Hill. The antioxidant vitamins and coronary heart disease: Part II. Randomized clinical trials.
Topics: Adult; Aged; alpha-Tocopherol; Antioxidants; Aspirin; beta Carotene; Cardiovascular Diseases; Corona | 2003 |
Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force.
Topics: Adult; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet; Evidence-Based Medicine; E | 2003 |
The renin-angiotensin-aldosterone system as a target in coronary disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents | 2003 |
The role of chronic inflammation in cardiovascular mortality of uremic patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive Protein; Cardiovascular Diseases; Human | 2003 |
Cardiovascular disorders. Primary prevention.
Topics: Aspirin; Benzofurans; Cardiovascular Diseases; Combined Modality Therapy; Exercise; Feeding Behavior | 2002 |
[Antiaggregation: aspirin].
Topics: Administration, Oral; Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Di | 2003 |
Drugs for cardiovascular risk reduction in the diabetic patient.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 1 | 2001 |
Current concepts of cardiovascular diseases in diabetes mellitus.
Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus | 2003 |
High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
Topics: Arteriosclerosis; Aspirin; C-Reactive Protein; Cardiovascular Diseases; Coronary Disease; Female; Fi | 2003 |
Inflammation, the metabolic syndrome and cardiovascular risk.
Topics: Arteriosclerosis; Aspirin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitu | 2003 |
[Secondary prevention after acute myocardial infarction: aspirin, warfarin or both?].
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Coronary Thrombosis; Drug Therapy, Combination; Fi | 2003 |
The platelet in diabetes: focus on prevention of ischemic events.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Humans; | 2003 |
Managing diabetes: what to do about cardiovascular disease.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Cardiova | 2003 |
Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Cardiovascular Diseases; Ce | 2002 |
[Indications for anticoagulant use in secondary prevention of strokes].
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cardiovas | 2003 |
An update on aspirin in the primary prevention of cardiovascular disease.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; | 2003 |
Aspirin for the prevention of cardiovascular events in the elderly.
Topics: Aged; Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention; | 2003 |
NCX-4016 NicOx.
Topics: Animals; Aspirin; Cardiovascular Diseases; Clinical Trials, Phase I as Topic; Clinical Trials, Phase | 2003 |
Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Drug Resistance; Eicosanoids; Humans; Isoprostan | 2003 |
[Prevention of cardiovascular diseases using a combined pharmacological approach: is there any place for a "polypill"?].
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Combinations; Folic Acid; Hematinics | 2003 |
Chronic myeloproliferative disorders.
Topics: Antineoplastic Agents; Aspirin; Cardiovascular Diseases; Chronic Disease; Hematopoietic Stem Cell Tr | 2003 |
Cardiovascular risk in patients with renal disease: treating the risk or treating the risk factor?
Topics: Adult; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Dietary Supplements; Folic Acid; H | 2004 |
The role of aspirin in cardiovascular diseases--forgotten benefits?
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Myo | 2004 |
The role of aspirin in cardiovascular diseases--forgotten benefits?
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Myo | 2004 |
The role of aspirin in cardiovascular diseases--forgotten benefits?
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Myo | 2004 |
The role of aspirin in cardiovascular diseases--forgotten benefits?
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Myo | 2004 |
Antiplatelet drugs in cardiovascular diseases.
Topics: Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Drug Resistance; Humans; Myocardial Infarctio | 2003 |
Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
Topics: Aged; Anticholesteremic Agents; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Female; | 2004 |
Clinical inquiries. Which healthy adults should take aspirin?
Topics: Adult; Aspirin; Cardiovascular Diseases; Evidence-Based Medicine; Humans; Patient Selection; Platele | 2004 |
[Is the supplementation with antioxidants effective in the treatment of atherosclerosis?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antioxidants; Arteriosclerosis; A | 2004 |
[Interactions of statins with antithrombotic drugs].
Topics: Animals; Anticholesteremic Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Clopidogrel; Cont | 2004 |
Antiplatelet therapy in cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Platelet Gl | 2004 |
Intense management of diabetes mellitus: role of glucose control and antiplatelet agents.
Topics: Aspirin; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combinatio | 2004 |
[Prevention of cardiovascular and degenerative diseases: I. Aspirin, statins, or vitamins?].
Topics: Anticholesteremic Agents; Aspirin; Cardiovascular Diseases; Humans; Neurodegenerative Diseases; Vita | 2003 |
Aspirin in cardiovascular disorders. What is the optimum dose?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; | 2004 |
First-generation agents: aspirin, heparin and coumarins.
Topics: Aspirin; Cardiovascular Diseases; Coumarins; Fibrinolytic Agents; Heparin; Humans; Practice Guidelin | 2004 |
Low-dose aspirin for primary prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Fibrinolytic Agents; Humans; Myocardial Infarction; Platelet Aggre | 2003 |
Aspirin in the XXI century: its major clinical impact, novel mechanisms of action, and new safer formulations.
Topics: Administration, Oral; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; Peptic Ul | 2004 |
Aspirin resistance: current concepts.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Fibrinolytic Agents; Humans; Platelet Activation; | 2004 |
[Clinical importance of aspirin resistance].
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Platelet Aggregation; Platelet Aggregatio | 2004 |
Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: possible interactions and implications for treatment of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Cardiovascular Diseases; Co | 2004 |
Prevention of cardiovascular disease: an evidence-based clinical aid 2004.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiova | 2004 |
Terms and conditions: semantic complexity and aspirin resistance.
Topics: Aspirin; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Cyclooxygenase Inhibitors; Drug | 2004 |
Terms and conditions: semantic complexity and aspirin resistance.
Topics: Aspirin; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Cyclooxygenase Inhibitors; Drug | 2004 |
Terms and conditions: semantic complexity and aspirin resistance.
Topics: Aspirin; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Cyclooxygenase Inhibitors; Drug | 2004 |
Terms and conditions: semantic complexity and aspirin resistance.
Topics: Aspirin; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Cyclooxygenase Inhibitors; Drug | 2004 |
Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
Topics: Adult; Age Distribution; Aged; Aspirin; Cardiovascular Diseases; Evidence-Based Medicine; Female; Ga | 2004 |
Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular events.
Topics: Aspirin; Cardiovascular Diseases; Guideline Adherence; Humans; Japan; Patient Selection; Platelet Ag | 2004 |
Cardioprotective effects and gastrointestinal risks of aspirin: maintaining the delicate balance.
Topics: Aged; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Ad | 2004 |
[Acetylsalicylic acid for the primary prevention of cardiovascular disease in diabetic patients].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Humans; Platelet Aggregation Inhibitors; P | 2004 |
Prevention of cardiovascular complications of diabetes mellitus by aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; | 2004 |
Use of aspirin to reduce risks of cardiovascular disease in patients with diabetes: clinical and research challenges.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors | 2004 |
Platelet function testing in cardiovascular diseases.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Case Management; Clopidogrel; Drug Resistance; H | 2004 |
[Cardiovascular risk in diabetes--diagnostic and therapeutic aspects].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antibodies, Mon | 2004 |
Prevention of cardiovascular events in diabetes.
Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Clopidogrel; Corona | 2003 |
[Acetylsalicylic acid resistance--clinical diagnosis with unclear mechanism].
Topics: Aspirin; Bleeding Time; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Interactions; Drug | 2004 |
[Primary prevention of cardiovascular disease].
Topics: Adult; Age Factors; Aged; Antihypertensive Agents; Aspirin; Body Mass Index; Cardiovascular Diseases | 2005 |
Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Diseases; Diabetes Complications; | 2005 |
Aggregation and activation of blood platelets in exercise and training.
Topics: Aspirin; Cardiac Rehabilitation; Cardiovascular Diseases; Exercise; Humans; Physical Education and T | 2005 |
Prevention of cardiovascular events in diabetes.
Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Bezafibrate; Cardiovascular Diseases; Corona | 2004 |
[Aspirin: recent advances in cardiovascular prevention].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregati | 2004 |
Combination antiplatelet agents in ischemic cerebrovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Clopidogrel; Dipyridamole; Drug Therapy, Combinati | 2005 |
Novel serologic markers of cardiovascular risk.
Topics: Antioxidants; Aspirin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cause of Death; Cyto | 2005 |
Narrative review: aspirin resistance and its clinical implications.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Platelet Activation; Platelet Aggregation | 2005 |
Aspirin response and failure in diabetic patients with cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans | 2005 |
Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Loss, Surgical; Cardiovascula | 2005 |
Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Loss, Surgical; Cardiovascula | 2005 |
Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Loss, Surgical; Cardiovascula | 2005 |
Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Loss, Surgical; Cardiovascula | 2005 |
Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Loss, Surgical; Cardiovascula | 2005 |
Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Loss, Surgical; Cardiovascula | 2005 |
Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Loss, Surgical; Cardiovascula | 2005 |
Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Loss, Surgical; Cardiovascula | 2005 |
Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Loss, Surgical; Cardiovascula | 2005 |
Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Loss, Surgical; Cardiovascula | 2005 |
Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Loss, Surgical; Cardiovascula | 2005 |
Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Loss, Surgical; Cardiovascula | 2005 |
Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Loss, Surgical; Cardiovascula | 2005 |
Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Loss, Surgical; Cardiovascula | 2005 |
Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Loss, Surgical; Cardiovascula | 2005 |
Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Loss, Surgical; Cardiovascula | 2005 |
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cardiovascular Diseases; Cycloox | 2005 |
Impact of nonsteroidal antiinflammatory drugs on the cardioprotective effects of aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors | 2005 |
Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Brain Ischemia; C-Reactive Prote | 2005 |
Keeping the diabetic heart healthy.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Family Practice; | 2005 |
The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cardiovascular Diseases; Confound | 2005 |
Aspirin and clopidogrel: a sweeping combination in cardiology.
Topics: Aspirin; Cardiology; Cardiovascular Diseases; Clopidogrel; Humans; Ticlopidine | 2005 |
COX-2 inhibitors and metabolism of essential fatty acids.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2; Cycloox | 2005 |
Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Aspir | 2005 |
Risk of hemorrhagic stroke with aspirin use: an update.
Topics: Adult; Aged; Aged, 80 and over; Angiography; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain | 2005 |
A critical appraisal of the phenomenon of aspirin resistance.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Drug Resistance; Humans; Platelet Aggregation; Pl | 2005 |
[Should we treat all diabetic patients with aspirin in primary prevention?].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors; Primar | 2005 |
Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery.
Topics: Administration, Oral; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Coron | 2005 |
Aspirin resistance.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; | 2005 |
Aspirin for the primary prevention of cardiovascular disease: a comprehensive review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cerebral Hemorrhage; Dose | 2005 |
[Recommendations for treatment with nonsteroidal anti-inflammatory drugs].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Aspirin; Cardiovascular Disease | 2005 |
Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin?
Topics: Animals; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; Hydroxymethylglutaryl- | 2005 |
[Results of the Women's Health Study].
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Fe | 2005 |
[Genetic basis of individual sensitivity to antiplatelet drugs].
Topics: Aspirin; Cardiovascular Diseases; Drug Hypersensitivity; Gene Expression; Humans; Platelet Aggregati | 2005 |
[Cardiovascular protection and prevention in patients with cardiac conditions and diabetes].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Glucose; Cardi | 2005 |
An update on nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibito | 2005 |
[Primary prevention of cardiovascular diseases with acetylsalicylic acid].
Topics: Aspirin; Cardiovascular Diseases; Humans; Meta-Analysis as Topic; Platelet Aggregation Inhibitors; P | 2005 |
Aspirin and clopidogrel resistance: an emerging clinical entity.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Resist | 2006 |
Aspirin resistance.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Fibrinolytic Agents; Humans; Platelet Aggregation | 2005 |
Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.
Topics: Aspirin; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Platelet | 2006 |
Metabolic syndrome.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Exercise; Humans; Hydroxymethylglutaryl | 2006 |
[Cardiological (pharmaco)therapy and dental practice].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Thrombosis; Defibrillators, Implantable; Hea | 2006 |
Does sex affect how patients respond to ASA?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; | 2006 |
[The role of aspirin in the primary prevention of cardiovascular disease].
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Platelet Aggregation Inhibitors; | 2006 |
Benefits, challenges, and registerability of the polypill.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Attitude of He | 2006 |
Aspirin and clopidogrel resistance.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Resistance, Multiple; Humans; Platelet Aggregati | 2006 |
Is there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Interaction | 2006 |
NO-NSAIDs: from inflammatory mediators to clinical readouts.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Blood Coagulation; Cardiovascu | 2006 |
Chronic aspirin therapy for the prevention of cardiovascular events: a waste of time, or worse?
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Humans; Platelet Aggregation Inhibit | 2006 |
Clinical implications of nonopioid analgesia for relief of mild-to-moderate pain in patients with or at risk for cardiovascular disease.
Topics: Acetaminophen; Aged; Aging; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspir | 2006 |
Gastrointestinal Considerations in Patients with Cardiovascular Disease Using Nonopioid Analgesics for Mild-to-Moderate Pain or Cardioprotection.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibito | 2006 |
Potential for drug-drug interactions in patients taking analgesics for mild-to-moderate pain and low-dose aspirin for cardioprotection.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Aspirin; Cardiotonic Agents; Cardiovascular Diseases; Cyclo | 2006 |
[Aspirin in primary prevention of cardiovascular events in women and men (a meta-analysis of randomized controlled trials)].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Ran | 2006 |
Aspirin resistance: does it exist and is it an important clinical problem?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidog | 2006 |
Priorities among effective clinical preventive services: results of a systematic review and analysis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cost-Benefit Analy | 2006 |
[The Polypill: between myths and reality in the treatment of type 2 diabetes mellitus].
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combinati | 2006 |
Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cardiova | 2006 |
Dyslipidaemia, hypercoagulability and the metabolic syndrome.
Topics: Adipose Tissue; Adiposity; Animals; Aspirin; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Ac | 2006 |
Drug therapies in the secondary prevention of cardiovascular diseases: Successes, shortcomings and future directions.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Aspirin; Atheroscler | 2006 |
Aspirin resistance.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Humans | 2006 |
Intravascular ultrasound in cardiovascular medicine.
Topics: Adult; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA | 2006 |
Unmet needs in non-steroidal anti-inflammatory drug-induced upper gastrointestinal diseases.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibito | 2006 |
Management of high-risk patients on non-steroidal anti-inflammatory drugs or aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Gastrointestinal Diseases | 2006 |
The dose of aspirin for the prevention of cardiovascular and cerebrovascular events.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Double-Blind Method; Humans; Meta-Analy | 2006 |
Aspirin for the primary prevention of cardiovascular events.
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Humans; Meta-Analysis as Topic; | 2006 |
Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2006 |
Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk?
Topics: Adrenal Cortex Hormones; Aging; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Ca | 2006 |
Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pl | 2006 |
[Aspirin therapy for cardiovascular prevention in the diabetic patient: what have we learned from the evidence?].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Humans; Platelet Aggregation Inhibitors | 2006 |
Prevention of cardiovascular events in diabetes.
Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Bezafibrate; Cardiovascular Diseases; Clopid | 2006 |
Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic, antiinflammatory drugs? Arguments against.
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cardiovascular Diseases; Cl | 2006 |
Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Contraindications; Cycloo | 2006 |
Possible mechanisms of drug-induced aspirin and clopidogrel resistance.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clopidogrel; Cytochrome P | 2006 |
Aspirin resistance: what, why and when?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Res | 2007 |
Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions.
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug | 2006 |
Reducing cardiovascular disease risk in patients with diabetes: a message from the National Diabetes Education Program.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; | 2006 |
From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention.
Topics: Animals; Apoptosis; Aspirin; Atherosclerosis; Cardiovascular Diseases; Cholesterol; Drug Therapy, Co | 2007 |
[Are the NSAIDs able to compromising the cardio-preventive efficacy of aspirin?].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clopidogrel; | 2006 |
[What is the impact of cardiovascular and renal complications on the benefit/risk ratio of the NSAIDs?].
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Contro | 2006 |
Spotlight on renin: cardiovascular outcomes in chronic kidney disease and suppression of the renin-angiotensin system.
Topics: Albuminuria; Aspirin; Cardiovascular Diseases; Chronic Disease; Glomerular Filtration Rate; Humans; | 2006 |
[Guidelines for the management of atherosclerotic diseases in diabetes mellitus].
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Complications; Dyslipidemias; Humans; Hy | 2006 |
Clopidogrel resistance?
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Humans; M | 2007 |
Aspirin resistance: a review of diagnostic methodology, mechanisms, and clinical utility.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Drug Resistance; Humans | 2006 |
Drug insight: aspirin resistance--fact or fashion?
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase Inhibito | 2007 |
Kawasaki disease.
Topics: Aspirin; Cardiovascular Diseases; Child, Preschool; Glucocorticoids; Humans; Immunoglobulins, Intrav | 2006 |
[Overview of cardiovascular risk factors].
Topics: Age Factors; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; As | 2006 |
Rapid desensitization protocols for patients with cardiovascular disease and aspirin hypersensitivity in an era of dual antiplatelet therapy.
Topics: Aspirin; Cardiovascular Diseases; Clinical Protocols; Desensitization, Immunologic; Drug Hypersensit | 2007 |
[Aspirin for primary prevention of cardiovascular diseases in diabetic patients: focus on gender difference and insulin resistance].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Female; Humans; Insulin Resistance; Male; | 2006 |
Aspirin resistance.
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Resistance; Forecasting; Hu | 2007 |
[The modern view on the use of aspirin for the primary prophylaxis of cardiovascular diseases in women].
Topics: Aspirin; Cardiovascular Diseases; Female; Fibrinolytic Agents; Humans; Primary Prevention; Women's H | 2006 |
The coxibs and traditional nonsteroidal anti-inflammatory drugs: a current perspective on cardiovascular risks.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibito | 2007 |
Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Coro | 2006 |
The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force.
Topics: Adenoma; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colonic P | 2007 |
Appropriate use of NSAIDs: considering cardiovascular risk in the elderly.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 In | 2007 |
The genetics of aspirin resistance.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Factor XIII; Fibrinolytic Agents; Humans; Platele | 2007 |
Antiplatelet therapy in the treatment of atherothrombotic disease: considering the evidence.
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Co | 2007 |
Multi-constituent cardiovascular pills (MCCP)--challenges and promises of population-based prophylactic drug therapy for prevention of heart attack.
Topics: Antihypertensive Agents; Aspirin; Atherosclerosis; Cardiovascular Agents; Cardiovascular Diseases; D | 2007 |
Variable platelet response to aspirin and clopidogrel in atherothrombotic disease.
Topics: Adenosine Diphosphate; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Biomarkers | 2007 |
Aspirin dose for the prevention of cardiovascular disease: a systematic review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregat | 2007 |
Aspirin--issues in daily practice: an update.
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Resistance; Humans; Treatment Outc | 2007 |
Clinical aspects of platelet inhibitors and thrombus formation.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Cardiovascular Diseases; Cilostazol; Clopidogrel; Dipyrid | 2007 |
[Adjuvant drug treatment in diabetic patients undergoing percutaneous coronary intervention].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Glucose; Cardiovascular Diseases; Chemotherapy, Adjuv | 2007 |
[Low-dose aspirin in patients with diabete melitus: risks and benefits regarding macro and microvascular complications].
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; Diabetic Angiopathies | 2007 |
Aspirin and bleeding in dentistry: an update and recommendations.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cardiovascular Diseases; Dental C | 2007 |
Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregati | 2007 |
Aspirin resistance.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Thrombos | 2007 |
Prevention of cancer in the upper gastrointestinal tract with COX-inhibition. Still an option?
Topics: Adenocarcinoma; Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Cell Transformation, Neop | 2007 |
How to advise aspirin use in patients who need NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibito | 2007 |
Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2007 |
Upper GI risks of NSAIDs and antiplatelet agents: key issues for the cardiologist.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cardiology; Cardiovascular Dise | 2005 |
Strategies to reduce the GI risks of antiplatelet therapy.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cardiova | 2005 |
The future of metabolic syndrome and cardiovascular disease prevention: polyhype or polyhope? Tales from the polyera.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Combinations; Drug Incompatibility; | 2007 |
Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cardiovascular Diseases; Cyclooxygenase 2 | 2007 |
PRO: Should aspirin be used in all women older than 65 years to prevent stroke?
Topics: Age Factors; Aged; Aspirin; Cardiovascular Diseases; Cost of Illness; Evidence-Based Practice; Femal | 2007 |
Clopidogrel: who, when, and how?
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug A | 2007 |
Clopidogrel and risk for acute coronary events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Human | 2007 |
Aspirin in the treatment and prevention of cardiovascular disease: current perspectives and future directions.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation | 2007 |
Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Cardiovascul | 2007 |
[Aspirin resistance in diabetic patients: laboratory entity or clinical reality?].
Topics: Aspirin; Cardiovascular Diseases; Chemoprevention; Diabetes Complications; Drug Resistance; Humans; | 2007 |
The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
Topics: Acute Disease; Anticholesteremic Agents; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination | 2008 |
Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors | 2007 |
[Aspirin in cardiovascular prevention: does the approach differ by gender?].
Topics: Aspirin; Cardiovascular Diseases; Female; Gender Identity; Humans; Male; Platelet Aggregation Inhibi | 2007 |
[Use of aspirin in diabetic patients].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Male; Platelet Aggregation Inhi | 2007 |
[Use of aspirin in patients taking angiotensin converting enzyme inhibitors].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Diseases; Drug Interactions; Drug | 2007 |
Aspirin and gastrointestinal toxicity.
Topics: Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; Helicobacter pylor | 2007 |
Aspirin: promise and resistance in the new millennium.
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Dr | 2008 |
Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Dose-Response Relationship, Drug; Humans; Multicen | 2008 |
Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Death, Sudden, Cardiac; Drug Resistance; | 2008 |
Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Death, Sudden, Cardiac; Drug Resistance; | 2008 |
Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Death, Sudden, Cardiac; Drug Resistance; | 2008 |
Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Death, Sudden, Cardiac; Drug Resistance; | 2008 |
Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: clinical evidence for and against the combination.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Drug The | 2008 |
Variability in individual responsiveness to aspirin: clinical implications and treatment.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Humans; Platelet Aggregation; Pl | 2007 |
[Platelet response to aspirin and clopidogrel. Biochemical evaluation, clinical impact, and pharmacological modulation].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Resistance; Flow Cytometry; Humans; Platelet Agg | 2007 |
Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events--a meta-analysis.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Coronary Disease; Drug Resistance; Humans; Platel | 2008 |
Drugs for cardiovascular disease prevention in women: implications of the AHA Guidelines--2007 Update.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Aspirin; Cardio | 2008 |
[The place of acetylsalicylic acid in the modern cardiovascular pharmacotherapy].
Topics: Aspirin; Cardiovascular Diseases; Global Health; Humans; Morbidity; Platelet Aggregation Inhibitors; | 2007 |
Aspirin resistance: biological and clinical implications.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Humans; Platele | 2008 |
Ibuprofen and cardiovascular safety: where do we stand?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors | 2007 |
Pharmacogenetics of aspirin resistance: a comprehensive systematic review.
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase 1; Drug Resistance; Genotype; Humans; Pharmacogenet | 2008 |
The role of aspirin in cardiovascular prevention: implications of aspirin resistance.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Drug Resistance; Heart Failure; Humans; Hyperte | 2008 |
Anti-inflammatory agents and antioxidants as a possible "third great wave" in cardiovascular secondary prevention.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Antioxidants; Aspirin; Cardiovascular D | 2008 |
The benefit of aspirin therapy in type 2 diabetes: what is the evidence?
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progres | 2008 |
Cardiovascular involvement in Kawasaki syndrome.
Topics: Adrenal Cortex Hormones; Age Factors; Arrhythmias, Cardiac; Arteritis; Aspirin; Cardiovascular Disea | 1983 |
[Kawasaki syndrome. Apropos of a case].
Topics: Aspirin; Cardiovascular Diseases; Child; Coronary Vessels; Diagnosis, Differential; Fever; Humans; I | 1984 |
Cardiovascular diseases in the elderly.
Topics: Aged; Aging; Amyloidosis; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Aspirin; Brain Ischemia; Car | 1983 |
The 'tomato effect' in clinical nutrition. New treatments languishing on the vine?
Topics: Adult; Arthritis, Rheumatoid; Aspirin; Attitude to Health; Cardiovascular Diseases; Child; Colchicin | 1984 |
An antagonist of prostaglandin synthesis in cardiovascular diseases.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Brain Diseases; Cardiovascular Diseases; Con | 1984 |
Potential therapeutic applications of aspirin and other cyclo-oxygenase inhibitors.
Topics: Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Digestive Sys | 1980 |
[Prevention of thrombosis by thrombocyte inhibition. 2. Clinical results].
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Clofibrate; Dextrans; | 1980 |
Sulfinpyrazone: a review of its pharmacological properties and therapeutic use.
Topics: Animals; Anti-Arrhythmia Agents; Antibody Formation; Aspirin; Blood Platelets; Cardiovascular Diseas | 1980 |
Platelet-active drugs in the secondary prevention of cardiovascular events: an overview.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Coronary Disease; Dipyridamole; Sulfinpyrazone; T | 1980 |
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary | 1982 |
Long-term aspirin in the prevention of cardiovascular disorders. Recent developments and variations on a theme.
Topics: Aspirin; Cardiovascular Diseases; Humans; Long-Term Care; Platelet Aggregation Inhibitors | 1995 |
Aspirin in the primary prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Humans; Randomized Controlled Trials as Topic | 1994 |
Haemostatic function, arterial disease and the prevention of arterial thrombosis.
Topics: Adult; Aged; Anticoagulants; Arteries; Aspirin; Blood Coagulation Factors; Cardiovascular Diseases; | 1994 |
Platelet inhibitors and antioxidant vitamins in cardiovascular disease.
Topics: Antioxidants; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Platelet Aggregati | 1994 |
[Acetylsalicylic acid treatment after peripheral vascular surgery].
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Humans; Ischemia; Leg; Postoperative Complications | 1994 |
The use of aspirin in cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Posto | 1993 |
Aspirin as an antiplatelet drug.
Topics: Arterial Occlusive Diseases; Aspirin; Cardiovascular Diseases; Drug Interactions; Humans; Platelet A | 1994 |
Aspirin as an antiplatelet drug.
Topics: Arterial Occlusive Diseases; Aspirin; Cardiovascular Diseases; Drug Interactions; Humans; Platelet A | 1994 |
Aspirin as an antiplatelet drug.
Topics: Arterial Occlusive Diseases; Aspirin; Cardiovascular Diseases; Drug Interactions; Humans; Platelet A | 1994 |
Aspirin as an antiplatelet drug.
Topics: Arterial Occlusive Diseases; Aspirin; Cardiovascular Diseases; Drug Interactions; Humans; Platelet A | 1994 |
Aspirin as an antiplatelet drug.
Topics: Arterial Occlusive Diseases; Aspirin; Cardiovascular Diseases; Drug Interactions; Humans; Platelet A | 1994 |
Aspirin as an antiplatelet drug.
Topics: Arterial Occlusive Diseases; Aspirin; Cardiovascular Diseases; Drug Interactions; Humans; Platelet A | 1994 |
Aspirin as an antiplatelet drug.
Topics: Arterial Occlusive Diseases; Aspirin; Cardiovascular Diseases; Drug Interactions; Humans; Platelet A | 1994 |
Aspirin as an antiplatelet drug.
Topics: Arterial Occlusive Diseases; Aspirin; Cardiovascular Diseases; Drug Interactions; Humans; Platelet A | 1994 |
Aspirin as an antiplatelet drug.
Topics: Arterial Occlusive Diseases; Aspirin; Cardiovascular Diseases; Drug Interactions; Humans; Platelet A | 1994 |
Aspirin as an antiplatelet drug.
Topics: Arterial Occlusive Diseases; Aspirin; Cardiovascular Diseases; Drug Interactions; Humans; Platelet A | 1994 |
Aspirin as an antiplatelet drug.
Topics: Arterial Occlusive Diseases; Aspirin; Cardiovascular Diseases; Drug Interactions; Humans; Platelet A | 1994 |
Aspirin as an antiplatelet drug.
Topics: Arterial Occlusive Diseases; Aspirin; Cardiovascular Diseases; Drug Interactions; Humans; Platelet A | 1994 |
Aspirin as an antiplatelet drug.
Topics: Arterial Occlusive Diseases; Aspirin; Cardiovascular Diseases; Drug Interactions; Humans; Platelet A | 1994 |
Aspirin as an antiplatelet drug.
Topics: Arterial Occlusive Diseases; Aspirin; Cardiovascular Diseases; Drug Interactions; Humans; Platelet A | 1994 |
Aspirin as an antiplatelet drug.
Topics: Arterial Occlusive Diseases; Aspirin; Cardiovascular Diseases; Drug Interactions; Humans; Platelet A | 1994 |
Aspirin as an antiplatelet drug.
Topics: Arterial Occlusive Diseases; Aspirin; Cardiovascular Diseases; Drug Interactions; Humans; Platelet A | 1994 |
Large-scale randomized evidence: large, simple trials and overviews of trials.
Topics: Aspirin; Bias; Breast Neoplasms; Cardiovascular Diseases; Effect Modifier, Epidemiologic; Female; Fi | 1993 |
Antiplatelet therapy in the treatment of cerebrovascular disease.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Male; Midd | 1993 |
The benefits of aspirin in acute myocardial infarction. Still a well-kept secret in the United States.
Topics: Aspirin; Cardiovascular Diseases; Humans; Myocardial Infarction; Thrombolytic Therapy; United States | 1994 |
Antiplatelet therapy--Part I.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Cardiovascular Diseases; Coronary Artery Bypass; Coronar | 1993 |
Aspirin as a therapeutic agent in cardiovascular disease. Special Writing Group.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Dose-Response Relationship, Drug; Humans; Thrombo | 1993 |
The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials.
Topics: Aged; Aspirin; Cardiovascular Diseases; Digestive System; Female; Gastrointestinal Diseases; Gastroi | 1993 |
Selections from current literature: using aspirin for primary or secondary prevention.
Topics: Aspirin; Cardiovascular Diseases; Colonic Neoplasms; Humans; Primary Prevention | 1993 |
Kawasaki disease in Adelaide: a review.
Topics: Adolescent; Anti-Bacterial Agents; Aspirin; Cardiovascular Diseases; Child; Child, Preschool; Female | 1993 |
Incidence, natural history, and risk factors in lacunar infarction.
Topics: Age Factors; Aged; Aspirin; Cardiovascular Diseases; Cerebral Infarction; Diabetic Angiopathies; Fem | 1993 |
Oral anticoagulation alone or in combination with aspirin: risks and benefits.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Coagulation Tests; Cardiovascular Diseases; Dru | 1996 |
Diabetes mellitus and peripheral vascular disease: is aspirin effective in preventing vascular events?
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Diabetes Complications; Diabetic Angiop | 1996 |
Who needs antiplatelet therapy?
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Tri | 1996 |
Aspirin in the treatment and prevention of cardiovascular disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Female; Humans; Male; Middle Aged | 1997 |
Aspirin therapy in diabetes.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Humans | 1997 |
Aspirin for the second hundred years: new uses for an old drug.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cardiovascular Disea | 1997 |
Aspirin therapy for cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; Platelet Aggregation Inhibitors | 1996 |
Multifactorial aspects of the treatment of the type II diabetic patient.
Topics: Arteriosclerosis; Aspirin; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Diabetes | 1997 |
[Acetylsalicylic acid in the treatment of cardiovascular and cerebrovascular diseases].
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Humans; Platelet Aggregation Inhibitors | 1997 |
North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group.
Topics: Angina Pectoris; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Consumer Product Safet | 1998 |
Aspirin: real benefits, but real risks, too.
Topics: Aspirin; Cardiovascular Diseases; Cerebral Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk | 1999 |
Platelets, aspirin, and cardiovascular disease.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Fibrinolytic Agents; Humans; Platelet Adhesivenes | 1998 |
Antiplatelet drugs.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Dipyridamole; Humans; Immunoglo | 1999 |
Therapeutic benefit. Aspirin revisited in light of the introduction of clopidogrel.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Decision Making; Humans; Platelet Aggregation Inhibit | 1999 |
Antiplatelet agents in the prevention of cardiovascular morbidity and mortality in older patients with vascular disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Female; Humans; Male; | 1999 |
Ticlopidine and clopidogrel.
Topics: Adenosine Diphosphate; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Angina, Unstable; Aspirin; Bo | 1999 |
The many faces of Kawasaki syndrome.
Topics: Acute Disease; Aftercare; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; | 2000 |
Clopidogrel and [symbol: see text] ticlopidine--improvements on aspirin?
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Contraindications; Platelet Aggregation Inhibitors; R | 1999 |
Aspirin, ticlopidine and clopidogrel in and out of the catheterization laboratory.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggr | 1999 |
[Aspirin and prevention of cardiovascular risk].
Topics: Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Ste | 2000 |
Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Fibrinolytic Agents; Humans; Platelet Aggregation Inh | 2000 |
The pathogenesis and management of essential thrombocythaemia.
Topics: Acute Disease; Alkylating Agents; Aspirin; Cardiovascular Diseases; Clone Cells; Gene Expression; He | 1999 |
Other drug treatments: the evidence.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspi | 2000 |
[Platelet antiaggregants].
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Dipyridamole; Drug Utilization; Fibrino | 2000 |
[Intensified treatment of type 2 diabetes mellitus. Is polypharmacy necessary and justified?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; | 2000 |
Anti-inflammatories for cardiovascular disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Cardiovascular Diseases | 2000 |
[Prevention of cardiovascular disease in type 2 diabetes].
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dietary Servic | 2000 |
An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Fibrinolytic Agents; Human | 2000 |
Novel platelet inhibitors.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Humans; Platelet A | 2001 |
Aspirin: new cardiovascular uses for an old drug.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors | 2001 |
Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Coronary Disease; Female; Hemorrhage; Humans; Male; Mortality; Myo | 2001 |
Aspirin in the treatment and prevention of cardiovascular disease.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Case-Control Studie | 2000 |
Multiple risk factor intervention in type 2 diabetes: an opportunity not to be missed.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Endothelium, Vascular; Humans; Hypercho | 2001 |
[Pharmacologic interventions in primary prevention: lipid lowering drugs, aspirin, antiobesity drugs, and antihypertensive agents].
Topics: Anti-Obesity Agents; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysi | 2001 |
[Prevention of cardiovascular diseases in type 2 diabetes with aspirin].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Prescriptions; Evidence-Based Medi | 2001 |
[The best in 2000 on clinical pharmacology].
Topics: Aspirin; Cardiovascular Diseases; Forecasting; Heart Diseases; Heparin; Hormone Replacement Therapy; | 2001 |
Management of diabetic nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Diseases; Diabetic Nephropathies; | 2001 |
[Digestive toxicity of low-dose aspirin: an underestimated and unresolved problem].
Topics: Aspirin; Cardiovascular Diseases; Gastrointestinal Diseases; Humans | 2001 |
Aspirin in cardiovascular disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Myocardial Infarc | 2001 |
Antioxidant strategy for cardiovascular diseases.
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Humans; Randomized Controlled Tr | 2001 |
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Blood Platelets; Cardiova | 2001 |
[Acetylsalicylic acid and bioptic methods in pneumology].
Topics: Aspirin; Biopsy; Bronchoscopy; Cardiovascular Diseases; Fiber Optic Technology; Humans; Lung; Venous | 2001 |
What is the relevance of the HOPE study in general practice?
Topics: Adrenergic beta-Antagonists; Algorithms; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic | 2001 |
An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2; Cycloox | 2001 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; M | 2002 |
C-reactive protein and cardiovascular disease: a review of risk prediction and interventions.
Topics: Age Factors; Arteriosclerosis; Aspirin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Fe | 2002 |
Cardiovascular disease: much more aggressive in patients with type 2 diabetes.
Topics: Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Di | 2002 |
Relative risk of cardiovascular events in patients with rheumatoid arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Cardiotonic Agents; C | 2002 |
Aspirin for the primary prevention of cardiovascular events: recommendations and rationale.
Topics: Aspirin; Cardiovascular Diseases; Chemoprevention; Evidence-Based Medicine; Humans; Patient Selectio | 2002 |
Translational medicine: targetting cyclo-oxygenase isozymes to prevent cancer.
Topics: Arachidonic Acid; Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; C | 2002 |
Cardiovascular risk reduction in renal transplantation. Strategies for success.
Topics: Arteriosclerosis; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Comorbidity; Cost-Benefit | 2002 |
Use of statins and aspirin to reduce risks of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Drug Synergism; Humans; Hydroxymethylglu | 2002 |
Current perspective on the cardiovascular effects of coxibs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Controlled Clinical Trial | 2002 |
Role of antiplatelet agents in cardioprotection.
Topics: Arteriosclerosis; Aspirin; Cardiotonic Agents; Cardiovascular Diseases; Clopidogrel; Female; Humans; | 2002 |
[Blood platelets and cardiovascular diseases. IV. Platelet-inhibiting drugs and antithrombotic agents].
Topics: Adenosine Diphosphate; Adrenergic beta-Antagonists; Analgesics; Anti-Inflammatory Agents; Arterioscl | 1976 |
Platelets, thromboembolism and the clinical utility of antiplatelet drugs.
Topics: Animals; Aspirin; Blood Coagulation Factors; Blood Platelets; Cardiovascular Diseases; Clofibrate; F | 1978 |
Antiplatelet agents: a review.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Clofi | 1979 |
Aspirin is good for you.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Musculoskeletal Disease | 1992 |
Aspirin for the prevention of vascular death in women.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Risk | 1992 |
Aspirin, platelet aggregation, and the circadian variation of acute thrombotic events.
Topics: Aspirin; Cardiovascular Diseases; Circadian Rhythm; Humans; Platelet Aggregation; Thrombosis | 1991 |
Aspirin in chronic cardiovascular disease and acute myocardial infarction.
Topics: Acute Disease; Aspirin; Cardiovascular Diseases; Chronic Disease; Humans; Myocardial Infarction; Pla | 1990 |
Thromboxane biosynthesis in cardiovascular diseases.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Activation; Risk Factors; Thromboxane A2; Thrombo | 1990 |
[Kawasaki syndrome].
Topics: Aspirin; Cardiovascular Diseases; Humans; Immunization, Passive; Mucocutaneous Lymph Node Syndrome; | 1989 |
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
Topics: Aspirin; Biomechanical Phenomena; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Myocar | 1989 |
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
Topics: Aspirin; Biomechanical Phenomena; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Myocar | 1989 |
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
Topics: Aspirin; Biomechanical Phenomena; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Myocar | 1989 |
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
Topics: Aspirin; Biomechanical Phenomena; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Myocar | 1989 |
Therapeutic progress--review XXXV. Aspirin in the next decade.
Topics: Aspirin; Cardiovascular Diseases; Humans | 1989 |
Platelet inhibitor agents in cardiovascular disease: an update.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Graf | 1989 |
Aspirin in cardiovascular disease; biochemical pharmacology and clinical trials.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Myocardial Infarction; Prospecti | 1989 |
Aspirin and cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Mal | 1989 |
Preventive cardiology: what is the value of antiplatelet agents and fish oils?
Topics: Aspirin; Cardiovascular Diseases; Coronary Thrombosis; Dipyridamole; Fish Oils; Humans; Platelet Agg | 1988 |
[Acetylsalicylic acid in cardiovascular pathology: therapeutic news about an old acquaintance].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Female; | 1988 |
Aspirin in cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Humans | 1988 |
The use of aminophylline and aspirin in small animal practice: effective therapy or dangerous placebos?
Topics: Aminophylline; Animals; Aspirin; Cardiovascular Diseases; Cat Diseases; Cats; Dog Diseases; Dogs; Re | 1986 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical | 1986 |
304 trials available for aspirin and Cardiovascular Diseases
| Article | Year |
|---|---|
Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers.
Topics: Aspirin; Biomarkers; Cardiovascular Diseases; Cell-Derived Microparticles; Diabetes Mellitus, Type 2 | 2021 |
[Rivaroxaban with aspirin for the secondary prevention of cardiovascular events in Chinese patients with stable cardiovascular diseases: subgroup analysis of COMPASS].
Topics: Aged; Aspirin; Cardiovascular Diseases; China; Drug Therapy, Combination; Factor Xa Inhibitors; Fema | 2021 |
Age-Dependent Effect of Ticagrelor Monotherapy Versus Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events: A Post Hoc Analysis of the TICO Randomized Trial.
Topics: Acute Coronary Syndrome; Age Distribution; Aged; Aspirin; Cardiovascular Diseases; Drug Therapy, Com | 2021 |
Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial-Adjudicated Direct Follow-up Data in the UK: Secondary Analysis of the ASCEND Randomized Clinical Trial.
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Fatty Acids, Omega-3; Female; H | 2021 |
The cost implications of a polypill for primary prevention in the TIPS-3 trial.
Topics: Aspirin; Cardiovascular Diseases; Drug Combinations; Humans; Hydroxymethylglutaryl-CoA Reductase Inh | 2022 |
Safety of Ceasing Aspirin Used Without a Clinical Indication After Age 70 Years: A Subgroup Analysis of the ASPREE Randomized Trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Humans; Platelet Aggregation Inhibitors | 2022 |
Comparative Study of Ex Vivo Antiplatelet Activity of Aspirin and Cilostazol in Patients with Diabetes and High Risk of Cardiovascular Disease.
Topics: Aspirin; Cardiovascular Diseases; Cilostazol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; | 2022 |
Effect of Aspirin on CKD Progression in Older Adults: Secondary Analysis From the ASPREE Randomized Clinical Trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Renal Insuf | 2022 |
Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiov
Topics: Adolescent; Adult; Aspirin; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; Multicenter S | 2022 |
Association of a Community Population and Clinic Education Intervention Program With Guideline-Based Aspirin Use for Primary Prevention of Cardiovascular Disease: A Nonrandomized Controlled Trial.
Topics: Adult; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Internet; Male; Pr | 2022 |
Polypill Strategy in Secondary Cardiovascular Prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Humans; Hy | 2022 |
Polypill Strategy in Secondary Cardiovascular Prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Humans; Hy | 2022 |
Polypill Strategy in Secondary Cardiovascular Prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Humans; Hy | 2022 |
Polypill Strategy in Secondary Cardiovascular Prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Humans; Hy | 2022 |
Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes.
Topics: Aged; Aspirin; Cardiovascular Diseases; Genotype; Humans; Lipoprotein(a); Primary Prevention | 2022 |
The EvidenceNOW Practice Support Initiative: The Heart of Virginia Healthcare.
Topics: Aspirin; Cardiovascular Diseases; Cholesterol; Delivery of Health Care; Fibrinolytic Agents; Humans; | 2022 |
TIPS to decide whether to prescribe aspirin for the primary prevention of cardiovascular events in chronic kidney disease.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention; Renal | 2023 |
Effects of a Polypill, Aspirin, and the Combination of Both on Cognitive and Functional Outcomes: A Randomized Clinical Trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cognition; Drug Combinations; Female; Humans; Hydrochlorothi | 2023 |
Prospective, randomized, controlled, trial to assess ASA DOSing by body mass index in HEalthy volunteers (DOSE study).
Topics: Adult; Aspirin; Body Mass Index; Cardiovascular Diseases; Female; Healthy Volunteers; Humans; Male; | 2023 |
Pro-inflammatory and pro-resolving lipid mediators of inflammation in HIV: effect of aspirin intervention.
Topics: Aspirin; Cardiovascular Diseases; Eicosanoids; HIV Infections; Humans; Inflammation; Inflammation Me | 2023 |
Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Thromboxane B2 | 2023 |
Polypill protects MAFLD patients from cardiovascular events and mortality: a prospective trial.
Topics: Aspirin; Cardiovascular Diseases; Drug Combinations; Humans; Non-alcoholic Fatty Liver Disease; Pros | 2023 |
An open label randomized controlled trial of atorvastatin versus aspirin in elite controllers and antiretroviral-treated people with HIV.
Topics: Anti-Retroviral Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; CD4 Lymphocyte Count; Female | 2023 |
Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Gastrointestinal Hemorrhage; Humans; Ma | 2023 |
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Hemorrhage; | 2023 |
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur | 2019 |
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur | 2019 |
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur | 2019 |
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur | 2019 |
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur | 2019 |
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur | 2019 |
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur | 2019 |
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur | 2019 |
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur | 2019 |
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur | 2019 |
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur | 2019 |
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur | 2019 |
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur | 2019 |
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur | 2019 |
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur | 2019 |
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur | 2019 |
Continuation of low-dose acetylsalicylic acid during perioperative period of laparoscopic inguinal hernia repair is safe: results of a prospective clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Dose-Response Relation | 2019 |
Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Hemo | 2019 |
Proteinuria is independently associated with the incidence of primary cardiovascular events in diabetic patients.
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Female; Fibrinolytic Agents; Humans; Inci | 2020 |
Effect of topical tranexamic acid in total hip arthroplasty patients who receive continuous aspirin for prevention of cardiovascular or cerebrovascular events: A prospective randomized study.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement | 2019 |
Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement.
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Clopid | 2020 |
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Clopidogrel; Drug Th | 2020 |
Intake of aspirin prior to metamizole does not completely prevent high on treatment platelet reactivity.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Disease | 2020 |
The effect of metoprolol and aspirin on cardiovascular risk in bereavement: A randomized controlled trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, No | 2020 |
Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents?
Topics: Aspirin; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Humans; Hydroxy | 2021 |
Cardiovascular Disease Guideline Adherence: An RCT Using Practice Facilitation.
Topics: Aspirin; Blood Pressure; Cardiovascular Diseases; Cholesterol; Goals; Guideline Adherence; Health Be | 2020 |
Effect of low-dose aspirin on serum uric acid levels in Chinese individuals over 60: subanalysis of a multicentre randomized clinical trial.
Topics: Administration, Oral; Aged; Asian People; Aspirin; Cardiovascular Diseases; China; Dose-Response Rel | 2020 |
Rivaroxaban in Peripheral Artery Disease after Revascularization.
Topics: Aged; Aspirin; Cardiovascular Diseases; Combined Modality Therapy; Double-Blind Method; Drug Therapy | 2020 |
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial.
Topics: Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; Drug | 2020 |
Computable Phenotype Implementation for a National, Multicenter Pragmatic Clinical Trial: Lessons Learned From ADAPTABLE.
Topics: Algorithms; Aspirin; Cardiovascular Diseases; Data Mining; Electronic Health Records; Humans; Multic | 2020 |
Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Drug-Eluting S | 2020 |
Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a Healthy Elderly Population.
Topics: Age Factors; Aged; Aspirin; Australia; Blood Platelets; Cardiovascular Diseases; Double-Blind Method | 2020 |
Evening aspirin intake results in higher levels of platelet inhibition and a reduction in reticulated platelets - a window of opportunity for patients with cardiovascular disease?
Topics: Aged; Aspirin; Cardiovascular Diseases; Cross-Over Studies; Female; Humans; Male; Platelet Aggregati | 2021 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Budgets; Cardiovascular Diseases; Ci | 2021 |
Effectiveness of Polypill for Prevention of Cardiovascular Disease (PolyPars): Protocol of a Randomized Controlled Trial.
Topics: Antihypertensive Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Female; | 2020 |
Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Hemorrhage; Humans; Renal Insu | 2021 |
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Double | 2021 |
Prescription Medication Use in Older Adults Without Major Cardiovascular Disease Enrolled in the Aspirin in Reducing Events in the Elderly (ASPREE) Clinical Trial.
Topics: Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Cross-Sectional Studies; Doubl | 2020 |
High-sensitivity Troponin T in hemodialysis patients: a randomized placebo-controlled sub-study investigating angiotensin-II-blockade, variation over time and associations with clinical outcome.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bi | 2020 |
Long-Term Blood Pressure Variability and Risk of Cardiovascular Disease Events Among Community-Dwelling Elderly.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Australia; Blood Pressure; Cardiovascular Di | 2020 |
Polypill with or without Aspirin in Persons without Cardiovascular Disease.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2021 |
Polypill with or without Aspirin in Persons without Cardiovascular Disease.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2021 |
Polypill with or without Aspirin in Persons without Cardiovascular Disease.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2021 |
Polypill with or without Aspirin in Persons without Cardiovascular Disease.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2021 |
Association between aspirin use and cardiovascular outcomes in ALLHAT participants with and without chronic kidney disease: A post hoc analysis.
Topics: Aspirin; Cardiovascular Diseases; Humans; Hypertension; Myocardial Infarction; Renal Insufficiency, | 2021 |
Aspirin and omega-3 fatty acid status interact in the prevention of cardiovascular diseases in Framingham Heart Study.
Topics: Aged; Arachidonic Acid; Aspirin; Cardiovascular Diseases; Docosahexaenoic Acids; Eicosapentaenoic Ac | 2021 |
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Female; Hemorrhage; Hospitalization; Humans | 2021 |
Aspirin and gastrointestinal bleeding risk in older people.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; | 2021 |
Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study.
Topics: Activities of Daily Living; Administration, Oral; Aged; Aged, 80 and over; Aging; Aspirin; Australia | 2017 |
Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cardiovascular | 2017 |
Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Aspirin; Atenolol; Biomarkers; Blood Pressure; | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Pre | 2017 |
Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and
Topics: Aged; Antineoplastic Agents; Apolipoprotein A-I; Aspirin; Cardiovascular Diseases; Cholesterol, HDL; | 2017 |
Combined effect of metformin with ascorbic acid versus acetyl salicylic acid on diabetes-related cardiovascular complication; a 12-month single blind multicenter randomized control trial.
Topics: Adult; Ascorbic Acid; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, T | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
The aspirin in reducing events in the elderly trial: Statistical analysis plan.
Topics: Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Double-Blind Method; Female; F | 2018 |
Favourable hypotensive effect after standardised tomato extract treatment in hypertensive subjects at high cardiovascular risk: a randomised controlled trial.
Topics: Adult; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Female; | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Peripheral blood gene expression signatures which reflect smoking and aspirin exposure are associated with cardiovascular events.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Platelet Aggregation; Smo | 2018 |
Rationale and Study Design for a Single-Arm Phase IIa Study Investigating Feasibility of Preventing Ischemic Cerebrovascular Events in High-Risk Patients with Acute Non-disabling Ischemic Cerebrovascular Events Using Remote Ischemic Conditioning.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Ther | 2018 |
Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients With High Posttreatment Platelet Reactivity: Results of the CREATIVE Trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cause of Death; Cilostazol; Clopidogrel; Cytochrome P-450 CY | 2018 |
Effects of Ramadan fasting on aspirin resistance in type 2 diabetic patients.
Topics: Aged; Aspirin; Blood Glucose; Blood Platelets; Cardiovascular Diseases; Diabetes Mellitus, Type 2; D | 2018 |
Quality of Cardiovascular Disease Care in Small Urban Practices.
Topics: Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Delivery of Health Care; Guideline Adhere | 2018 |
ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes.
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Ad | 2018 |
The potential benefits of aspirin for primary cardiovascular prevention in rheumatoid arthritis: a secondary analysis of the PRECISION Trial.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; | 2018 |
Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial.
Topics: Aged; Antioxidants; Asian People; Aspirin; Brain Ischemia; Cardiovascular Diseases; Cerebral Hemorrh | 2018 |
Design of healthy hearts in the heartland (H3): A practice-randomized, comparative effectiveness study.
Topics: Adult; Aspirin; Blood Pressure Determination; Cardiovascular Diseases; Female; Health Facility Size; | 2018 |
Effect of Aspirin on Cancer Chemoprevention in Japanese Patients With Type 2 Diabetes: 10-Year Observational Follow-up of a Randomized Controlled Trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Chemoprevention; Diabetes Mellitus | 2018 |
Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study).
Topics: Aged; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Disease Progression; Female; Glomerul | 2018 |
Evaluation of the antihypertensive effect of nocturnal administration of acetylsalicylic acid: a cross-over randomized clinical trial.
Topics: Antihypertensive Agents; Aspirin; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cardiovascu | 2019 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Dietary Su | 2018 |
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Dietary Su | 2018 |
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Dietary Su | 2018 |
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Dietary Su | 2018 |
Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Australia; Cardiovascular Diseases; Cost-Be | 2018 |
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Double-B | 2018 |
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Double-B | 2018 |
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Double-B | 2018 |
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Double-B | 2018 |
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Double-B | 2018 |
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Double-B | 2018 |
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Double-B | 2018 |
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Double-B | 2018 |
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Double-B | 2018 |
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70).
Topics: Aged; Asian People; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus; Dyslipidem | 2019 |
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Chronic Disease; Corona | 2019 |
Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Dose-Response Relation | 2019 |
Monitoring Emerging Data From the COMPASS Trial of an Antithrombotic Agent.
Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans | 2019 |
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
Topics: Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Enterocol | 2019 |
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
Topics: Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Enterocol | 2019 |
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
Topics: Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Enterocol | 2019 |
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
Topics: Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Enterocol | 2019 |
Genetic variation at the coronary artery disease risk locus GUCY1A3 modifies cardiovascular disease prevention effects of aspirin.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Female; G | 2019 |
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Fib | 2019 |
Assessing quality improvement capacity in primary care practices.
Topics: Aspirin; Cardiovascular Diseases; Humans; Hypertension; Idaho; Oregon; Patient-Centered Care; Primar | 2019 |
Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study.
Topics: Aged; Aged, 80 and over; Alloys; Angioplasty; Aspirin; Cardiovascular Diseases; Cilostazol; Constric | 2013 |
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2013 |
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2013 |
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2013 |
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2013 |
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2013 |
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2013 |
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2013 |
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2013 |
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2013 |
Risks and complications of transurethral resection of bladder tumor among patients taking antiplatelet agents for cardiovascular disease.
Topics: Aged; Aspirin; Blood Transfusion; Cardiovascular Diseases; Female; Follow-Up Studies; Hemorrhage; Hu | 2014 |
Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk.
Topics: Adult; Age Factors; Aged; Asian People; Aspirin; Cardiovascular Diseases; Diabetes Complications; Fe | 2013 |
Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelet Disorders; Blood Platelets; Card | 2013 |
Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial.
Topics: Activities of Daily Living; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Australia; Cardi | 2013 |
Use of proton pump inhibitors and the risk of coronary events in new users of low-dose acetylsalicylic acid in UK primary care.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Dru | 2014 |
A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
Topics: Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Aged; Angiotensin-Converting Enzyme In | 2015 |
Low dose of acetylsalicylic acid and oxidative stress-mediated endothelial dysfunction in diabetes: a short-term evaluation.
Topics: Aged; Aspirin; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Rel | 2015 |
Lack of effect of aspirin in primary CV prevention in type 2 diabetic patients with nephropathy: results from 8 years follow-up of NID-2 study.
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Eval | 2015 |
Hydroxychloroquine's Efficacy as an Antiplatelet Agent Study in Healthy Volunteers: A Proof of Concept Study.
Topics: Aspirin; Cardiovascular Diseases; Fibrinogen; Healthy Volunteers; Humans; Hydroxychloroquine; Platel | 2015 |
Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2015 |
Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2015 |
Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2015 |
Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2015 |
PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: results of two 6-month, phase 3 studies.
Topics: Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double-Blind | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Does rectal indomethacin given for prevention of post-ERCP pancreatitis increase bleeding after biliary endoscopic sphincterotomy or cardiovascular mortality?: Post hoc analysis using prospective clinical trial data.
Topics: Administration, Rectal; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C | 2014 |
Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women.
Topics: Age Factors; Aged; Aspirin; Cardiovascular Diseases; Decision Support Techniques; Drug Administratio | 2015 |
An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Australia; Cardiovascular Diseases; Cost | 2014 |
Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry.
Topics: Aged; Aspirin; Cardiovascular Diseases; Confidence Intervals; Female; Fibrinolytic Agents; Follow-Up | 2015 |
[Primary prevention with acetylsalicylic acid: large study, hardly any effects].
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation | 2015 |
Time-dependent effects of aspirin on blood pressure and morning platelet reactivity: a randomized cross-over trial.
Topics: Adolescent; Adult; Aged; Aspirin; Blood Pressure; Cardiovascular Diseases; Circadian Rhythm; Cross-O | 2015 |
[Perioperative acetylsalicylic acid and clonidine in noncardiac surgery patients (POISE-2 trial)].
Topics: Adrenergic alpha-2 Receptor Agonists; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clo | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Prospective study of plasma homocysteine level and risk of age-related macular degeneration in women.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Combinations; Female | 2015 |
Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Restenosis; Double-Blind Method; Drug Therapy, Comb | 2015 |
Intensive multifactorial treatment modifies the effect of family history of diabetes on glycaemic control in people with Type 2 diabetes: a post hoc analysis of the ADDITION-Denmark randomized controlled trial.
Topics: Aged; Antihypertensive Agents; Aspirin; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Ch | 2015 |
Arterial stiffening and systemic endothelial activation induced by smoking: The role of COX-1 and COX-2.
Topics: Adult; Analysis of Variance; Aspirin; Cardiovascular Diseases; Celecoxib; Cross-Over Studies; Cycloo | 2015 |
Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes.
Topics: Adult; Aspirin; Cardiovascular Diseases; Cross-Over Studies; Cyclooxygenase Inhibitors; Diabetes Mel | 2016 |
Feasibility and impact of implementing a private care system's diabetes quality improvement intervention in the safety net: a cluster-randomized trial.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; C | 2015 |
Usefulness of B-type Natriuretic Peptides to Predict Cardiovascular Events in Women (from the Women's Health Study).
Topics: Aged; Antioxidants; Aspirin; Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Female; | 2015 |
Baseline Platelet Activation and Reactivity in Patients with Critical Limb Ischemia.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Case-Control Studies; Collagen; Female; Fibrinoge | 2015 |
Baseline Platelet Activation and Reactivity in Patients with Critical Limb Ischemia.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Case-Control Studies; Collagen; Female; Fibrinoge | 2015 |
Baseline Platelet Activation and Reactivity in Patients with Critical Limb Ischemia.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Case-Control Studies; Collagen; Female; Fibrinoge | 2015 |
Baseline Platelet Activation and Reactivity in Patients with Critical Limb Ischemia.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Case-Control Studies; Collagen; Female; Fibrinoge | 2015 |
A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk.
Topics: Aged; Amlodipine; Antihypertensive Agents; Aspirin; Biomarkers; Calcium Channel Blockers; Cardiovasc | 2015 |
Effect of Triflusal on Primary Vascular Dysregulation Compared with Aspirin: A Double-Blind, Randomized, Crossover Trial.
Topics: Adult; Aspirin; Cardiovascular Diseases; Cross-Over Studies; Double-Blind Method; Female; Humans; In | 2015 |
PolyPill for Prevention of Cardiovascular Disease in an Urban Iranian Population with Special Focus on Nonalcoholic Steatohepatitis: A Pragmatic Randomized Controlled Trial within a Cohort (PolyIran - Liver) - Study Protocol.
Topics: Angiotensin II Type 1 Receptor Blockers; Aspirin; Atorvastatin; Cardiovascular Diseases; Diuretics; | 2015 |
Association between Antiplatelet or Anticoagulant Drugs and Retinal or Subretinal Hemorrhage in the Comparison of Age-Related Macular Degeneration Treatments Trials.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anticoagulants; Aspirin; Bevacizumab; Cardiovascul | 2016 |
Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk.
Topics: Aged; Aspirin; Cardiovascular Diseases; Dosage Forms; Drug Combinations; Female; Humans; Male; Middl | 2016 |
Impact of Modifiable Risk Factors on B-type Natriuretic Peptide and Cardiac Troponin T Concentrations.
Topics: Aged; Aspirin; Biomarkers; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; | 2016 |
Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cohort Studi | 2016 |
Aspirin Use in Secondary Cardiovascular Protection and the Development of Aspirin-Associated Erosions and Ulcers.
Topics: Adolescent; Adult; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Disease Progression; Dou | 2016 |
Reporting on the Strategies Needed to Implement Proven Interventions: An Example From a "Real-World" Cross-Setting Implementation Study.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiotonic Agents; Cardiovascular Diseases; Diab | 2016 |
Effect of Aspirin Supplementation on Hemostatic Responses in Firefighters Aged 40 to 60 Years.
Topics: Adult; Aspirin; Blood Coagulation; Cardiovascular Diseases; Cross-Over Studies; Double-Blind Method; | 2016 |
Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND).
Topics: Aspirin; Cardiovascular Diseases; Consent Forms; Cost-Benefit Analysis; Diabetes Mellitus; Dietary S | 2016 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular | 2016 |
A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Investig
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Bypass; Coronary Artery Disease; | 2016 |
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Female; Follow-Up Studies; Humans; Male; R | 2017 |
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Female; Follow-Up Studies; Humans; Male; R | 2017 |
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Female; Follow-Up Studies; Humans; Male; R | 2017 |
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Female; Follow-Up Studies; Humans; Male; R | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Resistance | 2008 |
Aspirin administered to women at 100 mg every other day produces less platelet inhibition than aspirin administered at 81 mg per day: implications for interpreting the women's health study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cohort Studies; Do | 2009 |
Influence of the timing of low-dose aspirin on tolerability of prolonged-release nicotinic acid in patients at elevated cardiovascular risk.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cholesterol, HDL; Dela | 2008 |
Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy.
Topics: Alleles; Anti-Inflammatory Agents, Non-Steroidal; Apolipoproteins A; Aspirin; Cardiovascular Disease | 2009 |
Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy.
Topics: Alleles; Anti-Inflammatory Agents, Non-Steroidal; Apolipoproteins A; Aspirin; Cardiovascular Disease | 2009 |
Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy.
Topics: Alleles; Anti-Inflammatory Agents, Non-Steroidal; Apolipoproteins A; Aspirin; Cardiovascular Disease | 2009 |
Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy.
Topics: Alleles; Anti-Inflammatory Agents, Non-Steroidal; Apolipoproteins A; Aspirin; Cardiovascular Disease | 2009 |
Treatment with aspirin and dipyridamole is more effective than aspirin in reducing low shear blood viscosity.
Topics: Adult; Aged; Aspirin; Blood Viscosity; Cardiovascular Diseases; Dipyridamole; Female; Hematocrit; Hu | 2008 |
Soluble P-selectin as a marker of in vivo platelet activation.
Topics: Aspirin; Biomarkers; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; P-Selectin; Platele | 2009 |
A randomized trial of low-dose aspirin in the prevention of clinical type 2 diabetes in women.
Topics: Aged; Aspirin; Cardiotonic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Ethnicity; Fe | 2009 |
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Foll | 2008 |
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus | 2008 |
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus | 2008 |
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus | 2008 |
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus | 2008 |
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus | 2008 |
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus | 2008 |
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus | 2008 |
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus | 2008 |
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus | 2008 |
The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin | 2009 |
Patients with peripheral arterial disease in the CHARISMA trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Epidemiologic Method | 2009 |
Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Card | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double- | 2009 |
Therapy for triggered acute risk prevention: a study of feasibility.
Topics: Acute Disease; Adult; Aged; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Exercise; Fem | 2009 |
Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] tri
Topics: Aspirin; Cardiovascular Diseases; Chi-Square Distribution; Clopidogrel; Diabetic Nephropathies; Drug | 2009 |
Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Blood Platelets; C | 2008 |
Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomized crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Aspirin; Cardiovascular Dis | 2009 |
Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Double-Blind Me | 2009 |
Low-dose aspirin and medical record-confirmed age-related macular degeneration in a randomized trial of women.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; | 2009 |
Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome.
Topics: Adult; Aged; Anti-Inflammatory Agents; Aspirin; Biomarkers; C-Reactive Protein; Cardiovascular Disea | 2009 |
Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster | 2010 |
To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Cardiovascular Diseases; Double-Blind Method | 2010 |
To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Cardiovascular Diseases; Double-Blind Method | 2010 |
To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Cardiovascular Diseases; Double-Blind Method | 2010 |
To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Cardiovascular Diseases; Double-Blind Method | 2010 |
Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT.
Topics: 6-Ketoprostaglandin F1 alpha; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, | 2010 |
Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial.
Topics: Aged; Ankle; Aspirin; Atherosclerosis; Blood Pressure; Brachial Artery; Cardiovascular Diseases; Dou | 2010 |
Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Antihypertensive Agents; Area Under Curve; Aspirin; Atenolo | 2010 |
Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme.
Topics: Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Benzimida | 2010 |
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Card | 2010 |
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Card | 2010 |
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Card | 2010 |
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Card | 2010 |
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Card | 2010 |
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Card | 2010 |
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Card | 2010 |
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Card | 2010 |
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Card | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Chronic Disease; Creatinine; Female; Glom | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Asthma, chronic obstructive pulmonary disease, and type 2 diabetes in the Women's Health Study.
Topics: Aspirin; Asthma; Bronchitis, Chronic; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Hu | 2010 |
A randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Cardiovascular Diseases; Female; Humans; Male; | 2010 |
The fat-mass and obesity-associated (FTO) gene, physical activity, and risk of incident cardiovascular events in white women.
Topics: Alleles; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Aspirin; Body Mass Index; Cardiovascular Dis | 2010 |
A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Attitude of Health Personnel; Biomarkers; B | 2011 |
A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Attitude of Health Personnel; Biomarkers; B | 2011 |
A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Attitude of Health Personnel; Biomarkers; B | 2011 |
A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Attitude of Health Personnel; Biomarkers; B | 2011 |
A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Attitude of Health Personnel; Biomarkers; B | 2011 |
A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Attitude of Health Personnel; Biomarkers; B | 2011 |
A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Attitude of Health Personnel; Biomarkers; B | 2011 |
A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Attitude of Health Personnel; Biomarkers; B | 2011 |
A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Attitude of Health Personnel; Biomarkers; B | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial.
Topics: Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Diseases; Cilostazol; Clopidog | 2011 |
High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial.
Topics: Aged; Aspirin; Atherosclerosis; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clopidogrel | 2011 |
Migraine and cardiovascular disease in women and the role of aspirin: subgroup analyses in the Women's Health Study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Female; Humans; Middle Ag | 2011 |
Reconsidering low-dose aspirin therapy for cardiovascular disease: a study protocol for physician and patient behavioral change.
Topics: Aspirin; Cardiovascular Diseases; Clinical Protocols; Colorado; Coronary Artery Disease; Decision Su | 2011 |
Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Interactio | 2012 |
Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects.
Topics: Aged; Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Female; Hemorrhage; Humans; Mi | 2011 |
The fixed-dose combination drug for secondary cardiovascular prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives.
Topics: Angiotensin-Converting Enzyme Inhibitors; Argentina; Aspirin; Cardiovascular Diseases; Drug Combinat | 2011 |
The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aspirin; Biomarkers; Blood Platelets; Cardiovascular Diseases; Chi-Square Distribution; | 2012 |
[Comparative evaluation of antiplatelet efectiveness drugs of original and reproduced enteric forms of acetylsalicylic acid (clinical study ICAR))].
Topics: Adenosine Diphosphate; Administration, Oral; Aged; Aspirin; Cardiovascular Diseases; Dosage Forms; D | 2012 |
Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome.
Topics: Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Cyclooxygenase 1; Cyclooxygenase Inhibitors | 2012 |
Statins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trial.
Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; | 2012 |
Esomeprazole alone compared with esomeprazole plus aspirin for the treatment of aspirin-related peptic ulcers.
Topics: Aged; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Chi-Square Distribution; Drug Therapy, Co | 2012 |
Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; | 2012 |
Combination therapy with warfarin plus clopidogrel improves outcomes in femoropopliteal bypass surgery patients.
Topics: Administration, Oral; Aged; Aspirin; Cardiovascular Diseases; Chi-Square Distribution; Clopidogrel; | 2012 |
The impact of decision aids to enhance shared decision making for diabetes (the DAD study): protocol of a cluster randomized trial.
Topics: Aspirin; Cardiovascular Diseases; Choice Behavior; Cluster Analysis; Comparative Effectiveness Resea | 2012 |
Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.
Topics: Administration, Oral; Aged; Analysis of Variance; Antihypertensive Agents; Aspirin; Atenolol; Biomar | 2012 |
Perioperative assessment of platelet function by Thromboelastograph Platelet Mapping in cardiovascular patients undergoing non-cardiac surgery.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Female; Fibrinolytic Agents; Humans; Male; Midd | 2013 |
Dual antiplatelet therapy in patients with aspirin resistance following coronary artery bypass grafting: study protocol for a randomized controlled trial [NCT01159639].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Bypass; Croatia; Drug Resistance; Dru | 2012 |
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Doub | 2012 |
Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Clinical | 2014 |
Do statins influence platelet reactivity on acetylsalicylic acid therapy in patients with type 2 diabetes?
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Cardiovascular Diseases; Chi-Square Distribution; Diabet | 2012 |
Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial.
Topics: Age Factors; Aged; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Dose-Response Relationship, | 2013 |
[109th Scientific Meeting of the Japanese Society of Internal Medicine: symposium: 2. Translational research and evidence-based medicine (EBM) in internal medicine in Japan, EBM; 1) How to understand the results of randomized controlled trials for primary
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Complications; Evidence-Based Medicine; Humans; Pro | 2012 |
Aspirin resistance in Chinese stroke patients increased the rate of recurrent stroke and other vascular events.
Topics: Aged; Asian People; Aspirin; Cardiovascular Diseases; Drug Resistance; Female; Humans; Male; Myocard | 2013 |
Burden of upper gastrointestinal symptoms in patients receiving low-dose acetylsalicylic acid for cardiovascular risk management: a prospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Gastrointestinal Diseases; | 2013 |
The evening versus morning polypill utilization study: the TEMPUS rationale and design.
Topics: Administration, Oral; Antihypertensive Agents; Aspirin; Biomarkers; Blood Platelets; Blood Pressure; | 2014 |
Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate.
Topics: Adult; Aged; Albuminuria; Aspirin; Cardiovascular Diseases; Cross-Over Studies; Diabetes Mellitus, T | 2003 |
Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial.
Topics: Aspirin; Cardiovascular Diseases; Cerebral Infarction; Double-Blind Method; Female; Hemorrhage; Huma | 2003 |
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Female; Fibrinolyti | 2003 |
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Female; Fibrinolyti | 2003 |
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Female; Fibrinolyti | 2003 |
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Female; Fibrinolyti | 2003 |
Prevalence of dry eye syndrome among US women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dry Eye Syndrome | 2003 |
Prevalence of dry eye syndrome among US women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dry Eye Syndrome | 2003 |
Prevalence of dry eye syndrome among US women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dry Eye Syndrome | 2003 |
Prevalence of dry eye syndrome among US women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dry Eye Syndrome | 2003 |
Prevalence of dry eye syndrome among US women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dry Eye Syndrome | 2003 |
Prevalence of dry eye syndrome among US women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dry Eye Syndrome | 2003 |
Prevalence of dry eye syndrome among US women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dry Eye Syndrome | 2003 |
Prevalence of dry eye syndrome among US women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dry Eye Syndrome | 2003 |
Prevalence of dry eye syndrome among US women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dry Eye Syndrome | 2003 |
Prevalence of dry eye syndrome among US women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dry Eye Syndrome | 2003 |
Prevalence of dry eye syndrome among US women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dry Eye Syndrome | 2003 |
Prevalence of dry eye syndrome among US women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dry Eye Syndrome | 2003 |
Prevalence of dry eye syndrome among US women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dry Eye Syndrome | 2003 |
Prevalence of dry eye syndrome among US women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dry Eye Syndrome | 2003 |
Prevalence of dry eye syndrome among US women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dry Eye Syndrome | 2003 |
Prevalence of dry eye syndrome among US women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dry Eye Syndrome | 2003 |
Prevalence of dry eye syndrome among US women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dry Eye Syndrome | 2003 |
Prevalence of dry eye syndrome among US women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dry Eye Syndrome | 2003 |
Prevalence of dry eye syndrome among US women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dry Eye Syndrome | 2003 |
Prevalence of dry eye syndrome among US women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dry Eye Syndrome | 2003 |
Prevalence of dry eye syndrome among US women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dry Eye Syndrome | 2003 |
Prevalence of dry eye syndrome among US women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dry Eye Syndrome | 2003 |
Prevalence of dry eye syndrome among US women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dry Eye Syndrome | 2003 |
Prevalence of dry eye syndrome among US women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dry Eye Syndrome | 2003 |
Prevalence of dry eye syndrome among US women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dry Eye Syndrome | 2003 |
Reducing CVD risk in type 2 DM.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2003 |
Long term prognosis in patients with peripheral arterial disease treated with antiplatelet agents.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cause of Death; Female; Follow-Up | 2003 |
Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors | 2003 |
Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE).
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Dementia, Vascular; Double-Blind Method; | 2003 |
Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.
Topics: Aged; Aspirin; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; | 2003 |
In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Drug Resistance; Female; Humans; Male; Middle Aged; P | 2004 |
Efficacy and safety of low-dose aspirin in polycythemia vera.
Topics: Aspirin; Cardiovascular Diseases; Disease-Free Survival; Double-Blind Method; Female; Hemorrhage; Hu | 2004 |
Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Topics: Arteriosclerosis; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Humans; | 2004 |
Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding.
Topics: Aged; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Th | 2005 |
Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding.
Topics: Aged; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Th | 2005 |
Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding.
Topics: Aged; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Th | 2005 |
Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding.
Topics: Aged; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Th | 2005 |
Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding.
Topics: Aged; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Th | 2005 |
Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding.
Topics: Aged; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Th | 2005 |
Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding.
Topics: Aged; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Th | 2005 |
Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding.
Topics: Aged; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Th | 2005 |
Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding.
Topics: Aged; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Th | 2005 |
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin | 2005 |
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cycloo | 2005 |
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cycloo | 2005 |
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cycloo | 2005 |
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cycloo | 2005 |
First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.
Topics: Adult; Aged; Alanine Transaminase; Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Chronic Disea | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
[Slide platelet aggregation test used as a monitor for patient treated with anti-pletelet drugs].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Drug Monitoring; Femal | 2005 |
Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial.
Topics: Aged; alpha-Tocopherol; Aspirin; Cardiovascular Diseases; Dietary Supplements; Double-Blind Method; | 2005 |
Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial.
Topics: Aged; alpha-Tocopherol; Aspirin; Cardiovascular Diseases; Dietary Supplements; Double-Blind Method; | 2005 |
Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial.
Topics: Aged; alpha-Tocopherol; Aspirin; Cardiovascular Diseases; Dietary Supplements; Double-Blind Method; | 2005 |
Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial.
Topics: Aged; alpha-Tocopherol; Aspirin; Cardiovascular Diseases; Dietary Supplements; Double-Blind Method; | 2005 |
Complement factor H Y402H gene polymorphism, C-reactive protein, and risk of incident myocardial infarction, ischaemic stroke, and venous thromboembolism: a nested case-control study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta Carotene; Brain Ischemia; C-Reactive Protein; Cardiova | 2006 |
Women's Health Study: low dose aspirin in primary prevention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Humans; Middle Aged; Women's Health | 2005 |
Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin.
Topics: Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Collagen; Cyclooxygenase 1; Dose-Response R | 2005 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Sex differences in platelet reactivity and response to low-dose aspirin therapy.
Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Cardiovascular Diseases; Collagen; Cyclooxygenase | 2006 |
Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients.
Topics: Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Collagen; Cyclooxygenase 1; Cyclooxygenase | 2006 |
Overcoming aspirin resistance: increased platelet inhibition with combination aspirin and clopidogrel and high dose aspirin therapy in aspirin resistant patients with peripheral vascular disease.
Topics: Aged; Aged, 80 and over; Arterial Occlusive Diseases; Aspirin; Blood Platelets; Cardiovascular Disea | 2006 |
Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Viscosity; Car | 2006 |
Celecoxib for the prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2006 |
Celecoxib for the prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2006 |
Celecoxib for the prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2006 |
Celecoxib for the prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Aspirin prevents stroke but not MI in women; vitamin E has no effect on CV disease or cancer.
Topics: Aged; Aspirin; Cardiovascular Diseases; Chemoprevention; Female; Humans; Middle Aged; Myocardial Inf | 2006 |
Aspirin therapy is still underutilized among patients with type 2 diabetes.
Topics: Adult; Analysis of Variance; Aspirin; Brazil; Cardiovascular Diseases; Contraindications; Diabetes M | 2006 |
Response to aspirin and clopidogrel in patients scheduled to undergo cardiovascular surgery.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Bypass; Female; Humans; Male; M | 2007 |
Beta carotene supplementation and age-related maculopathy in a randomized trial of US physicians.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; beta Carotene; Car | 2007 |
Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 In | 2007 |
Low dose aspirin and cognitive function in the women's health study cognitive cohort.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cognition Disorders; Cohort Studies; Health Status; Humans; | 2007 |
Lack of aspirin-induced decrease in thrombin formation in subjects resistant to aspirin.
Topics: Aspirin; Bleeding Time; Blood Platelets; Cardiovascular Diseases; Dose-Response Relationship, Drug; | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Disease-Free Survival; Drug Th | 2007 |
Plasma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study.
Topics: Aspirin; Body Mass Index; Cardiovascular Diseases; Dehydroepiandrosterone Sulfate; Diabetes Mellitus | 2007 |
Eight-year change in body mass index and subsequent risk of cardiovascular disease among healthy non-smoking men.
Topics: Adult; Aspirin; beta Carotene; Body Mass Index; Cardiovascular Diseases; Cause of Death; Cohort Stud | 2007 |
Aspirin, but not propranolol, attenuates the acute stress-induced increase in circulating levels of interleukin-6: a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 2008 |
Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Topics: Aged; Aspirin; Cardiovascular Diseases; Cohort Studies; Cross-Sectional Studies; Drug Prescriptions; | 2007 |
Comparison of cationic propyl gallate and adenosine diphosphate for the measurement of aspirin effectivity with optical aggregometry.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Case-Control Studi | 2007 |
Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2007 |
Blood pressure measures and risk of chronic kidney disease in men.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; beta Carotene; Blood Pressure; Blood | 2008 |
Potential adverse effects of a low-dose aspirin-diuretic combination on kidney function.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Creatinine; Cross-S | 2007 |
Effect of a multifactorial intervention on mortality in type 2 diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Behavior Therapy; Cardiovascular Diseases; | 2008 |
Effect of a multifactorial intervention on mortality in type 2 diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Behavior Therapy; Cardiovascular Diseases; | 2008 |
Effect of a multifactorial intervention on mortality in type 2 diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Behavior Therapy; Cardiovascular Diseases; | 2008 |
Effect of a multifactorial intervention on mortality in type 2 diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Behavior Therapy; Cardiovascular Diseases; | 2008 |
Effect of a multifactorial intervention on mortality in type 2 diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Behavior Therapy; Cardiovascular Diseases; | 2008 |
Effect of a multifactorial intervention on mortality in type 2 diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Behavior Therapy; Cardiovascular Diseases; | 2008 |
Effect of a multifactorial intervention on mortality in type 2 diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Behavior Therapy; Cardiovascular Diseases; | 2008 |
Effect of a multifactorial intervention on mortality in type 2 diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Behavior Therapy; Cardiovascular Diseases; | 2008 |
Effect of a multifactorial intervention on mortality in type 2 diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Behavior Therapy; Cardiovascular Diseases; | 2008 |
Lack of biological relevance of platelet cyclooxygenase-2 dependent thromboxane A2 production.
Topics: Aged; Algorithms; Aspirin; Blood Platelets; Cardiovascular Diseases; Cyclooxygenase 1; Cyclooxygenas | 2008 |
The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cross-Over S | 2008 |
Sulfinpyrazone: a review of its pharmacological properties and therapeutic use.
Topics: Animals; Anti-Arrhythmia Agents; Antibody Formation; Aspirin; Blood Platelets; Cardiovascular Diseas | 1980 |
Coming: a 'Dear Doctor' letter that you may want to ponder.
Topics: Aspirin; beta Carotene; Cardiovascular Diseases; Carotenoids; Clinical Trials as Topic; Double-Blind | 1982 |
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary | 1982 |
The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group.
Topics: Aspirin; Cardiovascular Diseases; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Male | 1980 |
Body mass index. An independent predictor of cataract.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta Carotene; Body Constitution; Body Mass Index; Cardiova | 1995 |
Migraine and subsequent risk of stroke in the Physicians' Health Study.
Topics: Adult; Aged; Aspirin; beta Carotene; Cardiovascular Diseases; Carotenoids; Cerebrovascular Disorders | 1995 |
The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Aged, 80 and over; Angiotensin-Converting Enzym | 1994 |
The PACE pilot study: 12-month results and implications for future primary prevention trials in the elderly. (Prevention with low-dose Aspirin of Cardiovascular disease in the Elderly)
Topics: Aged; Aged, 80 and over; Alcohol Drinking; Aspirin; Australia; Blood Pressure; Cardiovascular Diseas | 1994 |
Randomized trials of primary prevention of cardiovascular disease in women. An investigator's view.
Topics: Aspirin; beta Carotene; Cardiovascular Diseases; Carotenoids; Female; Humans; Middle Aged; Primary P | 1994 |
Antiplatelet therapy--Part I.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Cardiovascular Diseases; Coronary Artery Bypass; Coronar | 1993 |
Adverse effects of low-dose aspirin in a healthy elderly population.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Double-Blind M | 1993 |
Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women.
Topics: Adenosine Diphosphate; Administration, Oral; Adult; Arachidonic Acid; Aspirin; Blood Platelets; Card | 1996 |
Effect of a mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease. Insights into the cardioprotective effect of certain nutriments.
Topics: Aspirin; Cardiovascular Diseases; Coronary Disease; Diet; Humans; Mediterranean Sea; Nutritional Phy | 1996 |
Prospective study of moderate alcohol consumption and risk of peripheral arterial disease in US male physicians.
Topics: Adult; Alcohol Drinking; Arteries; Aspirin; beta Carotene; Cardiovascular Diseases; Double-Blind Met | 1997 |
Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Aspirin; beta Carotene; Cardiovascular Diseases; Cereb | 1997 |
Is there any evidence for a protective effect of antithrombotic medication on cognitive function in men at risk of cardiovascular disease? Some preliminary findings.
Topics: Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Cognition; Cognition Disorders; Double-Blind | 1997 |
We need stronger predictors of major vascular events in patients with a recent transient ischemic attack or nondisabling stroke. Dutch TIA Trial Study Group.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Dose-Response Relationship, Drug; | 1997 |
Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISA
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Combined Modality | 1997 |
Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Dose-Respo | 1997 |
The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability.
Topics: Aged; Antihypertensive Agents; Aspirin; Blood Pressure; Calcium Channel Blockers; Cardiovascular Dis | 1997 |
[Long-term clinical tolerance of antihypertensive treatment during the HOT study. Groupe français de l'etude HOT].
Topics: Antihypertensive Agents; Aspirin; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; | 1997 |
[Comparative study of the effect of low-dosage acetylsalicylic acid and triflusal in the prevention of cardiovascular events among young adults with ischemic cerebrovascular disease].
Topics: Adult; Aspirin; Brain Ischemia; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double-Bl | 1997 |
Aspirin use and incident stroke in the cardiovascular health study. CHS Collaborative Research Group.
Topics: Aged; Aspirin; Brain Ischemia; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebrovascular Disorde | 1998 |
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; | 1998 |
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; | 1998 |
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; | 1998 |
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; | 1998 |
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; | 1998 |
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; | 1998 |
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; | 1998 |
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; | 1998 |
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; | 1998 |
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; | 1998 |
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; | 1998 |
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; | 1998 |
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; | 1998 |
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; | 1998 |
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; | 1998 |
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; | 1998 |
[Influence of some parameters on the blood pressure reduction under treatment: experience from the Hypertension Optimal Treatment Study].
Topics: Aged; Antihypertensive Agents; Aspirin; Blood Pressure; Cardiovascular Diseases; Diastole; Drug Ther | 1998 |
The HOT Study. Hypertension Optimal Therapy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Cerebrovascular | 1998 |
[Lowering of diastolic blood pressure < or = 90 mmHg should not be attempted, except in type 2 diabetics; the 'Hypertension optimal treatment' (HOT) trial].
Topics: Adult; Aged; Aspirin; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Me | 1999 |
Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta Carotene; Biomarkers; C-Reactive Protein; Cardiovascul | 1999 |
Vitamin E, a modifier of platelet function: rationale and use in cardiovascular and cerebrovascular disease.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Double-Blind Method; H | 1999 |
Aspirin for primary prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Child; Dose-Response Relationship, Drug; Double-Blind Method; Huma | 2000 |
Self-selected posttrial aspirin use and subsequent cardiovascular disease and mortality in the physicians' health study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Confounding Factors, Epidemiologic | 2000 |
Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment.
Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Blood Pressure; Cardiovascul | 2000 |
Alcohol consumption and risk of coronary heart disease by diabetes status.
Topics: Alcohol Drinking; Aspirin; beta Carotene; Cardiovascular Diseases; Coronary Disease; Diabetes Mellit | 2000 |
Baseline self-reported cataract and subsequent mortality in Physicians' Health Study I.
Topics: Adult; Aged; Aged, 80 and over; Aging; Aspirin; Cardiovascular Diseases; Cataract; Cause of Death; H | 2000 |
Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians' Health Study (United States).
Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta Carotene; Body Mass Index; Cardiovascular Diseases; Co | 2000 |
Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Family Practice; Female; Fibrinolytic Age | 2001 |
Age-related maculopathy in a randomized trial of low-dose aspirin among US physicians.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta Carotene; Cardiovascular Diseases; Double-Blind Method | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Body mass index and the incidence of visually significant age-related maculopathy in men.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta Carotene; Body Mass Index; Cardiovascular Diseases; Do | 2001 |
In vitro bleeding test with PFA-100-aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease.
Topics: Adult; Aged; Anticoagulants; Aspirin; Blood Coagulation Tests; Cardiovascular Diseases; Case-Control | 2001 |
Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy.
Topics: Aged; Antihypertensive Agents; Aspirin; Blood Pressure; Cardiovascular Diseases; Cardiovascular Syst | 2002 |
Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Bias; Cardiovascular Diseases; Confounding Factors, Epidemi | 2002 |
Issues in the early termination of the aspirin component of the Physicians' Health Study. Data Monitoring Board of the Physicians' Health Study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta Carotene; Cardiovascular Diseases; Carotenoids; Double | 1991 |
Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; beta Carotene; Cardiovascular Diseases; Ca | 1991 |
Rationale for a primary prevention study using low-dose aspirin to prevent coronary and cerebrovascular disease in the elderly.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Coronary Disease; Female; Humans; | 1991 |
High dose polyoestradiol phosphate with and without acetosalicylic acid versus orchiectomy in the treatment of prostatic cancer. Finnprostate Group.
Topics: Aged; Aspirin; Cardiovascular Diseases; Estradiol; Estradiol Congeners; Follow-Up Studies; Humans; M | 1989 |
Final report on the aspirin component of the ongoing Physicians' Health Study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebrovascular Disor | 1989 |
Aspirin prophylaxis for cardiovascular disease. U.S. Preventive Services Task Force.
Topics: Adult; Aged; Aged, 80 and over; American Heart Association; Aspirin; Cardiovascular Diseases; Clinic | 1989 |
Aspirin in cardiovascular disease; biochemical pharmacology and clinical trials.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Myocardial Infarction; Prospecti | 1989 |
United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. UK-TIA Study Group.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Dose-Re | 1988 |
Thromboxane synthetase inhibitors, thromboxane receptor antagonists, and aspirin in cardiovascular disease.
Topics: Animals; Aspirin; Cardiovascular Diseases; Cats; Clinical Trials as Topic; Dogs; Female; Humans; Imi | 1985 |
[Acetylsalicylic acid in cardiovascular pathology: therapeutic news about an old acquaintance].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Female; | 1988 |
Aspirin and risk of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans | 1988 |
Preliminary report: Findings from the aspirin component of the ongoing Physicians' Health Study.
Topics: Adult; Aged; Aspirin; beta Carotene; Cardiovascular Diseases; Carotenoids; Cerebrovascular Disorders | 1988 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical | 1986 |
Aspirin and the prevention of stroke after transient ischaemic attack.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Blind | 1986 |
A randomized trial of aspirin and beta-carotene among U.S. physicians.
Topics: Adult; Aged; Aspirin; beta Carotene; Cardiovascular Diseases; Carotenoids; Clinical Trials as Topic; | 1985 |
[Therapeutic prospects and prostaglandins in vascular pathology].
Topics: Angina Pectoris; Anti-Inflammatory Agents; Arachidonic Acid; Arachidonic Acids; Arteritis; Aspirin; | 1985 |
1329 other studies available for aspirin and Cardiovascular Diseases
| Article | Year |
|---|---|
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors | 2021 |
Polypills with or without aspirin for primary prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Drug Combinations; Humans; Primary Prevention | 2021 |
Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis.
Topics: Aspirin; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Female; Gastrointestina | 2021 |
A Transatlantic Comparison of Patient-Reported Access to and Use of Aspirin in Contemporary Preventive Cardiology.
Topics: Aspirin; Cardiovascular Diseases; Europe; Fibrinolytic Agents; Humans; Nonprescription Drugs; Primar | 2021 |
Similar mortality risk in incident cognitive impairment and dementia: Evidence from the ASPirin in Reducing Events in the Elderly (ASPREE) trial.
Topics: Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Cognitive Dysfunction; Dementi | 2021 |
Use of aspirin for primary prevention in patients with diabetes during the COVID-19 pandemic.
Topics: Aspirin; Cardiovascular Diseases; COVID-19; Diabetes Mellitus; Humans; Pandemics; Platelet Aggregati | 2022 |
Eastern Association for the Surgery of Trauma Multicenter Trial: Comparison of pre-injury antithrombotic use and reversal strategies among severe traumatic brain injury patients.
Topics: Aged; Anticoagulant Reversal Agents; Aspirin; Brain Injuries, Traumatic; Cardiovascular Diseases; Co | 2022 |
The role of aspirin for the primary prevention of cardiovascular disease in individuals with chronic kidney disease.
Topics: Aspirin; Cardiovascular Diseases; Humans; Primary Prevention; Renal Insufficiency, Chronic | 2022 |
In ASCVD, 81 mg and 325 mg of aspirin did not differ for CV or bleeding events.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans | 2021 |
Arterial Stiffness as a Cardiovascular Risk Factor for the Development of Preeclampsia and Pharmacopreventive Options.
Topics: Aspirin; Cardiovascular Diseases; Female; Heart Disease Risk Factors; Humans; Pre-Eclampsia; Pregnan | 2022 |
Would You Recommend Aspirin to This Patient for Primary Prevention of Atherosclerotic Cardiovascular Disease? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Female; Humans; Platelet Aggregation Inhibi | 2021 |
Utility of a pharmacogenetic-driven algorithm in guiding dual antiplatelet therapy for patients undergoing coronary drug-eluting stent implantation in China.
Topics: Aged; Algorithms; Asian People; Aspirin; Cardiovascular Diseases; China; Clopidogrel; Comorbidity; C | 2022 |
Should my older adult patients take aspirin for primary prevention of cardiovascular disease?
Topics: Aged; Aspirin; Cardiovascular Diseases; Humans; Primary Prevention; Secondary Prevention | 2021 |
Dual pathway inhibition in atherothrombosis prevention: yes, now we can!
Topics: Aspirin; Cardiovascular Diseases; Drug-Eluting Stents; Hemorrhage; Humans; Platelet Aggregation Inhi | 2023 |
Trends in the use of oral anticoagulants, antiplatelets and statins in four European countries: a population-based study.
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Utilization | 2022 |
[Two decades later, the polypill revisited].
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Combinations; Humans; Hydroxymethylg | 2021 |
The Effect of Aspirin on the Primary Prevention of Major Adverse Cardiac and Cerebrovascular Events in Chinese Older Adults: A Registration Study.
Topics: Aged; Aspirin; Cardiovascular Diseases; China; Humans; Male; Middle Aged; Myocardial Infarction; Pla | 2022 |
Should Antiplatelet Therapy Be Withheld Perioperatively? The First Study Examining Outcomes in Patients Receiving Dual Antiplatelet Therapy in the Lower Extremity Free Flap Population.
Topics: Aged; Aspirin; Blood Transfusion; Cardiovascular Diseases; Clopidogrel; Dual Anti-Platelet Therapy; | 2022 |
Cardiovascular Disease Preventive Services Among Smaller Primary Care Practices.
Topics: Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Humans; Primary Health Care; Quality Impr | 2022 |
A fixed-dose combination treatment strategy to reduce premature cardiovascular disease deaths globally.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Humans; Mortality, Premature | 2021 |
In persons at intermediate risk for CVD, polypills reduce a composite of CV events at 5 y.
Topics: Aspirin; Cardiovascular Diseases; Drug Combinations; Humans; Primary Prevention | 2022 |
COX-1, COX-2 and CYP2C19 variations may be related to cardiovascular events due to acetylsalicylic acid resistance.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Cyclooxygenase 1; Cyclooxygenase 2; Cytochrome P-450 | 2022 |
Aspirin for Primary and Secondary Prevention of Cardiovascular Disease: Time to Stop?
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention; Secon | 2022 |
Managing Hypertension, Diabetes, and Cardiovascular Disease Risk via Short-Term Medical Trips: A Retrospective Longitudinal Study in Santo Domingo.
Topics: Aspirin; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Hu | 2022 |
Potential Impact of the 2019 ACC/AHA Guidelines on the Primary Prevention of Cardiovascular Disease Recommendations on the Inappropriate Routine Use of Aspirin and Aspirin Use Without a Recommended Indication for Primary Prevention of Cardiovascular Disea
Topics: American Heart Association; Aspirin; Atherosclerosis; Cardiology; Cardiovascular Diseases; Humans; H | 2022 |
Safety and effectiveness of low-dose aspirin for the prevention of gastrointestinal cancer in adults without atherosclerotic cardiovascular disease: a population-based cohort study.
Topics: Adult; Aspirin; Cardiovascular Diseases; Cohort Studies; Gastrointestinal Hemorrhage; Gastrointestin | 2022 |
Association between aspirin use during pregnancy and cardiovascular risk factors 2-7 years after delivery: The nuMoM2b Heart Health Study.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Heart Disease Risk Factors; Hum | 2022 |
Does Stopping Aspirin Differ Fundamentally From Not Starting Aspirin in the Primary Prevention of Cardiovascular Disease Among Older Adults?
Topics: Aged; Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention | 2022 |
Egg consumption and risk of cardiovascular events among Iranians: results from Isfahan Cohort Study (ICS).
Topics: Adult; Aspirin; Cardiovascular Diseases; Cohort Studies; Eggs; Follow-Up Studies; Humans; Iran; Myoc | 2022 |
Contextualizing National Policies Regulating Access to Low-Dose Aspirin in America and Europe Using the Full Report of a Transatlantic Patient Survey of Aspirin in Preventive Cardiology.
Topics: Adult; Aspirin; Cardiology; Cardiovascular Diseases; Europe; Female; Humans; Male; Policy; Primary P | 2022 |
The end of aspirin for dementia prevention in diabetes?
Topics: Aspirin; Cardiovascular Diseases; Cognition; Dementia; Diabetes Mellitus; Humans; Platelet Aggregati | 2022 |
Whom to Treat for Primary Prevention of Atherosclerotic Cardiovascular Disease: The Aspirin Dilemma.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary | 2022 |
Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Modeling Study for the US Preventive Services Task Force.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Female; Gastrointestinal Hemorr | 2022 |
Use of Aspirin to Prevent Cardiovascular Disease.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention | 2022 |
Should Patients Take Aspirin for Primary Cardiovascular Prevention?: Updated Recommendations From the US Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Cardiovascular Diseases; Cardiovascular System; Humans; Preventive Hea | 2022 |
Trends and Determinants of Self-reported Aspirin Use Among Patients With Diabetes Stratified by Presence and Risk of Cardiovascular Diseases: A Repeated Pan-Canadian Cross-sectional Study.
Topics: Aspirin; Canada; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus; Humans; Platel | 2022 |
Chronic aspirin use and survival following sepsis-A propensity-matched, observational cohort study.
Topics: Aspirin; Cardiovascular Diseases; Cohort Studies; Humans; Platelet Aggregation Inhibitors; Retrospec | 2022 |
Therapeutic implementation in arterial thrombosis with pulmonary administration of fucoidan microparticles containing acetylsalicylic acid.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Polysaccharides; Thrombos | 2022 |
Will the new pharmaceutical lipid-aspirin complex formulation restore the once lost trust of aspirin on cardiovascular protection?
Topics: Aspirin; Cardiovascular Diseases; Humans; Lipids; Pharmaceutical Preparations; Platelet Aggregation | 2022 |
Apolipoprotein E*Ɛ2 carriers exhibit high aspirin-treated platelet reactivity and low cardiovascular risk during long-term aspirin treatment.
Topics: Apolipoprotein E2; Aspirin; Cardiovascular Diseases; Heart Disease Risk Factors; Humans; Risk Factor | 2022 |
[Recent developments in secondary cardiovascular prevention: the pros and cons of dual pathway inhibition].
Topics: Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Hemorrhage; Human | 2022 |
Non-vitamin K oral anticoagulant compared with aspirin may not significantly reduce the rate of ischaemic stroke in patients with mixed cardiovascular disease in sinus rhythm.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cardiovascular D | 2022 |
Aspirin for the Primary Prevention of Atherosclerotic Cardiovascular Disease in Women.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Female; Humans; Platelet Aggregation Inhibitors; | 2022 |
Impact of the
Topics: Adenosine Diphosphate; Aspirin; Cardiovascular Diseases; China; Clopidogrel; Humans; Hyperglycemia; | 2022 |
USPSTF updates recommendations on aspirin and CVD.
Topics: Aspirin; Cardiovascular Diseases; Humans; Primary Prevention | 2022 |
Cost-Effectiveness of Vonoprazan Compared With Proton Pump Inhibitors in Patients Taking Low-Dose Aspirin for Secondary Prevention of Cardiovascular Events in Japan.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Esomeprazole; Gastrointestinal Hemorr | 2023 |
Aspirin for the Primary Prevention of Cardiovascular Disease: Time for a Platelet-Guided Approach.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Cholesterol; Humans; Hydroxymethylglutary | 2022 |
USPSTF recommends aspirin to prevent CVD in adults 40 to 59 y as an individual decision; not recommended for adults ≥60 y.
Topics: Adult; Advisory Committees; Aspirin; Cardiovascular Diseases; Humans; Preventive Health Services; Ri | 2022 |
Cardiovascular Disease Prevention: Pharmacologic Prevention.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; | 2022 |
Aspirin Use to Prevent Cardiovascular Disease.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention | 2022 |
Aspirin Use to Prevent Cardiovascular Disease.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention | 2022 |
The pattern of epistaxis recurrence in patients taking prophylactic acetylsalicylic acid (ASA) from a 10 year cohort.
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Epistaxis; Humans; Recurrence; Retrospective Studi | 2023 |
Low Body Mass Index without Malnutrition Is an Independent Risk Factor for Major Cardiovascular Events in Patients with Hemodialysis.
Topics: Albumins; Aspirin; Blood Proteins; Body Mass Index; Cardiovascular Diseases; Cholesterol; Heart Fail | 2022 |
Effect of aspirin on primary prevention of cardiovascular disease and mortality among patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Middle Aged; Platelet | 2022 |
Low-dose aspirin as primary prevention for adults without cardiovascular disease.
Topics: Adult; Aspirin; Cardiovascular Diseases; Humans; Primary Prevention; Randomized Controlled Trials as | 2022 |
USPSTF Recommends Against Initiating Aspirin for Primary Prevention of CVD in Adults 60 Years or Older.
Topics: Adult; Aspirin; Cardiovascular Diseases; Humans; Primary Prevention | 2022 |
USPSTF Recommends Against Initiating Aspirin for Primary Prevention of CVD in Adults 60 Years or Older.
Topics: Adult; Aspirin; Cardiovascular Diseases; Humans; Primary Prevention | 2022 |
USPSTF Recommends Against Initiating Aspirin for Primary Prevention of CVD in Adults 60 Years or Older.
Topics: Adult; Aspirin; Cardiovascular Diseases; Humans; Primary Prevention | 2022 |
USPSTF Recommends Against Initiating Aspirin for Primary Prevention of CVD in Adults 60 Years or Older.
Topics: Adult; Aspirin; Cardiovascular Diseases; Humans; Primary Prevention | 2022 |
USPSTF Recommends Against Initiating Aspirin for Primary Prevention of CVD in Adults 60 Years or Older.
Topics: Adult; Aspirin; Cardiovascular Diseases; Humans; Primary Prevention | 2022 |
USPSTF Recommends Against Initiating Aspirin for Primary Prevention of CVD in Adults 60 Years or Older.
Topics: Adult; Aspirin; Cardiovascular Diseases; Humans; Primary Prevention | 2022 |
USPSTF Recommends Against Initiating Aspirin for Primary Prevention of CVD in Adults 60 Years or Older.
Topics: Adult; Aspirin; Cardiovascular Diseases; Humans; Primary Prevention | 2022 |
USPSTF Recommends Against Initiating Aspirin for Primary Prevention of CVD in Adults 60 Years or Older.
Topics: Adult; Aspirin; Cardiovascular Diseases; Humans; Primary Prevention | 2022 |
USPSTF Recommends Against Initiating Aspirin for Primary Prevention of CVD in Adults 60 Years or Older.
Topics: Adult; Aspirin; Cardiovascular Diseases; Humans; Primary Prevention | 2022 |
Deprescription of aspirin for primary prevention is uncommon at discharge in hospitalised patients with gastrointestinal bleeding.
Topics: Aftercare; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; H | 2023 |
Deprescription of aspirin for primary prevention is uncommon at discharge in hospitalised patients with gastrointestinal bleeding.
Topics: Aftercare; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; H | 2023 |
Deprescription of aspirin for primary prevention is uncommon at discharge in hospitalised patients with gastrointestinal bleeding.
Topics: Aftercare; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; H | 2023 |
Deprescription of aspirin for primary prevention is uncommon at discharge in hospitalised patients with gastrointestinal bleeding.
Topics: Aftercare; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; H | 2023 |
Deprescription of aspirin for primary prevention is uncommon at discharge in hospitalised patients with gastrointestinal bleeding.
Topics: Aftercare; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; H | 2023 |
Deprescription of aspirin for primary prevention is uncommon at discharge in hospitalised patients with gastrointestinal bleeding.
Topics: Aftercare; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; H | 2023 |
Deprescription of aspirin for primary prevention is uncommon at discharge in hospitalised patients with gastrointestinal bleeding.
Topics: Aftercare; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; H | 2023 |
Deprescription of aspirin for primary prevention is uncommon at discharge in hospitalised patients with gastrointestinal bleeding.
Topics: Aftercare; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; H | 2023 |
Deprescription of aspirin for primary prevention is uncommon at discharge in hospitalised patients with gastrointestinal bleeding.
Topics: Aftercare; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; H | 2023 |
Low-dose Aspirin as Primary Prevention for Adults without Cardiovascular Disease.
Topics: Adult; Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention | 2022 |
Low-dose Aspirin as Primary Prevention for Adults without Cardiovascular Disease.
Topics: Adult; Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention | 2022 |
Low-dose Aspirin as Primary Prevention for Adults without Cardiovascular Disease.
Topics: Adult; Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention | 2022 |
Low-dose Aspirin as Primary Prevention for Adults without Cardiovascular Disease.
Topics: Adult; Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention | 2022 |
In CV disease, clopidogrel reduces nonfatal MI and MACE vs. aspirin but not stroke or mortality.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke | 2022 |
In CV disease, clopidogrel reduces nonfatal MI and MACE vs. aspirin but not stroke or mortality.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke | 2022 |
In CV disease, clopidogrel reduces nonfatal MI and MACE vs. aspirin but not stroke or mortality.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke | 2022 |
In CV disease, clopidogrel reduces nonfatal MI and MACE vs. aspirin but not stroke or mortality.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke | 2022 |
Long-Term Adherence and Persistence to Low-Dose Aspirin for the Prevention of Cardiovascular Disease: A Population-Based Cohort Study.
Topics: Adult; Aspirin; Cardiovascular Diseases; Cohort Studies; Germany; Humans; Medication Adherence; Unit | 2022 |
Aspirin for primary prevention of cardiovascular disease in women.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Primary Prevention; Risk | 2023 |
How Does Prior Experience Pay Off in Large-Scale Quality Improvement Initiatives?
Topics: Aspirin; Cardiovascular Diseases; Cholesterol; Humans; Primary Health Care; Quality Improvement | 2022 |
Temporal Trends in Low-Dose Aspirin Use (from the CoLaus|PsyCoLaus Study).
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Humans; Primary Prevention | 2023 |
Dual pathway inhibition for atherosclerotic cardiovascular disease: Recent advances.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Cardiovascular Diseases; Drug Therapy, Combinatio | 2022 |
Continuous Improvement of Antiplatelet Therapy in Cardiovascular Disease.
Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors | 2023 |
Adherence to European guidelines for the use of aspirin in primary health care.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseases; Fibrinolytic Agents; Humans; Myoc | 2023 |
Appropriateness of aspirin use among diabetic patients in primary prevention of atherosclerotic cardiovascular diseases: an analysis of the ASSOS study.
Topics: American Heart Association; Aspirin; Atherosclerosis; Cardiology; Cardiovascular Diseases; Diabetes | 2023 |
Aspirin in diabetic patients at primary prevention: insights of the VITAL cohort.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hypertension; Male; Retrospective Studi | 2023 |
Trends in Provision of Medications and Lifestyle Counseling in Ambulatory Settings by Gender and Race for Patients With Atherosclerotic Cardiovascular Disease, 2006-2016.
Topics: Adult; Aspirin; Atherosclerosis; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; H | 2023 |
Detection and analysis of potential drug-drug interactions among patients admitted to the cardiac care unit in a tertiary care hospital.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Enoxaparin; Furosemide; Humans; Li | 2023 |
Kinetics of Circulating Extracellular Vesicles Over the 24-Hour Dosing Interval After Low-Dose Aspirin Administration in Patients at Cardiovascular Risk.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Extracellular Vesicles; Heart Disease Risk Factor | 2023 |
Acetylsalicylic acid challenge or desensitization in sensitive patients with cardiovascular disease.
Topics: Acute Coronary Syndrome; Anaphylaxis; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 2023 |
Cardiovascular disease preventive effects of aspirin combined with different statins in the United States general population.
Topics: Aspirin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Rosuvastat | 2023 |
Temporal trends in low-dose aspirin therapy for primary prevention of cardiovascular disease in European adults with and without diabetes.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Europe; Female; | 2023 |
Low-dose aspirin in the primary prevention of cardiovascular diseases: A retrospective, propensity score matched study.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Primary Prevention; Propensity Score; Retros | 2023 |
Are P2Y12 inhibitors superior to aspirin for long-term secondary prevention of cardiovascular disease?
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregati | 2023 |
Immigration and use of preventive aspirin by Hispanics and non-Hispanic whites and non-Hispanic blacks in the US.
Topics: Adult; Aspirin; Black or African American; Cardiovascular Diseases; Emigration and Immigration; Ethn | 2023 |
Aspirin deprescribing in primary prevention of cardiovascular disease: a prospective risk-benefit approach.
Topics: Aspirin; Cardiovascular Diseases; Deprescriptions; Gastrointestinal Hemorrhage; Humans; Primary Prev | 2023 |
[Interpretation of the US preventive services task force recommendation statement on aspirin used to prevent cardiovascular disease].
Topics: Aspirin; Cardiovascular Diseases; Humans; Mass Screening; Platelet Aggregation Inhibitors; Risk Asse | 2023 |
Low-dose aspirin therapy for primary prevention of cardiovascular disease: where are we at?
Topics: Adult; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors; | 2023 |
Interactions of Nonsteroidal Antiinflammatory Drugs and Aspirin and Risk of Cardiovascular Disease in Patients With Osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Ibuprofen; Naprox | 2023 |
Prediabetes, diabetes and loss of disability-free survival in a community-based older cohort: a post-hoc analysis of the ASPirin in Reducing Events in the Elderly trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Prediabetic State; Prognosis | 2023 |
Aspirin for primary prevention of cardiovascular disease: What do the current USPSTF guidelines say?
Topics: Adult; Aspirin; Cardiovascular Diseases; Humans; Middle Aged; Preventive Health Services; Primary Pr | 2023 |
Aspirin in primary prevention of cardiovascular events: Key questions remain.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention | 2023 |
Redefining the Roles of Aspirin across the Spectrum of Cardiovascular Disease Prevention.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseases; Female; Fibrinolytic Agents; Huma | 2023 |
The underutilization of preventive cardiovascular measures in patients with cancer: an analysis of the Behavioural Risk Factor Surveillance System, 2011-22.
Topics: Anticholesteremic Agents; Aspirin; Behavioral Risk Factor Surveillance System; Cardiovascular Diseas | 2023 |
Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE.
Topics: Aged; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Infarction; Renal Insufficien | 2023 |
[Acetylsalicylic acid in primary and secondary prevention of atherosclerotic cardiovascular disease].
Topics: Adult; Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Gastrointestinal Tract; Humans; Male | 2023 |
Pre-aspirin use has no benefit on the neurological disability and mortality after cardiovascular events: A nation-wide population-based cohort study.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cohort Studies; Hemorrhagic Stroke; Humans; Platelet Aggrega | 2023 |
Association Between Aspirin-Exacerbated Respiratory Disease and Atherosclerotic Cardiovascular Disease: A Retrospective Review of US Claims Data.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Cardiovascular Di | 2023 |
One Pill for Everyone? Twenty Years of Polypill for Cardiovascular Disease.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Drug Combinations; | 2023 |
Differences in Use of Clinical Decision Support Tools and Implementation of Aspirin, Blood Pressure Control, Cholesterol Management, and Smoking Cessation Quality Metrics in Small Practices by Race and Sex.
Topics: Aspirin; Benchmarking; Blood Pressure; Cardiovascular Diseases; Cholesterol; Cross-Sectional Studies | 2023 |
Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, and High-Income Countries.
Topics: Adult; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Developed Countries; Female; Human | 2023 |
Aspirin for primary prevention in patients with high cardiovascular risk: insights from CORE-Thailand registry.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Heart Disease Risk Factors; Humans; Longitudinal | 2023 |
Trends in Upper Gastrointestinal Bleeding in Patients on Primary Prevention Aspirin: A Nationwide Emergency Department Sample Analysis, 2016-2020.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Emergency Service, | 2023 |
Influence of Socioeconomic Gender Inequality on Sex Disparities in Prevention and Outcome of Cardiovascular Disease: Data From a Nationwide Population Cohort in China.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular | 2023 |
Identifying and reducing inappropriate aspirin use in primary care.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Humans; Primary Health Care; Prospective | 2023 |
Major cardiovascular and bleeding events with long-term use of aspirin in patients with prior cardiovascular diseases: 1-year follow-up results from the Management of Aspirin-induced Gastrointestinal Complications (MAGIC) study.
Topics: Aged; Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Female; Fibrinolytic Agents; H | 2020 |
The 2016 Joint European Prevention Guidelines and the uses of polypills: Time to update the evidence.
Topics: Administration, Oral; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Combinations; | 2020 |
Risks May Outweigh Benefits Of Aspirin Use in Diabetes.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors; Risk F | 2019 |
Barriers and Facilitators to the Use of Cardiovascular Fixed-Dose Combination Medication (Polypills) in Andhra Pradesh, India: A Mixed-Methods Study.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Drug Combinations; | 2019 |
Effects of low-dose aspirin on clinical outcome and disease progression in patients with gastroenteropancreatic neuroendocrine neoplasm.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Disease Progression; F | 2019 |
[Interpretation and comments about the rise and fall of aspirin in the primary prevention of cardiovascular disease].
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention | 2019 |
Aspirin better than clopidogrel on major adverse cardiovascular events reduction after ischemic stroke: A retrospective nationwide cohort study.
Topics: Aged; Aspirin; Brain Ischemia; Cardiovascular Diseases; Cerebral Hemorrhage; Clopidogrel; Female; Ga | 2019 |
Role of risk attitude and time preference in preventive aspirin use adherence.
Topics: Aspirin; Cardiovascular Diseases; Humans; Logistic Models; Medication Adherence; Mental Disorders; P | 2020 |
Aspirin for primary prevention in the elderly.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Platel | 2019 |
Estimating individual lifetime benefit and bleeding risk of adding oral anticoagulation to aspirin for patients with stable cardiovascular disease: directions from COMPASS?
Topics: Aspirin; Cardiovascular Diseases; Factor Xa Inhibitors; Humans; Platelet Aggregation Inhibitors; Riv | 2019 |
Personalized Prediction of Cardiovascular Benefits and Bleeding Harms From Aspirin for Primary Prevention: A Benefit-Harm Analysis.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; Middle Aged; Platel | 2019 |
Editorial commentary: MicroRNAs as effectors and indicators of aspirin therapeutic potential.
Topics: Aspirin; Cardiovascular Diseases; Humans; MicroRNAs; Platelet Aggregation Inhibitors | 2020 |
The influence of the baseline 10-year atherosclerotic cardiovascular disease risk on cardiovascular outcomes with aspirin for primary prevention: a meta-regression analysis.
Topics: Aspirin; Cardiovascular Diseases; Humans; Primary Prevention; Randomized Controlled Trials as Topic; | 2020 |
The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: New features and the ‘Ten Commandments’ of the 2019 Guidelines are discussed by Professor Peter J. Grant and Professor Francesco Cosen
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Blood Pressure; Cardiovascular Diseases; Cholesterol, | 2019 |
Cases in Precision Medicine: A Personalized Approach to Stroke and Cardiovascular Risk Assessment in Women.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Evidence-Bas | 2019 |
Dual Antiplatelet Therapy for Patients with Cardiovascular Disease.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregati | 2019 |
Delayed progression of atherosclerosis and cardiovascular events in asymptomatic patients with atherosclerotic plaques: 3-year prevention with the supplementation with Pycnogenol®+Centellicum®.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Carotid Intima-Media Thickness; Centella; D | 2020 |
Central cardiovascular calcifications: supplementation with Pycnogenol® and Centellicum®: variations over 12 months.
Topics: Aspirin; Cardiovascular Diseases; Centella; Coronary Artery Disease; Dietary Supplements; Disease Ma | 2020 |
The cardiovascular benefits of low-dosage acetylsalicylic acid.
Topics: Aspirin; Cardiovascular Diseases; Cardiovascular System; Humans | 2019 |
After PCI and 3 mo of DAPT, P2Y12-inhibitor monotherapy was noninferior to DAPT at 12 mo.
Topics: Aspirin; Cardiovascular Diseases; Drug-Eluting Stents; Humans; Percutaneous Coronary Intervention; P | 2019 |
Review: In newer CVD primary prevention trials, aspirin vs no aspirin does not reduce MI and increases major bleeding.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention | 2019 |
Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2 | 2020 |
Aspirin for primary prevention of CVD in CKD: where do we stand?
Topics: Aspirin; Cardiovascular Diseases; Humans; Primary Prevention; Renal Insufficiency, Chronic; Secondar | 2019 |
Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; China; Cost-Benefit Analysis; Diabetes Me | 2019 |
Low-Dose Aspirin for Primary Prevention of Cardiovascular Disease: Use Patterns and Impact Across Race and Ethnicity in the Southern Community Cohort Study.
Topics: Adult; Aged; Aspirin; Black or African American; Cardiovascular Diseases; Cohort Studies; Female; Hu | 2019 |
A Decision-Support Software to Improve the Standard Care in Chinese Type 2 Diabetes.
Topics: Antihypertensive Agents; Aspirin; Blood Glucose; Blood Pressure; Cardiovascular Diseases; China; Dec | 2019 |
Assessment of Cardiovascular Risk by the Combination of Clinical Risk Scores Plus Platelet Expression of FcγRIIa.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cohort Studies; Drug Therapy, Combination; Flow C | 2020 |
All-cause mortality following low-dose aspirin treatment for patients with high cardiovascular risk in remote Australian Aboriginal communities: an observational study.
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Female; Humans; Incidence; Male; | 2020 |
Extracting the benefits of berberine for colorectal cancer.
Topics: Adenoma; Antineoplastic Agents, Phytogenic; Aspirin; Berberine; Cardiovascular Diseases; Case-Contro | 2020 |
Aspirin moderates the association between cardiovascular risk, brain white matter hyperintensity total lesion volume and processing speed in normal ageing.
Topics: Aged; Aging; Aspirin; Cardiovascular Diseases; Cognition; Female; Humans; Magnetic Resonance Imaging | 2020 |
Urgent to correctly understand the role of aspirin in cardiovascular disease.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reducta | 2020 |
Role of health plan administrative claims data in participant recruitment for pragmatic clinical trials: An Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) example.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Data Collection; Electronic Mail; Female; | 2020 |
Aspirin for Prevention of Cardiovascular Disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Secondary Prevent | 2020 |
Aspirin Use and Awareness for Cardiovascular Disease Prevention Among Hispanics: Prevalence and Associations with Health Behavior Beliefs.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Female; Health Behavior; Hispanic or Latino; Humans; | 2020 |
Aspirin in Primary and Secondary Prevention of Cardiovascular Disease.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Primary Preve | 2020 |
Adherence to Triple-Free-Drug Combination Therapies Among Patients With Cardiovascular Disease.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel B | 2020 |
Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study.
Topics: Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Therapy, Combination; Factor Xa Inhibi | 2020 |
PURL: Aspirin, Yes, for at-risk elderly-but what about the healthy elderly?
Topics: Aged; Aspirin; Cardiovascular Diseases; Health Status; Hemorrhage; Humans; Primary Prevention | 2020 |
[Combined Antithrombotic Therapy in Patients with a Stable Atherosclerotic Cardiovascular Diseases: What Direction did COMPASS Show?]
Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Platelet A | 2020 |
Aspirin for primary prevention of cardiovascular disease in women.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Female; Hemorrh | 2020 |
[Primary prevention of chronic non-communicable diseases and acetylsalicylic acid: ambiguity of opinions].
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Humans; Middle Aged; Noncommunicable Diseases; Platel | 2020 |
Aspirin for secondary prevention of cardiovascular disease.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary | 2020 |
Canadian Stroke Best Practice Recommendations, seventh edition: acetylsalicylic acid for prevention of vascular events.
Topics: Aspirin; Canada; Cardiovascular Diseases; Decision Making, Shared; Humans; Primary Prevention; Risk | 2020 |
Analysis of quinary therapy targeting multiple cardiovascular diseases using UV spectrophotometry and chemometric tools.
Topics: Algorithms; Aspirin; Atenolol; Capsules; Cardiovascular Diseases; Chromatography, High Pressure Liqu | 2020 |
2019 Chinese expert consensus statement on aspirin application in primary prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; China; Consensus; Humans; Primary Prevention | 2020 |
Polypill for Population-Level Primary Cardiovascular Prevention in Underserved Populations-A Social Epidemiology Counterargument.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Delivery of Health Care; Diet; Drug Combi | 2020 |
Add-On Therapies in Cardiovascular Disease: Reviewing ICER's Report and the Potential Effect on Payers.
Topics: Age Factors; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Dr | 2020 |
Aspirin as a painkiller in patients with a high cardiovascular risk profile.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregat | 2020 |
Reply to 'Aspirin as a painkiller in patients with a high cardiovascular risk profile'.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregat | 2020 |
Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Cardiovascular Dise | 2020 |
Performance comparison of platelet function analyzers in cardiology patients: VerifyNow and Anysis-200 aspirin assays.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Mid | 2020 |
Aspirin for Primary Prevention in Adults Older than 70 Years is Not Supported by High-Quality Trial Data and May Cause Harm.
Topics: Adult; Aspirin; Cardiovascular Diseases; Humans; Judgment; Primary Prevention | 2020 |
New methodological approaches for assessing thrombus formation in cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervent | 2020 |
Validity of Medical Record Abstraction and Electronic Health Record-Generated Reports to Assess Performance on Cardiovascular Quality Measures in Primary Care.
Topics: Aspirin; Blood Pressure Determination; Cardiovascular Diseases; Cross-Sectional Studies; Electronic | 2020 |
Aspirin in a diabetic retinopathy setting: Insights from NO BLIND study.
Topics: Aged; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mel | 2020 |
Safety and Efficacy of Single Versus Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiovascular Diseases; Cl | 2020 |
Preparation and characterization of polypills containing aspirin and simvastatin using 3D printing technology for the prevention of cardiovascular diseases.
Topics: Aspirin; Cardiovascular Diseases; Humans; Printing, Three-Dimensional; Simvastatin; Technology, Phar | 2020 |
Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases.
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Cost-Benefit Analysis; Do | 2021 |
Recommendation of Aspirin-Guide App and Physicians Clinical Decision of Aspirin Use to Prevent CVD Among Diabetic Patients, Is there any Differences?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clinical Decision-Making; Cross-Se | 2021 |
Hemodynamic modeling of long-term aspirin effects on blood oxygenated level dependent responses at 7 Tesla in patients at cardiovascular risk.
Topics: Aged; Aspirin; Brain; Brain Mapping; Cardiovascular Diseases; Heart Disease Risk Factors; Hemodynami | 2021 |
Estimating Aspirin Overuse for Primary Prevention of Atherosclerotic Cardiovascular Disease (from a Nationwide Healthcare System).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Deliv | 2020 |
Is continuation of anti-platelet treatment safe for elective total hip arthroplasty patients?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Aspirin; Blood Los | 2020 |
Treatment effect of aspirin for primary prevention does not differ according to baseline ASCVD risk.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Humans; Primary Prevention; Regression Analysis | 2020 |
PURL:Rethinking daily aspirin for primary prevention.
Topics: Aspirin; Cardiovascular Diseases; Humans; Primary Prevention; Randomized Controlled Trials as Topic; | 2020 |
Residual platelet reactivity in low-dose aspirin-treated patients with class 1 obesity.
Topics: Aged; Angioplasty; Aspirin; Biomarkers; Blood Platelets; Cardiovascular Diseases; Dual Anti-Platelet | 2021 |
Polypill plus aspirin reduces the risk of cardiovascular disease.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors | 2021 |
Risks of adverse events for users of proton-pump inhibitors plus aspirin or clopidogrel in patients with aspirin-related ulcer bleeding.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Databases, Factual; F | 2021 |
Long-Term Aspirin Use and 5-Year Survival in Healthy Adults: A Population-Based Cohort Study in South Korea.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cause of Death; | 2020 |
Combining antiplatelet and anticoagulant therapy in cardiovascular disease.
Topics: Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; Humans; Male; P | 2020 |
[Decreasing cardiovascular morbidity: how to improve adherence to the treatment in the translational era].
Topics: Aspirin; Cardiovascular Diseases; Humans; Morbidity; Russia; Tablets, Enteric-Coated | 2020 |
A one-size-fits-all polypill strategy for primary prevention in the era of precision medicine?
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Humans; Precision Medicine; Primary Prevent | 2021 |
A Pathophysiologic Primary Prevention Review of Aspirin Administration to Prevent Cardiovascular Thrombosis.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Humans; Plaque, Atherosclerotic; Pr | 2020 |
Polypills - A Central Strategy for Improving Cardiovascular Health.
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Drug Combinations; Humans | 2021 |
Association between renal function and platelet reactivity during aspirin therapy in elderly patients with atherosclerotic cardiovascular disease.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Cardiovascular Diseases; Female; Humans; Male; Pl | 2021 |
"To take or not to take an aspirin?" The age-old question of cardiovascular disease primary prevention for people with chronic kidney disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention; Renal Insufficiency, | 2021 |
Clinician engagement in the ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness) trial.
Topics: Aspirin; Cardiovascular Diseases; Electronic Health Records; Humans; Patient-Centered Care; Pragmati | 2021 |
Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease and Colorectal Carcinomas.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Colorectal Neoplasms; Humans; Primary Prevention | 2021 |
Author Response to "Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease and Colorectal Carcinomas".
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Colorectal Neoplasms; Humans; Primary Prevention | 2021 |
Aspirin Use and Misuse for the Primary Prevention of Cardiovascular Diseases.
Topics: Adult; Aspirin; Cardiovascular Diseases; Female; Humans; Hypertension; Male; Primary Prevention; Ris | 2021 |
Sex and gender differences in presentation, treatment and outcomes in acute coronary syndrome, a 10 year study from a multi-ethnic Asian population: The Malaysian National Cardiovascular Disease Database-Acute Coronary Syndrome (NCVD-ACS) registry.
Topics: Acute Coronary Syndrome; Angiotensin-Converting Enzyme Inhibitors; Asian People; Aspirin; Cardiovasc | 2021 |
Non-persistence with anti-platelet therapy and long-term mortality after ischemic stroke: A nationwide study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Cardiovascular Diseases; C | 2021 |
Preventing cardiovascular events after pneumonia with aspirin: one step forward, but still many to go.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Pneumonia | 2021 |
Prevalence of Guideline-Directed Medical Therapy for Cardiovascular Disease Among Baltimore City Adults in the Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS) Study.
Topics: Adult; Aspirin; Baltimore; Cardiovascular Diseases; Cross-Sectional Studies; Female; Healthy Aging; | 2022 |
Age-Related Trajectories of Cardiovascular Risk and Use of Aspirin and Statin Among U.S. Adults Aged 50 or Older, 2011-2018.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Fem | 2021 |
The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus; | 2021 |
The value of the polypill in cardiovascular disease: an Italian multidisciplinary Delphi panel consensus.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Consensus; Delphi Technique; Drug Combina | 2021 |
Aspirin prescribing for cardiovascular disease in middle-aged and older adults in Ireland: Findings from The Irish Longitudinal Study on Ageing.
Topics: Aged; Aging; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Ireland; Lon | 2021 |
[Atherosclerotic Cardiovascular Diseases and Type 2 Diabetes Mellitus - new Developments in the Treatment].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Plat | 2021 |
ISSUE INTRODUCTION: The Diminishing Role of Aspirin in Cardiovascular Medicine: A Special Supplement to The American Journal of Cardiology.
Topics: Aspirin; Cardiovascular Diseases; Fibrinolytic Agents; Humans | 2021 |
Low-dose aspirin was associated with an increased risk of cardiovascular events in patients with chronic kidney disease patients and low bodyweight: results from KNOW-CKD study.
Topics: Aspirin; Body Weight; Cardiovascular Diseases; Glomerular Filtration Rate; Humans; Kidney Function T | 2021 |
Promoting Aspirin Use for Cardiovascular Disease Prevention Among an Adult Internet-Using Population: A Pilot Study.
Topics: Adult; Aspirin; Cardiovascular Diseases; Female; Humans; Internet; Male; Minnesota; Pilot Projects | 2021 |
In at-risk patients without CVD, polypill plus aspirin reduced a composite of major CV events at 4.6 y.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Diseases; Drug Combinations; Human | 2021 |
Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis.
Topics: Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Cross-Sectional Studies; Diabetes Mellitus, | 2021 |
Aspirin Use for Primary Cardiovascular Prevention During the COVID-19 Pandemic.
Topics: Aspirin; Cardiovascular Diseases; COVID-19; Humans; Pandemics; Primary Prevention; Regression Analys | 2021 |
The Reply.
Topics: Aspirin; Cardiovascular Diseases; Humans; Regression Analysis | 2021 |
Polypill in Persons without Cardiovascular Disease.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Humans; Hydrochlorothiazide | 2021 |
Polypill in Persons without Cardiovascular Disease.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Humans; Hydrochlorothiazide | 2021 |
Polypill in Persons without Cardiovascular Disease.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Humans; Hydrochlorothiazide | 2021 |
Polypill in Persons without Cardiovascular Disease.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Humans; Hydrochlorothiazide | 2021 |
Polypill in Persons without Cardiovascular Disease.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Humans; Hydrochlorothiazide | 2021 |
Low-dose aspirin for primary prevention of cardiovascular disease: Trends in use patterns among African American adults in Minnesota, 2015-2019.
Topics: Adult; Aged; Aspirin; Black or African American; Cardiovascular Diseases; Cross-Sectional Studies; F | 2021 |
Screening for Asymptomatic Carotid Artery Stenosis: Recommendation Statement.
Topics: Aged; Aspirin; Asymptomatic Diseases; Cardiovascular Diseases; Carotid Stenosis; Health Behavior; He | 2021 |
Statin but not aspirin treatment is associated with reduced cardiovascular risk in patients with diabetes without obstructive coronary artery disease: a cohort study from the Western Denmark Heart Registry.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Cohort Studies; Coronary Artery Disease; Denmark; | 2022 |
Pragmatic Trials - Need for ADAPTABLE Design.
Topics: Aspirin; Cardiovascular Diseases; Humans; Research Design | 2021 |
Use of Preventive Aspirin Among Older US Adults With and Without Diabetes.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dia | 2021 |
Appropriateness of aspirin prescribing for primary and secondary prevention of cardiovascular disease in type 2 diabetes in different care settings.
Topics: Adult; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Humans; | 2022 |
Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998-2018.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Denmark; Female; Hemorrhage; | 2021 |
Cardiovascular disease and prevention among people living with HIV in South Florida.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Florida; Heart Disease Ris | 2021 |
Aspirin I.V. Loading during Elective Percutaneous Coronary Intervention.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Dose-Respons | 2021 |
Aspirin Dosing in Cardiovascular Disease.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors | 2021 |
Aspirin Dosing in Cardiovascular Disease.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors | 2021 |
Aspirin Dosing in Cardiovascular Disease.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors | 2021 |
Aspirin Dosing in Cardiovascular Disease. Reply.
Topics: Aspirin; Cardiovascular Diseases; Humans | 2021 |
Low-dose aspirin confers a survival benefit in patients with pathological advanced-stage oral squamous cell carcinoma.
Topics: Aspirin; Carcinoma, Squamous Cell; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Mouth | 2021 |
Foreword.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Patient Compliance; Platelet Agg | 2017 |
The genomic potential of the Aspirin in Reducing Events in the Elderly and Statins in Reducing Events in the Elderly studies.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Australia; Biological Specimen Banks; Cardio | 2017 |
Reducing CV risk in diabetes: An ADA update.
Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; | 2017 |
USPSTF recommendations: A 2017 roundup.
Topics: Advisory Committees; Aspirin; Breast Feeding; Cardiovascular Diseases; Colorectal Neoplasms; Dose-Re | 2017 |
Safety and feasibility of liver resection with continued antiplatelet therapy using aspirin.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Cardiovascular Diseases; Feasibility Studies | 2017 |
Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
Topics: Adult; Antirheumatic Agents; Aspirin; Cardiovascular Diseases; Drug Synergism; Drug Therapy, Combina | 2017 |
Low-Dose Aspirin Reduces Breast Cancer Risk in Women with Diabetes: A Nationwide Retrospective Cohort Study in Taiwan.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Cardiovascular Dise | 2017 |
Quantification of bleeding during dental extraction in patients on dual antiplatelet therapy.
Topics: Aspirin; Blood Loss, Surgical; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Dental Ca | 2017 |
Appropriateness of antiplatelet therapy for primary and secondary cardio- and cerebrovascular prevention in acutely hospitalized older people.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Cardiology; Cardiovascular Diseases; Cerebrovascular | 2017 |
Combination cardiovascular drugs.
Topics: Aminobutyrates; Amlodipine; Aspirin; Biphenyl Compounds; Cardiovascular Agents; Cardiovascular Disea | 2017 |
Treatment and outcomes of type 2 myocardial infarction and myocardial injury compared with type 1 myocardial infarction.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2018 |
End-of-life prescribing of aspirin in patients with breast or colorectal cancer.
Topics: Aged; Aged, 80 and over; Aspirin; Breast Neoplasms; Cancer Survivors; Cardiovascular Agents; Cardiov | 2019 |
Tailoring naringenin conjugates with amplified and triple antiplatelet activity profile: Rational design, synthesis, human plasma stability and in vitro evaluation.
Topics: Aspirin; Cardiovascular Diseases; Computer Simulation; Cyclooxygenase 1; Docosahexaenoic Acids; Flav | 2017 |
Aspirin Monotherapy Should Not Be Recommended for Cardioprotection in Patients With Symptomatic Peripheral Artery Disease.
Topics: Aspirin; Cardiovascular Diseases; Clinical Decision-Making; Clopidogrel; Evidence-Based Medicine; Hu | 2017 |
Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Female; Humans; | 2017 |
Aspirin Use and Mortality in Two Contemporary US Cohorts.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cause of Death; Cohort Studies; Female; Humans; Male; Middle | 2018 |
V. Aboyans et al. in response to the article by M. Helfre et al.: Usefulness of a systematic screening of carotid atherosclerosis in asymptomatic people with type 2 diabetes for cardiovascular risk reclassification. Ann Endocrinol (Paris). 2017;78:14-19.
Topics: Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Humans; Risk F | 2017 |
Aspirin for Prevention of Cardiovascular Disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Fibrinolytic Agents; Humans; Male; Middle Aged; Mississippi | 2017 |
Antithrombotic therapy: COMPASS points to low-dose rivaroxaban and aspirin for secondary prevention.
Topics: Aspirin; Cardiovascular Diseases; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Riva | 2017 |
Cardiovascular events associated with proton pump inhibitors.
Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Heart Failure; Humans; Mortality; Myocard | 2017 |
Incidence of colorectal cancer in new users and non-users of low-dose aspirin without existing cardiovascular disease: A cohort study using The Health Improvement Network.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cohort Studies; Colorectal Neoplas | 2017 |
Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; | 2017 |
Contemporary Primary Prevention Aspirin Use by Cardiovascular Disease Risk: Impact of US Preventive Services Task Force Recommendations, 2007-2015: A Serial, Cross-sectional Study.
Topics: Aged; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Clinical Decision-Making; Cross-Secti | 2017 |
Pharmacotherapy: Aspirin discontinuation increases risk of cardiovascular events.
Topics: Aspirin; Cardiovascular Diseases; Cohort Studies; Humans; Platelet Aggregation Inhibitors; Sweden | 2017 |
PFA-100-measured aspirin resistance is the predominant risk factor for hospitalized cardiovascular events in aspirin-treated patients: A 5-year cohort study.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cardiovascular System; Cohort Studies; Drug Resistance; Fema | 2018 |
Review of article: Rivaroxaban with or without aspirin in stable cardiovascular disease. Eikelboom JW, Connolly SJ, Bosch J, et al. for the COMPASS investigators.
Topics: Aspirin; Cardiovascular Diseases; Factor Xa Inhibitors; Humans; Rivaroxaban | 2017 |
Gastrointestinal risk factors and prescribing pattern of antiulcer agents in patients taking low-dose aspirin in Japan.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cardio | 2018 |
Clinical characteristics and outcomes of patients with coronary artery spasm who initially presented with acute myocardial infarction.
Topics: Adult; Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Dise | 2018 |
Risk of non-cardiac surgery after percutaneous coronary intervention with drug-eluting stents.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Drug-Eluting Stents; Female; Humans; In | 2017 |
Changes in cardiovascular care provision after the Affordable Care Act.
Topics: Adult; Aspirin; Cardiovascular Diseases; Cholesterol; Female; Health Care Surveys; Humans; Male; Mas | 2017 |
Should This Patient Receive Aspirin?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Topics: Anticholesteremic Agents; Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; Humans; Hyp | 2017 |
Genetic variants in PPARGC1B and CNTN4 are associated with thromboxane A
Topics: Aged; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Carrier Proteins; Contactins; Europe; | 2018 |
Prior exposure to aspirin in acute coronary syndrome patients: a cardiovascular risk marker or a predictor of adverse outcome? A contemporary data of a national registry.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; | 2018 |
Bladder cancer risk in users of selected drugs for cardiovascular disease prevention.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiotonic Agents | 2019 |
How aspirin prevents cardiovascular diseases.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention; Progn | 2018 |
Rivaroxaban with or without aspirin for prevention of cardiovascular disease.
Topics: Aspirin; Blood Coagulation; Cardiovascular Diseases; Clinical Decision-Making; Evidence-Based Medici | 2018 |
Treatment of Cardiovascular Diseases Among Elderly Residents of Long-term Care Facilities.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2018 |
USPSTF Recommendations: New and Updated in 2016.
Topics: Advisory Committees; Aspirin; Autism Spectrum Disorder; Breast Neoplasms; Cardiovascular Diseases; C | 2017 |
Prognostic Implications of Dual Platelet Reactivity Testing in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Coronary Angiograp | 2018 |
Aspirin is associated with low oral pH levels and antacid helps to increase oral pH.
Topics: Aged; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Female; H | 2018 |
Glycaemic control and cardiovascular risk factor management in patients with diabetes with and without coronary artery disease: insights from the diabetes mellitus status in Canada survey.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Glu | 2016 |
Platelet function testing: dead or alive.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelets; Cardiovascular Diseases; Cell Adhesio | 2018 |
Decision Criterion and Value of Information Analysis: Optimal Aspirin Dosage for Secondary Prevention of Cardiovascular Events.
Topics: Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Data Interpretation, Statistical; Decision | 2018 |
Impact of Depressive Disorder on Access and Quality of Care in Veterans With Prevalent Cardiovascular Disease.
Topics: Age Distribution; Aged; Angina Pectoris; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; | 2018 |
Review: Adding clopidogrel to ASA reduces CV morbidity but increases bleeding in patients at high risk for CV events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2018 |
Cytoreductive treatment patterns among US veterans with polycythemia vera.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cytoreduction Surgical Procedures; | 2018 |
Evaluation of community pharmacists' preparedness for the provision of cardiovascular disease risk assessment and management services: A study with simulated patients.
Topics: Adult; Aspirin; Cardiovascular Diseases; Clinical Competence; Community Pharmacy Services; Female; H | 2019 |
Letter by Yi-tong Regarding Article, "Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study".
Topics: Aspirin; Cardiovascular Diseases; Cohort Studies; Humans; Research Design; Sweden | 2018 |
Response by Oldgren and Sundström to Letter Regarding Article, "Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study".
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cohort Studies; Humans; S | 2018 |
Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease. Associations with laboratory findings, comorbidities, and medications.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Calcium Channel Blockers; Cardiovascu | 2018 |
Targeting Cardiovascular Disease in Patients with Chronic Kidney Disease: Is Primary Prevention with Aspirin Ready for Prime Time? : Editorial to: "Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Di
Topics: Aspirin; Cardiovascular Diseases; Disease Progression; Humans; Primary Prevention; Renal Insufficien | 2018 |
Annual Risk of Major Bleeding Among Persons Without Cardiovascular Disease Not Receiving Antiplatelet Therapy.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Female; Gastrointestinal Hemorrhage; Hemorrhage; Hosp | 2018 |
Aspirin in Primary Prevention of Myocardial Infarction/Angina and Stroke in Hypertensive Patients.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Cardiovascular Diseases; Cross-Sectional S | 2018 |
ASPIRIN FOR PRIMARY PREVENTION IN PATIENTS WITH TYPE 2 DIABETES.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Patient | 2018 |
Lipoprotein(a) and Cardiovascular Risk Prediction Among Women.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In | 2018 |
Weight-adjusted aspirin for cardiovascular prevention.
Topics: Aspirin; Cardiovascular Diseases; Platelet Aggregation Inhibitors; Primary Prevention | 2018 |
Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials.
Topics: Age Factors; Aged; Aspirin; Body Height; Body Weight; Cardiovascular Diseases; Colorectal Neoplasms; | 2018 |
Cessation of dual antiplatelet therapy and cardiovascular events following acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Female; | 2019 |
Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocar | 2018 |
Critical appraisal of the COMPASS trial.
Topics: Aspirin; Cardiovascular Diseases; Humans; Orientation; Rivaroxaban | 2018 |
Aspirin for primary prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention | 2018 |
Patients with Peripheral Artery Disease in the COMPASS Trial.
Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Hemorrhage; Humans; Peripheral Arterial | 2018 |
The effects of cardiovascular risk factor combined anti-platelet therapy and the risk of cerebrovascular events in patients with T2DM in an urban community over 96-months follow-up: The Beijing communities diabetes study 19.
Topics: Aged; Aspirin; Beijing; Cardiovascular Diseases; Cerebrovascular Disorders; Diabetes Mellitus, Type | 2018 |
Aspirin for primary prevention of CVD: a matter of balance.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Primary Prevention | 2018 |
Epidemiology of non-steroidal anti-inflammatory drugs consumption in Spain. The MCC-Spain study.
Topics: Adult; Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Dise | 2018 |
Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Cost-Benefit Analy | 2018 |
Should Aspirin Be Used for Primary Prevention in the Post-Statin Era?
Topics: Aspirin; Cardiovascular Diseases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregati | 2018 |
Aspirin for patients undergoing major lung resections: hazardous or harmless?†.
Topics: Aged; Aspirin; Blood Loss, Surgical; Blood Transfusion; Cardiovascular Diseases; Female; Humans; Lun | 2019 |
Are the benefits of aspirin likely to exceed the risk of major bleeds among people in whom aspirin is recommended for the primary prevention of cardiovascular disease?
Topics: Adult; Aged; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Female; Hemorrhage; Humans; | 2018 |
Preventing cardiovascular disease in New Zealand: making better use of statins but also tobacco control, changing the food supply and other strategies.
Topics: Alcohol Drinking; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Decision Making; Drug C | 2018 |
Budget Impact of Appropriate Low-Dose Aspirin Use for Primary and Secondary Cardiovascular Event Prevention in the Managed Care Setting.
Topics: Aged; Aspirin; Budgets; Cardiovascular Diseases; Cost Savings; Female; Health Care Costs; Humans; Ma | 2018 |
Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS.
Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Platelet | 2018 |
More Evidence to Help Guide Decision Making About Aspirin for Primary Prevention.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clinic | 2018 |
Aspirin for primary prevention of cardiovascular disease events in diabetes: the balancing act?
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Primary Prevention | 2018 |
Long Term Cardiovascular Outcome Based on Aspirin and Clopidogrel Responsiveness Status in Young ST-Elevated Myocardial Infarction Patients.
Topics: Adult; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Resistance; Female; Follow-Up Studies; Hu | 2019 |
Aspirin for Primary Prevention Takes a Hit With New Trial Results.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Middle Aged; Platelet Aggregatio | 2018 |
The remarkable story of a wonder drug, which now comes to an end in the primary prevention setting: say bye-bye to aspirin!
Topics: Aspirin; Cardiovascular Diseases; Humans; Primary Prevention; Randomized Controlled Trials as Topic | 2019 |
Aspirin Use and Cardiovascular Outcome in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Population-Based Cohort Study.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Female; Heart Fai | 2018 |
Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.
Topics: Aged; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Cohort Studies; Diabetes Complicati | 2019 |
Aspirin for primary prevention of cardiovascular disease in diabetes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans | 2019 |
In healthy older adults, aspirin did not affect disability-free survival or CVD but increased death and bleeding.
Topics: Aged; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention | 2019 |
Rivaroxaban (Xarelto) plus aspirin for secondary prevention of cardiovascular events.
Topics: Aspirin; Blood Coagulation; Cardiovascular Diseases; Drug Interactions; Drug Therapy, Combination; F | 2018 |
What have we learned about using aspirin for primary prevention from the ASCEND and ARRIVE trials?
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Clinical Decision-Making; Diabetes Mellitus | 2019 |
Circulating monocyte-platelet aggregates are a robust marker of platelet activity in cardiovascular disease.
Topics: Adult; Aspirin; Biomarkers; Blood Platelets; Cardiovascular Diseases; Case-Control Studies; Female; | 2019 |
Aspirin for primary cardiovascular disease prevention: time to re-evaluate guidelines?
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Humans; Practice Guidelines as Topic; Prima | 2019 |
Aspirin for primary cardiovascular disease prevention: what we know and what we don't know.
Topics: Aspirin; Cardiovascular Diseases; Fibrinolytic Agents; Humans; Primary Prevention | 2019 |
Fixed Dose Combination Formulations: Multilayered Platforms Designed for the Management of Cardiovascular Disease.
Topics: Aspirin; Cardiovascular Diseases; Dosage Forms; Drug Combinations; Drug Compounding; Drug Delivery S | 2019 |
[Aspirin in primary prevention: the ARRIVE, ASCEND and ASPREE aftermath].
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention | 2019 |
Aspirin in people with diabetes: Time to clean up the prescription list?
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Primary Prevention; Risk Assessment | 2019 |
Are We There Yet? Another Milepost in the Journey to Identify Appropriate Candidates for Aspirin Primary Prevention.
Topics: Aspirin; Cardiovascular Diseases; Cohort Studies; Hemorrhage; Humans; Primary Prevention | 2019 |
Predicting Bleeding Risk to Guide Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Cohort Study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Female; Hemo | 2019 |
Goal-driven management of interacting clinical guidelines for multimorbidity patients.
Topics: Algorithms; Aspirin; Cardiovascular Diseases; Decision Support Systems, Clinical; Duodenal Ulcer; Go | 2018 |
Association of Long-term Use of Low-Dose Aspirin as Chemoprevention With Risk of Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Dis | 2019 |
Radical cystectomy under continuous antiplatelet therapy with acetylsalicylic acid.
Topics: Aged; Aspirin; Blood Loss, Surgical; Blood Transfusion; Cardiovascular Diseases; Case-Control Studie | 2019 |
Recruiting general practice patients for large clinical trials: lessons from the Aspirin in Reducing Events in the Elderly (ASPREE) study.
Topics: Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Female; General Practice; Gene | 2019 |
Acetylsalicylic acid on primary prevention of cardiovascular diseases.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention | 2019 |
Aspirin for the Primary Prevention of Cardiovascular Disease: Weighing Up the Evidence.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Hemorr | 2019 |
The New 2019 AHA/ACC Guideline on the Primary Prevention of Cardiovascular Disease.
Topics: American Heart Association; Aspirin; Cardiology; Cardiovascular Diseases; Consensus; Diet, Healthy; | 2020 |
Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; | 2019 |
Aspirin Use for Cardiovascular Disease Prevention in an African American Population: Prevalence and Associations with Health Behavior Beliefs.
Topics: Aged; Aspirin; Black or African American; Cardiovascular Diseases; Diabetes Mellitus; Female; Health | 2019 |
No beneficial effects of aspirin on secondary cardiovascular prevention in patients with type 2 diabetes using non-steroidal anti-inflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, | 2019 |
A precision medicine approach for the primary prevention of cardiovascular events in diabetic patients.
Topics: Aspirin; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus; Humans; Precision Medici | 2019 |
Response to Commentary for 'Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials'.
Topics: Aspirin; Cardiovascular Diseases; Humans; Primary Prevention; Randomized Controlled Trials as Topic | 2019 |
Aspirin for primary cardiovascular prevention: is there a need for risk stratification?
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention; Rando | 2019 |
Editor's presentation.
Topics: Aspirin; Cardiac Rehabilitation; Cardiovascular Diseases; Exercise Therapy; Humans; Preventive Healt | 2019 |
Aspirin for Primary Prevention Reduces Cardiovascular Events, Increases Bleeding Risk.
Topics: Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Platelet Aggregat | 2019 |
Aspirin for primary prevention: It depends.
Topics: Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Humans; Primary Prevention | 2019 |
Effects of Aspirin in the Healthy Elderly.
Topics: Aged; Aspirin; Cardiovascular Diseases; Humans | 2019 |
Effects of Aspirin in the Healthy Elderly.
Topics: Aged; Aspirin; Cardiovascular Diseases; Humans | 2019 |
Effects of Aspirin in the Healthy Elderly.
Topics: Aged; Aspirin; Cardiovascular Diseases; Humans | 2019 |
Effects of Aspirin in the Healthy Elderly. Reply.
Topics: Aged; Aspirin; Cardiovascular Diseases; Humans | 2019 |
Administrative claims data to support pragmatic clinical trial outcome ascertainment on cardiovascular health.
Topics: Administrative Claims, Healthcare; Aged; Aspirin; Cardiovascular Diseases; Electronic Health Records | 2019 |
"Doctor, Should I Keep Taking an Aspirin a Day?"
Topics: Aged; Aspirin; Cardiovascular Diseases; Humans; Male; Platelet Aggregation Inhibitors; Primary Preve | 2019 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Secondary prevention advices after cardiovascular index event: From drug prescription to risk factors control in real world practice.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Blood Pressure; Cardiovascular Diseases; | 2019 |
Review: In adults without CVD, aspirin reduces CV events and increases major bleeding compared with no aspirin.
Topics: Adult; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention | 2019 |
Primary prevention of cardiovascular disease: 2019 and beyond.
Topics: Aspirin; Cardiovascular Diseases; Guidelines as Topic; Healthy Lifestyle; Humans; Hydroxymethylgluta | 2019 |
Rethinking Aspirin for the Primary Prevention of Cardiovascular Disease.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Risk Factors | 2019 |
Should aspirin be used for primary prevention in the healthy elderly?
Topics: Aged; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention | 2019 |
[The Polypill - A Practicable Approach?]
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Drug Combinations; | 2019 |
Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
Topics: Adrenergic beta-Antagonists; Aspirin; Atenolol; Budgets; Cardiovascular Diseases; Cost Savings; Cost | 2019 |
Meta-analysis of Aspirin for Primary Prevention of Cardiovascular Events.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention | 2019 |
Meta-analysis of Aspirin for Primary Prevention of Cardiovascular Events.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention | 2019 |
Meta-analysis of Aspirin for Primary Prevention of Cardiovascular Events-Reply.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention | 2019 |
What Is So Hard About Aspirin for Primary Prevention?
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention | 2019 |
miR-34b-3p May Promote Antiplatelet Efficiency of Aspirin by Inhibiting Thromboxane Synthase Expression.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers, Pharmacological; Blood Platelets; Cardiovascular Disea | 2019 |
Variability in aspirin efficacy: all in the genes?
Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Genetic Variation; Humans; Platelet Aggre | 2019 |
Acetylsalicylic acid for primary prevention of cardiovascular events.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention; Risk | 2019 |
Update on acetylsalicylic acid for primary prevention of cardiovascular disease: Not initiating is not the same thing as discontinuing.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Platelet Aggregation Inhibitors; | 2019 |
Impact of platelet turnover on long-term adverse cardiovascular outcomes in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Diseas | 2019 |
Prevalence of Aspirin Use for Primary Prevention of Cardiovascular Disease in the United States: Results From the 2017 National Health Interview Survey.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardi | 2019 |
Trajectories of Adherence to Low-Dose Aspirin Treatment Among the French Population.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Comorbidity; Datab | 2020 |
Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Drug-Eluting Stents; Europe; Female | 2019 |
2012 Lucian Award: Garret FitzGerald.
Topics: Animals; Aspirin; Awards and Prizes; Biological Clocks; Canada; Cardiology; Cardiovascular Diseases; | 2013 |
The aspirin cardiovascular/gastrointestinal risk calculator--a tool to aid clinicians in practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Aspirin; Cardiovascular Diseases; Dose-Respo | 2013 |
[Is antiplatelet therapy always effective?].
Topics: Adult; Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Middle Aged; Platelet Aggregation; Pla | 2012 |
Comparative effect of clopidogrel plus aspirin and aspirin monotherapy on hematological parameters using propensity score matching.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Erythrocyte Count; F | 2013 |
Protocol for a systematic review of the diagnostic and prognostic utility of tests currently available for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Resistance; Humans; Platelet Aggregati | 2013 |
A Boolean view separates platelet activatory and inhibitory signalling as verified by phosphorylation monitoring including threshold behaviour and integrin modulation.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Iloprost; Integr | 2013 |
Is aspirin intake associated with early age-related macular degeneration? The Singapore Indian Eye Study.
Topics: Adult; Age of Onset; Aged; Asian People; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; | 2013 |
Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Angiotensin Receptor Antagonists; Aspirin; Card | 2013 |
Commentary on the risk and benefit of aspirin therapy: an application of the concepts of unqualified success and unmitigated failure.
Topics: Aspirin; Cardiovascular Diseases; Humans; Randomized Controlled Trials as Topic | 2013 |
Combination therapy to prevent cardiovascular disease: slow progress.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Cost Control; Drug Combinations; Drug Cos | 2013 |
Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.
Topics: Adult; Aged; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Drug | 2013 |
The use, misuse and abuse of dabigatran.
Topics: Advertising; Anticoagulants; Antithrombins; Aspirin; Australia; Benzimidazoles; beta-Alanine; Cardio | 2013 |
Towards a global brief on aspirin.
Topics: Aspirin; Cardiovascular Diseases; Global Health; Health Behavior; Humans; Patient Compliance; Platel | 2013 |
Preserved thrombin-inducible platelet activation in thienopyridine-treated patients.
Topics: Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopido | 2013 |
Confirmation of reported aspirin use in community studies: utility of serum thromboxane B2 measurement.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Monitoring; Fe | 2014 |
Letter: the burden of co-morbidity in the population contributes more to upper gastrointestinal bleeding than aspirin.
Topics: Algorithms; Aspirin; Cardiovascular Diseases; Female; Gastrointestinal Hemorrhage; Humans; Male; Pla | 2013 |
Letter: the burden of co-morbidity in the population contributes more to upper gastrointestinal bleeding than aspirin--authors' reply.
Topics: Algorithms; Aspirin; Cardiovascular Diseases; Female; Gastrointestinal Hemorrhage; Humans; Male; Pla | 2013 |
When is the use of aspirin for CVD prevention in women appropriate?
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cardiovascular | 2014 |
Sex-specific-differences in cardiometabolic risk in type 1 diabetes: a cross-sectional study.
Topics: Adult; Aspirin; Blood Pressure; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Complicat | 2013 |
Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; | 2014 |
Aspirin for primary prevention: no.
Topics: Aspirin; Cardiovascular Diseases; Humans; Primary Prevention | 2013 |
Non-steroidal anti-inflammatory drugs (NSAIDs).
Topics: Administration, Topical; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; As | 2013 |
Guideline-adherent aspirin use in individuals with age-related macular degeneration.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Guideline Adherence; Humans; Incidence; Macular Dege | 2013 |
The association between low-dose aspirin use and the incidence of colorectal cancer: a nationwide cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Dis | 2013 |
Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Pharmacogenetics; Purinergic P2Y Receptor Ant | 2013 |
Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events.
Topics: Aspirin; Bayes Theorem; Blood Platelets; Cardiovascular Diseases; Genes; Humans; Microarray Analysis | 2013 |
Effect of baseline gastrointestinal risk and use of proton pump inhibitors on frequency of discontinuation of aspirin for secondary cardiovascular prevention in United kingdom primary care.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Dose-Response Relat | 2013 |
Toward a genomic definition of aspirin resistance.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Genes; Humans; Proteomics; RNA | 2013 |
Long-term effect of dual antiplatelet treatment after off-pump coronary artery bypass grafting.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Corona | 2013 |
Aspirin for primary prevention: no. Author’s response.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Platelet Aggregation Inhibitors; Primary Pre | 2013 |
The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease.
Topics: Aged; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Drug Combi | 2013 |
Improving cardiovascular disease management in Australia: NPS MedicineWise.
Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Australia; Cardiovascular Diseases; Datab | 2013 |
Polypill. Faulty logic justifies aspirin use for primary prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Coronary Disease; Female; Humans; Male; Platelet Aggregation Inhib | 2013 |
Mortality trends in women and men presenting with acute coronary syndrome: insights from a 20-year registry.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors | 2013 |
Association of gastric mucosal injury severity with platelet function and gastric pH during low-dose aspirin treatment.
Topics: Aspirin; Cardiovascular Diseases; Female; Gastric Mucosa; Gastroscopy; Healthy Volunteers; Humans; H | 2013 |
Commentary: the association between low-dose aspirin use and the incidence of colorectal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Fem | 2013 |
Polypill for cardiovascular disease prevention.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Combinations; Humans; Hydroxymethylg | 2013 |
Polypill for cardiovascular disease prevention--reply.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Combinations; Humans; Hydroxymethylg | 2013 |
Cardiovascular and upper gastrointestinal bleeding consequences of low-dose acetylsalicylic acid discontinuation.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Case-Control Studies; Female; Follow-Up S | 2013 |
Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index in adults: U.S. Preventive Services Task Force recommendation statement.
Topics: Adult; Ankle Brachial Index; Aspirin; Asymptomatic Diseases; Cardiovascular Diseases; Cost of Illnes | 2013 |
More pain for painkillers.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase | 2013 |
[ASA and clopidogrel for urological operations. Perioperative management].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Perioperative Care; Platelet Aggregation Inhi | 2013 |
Aspirin resistance in patients with impaired renal functions.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Drug Resistance; Female; Humans; Male; Middle Aged; P | 2014 |
Aspirin use and aging macula disorder.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Risk Assessment; | 2014 |
Laboratory aspirin resistance and the risk of major adverse cardiovascular events in patients with coronary heart disease on confirmed aspirin adherence.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Patient Compliance; Risk Factors | 2014 |
An aspirin a day? Aspirin use across a spectrum of risk: cardiovascular disease, cancers and bleeds.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Neoplasms; Platelet Aggregation Inhibitors; Pr | 2014 |
How important is it to keep taking the aspirin?
Topics: Aspirin; Cardiovascular Diseases; Female; Gastrointestinal Hemorrhage; Humans; Platelet Aggregation | 2013 |
Low-dose aspirin and upper gastrointestinal bleeding in primary versus secondary cardiovascular prevention: a population-based, nested case-control study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Case-Control Studies; Dose-Respons | 2014 |
Aspirin usage pre-race to prevent cardiac arrest in marathon runners during races.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Primary Preventio | 2013 |
Aspirin responsiveness safely lowers perioperative cardiovascular risk.
Topics: Aged; Aspirin; Brazil; Cardiovascular Diseases; Dose-Response Relationship, Drug; Female; Follow-Up | 2013 |
Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes.
Topics: Aged; Aspirin; Blood Coagulation; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Cytochrome | 2014 |
Fatty acids and TxA(2) generation, in the absence of platelet-COX-1 activity.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Cardiovascular Diseases; Chromatography, Liquid; Cycloox | 2014 |
Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty.
Topics: Adenosine Diphosphate; Aged; Angioplasty; Angioplasty, Balloon, Coronary; Arachidonic Acid; Aspirin; | 2014 |
Antiplatelet therapies: aspirin at the heart of new directions.
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; Platelet Aggregation; Platelet | 2013 |
Feasibility of aspirin continuation during the perioperative period for pulmonary resection in lung cancer patients: a retrospective study at a single institute in Japan.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Feasibility St | 2014 |
Aspirin use and knowledge in the community: a population- and health facility based survey for measuring local health system performance.
Topics: Adult; Aged; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Community Health Services; Com | 2014 |
[I Brazilian Guidelines for cardiovascular prevention].
Topics: Aspirin; Brazil; Cardiovascular Diseases; Evidence-Based Medicine; Female; Health Promotion; Humans; | 2013 |
Cytokines and hs-CRP levels in individuals treated with low-dose aspirin for cardiovascular prevention: a population-based study (CoLaus Study).
Topics: Adult; Aged; Aspirin; Body Composition; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases | 2014 |
Regular use of aspirin for cardiovascular disease prevention in Italy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; | 2014 |
Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes.
Topics: Asian People; Aspirin; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Resista | 2014 |
Implementation of best medical therapy for cardiovascular risk factors in vascular surgery patients treated in a tertiary referral regional unit.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Guideline Adherence; Humans; Hydr | 2014 |
Impaired resolution of inflammation in human chronic heart failure.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Cardiovascular Diseases; Chronic | 2014 |
Public-minded.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Health Behavior; Health Promotion; Humans; Life Style | 2014 |
Impact of polypill difficult to demonstrate from varied studies, say Cochrane reviewers.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Humans; Platele | 2014 |
Aspirin continues to attract research and debate, 115 years after its synthesis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Plate | 2013 |
Cardiovascular and bleeding risk of non-cardiac surgery in patients on antiplatelet therapy.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Hemorrhage; Heparin; Humans; Male; Membrane Proteins | 2014 |
One pill, four questions: what we still need to know about reducing cardiovascular risk with combination therapy.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Humans; Platele | 2014 |
Risk factors for small-bowel mucosal breaks in chronic low-dose aspirin users: data from a prospective multicenter capsule endoscopy registry.
Topics: Aged; Aged, 80 and over; Aspirin; Capsule Endoscopy; Cardiovascular Diseases; Cross-Sectional Studie | 2014 |
A 16-month community-based intervention to increase aspirin use for primary prevention of cardiovascular disease.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Community Health Services; Cross-Sectiona | 2014 |
Million hearts: prevalence of leading cardiovascular disease risk factors--United States, 2005-2012.
Topics: Adolescent; Adult; Aged; Aspirin; Cardiovascular Diseases; Female; Health Promotion; Humans; Hyperch | 2014 |
Evaluation of preventive cardiovascular pharmacotherapy after coronary artery bypass graft surgery.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Canada; Cardio | 2014 |
Aspirin for prevention of cardiovascular events in bipolar disorders.
Topics: Antimanic Agents; Antipsychotic Agents; Aspirin; Bipolar Disorder; Cardiovascular Diseases; Humans | 2014 |
Low-dose aspirin in primary prevention revisited.
Topics: Aspirin; Cardiovascular Diseases; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors | 2014 |
Discrepancies in cardiovascular disease risk calculation affect aspirin use recommendations in patients with diabetes.
Topics: Adolescent; Adult; Aged; Aspirin; Black or African American; Cardiovascular Diseases; Decision Suppo | 2014 |
Use of aspirin for primary and secondary cardiovascular disease prevention in the United States, 2011-2012.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Medication Adherence; Middle Ag | 2014 |
Represcription of low-dose acetylsalicylic acid after discontinuation in patients receiving treatment for secondary cardiovascular disease prevention in the UK.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Comorbidity; Female; Humans; Incidence; M | 2014 |
Polymorphisms in catechol-O-methyltransferase modify treatment effects of aspirin on risk of cardiovascular disease.
Topics: Amino Acid Substitution; Aspirin; Cardiovascular Diseases; Catechol O-Methyltransferase; Female; Fol | 2014 |
Circulating dickkopf-1 in diabetes mellitus: association with platelet activation and effects of improved metabolic control and low-dose aspirin.
Topics: Aged; Arginine; Aspirin; Biomarkers; Cardiovascular Diseases; Case-Control Studies; CD40 Ligand; Cro | 2014 |
[Diclofenac: update on tolerableness and spinal anti-inflammatory action].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood-Brain Barrier; Car | 2014 |
Do clinicians recommend aspirin to patients for primary prevention of cardiovascular disease?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Female; H | 2015 |
Low-dose aspirin for prevention of cardiovascular disease in patients with chronic kidney disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabete | 2014 |
Patterns in the use of low-dose acetylsalicylic acid and other therapies following upper gastrointestinal bleeding.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cardiovascular Diseases; Cohort Studies; Da | 2014 |
Aspirin for primary prevention: a challenging decision.
Topics: Aspirin; Cardiovascular Diseases; Decision Making; Humans; Patient Participation; Platelet Aggregati | 2014 |
Age-related prevalence of diabetes mellitus, cardiovascular disease and anticoagulation therapy use in a urolithiasis population and their effect on outcomes: the Clinical Research Office of the Endourological Society Ureteroscopy Global Study.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cardiovascula | 2015 |
Impact of blood type, functional polymorphism (T-1676C) of the COX-1 gene promoter and clinical factors on the development of peptic ulcer during cardiovascular prophylaxis with low-dose aspirin.
Topics: ABO Blood-Group System; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Case-Control Stud | 2014 |
Evaluation of aspirin use in patients with diabetes receiving care in community health.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Data Collection; Diabe | 2015 |
Contemporary use of dual antiplatelet therapy for preventing cardiovascular events.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male | 2014 |
Community-based interventions to improve outcomes for cardiovascular disease [letter].
Topics: Aspirin; Cardiovascular Diseases; Community Health Services; Female; Humans; Male | 2014 |
Opportunities for improving global cardiovascular quality of care and outcomes.
Topics: American Heart Association; Aspirin; Cardiovascular Diseases; Female; Global Health; Healthcare Disp | 2014 |
Adherence to antiplatelet therapy after percutaneous coronary intervention: a population study in a region of Italy.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Female; Humans; Italy; Longitudinal Stud | 2015 |
Evolving concepts in the primary prevention of cardiovascular disease: aspirin then and now.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors | 2014 |
Dipstick proteinuria is an independent predictor of high on treatment platelet reactivity in patients on clopidogrel, but not aspirin, admitted for major adverse cardiovascular events.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Cohort Stud | 2015 |
Should aspirin be used for the primary prevention of cardiovascular disease in the general population?
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as To | 2015 |
Continuing aspirin therapy during percutaneous nephrolithotomy: unsafe or under-utilized?
Topics: Aged; Aspirin; Blood Loss, Surgical; Blood Transfusion; Cardiovascular Diseases; Cohort Studies; Fem | 2014 |
Fixed-dose combination therapy (polypill) for the prevention of cardiovascular disease.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Humans; Platele | 2014 |
When should aspirin be used for prevention of cardiovascular events?
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation | 2014 |
Percutaneous nephrolithotomy during uninterrupted aspirin therapy in high-cardiovascular risk patients: preliminary report.
Topics: Aged; Aspirin; Blood Transfusion; Body Mass Index; Cardiovascular Diseases; Female; Humans; Kidney C | 2014 |
Antiplatelet therapy: risks and benefits of extended DAPT after stenting.
Topics: Aspirin; Cardiovascular Diseases; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet A | 2015 |
Atherosclerosis: low-dose aspirin failed to improve cardiovascular outcomes.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation | 2015 |
Aspirin for primary prevention: what's a clinician to do?
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Physician's Role; Primary Prevention | 2015 |
Risk of uncomplicated peptic ulcer disease in a cohort of new users of low-dose acetylsalicylic acid for secondary prevention of cardiovascular events.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; | 2014 |
Cons outweigh pros of preventive aspirin in women, study finds.
Topics: Aspirin; Cardiovascular Diseases; Female; Gastrointestinal Hemorrhage; Humans; Neoplasms; Platelet A | 2014 |
[Chinese subgroup analysis of the global anticoagulant registry in the FIELD (GARFIELD) registry in the patients with non-valvular atrial fibrillation].
Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; China; Female; H | 2014 |
A short-term risk-benefit analysis of occasional and regular use of low-dose aspirin in primary prevention of vascular diseases: a nationwide population-based study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Databases, | 2015 |
The role of the cardiologist in the primary prevention of cardiovascular disease with aspirin.
Topics: Aspirin; Cardiovascular Diseases; Female; Gastrointestinal Hemorrhage; Humans; Male; Primary Prevent | 2015 |
[Changes in the diagnosis and treatment of hospitalized patients with acute coronary syndrome from 2006 to 2012 in China].
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; China; Clopidogrel; Female; Hospita | 2014 |
Aspirin Has a Protective Effect Against Adverse Outcomes in Patients with Nonvariceal Upper Gastrointestinal Bleeding.
Topics: Adult; Aged; Aging; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Female; Fibrinolytic Agents | 2015 |
Identifying opportunities to improve aspirin utilization for the primary prevention of cardiovascular disease in a regional health care system.
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Electronic Health Records | 2014 |
Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease.
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; California; Cardiovascular Diseases; | 2015 |
Aspirin for prevention of cardiovascular events in older Japanese patients.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation | 2015 |
Long-term survival following bariatric surgery in the VA health system.
Topics: Aspirin; Bariatric Surgery; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Ob | 2015 |
Aspirin for prevention of cardiovascular events in older Japanese patients--reply.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation | 2015 |
Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy.
Topics: Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Coronary Disease; Cytochrome P | 2015 |
Carotid intima-media thickness measurement promises to improve cardiovascular risk evaluation in head and neck cancer patients.
Topics: Aspirin; Cardiovascular Diseases; Carotid Intima-Media Thickness; Coronary Vessels; Female; Head and | 2015 |
Investigating the effectiveness of different aspirin dosing regimens and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: protocol for a systematic review.
Topics: Aspirin; Cardiovascular Diseases; Clinical Protocols; Dose-Response Relationship, Drug; Drug Adminis | 2015 |
Risk factor burden and control at the time of admission in patients with acute myocardial infarction: Results from the NCDR.
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Dyslipidemias; Female; Guideline Adherenc | 2015 |
Aspirin for Primary Prevention of Cardiovascular Disease and Cancer. A Benefit and Harm Analysis.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; | 2015 |
[The ISAR-SAFE study].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Disease; Coronary Restenosis; Drug Administr | 2015 |
Preventive Effects of Aspirin on Cardiovascular Complications in Prostate Cancer Cases after Endocrinotherapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Car | 2015 |
Soluble CD40 Ligand in Aspirin-Treated Patients Undergoing Cardiac Catheterization.
Topics: Aspirin; Cardiac Catheterization; Cardiovascular Diseases; CD40 Ligand; Clopidogrel; Female; Humans; | 2015 |
Aspirin resistance and its importance.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Platelet | 2015 |
[A comprehensive understanding of compliance with aspirin therapy].
Topics: Aspirin; Cardiovascular Diseases; Humans; Medication Adherence; Platelet Aggregation Inhibitors | 2015 |
Aspirin response: Differences in serum thromboxane B2 levels between clinical studies.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Cardiovascular Diseases; Chromatography, Liquid; Enzyme- | 2016 |
Utility of VerifyNow for Point-of-Care Identification of an Aspirin Effect Prior to Emergency Cardiac Surgery.
Topics: Aspirin; Cardiovascular Diseases; Emergencies; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male | 2015 |
Concurrent Use of Low-Dose Aspirin and Omega-3 Fatty Acids and Risk of Upper Gastrointestinal Complications: A Cohort Study with Nested Case-Control Analysis.
Topics: Aged; Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Synergism; Drug Thera | 2016 |
Prevention of cardiovascular events with antiplatelet treatment: does time of intake matter for aspirin and ADP receptor blockers?
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Circadian Rhythm; Drug Administration Schedule; H | 2016 |
Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries?
Topics: Africa; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Developing C | 2015 |
US panel narrows recommendations for low dose aspirin for cardiovascular disease prevention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Evidence-Based Medicine; H | 2015 |
Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancer.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; | 2015 |
Aspirin resistance in the era of personalized medicine: Should we not take it personally?
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Resistance; Humans; Platelet Aggre | 2015 |
"Risky business": periprocedural aspirin use for colonoscopy with polypectomy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colonic Polyps; Colonosco | 2015 |
Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Argentina; Aspirin; Banglades | 2016 |
The Implication of the Polymorphisms of COX-1, UGT1A6, and CYP2C9 among Cardiovascular Disease (CVD) Patients Treated with Aspirin.
Topics: Adolescent; Adult; Aged; Asian People; Aspirin; Cardiovascular Diseases; Cyclooxygenase 1; Cytochrom | 2015 |
Low-dose acetylsalicylic acid for primary prevention of cardiovascular disease: Do not misinterpret the recommendations.
Topics: Aspirin; Cardiovascular Diseases; Family Practice; Humans; Platelet Aggregation Inhibitors; Practice | 2015 |
Evening intake of aspirin is associated with a more stable 24-h platelet inhibition compared to morning intake: a study in chronic aspirin users.
Topics: Adolescent; Adult; Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Female; Humans; Male; Mi | 2016 |
My approach to the use of aspirin.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Risk Adjustment; Secondar | 2016 |
A long-term risk-benefit analysis of low-dose aspirin in primary prevention.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Databases, Factual; Female; Gastro | 2016 |
Antiplatelet effects of aspirin in chronic kidney disease patients.
Topics: Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Blood Platelets; Cardiovascular Diseases; Cross- | 2016 |
Aspirin in the prevention of cardiovascular events in patients with diabetes.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Drug Admin | 2016 |
Use of cardiovascular medicines in newly treated type 2 diabetes patients: A retrospective cohort study in general practice.
Topics: Administrative Claims, Healthcare; Adult; Age Factors; Aged; Aged, 80 and over; Antihypertensive Age | 2016 |
Validation of low-dose aspirin prescription data in The Health Improvement Network: how much misclassification due to over-the-counter use?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Databases, Factual; Female; Humans | 2016 |
Population Trends in Aspirin Use for Cardiovascular Disease Prevention 1980-2009: The Minnesota Heart Survey.
Topics: Adult; Age Factors; Aged; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; | 2015 |
Cost-Effectiveness of a Statewide Campaign to Promote Aspirin Use for Primary Prevention of Cardiovascular Disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Female; Health Promotion; Humans; Mal | 2015 |
Dual platelet inhibition in cases of severe retrobulbar hemorrhage following retrobulbar and peribulbar anesthesia.
Topics: Aged; Anesthesia, Local; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Cardiac Surgical Proc | 2015 |
Heart-Healthy Nutrition Approach for Chronic Kidney Disease Patients.
Topics: Aspirin; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cardiovascular System; Cholesterol; | 2016 |
Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Captopril; Cardiovascular Diseases; Diabeti | 2016 |
Risk of prostate cancer in low-dose aspirin users: A retrospective cohort study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebr | 2016 |
Low-dose aspirin for prevention of cardiovascular disease in patients on hemodialysis: A 5-y prospective cohort study.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors | 2016 |
Decision-making in an era of cancer prevention via aspirin: New Zealand needs updated guidelines and risk calculators.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clinical Decision-M | 2016 |
Ask the doctors. I am a 78-year-old woman and have atrial fibrillation. My physician prescribed me Coumadin. Last month aspirin was added to my regimen. Is it okay to take both of these drugs together?
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Female; Humans; Warfarin | 2013 |
How to translate clinical trial results into gain in healthy life expectancy for individual patients.
Topics: Age Distribution; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Decision Support Techniqu | 2016 |
Statin and Aspirin Use Among Hispanic and Latino Adults at High Cardiovascular Risk: Findings From the Hispanic Community Health Study/Study of Latinos.
Topics: Adolescent; Adult; Aged; Aspirin; Cardiovascular Diseases; Central America; Cuba; Dominican Republic | 2016 |
[The present status of aspirin use for primary prevention among hypertensive outpatients in China].
Topics: Aspirin; Cardiovascular Diseases; China; Cross-Sectional Studies; Fibrinolytic Agents; Hospitals; Hu | 2016 |
Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; | 2016 |
Proton pump inhibitors and other disease-based factors in the recurrence of adverse cardiovascular events following percutaneous coronary angiography: A long-term cohort.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Drug Combinations; Female; Foll | 2016 |
A Step Ahead in Secondary Prevention of Cardiovascular Risk. Consensus Document on Clinical Use of the Polypill.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Drug Combi | 2016 |
Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force.
Topics: Adult; Aged; Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Decisi | 2016 |
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.
Topics: Adult; Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Fibrinolytic | 2016 |
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.
Topics: Adult; Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Fibrinolytic | 2016 |
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.
Topics: Adult; Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Fibrinolytic | 2016 |
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.
Topics: Adult; Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Fibrinolytic | 2016 |
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: Recommendations From the U.S. Preventive Services Task Force.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Aspirin; Cardiovascular Diseases; Cerebral Hemorrha | 2016 |
Aspirin for Disease Prevention: Public Policy or Personal Choice?
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention; Publi | 2016 |
The polypill: an emerging treatment alternative for secondary prevention of cardiovascular disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Diseases; Drug Combinations; Fibri | 2016 |
US panel recommends low dose aspirin to prevent cardiovascular disease and colorectal cancer.
Topics: Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Dose-Response Rel | 2016 |
Cardiovascular events occur independently of high on-aspirin platelet reactivity and residual COX-1 activity in stable cardiovascular patients.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Cardiovascular Diseases; Cohort Studies; C | 2016 |
Dual anti-platelet therapy after coronary drug-eluting stent implantation and surgery-associated major adverse events.
Topics: Aged; Aspirin; Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Drug-Eluting Stents; F | 2016 |
Microparticle Shedding by Erythrocytes, Monocytes and Vascular Smooth Muscular Cells Is Reduced by Aspirin in Diabetic Patients.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Cell-Derived Microparticles; Diabete | 2016 |
Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovas | 2016 |
Updated Meta-Analysis of Aspirin in Primary Prevention of Cardiovascular Disease.
Topics: Aspirin; Cardiovascular Diseases; Humans; Primary Prevention | 2016 |
Risks of Bleeding Recurrence and Cardiovascular Events With Continued Aspirin Use After Lower Gastrointestinal Hemorrhage.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Female; Gastrointes | 2016 |
Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: a Markov modelling study.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel B | 2016 |
Topics: Aspirin; Atherosclerosis; Brazil; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitu | 2014 |
Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study.
Topics: Adult; Aspirin; Cardiovascular Diseases; Cause of Death; Female; Humans; Incidence; Italy; Kaplan-Me | 2016 |
High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction.
Topics: Acute Disease; Adenosine; Aspirin; Blood Platelets; Brain Ischemia; Cardiovascular Diseases; Clopido | 2016 |
Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease: Shared Decision Making in Clinical Practice.
Topics: Age Factors; Aged; Algorithms; Aspirin; Cardiovascular Diseases; Cause of Death; Colorectal Neoplasm | 2016 |
Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations.
Topics: Adenosine; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cause of Death; Clinical Trial | 2016 |
The association between regular use of aspirin and the prevalence of prostate cancer: Results from the National Health Interview Survey.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cross-Sectional St | 2016 |
Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cerebral Hemorrhage; Female; Heart Failure; Humans; Incidenc | 2016 |
Dispensing data captures individual-level use of aspirin for cardiovascular disease prevention, despite availability over-the-counter.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Databases, Pharmaceutical; Drug Prescript | 2016 |
Individualised benefit-harm balance of aspirin as primary prevention measure - a good proof-of-concept, but could have been better….
Topics: Aspirin; Cardiovascular Diseases; Humans; Neoplasms; Primary Prevention | 2016 |
Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Cos | 2017 |
Proton pump inhibitor use by aspirin-treated coronary artery disease patients is not associated with increased risk of cardiovascular events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cause of Death; Female; Follow-Up | 2016 |
Aspirin and proton-pump inhibitors: interpreting the interplay.
Topics: Aspirin; Cardiovascular Diseases; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; H | 2016 |
[CHARISMA study].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Embolism; Female; Humans; Male; Middle Aged; Plaque, | 2016 |
Does Early Resumption of Low-Dose Aspirin After Evacuation of Chronic Subdural Hematoma With Burr-Hole Drainage Lead to Higher Recurrence Rates?
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Craniotomy; Drainage; Female; Hematoma, S | 2016 |
Aspirin for Primary and Secondary Prevention of Cardiovascular Disease.
Topics: Aged; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; Mid | 2016 |
Systems Pharmacogenomics Finds RUNX1 Is an Aspirin-Responsive Transcription Factor Linked to Cardiovascular Disease and Colon Cancer.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Line, Tumor; Colonic Neoplasms; Core Binding | 2016 |
Impact of genetic variation in the 5-HT transporter and receptor on platelet function in patients with stable CAD taking aspirin.
Topics: Amino Acid Sequence; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cardiovascul | 2016 |
Comparison of preoperative continuation and discontinuation of aspirin in patients undergoing total hip or knee arthroplasty.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Blood Loss, Surgical; Cardiovascular Diseases; Femal | 2016 |
Compliance with USPSTF recommendations on aspirin for prevention of cardiovascular disease in men.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Gastrointestinal Hemorrhage; Guidel | 2016 |
Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Risk Factors | 2016 |
Using Large-Scale Linkage Data to Evaluate the Effectiveness of a National Educational Program on Antithrombotic Prescribing and Associated Stroke Prevention in Primary Care.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; General Practitioners; Humans; Information Storage a | 2016 |
Acetylsalicylic Acid Resistance After Simultaneous Pancreas-Kidney Transplantation.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Drug Resistance; Female; Humans; Kidney Transplantati | 2016 |
[Towards new targets in the treatment of hypertension?]
Topics: Aged; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2016 |
Aspirin reduces cardiovascular events in primary prevention of cardiovascular disease but at a near equivalent risk of increased bleeding.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Primary Preve | 2016 |
Review: In adults with diabetes, aspirin does not prevent CV events compared with placebo.
Topics: Adult; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors | 2016 |
Does low-dose aspirin use for cardiovascular disease prevention reduce colorectal cancer deaths? A comparison of two cohorts in the Florence district, Italy.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; | 2018 |
Different impact of aspirin on renal progression in patients with predialysis advanced chronic kidney disease with or without previous stroke.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cause of Death; Comorbidity; Female; Hematinics; Hemorrhage; | 2017 |
Gastric and renal effects of COX-2 selective and non-selective NSAIDs in rats receiving low-dose aspirin therapy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Creatinine; Cycl | 2016 |
The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and Older.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; | 2016 |
Aspirin in prevention of cardiovascular events. Dr. Gordon Guyatt in an interview with Dr. Roman Jaeschke.
Topics: Aspirin; Cardiovascular Diseases; Humans; Primary Prevention | 2016 |
Mortality in patients who discontinue low-dose acetylsalicylic acid therapy after upper gastrointestinal bleeding.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Cohort S | 2017 |
Shared Decision Making Regarding Aspirin in Primary Prevention of Cardiovascular Disease.
Topics: Aspirin; Cardiovascular Diseases; Decision Making; Humans; Platelet Aggregation Inhibitors; Primary | 2016 |
Shared Decision Making Regarding Aspirin in Primary Prevention of Cardiovascular Disease-Reply.
Topics: Aspirin; Cardiovascular Diseases; Decision Making; Humans; Platelet Aggregation Inhibitors; Primary | 2016 |
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer.
Topics: Age Factors; Aspirin; Cardiovascular Diseases; Clinical Decision-Making; Colorectal Neoplasms; Femal | 2016 |
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: Recommendation Statement.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colorectal N | 2016 |
Polypill: Can its Potential Enhancement of Efficacy Trigger New Interest?
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Combinations; | 2016 |
[Aspirin use for the primary prevention of cardiovascular disease and cancer: reflections on the 2016 U.S. Preventive Services Task Force recommendation statement].
Topics: Aspirin; Cardiovascular Diseases; Humans; Neoplasms; Platelet Aggregation Inhibitors; Primary Preven | 2016 |
Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention.
Topics: Aspirin; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cardiovascular Diseases; Cholangiocarcinoma; | 2017 |
Use of statins and aspirin to prevent cardiovascular disease among HIV-positive patients. A survey among Italian HIV physicians.
Topics: Aspirin; Cardiovascular Diseases; Data Collection; HIV Infections; Humans; Hydroxymethylglutaryl-CoA | 2017 |
Association between the use of proton pump inhibitors and cardiovascular events: A note of caution.
Topics: Aspirin; Cardiovascular Diseases; Gastroesophageal Reflux; Humans; Proton Pump Inhibitors; Proton Pu | 2017 |
RE: Risks of Bleeding Recurrence and Cardiovascular Events With Continued Aspirin Use After Lower Gastrointestinal Hemorrhage.
Topics: Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; Humans; Platelet Aggregation Inhibito | 2017 |
Burr-Hole Drainage for Chronic Subdural Hematoma Under Low-Dose Acetylsalicylic Acid: A Comparative Risk Analysis Study.
Topics: Aged; Aspirin; Cardiovascular Diseases; Decompressive Craniectomy; Dose-Response Relationship, Drug; | 2017 |
Another Go Around for Aspirin: The Gut Is the Heart of the Matter this Time.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colonic Neopl | 2017 |
The budget impact of using enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg to prevent recurrent cardiovascular events.
Topics: Adult; Aged; Aspirin; Budgets; Cardiovascular Diseases; Clopidogrel; Drug Combinations; Female; Gast | 2017 |
Risk and Benefit Information and Use of Aspirin.
Topics: Aspirin; Cardiovascular Diseases; Platelet Aggregation Inhibitors; Risk; Risk Factors | 2017 |
[Aspirin for primary cardiovascular disease prevention - an update].
Topics: Aspirin; Cardiovascular Diseases; Guidelines as Topic; Humans; Meta-Analysis as Topic; Platelet Aggr | 2017 |
Aspirin for the Prevention of Cardiovascular Disease and Colorectal Cancer: New Recommendations from the USPSTF.
Topics: Aged; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Humans; Middle Aged; Platelet Aggregat | 2017 |
Overview of advances in cardiovascular disease treatment and prevention: the evolving role of antiplatelet therapy.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clinical Protocols; Clopidogrel; Drug Therapy; Female; Human | 2008 |
Aspirin for primary prevention of coronary heart disease: using the Framingham Risk Score to improve utilization in a primary care clinic.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cohort Studies; Fem | 2008 |
Re-examining the cardiovascular therapeutic benefits of aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Evidence-Based Medicine; | 2008 |
An assessment of the joint associations of aspirin and statin use with C-reactive protein concentration.
Topics: Aged; Aspirin; C-Reactive Protein; Cardiovascular Diseases; Cross-Sectional Studies; Dose-Response R | 2008 |
Relationship between haemoglobin A1C values and recurrent cardiac events: A retrospective, longitudinal cohort study.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascula | 2008 |
Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease.
Topics: Adult; Aged; Aspirin; beta Carotene; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Diabe | 2008 |
Aspirin resistance: myth or major problem?
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Resistance; Huma | 2008 |
Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2009 |
Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; | 2008 |
Serum uric acid level reduction, cardiovascular outcome, and mortality: comment on the article by Ioachimescu et al.
Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; H | 2008 |
Interrelationships among the MTHFR 677C>T polymorphism, migraine, and cardiovascular disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Genetic Predisposition to Disease; Humans; Methylene | 2008 |
Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Disease; Cost-Benefit Analysis; Dose-Response Relat | 2008 |
Variability in platelet response to a single daily dose of 150 mg enteric coated aspirin in a high risk population.
Topics: Aged; Aspirin; Bleeding Time; Cardiovascular Diseases; Developing Countries; Dose-Response Relations | 2008 |
More evidence standard preventative measures can prevent COX-2 inhibitor-induced infarctions.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibito | 2008 |
Age threshold for vascular prophylaxis by aspirin in patients without diabetes.
Topics: Adult; Age Factors; Aged; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Female; Gastroi | 2008 |
No easy way to identify aspirin resistance.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Platelet Aggregation Inhibitors | 2008 |
Life saving early and immediate aspirin: too little too late.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors | 2008 |
'Aspirin resistance' or treatment non-compliance: which is to blame for cardiovascular complications?
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Myocardial Infarction; Platelet Aggregati | 2008 |
Aspirin for all over 50 revisited.
Topics: Aged; Aspirin; Cardiovascular Diseases; Humans; Middle Aged; Platelet Aggregation Inhibitors; Primar | 2008 |
Chemoprevention and Barrett's esophagus: decisions, decisions.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyc | 2008 |
Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyc | 2008 |
Associations of plasma carotenoids with risk factors and biomarkers related to cardiovascular disease in middle-aged and older women.
Topics: Aged; Aspirin; Biomarkers; Cardiovascular Diseases; Carotenoids; Cross-Sectional Studies; Female; Fr | 2008 |
Usefulness of hypertensive blood pressure response during a single-stage exercise test to predict long-term outcome in patients with peripheral arterial disease.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Blood Pressure; Cardiovascular Diseases; Cause of Death; | 2008 |
Utility of the PFA-100 instrument and the novel multiplate analyzer for the assessment of aspirin and clopidogrel effects on platelet function in patients with cardiovascular disease.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel | 2009 |
Anticoagulant and/or antiplatelet treatment in patients with atrial fibrillation after percutaneous coronary intervention. A single-center experience.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspir | 2008 |
Biochemical evaluation of the antiplatelet effect of aspirin in patients at different levels of cardiovascular risk.
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Enzyme-Linked Immunosorbent Assay; Female | 2008 |
The impact of preinjury antiplatelet and anticoagulant pharmacotherapy on outcomes in elderly patients with hemorrhagic brain injury.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Brain Hemorrhage, Traumatic; Cardiovascular Diseases; Ca | 2008 |
[Thrombocyte aggregation inhibitor after surgery for an abdominal aortic aneurysm].
Topics: Aortic Aneurysm, Abdominal; Arteriosclerosis; Aspirin; Blood Vessel Prosthesis Implantation; Cardiov | 2008 |
Aspirin for prevention of cardiovascular events.
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Humans | 2008 |
News of the polypill.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cardiovascular Disea | 2008 |
Aspirin, NSAIDs, and cardiovascular risk: is there a link?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors | 2008 |
Aspirin for primary prevention of cardiovascular events in diabetes: still an open question.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Platelet | 2008 |
Prognostic value of hypotensive blood pressure response during single-stage exercise test on long-term outcome in patients with known or suspected peripheral arterial disease.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Blood Pressure; Cardiovascular Diseases; Exercise Test; | 2008 |
Reflections on the regulation of the Polypill.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agent | 2009 |
Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
Topics: Aged; Aged, 80 and over; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Canada; Cardi | 2009 |
Challenges of designing trials for the primary prevention of stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Humans; National Institute of Neurologica | 2009 |
The effects of clopidogrel on elderly traumatic brain injured patients.
Topics: Aged; Aspirin; Brain Damage, Chronic; Brain Injuries; Cardiovascular Diseases; Case-Control Studies; | 2008 |
Ethical considerations in relation to aspirin prophylaxis.
Topics: Age Factors; Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Ethics, Medical; Ga | 2008 |
Incidence of aspirin resistance and its relationship with cardiovascular risk factors and graft function in renal transplant recipients.
Topics: Adolescent; Adult; Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Female; Human | 2008 |
Another view on prasugrel.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Platelets; Cardiovascu | 2009 |
Improving outcomes with antiplatelet therapies in percutaneous coronary intervention and stenting.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug-Eluting Stents; | 2009 |
Primary prevention of cardiovascular events in diabetes: is there a role for aspirin?
Topics: Antioxidants; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Humans; Pe | 2009 |
Platelet function analysis: at the edge of meaning.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cell Adhesi | 2009 |
Barriers to clopidogrel adherence following placement of drug-eluting stents.
Topics: Adult; Aspirin; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Drug-Eluting Stents; Exanthema | 2009 |
["Diabetes in Germany"(DIG) study. A prospective 4-year-follow-up study on the quality of treatment for type 2 diabetes in daily practice].
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Diabetes | 2009 |
Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2009 |
Treatment choices and patterns in migraine patients with and without a cardiovascular risk profile.
Topics: Adolescent; Adult; Aged; Aspirin; Cardiovascular Diseases; Drug Combinations; Ergotamine; Female; Hu | 2009 |
By the way, doctor. I read about statin having anti-inflammatory effects and lowering CRP levels. So why are we now being told that some people need to take two anti-inflammatories--aspirin and a statin?
Topics: Anti-Inflammatory Agents; Aspirin; C-Reactive Protein; Cardiovascular Diseases; Humans; Hydroxymethy | 2009 |
Rosuvastatin in patients with elevated C-reactive protein.
Topics: Aspirin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Female; Fluorobenzenes; Guideline | 2009 |
[Does JUPITER change the daily routine of our practice?].
Topics: Adult; Age Factors; Aged; Aspirin; C-Reactive Protein; Cardiovascular Diseases; Female; Humans; Hydr | 2009 |
[Acetylsalicylic acid does not prevent cardiovascular diseases in diabetic patients].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2 | 2009 |
Summaries for patients. What aspirin dose is safest and most effective for preventing heart disease?
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2009 |
Summaries for patients. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2009 |
Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Femal | 2009 |
Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement.
Topics: Age Factors; Aged; Aspirin; Brain Ischemia; Cardiovascular Diseases; Cost of Illness; Female; Gastro | 2009 |
Aspirin for prevention and treatment of cardiovascular disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhi | 2009 |
PCI, stents, clopidogrel and non-cardiac surgery.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggr | 2009 |
Does aspirin use reduce cardiovascular risk in diabetes?
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Platelet Aggre | 2009 |
Who should take aspirin as CVD primary preventive?
Topics: Age Factors; Aged; Aspirin; Cardiovascular Diseases; Female; Humans; Middle Aged; Platelet Aggregati | 2009 |
Dual antiplatelet drug resistance is a risk factor for cardiovascular events after percutaneous coronary intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Drug Resistance; Female; Humans | 2009 |
Use of antithrombotic drugs and the presence of cerebral microbleeds: the Rotterdam Scan Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain; Cardiovascular Diseases; Causality; Cerebra | 2009 |
Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women.
Topics: Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Fasting; Female; Humans; Hyperch | 2009 |
Aspirin resistance testing not ready for "prime time".
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Platelet Aggregation Inhibitors | 2009 |
Aspirin "resistance" and its impact on cardiovascular morbidity and mortality: it is real, clinically relevant and should be measured.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Platelet Aggregation Inhibitors | 2009 |
Aspirin and secondary prevention in peripheral artery disease: a perspective for the early 21st century.
Topics: Aspirin; Cardiovascular Diseases; Humans; Peripheral Vascular Diseases; Platelet Aggregation Inhibit | 2009 |
Low-dose aspirin is a prominent cause of bleeding ulcers in patients who underwent emergency endoscopy.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cerebrovascular Dis | 2009 |
Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Aspirin; Cardiovascular Diseases; Case-Control Studi | 2009 |
Evidence guided antiplatelet treatment: time to move from bench to bedside.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiology; Cardiovascular Diseases; Clopidogrel; | 2009 |
Acknowledging a failed strategy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2009 |
Antiplatelet effects of n-3 polyunsaturated fatty acids compared with aspirin: a pilot study with whole-blood aggregometry.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Cardiovascular Diseases; Co | 2009 |
Should aspirin be used for the primary prevention of cardiovascular disease in people with diabetes?
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; | 2009 |
Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Databases, Factual; Drug | 2009 |
Clinical and laboratory factors associated with shear-dependent platelet hyper-reactivity in patients on chronic aspirin therapy.
Topics: Adenosine Diphosphate; Aspirin; Biomarkers; Blood Platelets; Cardiovascular Diseases; Cohort Studies | 2010 |
Cerebral microbleeds: evidence of heightened risk associated with aspirin use.
Topics: Aspirin; Biomarkers; Cardiovascular Diseases; Cerebral Arteries; Cerebral Hemorrhage; Cohort Studies | 2009 |
Use of cardioprotective medications in kidney transplant recipients.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2009 |
Letter by cattaneo regarding article, "incomplete inhibition of thromboxane biosynthesis by acetylsalicylic Acid: determinants and effect on cardiovascular risk".
Topics: Aged; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Foll | 2009 |
Aspirin for the masses.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention | 2009 |
Myocardial perfusion imaging and cardiovascular outcomes in a cancer population.
Topics: Age Factors; Aged; Aspirin; Atrial Fibrillation; Cardiovascular Agents; Cardiovascular Diseases; Fem | 2009 |
Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive Protein; Cardiovascular Diseases; Chole | 2009 |
Aspirin for primary prevention. Consensus is urgently required.
Topics: Aspirin; Cardiovascular Diseases; Consensus; Fibrinolytic Agents; Humans | 2009 |
Premature preoperative discontinuation of antiplatelet drug therapy in cardiovascular risk patients: a preliminary study on the role of P2Y12 receptor monitoring.
Topics: Adult; Aged; Aspirin; Blood Loss, Surgical; Cardiovascular Diseases; Case-Control Studies; Cell Adhe | 2010 |
[The concept of aspirin "resistance": mechanisms and clinical relevance].
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Resistance; Huma | 2009 |
[Anti-platelet treatment for all diabetic patients?].
Topics: Aged; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Complications; Female; Hum | 2010 |
Using aspirin to prevent cardiovascular disease in adults.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Female; Fibrinolytic Agents; Humans; Male; Middle Age | 2009 |
Common drugs can harm elderly patients.
Topics: Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Cerebral Hemorrhage; Drug Therapy, Combinati | 2009 |
Aspirin increases mortality in diabetic patients without cardiovascular disease: a Swedish record linkage study.
Topics: Age Factors; Aged; Aspirin; Cardiovascular Diseases; Diabetes Complications; Female; Gastrointestina | 2009 |
New guidelines refine aspirin prescription. Task force offers recommendation for women and guidance on dosage.
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Female; Humans; Male; Platelet Aggregat | 2009 |
Weighing benefits and risks--the FDA's review of prasugrel.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Causality; Clini | 2009 |
Aspirin in the primary prevention of vascular disease.
Topics: Aspirin; Cardiovascular Diseases; Humans; Meta-Analysis as Topic; Platelet Aggregation Inhibitors; P | 2009 |
Aspirin for prevention of stroke and cardiovascular events among patients with peripheral artery disease.
Topics: Aspirin; Cardiovascular Diseases; Dipyridamole; Humans; Peripheral Vascular Diseases; Platelet Aggre | 2009 |
Should aspirin be used for the primary prevention of cardiovascular disease in people with diabetes?
Topics: Age Distribution; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascula | 2009 |
Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Biomarkers; Blood Pressure; Cardio | 2009 |
Induced cardiovascular procedural costs and resource consumption patterns after coronary artery calcium screening: results from the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) study.
Topics: Aged; Aspirin; Calcinosis; Cardiovascular Diseases; Coronary Angiography; Coronary Artery Disease; C | 2009 |
Comparison of bleeding complications with omega-3 fatty acids + aspirin + clopidogrel--versus--aspirin + clopidogrel in patients with cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combi | 2009 |
[Use of aspirin for primary prevention of cardiovascular events in diabetic patients--is it justified?].
Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus | 2009 |
Responses to USPSTF guideline on aspirin for prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention; Risk | 2009 |
Responses to USPSTF guideline on aspirin for prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention; Risk | 2009 |
A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Databases, Factual; Drug Cos | 2009 |
Thrombophilic factors do not predict outcomes in renal transplant recipients under prophylactic acetylsalicylic acid.
Topics: Acute Disease; Adult; Aspirin; Cardiovascular Diseases; Cohort Studies; Creatinine; Female; Fibrinol | 2010 |
The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy.
Topics: Adult; Aged; Aspirin; Blood Glucose; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Diabetes | 2009 |
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2009 |
Lack of benefits for prevention of cardiovascular disease with aspirin therapy in type 2 diabetic patients--a longitudinal observational study.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Female; Fo | 2009 |
Aspirin for primary prevention of cardiovascular disease?
Topics: Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Humans; Meta-Analysis as Topic; Off-Label U | 2009 |
Aspirin for the primary prevention of vascular events?
Topics: Adult; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Humans; Middle Aged; Primary Prevent | 2009 |
Aspirin is associated with reduced cardiovascular and all-cause mortality in type 2 diabetes in a primary prevention setting: the Fremantle Diabetes study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Australia; Body Mass Index; Cardiovascular D | 2010 |
Another look at the results of the JUPITER trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Body Mass Index; C-Reactive Prot | 2009 |
Aspirin withdrawal in acute peptic ulcer bleeding: are we harming patients?
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Gastrointestinal Hemorrhage; Humans; Pe | 2010 |
Summaries for patients. Benefits and risks of continuing aspirin in patients with peptic ulcer bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster | 2010 |
The right oral antithrombotics in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; He | 2009 |
Do the current medical and economic times dictate the need for the "polypill"?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Ant | 2009 |
Aspirin therapy in women: back to the ABCs.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Platelet Aggregation Inhibitors; Risk Factors; Wom | 2009 |
Aspirin use, dose, and clinical outcomes in postmenopausal women with stable cardiovascular disease: the Women's Health Initiative Observational Study.
Topics: Aged; Angina Pectoris; Aspirin; Cardiovascular Diseases; Death, Sudden, Cardiac; Dose-Response Relat | 2009 |
Frontiers in platelet inhibition.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Models, Biological; Platelet Aggregation Inhi | 2009 |
[Influence of anticoagulants on the appearance of chronic subdural hematoma].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cardiovascular Diseases; Chronic Disease; C | 2009 |
[Clinical trials meta-analysis doubting about the position of aspirin in primary prevention of the cardiovascular diseases].
Topics: Aspirin; Cardiovascular Diseases; Humans; Meta-Analysis as Topic; Primary Prevention | 2009 |
An aspirin a day: are we barking up the wrong willow tree?
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Therapy, Com | 2010 |
Benefit assessment in Germany.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Comparative Effectiveness Research; Germany; Governme | 2010 |
[Aspirin in first prevention for cardiovascular disease:present and future].
Topics: Aspirin; Cardiovascular Diseases; Humans; Primary Prevention | 2009 |
Serum thromboxane B2 compared to five other platelet function tests for the evaluation of aspirin effect in stable cardiovascular disease.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Pressure; Cardiovascular Diseases; Case-Control Studi | 2010 |
Inconsistent trial assessments by the National Institute for Health and Clinical Excellence and IQWiG: standards for the performance and interpretation of subgroup analyses are needed.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; England; Evidence-Based Medicine; Germany; Humans; In | 2010 |
[Cardiac workup after cerebral ischemia. Consensus paper of the Working Group on Heart and Brain of the German Cardiac Society and German Stroke Society].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cardiovascular Diseases; Clopidogrel; | 2010 |
Are at-risk New Zealand women receiving recommended cardiovascular preventive therapy?
Topics: Adult; Aged; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; E | 2010 |
Aspirin as preventive therapy in patients with asymptomatic vascular disease.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Hemorrhage; Humans; Platelet Aggregation Inhibito | 2010 |
Comparison of evidence-based versus non-evidence-based pharmacotherapy on the risk of cardiovascular hospitalization and all-cause mortality among patients with established cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular | 2010 |
[Aspirin as primary prevention for diabetic patients].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Humans; Platelet Aggregation Inhibitors; P | 2010 |
Aspirin in primary prevention. GPs left in a quandary.
Topics: Aspirin; Cardiovascular Diseases; Family Practice; Fibrinolytic Agents; Humans | 2010 |
Impact of anticoagulant therapy with dual antiplatelet therapy on prognosis after treatment with drug-eluting coronary stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Coronary Dis | 2010 |
Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD).
Topics: Adult; Aged; Aged, 80 and over; Ankle Brachial Index; Aspirin; Cardiovascular Agents; Cardiovascular | 2010 |
Effect of obesity on platelet reactivity and response to low-dose aspirin.
Topics: Adult; Arachidonic Acid; Aspirin; Blood Platelets; Cardiovascular Diseases; Case-Control Studies; Co | 2010 |
An aspirin a day?
Topics: Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; Humans; Risk Factors | 2010 |
Platelet reactivity with prolonged aspirin treatment--steady going at 2 year.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Plat | 2010 |
Antiplatelet therapy in the treatment of Takayasu arteritis.
Topics: Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; Humans; Ischemia; Platelet Aggregatio | 2010 |
Withdrawal of clopidogrel in active gastric bleeding.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Gastrointestinal Hemorrhag | 2010 |
Serum cholesterol concentration associated with aspirin esterase activity in older people: preliminary data.
Topics: Aged; Aspirin; Blood Chemical Analysis; Body Composition; Body Mass Index; Carboxylic Ester Hydrolas | 2010 |
Aspirin, flu and general practice research.
Topics: Aged; Aspirin; Australia; Biomedical Research; Cardiovascular Diseases; Dose-Response Relationship, | 2010 |
Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College
Topics: American Heart Association; Aspirin; Cardiovascular Diseases; Diabetes Complications; Dose-Response | 2010 |
Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College
Topics: American Heart Association; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Melli | 2010 |
Antiplatelet therapy: aspirin for asymptomatic atherosclerosis?
Topics: Arteriosclerosis; Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Risk; R | 2010 |
Aspirin for prevention of cardiovascular events in individuals with low ankle brachial index.
Topics: Ankle; Aspirin; Atherosclerosis; Cardiovascular Diseases; Data Interpretation, Statistical; Humans; | 2010 |
AAA- a further step towards a moratorium for aspirin in the primary prevention.
Topics: Aged; Ankle Brachial Index; Aspirin; Atherosclerosis; Cardiovascular Agents; Cardiovascular Diseases | 2010 |
Aspirin and age-related macular degeneration.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Health Personnel; Humans; | 2010 |
Chronic disease in men with newly diagnosed cancer: a nested case-control study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; beta Carotene; Car | 2010 |
Aspirin use in elderly women receiving medication therapy management services.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Comorbidity; Contraindications; Diabetes | 2010 |
[Uncertain benefit of low dosage ASA in peripheral arterial disease. Low dosage in symptomatic--individual assessment in asymptomatic disease].
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Evidence-Based Medicine; Fibrino | 2010 |
Type 2 diabetes and ASA.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2 | 2010 |
Aspirin is indicated for primary prevention of cardiovascular events in HIV-infected patients.
Topics: Aged; Aspirin; Cardiovascular Diseases; Chemoprevention; Female; HIV Infections; Humans; Male; Middl | 2010 |
The role of weight and enteric coating on aspirin response in cardiovascular patients.
Topics: Aged; Aspirin; Body Weight; Cardiology; Cardiovascular Diseases; Humans; Middle Aged; Patient Compli | 2010 |
On the unfulfilled public health potential of aspirin.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Neoplas | 2010 |
The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular risk.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Female; Gastrointestinal Diseases; Humans; Male; Medi | 2010 |
Aspirin for people with diabetes: a misleading inference in a recent meta-analysis?
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Humans; Meta-Analysis as Topic; Primary Pr | 2010 |
Racial and ethnic disparities in cardiovascular medication use among older adults in the United States.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Comorbidity; Ethni | 2010 |
Population and individual health: the two faces of Janus.
Topics: Age Factors; Aspirin; Cardiovascular Diseases; Decision Making; Ethics, Medical; Family Practice; Fe | 2010 |
Aspirin for primary prevention: yes or no?
Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Fam | 2010 |
Should we give aspirins and statins to the elderly?
Topics: Age Factors; Aged; Aspirin; Cardiovascular Diseases; Frail Elderly; Guideline Adherence; Health Poli | 2009 |
Use of aspirin and statins for cardiovascular risk reduction in New Zealand: the residential care story.
Topics: Aged; Aspirin; Cardiovascular Diseases; Health Care Surveys; Humans; Hydroxymethylglutaryl-CoA Reduc | 2009 |
High platelet turnover and reactivity in renal transplant recipients patients.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Count; Cells, Cultured; Female; | 2010 |
Should we give aspirins and statins to the elderly?
Topics: Age Factors; Aged; Aspirin; Cardiovascular Diseases; Guideline Adherence; Health Services for the Ag | 2009 |
Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon; Aspirin; Blood Platelets; C-Reactive Protein; C | 2010 |
The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cl | 2010 |
Potential economic impact of increasing low dose aspirin usage on CVD in the US.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Chemoprevention; Cost | 2010 |
Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Dru | 2011 |
Fine-tuning therapy for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Angiography; Hemorr | 2010 |
Can aspirin do "that," too? Pain relief? Check. Cardiovascular disease prevention? Check. Protection against cancer? To be decided.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Neoplasms; Pain | 2010 |
Aspirin and the prevention of cardiovascular disease in chronic kidney disease: time to move forward?
Topics: Aspirin; Cardiovascular Diseases; Chronic Disease; Creatinine; Glomerular Filtration Rate; Hemorrhag | 2010 |
Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; C-Reactive Protein; Cardiovasc | 2010 |
Prophylactic use of aspirin does not induce anaemia among adults.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anemia; Anti-Inflammatory Agents, Non-Steroidal; Aspiri | 2010 |
Association of warfarin use with CHADS(2) score in 441 patients with nonvalvular atrial fibrillation and no contraindications to warfarin.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Female; Fibrinolytic Ag | 2010 |
Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Agg | 2010 |
No inconsistent trial assessments by NICE and IQWiG: different assessment goals may lead to different assessment results regarding subgroup analyses.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; England; Evidence-Based Medicine; Germany; Humans; Pr | 2010 |
Acceptance of a Polypill approach to prevent cardiovascular disease among a sample of U.S. physicians.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Combinations; Female; Folic Acid; He | 2011 |
Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cilostazol; Diabetes Mellitus, Ty | 2011 |
Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Analyses from the JPAD, POPADAD and AAA trials.
Topics: Aged; Ankle Brachial Index; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials | 2010 |
Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Chi | 2010 |
Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists?
Topics: Aspirin; Cardiovascular Diseases; Drug Interactions; Drug Therapy, Combination; Humans; Platelet Agg | 2010 |
Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists?
Topics: Aspirin; Cardiovascular Diseases; Drug Interactions; Drug Therapy, Combination; Humans; Platelet Agg | 2010 |
Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists?
Topics: Aspirin; Cardiovascular Diseases; Drug Interactions; Drug Therapy, Combination; Humans; Platelet Agg | 2010 |
Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists?
Topics: Aspirin; Cardiovascular Diseases; Drug Interactions; Drug Therapy, Combination; Humans; Platelet Agg | 2010 |
Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Colonic Neoplasms; Colorectal Neoplasms; Follow-Up Studies; Humans | 2010 |
Simvastatin administration reduces thromboxane production in subjects taking aspirin: links between aspirin resistance and thrombin generation.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Hydroxymethylglutaryl-CoA Reductase Inhib | 2012 |
Resistance to aspirin and clopidogrel therapy.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Resistance; Humans; Platelet Aggregation Inhibit | 2011 |
Review of an article: aspirin for primary prevention of cardiovascular events in people with diabetes. A position statement of the American Diabetes Association (ADA), a scientific statement of the American Heart Association(AHA), and an expert consensus
Topics: American Heart Association; Aspirin; Cardiology; Cardiovascular Diseases; Diabetes Complications; Ev | 2010 |
Automated processing of electronic medical records is a reliable method of determining aspirin use in populations at risk for cardiovascular events.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Utilization; Humans; Medical Recor | 2010 |
[The value of acetylsalicylic acid in retinal vein occlusion].
Topics: Aspirin; Cardiovascular Diseases; Humans; Macular Edema; Platelet Aggregation Inhibitors; Retinal Ve | 2010 |
Aspirin in the primary prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Female; Hemorrhage; Humans; Male; Platelet | 2011 |
Weighing the benefits and risks of aspirin for primary prevention of vascular disease.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention | 2010 |
Physician support for a population-based pharmaceutical approach to cardiovascular prevention: not there yet.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Combinations; Humans; Hydroxymethylg | 2011 |
The Polypill in the prevention of cardiovascular disease.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Combinations; Evidence-Based Medicin | 2011 |
Hughes syndrome (the antiphospholipid syndrome): a disease of our time.
Topics: Abortion, Spontaneous; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Arterial Occlusive D | 2011 |
Hemoptysis under diclofenac and antiplatelet doses of aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Back Pain; Cardiovascular Diseases; Diclofenac; Dr | 2011 |
Cardiovascular effects of low-dose aspirin, traditional non-steroidal anti-inflammatory drugs and coxibs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Aspirin; Blood Platelets; Cardiovascular | 2010 |
Should prophylactic low-dose aspirin therapy be continued in peptic ulcer bleeding?
Topics: Aspirin; Cardiovascular Diseases; Endoscopy, Gastrointestinal; Humans; Omeprazole; Peptic Ulcer Hemo | 2011 |
What is the best dose of aspirin in association with P2Y12 antagonists?
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, | 2011 |
[Renal artery stenosis: angioplasty or drug treatment?].
Topics: Aged; Angioplasty; Anticoagulants; Antihypertensive Agents; Aspirin; Blood Pressure; Cardiovascular | 2011 |
Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Cardiovascular Diseases; Female; Humans; M | 2011 |
[Antiplatelet agents and diabetes mellitus].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus, Type 2; Humans; Platelet Aggregati | 2010 |
[Aspirin for primary prevention of cardiovascular diseases--lessons from recent studies].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Controlled Clinical Trial | 2010 |
Double-dose clopidogrel in patients undergoing PCI for ACS.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2011 |
Double-dose clopidogrel in patients undergoing PCI for ACS.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2011 |
Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cohort Studies | 2011 |
Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cohort Studies | 2011 |
Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cohort Studies | 2011 |
Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cohort Studies | 2011 |
Incomplete inhibition of platelet function as assessed by the platelet function analyzer (PFA-100) identifies a subset of cardiovascular patients with high residual platelet response while on aspirin.
Topics: Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Female; Humans; | 2011 |
Aspirin: a historical and contemporary therapeutic overview.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; History, 19th Century; Hi | 2011 |
Effects of benefits and harms on older persons' willingness to take medication for primary cardiovascular prevention.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiotonic Agents; Cardiovascular Diseases; Drug-Related Side Eff | 2011 |
Performance of immunochemical fecal occult blood tests among users of low-dose aspirin.
Topics: Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Gastrointestinal Hemorrhage; Humans; Occult | 2011 |
A national survey on aspirin patterns of use and persistence in community outpatients in Italy.
Topics: Adult; Aged; Ambulatory Care; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Cross-Section | 2011 |
Cardiovascular disease risk factors: prevalence and management in adult hemophilia patients.
Topics: Adult; Aged; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Disease Management; Hemophil | 2011 |
Individual and population benefits of daily aspirin therapy: a proposal for personalizing national guidelines.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Decision Making; Female; Health Pl | 2011 |
Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin.
Topics: Aged; Aged, 80 and over; Aspirin; Buffers; Cardiovascular Diseases; Female; Gastrointestinal Hemorrh | 2011 |
[Does combination therapy of aspirin plus antiplatelet therapy increase the risk of upper gastrointestinal hemorrhage?].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Endos | 2011 |
[The effect of aspirin alone or aspirin plus additional antiplatelets therapy on upper gastrointestinal hemorrhage].
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; | 2011 |
Antiplatelet therapy for every diabetic person?
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors; Random | 2011 |
[The CURRENT-OASIS 7 study].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2011 |
Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Denmark; Drug Interactions; Humans; Kaplan-Meier Esti | 2011 |
Aspirin in the prevention of cancer.
Topics: Age Distribution; Age Factors; Aged; Aged, 80 and over; Anticarcinogenic Agents; Antihypertensive Ag | 2011 |
Personalizing evidence-based primary prevention with aspirin: individualized risks and patient preference.
Topics: Aspirin; Cardiovascular Diseases; Evidence-Based Medicine; Humans; Patient Participation; Platelet A | 2011 |
Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cohort Studies; Cost-Benefit Analy | 2011 |
Appropriate aspirin use for primary prevention of cardiovascular disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhi | 2011 |
The case against routine aspirin use for primary prevention in low-risk adults.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Contraindications; Evidence-Based Medicine; Female; H | 2011 |
Aspirin for the prevention of cardiovascular disease: recommendation statement.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Gastrointestinal Hemorrhag | 2011 |
Aspirin for the prevention of cardiovascular disease.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Decision Making; Evidence-Based Medicine; | 2011 |
Appropriate prophylactic aspirin use for Mississippi physicians.
Topics: Aspirin; Cardiovascular Diseases; Humans; Practice Guidelines as Topic | 2011 |
Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004.
Topics: Aged; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Ca | 2011 |
Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004.
Topics: Aged; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Ca | 2011 |
Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004.
Topics: Aged; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Ca | 2011 |
Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004.
Topics: Aged; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Ca | 2011 |
The prevalence of co-administration of clopidogrel and proton pump inhibitors.
Topics: Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Drug Therapy, C | 2011 |
Platelet reactivity is a stable and global phenomenon in aspirin-treated cardiovascular patients.
Topics: Adenosine Diphosphate; Aged; Aspirin; Cardiovascular Diseases; Epinephrine; Female; Follow-Up Studie | 2011 |
Impact of gastrointestinal problems on adherence to low-dose acetylsalicylic Acid: a quantitative study in patients with cardiovascular risk.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Female; Gastrointestinal Diseases; Humans; Internet; | 2011 |
Discontinuation of aspirin for secondary prevention.
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Humans; Risk Factors; Secondary Prevention; | 2011 |
Non-cardiac surgery in patients with coronary stents: the RECO study.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr | 2011 |
Non-cardiac surgery in patients with coronary stents: the RECO study.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr | 2011 |
Non-cardiac surgery in patients with coronary stents: the RECO study.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr | 2011 |
Non-cardiac surgery in patients with coronary stents: the RECO study.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr | 2011 |
Dual oral antiplatelet therapy and unplanned surgery: possible role for intravenous platelet glycoprotein receptor inhibitors.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Biliary Tract Surgical Procedur | 2011 |
Aspirin for prevention of cancer and cardiovascular disease.
Topics: Adult; Aged; Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Fibrinolytic Agents; Humans; | 2011 |
Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Diseases; Clop | 2011 |
Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian Cohort.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Aspirin; Australia; Cardiovascular Diseases; Computer Simu | 2013 |
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)?
Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Approval; Drug Interactions; Drug The | 2011 |
Aspirin for CV prevention -- for which patients?
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Drug Resistance; Female; Fibrinolytic Age | 2011 |
Aspirin bleeding in perspective.
Topics: Anti-Inflammatory Agents; Anticoagulants; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; He | 2011 |
PPI therapy: PPI plus aspirin for secondary cardiovascular disease prevention.
Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Pr | 2011 |
Associations between aspirin use and aging macula disorder: the European Eye Study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cholesterol; Cross- | 2012 |
Letter by Fürstenwerth regarding article, "aspirin: a historical and contemporary therapeutic overview".
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans | 2011 |
Trials of primary prevention of cardiovascular events using aspirin.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary Prevention | 2011 |
Primary prevention for cardiovascular diseases: can statins replace aspirin?
Topics: Anticholesteremic Agents; Aspirin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reduct | 2011 |
Update on aspirin. People with heart disease should take aspirin; the decision is trickier for those without it.
Topics: Aspirin; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; | 2011 |
Killing two birds with one salicylate: aspirin's dual roles in preventative health.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anticarcinogenic Agents; Aspirin; Cardiovascular Agents; Car | 2011 |
A retrospective study to assess the morbidity associated with transurethral prostatectomy in patients on antiplatelet or anticoagulant drugs.
Topics: Aged; Anticoagulants; Aspirin; Blood Loss, Surgical; Cardiovascular Diseases; Case-Control Studies; | 2011 |
Termination of refractory focal status epilepticus by the P-glycoprotein inhibitor verapamil.
Topics: Aged, 80 and over; Anticonvulsants; Aspirin; ATP Binding Cassette Transporter, Subfamily B, Member 1 | 2011 |
On the potential contribution of aspirin to healthy ageing programmes.
Topics: Age Factors; Aging; Anticarcinogenic Agents; Aspirin; Cardiovascular Agents; Cardiovascular Diseases | 2016 |
Aspirin therapy in primary prevention: comment on "effect of aspirin on vascular and nonvascular outcomes".
Topics: Aspirin; Cardiovascular Diseases; Humans; Randomized Controlled Trials as Topic | 2012 |
Risks of aspirin outweigh benefits in people without cardiovascular disease, shows analysis.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Meta-Analysis as Topic; Risk Factors | 2012 |
Aspirin use and bleeding risk after endoscopic submucosal dissection in patients with gastric neoplasms.
Topics: Adenocarcinoma; Adenoma; Aged; Aspirin; Cardiovascular Diseases; Female; Gastric Mucosa; Gastrointes | 2012 |
New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Gastrointestinal Hemorrhage; Helic | 2012 |
Predictors and time trends in clopidogrel and proton pump inhibitor coprescription with low-dose acetylsalicylic acid.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; D | 2012 |
What the million hearts initiative means for stroke: a presidential advisory from the American Heart Association/American Stroke Association.
Topics: American Heart Association; Aspirin; Blood Pressure; Cardiovascular Diseases; Centers for Disease Co | 2012 |
Underuse of aspirin for primary and secondary prevention of cardiovascular disease events in women.
Topics: Adult; Aspirin; Cardiovascular Diseases; Female; Health Surveys; Humans; Male; Middle Aged; National | 2012 |
Aspirin and angioplasty.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Health Care | 2012 |
Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Fema | 2013 |
Urinary 11-dehydro-thromboxane B₂ and 2,3-dinor-6-keto-prostaglandin-F₁α in healthy post-menopausal and pre-menopausal women receiving aspirin 100 mg.
Topics: Adult; Aspirin; Cardiovascular Diseases; Female; Humans; Middle Aged; Platelet Aggregation Inhibitor | 2012 |
Effects of preoperative aspirin on cardiocerebral and renal complications in non-emergent cardiac surgery patients: a sub-group and cohort study.
Topics: Aged; Aspirin; Cardiac Surgical Procedures; Cardiovascular Diseases; Case-Control Studies; Cohort St | 2012 |
Aspirin use and cardiovascular events in social networks.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Female; Health Beha | 2012 |
Prevention. Aspirin in primary prevention--good news and bad news.
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; Primary Prevention; Risk Factor | 2012 |
The purification step is not crucial in EIA measurements of thromboxane B2 and 11-dehydrothromboxane B2 in human plasma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cardiovascular Diseases; Humans; | 2012 |
Radical prostatectomy with robot-assisted radical prostatectomy and laparoscopic radical prostatectomy under low-dose aspirin does not significantly increase blood loss.
Topics: Aged; Aspirin; Blood Loss, Surgical; Cardiovascular Diseases; Humans; Intraoperative Period; Laparos | 2012 |
Cardiology patient page: Aspirin.
Topics: Aspirin; Blood Coagulation; Cardiovascular Diseases; Coronary Artery Disease; Drug Therapy, Combinat | 2012 |
The effect of cluster size imbalance and covariates on the estimation performance of quadratic inference functions.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Cluster Analysi | 2012 |
The prevalence, risk factors and prognosis of aspirin resistance in elderly male patients with cardiovascular disease.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Drug Resistance; Human | 2012 |
Gastric injury caused by low-dose aspirin therapy in consecutive Japanese patients: a prospective study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Antibodies, Bacterial; Asia | 2012 |
Why P is not perfect.
Topics: Aspirin; Bayes Theorem; Cardiovascular Agents; Cardiovascular Diseases; Data Interpretation, Statist | 2012 |
Aspirin and cancer prevention.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Neoplasms; Patien | 2012 |
Daily low-dose aspirin: beware of GI bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Dose-Response Relationshi | 2012 |
Kawasaki disease: a case report and overview of symptoms, signs, investigations and treatment.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Child, Preschool; Diagnos | 2012 |
Aspirin: the balance between benefits and harms. Preface.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colonic Neoplasms; Common | 2012 |
Aspirin provides minimal cardiac protection to healthy adults. Risk of serious internal bleeding far outweighs any benefit.
Topics: Adult; Age Factors; Aged; Aspirin; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; Middle | 2012 |
Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Female; Genetic Testing; Humans; Male | 2012 |
A revised health impact assessment of increased use of aspirin in Wales.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Health Policy; Humans; Male; Middle Aged; Neoplasms; | 2012 |
[Aspirin use in cardiovascular disease prevention: a population-based study].
Topics: Adult; Aged; Aspirin; Brazil; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Life | 2012 |
Recommended use of aspirin and other antiplatelet medications among adults--National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, United States, 2005-2008.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Guideline Adhe | 2012 |
Aspirin in the primary prevention of cardiovascular disease in the Women's Health Study: effect of noncompliance.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Body Mass Index; Cardiovascular Di | 2012 |
Association of aspirin use with major bleeding in patients with and without diabetes.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Case-Control Studies; Cohort Studi | 2012 |
Prophylactic aspirin and public health.
Topics: Aspirin; Cardiovascular Diseases; Decision Making; Health Knowledge, Attitudes, Practice; Humans; Pl | 2012 |
Medicare coverage of intensive behavioral therapy for cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Humans; Randomized Controlled Trials as Topic | 2012 |
Polypill remains the only panacea in sight for cardiovascular disease, trial organiser says.
Topics: Anti-Inflammatory Agents; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Combinatio | 2012 |
Reducing the cardiovascular disease burden: justified means for getting to the end.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Evidence-Based Medicine; Health Policy; H | 2012 |
Performance measures in million hearts: 2 partners' perspective.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Endpoint Determination; Evidence-Based Me | 2012 |
Million hearts--where population health and clinical practice intersect.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Clinical Competence; Endpoint Determinati | 2012 |
Aspirin prophylaxis in people without prior cardiovascular disease does not lead to reductions in cardiovascular death or cancer mortality.
Topics: Aspirin; Cardiovascular Diseases; Humans; Randomized Controlled Trials as Topic | 2013 |
Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Greece; Human | 2012 |
[Correlation analysis of aspirin resistance and cycloxygenase-1 haplotype in old Chinese patients with cardio-cerebrovascular diseases].
Topics: Aged; Aged, 80 and over; Asian People; Aspirin; Cardiovascular Diseases; Case-Control Studies; Cereb | 2012 |
Impact of platelet reactivity on long-term clinical outcomes and bleeding events in Japanese patients receiving antiplatelet therapy with aspirin.
Topics: Aged; Aspirin; Blood Platelets; Body Mass Index; Cardiovascular Diseases; Female; Follow-Up Studies; | 2012 |
[Primary prevention with aspirin].
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Evidence-Based Medicine; Humans; Meta-An | 2012 |
Primary and secondary prevention of cardiovascular disease in diabetes with aspirin.
Topics: Animals; Aspirin; Cardiovascular Diseases; Diabetes Complications; Humans; Platelet Aggregation Inhi | 2012 |
Discontinuation of low-dose aspirin therapy after peptic ulcer bleeding increases risk of death and acute cardiovascular events.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cohort Studies; Female; Gastrointestinal Hemorrhage; Humans; | 2013 |
[Evidence-based anti-platelet treatment: PAPPS recommendations].
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors | 2012 |
Safety of aspirin desensitization in patients with reported aspirin allergy and cardiovascular disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Desensitization, Immunolo | 2013 |
The prevalence and factors associated with aspirin resistance in patients premedicated with aspirin.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Drug Resistance; Female; Human | 2012 |
Aspirin for primary prevention of CVD: are the right people using it?
Topics: Adult; Age Factors; Aged; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Demography; Eth | 2012 |
Bleeding risk with aspirin must be balanced against benefit.
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Gastrointestinal Hemorrhage; Hea | 2012 |
Frequency, risk factors, prognosis, and genetic polymorphism of the cyclooxygenase-1 gene for aspirin resistance in elderly Chinese patients with cardiovascular disease.
Topics: Aged; Aged, 80 and over; Asian People; Aspirin; Cardiovascular Diseases; China; Cyclooxygenase 1; Dr | 2013 |
The future of preventive medicine: polypill prescriptions in the context of Plato's physical perspective.
Topics: Adult; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Combinations; Humans; Hypolip | 2012 |
The role of aspirin in cardiovascular disease prevention.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors | 2012 |
Know the benefits and risks of daily aspirin therapy. A small dose can have big benefits for many patients with heart disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Dose-Response Relationshi | 2011 |
Statements of the Malaysian Society of Gastroenterology & Hepatology and the National Heart Association of Malaysia task force 2012 working party on the use of antiplatelet therapy and proton pump inhibitors in the prevention of gastrointestinal bleeding.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Gastrointestinal Hemorrhage; Human | 2013 |
Lowering homocysteine levels may prevent cardiovascular impairments? Possible therapeutic behaviors.
Topics: Acetylcysteine; Aspirin; Blood Vessels; Cardiovascular Diseases; Clopidogrel; Diuretics; Fatty Acids | 2012 |
Lack of subjective tendency to bleed as clinical marker for aspirin resistance.
Topics: Aspirin; Biomarkers; Cardiovascular Diseases; Drug Resistance; Ecchymosis; Humans; Platelet Aggregat | 2014 |
Is low-dose aspirin safe for you? If you take daily aspirin, make sure you know why and understand the small but real bleeding risk.
Topics: Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Gastrointestinal Hemorrhage; Hea | 2012 |
Pharmacologic treatment in dialysis patients hospitalized for cardiovascular reasons: do we follow the guidelines?
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2013 |
The relationship of plasma ADMA levels with cardiac functions and metabolic parameters in peritoneal dialysis patients.
Topics: Adolescent; Aged; Arginine; Aspirin; Body Mass Index; Cardiovascular Diseases; Cross-Sectional Studi | 2013 |
[First WARFASA, now ASPIRE. The new career of ASS in long-term thromboembolism prevention].
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; | 2012 |
Unmet needs of diabetic patients.
Topics: Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus; Health Services Needs and Dem | 2012 |
Body mass index predicts failure of surgical management in benign prostatic hyperplasia.
Topics: Aged; Aspirin; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; | 2013 |
Dietary nitrate and reductive polyphenols may potentiate the vascular benefit and alleviate the ulcerative risk of low-dose aspirin.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Catechin; Gastric Mucosa; Gastrointestinal Hemorr | 2013 |
Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism.
Topics: Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Cyclooxygenase Inhibitors; | 2013 |
A 'polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America.
Topics: Aged; Antihypertensive Agents; Aspirin; Atenolol; Cardiovascular Diseases; Cohort Studies; Cost-Bene | 2013 |
Aspirin in the secondary prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Preventive Medicine; Seco | 2013 |
The association of aspirin use with age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Cohort Studies; Female; Humans | 2013 |
Family practice patients' use of acetylsalicylic acid for cardiovascular disease prevention.
Topics: Aged; Aged, 80 and over; Alberta; Ambulatory Care Facilities; Aspirin; Cardiovascular Diseases; Cros | 2013 |
Nuggets of knowledge: aspirin-yes?-no?-maybe?
Topics: Aspirin; Cardiovascular Diseases; Humans; Neoplasms; Primary Prevention | 2012 |
Low-dose aspirin use and recurrent gout attacks.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiotonic Agents; Cardiovascular Diseases; Cross-Over Stu | 2014 |
Characterization of aspirin allergies in patients with coronary artery disease.
Topics: Aged; Aged, 80 and over; Aspirin; California; Cardiovascular Diseases; Clopidogrel; Coronary Artery | 2013 |
Underutilization of aspirin for secondary prophylaxis of cardiovascular disease in a long-term-care facility.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Utilization; H | 2002 |
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
Topics: Aspirin; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Cyclooxygenase Inhibitors; Hu | 2002 |
Aspirin therapy should be first-line treatment in secondary prevention of stroke--against.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Drug | 2002 |
Experimental study of biological activity of angiogen in experimental cardiovascular and hemostasis pathology.
Topics: Animals; Aspirin; Blood Coagulation; Blood Pressure; Cardiovascular Agents; Cardiovascular Diseases; | 2002 |
Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Dis | 2002 |
Pravastatin and Aspirin.
Topics: Advisory Committees; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Drug Packaging; Drug T | 2002 |
Aspirin for the primary prevention of cardiovascular events.
Topics: Aspirin; Cardiovascular Diseases; Fibrinolytic Agents; Humans; Primary Prevention | 2002 |
Media coverage of scientific presentations.
Topics: Aspirin; Cardiovascular Diseases; Congresses as Topic; Humans; Journalism; Peer Review, Research; Re | 2002 |
Aspirin for the primary prevention of cardiovascular events.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Risk Assessment; | 2002 |
Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Administration | 2002 |
Low-dose aspirin for everyone?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; | 2002 |
Reasons for resistance to aspirin in cardiovascular disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Coagulation; Cardiovascular Diseases; Cycloo | 2002 |
Comparison of baseline characteristics and mortality experience of participants and nonparticipants in a randomized clinical trial: the Physicians' Health Study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta Carotene; Cardiovascular Diseases; Cause of Death; Hum | 2002 |
Improving aspirin prophylaxis in a primary care diabetic population.
Topics: Aspirin; Cardiovascular Diseases; Data Collection; Diabetes Complications; Drug Utilization; Humans; | 2003 |
Geographical variation in cardiovascular disease, risk factors, and their control in older women: British Women's Heart and Health Study.
Topics: Aged; Anticholesteremic Agents; Aspirin; Blood Pressure; Cardiovascular Diseases; Cholesterol; Engla | 2003 |
[Which interactions are there for equal doses of acetylsalicylic acid and ACE inhibitors?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Diseases; Coronary Disease; Drug I | 2003 |
Parsing an enigma: the pharmacodynamics of aspirin resistance.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Resistance; Humans | 2003 |
Effect of ibuprofen on cardioprotective effect of aspirin.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Dis | 2003 |
Aspirin and ibuprofen: potential mediators of the cardiovascular risk due to smoking?
Topics: Adolescent; Adult; Aged; Aspirin; C-Reactive Protein; Cardiovascular Diseases; Data Collection; Fema | 2003 |
Aspirin for the prevention of cardiovascular disease: calculating benefit and harm in the individual patient.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Evidence-Based Medicine; Gastrointestinal | 2003 |
[Anticoagulation and antiaggregation in cardiac patients].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Clo | 2003 |
[New antiaggregants and their importance for the practitioner].
Topics: Abciximab; Administration, Oral; Adult; Anesthesia, Spinal; Antibodies, Monoclonal; Aspirin; Cardiov | 2003 |
Aspirin resistance: a new independent predictor of vascular events?
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Fibrinolytic Agents; Humans; Out | 2003 |
Smoking and the risk of hemorrhagic stroke in men.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alcohol Drinking; Aspirin; beta Carotene; Body Mass Ind | 2003 |
Under-prescribing of cardiovascular therapies for diabetes in primary care.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2003 |
A quantitative illustration of the public health potential of aspirin.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Finland; Humans; Male; Middle Aged; Neoplasms; Risk | 2003 |
NSAIDs and aspirin: friends or foes?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Interactions; Humans | 2003 |
[Use of anti-aggregant drugs in primary and secondary cardiovascular prevention in diabetics in town and country in the León area].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Primary Health Care; Primary Prevention | 2003 |
Suggestions made for reducing cardiac drug errors.
Topics: American Heart Association; Aspirin; Cardiovascular Diseases; Fibrinolytic Agents; Heparin; Humans; | 2002 |
Effect of ibuprofen on cardioprotective effect of aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Interactions; Humans | 2003 |
Effect of ibuprofen on cardioprotective effect of aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Interactions; Humans | 2003 |
Effect of ibuprofen on cardioprotective effect of aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Interactions; Humans | 2003 |
Effect of ibuprofen on cardioprotective effect of aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Interactions; Humans | 2003 |
Effect of ibuprofen on cardioprotective effect of aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Interactions; Epidem | 2003 |
Effect of ibuprofen on cardioprotective effect of aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Interactions; Eviden | 2003 |
Twenty years and counting.
Topics: Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; beta Carotene; Cardiovascular Di | 2003 |
Nitric oxide-donating non-steroidal anti-inflammatory drugs: the case of nitroderivatives of aspirin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Models, | 2003 |
Avoid an aspirin roadblock.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans | 2003 |
Celecoxib versus diclofenac and omeprazole to prevent recurrent ulcer bleeding.
Topics: Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; Helicobacter Infections; Helicobacter | 2003 |
A cure for cardiovascular disease? Combination treatment has enormous potential, especially in developing countries.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Combinations; Folic Acid; Humans; Hy | 2003 |
Aspirin and cyclooxygenase-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors | 2003 |
Analgesic use and change in kidney function in apparently healthy men.
Topics: Acetaminophen; Adult; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovasc | 2003 |
Genetic and acquired determinants of individual variability of response to antiplatelet drugs.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Interactions; Drug Resistance; Genetic Varia | 2003 |
Cardioprotective effects of aspirin compromised by other NSAIDs.
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Contraindicat | 2003 |
The use of acetylsalicylic acid in the treatment of the arthritic patient with far advanced cardiovascular disease.
Topics: Arthritis; Arthritis, Rheumatoid; Aspirin; Cardiovascular Diseases; Heart Diseases; Humans | 1958 |
Statin compliance in the Umbrian population.
Topics: Age Factors; Aged; Aspirin; Cardiovascular Diseases; Cohort Studies; Female; Humans; Hydroxymethylgl | 2003 |
Cardiovascular death and disability can be reduced more than 50 percent.
Topics: Anticholesteremic Agents; Aspirin; Cardiovascular Diseases; Developing Countries; Drug Therapy, Comb | 2003 |
Decisional attributes of patients with diabetes: the aspirin choice.
Topics: Adult; Aged; Aspirin; Attitude to Health; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes | 2003 |
Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Fibrinolytic Agents; Humans | 2003 |
Summaries for patients. Gastrointestinal side effects of rofecoxib and naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors | 2003 |
[Gastroduodenal injury in patients with low-dose enteric coated aspirin treatment].
Topics: Aged; Aspirin; Cardiovascular Diseases; Esophagitis; Female; Gastritis; Gastrointestinal Diseases; H | 2003 |
Should aspirin be used to counteract 'salicylate deficiency'?
Topics: Alzheimer Disease; Aspirin; Cardiovascular Diseases; Chronic Disease; Fruit; Humans; Neoplasms; Publ | 2003 |
Aspirin for primary prevention of cardiovascular events in diabetes.
Topics: Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Humans; Platelet Aggregation Inhibitors | 2003 |
Lost in translation.
Topics: Aspirin; Cardiovascular Diseases; Clinical Medicine; Diffusion of Innovation; Humans; Treatment Outc | 2003 |
The clinical and economic impact of a secondary heart disease prevention clinic jointly implemented by a practice nurse and pharmacist.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Cardiovascular Diseases; Clinical Protocols; Diet; Exerc | 2003 |
Aspirin therapy in type 2 diabetes in a general practice in Italy.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Family Practice; Female; H | 2003 |
Aspirin for cardiovascular disease prevention.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticlopidine; | 2004 |
Periodontal disease and biomarkers related to cardiovascular disease.
Topics: Age Factors; Aged; Aged, 80 and over; Alcohol Drinking; Antigens, CD; Aspirin; Biomarkers; C-Reactiv | 2004 |
Periodontal disease and biomarkers related to cardiovascular disease.
Topics: Age Factors; Aged; Aged, 80 and over; Alcohol Drinking; Antigens, CD; Aspirin; Biomarkers; C-Reactiv | 2004 |
Periodontal disease and biomarkers related to cardiovascular disease.
Topics: Age Factors; Aged; Aged, 80 and over; Alcohol Drinking; Antigens, CD; Aspirin; Biomarkers; C-Reactiv | 2004 |
Periodontal disease and biomarkers related to cardiovascular disease.
Topics: Age Factors; Aged; Aged, 80 and over; Alcohol Drinking; Antigens, CD; Aspirin; Biomarkers; C-Reactiv | 2004 |
[Acetylsalicylic acid consumption in patients with diabetes mellitus].
Topics: Adult; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Female; Humans; M | 2004 |
[Underutilization of acetylsalicylic acid of cardiovascular prevention in patients with diabetes mellitus].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Humans; Platelet Aggrega | 2004 |
Weighing the risks and benefits of clinical interventions.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Cholesterol; Decision Making; Female; Humans; Male; M | 2004 |
Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cohort Studies; Disease-Free Survival; Drug Resis | 2004 |
Prevention of cardiovascular disease: an evidence-based clinical aid.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Evidence-Based Medicine; Guideline Adhere | 2004 |
Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease?
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cardiovascula | 2004 |
Panacea in a pill?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspi | 2004 |
British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary.
Topics: Algorithms; Antihypertensive Agents; Aspirin; Blood Pressure Determination; Cardiovascular Diseases; | 2004 |
[Chemopreventive agents in colorectal cancer].
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2003 |
The miracle in the cabinet. A look at the future of aspirin.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cycloo | 2004 |
Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001.
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Body Mass Inde | 2004 |
C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Topics: Acute-Phase Reaction; Aspirin; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases | 2004 |
Guidelines on the management of secondary prophylaxis of vascular events in stable patients in primary care.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Bypass; Dipyrida | 2004 |
[Recommendations for cardiovascular rehabilitation in diabetes mellitus].
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Angioplasty, Balloon; Aspirin; Blood Glucose; Cardiov | 2003 |
Therapeutic failure or resistance to aspirin.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Fibrinolytic Agents; Humans; Myocardial Infarctio | 2004 |
Concomitant use of buffered and enteric-coated low-dose aspirin products and antisecretory drugs.
Topics: Administration, Oral; Aspirin; Cardiovascular Diseases; Databases, Factual; Drug Prescriptions; Gast | 2004 |
Low-dose aspirin in polycythemia vera.
Topics: Aspirin; Cardiovascular Diseases; Erythrocyte Volume; Hematocrit; Humans; Platelet Aggregation Inhib | 2004 |
Underuse of aspirin in type 2 diabetes mellitus: prevalence and correlates of therapy in rural Canada.
Topics: Adult; Aged; Aged, 80 and over; Alberta; Aspirin; Cardiovascular Diseases; Cohort Studies; Diabetes | 2004 |
Methods to evaluate risks for composite end points and their individual components.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; beta | 2004 |
Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention.
Topics: Aged; Aspirin; Biomarkers; Blood Coagulation; Cardiovascular Diseases; CD40 Ligand; Cohort Studies; | 2004 |
Will changes in primary care improve health outcomes? Modelling the impact of financial incentives introduced to improve quality of care in the UK.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Cholesterol; Fem | 2004 |
Aspirin or clopidogrel for secondary prevention of cardiovascular events: is there a winner?
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Fibrinolytic Agents; Humans; Platelet Aggregation Inh | 2004 |
[Risk intervention in persons with diabetes mellitus in general practice].
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Di | 2004 |
Cardiovascular disease risk reduction in the Behavioral Risk Factor Surveillance System.
Topics: Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Exercise; Feeding Behavior; Female; Healt | 2004 |
Aspirin chemoprevention recommendations.
Topics: Aspirin; Cardiovascular Diseases; Chemoprevention; Fibrinolytic Agents; Humans; Primary Prevention | 2004 |
[Aspirin use in patients with diabetes mellitus].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Humans; Pharmacoepidemiology; Platelet Agg | 2004 |
[Aspirin use in patients with diabetes mellitus].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Female; Humans; Male; P | 2004 |
[Aspirin use in patients with diabetes mellitus].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Humans; Platelet Aggreg | 2004 |
[Aspirin use in patients with diabetes mellitus].
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitu | 2004 |
[Aspirin use in patients with diabetes mellitus].
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitu | 2004 |
Aspirin therapy. Association recommends widespread use.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Female; Humans; Male; United States | 2003 |
[Cardiovascular pharmacology].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Fatty Acids, Omega-3; Fibrinolytic Agents; Graft Occl | 2004 |
A prospective study of red meat consumption and type 2 diabetes in middle-aged and elderly women: the women's health study.
Topics: Ascorbic Acid; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Energy Intake; Feeding B | 2004 |
Aspirin use in advanced uncontrolled glaucoma.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cohort Studies; Disease Progression; Female; Glaucoma, Open- | 2004 |
Statins could be the next aspirin.
Topics: Aspirin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; United Sta | 2004 |
The challenge of secondary prevention for coronary heart disease in older patients: findings from the British Women's Heart and Health Study and the British Regional Heart Study.
Topics: Aged; Anticholesteremic Agents; Aspirin; Blood Pressure; Cardiovascular Diseases; Cholesterol; Engla | 2004 |
Association of aspirin use with vitamin B12 deficiency (results of the BACH study).
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Viral; Aspirin; Biomarkers; | 2004 |
The American Heart Association Get With The Guidelines program.
Topics: Adrenergic beta-Antagonists; American Heart Association; Angiotensin-Converting Enzyme Inhibitors; A | 2004 |
Sub-optimal drug treatment of diabetes and cardiovascular risk in diabetic patients in Turkey. A countrywide survey.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antihyperte | 2004 |
Canadian Hypertension Education Program. Brief overview of 2004 recommendations.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Canada; Cardiovascular D | 2004 |
Research in the aged.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Gastrointestinal He | 2004 |
[Acetylsalicylic acid in patients with diabetes for the primary prevention of cardiovascular disease].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Platelet Aggregation Inhibitors | 2004 |
Changing aspirin use in patients with Type 2 diabetes in the UKPDS.
Topics: Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; D | 2004 |
Pharmacotherapy in cardiovascular diseases and vascular interventions.
Topics: Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Cardiovascular Diseases; Endothelium, V | 2004 |
Rofecoxib, Merck, and the FDA.
Topics: Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Approval; Drug Interact | 2004 |
Reducing the risks of gastrointestinal bleeding with antiplatelet therapies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Clopid | 2005 |
A "poly-portfolio" for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel Bloc | 2005 |
Aspirin for primary prevention in patients with diabetes mellitus.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Female; Fibrinolytic Agents; G | 2005 |
Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Cardiovascular Diseas | 2005 |
Who can resist aspirin?
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Nursing Assessment; Platelet Aggregation | 2005 |
Summaries for patients. Is it cost-effective to treat high-risk cardiac patients with clopidogrel plus aspirin as opposed to aspirin alone?
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A | 2005 |
A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A | 2005 |
Plasma leptin concentration in patients with Type 2 diabetes: relationship to cardiovascular disease risk factors and insulin resistance.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; C-Reactive Protein; Cardiov | 2005 |
The withdrawal of rofecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; | 2005 |
[Practical prevention and treatment of cardiovascular diseases in patients with diabetes mellitus type 2 in an endocrinological department].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type | 2004 |
Use of biological based therapy in patients with cardiovascular diseases in a university-hospital in New York City.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Cardiac Care Facilities; Cardi | 2005 |
Statins and aspirin in chronic kidney disease: what does the UK-HARP-I trial tell us?
Topics: Aspirin; Cardiovascular Diseases; Cholesterol; Chronic Disease; Disease Progression; Hemorrhage; Hum | 2005 |
Optimizing cardiovascular and chemopreventive benefits of aspirin: what role for the proton-pump inhibitors?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Eso | 2005 |
The puzzle of aspirin and sex.
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Female; Humans; Male; Myocardial Infarc | 2005 |
Would it be more beneficial to take aspirin in the evening for prevention of cardiovascular diseases?
Topics: Aspirin; Cardiovascular Diseases; Circadian Rhythm; Humans; Platelet Aggregation Inhibitors; Time Fa | 2005 |
Improving secondary prevention in coronary bypass patients: closing the audit loop.
Topics: Aspirin; Blood Pressure; Cardiovascular Diseases; Cholesterol; Coronary Artery Bypass; Drug Utilizat | 2005 |
Cardiovascular disease morbidity and mortality in patients with type 1 diabetes mellitus : management strategies.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Humans; Hypogl | 2005 |
[Gastrointestinal bleeding during low dose acetylsalicylic acid. Is Godamed-100 TAH an alternative to conventional ASS preparations?].
Topics: Aspirin; Cardiovascular Diseases; Drug Combinations; Gastrointestinal Hemorrhage; Glycine; Humans; P | 2005 |
Clopidogrel versus aspirin and esomeprazole to prevent recurrent bleeding.
Topics: Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Gastroi | 2005 |
Cardiovascular risk in patients with type 2 diabetes.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Aspirin; Ca | 2005 |
Controversies in antiplatelet therapy for patients with cardiovascular disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Cyclooxyge | 2005 |
[Primary prevention of cardiovascular disease with acetylsalicylic acid: in high-risk patients].
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Female; Huma | 2005 |
Is aspirin resistance a risk factor?
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Platelet Aggregation; Platelet Aggregatio | 2005 |
Use of antiplatelet therapy in a diabetic outpatient service of a large urban public hospital.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; | 2005 |
[Aspirin and cardiovascular prevention: last minute information].
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Female; Humans; Male; Peptic Ulcer Hemorrhage; | 2005 |
"Polypill-aspostatinoprilololazide folate"--coprescription for at the risk Asian Indian in chronic non communicable diseases.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; | 2005 |
When it comes to aspirin, men and women are not equal: aspirin acts differently in women.
Topics: Aspirin; Cardiovascular Diseases; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Pl | 2005 |
Prevalence of aspirin resistance in patients with type 2 diabetes.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; | 2005 |
A health impact assessment of increased aspirin use in Wales.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Platelet Aggregation Inhibitors; Risk Factor | 2005 |
[Frequency and characteristics of aspirin resistance in Chilean cardiovascular patients].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Chile; Drug Resistance; Female; Hu | 2005 |
ASHP therapeutic position statement on the daily use of aspirin for preventing cardiovascular events.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Practice Guidelines as Topic; So | 2005 |
Cardiovascular disease and the dental team.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cardiovascular Diseases; Humans; P | 2005 |
[Highlights from the American College of Cardiology Annual Scientific Session 2005: March 5-9, 2005, Orlando, Florida].
Topics: Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Clopidogrel; Humans; Hypercholesterolemia; Obesi | 2005 |
Low-dose aspirin and vitamin E: challenges and opportunities in cancer prevention.
Topics: alpha-Tocopherol; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Female; Humans; Neopl | 2005 |
Aspirin for everyone over 50? Avoid the harm.
Topics: Aged; Aspirin; Cardiovascular Diseases; Humans; Middle Aged; Platelet Aggregation Inhibitors | 2005 |
Citizen jury should consider aspirin prophylaxis.
Topics: Aspirin; Cardiovascular Diseases; Humans; Patient Participation; Platelet Aggregation Inhibitors | 2005 |
Aspirin for everyone over 50? Are we treating a nutritional deficiency?
Topics: Aged; Aspirin; Cardiovascular Diseases; Humans; Malnutrition; Middle Aged; Phytotherapy; Platelet Ag | 2005 |
Aspirin for everyone over 50? Don't forget aspirin resistance.
Topics: Aged; Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Middle Aged; Platelet Aggregation I | 2005 |
Appropriate use of antiplatelets: is prescription in daily practice influenced by the global cardiovascular risk?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Drug Util | 2005 |
Should you be taking aspirin? It depends.
Topics: Age Factors; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Platelet Aggregation Inhibitors | 2005 |
Prospects and possible pitfalls of a preventive Polypill: confessions of a health promotion convert.
Topics: Aged; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Combinations; Female; Folic Ac | 2005 |
High frequency of aspirin resistance in patients with acute coronary syndrome.
Topics: Adult; Aged; Angiography; Aspirin; Blood Platelets; Cardiovascular Diseases; Cardiovascular System; | 2005 |
Can the time of taking aspirin influence the frequency of cardiovascular events?
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Humans; Incidence; Platelet Aggregat | 2005 |
[The polypill: optimal strategy for reduction of cardiovascular disease].
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Combinations; | 2005 |
[The polypill: not an effective strategy for reduction of cardiovascular disease].
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Combinations; Evidence-Based Medicin | 2005 |
Oral surgery procedures in patients on anticoagulants. Preliminary report.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cardiovascular Diseases; Coumarins; Female; | 2005 |
Monitoring acetylsalicylic acid effects with the platelet function analyzer PFA-100.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Brain Ischemia; Cardiovascular Diseases; Clinical Trials | 2005 |
Cyclooxygenase-1 haplotype modulates platelet response to aspirin.
Topics: Adult; Arachidonic Acid; Aspirin; Cardiovascular Diseases; Cyclooxygenase 1; Cyclooxygenase Inhibito | 2005 |
Evaluating national guidelines for prevention of cardiovascular disease in primary care.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Australia; Canada; Car | 2005 |
Molecular mechanism of Clopidogrel and Aspirin therapy-induced bleeding episodes.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Eicosanoids; Hemorrhage; Humans; Ticlopidine | 2006 |
Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Drug Therapy | 2005 |
Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Drug Therapy | 2005 |
Adverse effects of etoricoxib: other considerations.
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug | 2005 |
The lady aspirin for cardiovascular disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pl | 2005 |
Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease.
Topics: Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Female; Humans; Middle Aged; Tablets, Enter | 2005 |
Cardiovascular involvement in Kawasaki disease.
Topics: Age Distribution; Arrhythmias, Cardiac; Aspirin; Cardiovascular Diseases; Child; Child, Preschool; C | 2005 |
Coxibs and cardiovascular risk.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; | 2005 |
Coxibs and cardiovascular risk.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cardiovascular Diseases; Celecoxib; Cli | 2005 |
[ASS or clopidogrel plus esomeprazole after bleeding from an ulcer].
Topics: Aged; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Do | 2005 |
Women's study finds vitamin E, aspirin not so helpful.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Female; Humans; Middle Ag | 2005 |
Association between body mass index and CKD in apparently healthy men.
Topics: Adult; Aspirin; beta Carotene; Body Mass Index; Cardiovascular Diseases; Chronic Disease; Cohort Stu | 2005 |
Women's health research: evidence from two major trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; Cardiovascular Diseases; Female; Hum | 2005 |
[Antiplatelet drugs and gastrointestinal bleeding: numquam periclum sine periclo vincitur].
Topics: Age Factors; Aged; Aged, 80 and over; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A | 2005 |
Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease.
Topics: Adult; Aged; Ambulatory Care; Aspirin; Cardiovascular Diseases; Female; Health Care Surveys; Humans; | 2005 |
The cardiovascular pharmacology of COX-2 inhibition.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Blood Pressure; Cardiova | 2005 |
Polymorphisms in genes encoding acetylsalicylic acid metabolizing enzymes are unrelated to upper gastrointestinal health in cardiovascular patients on acetylsalicylic acid.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascula | 2005 |
Underutilization of aspirin in hemodialysis patients for primary and secondary prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Utilization; Female; Humans; Male; | 2005 |
Underuse of antiplatelets and inappropriate use.
Topics: Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Drug Utilization; Humans; Italy; Platelet | 2006 |
Aspirin overprescription in primary cardiovascular prevention.
Topics: Aged; Aspirin; Blood Pressure; Cardiovascular Diseases; Cholesterol; Drug Utilization Review; Female | 2006 |
[Characteristics of colon cancer diagnosed in patients taking aspirin or warfarin].
Topics: Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Colonic Neoplasms; Female; Gastrointestinal | 2005 |
[Role of cyclo-oxygenases in the effects of angiotensin II].
Topics: Angiotensin II; Animals; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; Lacton | 2006 |
Aspirin, "super aspirin" use in women for cardioprevention probed.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Platelet Aggregation Inhibitors; Platelet Glycopro | 2006 |
Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesis.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Fibrinolytic Agents; Humans; Incidence; Male; Random | 2006 |
Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesis.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Fibrinolytic Agents; Humans; Incidence; Male; Random | 2006 |
Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesis.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Fibrinolytic Agents; Humans; Incidence; Male; Random | 2006 |
Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesis.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Fibrinolytic Agents; Humans; Incidence; Male; Random | 2006 |
Massive rectus sheath hematoma.
Topics: Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Enoxaparin; Epigastric Arteries; Female; Hem | 2006 |
Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System.
Topics: Adult; Aged; Aspirin; Behavioral Risk Factor Surveillance System; Cardiovascular Diseases; Diabetes | 2006 |
Use of nonprescription medications for perceived cardiovascular health.
Topics: Adult; Age Distribution; Aged; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dietary Su | 2006 |
A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Ec | 2006 |
Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitu | 2006 |
Polypill holds promise for people with chronic disease.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Chemoprevention; Chronic Disease; Develop | 2005 |
Impact of aspirin treatment on long-term outcome (over 10 years) after percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle | 2006 |
Other studies show aspirin use is high.
Topics: Ambulatory Care; Aspirin; Cardiovascular Diseases; Guideline Adherence; Health Maintenance Organizat | 2006 |
Characteristics of Kawasaki disease in infants younger than six months of age.
Topics: Age Factors; Age of Onset; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases | 2006 |
[Germany's girths in an international comparison].
Topics: Abdominal Fat; Adult; Anthropometry; Aspirin; Aspirin, Dipyridamole Drug Combination; Body Mass Inde | 2005 |
Aspirin therapy as primary prevention in hypertensive patients at Srinagarind hospital.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Humans; Hypertension; Male; Middle Aged; Platelet Ag | 2005 |
The charisma of subgroups and the subgroups of CHARISMA.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Confidence Intervals; Data Interpretation, Statistica | 2006 |
Aspirin for primary prevention of cardiovascular disease in women: does sex matter?
Topics: Age Factors; Aged; Aspirin; Australia; Cardiovascular Diseases; Dose-Response Relationship, Drug; Dr | 2006 |
A health impact assessment of increased aspirin use in Wales.
Topics: Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; Humans; Platelet Aggregation Inhibito | 2006 |
The prevalence of risk factors for gastrointestinal complications and use of gastroprotection among persons hospitalized for cardiovascular disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Enzyme Inhibitors; | 2006 |
Differential antiplatelet effects of angiotensin converting enzyme inhibitors: comparison of ex vivo platelet aggregation in cardiovascular patients with ramipril, captopril and enalapril.
Topics: Adenosine Diphosphate; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Aspirin | 2006 |
Inhibition of rat platelet aggregation by Urtica dioica leaves extracts.
Topics: Animals; Aspirin; Cardiovascular Diseases; Female; Male; Mice; Phytotherapy; Plant Extracts; Plant L | 2006 |
[The clinical use of aspirin in patients with atherosclerotic cardiovascular disease: 2005 Chinese Expert Consensus Document].
Topics: Arteriosclerosis; Aspirin; Cardiovascular Diseases; Humans; Professional Staff Committees | 2006 |
Increased cardiovascular risk associated with diabetes in Dallas County.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Glucose; Calcium; Cardiovascular Dis | 2006 |
[Aspirin resistance in patients taking small dose of aspirin].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Dose-Re | 2006 |
Influence of cardiac risk factors and medication on length of hospitalization in patients undergoing major vascular surgery.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aspirin; Cardiovascular Diseases; | 2006 |
Acetylsalicylic acid (ASA) use among Polish adults with diabetes mellitus.
Topics: Adult; Aspirin; Cardiovascular Diseases; Causality; Comorbidity; Diabetes Complications; Diabetes Me | 2005 |
The management of aspirin in transurethral prostatectomy: current practice in the UK.
Topics: Aspirin; Blood Loss, Surgical; Cardiovascular Diseases; Humans; Male; Platelet Aggregation Inhibitor | 2006 |
Aspirin and clopidogrel resistance: an emerging clinical entity.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Resistance; Humans; Platelet Aggregation Inhibit | 2006 |
What price pain relief?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cardiovascular Diseases; Cyclooxyg | 2006 |
Sub-Tenon's anesthesia with aspirin, warfarin, and clopidogrel.
Topics: Adult; Aged; Aged, 80 and over; Anesthesia, Local; Anticoagulants; Aspirin; Cardiovascular Diseases; | 2006 |
Aspirin and clopidogrel resistance.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Resistance, Multiple; Humans; Platelet Aggregati | 2006 |
Aspirin for primary prevention of cardiovascular disease (revisited).
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Meta-Analysis as Topic; Platelet Aggregation | 2006 |
Softening the blow.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Car | 2006 |
Use of aspirin as primary prevention of cardiovascular events.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Meta-Analysis as Topic; Middle Aged; P | 2006 |
Clopidogrel for the prevention of atherothrombotic events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, Statistical; Drug Therapy, Combi | 2006 |
Clopidogrel for the prevention of atherothrombotic events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combinatio | 2006 |
Clopidogrel for the prevention of atherothrombotic events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Incide | 2006 |
Clopidogrel for the prevention of atherothrombotic events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platel | 2006 |
Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibito | 2006 |
The use of cardiovascular risk factor information in practice databases: making the best of patient data.
Topics: Adult; Aged; Antihypertensive Agents; Aspirin; Blood Pressure; Cardiovascular Diseases; Cost-Benefit | 2006 |
Aspirin prophylaxis and the prevalence of anaemia.
Topics: Aged; Anemia; Aspirin; Cardiovascular Diseases; Cohort Studies; Comorbidity; Cross-Sectional Studies | 2006 |
[Health economic evaluation of low-dose acetylsalicylic acid in the primary prevention of cardiovascular disease].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Budgets; Cardiovascular Diseases; Cost-Benefit Analysis; Fe | 2006 |
Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation.
Topics: Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Models, | 2006 |
[Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark].
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Bypass; Coronary | 2006 |
Comment and reply on: the dose of aspirin for the prevention of cardiovascular and cerebrovascular events.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Human | 2006 |
[NSAIDs and cardiovascular and renal complications].
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenas | 2006 |
[The CHARISMA study: in search of the best antiplatelet strategy for cardiovascular prevention].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Female; Humans; Male; Middle Aged; Multicenter Studie | 2006 |
[Finding the right platelet anti-aggregant prescription for type-2 diabetes patients, according to the ADA 2003 criteria].
Topics: Adult; Aged; Aspirin; Body Mass Index; Cardiovascular Diseases; Confidence Intervals; Diabetes Melli | 2006 |
Variation and importance of aspirin resistance in patients with known cardiovascular disease.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Drug Resistance; Female; Follow-Up Studie | 2007 |
Aspirin-triggered lipoxin A4 blocks reactive oxygen species generation in endothelial cells: a novel antioxidative mechanism.
Topics: Antioxidants; Aspirin; Cardiovascular Diseases; Cells, Cultured; Endothelium, Vascular; Humans; Lipo | 2007 |
Aspirin resistance: is it real? Is it clinically significant?
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Resistance | 2007 |
Risk of low-dose aspirin: emphasis on outliers undermines the credibility of the conclusions.
Topics: Adrenal Cortex Hormones; Aging; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Ca | 2007 |
The frequency of aspirin resistance and its risk factors in patients with metabolic syndrome.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Carotid Stenosis; Cross-Sectional Studies; Dose-Respo | 2007 |
[Polypharmacy, compliance and non-prescription medication in patients with cardiovascular disease in Germany].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angio | 2007 |
Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Costs; Female; Fibrinolytic Agen | 2007 |
Blood levels of long-chain polyunsaturated fatty acids, aspirin, and the risk of colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Dis | 2007 |
A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Dr | 2007 |
[Milestones of cardivascular pharmacotherapy: salicylates and aspirin].
Topics: Aspirin; Cardiovascular Diseases; History, 18th Century; History, 19th Century; History, 20th Centur | 2006 |
Drug insight: aspirin resistance-fact or fashion?
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Humans; Platelet Aggregation; Pl | 2007 |
Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to p-selectin and antithrombotic therapy.
Topics: Aged; Aspirin; Atrial Fibrillation; Blood Coagulation Factors; Blood Platelets; Cardiovascular Disea | 2007 |
Inhaled corticosteroids and mortality in COPD.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Angiotensin-Conver | 2007 |
[Primary prevention with aspirin for cardiovascular diseases in diabetic patients. What evidence supports the criteria of the ADA?].
Topics: Adult; Age Factors; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Confidence Intervals | 2007 |
Letter by Cen regarding article, "Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas".
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Color | 2007 |
Can aspirin keep mortality at bay?
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Humans; Platelet Aggregation Inhibitors; R | 2007 |
Long-term aspirin use and mortality in women.
Topics: Adult; Age Factors; Aspirin; Cardiovascular Diseases; Case-Control Studies; Cause of Death; Female; | 2007 |
Cardiovascular aspirin--what is the ideal dose?
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Human | 2006 |
A health-economic evaluation of aspirin: primary prevention and cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Health Promotion; Humans; Practice Guidelines as Topic; Primary Pr | 2007 |
Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1.
Topics: Adult; Arachidonic Acid; Aspirin; beta-Thromboglobulin; Black or African American; Blood Platelets; | 2007 |
Aspirin use among adults aged 40 and older in the United States: results of a national survey.
Topics: Adult; Aged; Aged, 80 and over; Aging; Aspirin; Cardiovascular Diseases; Female; Health Surveys; Hum | 2007 |
Aspirin and cognitive function.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cognition Disorders; Humans; Nootropic Agents | 2007 |
Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Drug Costs; Evidence-Based Medicine; Humans; Hydro | 2007 |
Heritability, platelet function, and aspirin: a link established but cause unknown.
Topics: Arachidonic Acid; Aspirin; Black or African American; Blood Platelets; Cardiovascular Diseases; Cycl | 2007 |
The impact of pharmaceuticals on the decline of cardiovascular mortality in Germany.
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Germany; Humans; Hydroxymethylglutaryl-CoA | 2007 |
Prognostic value of ankle-brachial index and dobutamine stress echocardiography for cardiovascular morbidity and all-cause mortality in patients with peripheral arterial disease.
Topics: Aged; Ankle; Aspirin; Blood Pressure; Brachial Artery; Cardiovascular Diseases; Coronary Artery Dise | 2007 |
Laboratory detection of 'aspirin resistance': what test should we use (if any)?
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cyclooxygenase 1; Drug Resistance; Humans; Platel | 2007 |
The effectiveness of antiplatelet treatment with aspirin in polymorbid patients.
Topics: Administration, Oral; Aged; Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Fema | 2007 |
Do polyunsaturated fatty acids behave like an endogenous "polypill"?
Topics: Antihypertensive Agents; Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Therapy, Combinatio | 2008 |
Aspirin: a treatment for the headache of shunt-dependent pulmonary blood flow and parallel circulation?
Topics: Aspirin; Cardiovascular Diseases; Cardiovascular Surgical Procedures; Humans; Pulmonary Artery; Pulm | 2007 |
[Daily low dose aspirin for patients in high risk].
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Risk Factors | 2007 |
Aggressive antiplatelet strategies: time to reconsider?
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Randomized C | 2007 |
Aspirin for primary prevention of cardiovascular disease in Japan.
Topics: Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; Humans; Japan; Platelet Aggregation I | 2007 |
Aspirin dose and cardiovascular disease prevention.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregat | 2007 |
Aspirin dose and cardiovascular disease prevention.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregat | 2007 |
[Soluble CD40 ligand: a potential marker of cardiovascular risk].
Topics: Abciximab; Acute Coronary Syndrome; Alanine; Angina, Unstable; Animals; Antibodies, Monoclonal; Anti | 2007 |
[Control of aspirin effect in chronic cardiovascular patients using two whole blood platelet function assays. PFA-100 and Multiplate].
Topics: Aspirin; Blood Coagulation; Blood Donors; Blood Platelets; Cardiovascular Diseases; Chronic Disease; | 2007 |
[Control of aspirin effect in chronic cardiovascular patients using two whole blood platelet function assays. PFA-100 and Multiplate].
Topics: Aspirin; Blood Coagulation; Blood Donors; Blood Platelets; Cardiovascular Diseases; Chronic Disease; | 2007 |
[Control of aspirin effect in chronic cardiovascular patients using two whole blood platelet function assays. PFA-100 and Multiplate].
Topics: Aspirin; Blood Coagulation; Blood Donors; Blood Platelets; Cardiovascular Diseases; Chronic Disease; | 2007 |
[Control of aspirin effect in chronic cardiovascular patients using two whole blood platelet function assays. PFA-100 and Multiplate].
Topics: Aspirin; Blood Coagulation; Blood Donors; Blood Platelets; Cardiovascular Diseases; Chronic Disease; | 2007 |
An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cardiovascular Diseases; Clopidogre | 2008 |
Incomplete Kawasaki disease: a pediatric diagnostic conflict.
Topics: Aspirin; Cardiovascular Diseases; Child, Preschool; Diagnosis, Differential; Emergency Treatment; Hu | 2007 |
The "clopidogrel resistance" trap.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Humans; P | 2007 |
Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Collagen; Female; Hu | 2008 |
Creating and synthesizing evidence with decision makers in mind: integrating evidence from clinical trials and other study designs.
Topics: Aspirin; Cardiovascular Diseases; Decision Making; Drug Evaluation; Endarterectomy, Carotid; Evidenc | 2007 |
CON: Should aspirin be used in all women older than 65 years to prevent stroke?
Topics: Age Factors; Aspirin; Cardiovascular Diseases; Female; Humans; Patient Selection; Platelet Aggregati | 2007 |
Roles of platelet and endothelial cell COX-1 in hypercholesterolemia-induced microvascular dysfunction.
Topics: Animals; Aspirin; Blood Platelets; Bone Marrow Transplantation; Cardiovascular Diseases; Cell Adhesi | 2007 |
Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain.
Topics: Aged; Ambulatory Care; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Female; Follow-Up Studie | 2007 |
The patterns of antihypertensive drug prescription by cardiologists in Kerman province of Iran, 2006.
Topics: Adult; Aged; Ambulatory Care; Antihypertensive Agents; Aspirin; Cardiology; Cardiovascular Diseases; | 2008 |
A possible overestimation of the effect of aspirin.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Neoplasms; Platelet Aggregation Inhibitors; Surviv | 2007 |
Aspirin use in the prevention of cardiovascular events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; | 2007 |
The assessment and management of albuminuria in primary care.
Topics: Aged; Albuminuria; Aspirin; Blood Glucose; Cardiovascular Diseases; Chronic Disease; Diabetes Mellit | 2008 |
Heart health and diet.
Topics: Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Diet; Diet, Mediterranean; Dietary Fats; Dose-Re | 2008 |
Aspirin resistance in cardiovascular disease.
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Prognosis; Risk Factors | 2008 |
Participation of IIb-IIIa glycoprotein in spontaneous platelet aggregation.
Topics: Antibodies, Monoclonal; Aspirin; Blood Platelets; Cardiovascular Diseases; Fibrinogen; Humans; Mutat | 2007 |
Low-dose aspirin prevents age-related endothelial dysfunction in a mouse model of physiological aging.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Acetylcholine; Age Factors; Aging; Animals; Antioxidants; Aorta; Aspiri | 2008 |
Should we prescribe statin and aspirin for every diabetic patient? Is it time for a polypill?
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Disease; Diabetes Complications | 2008 |
Should we be more aggressive in the therapy against cardiovascular risk factors? Should we prescribe statin and aspirin for every diabetic patient, or is it time for a polypill?
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetic Angiopathies; Drug Therapy, Com | 2008 |
Aspirin resistance: What is the risk of cardiovascular morbidity?
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Risk Fac | 2008 |
Anti-inflammatory effects of combined treatment with acetyl salicylic acid and atorvastatin in haemodialysis patients affected by Normal Weight Obese syndrome.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Atorvastati | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
Evidence for prolonged prescribing of aspirin-clopidogrel combination in Scottish primary care.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Cross-Sectional Studies; Drug Therapy, Combinat | 2008 |
Aspirin revisited: helpful or harmful? What is the correct dose for a certain population?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors | 2008 |
Laboratory-defined aspirin resistance and recurrent cardiovascular events.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Recurren | 2008 |
Is aspirin resistance due to noncompliance?
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Patient Compliance; Platelet Aggregation | 2008 |
NSAIDs and cardiovascular disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibito | 2008 |
Effect of aspirin use on thiazolidinediones and cardiovascular events.
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Interactions; Humans; Hypoglycemic | 2008 |
Underutilization of gastroprotective strategies in aspirin users at increased risk of upper gastrointestinal complications.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Therapy, Combi | 2008 |
What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Clopidogrel; Fibri | 2008 |
Single antiplatelet therapy for patients with previous gastrointestinal bleeds.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Gastrointest | 2008 |
A new horizon in primary prevention of cardiovascular disease, can we prevent heart attack by "heart polypill"?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Disea | 2008 |
Platelet inhibition by aspirin 81 and 325 mg/day in men versus women without clinically apparent cardiovascular disease.
Topics: Adult; Aspirin; Cardiovascular Diseases; Female; Hematocrit; Humans; Lipids; Logistic Models; Male; | 2008 |
The genetic response to short-term interventions affecting cardiovascular function: rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study.
Topics: Adult; Aspirin; Blood Pressure; Cardiovascular Diseases; Female; Genetic Predisposition to Disease; | 2008 |
Aspirin is insufficient in inhibition of platelet aggregation and thromboxane formation early after coronary artery bypass surgery.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Bypass; Female; Humans; Male; Middle Aged; P | 2009 |
How many cardiovascular events can be prevented with optimal management of high-risk Canadians?
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Canada; Cardiovascular D | 2008 |
Adherence to statin or aspirin or both in patients with established cardiovascular disease: exploring healthy behaviour vs. drug effects and 10-year follow-up of outcome.
Topics: Aspirin; Cardiovascular Diseases; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Hydroxymet | 2008 |
Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
Topics: Age Factors; Aged; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Evaluation; Female; | 2008 |
Overview of recent clinical and methodological advances from clinical trials of cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Di | 1982 |
Platelet factor 4 (PF4) and heparin-released platelet factor 4 (HR-PF4) in patients with cardiovascular disorders.
Topics: Adult; Aged; Aspirin; beta-Thromboglobulin; Blood Coagulation Factors; Cardiovascular Diseases; Dipy | 1983 |
Cardiovascular disease and the need for prophylaxis.
Topics: Aspirin; Cardiovascular Diseases; Cholesterol; Humans; Hypertension; Middle Aged; Smoking | 1980 |
Prostaglandins and vascular function.
Topics: Aspirin; Blood Platelets; Blood Vessels; Cardiovascular Diseases; Diet; Epoprostenol; Hemostasis; Hu | 1984 |
Enhanced in vivo platelet activation in diabetes mellitus.
Topics: Adult; Aged; Aging; Aspirin; Blood Platelets; Calcium Channel Blockers; Cardiovascular Diseases; Dia | 1982 |
The anti-thrombotic effects of prostacyclin.
Topics: Animals; Arteries; Aspirin; Cardiovascular Diseases; Dipyridamole; Epoprostenol; Fatty Acids; Hemost | 1980 |
Iron, aspirin, and heart disease risk.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Iron; Male; Platelet Aggregation; Risk | 1982 |
[Prevention of cardiovascular diseases by inhibitors of platelet aggregation (author's transl)].
Topics: Anti-Inflammatory Agents; Aspirin; Cardiovascular Diseases; Dipyridamole; Humans; Platelet Aggregati | 1982 |
Mucocutaneous lymph node syndrome (Kawasaki disease) in an adult.
Topics: Adult; Anti-Bacterial Agents; Arteritis; Aspirin; Cardiovascular Diseases; Central Nervous System Di | 1981 |
Spectrum of cardiovascular lesions in mucocutaneous lymph node syndrome: analysis of eight cases.
Topics: Adrenal Cortex Hormones; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Cardiovascular Diseas | 1980 |
Clinical applications.
Topics: Abortion, Induced; Aspirin; Blood Pressure; Cardiovascular Diseases; Cervix Uteri; Digestive System; | 1980 |
An unusual request to a willing study population.
Topics: Aged; Aspirin; beta Carotene; Cardiovascular Diseases; Carotenoids; Humans; Male; Middle Aged; Neopl | 1981 |
[Cardiovascular pharmacotherapy in old age: How beneficial is it? What does it cost?].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin | 1995 |
Epidemiological feasibility of cardiovascular primary prevention in general practice: a trial of vitamin E and aspirin. Collaborative group of the Primary Prevention Project.
Topics: Aged; Arteriosclerosis; Aspirin; Cardiovascular Diseases; Clinical Protocols; Contraindications; Dia | 1995 |
Prophylactic aspirin and risk of peptic ulcer bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Case-Control Studies; Che | 1995 |
Prophylactic aspirin and risk of peptic ulcer bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Case-Control Studies; Che | 1995 |
Prophylactic aspirin and risk of peptic ulcer bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Case-Control Studies; Che | 1995 |
Prophylactic aspirin and risk of peptic ulcer bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Case-Control Studies; Che | 1995 |
Thrombolysis in patients with diabetes. Prophylaxis with aspirin should be considered.
Topics: Aspirin; Cardiovascular Diseases; Contraindications; Diabetic Retinopathy; Humans; Myocardial Infarc | 1995 |
Low-dose acetylsalicylic acid use and hemoglobin levels. Effects in a primary care population.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Family Practice; Female; Gastroint | 1995 |
No aspirin in red wine.
Topics: Aspirin; Cardiovascular Diseases; Free Radical Scavengers; Humans; Salicylates; Salicylic Acid; Wine | 1994 |
Prostaglandin synthase. At the heart of the matter.
Topics: Aspirin; Binding Sites; Cardiovascular Diseases; Cell Membrane; Humans; Models, Molecular; Molecular | 1994 |
Dysfunctional recovery of prostacyclin synthase in aspirin-treated vascular cells: implications for prophylaxis of cardiovascular disease.
Topics: Arachidonic Acid; Aspirin; Cardiovascular Diseases; Cell Line; Cytochrome P-450 Enzyme System; Epopr | 1994 |
[Acetylsalicylic acid, a new era for an old drug?].
Topics: Aspirin; Cardiovascular Diseases; Humans | 1994 |
[Changes in parameters of the coagulation and fibrinolysis system of the blood in patients with prostate cancer in the framework of estrogen therapy].
Topics: Aged; Antihypertensive Agents; Aspirin; Blood Coagulation Disorders; Blood Coagulation Tests; Cardio | 1994 |
[Clarification of mechanism of acetylsalicylic acid].
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Humans; Prostaglandin Antagonists | 1994 |
[Acetylsalicylic acid therapy and vascular surgery].
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Humans; Postoperative Care; Vascular Surgical Proc | 1994 |
Sample size requirements and length of study for testing interaction in a 2 x k factorial design when time-to-failure is the outcome [corrected].
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Female; Health Status; Humans; Male; Mod | 1993 |
[The mechanism of acetylsalicylic acid becomes clearer].
Topics: Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Humans; Prostaglandins | 1994 |
The trials and tribulations of clinical trials in the elderly.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Female; Health Status; Humans; Mal | 1994 |
Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Carotid Artery, Internal; Cerebrovascular Disorders; | 1993 |
A hearty endorsement for aspirin.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Meta-Analysis as Topic; Risk Factors; Thromb | 1994 |
The aspirin papers.
Topics: Aspirin; Blood Vessel Prosthesis; Cardiovascular Diseases; Humans; Vascular Patency | 1994 |
Use of antiplatelet agents in the management of thrombotic disorders.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Thrombosis | 1993 |
Prevalence and descriptors of aspirin use as an antiplatelet agent in two New England communities.
Topics: Adolescent; Adult; Aspirin; Cardiovascular Diseases; Confidence Intervals; Cross-Sectional Studies; | 1993 |
[Acetylsalicylic acid as free radical scavenger. An argument for increased dosages in acute and preventive therapy of vascular diseases].
Topics: Adult; Aspirin; Biotransformation; Cardiovascular Diseases; Cerebrovascular Disorders; Dose-Response | 1995 |
Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease.
Topics: Analysis of Variance; Anticoagulants; Aspirin; Cardiovascular Diseases; Chronic Disease; Cross-Over | 1996 |
An aspirin a day.
Topics: Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Humans; Platelet Aggregation Inhibitors | 1996 |
Confirmation of self-reported cataract in the Physicians' Health Study.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Aspirin; beta Carotene; Cardiovascular Diseases; Carot | 1994 |
Kawasaki disease in Malaysia.
Topics: Anti-Bacterial Agents; Aspirin; Cardiovascular Diseases; Child; Child, Preschool; Drug Therapy, Comb | 1996 |
Prevention of vascular events in diabetes mellitus: which "antithrombotic" therapy?
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetic Angiopathies; Fibrinolytic Agents | 1996 |
Assessing the evidence on aspirin in diabetes mellitus. Gemini or Libra; lumping or splitting; surrogate or hard; low or high; interventionist or nihilist.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Diabetes Complications; Diabetic Angiop | 1996 |
Antiplatelet therapy.
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Humans; Platelet Aggregation Inhibit | 1996 |
Inflammation, aspirin, and the risk of cardiovascular disease.
Topics: Aspirin; Blood Platelets; C-Reactive Protein; Cardiovascular Diseases; Humans; Inflammation | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease.
Topics: Aspirin; Blood Coagulation; C-Reactive Protein; Cardiovascular Diseases; Humans; Inflammation | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease.
Topics: Aspirin; Blood Platelets; C-Reactive Protein; Cardiovascular Diseases; Humans; Inflammation | 1997 |
Aspirin use in middle-aged men with cardiovascular disease: are opportunities being missed?
Topics: Aged; Aspirin; Cardiovascular Diseases; Humans; Longitudinal Studies; Male; Middle Aged; Platelet Ag | 1997 |
[A 100 years of aspirin: a drug with a future?].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cerebrovascular Di | 1997 |
What have we learned from the HOT (Hypertension Optimal Treatment) study?
Topics: Aspirin; Cardiovascular Diseases; Goals; Humans; Hypertension; Morbidity; Prospective Studies; Rando | 1997 |
Aspirin therapy in diabetes. American Diabetes Association.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Female; Humans; Male | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
Topics: Aspirin; Cardiovascular Diseases; Humans; Male; Myocardial Infarction; Primary Prevention | 1997 |
Ticlopidine-associated pancytopenia: implications of an acetylsalicylic acid alternative.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Fatal Outcome; Female; Humans; Middle Aged; Neutr | 1997 |
In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia.
Topics: Antioxidants; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Cyclooxygenase Inhibitors; | 1997 |
Deciphering aspirin's many modes of action.
Topics: Alzheimer Disease; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Humans | 1996 |
[Should one prescribe aspirin for all diabetics?].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Humans; Platelet Aggrega | 1997 |
Apo E4/3-rich remnant lipoproteins and platelet aggregation: a case report.
Topics: 2-Chloroadenosine; Adenosine Diphosphate; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; A | 1998 |
Novel antioxidant action of aspirin may contribute to its beneficial cardiovascular actions.
Topics: Antioxidants; Aspirin; Cardiovascular Diseases; Ferritins; Humans; Iron | 1998 |
J-curve not burned off by HOT study. Hypertension Optimal Treatment.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Blood Pressure; Cardiovas | 1998 |
From molecular analysis to medical practice: recent studies reveal new therapeutic targets for an old medicine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Ger | 1998 |
Phacoemulsification and lens implantation in patients treated with aspirin or warfarin.
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Conjunctival Diseases; | 1998 |
Aspirin for primary prevention of cardiovascular events.
Topics: Aspirin; Cardiovascular Diseases; Decision Support Techniques; Humans; Platelet Aggregation Inhibito | 1998 |
Individualizing aspirin therapy for prevention of cardiovascular events.
Topics: Aspirin; Cardiovascular Diseases; Cerebral Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk | 1998 |
[Prevention in the 21st century. Athero-thrombosis and ischemic events].
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Female; Forecasting; Human | 1998 |
Experimental treatment of the acute cardiovascular toxicity of caffeine.
Topics: Animals; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Arrhythmias, Cardiac; Aspi | 1999 |
Aspirin inhibits inducible nitric oxide synthase expression and tumour necrosis factor-alpha release by cultured smooth muscle cells.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blotting, W | 1999 |
AWOL on health tests. Fewer volunteers makes research tougher.
Topics: Aspirin; Bone Marrow Transplantation; Cardiovascular Diseases; Estrogen Replacement Therapy; Female; | 1995 |
Underuse of aspirin for secondary prevention of vascular disease.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Drug Utilization Review; Hospitalizatio | 1999 |
British Hypertension Society guidelines for hypertension management 1999: summary.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Blood Pressure Determination; Card | 1999 |
[Prevention of cardiovascular events with antiplatelet drugs: aspirin (and others)?].
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors | 1999 |
COX-2 selective NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors | 2000 |
Aspirin in the treatment of type 2 diabetes.
Topics: Adult; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Lipids; Platelet Aggrega | 2000 |
Iron deficiency anaemia and aspirin use in old age.
Topics: Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Aspirin; Cardiovascular Diseases; Humans; Platelet | 1999 |
What is the risk of aspirin withdrawal in the surgical patient?
Topics: Aspirin; Blood Loss, Surgical; Cardiovascular Diseases; Humans; Preoperative Care; Risk Factors | 2000 |
Coverage by the news media of the benefits and risks of medications.
Topics: Alendronate; Anticholesteremic Agents; Aspirin; Biomedical Research; Cardiovascular Diseases; Confli | 2000 |
[Primary prevention of cardiovascular events by acetylsalicylic acid in patients with hypertension in Spain].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Female; Humans; Hyp | 2000 |
Meeting report of the ASPET-Ray Fuller Symposium: insulin resistance in diabetes and hypertension: syndrome X and beyond.
Topics: Aspirin; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Complications; Diabetes Mellitus; Endot | 2000 |
Aspirin-associated intracerebral hemorrhage: clinical and radiologic features.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Case-Control Studies; Cerebral Hem | 2000 |
Effect of ramipril on cardiovascular events in high-risk patients.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Asp | 2000 |
Intermediate but not low doses of aspirin can suppress angiotensin-converting enzyme inhibitor-induced cough.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Diseases; Cough; Dose-Respon | 2000 |
Primary prevention studies and the healthy elderly: evaluating barriers to recruitment.
Topics: Aged; Aspirin; Attitude to Health; Cardiovascular Diseases; Communication Barriers; Confounding Fact | 2000 |
Antiplatelet drugs in cardiovascular prevention: take adverse effects and costs into account.
Topics: Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Dipyridamole; Drug Costs; Flurbiprofen; Hum | 2000 |
Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention.
Topics: Angina, Unstable; Angioplasty; Anticoagulants; Aspirin; Cardiovascular Diseases; Clinical Trials as | 2000 |
[Pharmacological prevention of cardiovascular diseases in general practice].
Topics: Adult; Aged; Antihypertensive Agents; Aspirin; Benzothiadiazines; Cardiovascular Diseases; Cost-Bene | 2000 |
Aspirin--the first hundred years.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cardiovascular Diseases; History, | 2000 |
Who should take aspirin for primary prophylaxis of coronary heart disease?
Topics: Aspirin; Cardiovascular Diseases; Coronary Disease; Hemorrhage; Humans; Platelet Aggregation Inhibit | 2001 |
Aspirin for primary prevention of cardiovascular events.
Topics: Aspirin; Cardiovascular Diseases; Fibrinolytic Agents; Humans | 2001 |
Risk factors for hospitalized gastrointestinal bleeding among older persons. Cardiovascular Health Study Investigators.
Topics: Activities of Daily Living; Age Distribution; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non | 2001 |
Aspirin therapy in diabetes is underutilized.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetic Angiopathies; Humans | 2001 |
Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey.
Topics: Adult; Albuminuria; Angina Pectoris; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabe | 2001 |
ACE inhibitor reduces cardiovascular events by 22%.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Diseases; Humans; Multicenter Stud | 2000 |
Medical memo. Low-dose aspirin gets the nod.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors | 2001 |
Colorectal cancer among users of aspirin and non-steroidal antiinflammatory drugs.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; Cardiovascular Diseases; Cohort | 2001 |
Antioxidant strategy for cardiovascular diseases.
Topics: Antioxidants; Aspirin; Cardiovascular Diseases; Cause of Death; Data Interpretation, Statistical; Hu | 2001 |
Antioxidant strategy for cardiovascular disease.
Topics: Antioxidants; Aspirin; Cardiovascular Diseases; Follow-Up Studies; Humans; Randomized Controlled Tri | 2001 |
[Kawasaki disease--personal observations].
Topics: Aspirin; Cardiovascular Diseases; Child, Preschool; Drug Therapy, Combination; Female; gamma-Globuli | 2001 |
[The Primary Prevention Project Study Group. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice].
Topics: Antioxidants; Aspirin; Cardiovascular Diseases; Fibrinolytic Agents; Humans; Randomized Controlled T | 2001 |
Profile and prevalence of aspirin resistance in patients with cardiovascular disease.
Topics: Adult; Aspirin; Cardiovascular Diseases; Drug Resistance; Female; Humans; Male; Middle Aged; Platele | 2001 |
Antioxidant strategy for cardiovascular disease.
Topics: Adult; Aspirin; Cardiovascular Diseases; Humans; Risk Factors | 2001 |
The importance of addressing the condition of nonsteroidal anti-inflammatory drug-related gastropathy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cost of Illness; Cyclooxy | 2001 |
Aspirin use for the prevention of cardiovascular disease: the British Women's Heart and Health Study.
Topics: Aged; Aspirin; Cardiovascular Diseases; Confidence Intervals; Female; Humans; Middle Aged; Platelet | 2001 |
Treatment of cardiac risk factors in diabetic patients: How well do we follow the guidelines?
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Pressure | 2001 |
American Heart Association 2001 scientific sessions: late-breaking science-statins: the new aspirin?
Topics: Adult; Aged; Anticholesteremic Agents; Antioxidants; Aspirin; Cardiovascular Diseases; Humans; Male; | 2001 |
High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; C-Reactive Protein; Cardiovascular Dis | 2001 |
Detecting aspirin resistance with the platelet function analyzer (PFA-100).
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Platelet Aggregation; Platelet Aggregatio | 2001 |
Cardiovascular events and COX-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive Protein; Cardiovascular Diseases; Cyclo | 2001 |
Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology--WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME.
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Electric Count | 2001 |
The coxibs, selective inhibitors of cyclooxygenase-2.
Topics: Acute Kidney Injury; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cycl | 2001 |
Factors affecting over-the-counter use of aspirin in the secondary prophylaxis of cardiovascular disease.
Topics: Age Factors; Aged; Aspirin; Cardiovascular Diseases; Female; Humans; Logistic Models; Male; Middle A | 2001 |
[Primary prevention of cardiovascular events by ASS and vitamin E. PPP--Primary Prevention Project].
Topics: Antioxidants; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Myocardial Infarct | 2001 |
Treatment of acute coronary syndromes.
Topics: Acute Disease; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; | 2002 |
Article makes simple errors and could cause unnecessary deaths.
Topics: Aspirin; Cardiovascular Diseases; Data Interpretation, Statistical; Humans; Meta-Analysis as Topic; | 2002 |
Efficacy and safety of aspirin in the long-term management of atherothrombosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Blood Platelets; Cardiovascular | 2002 |
No reduction in cardiovascular risk with NSAIDs-including aspirin?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Bias; Cardiovascular Diseases; Clinical | 2002 |
Aspirin resistance.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Drug Resistance; Humans; Platelet Aggreg | 2002 |
Should patients who have not had a cardiac event take ASA to prevent one?
Topics: Administration, Oral; Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ca | 2002 |
Towards a definition of aspirin resistance: a typological approach.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrov | 2002 |
Lowering cardiac risk in noncardiac surgery.
Topics: Aspirin; Cardiovascular Diseases; Humans; Intraoperative Complications; Platelet Aggregation Inhibit | 2002 |
Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2?
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Resistance | 2002 |
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Canada; Cardiovascular Diseases; Case-Contr | 2002 |
Resisting aspirin.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Thromboxanes | 2002 |
Aspirin resistance may increase death risk in some patients with heart disease.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Risk Fac | 2002 |
Cardiovascular disease. Does inflammation cut to the heart of the matter?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Biological Evol | 2002 |
Aspirin use and counseling about aspirin among patients with diabetes.
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Female; Health Kno | 2002 |
Clinical evidence of dose-dependent interaction between aspirin and angiotensin-converting enzyme inhibitors.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Diseases; Cough; Cyclooxygenase In | 2002 |
An aspirin a day keeps the MI away (for some).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Drug Antagonism; H | 2002 |
Aspirin for the primary prevention of cardiovascular events: recommendations and rationale.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Platelet Aggregati | 2002 |
Optimizing drug therapy in patients with cardiovascular disease: the impact of pharmacist-managed pharmacotherapy clinics in a primary care setting.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cardiovascular Disea | 2002 |
[Tolerability of Asacard--controlled-release aspirin and aspirin-induced asthma].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cardiovascular Diseases; Delayed-Ac | 2002 |
[Prevention of cardiovascular complications in manifest arteriosclerosis by the use of Micristine].
Topics: Adenosine Diphosphate; Anticoagulants; Arteriosclerosis; Aspirin; Cardiovascular Diseases; Humans; P | 1979 |
Methods for detection of hypersensitive platelets. Philadelphia, June 1977.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Blood Coagulation Tests; Blood Platelets; Cardiovascular | 1978 |
Does aspirin have a prophylactic vascular effect?
Topics: Arteriosclerosis; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Hum | 1979 |
Measurement of platelet regeneration time in cardiovascular patients.
Topics: Adult; Aged; Arachidonic Acids; Arterial Occlusive Diseases; Aspirin; Blood Platelets; Cardiovascula | 1979 |
Cardiopulmonary catastrophes in drug-overdosed patients.
Topics: Adolescent; Adult; Amphetamines; Antidepressive Agents; Arrhythmias, Cardiac; Aspirin; Cardiovascula | 1979 |
Dollars: prophylaxis or cure?
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation; Prostaglandins | 1979 |
Mortality among arthritics.
Topics: Aged; Arthritis, Rheumatoid; Aspirin; Cardiovascular Diseases; Central Nervous System Diseases; Coro | 1976 |
Platelets, aspirin and cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Humans; Myocardial Infarction; Platelet Aggregation; Thromboemboli | 1976 |
[Influence of genetic factors, of ulcerogenic drugs and of a sound disease on both the incidence and characteristics of peptic ulcer].
Topics: Adrenal Cortex Hormones; Aspirin; Cardiovascular Diseases; Diabetes Complications; Humans; Kidney Fa | 1976 |
The role of aspirin in the prevention of cardiovascular and cerebrovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Humans | 1992 |
A prospective study of cigarette smoking and risk of cataract in men.
Topics: Adult; Aged; Aspirin; beta Carotene; Cardiovascular Diseases; Carotenoids; Cataract; Follow-Up Studi | 1992 |
Forum offers hints of future therapy, prevention programs for combating cardiovascular problems.
Topics: Animals; Arteriosclerosis; Aspirin; Cardiomegaly; Cardiovascular Diseases; Female; Genetic Therapy; | 1992 |
Cardiovascular disease.
Topics: Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Cardiovascular Diseases; Female; Humans; | 1992 |
Aspirin use and cardiovascular disease in women.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Follow-Up Studies; Humans; Male; | 1992 |
Does an apple a day keep the cardiologist away?
Topics: Aspirin; Cardiovascular Diseases; Fruit; Humans; Salicylates | 1992 |
Which categories of patients are known to benefit from aspirin?
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged | 1991 |
Periodic health examination, 1991 update: 6. Acetylsalicylic acid and the primary prevention of cardiovascular disease. Canadian Task Force on the Periodic Health Examination.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Canada; Cardiovascular Diseases; Clinical Trials as Topic; | 1991 |
Use of acetylsalicylic acid by physicians and in the community.
Topics: Adolescent; Adult; Aged; Angina, Unstable; Aspirin; Cardiovascular Diseases; Community Medicine; Dru | 1991 |
Mechanisms of eicosanoid action.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Eicosanoids; Epoprostenol; Humans; Thromboxane A2 | 1991 |
[Cardiovascular effects of aspirin].
Topics: Aspirin; Cardiovascular Diseases; Humans | 1991 |
Estimating the effect of the run-in on the power of the Physicians' Health Study.
Topics: Aspirin; beta Carotene; Cardiovascular Diseases; Carotenoids; Data Interpretation, Statistical; Doub | 1991 |
Circadian rhythms in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Cardiovascular Diseases; Circadian R | 1990 |
An epidemiologic study of abuse of analgesic drugs. Effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968 to 1987)
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Female; Humans; Hyp | 1991 |
[Pharmacokinetics of acetylsalicylic acid for the prophylaxis of cardiovascular pathology].
Topics: Adult; Aspirin; Cardiovascular Diseases; Delayed-Action Preparations; Female; Humans; Male; Salicyla | 1991 |
Low dose acetylsalicylic acid and thromboxane release at the site of plug formation in vivo in elderly patients with cardiovascular disease.
Topics: Aged; Aged, 80 and over; Aspirin; Bleeding Time; Cardiovascular Diseases; Cerebrovascular Disorders; | 1990 |
The recent trials for aspirin in the prevention of cardiovascular mortality.
Topics: Aspirin; Cardiovascular Diseases; Humans | 1989 |
Physicians' health study: aspirin and primary prevention of coronary heart disease.
Topics: Aspirin; Cardiovascular Diseases; Coronary Disease; Humans; Male; Middle Aged; Physicians | 1989 |
[Acetylsalicylic acid-aspirin-against heart and vascular diseases. A new use of an old and wellknown preparation].
Topics: Aspirin; Cardiovascular Diseases; Health Education; Humans; Patient Education as Topic | 1989 |
Cardiovascular disease.
Topics: Adult; Aspirin; Cardiovascular Diseases; Coronary Disease; Electrophysiology; Humans | 1989 |
Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Clofibrate; | 1985 |
Aspirin all round?
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Humans | 1988 |
Aspirin all round?
Topics: Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Humans | 1988 |
Aspirin and vascular disease--an update.
Topics: Aspirin; Cardiovascular Diseases; Coronary Disease; Humans | 1988 |
Use of aspirin for prevention of cardiovascular disease--1981-82 to 1985-86: the Minnesota Heart Survey.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Drug Utilization; Female; He | 1988 |
Hennekens reconsidered.
Topics: Aspirin; Cardiovascular Diseases; Humans; Myocardial Infarction; Research Design; Risk | 1988 |
[Aspirin for all? All for aspirin?].
Topics: Aspirin; Cardiovascular Diseases; Humans | 1988 |
Prevention of cardiovascular disease. Of what value are risk factor modification, exercise, fish consumption, and aspirin therapy?
Topics: Animals; Aspirin; Cardiovascular Diseases; Feeding Behavior; Fish Products; Humans; Hyperlipidemias; | 1987 |
Letter: Mortality and anaemia in women.
Topics: Anemia, Hypochromic; Aspirin; Cardiovascular Diseases; Contraceptives, Oral; Death, Sudden; Female; | 1974 |
Excerpts from the casebook of Jason Harbro, M.D., AME.
Topics: Adult; Anticholesteremic Agents; Aspirin; Cardiovascular Diseases; Cholesterol; Humans; Male; Middle | 1974 |